INDEX,Trial,DrugName,Indications,DrugClass,Approval_FDA,Uniprot,GeneSymbol,Gene,ProteinName,TargetMainClass,TargetClass,Target_Novelty_VALIDATED
1,3196,3196,anticholesterolaemic agent,Small molecule,not approved,P10828,THB_HUMAN,THRB,Thyroid hormone receptor beta OS=Homo sapiens GN=THRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
2,"[(+)-phenserine tartrate,Posiphen",Posiphen,for treatment of Alzheimer's disease,small molecule,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
2,"[(+)-phenserine tartrate,Posiphen",Posiphen,for treatment of Alzheimer's disease,small molecule,not approved,P56817,BACE1_HUMAN,BACE1,Beta-secretase 1,Enzymes,EC:3.4.23.46,Novel Target
3,"105AD7,Onyvax 105",Onyvax-105 (105AD7),antineoplastic agent,monoclonal antibody,not approved,P08174,DAF_HUMAN,CD55,Complement decay-accelerating factor (CD antigen CD55),Miscellaneous,Receptors of complement activation (RCA) family,Novel Target
4,"131I-81C6, Neuradiab",Neuradiab ,antineoplastic agent,monoclonal antibody,not approved,P24821,TENA_HUMAN,TNC,Tenascin (TN) (Cytotactin) (GMEM) (GP 150-225) (Glioma-associated-extracellular matrix antigen) (Hexabrachion) (JI) (Myotendinous antigen) (Neuronectin) (Tenascin-C) (TN-C),Miscellaneous,Miscellaneous;Extracellular matrix protein,Novel Target
5,"19063,Metabasis Therapeutics Inc/",MBO7133 (cytarabine prodrug),antineoplastic agent,Small molecule,not approved,P06746,DPOLB_HUMAN,POLB,DNA polymerase beta OS=Homo sapiens GN=POLB PE=1 SV=3,Enzymes,EC:2.7.7.7; 4.2.99.-,Established target
6,1D09C3,1D09C3,antineoplastic agent,monoclonal antibody,not approved,P01903,DRA_HUMAN,HLA-DRB3,"HLA class II histocompatibility antigen, DR alpha chain (MHC class II antigen DRA)",Miscellaneous,Ligand;MHC,Novel Target
6,1D09C3,1D09C3,antineoplastic agent,monoclonal antibody,not approved,P79483,DRB3_HUMAN,HLA-DRB4,"HLA class II histocompatibility antigen, DR beta 3 chain (MHC class II antigen DRB3)",Miscellaneous,StructuralAndAdhesion;MHC claas II,Novel Target
6,1D09C3,1D09C3,antineoplastic agent,monoclonal antibody,not approved,P13762,DRB4_HUMAN,HLA-DRB5,"HLA class II histocompatibility antigen, DR beta 4 chain (MHC class II antigen DRB4)",Miscellaneous,StructuralAndAdhesion;MHC claas II,Novel Target
7,4SC-202,4SC-202,antineoplastic agent,Small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
7,4SC-202,4SC-202,antineoplastic agent,Small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
7,4SC-202,4SC-202,antineoplastic agent,Small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
7,4SC-202,4SC-202,antineoplastic agent,Small molecule,not approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
8,4SC-203,4SC-202,antineoplastic agent,Small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
8,4SC-203,4SC-202,antineoplastic agent,Small molecule,not approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
9,4SC-205,4SC-205,antineoplastic agent,Small molecule,not approved,P52732,KIF11_HUMAN,KIF11,Kinesin-like protein KIF11 (Kinesin-like protein 1) (Kinesin-like spindle protein HKSP) (Kinesin-related motor protein Eg5) (Thyroid receptor-interacting protein 5) (TR-interacting protein 5) (TRIP-5),Miscellaneous,Miscellaneous;motor protein,Novel Target
10,"768974, parathyroid hormone analog",768974,antiosteoporotic agent,Small molecule,not approved,Q03431,PTH1R_HUMAN,PTH1R,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
11,"7a-methyl-19-nortestosterone,MENT","7a-methyl-19-nortestosterone,MENT","hormone replacement,male contraceptive",Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
12,A-007,A-007 ,antineoplastic agent,Small molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
12,A-007,A-007 ,antineoplastic agent,Small molecule,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
13,A-623,blisibimod,antiinflammatory agent,fusion protein,not approved,Q9Y275,TN13B_HUMAN,TNFSF13B,Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved int,Miscellaneous,Ligand;Cytokine,Established target
14,AA-2010,oxybutynin,for treatment of incontinence,Small molecule,not approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
14,AA-2010,oxybutynin,for treatment of incontinence,Small molecule,not approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
14,AA-2010,oxybutynin,for treatment of incontinence,Small molecule,not approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
15,"AA2600, androgen transmucosal film",Testosterone,hormone replacement,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
16,"AAV-BNP gene therapy,Biostrophin",dystrophin,for treatment of Duchenne muscular dystrophy,adenoviral vector,not approved,P11532,DMD_HUMAN,DMD,Dystrophin,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Novel Target
17,AB-1001,not disclosed,antiemetic,unknown,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
17,AB-1001,not disclosed,antiemetic,unknown,approved,O95264,5HT3B_HUMAN,HTR3B,5-hydroxytryptamine receptor 3B (5-HT3-B) (5-HT3B) (Serotonin receptor 3B),Receptors,TC:1.A.9,Established target
18,"abagovomab, MEN-2234, ACA 125",abagovomab,antineoplastic agent,monoclonal antibody,not approved,Q8WXI7,MUC16_HUMAN,MUC16,Mucin-16 (MUC-16) (Ovarian cancer-related tumor marker CA125) (CA-125) (Ovarian carcinoma antigen CA125),Miscellaneous,StructuralAndAdhesion;Mucin_16,Novel Target
19,"abarelix, Plenaxis",abarelix,antineoplastic agent,peptide,"approved, withdrawn",P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
20,ABC294640,ABC294640 ,antineoplastic agent,Small molecule,not approved,Q9NYA1,SPHK1_HUMAN,SPHK1,Sphingosine kinase 1 (SK 1) (SPK 1) (EC 2.7.1.91),Enzymes,EC:2.7.1.91,Novel Target
20,ABC294640,ABC294640 ,antineoplastic agent,Small molecule,not approved,Q9NRA0,SPHK2_HUMAN,SPHK2,Sphingosine kinase 2 (SK 2) (SPK 2) (EC 2.7.1.91),Enzymes,EC:2.7.1.91,Novel Target
21,"abciximab, c7E3,ReoPro",abciximab,anticoagulant,monoclonal antibody,approved,P08514,ITA2B_HUMAN,ITGA2B,"Integrin alpha-IIb (GPalpha IIb) (GPIIb) (Platelet membrane glycoprotein IIb) (CD antigen CD41) [Cleaved into: Integrin alpha-IIb heavy chain; Integrin alpha-IIb light chain, form 1; Integrin alpha-IIb light chain, form 2]",Receptors,Receptors;Integrin,Established target
21,"abciximab, c7E3,ReoPro",abciximab,anticoagulant,monoclonal antibody,approved,P05106,ITB3_HUMAN,ITGB3,Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
22,Abilify,Aripiprazole,antipsychotic agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
22,Abilify,Aripiprazole,antipsychotic agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
22,Abilify,Aripiprazole,antipsychotic agent,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
23,Abraxane,paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
23,Abraxane,paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
24,ABT-263,"navitoclax, ABT-263",antineoplastic agent,Small molecule,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
24,ABT-263,"navitoclax, ABT-263",antineoplastic agent,Small molecule,not approved,Q07817,B2CL1_HUMAN,BCL2L1,Bcl-2-like protein 1,Miscellaneous,regulator of apoptosis,Novel Target
24,ABT-263,"navitoclax, ABT-263",antineoplastic agent,Small molecule,not approved,Q92843,B2CL2_HUMAN,BCL2L2,Bcl-2-like protein 2,Miscellaneous,regulator of apoptosis,Novel Target
25,"ABT-335, choline fenofibrate,TriLipix",fenofibrate,antidyslipidaemic agent,Small Molecule,approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
26,ABT-510,ABT-510,antineoplastic agent,peptide,not approved,P16671,CD36_HUMAN,CD36,Platelet glycoprotein 4,Miscellaneous,Miscellaneous;glycoprotein,Novel Target
26,ABT-510,ABT-510,antineoplastic agent,peptide,not approved,Q08722,CD47_HUMAN,CD47,Leukocyte surface antigen CD47 (Antigenic surface determinant protein OA3) (Integrin-associated protein) (IAP) (Protein MER6) (CD antigen CD47),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Novel Target
27,"ABT-869, Linifanib",Linifanib,antineoplastic agent,Small molecule,not approved,P07333,CSF1R_HUMAN,CSF1R,Macrophage colony-stimulating factor 1 receptor OS=Homo sapiens GN=CSF1R PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
27,"ABT-869, Linifanib",Linifanib,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
27,"ABT-869, Linifanib",Linifanib,antineoplastic agent,Small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
27,"ABT-869, Linifanib",Linifanib,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
27,"ABT-869, Linifanib",Linifanib,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
27,"ABT-869, Linifanib",Linifanib,antineoplastic agent,Small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
27,"ABT-869, Linifanib",Linifanib,antineoplastic agent,Small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
27,"ABT-869, Linifanib",Linifanib,antineoplastic agent,Small molecule,not approved,P07949,RET_HUMAN,RET,Proto-oncogene tyrosine-protein kinase receptor ret OS=Homo sapiens GN=RET PE=1 SV=3,Receptors,EC:2.7.10.1,Established target
27,"ABT-869, Linifanib",Linifanib,antineoplastic agent,Small molecule,not approved,Q02763,TIE2_HUMAN,TIE2,Angiopoietin-1 receptor (EC 2.7.10.1) (Tunica interna endothelial cell kinase) (Tyrosine-protein kinase receptor TEK) (Tyrosine-protein kinase receptor TIE-2) (hTIE2) (p140 TEK) (CD antigen CD202b),Receptors,EC:2.7.10.1,Established target
28,ABX-0401,ABX-0401,antineoplastic agent,antibody fragment,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
29,"AC-100,Dentonin","AC-100,Dentonin",dental ossificant,peptide,not approved,P34995,PE2R1_HUMAN,PTGER1,Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens GN=PTGER1 PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
29,"AC-100,Dentonin","AC-100,Dentonin",periodontal ossificant,peptide,not approved,P43116,PE2R2_HUMAN,PTGER2,Prostaglandin E2 receptor EP2 subtype OS=Homo sapiens GN=PTGER2 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
29,"AC-100,Dentonin","AC-100,Dentonin",periodontal ossificant,peptide,not approved,P43115,PE2R3_HUMAN,PTGER3,Prostaglandin E2 receptor EP3 subtype OS=Homo sapiens GN=PTGER3 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
29,"AC-100,Dentonin","AC-100,Dentonin",periodontal ossificant,peptide,not approved,P35408,PE2R4_HUMAN,PTGER4,Prostaglandin E2 receptor EP4 subtype OS=Homo sapiens GN=PTGER4 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
30,AC-201,AC-201,antidiabetic,Small molecule,not approved,P01584,IL1B_HUMAN,IL1B,Interleukin-1 beta (IL-1 beta) (Catabolin),Miscellaneous,Ligand;Cytokine,Established target
30,AC-201,AC-201,antidiabetic,Small molecule,not approved,P18510,IL1RA_HUMAN,IL1RN,Interleukin-1 receptor antagonist protein (IL-1RN) (IL-1ra) (IRAP) (ICIL-1RA) (IL1 inhibitor) (Anakinra),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
31,AC-220,quizartinib,antineoplastic agent,Small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
32,AC430,AC430,"antiinflammatory agent,antineoplastic agent",Small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
33,AC480,AC480,antineoplastic agent,Small molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
33,AC480,AC480,antineoplastic agent,Small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
33,AC480,AC480,antineoplastic agent,Small molecule,not approved,P21860,ERBB3_HUMAN,ERBB3,Receptor tyrosine-protein kinase erbB-3 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-3) (Tyrosine kinase-type cell surface receptor HER3),Receptors,EC:2.7.10.1,Novel Target
33,AC480,AC480,antineoplastic agent,Small molecule,not approved,Q15303,ERBB4_HUMAN,ERBB4,Receptor tyrosine-protein kinase erbB-4 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-4) (Tyrosine kinase-type cell surface receptor HER4) (p180erbB4) [Cleaved into: ERBB4 intracellular domain (4ICD) (E4ICD) (s80HER4)],Receptors,EC:2.7.10.1,Novel Target
34,"acamprosate,Campral",acamprosate,for treatment of alcohol-dependance,Small Molecule,approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
34,"acamprosate,Campral",acamprosate,antineoplastic agent,Small Molecule,approved,P41594,GRM5_HUMAN,GRM5,Metabotropic glutamate receptor 5 (mGluR5),Receptors,GPCR;Glutamate,Established target
35,Acapodene,toremifene,"antineoplastic agent,SERM",Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
36,"acarbose,Glucobay",acarbose,antidiabetic,Small Molecule,approved,P04746,AMYP_HUMAN,AMY2A,Pancreatic alpha-amylase OS=Homo sapiens GN=AMY2A PE=1 SV=2,Enzymes,EC:3.2.1.1,Established target
36,"acarbose,Glucobay",acarbose,antidiabetic,Small Molecule,approved,P10253,LYAG_HUMAN,GAA,Lysosomal alpha-glucosidase OS=Homo sapiens GN=GAA PE=1 SV=2,Enzymes,EC:3.2.1,Established target
36,"acarbose,Glucobay",acarbose,antidiabetic,Small Molecule,approved,O43451,MGA_HUMAN,MGAM,"Maltase-glucoamylase, intestinal OS=Homo sapiens GN=MGAM PE=1 SV=5",Enzymes,EC:3.2.1,Established target
36,"acarbose,Glucobay",acarbose,antidiabetic,Small Molecule,approved,P14410,SUIS_HUMAN,SI,"Sucrase-isomaltase, intestinal [Cleaved into: Sucrase (EC 3.2.1.48); Isomaltase (EC 3.2.1.10)]",Enzymes,EC:3.2.1,Established target
37,"ACC-001,  Alzheimer's vaccine",ACC-001,for treatment of Alzheimer's disease,vaccine,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
38,ACCLAIM,organic nitrate + l-arginine,vasodilator,small molecule,not approved,P29474,NOS3_HUMAN,NOS3,"Nitric oxide synthase, endothelial OS=Homo sapiens GN=NOS3 PE=1 SV=3",Enzymes,EC:1.14.13.39,Established target
39,Accretropin,Acccretropin,for treatment of turnerïs syndrome,Small molecule,approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
40,ACE-011,ACE-011,"erythropoietic agent,antiosteoporotic agent",fusion protein,not approved,P27037,AVR2A_HUMAN,ACVR2A,Activin receptor type-2A (EC 2.7.11.30) (Activin receptor type IIA) (ACTR-IIA) (ACTRIIA),Receptors,EC:2.7.11.30,Novel Target
41,ACE-031,ACE-031,muscle mass and strength stimulating agent,fusion protein,not approved,Q13705,AVR2B_HUMAN,ACVR2B,Activin receptor type-2B (EC 2.7.11.30) (Activin receptor type IIB) (ACTR-IIB),Receptors,EC:2.7.11.30,Novel Target
42,ACE-041,dalantercept,"antineoplastic agent,antiangiogenic agent",fusion protein,not approved,P37023,ACVL1_HUMAN,ACVRL1,Serine/threonine-protein kinase receptor R3 (SKR3) (EC 2.7.11.30) (Activin receptor-like kinase 1) (ALK-1) (TGF-B superfamily receptor type I) (TSR-I),Receptors,EC:2.7.11.30,Novel Target
43,Aciphex,rabeprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
44,Aclidinium,aclidinium,bronchodilator,Small molecule,not approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
44,Aclidinium,aclidinium,bronchodilator,Small molecule,not approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
44,Aclidinium,aclidinium,bronchodilator,Small molecule,not approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
44,Aclidinium,aclidinium,bronchodilator,Small molecule,not approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
44,Aclidinium,aclidinium,bronchodilator,Small molecule,not approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
45,"acotiamide hydrochloride, YM-443, Z-338",acotiamide,for treatment of functional dyspepsia,Small molecule,not approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
46,ACP-001,ACP-001,hormone replacement,Small molecule,not approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
47,ACP-104,ACP-104,antipsychotic agent,Small molecule,not approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
47,ACP-104,ACP-104,antipsychotic agent,Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
47,ACP-104,ACP-104,antipsychotic agent,Small molecule,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
47,ACP-104,ACP-104,antipsychotic agent,Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
48,ACTB1003,ACTB1003,antineoplastic agent,Small molecule,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
48,ACTB1003,ACTB1003,antineoplastic agent,Small molecule,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
48,ACTB1003,ACTB1003,antineoplastic agent,Small molecule,not approved,P22607,FGFR3_HUMAN,FGFR3,Fibroblast growth factor receptor 3 OS=Homo sapiens GN=FGFR3 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
48,ACTB1003,ACTB1003,antineoplastic agent,Small molecule,not approved,P22455,FGFR4_HUMAN,FGFR4,Fibroblast growth factor receptor 4 OS=Homo sapiens GN=FGFR4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
48,ACTB1003,ACTB1003,antineoplastic agent,Small molecule,not approved,P23443 ,KS6B1_HUMAN,RPS6KB1,Ribosomal protein S6 kinase beta-1,Enzymes,EC:2.7.11.1,Novel Target
49,ACY-1215,ACY-1215,antineoplastic agent,Small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
50,AD 337,AD 337,"analgesic,for treatment of fibromyalgia",Small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
50,AD 337,AD 337,"analgesic,for treatment of fibromyalgia",Small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
51,AD 923,fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
51,AD 923,fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
52,AD01,AD01,"for treatment of Alzheimer's disease,vaccine",vaccine,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
53,"ADC4022, low-dose inhaled theophylline",theophylline,bronchodilator,Small Molecule,approved,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
53,"ADC4022, low-dose inhaled theophylline",theophylline,bronchodilator,Small Molecule,approved,P29274,AA2AR_HUMAN,ADORA2A,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
53,"ADC4022, low-dose inhaled theophylline",theophylline,bronchodilator,Small Molecule,approved,P29275,AA2BR_HUMAN,ADORA2B,Adenosine receptor A2b OS=Homo sapiens GN=ADORA2B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
53,"ADC4022, low-dose inhaled theophylline",theophylline,bronchodilator,Small Molecule,approved,Q14432,PDE3A_HUMAN,PDE3A,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A OS=Homo sapiens GN=PDE3A PE=1 SV=3",Enzymes,EC:3.1.4,Established target
53,"ADC4022, low-dose inhaled theophylline",theophylline,bronchodilator,Small Molecule,approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
53,"ADC4022, low-dose inhaled theophylline",theophylline,bronchodilator,Small Molecule,approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
53,"ADC4022, low-dose inhaled theophylline",theophylline,bronchodilator,Small Molecule,approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
54,"adecatumumab,  MT201",adecatumumab,antineoplastic agent,monoclonal antibody,not approved,P16422,EPCAM_HUMAN,EPCAM,Epithelial cell adhesion molecule (Ep-CAM) (Adenocarcinoma-associated antigen) (Cell surface glycoprotein Trop-1) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Epithelial glycoprotein 314) (EGP314) (hEGP314) (KS 1/4 antigen) (KSA) (Ma,Miscellaneous,StructuralAndAdhesion;,Novel Target
55,ADL5747,ADL5747,analgesic,Small molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
56,"ADL5859, PF-04856880",ADL5859,analgesic,Small molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
57,ADL5945,ADL5945,motilitant,Small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
58,ADL7445,ADL7445,motilitant,Small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
59,Adlea,capsaicin,analgesic,Small molecule,not approved (orphan status),Q8NER1,TRPV1_HUMAN,TRPV1,Transient receptor potential cation channel subfamily V member 1 (TrpV1) (Capsaicin receptor) (Osm-9-like TRP channel 1) (OTRPC1) (Vanilloid receptor 1),Transporters,TC:1.A.4,Established target
60,Ad-RTS-IL-12,Ad-RTS-IL-12,antineoplastic agent,adenoviral vector,not approved,P29459,IL12A_HUMAN,IL12A,Interleukin-12 subunit alpha (IL-12A) (IL-12 subunit p35) (Cytotoxic lymphocyte maturation factor 35 kDa subunit) (CLMF p35) (NK cell stimulatory factor chain 1) (NKSF1),Miscellaneous,Ligand;Cytokine,Established target
60,Ad-RTS-IL-12,Ad-RTS-IL-12,antineoplastic agent,adenoviral vector,not approved,P29460,IL12B_HUMAN,IL12B,Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2),Receptors,Receptor; Type 1 cytokine receptor,Established target
61,Advair/Seretide/Adoair,fluticasone propionate,bronchodilator,Small molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
61,Advair/Seretide/Adoair,salmeterol,bronchodilator,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
62,ADX10059,ADX10059,"antimigraine agent,for treatment of gastroesophageal reflux disease",Small molecule,not approved,P41594,GRM5_HUMAN,GRM5,Metabotropic glutamate receptor 5 (mGluR5),Receptors,GPCR;Glutamate,Established target
63,ADX415,ADX415,antihypertensive agent,Small molecule,not approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
64,ADX-71149,ADX-71149,"antipsychotic agent,antidepressant,anxiolytic",Small molecule,not approved,Q14416,GRM2_HUMAN,GRM2,Metabotropic glutamate receptor 2 (mGluR5),Receptors,GPCR;Glutamate,Novel Target
65,AE37 vaccine,AE37,antineoplastic agent,vaccine,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
66,"AE-941,Neovastat",AE-941,antineoplastic agent,shark cartilage extract,not approved (orphan status),P08253,MMP2_HUMAN,MMP2,72 kDa type IV collagenase OS=Homo sapiens GN=MMP2 PE=1 SV=2,Enzymes,EC:3.4.24.24,Novel Target
66,"AE-941,Neovastat",AE-941,antineoplastic agent,shark cartilage extract,not approved (orphan status),P14780,MMP9_HUMAN,MMP9,Matrix metalloproteinase-9 OS=Homo sapiens GN=MMP9 PE=1 SV=2,Enzymes,EC:3.4.24.35,Novel Target
66,"AE-941,Neovastat",AE-941,antineoplastic agent,shark cartilage extract,not approved (orphan status),P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
67,"AEG35156, GEM 640","AEG35156, GEM 640",antineoplastic agent,antisense oligo,not approved,P98170,XIAP_HUMAN,XIAP,Baculoviral IAP repeat-containing protein 4 (EC 6.3.2.-) (E3 ubiquitin-protein ligase XIAP) (IAP-like protein) (ILP) (hILP) (Inhibitor of apoptosis protein 3) (IAP-3) (hIAP-3) (hIAP3) (X-linked inhibitor of apoptosis protein) (X-linked IAP),Miscellaneous,Inhibitor of apoptosis,Novel Target
68,"AER001,Aerovant","AER001,Aerovant",antiasthamatic agent,recombinant protein,not approved,P24394,IL4RA_HUMAN,IL4RA,Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL,Receptors,Receptor; Type 1 cytokine receptor,Novel Target
68,"AER001,Aerovant","AER001,Aerovant",antiasthamatic agent,recombinant protein,not approved,P78552 ,I13R1_HUMAN,IL13RA1,Interleukin-13 receptor subunit alpha-1,,Receptor; Type 1 cytokine receptor,Novel Target
68,"AER001,Aerovant","AER001,Aerovant",antiasthamatic agent,recombinant protein,not approved,Q14627 ,I13R2_HUMAN,IL13RA2,Interleukin-13 receptor subunit alpha-2,,Receptor; Type 1 cytokine receptor,Novel Target
69,AeroLEF,fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
69,AeroLEF,fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
70,AES-103,AES-103,for treatment of sickle-cell disease,Small molecule,not approved,P68871,HBB_HUMAN,HBB,Hemoglobin subunit beta,Miscellaneous,Miscellaneous;hemoglobin,Novel Target
71,"AEZS-108, AN-152",doxorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
72,"AEZS-112, ZEN-012","AEZS-112, ZEN-012",antineoplastic agent,Small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
72,"AEZS-112, ZEN-012","AEZS-112, ZEN-012",antineoplastic agent,Small molecule,not approved,P07437,TBB5_HUMAN,TUBB,Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
72,"AEZS-112, ZEN-012","AEZS-112, ZEN-012",antineoplastic agent,Small molecule,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
73,Afamelanotide,Afamelanotide,dermatological agent,Small molecule,not approved,Q01726,MSHR_HUMAN,MC1R,Melanocyte-stimulating hormone receptor (MSH-R) (Melanocortin receptor 1) (MC1-R),Receptors,GPCR;Rhodopsin,Novel Target
74,"afatinib, BIBW 2992,Tovok",afatinib,antineoplastic agent,Small molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
74,"afatinib, BIBW 2992,Tovok",afatinib,antineoplastic agent,Small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
75,AFM13,AFM13,antineoplastic agent,monoclonal antibody,not approved,P28908,TNR8_HUMAN,TNFRSF8,Tumor necrosis factor receptor superfamily member 8 (CD30L receptor) (Ki-1 antigen) (Lymphocyte activation antigen CD30) (CD antigen CD30),Receptors,Receptors;TNFNGF,Novel Target
76,Afresa,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
77,"afutuzumab, R-7159, GA-101",afutuzumab,antineoplastic agent,monoclonal antibody,not approved,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Miscellaneous,MS4A family,Established target
78,AG-200-15,ethinyl estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
78,AG-200-15,levonorgestrel,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
78,AG-200-15,levonorgestrel,contraceptive,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
78,AG-200-15,levonorgestrel,contraceptive,Small Molecule,approved,P18405,S5A1_HUMAN,SRD5A1,3-oxo-5-alpha-steroid 4-dehydrogenase 1 OS=Homo sapiens GN=SRD5A1 PE=1 SV=1,Enzymes,EC:1.3.99,Established target
79,"agalsidase alfa,Replagal",agalsidase alfa,enzyme replacement therapy for treatment of Fabry disease,protein,not approved,globotriaosylceramide (Gb3),A4GAT_HUMAN,globotriaosylceramide (Gb3),"Lactosylceramide 4-alpha-galactosyltransferase (EC 2.4.1.228) (Alpha-1,4-N-acetylglucosaminyltransferase) (Alpha-1,4-galactosyltransferase) (Alpha4Gal-T1) (CD77 synthase) (Globotriaosylceramide synthase) (Gb3 synthase) (P1/Pk synthase) (UDP-galactose:beta",Enzymes,EC:2.4.1.228,Novel Target
80,"agalsidase beta,Fabrazyme",agalsidase alfa,enzyme replacement therapy for treatment of Fabry disease,protein,not approved,globotriaosylceramide (Gb3),A4GAT_HUMAN,globotriaosylceramide (Gb3),"Lactosylceramide 4-alpha-galactosyltransferase (EC 2.4.1.228) (Alpha-1,4-N-acetylglucosaminyltransferase) (Alpha-1,4-galactosyltransferase) (Alpha4Gal-T1) (CD77 synthase) (Globotriaosylceramide synthase) (Gb3 synthase) (P1/Pk synthase) (UDP-galactose:beta",Enzymes,EC:2.4.1.228,Novel Target
81,"AGI-004,  mecamylamine transdermal patch, CR",mecamylamine,motilitant,Small Molecule,approved,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
82,AGI-1067,"AGI-1067, succinobucol",antiatherosclerosis agent,Small molecule,not approved,P19320,VCAM1_HUMAN,VCAM1,Vascular cell adhesion protein 1 (V-CAM 1) (VCAM-1) (INCAM-100) (CD antigen CD106),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Novel Target
83,AGIX-4207,AGIX-4207,"antiinflammatory agent,DMARD",Small molecule,not approved,unknown,unknown,unknown,unknown,unknown,unknown,unknown
84,"AGN-211745, Sirna-027",AGN-211745,for treatment of age-related macular degeneration,siRNA,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
85,AGN-214868,AGN-214868,"analgesic,neuralgia",Small molecule,not approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
85,AGN-214868,AGN-214868,"analgesic,neuralgia",Small molecule,not approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
85,AGN-214868,AGN-214868,"analgesic,neuralgia",Small molecule,not approved,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
85,AGN-214868,AGN-214868,"analgesic,neuralgia",Small molecule,not approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
85,AGN-214868,AGN-214868,"analgesic,neuralgia",Small molecule,not approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
85,AGN-214868,AGN-214868,"analgesic,neuralgia",Small molecule,not approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
86,"agomelatine , AGO178C, S-20098,Valdoxan, Thymanax",agomelatine,antidepressant,Small molecule,not approved,P49286,MTR1B_HUMAN,MTNR1B,Melatonin receptor type 1B OS=Homo sapiens GN=MTNR1B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
87,"agomelatine, AGO178C, S-20098,Valdoxan, Thymanax",agomelatine,antidepressant,Small molecule,not approved,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
87,"agomelatine, AGO178C, S-20098,Valdoxan, Thymanax",agomelatine,antidepressant,Small molecule,not approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
87,"agomelatine, AGO178C, S-20098,Valdoxan, Thymanax",agomelatine,antidepressant,Small molecule,not approved,P48039,MTR1A_HUMAN,MTNR1A,Melatonin receptor type 1A OS=Homo sapiens GN=MTNR1A PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
88,AGS-1C4D4,AGS-1C4D4,antineoplastic agent,monoclonal antibody,not approved,O43653,PSCA_HUMAN,PSCA,Prostate stem cell antigen,Miscellaneous,Miscellaneous; prostate cell antigen,Novel Target
89,AGS-PSCA,AGS-PSCA,antineoplastic agent,monoclonal antibody,not approved,O43653,PSCA_HUMAN,PSCA,Prostate stem cell antigen,Miscellaneous,Miscellaneous; prostate cell antigen,Novel Target
90,"AHCQ, aersolized hydroxychloroquine",hydroxychloroquine,antirheumatic agent,Small Molecule,approved,Q9NYK1,TLR7_HUMAN,TLR7,Toll-like receptor 7 OS=Homo sapiens GN=TLR7 PE=1 SV=1,Receptors,Receptors;TOLL,Established target
90,"AHCQ, aersolized hydroxychloroquine",hydroxychloroquine,antirheumatic agent,Small Molecule,approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
91,AI-850,paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
91,AI-850,paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
92,AIKO-150,AIKO-150,opioid antagonist,Small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
93,Aimpila,Aimpila,antineoplastic agent,protein,not approved,P08107 ,HSP71_HUMAN,HSPA1A,Heat shock 70 kDa protein 1A/1B,Miscellaneous,Heat shock protein 70 family,Novel Target
94,AIR645,AIR645,antiasthmatic agent,Small molecule,not approved,P24394,IL4RA_HUMAN,IL4RA,Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL,Receptors,Receptor; Type 1 cytokine receptor,Novel Target
95,AKB-6548,AKB-6548,for treatment of anaemia,Small Molecule,not approved,Q9GZT9,EGLN1_HUMAN,EGLN1,Egl nine homolog 1 (EC 1.14.11.-) (Hypoxia-inducible factor prolyl hydroxylase 2) (HIF-PH2) (HIF-prolyl hydroxylase 2) (HPH-2) (Prolyl hydroxylase domain-containing protein 2) (PHD2) (SM-20),Enzymes,EC:1.14.11.29,Novel Target
95,AKB-6548,AKB-6548,for treatment of anaemia,Small Molecule,not approved,Q96KS0,EGLN2_HUMAN,EGLN2,Egl nine homolog 2 (EC 1.14.11.-) (Estrogen-induced tag 6) (HPH-3) (Hypoxia-inducible factor prolyl hydroxylase 1) (HIF-PH1) (HIF-prolyl hydroxylase 1) (HPH-1) (Prolyl hydroxylase domain-containing protein 1) (PHD1),Enzymes,EC:1.14.11.29,Novel Target
96,"AKL-0707, GHRH analog",AKL-0707,hormone replacement,Small molecule,not approved,Q02643,GHRHR_HUMAN,GHRH,Growth hormone-releasing hormone receptor OS=Homo sapiens GN=GHRHR PE=1 SV=2,Receptors,GPCR;Secretin,Established target
98,"alacizumab pegol, CDP-791",alacizumab pego,antineoplastic agent,peptide,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
99,ALB109564(a),ALB109564(a),antineoplastic agent,Small molecule,not approved,P07437,TBB5_HUMAN,TUBB,Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
100,ALB-127158(a),ALB-127158(a),antiobesity agent,Small molecule,not approved,Q99705,MCHR1_HUMAN,MCHR1,Melanin-concentrating hormone receptor 1 (MCH receptor 1) (MCH-R1) (MCHR-1) (G-protein coupled receptor 24) (MCH-1R) (MCH1R) (MCHR) (SLC-1) (Somatostatin receptor-like protein),Receptors,GPCR;Rhodopsin,Novel Target
101,"albiglutide, GSK716155,Syncria",albiglutide,antidiabetic,fusion protein,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
102,"albuterol,Ventolin",salbutamol,bronchodilator,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
103,Albutropin,Albutropin,hormone replacement,fusion protein,not approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
104,"ALD518, BMS-945429",ALD518 ,antineoplastic agent,monoclonal antibody,not approved,P05231,IL6_HUMAN,IL6,Interleukin-6 (IL-6) (B-cell stimulatory factor 2) (BSF-2) (CTL differentiation factor) (CDF) (Hybridoma growth factor) (Interferon beta-2) (IFN-beta-2),Miscellaneous,Ligand;Cytokine,Novel Target
105,"aleglitazar, R1439",aleglitazar,cardiovascular agent,Small molecule,not approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
105,"aleglitazar, R1439",aleglitazar,cardiovascular agent,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
106,alfimeprase,alfimeprase,thrombolytic agent,recombinant protein,not approved,P02671,FIBA_HUMAN,FGA,Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Established target
106,alfimeprase,alfimeprase,thrombolytic agent,recombinant protein,not approved,P02675,FIBB_HUMAN,FGB,Fibrinogen beta chain,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Novel Target
106,alfimeprase,alfimeprase,thrombolytic agent,recombinant protein,not approved,P02679,FIBG_HUMAN,FGG,Fibrinogen gamma chain,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Novel Target
107,"alfuzosin,UroXatral",alfuzosin,for treatment of benign prostatic hyperplasia,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
107,"alfuzosin,UroXatral",alfuzosin,for treatment of benign prostatic hyperplasia,Small Molecule,approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
107,"alfuzosin,UroXatral",alfuzosin,for treatment of benign prostatic hyperplasia,Small Molecule,approved,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
108,"ALGRX 3268,Zingo",lidocaine,anesthetic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
108,"ALGRX 3268,Zingo",lidocaine,anesthetic,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
108,"ALGRX 3268,Zingo",lidocaine,anesthetic,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
109,Alimta,pemetrexed,antineoplastic agent,Small molecule,not approved,P00374,DYR_HUMAN,DHFR,Dihydrofolate reductase OS=Homo sapiens GN=DHFR PE=1 SV=2,Enzymes,EC:1.5.1.3,Established target
109,Alimta,pemetrexed,antineoplastic agent,Small molecule,not approved,P22102,PUR2_HUMAN,GART,Trifunctional purine biosynthetic protein adenosine-3 OS=Homo sapiens GN=GART PE=1 SV=1,Enzymes,EC:6.3.4.13; 6.3.3.1; 2.1.2.2,Established target
109,Alimta,pemetrexed,antineoplastic agent,Small molecule,not approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
110,Aliskiren,aliskiren,antihypertensive agent,Small Molecule,approved,P00797,RENI_HUMAN,REN,Renin OS=Homo sapiens GN=REN PE=1 SV=1,Enzymes,EC:3.4.23.15,Established target
111,"aliskiren + amlodipine,Tekamlo",aliskiren,antihypertensive agent,Small Molecule,approved,P00797,RENI_HUMAN,REN,Renin OS=Homo sapiens GN=REN PE=1 SV=1,Enzymes,EC:3.4.23.15,Established target
111,"aliskiren + amlodipine,Tekamlo",amlodipine,antihypertensive agent,Small Molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
111,"aliskiren + amlodipine,Tekamlo",amlodipine,antihypertensive agent,Small Molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
111,"aliskiren + amlodipine,Tekamlo",amlodipine,antihypertensive agent,Small Molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
111,"aliskiren + amlodipine,Tekamlo",amlodipine,antihypertensive agent,Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
111,"aliskiren + amlodipine,Tekamlo",amlodipine,antihypertensive agent,Small Molecule,approved,Q08289,CACB2_HUMAN,CACNB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
112,"alitretinoin, ALRT-1057,Panretin",Alitretionine,antineoplastic agent,Small Molecule,approved,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
112,"alitretinoin, ALRT-1057,Panretin",Alitretionine,antineoplastic agent,Small Molecule,approved,P10826,RARB_HUMAN,RARB,Retinoic acid receptor beta OS=Homo sapiens GN=RARB PE=1 SV=2,Receptors,Nuclear receptor,Established target
112,"alitretinoin, ALRT-1057,Panretin",Alitretionine,antineoplastic agent,Small Molecule,approved,P13631,RARG_HUMAN,RARG,Retinoic acid receptor gamma OS=Homo sapiens GN=RARG PE=1 SV=1,Receptors,Nuclear receptor,Established target
112,"alitretinoin, ALRT-1057,Panretin",Alitretionine,antineoplastic agent,Small Molecule,approved,P19793,RXRA_HUMAN,RXRA,Retinoic acid receptor RXR-alpha OS=Homo sapiens GN=RXRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
112,"alitretinoin, ALRT-1057,Panretin",Alitretionine,antineoplastic agent,Small Molecule,approved,P28702,RXRB_HUMAN,RXRB,Retinoic acid receptor RXR-beta OS=Homo sapiens GN=RXRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
112,"alitretinoin, ALRT-1057,Panretin",Alitretionine,antineoplastic agent,Small Molecule,approved,P48443,RXRG_HUMAN,RXRG,Retinoic acid receptor RXR-gamma OS=Homo sapiens GN=RXRG PE=1 SV=1,Receptors,Nuclear receptor,Established target
113,"alitretinoin, BAL4079,Toctino",Alitretionine,antineoplastic agent,Small Molecule,approved,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
113,"alitretinoin, BAL4079,Toctino",Alitretionine,antineoplastic agent,Small Molecule,approved,P10826,RARB_HUMAN,RARB,Retinoic acid receptor beta OS=Homo sapiens GN=RARB PE=1 SV=2,Receptors,Nuclear receptor,Established target
113,"alitretinoin, BAL4079,Toctino",Alitretionine,antineoplastic agent,Small Molecule,approved,P13631,RARG_HUMAN,RARG,Retinoic acid receptor gamma OS=Homo sapiens GN=RARG PE=1 SV=1,Receptors,Nuclear receptor,Established target
113,"alitretinoin, BAL4079,Toctino",Alitretionine,antineoplastic agent,Small Molecule,approved,P19793,RXRA_HUMAN,RXRA,Retinoic acid receptor RXR-alpha OS=Homo sapiens GN=RXRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
113,"alitretinoin, BAL4079,Toctino",Alitretionine,antineoplastic agent,Small Molecule,approved,P28702,RXRB_HUMAN,RXRB,Retinoic acid receptor RXR-beta OS=Homo sapiens GN=RXRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
113,"alitretinoin, BAL4079,Toctino",Alitretionine,antineoplastic agent,Small Molecule,approved,P48443,RXRG_HUMAN,RXRG,Retinoic acid receptor RXR-gamma OS=Homo sapiens GN=RXRG PE=1 SV=1,Receptors,Nuclear receptor,Established target
114,Alkermes',insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
115,ALKS 29,ALKS 33,"for treatment of alcohol dependance,antidepressant",Small molecule,not approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
115,ALKS 29,ALKS 33,"for treatment of alcohol dependance,antidepressant",Small molecule,not approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
115,ALKS 29,ALKS 33,"for treatment of alcohol dependance,antidepressant",Small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
115,ALKS 29,baclofen,for treatment of alcohol dependance,Small Molecule,approved,Q9UBS5,GABR1_HUMAN,GABBR1,Gamma-aminobutyric acid type B receptor subunit 1 OS=Homo sapiens GN=GABBR1 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
115,ALKS 29,baclofen,for treatment of alcohol dependance,Small Molecule,approved,O75899,GABR2_HUMAN,GABBR2,Gamma-aminobutyric acid type B receptor subunit 2 OS=Homo sapiens GN=GABBR2 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
116,ALKS 33,ALKS 33,"for treatment of alcohol dependance,antidepressant",Small molecule,not approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
116,ALKS 33,ALKS 33,"for treatment of alcohol dependance,antidepressant",Small molecule,not approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
116,ALKS 33,ALKS 33,"for treatment of alcohol dependance,antidepressant",Small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
117,ALKS 37,ALKS 37,motilitant,Small molecule,not approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
117,ALKS 37,ALKS 37,motilitant,Small molecule,not approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
117,ALKS 37,ALKS 37,motilitant,Small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
118,ALKS 5461,ALKS 33,"for treatment of alcohol dependance,antidepressant",Small molecule,not approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
118,ALKS 5461,ALKS 33,"for treatment of alcohol dependance,antidepressant",Small molecule,not approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
118,ALKS 5461,ALKS 33,"for treatment of alcohol dependance,antidepressant",Small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
118,ALKS 5461,buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
118,ALKS 5461,buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
119,"almorexant, ACT-078573",almorexant,sleep disorder treatment ,Small molecule,not approved,O43613,OX1R_HUMAN,HCRTR1,Orexin receptor type 1 (Ox-1-R) (Ox1-R) (Ox1R) (Hypocretin receptor type 1),Receptors,GPCR;Rhodopsin,Novel Target
119,"almorexant, ACT-078573",almorexant,sleep disorder treatment ,Small molecule,not approved,O43614,OX2R_HUMAN,HCRTR2,Orexin receptor type 2 (Ox-2-R) (Ox2-R) (Ox2R) (Hypocretin receptor type 2),Receptors,GPCR;Rhodopsin,Novel Target
120,"almotriptan,Axert, Almogran, Amignul",almotriptan,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
120,"almotriptan,Axert, Almogran, Amignul",almotriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
121,ALN-VSP,ALN-VSP,antineoplastic agent,siRNA,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
121,ALN-VSP,ALN-VSP,antineoplastic agent,siRNA,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
121,ALN-VSP,ALN-VSP,antineoplastic agent,siRNA,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
121,ALN-VSP,ALN-VSP,antineoplastic agent,siRNA,not approved,P52732,KIF11_HUMAN,KIF11,Kinesin-like protein KIF11 (Kinesin-like protein 1) (Kinesin-like spindle protein HKSP) (Kinesin-related motor protein Eg5) (Thyroid receptor-interacting protein 5) (TR-interacting protein 5) (TRIP-5),Miscellaneous,Miscellaneous;motor protein,Novel Target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",naltrexone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",naltrexone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",naltrexone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",naltrexone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",naltrexone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",naltrexone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
122,"ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT",naltrexone,analgesic,Small Molecule,approved,Q99720 ,OPRS1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
123,"alogliptin, SYR-322,Nesina",alogliptin,antidiabetic,Small molecule,not approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
124,"alosetron,Lotronex",alosetron,for treatment of irritable bowel syndrome,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
125,"alpha-1 proteinase inhibitor,Aralast",alpha-1 proteinase inhibitor,for treatment of emphysema,protein,approved,P08246,ELNE_HUMAN,ELANE,Leukocyte elastase OS=Homo sapiens GN=ELA2 PE=1 SV=1,Enzymes,EC:3.4.21.37,Established target
126,"Alpha1-Proteinase Inhibitor,Zemaira",alpha-1 proteinase inhibitor,for treatment of emphysema,protein,approved,P08246,ELNE_HUMAN,ELANE,Leukocyte elastase OS=Homo sapiens GN=ELA2 PE=1 SV=1,Enzymes,EC:3.4.21.37,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
127,"alprazolam,Xanax, Xanax  XR",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
128,"alprostadil,Alista",alprostadil,"for treatment of erectile dysfunction,for treatment of sexual dysfunction in women",Small Molecule,approved,P34995,PE2R1_HUMAN,PTGER1,Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens GN=PTGER1 PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
128,"alprostadil,Alista",alprostadil,"for treatment of erectile dysfunction,for treatment of sexual dysfunction in women",Small Molecule,approved,P43116,PE2R2_HUMAN,PTGER2,Prostaglandin E2 receptor EP2 subtype OS=Homo sapiens GN=PTGER2 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
129,"alprostadil,Femprox",alprostadil,"for treatment of erectile dysfunction,for treatment of sexual dysfunction in women",Small Molecule,approved,P34995,PE2R1_HUMAN,PTGER1,Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens GN=PTGER1 PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
129,"alprostadil,Femprox",alprostadil,"for treatment of erectile dysfunction,for treatment of sexual dysfunction in women",Small Molecule,approved,P43116,PE2R2_HUMAN,PTGER2,Prostaglandin E2 receptor EP2 subtype OS=Homo sapiens GN=PTGER2 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
130,"alprostadil,Topiglan",alprostadil,"for treatment of erectile dysfunction,for treatment of sexual dysfunction in women",Small Molecule,approved,P34995,PE2R1_HUMAN,PTGER1,Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens GN=PTGER1 PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
130,"alprostadil,Topiglan",alprostadil,"for treatment of erectile dysfunction,for treatment of sexual dysfunction in women",Small Molecule,approved,P43116,PE2R2_HUMAN,PTGER2,Prostaglandin E2 receptor EP2 subtype OS=Homo sapiens GN=PTGER2 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
133,ALT-110,ALT-110,antineoplastic agent,vaccine,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
134,"alteplase,Activase, Actilyse",alteplase,Thrombolytic agent,recombinant protein,approved,P02671,FIBA_HUMAN,FGA,Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Established target
134,"alteplase,Activase, Actilyse",alteplase,Thrombolytic agent,recombinant protein,approved,P00747,FIBA_HUMAN,PLG,Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Established target
135,altropane,altropane,diagnostic agent for parkinson's disease and ADHD,Small molecule,not approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
136,"ALTU-238, somatropin",somatropin,hormone replacement,recombinant protein,approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
137,"alvespimycin hydrochloride, KOS-1022 (DMAG), NSC-707545",Alvespimycin,antineoplastic agent,Small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
137,"alvespimycin hydrochloride, KOS-1022 (DMAG), NSC-707545",Alvespimycin,antineoplastic agent,Small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
138,ALX-0061,ALC-0061,"antiinflammatory agent,DMARD",antibody fragment,not approved,P08887,IL6RA_HUMAN,IL6R,Interleukin-6 receptor subunit alpha (IL-6 receptor subunit alpha) (IL-6R subunit alpha) (IL-6R-alpha) (IL-6RA) (IL-6R 1) (Membrane glycoprotein 80) (gp80) (CD antigen CD126),Receptors,Receptor; Type 1 cytokine receptor,Established target
139,"ALX-0081, ALX-0681, anti-von Willebrand factor nanobodies",ALX-0081 ,antithrombotic,antibody fragment,not approved,P04275,VWF_HUMAN,VWF,von Willebrand factor (vWF) [Cleaved into: von Willebrand antigen 2 (von Willebrand antigen II)],Miscellaneous,StructuralAndAdhesion;Collagen;F8;F2,Established target
139,"ALX-0081, ALX-0681, anti-von Willebrand factor nanobodies",ALX-0681,antithrombotic,antibody fragment,not approved,P04275,VWF_HUMAN,VWF,von Willebrand factor (vWF) [Cleaved into: von Willebrand antigen 2 (von Willebrand antigen II)],Miscellaneous,StructuralAndAdhesion;Collagen;F8;F2,Established target
140,ALX-0141,ALX-0141,for treatment of degenerative bone diseases,antibody fragment,not approved,O14788,TNF11_HUMAN,TNFSF11,Tumor necrosis factor ligand superfamily member 11 (Osteoclast differentiation factor) (ODF) (Osteoprotegerin ligand) (OPGL) (Receptor activator of nuclear factor kappa-B ligand) (RANKL) (TNF-related activation-induced cytokine) (TRANCE) (CD antigen CD254,Miscellaneous,Ligand;Cytokine,Established target
141,AM-101,AM-101,for treatment of tinnitus,Small molecule,not approved,Q05586,NMDZ1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo sapiens GN=GRIN1 PE=1 SV=1,Receptors,TC:1.A.10.1.6,Established target
141,AM-101,AM-101,for treatment of tinnitus,Small molecule,not approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
141,AM-101,AM-101,for treatment of tinnitus,Small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
141,AM-101,AM-101,for treatment of tinnitus,Small molecule,not approved,Q14957,NMDE3_HUMAN,GRIN2C,Glutamate [NMDA] receptor subunit epsilon-3 (N-methyl D-aspartate receptor subtype 2C) (NMDAR2C) (NR2C),Receptors,TC:1.A.10.1.3,Novel Target
141,AM-101,AM-101,for treatment of tinnitus,Small molecule,not approved,O15399,NMDE4_HUMAN,GRIN2D,Glutamate [NMDA] receptor subunit epsilon-4 OS=Homo sapiens GN=GRIN2D PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
141,AM-101,AM-101,for treatment of tinnitus,Small molecule,not approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
141,AM-101,AM-101,for treatment of tinnitus,Small molecule,not approved,O60391,NMD3B_HUMAN,GRIN3B,Glutamate [NMDA] receptor subunit 3B OS=Homo sapiens GN=GRIN3B PE=2 SV=2,Receptors,TC:1.A.10.1,Established target
142,AM-103,AM-103,antiinflammatory agent,Small molecule,not approved,P20292,AL5AP_HUMAN,ALOX5AP,Arachidonate 5-lipoxygenase-activating protein (FLAP) (MK-886-binding protein),Miscellaneous,Enzyme regulator,Novel Target
143,AM-111,AM-111,for treatment of acute hearing loss,peptide,not approved,P53779,MK10_HUMAN,MAPK10,Mitogen-activated protein kinase 10 (MAP kinase 10) (MAPK 10) (EC 2.7.11.24) (MAP kinase p49 3F12) (Stress-activated protein kinase JNK3) (c-Jun N-terminal kinase 3),Enzymes,EC:2.7.11.24,Novel Target
143,AM-111,AM-111,for treatment of acute hearing loss,peptide,not approved,P45983,MK08_HUMAN,MAPK8,Mitogen-activated protein kinase 8 (MAP kinase 8) (MAPK 8) (EC 2.7.11.24) (JNK-46) (Stress-activated protein kinase 1) (Stress-activated protein kinase JNK1) (c-Jun N-terminal kinase 1),Enzymes,EC:2.7.11.24,Novel Target
143,AM-111,AM-111,for treatment of acute hearing loss,peptide,not approved,P45984,MK09_HUMAN,MAPK9,Mitogen-activated protein kinase 9 (MAP kinase 9) (MAPK 9) (EC 2.7.11.24) (JNK-55) (Stress-activated protein kinase JNK2) (c-Jun N-terminal kinase 2),Enzymes,EC:2.7.11.24,Novel Target
144,AM-152,AM-152,"antiinflammatory agent,antifibrotic agent",Small molecule,not approved,Q92633,LPAR1_HUMAN,LPAR1,Lysophosphatidic acid receptor 1 (LPA receptor 1) (LPA-1) (Lysophosphatidic acid receptor Edg-2),Receptors,GPCR;Rhodopsin,Novel Target
145,AM-211,AM-211,"antiinflammatory agent,antiallergy agent",Small molecule,not approved,Q9Y5Y4,GPR44_HUMAN,GPR44,Putative G-protein coupled receptor 44 (Chemoattractant receptor-homologous molecule expressed on Th2 cells) (CD antigen CD294),Receptors,GPCR;Rhodopsin,Novel Target
146,AM-461,AM-461,antiinflammatory agent,Small molecule,not approved,Q13258,PD2R_HUMAN,PTGDR,Prostaglandin D2 receptor (PGD receptor) (PGD2 receptor) (Prostanoid DP receptor),Receptors,GPCR;Rhodopsin,Established target
147,AM-803,AM-803,antiinflammatory agent,Small molecule,not approved,P20292,AL5AP_HUMAN,ALOX5AP,Arachidonate 5-lipoxygenase-activating protein (FLAP) (MK-886-binding protein),Miscellaneous,Enzyme regulator,Novel Target
148,AMAP102,AMAP102,"antiinflammatory agent,DMARD",Small molecule,not approved,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
148,AMAP102,AMAP102,"antiinflammatory agent,DMARD",Small molecule,not approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
149,"amatuximab, MORAb-009",amatuximab,antineoplastic agent,monoclonal antibody,not approved,Q13421,MSLN_HUMAN,MSLN,"Mesothelin (CAK1 antigen) (Pre-pro-megakaryocyte-potentiating factor) [Cleaved into: Megakaryocyte-potentiating factor (MPF); Mesothelin, cleaved form]",Miscellaneous,Mesothelin family,Novel Target
150,AMD-070,AMD-070,"antiviral agent,HIV",Small molecule,not approved,P61073,CXCR4_HUMAN,CXCR4,C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (Fusin) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD antigen CD184),Receptors,GPCR;Rhodopsin,Established target
151,AME-527,AME-527,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
152,"amediplase, K2tu-PA",amediplase,antithrombotic,fusion protein,not approved,P00747,TPA_HUMAN,PLG,Tissue-type plasminogen activator OS=Homo sapiens GN=PLAT PE=1 SV=1,Enzymes,StructuralAndAdhesion;Fibrinogen,Established target
153,"AMG0714, HuMax-IL15",AMG0714,"antiinflammatory agent,DMARD",antibody,not approved,P40933,IL15_HUMAN,IL15,Interleukin-15 (IL-15),Miscellaneous,Ligand;Cytokine,Novel Target
154,AMG-102,AMG-102,antineoplastic agent,monoclonal antibody,not approved,P14210,HGF_HUMAN,HGF,Hepatocyte growth factor (Hepatopoeitin-A) (Scatter factor) (SF) [Cleaved into: Hepatocyte growth factor alpha chain; Hepatocyte growth factor beta chain],Ligand,Ligand;HGF,Novel Target
155,AMG-108,AMG-108,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P01583,IL1A_HUMAN,IL1A,Interleukin-1 alpha (IL-1 alpha) (Hematopoietin-1),Miscellaneous,Ligand;Cytokine,Established target
156,"AMG-222, ALS 2-0426",ALS 2-0426,antidiabetic,Small molecule,not approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
157,AMG-479,AMG-479,antineoplastic agent,monoclonal antibody,not approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
158,"amibegron, SR 58611",amibegron,antidepressant,Small molecule,not approved,P13945,ADRB3_HUMAN,ADRB3,Beta-3 adrenergic receptor (Beta-3 adrenoreceptor) (Beta-3 adrenoceptor),Receptors,GPCR;Rhodopsin,Novel Target
159,"amifostine,Ethyol",amifostine,radiation-protective agent,Small Molecule,approved,P10696,PPBN_HUMAN,ALPPL2,"Alkaline phosphatase, placental-like OS=Homo sapiens GN=ALPPL2 PE=1 SV=4",Enzymes,EC:3.1.3.1,Established target
160,"amiodarone HCl,Amio-Aqueous IV",amiodarone,antiarrhytmic agent,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
160,"amiodarone HCl,Amio-Aqueous IV",amiodarone,antiarrhytmic agent,Small Molecule,approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
160,"amiodarone HCl,Amio-Aqueous IV",amiodarone,antiarrhytmic agent,Small Molecule,approved,Q12809,KCNH2_HUMAN,KCNH2,Potassium voltage-gated channel subfamily H member 2 OS=Homo sapiens GN=KCNH2 PE=1 SV=1,Transporters,TC:1.A.1.20.1,Established target
161,"amisulpride,Solian",amisulpride,antipsychotic agent,Small Molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
161,"amisulpride,Solian",amisulpride,antipsychotic agent,Small Molecule,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
162,"amitriptyline + ketamine,Epicept NP-1",amitriptyline,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
162,"amitriptyline + ketamine,Epicept NP-1",amitriptyline,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
162,"amitriptyline + ketamine,Epicept NP-1",ketamine,analgesic,Small Molecule,approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
163,"amlodipine besylate,Norvasc",amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
163,"amlodipine besylate,Norvasc",amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
163,"amlodipine besylate,Norvasc",amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
163,"amlodipine besylate,Norvasc",amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
163,"amlodipine besylate,Norvasc",amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,Q08289,CACB2_HUMAN,CACNB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
164,"amonafide,Quinamed",amonafide,antineoplastic agent,Small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
164,"amonafide,Quinamed",amonafide,antineoplastic agent,Small molecule,not approved,Q02880,TOP2B_HUMAN,TOP2B,"DNA topoisomerase 2-beta (EC 5.99.1.3) (DNA topoisomerase II, beta isozyme)",Enzymes,EC:5.99.1.3,Established target
165,"AMT-011, AMT-010,Glybera",AMT-011,enzyme replacement therapy,adenoviral vector,not approved,P06858,LIPL_HUMAN,LPL,Lipoprotein lipase OS=Homo sapiens GN=LPL PE=1 SV=1,Enzymes,EC:3.1.1.34,Established target
166,Amturnide,aliskiren,antihypertensive agent,Small Molecule,approved,P00797,RENI_HUMAN,REN,Renin OS=Homo sapiens GN=REN PE=1 SV=1,Enzymes,EC:3.4.23.15,Established target
166,Amturnide,amlodipine,antihypertensive agent,Small Molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
166,Amturnide,amlodipine,antihypertensive agent,Small Molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
166,Amturnide,amlodipine,antihypertensive agent,Small Molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
166,Amturnide,amlodipine,antihypertensive agent,Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
166,Amturnide,amlodipine,antihypertensive agent,Small Molecule,approved,Q08289,CACB2_HUMAN,CACNB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
166,Amturnide,hydrochlorothiazide,antihypertensive agent,Small Molecule,approved,P55017,S12A3_HUMAN,SLC12A3,Solute carrier family 12 member 3 OS=Homo sapiens GN=SLC12A3 PE=1 SV=2,Transporters,TC:2.A.30.4.2,Established target
167,"AN-072, E-2014,Myobloc, N/",BOTULINUM TOXIN TYPE B,for treatment of dystonia,peptide,approved,Q8N9I0,SYT2_HUMAN,SYT2,Synaptotagmin-2 OS=Homo sapiens GN=SYT2 PE=1 SV=2,Miscellaneous,Miscellaneous;Synaptotagmin,Established target
167,"AN-072, E-2014,Myobloc, N/",BOTULINUM TOXIN TYPE B,for treatment of dystonia,peptide,approved,P23763,VAMP1_HUMAN,VAMP1,Vesicle-associated membrane protein 1 OS=Homo sapiens GN=VAMP1 PE=1 SV=1,Transporters,TC:1.F.1.1.1,Established target
167,"AN-072, E-2014,Myobloc, N/",BOTULINUM TOXIN TYPE B,for treatment of dystonia,peptide,approved,P63027,VAMP2_HUMAN,VAMP2,Vesicle-associated membrane protein 2 OS=Homo sapiens GN=VAMP2 PE=1 SV=2,Transporters,TC:1.F.1.1.1,Established target
168,AN-2728,AN-2728,"antiinflammatory agent, antipsoriatic",Small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
168,AN-2728,AN-2728,"antiinflammatory agent, antipsoriatic",Small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
169,AN-2898,AN-2898,"antiinflammatory agent, antipsoriatic",Small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
169,AN-2898,AN-2898,"antiinflammatory agent, antipsoriatic",Small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
171,ANA773,ANA773,antineoplastic agent,Small molecule,not approved,Q9NYK1,TLR7_HUMAN,TLR7,Toll-like receptor 7 OS=Homo sapiens GN=TLR7 PE=1 SV=1,Receptors,Receptors;TOLL,Established target
172,Anacetrapib,Anacetrapib,for treatment of dyslipidemia,Small molecule,not approved,P11597,CETP_HUMAN,CETP,Cholesteryl ester transfer protein (Lipid transfer protein I),Miscellaneous,BLI/LBP/Plunc superfamily,Novel Target
174,"anakinra,Kineret",anakinra,"antiinflammatory agent,DMARD",recombinant protein,approved,P14778,IL1R1_HUMAN,IL1R1,Interleukin-1 receptor type I OS=Homo sapiens GN=IL1R1 PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
175,"anamorelin, RC-1291",anamorelin,appetite stimulating agent,Small molecule,not approved,Q92847,GHSR_HUMAN,GHSR,Growth hormone secretagogue receptor type 1 (GHS-R) (GH-releasing peptide receptor) (GHRP) (Ghrelin receptor),Receptors,GPCR;Rhodopsin,Novel Target
176,"anastrozole,Arimidex",anastrozole,antineoplastic agent,Small Molecule,approved,P11511,CP19A_HUMAN,CYP19A1,Cytochrome P450 19A1 OS=Homo sapiens GN=CYP19A1 PE=1 SV=3,Enzymes,EC:1.14.14,Established target
177,anatibant,anatibant,for treatment of traumatic brain injury,Small molecule,not approved,P30411,BKRB2_HUMAN,BDKRB2,B2 bradykinin receptor OS=Homo sapiens GN=BDKRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
178,ANAVEX 2-73,ANAVEX 2-73,for treatment of Alzheimer's disease,Small molecule,not approved,Q99720,OPRS1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
179,Androxal,clomifene,for treatment of testosterone deficiency,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
180,ANG1005,ANG1005,antineoplastic agent,fusion protein,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
180,ANG1005,ANG1005,antineoplastic agent,fusion protein,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
181,anhydrovinblastin,anhydrovinblastin,antineoplastic agent,Small molecule,not approved,P07437,TBB5_HUMAN,TUBB,Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
182,anti-alpha5Beta1-integrin antibody,F200,antineoplastic agent,antibody,not approved,P08648,ITA5_HUMAN,ITGA5,Integrin alpha-5 (CD49 antigen-like family member E) (Fibronectin receptor subunit alpha) (Integrin alpha-F) (VLA-5) (CD antigen CD49e) [Cleaved into: Integrin alpha-5 heavy chain; Integrin alpha-5 light chain],Receptors,Receptors;Integrin,Novel Target
182,anti-alpha5Beta1-integrin antibody,F200,antineoplastic agent,antibody,not approved,P05556,ITB1_HUMAN,ITGB1,Integrin beta-1 (Fibronectin receptor subunit beta) (VLA-4 subunit beta) (CD antigen CD29),Receptors,Receptors;Integrin,Established target
183,anti-CD3 monoclonal antibody,anti-CD3 monoclonal antibody,antiinflammatory agent,monoclonal antibody,not approved,P04234,CD3D_HUMAN,CD3D,T-cell surface glycoprotein CD3 delta chain (T-cell receptor T3 delta chain) (CD antigen CD3d),Receptors,Receptor; T-cell receptor subunit,Established target
183,anti-CD3 monoclonal antibody,anti-CD3 monoclonal antibody,antiinflammatory agent,monoclonal antibody,not approved,P07766,CD3E_HUMAN,CD3E,T-cell surface glycoprotein CD3 epsilon chain OS=Homo sapiens GN=CD3E PE=1 SV=2,Receptors,Receptor; T-cell receptor subunit,Established target
183,anti-CD3 monoclonal antibody,anti-CD3 monoclonal antibody,antiinflammatory agent,monoclonal antibody,not approved,P09693,CD3G_HUMAN,CD3G,T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g),Receptors,Receptor; T-cell receptor subunit,Established target
184,"Anti-EGFL7 Mab, MEGF0444A",Anti-EGFL7 ,antineoplastic agent,antibody,not approved,Q9UHF1,EGFL7_HUMAN,EGFL7,Epidermal growth factor-like protein 7 (EGF-like protein 7) (Multiple epidermal growth factor-like domains protein 7) (Multiple EGF-like domains protein 7) (NOTCH4-like protein) (Vascular endothelial statin) (VE-statin) (Zneu1),Miscellaneous,Ligand;growth factor,Novel Target
185,"antihemophilic factor,Alphanate",antihemophilic factor,for treatment of hemophilia A,protein,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
185,"antihemophilic factor,Alphanate",antihemophilic factor,for treatment of hemophilia A,protein,approved,P00740,FA9_HUMAN,F9,Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2,Enzymes,EC:3.4.21.22,Established target
185,"antihemophilic factor,Alphanate",antihemophilic factor,for treatment of hemophilia A,protein,approved,P04275,VWF_HUMAN,VWF,von Willebrand factor (vWF) [Cleaved into: von Willebrand antigen 2 (von Willebrand antigen II)],Miscellaneous,StructuralAndAdhesion;Collagen;F8;F2,Established target
186,"Anti-NRP1 Mab, MNRP1685A",Anti-NRP1 Mab,antineoplastic agent,monoclonal antibody,not approved,O14786,NRP1_HUMAN,NRP1,Neuropilin-1 (Vascular endothelial cell growth factor 165 receptor) (CD antigen CD304),Receptors,Receptors;Neuropilin,Established target
187,"ANX-514, lyophilized docetaxel",docetaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
188,AOD9604,AOD9604,antiobesity agent,peptide,not approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
189,AP1030,AP1030,antiobesity agent,Small molecule,not approved,Q01726,MSHR_HUMAN,MC1R,Melanocyte-stimulating hormone receptor (MSH-R) (Melanocortin receptor 1) (MC1-R),Receptors,GPCR;Rhodopsin,Novel Target
189,AP1030,AP1030,antiobesity agent,Small molecule,not approved,P32245,MC4R_HUMAN,MC4R,Melanocortin receptor 4 (MC4-R),Receptors,GPCR;Rhodopsin,Novel Target
190,"AP-1034,Anturol",oxybutynin,for treatment of overactive bladder,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
190,"AP-1034,Anturol",oxybutynin,for treatment of overactive bladder,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
190,"AP-1034,Anturol",oxybutynin,for treatment of overactive bladder,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
191,APC-100,APC-100,antineoplastic agent,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
192,APD125,APD125,for treatment of insomnia,Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
193,APD421,APD421,antiemetic,Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
194,APD668,APD668,antidiabetic,Small molecule,not approved,Q8TDV5 ,GP119_HUMAN,GPR119,Glucose-dependent insulinotropic receptor,Receptors,GPCR;Rhodopsin,Novel Target
195,APD791,APD791,antithrombotic,Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
196,APD916,APD916,for treatment of narcolepsy,Small molecule,not approved,Q9Y5N1,HRH3_HUMAN,HRH3,Histamine H3 receptor (H3R) (HH3R) (G-protein coupled receptor 97),Receptors,GPCR;Rhodopsin,Novel Target
197,"APF 112, mepivacaine sustained-release",mepivacaine,anestethic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
198,"APF530, granisetron",granisetron,antiemetic,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
199,APG101,APG101,antineoplastic agent,fusion protein,not approved,P48023,TNFL6_HUMAN,FASLG,"Tumor necrosis factor ligand superfamily member 6 (Apoptosis antigen ligand) (APTL) (CD95 ligand) (CD95-L) (Fas antigen ligand) (Fas ligand) (CD antigen CD178) [Cleaved into: Tumor necrosis factor ligand superfamily member 6, membrane form; Tumor necrosis",Miscellaneous,Ligand;Cytokine,Novel Target
200,"apilimod, STA-5326",apilimod,"antiinflammatory agent, antipsoriatic",Small molecule,not approved,unknown,unknown,unknown,unknown,unknown,unknown,unknown
201,Apixaban,apixaban,antithrombotic,Small molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
202,"APL-202,Isprelor",misoprostol,labor-inducing agent,Small Molecule,approved,P43119,PI2R_HUMAN,PTGIR,Prostacyclin receptor OS=Homo sapiens GN=PTGIR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
203,"Aplindore, DAB-452",Aplindore,"antiparkinson agent,for treatment of restlegs legs syndrome",Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
205,ApoB SNALP,TKM-ApoB,anticholesterolaemic agent,siRNA,not approved,P04114,APOB_HUMAN,APOB,Apolipoprotein B-100 (Apo B-100) [Cleaved into: Apolipoprotein B-48 (Apo B-48)],Miscellaneous,Enzyme cofactor ,Novel Target
206,"apomorphine HCl,Uprima, Ixense",apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
206,"apomorphine HCl,Uprima, Ixense",apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
206,"apomorphine HCl,Uprima, Ixense",apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
207,"apomorphine hydrochloride,Apokyn, APO-go",apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
207,"apomorphine hydrochloride,Apokyn, APO-go",apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
207,"apomorphine hydrochloride,Apokyn, APO-go",apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
208,"apremilast, CC-10004",apremilast,"antiinflammatory agent, DMARD, antipsoriatic",Small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
208,"apremilast, CC-10004",apremilast,"antiinflammatory agent, DMARD, antipsoriatic",Small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
209,"aprepitant, MK-869, fosaprepitant dimeglumine, MK-0517,Emend",aprepitant,antiemetic,Small Molecule,approved,P25103,NK1R_HUMAN,TACR1,Substance-P receptor OS=Homo sapiens GN=TACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
210,"apricoxib, TG01,Capoxigem",apricoxib,antineoplastic agent,Small molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
211,AR-12,AR-12,antineoplastic agent,Small molecule,not approved,Q15118,PDK1_HUMAN,PDK1,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial (EC 2.7.11.2) (Pyruvate dehydrogenase kinase isoform 1)",Enzymes,EC:2.7.11.2,Novel Target
212,AR-12286,AR-12286,for treatment of  glaucoma ,Small molecule,not approved,Q13464,ROCK1_HUMAN,ROCK1,"Rho-associated protein kinase 1 (EC 2.7.11.1) (Renal carcinoma antigen NY-REN-35) (Rho-associated, coiled-coil-containing protein kinase 1) (p160 ROCK-1) (p160ROCK)",Enzymes,EC:2.7.11.1,Novel Target
212,AR-12286,AR-12286,for treatment of  glaucoma ,Small molecule,not approved,O75116,ROCK2_HUMAN,ROCK2,"Rho-associated protein kinase 2 (EC 2.7.11.1) (Rho kinase 2) (Rho-associated, coiled-coil-containing protein kinase 2) (p164 ROCK-2)",Enzymes,EC:2.7.11.1,Novel Target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,Q96DB2,HDA11_HUMAN,HDAC11,Histone deacetylase 11 (HD11) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,P56524,HDAC4_HUMAN,HDAC4,Histone deacetylase 4 (HD4) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,Q9UQL6,HDAC5_HUMAN,HDAC5,Histone deacetylase 5 (HD5) (EC 3.5.1.98) (Antigen NY-CO-9),Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,Q8WUI4,HDAC7_HUMAN,HDAC7A,Histone deacetylase 7 (HD7) (EC 3.5.1.98) (Histone deacetylase 7A) (HD7a),Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
213,AR-42,AR-42,antineoplastic agent,Small molecule,not approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
214,AR9281,AR9281,antihypertensive agent,Small molecule,not approved,P07099,HYEP_HUMAN,EPHX1,Epoxide hydrolase 1 (EC 3.3.2.9) (Epoxide hydratase) (Microsomal epoxide hydrolase),Enzymes,EC:3.3.2.9,Novel Target
214,AR9281,AR9281,antihypertensive agent,Small molecule,not approved,P34913,HYES_HUMAN,EPHX2,Epoxide hydrolase 2 (EC 3.3.2.10) (Cytosolic epoxide hydrolase) (CEH) (Epoxide hydratase) (Soluble epoxide hydrolase) (SEH),Enzymes,EC:3.3.2.10,Novel Target
215,Aranesp,epoetin alfa,for treatment of anemia,recombinant protein,approved,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
216,Arbaclofen,arbaclofen,symptomatic treatment for fragile X syndrome,Small molecule,not approved,Q9UBS5,GABR1_HUMAN,GABBR1,Gamma-aminobutyric acid type B receptor subunit 1 OS=Homo sapiens GN=GABBR1 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
216,Arbaclofen,arbaclofen,symptomatic treatment for fragile X syndrome,Small molecule,not approved,O75899,GABR2_HUMAN,GABBR2,Gamma-aminobutyric acid type B receptor subunit 2 OS=Homo sapiens GN=GABBR2 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
217,"ARC 100 , TPI 287",ARC100,antineoplastic agent,Small molecule,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
218,ARC1779,ARC1779,antithrombotic,aptamer,not approved,P04275,VWF_HUMAN,VWF,von Willebrand factor (vWF) [Cleaved into: von Willebrand antigen 2 (von Willebrand antigen II)],Miscellaneous,StructuralAndAdhesion;Collagen;F8;F2,Established target
219,ARC1905,ARC1905,for treatment of age-related macular degeneration,aptamer,not approved,P01031,CO5_HUMAN,C5,Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4,Miscellaneous,Immune response;Complement system,Established target
220,"ARC-4558, 0.1% clonidine hycrochloride gel",clonidine,"for treatment of diabetic neuropathy,for treatment of ADHD,antimucositic",Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
220,"ARC-4558, 0.1% clonidine hycrochloride gel",clonidine,"for treatment of diabetic neuropathy,for treatment of ADHD,antimucositic",Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
220,"ARC-4558, 0.1% clonidine hycrochloride gel",clonidine,"for treatment of diabetic neuropathy,for treatment of ADHD,antimucositic",Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
221,"arcitumomab,CEA-Scan",arcitumomab,diagnostic agent,antibody fragment,approved,P13688,CEAM1_HUMAN,CEACAM1,Carcinoembryonic antigen-related cell adhesion molecule 1 OS=Homo sapiens GN=CEACAM1 PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
222,ARD-07,ARD-07,for treatment of growth hormone deficiency,Small molecule,not approved,Q9UBU3,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
223,ARG098,ARG098,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P25445,TNR6_HUMAN,FAS,Tumor necrosis factor receptor superfamily member 6 (Apo-1 antigen) (Apoptosis-mediating surface antigen FAS) (FASLG receptor) (CD antigen CD95),Receptors,Receptor; Fas-Ligand receptor,Novel Target
224,Argatroban,Argatroban,anticoagulant,Small molecule,approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
225,ARI-2243,ARI-2243,antidiabetic,Small molecule,not approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
226,ARI-3037MO,ARI-3037MO,"Vitamin B analog,for treatment for hyperlipidemia",Small molecule,not approved,Q8TDS4,NIAR1_HUMAN,GPR109A,Niacin receptor 1 OS=Homo sapiens GN=NIACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
226,ARI-3037MO,ARI-3037MO,"Vitamin B analog,for treatment for hyperlipidemia",Small molecule,not approved,P49019,G109B_HUMAN,GPR109B,Niacin receptor 2 OS=Homo sapiens GN=NIACR2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
226,ARI-3037MO,ARI-3037MO,"Vitamin B analog,for treatment for hyperlipidemia",Small molecule,not approved,P40261,NNMT_HUMAN,NNMT,Nicotinamide N-methyltransferase (EC 2.1.1.1),Enzymes,EC:2.1.1.1,Established target
226,ARI-3037MO,ARI-3037MO,"Vitamin B analog,for treatment for hyperlipidemia",Small molecule,not approved,Q15274,NADC_HUMAN,QPRT,Nicotinate-nucleotide pyrophosphorylase [carboxylating] (EC 2.4.2.19) (Quinolinate phosphoribosyltransferase [decarboxylating]) (QAPRTase) (QPRTase),Enzymes,EC:2.4.2.19,Established target
227,"armodafinil, R-modafinil,Nuvigil",armodafinil,central nervous system stimulant,Small molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
228,ARN-509,ARN-509,antineoplastic agent,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
229,ARQ-197,ARQ-197,antineoplastic agent,Small molecule,not approved,P08581,MET_HUMAN,MET,Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met),Receptors,EC:2.7.10.1,Established target
230,ARQ-501,ARQ-501,antineoplastic agent,Small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
231,ARQ-621,ARQ-621,antineoplastic agent,Small molecule,not approved,P52732,KIF11_HUMAN,KIF11,Kinesin-like protein KIF11 (Kinesin-like protein 1) (Kinesin-like spindle protein HKSP) (Kinesin-related motor protein Eg5) (Thyroid receptor-interacting protein 5) (TR-interacting protein 5) (TRIP-5),Miscellaneous,Miscellaneous;motor protein,Novel Target
232,ARRY-162,ARRY-162,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,Q02750,MP2K1_HUMAN,MAP2K1,Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1),Enzymes,EC:2.7.12.2,Novel Target
232,ARRY-162,ARRY-162,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P36507,MP2K2_HUMAN,MAP2K2,Dual specificity mitogen-activated protein kinase kinase 2 (MAP kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2) (MAPK/ERK kinase 2) (MEK 2),Enzymes,EC:2.7.12.2,Novel Target
233,ARRY-300,ARRY-300,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,Q02750,MP2K1_HUMAN,MAP2K1,Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1),Enzymes,EC:2.7.12.2,Novel Target
233,ARRY-300,ARRY-300,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P36507,MP2K2_HUMAN,MAP2K2,Dual specificity mitogen-activated protein kinase kinase 2 (MAP kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2) (MAPK/ERK kinase 2) (MEK 2),Enzymes,EC:2.7.12.2,Novel Target
234,ARRY-334543,ARRY-334543,antineoplastic agent,Small molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
234,ARRY-334543,ARRY-334543,antineoplastic agent,Small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
235,ARRY-380,ARRY-380,antineoplastic agent,Small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
236,ARRY-403,ARRY-403,antidiabetic,Small molecule,not approved,P35557,HXK4_HUMAN,GCK,Glucokinase (EC 2.7.1.2) (Hexokinase type IV) (HK IV) (Hexokinase-4) (HK4) (Hexokinase-D),Enzymes,EC:2.7.1.2,Novel Target
237,ARRY-614,ARRY-614,for treatment of myelodysplastic syndrome,Small molecule,not approved,P00519,ABL1_HUMAN,ABL1,Proto-oncogene tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4,Enzymes,EC:2.7.10.2,Established target
237,ARRY-614,ARRY-614,for treatment of myelodysplastic syndrome,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
237,ARRY-614,ARRY-614,for treatment of myelodysplastic syndrome,Small molecule,not approved,Q15759,MK11_HUMAN,MAPK11,Mitogen-activated protein kinase 11 (MAP kinase 11) (MAPK 11) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 beta) (MAP kinase p38 beta) (p38b) (Stress-activated protein kinase 2) (p38-2),Enzymes,EC:2.7.11.24,Novel Target
237,ARRY-614,ARRY-614,for treatment of myelodysplastic syndrome,Small molecule,not approved,P53778,MK12_HUMAN,MAPK12,Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3),Enzymes,EC:2.7.11.24,Novel Target
237,ARRY-614,ARRY-614,for treatment of myelodysplastic syndrome,Small molecule,not approved,O15264,MK13_HUMAN,MAPK13,Mitogen-activated protein kinase 13 (MAP kinase 13) (MAPK 13) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 delta) (MAP kinase p38 delta) (Stress-activated protein kinase 4),Enzymes,EC:2.7.11.24,Novel Target
237,ARRY-614,ARRY-614,for treatment of myelodysplastic syndrome,Small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
237,ARRY-614,ARRY-614,for treatment of myelodysplastic syndrome,Small molecule,not approved,Q02763,TIE2_HUMAN,TEK,Angiopoietin-1 receptor (EC 2.7.10.1) (Tunica interna endothelial cell kinase) (Tyrosine-protein kinase receptor TEK) (Tyrosine-protein kinase receptor TIE-2) (hTIE2) (p140 TEK) (CD antigen CD202b),Receptors,EC:2.7.10.1,Novel Target
238,ARRY-797,ARRY-797,antineoplastic agent,Small molecule,not approved,Q15759,MK11_HUMAN,MAPK11,Mitogen-activated protein kinase 11 (MAP kinase 11) (MAPK 11) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 beta) (MAP kinase p38 beta) (p38b) (Stress-activated protein kinase 2) (p38-2),Enzymes,EC:2.7.11.24,Novel Target
238,ARRY-797,ARRY-797,antineoplastic agent,Small molecule,not approved,P53778,MK12_HUMAN,MAPK12,Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3),Enzymes,EC:2.7.11.24,Novel Target
238,ARRY-797,ARRY-797,antineoplastic agent,Small molecule,not approved,O15264,MK13_HUMAN,MAPK13,Mitogen-activated protein kinase 13 (MAP kinase 13) (MAPK 13) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 delta) (MAP kinase p38 delta) (Stress-activated protein kinase 4),Enzymes,EC:2.7.11.24,Novel Target
238,ARRY-797,ARRY-797,antineoplastic agent,Small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
239,"arsenic trioxide,Trisenox",arsenic trioxide,antineoplastic agent,Small Molecule,approved,P24385,CCND1_HUMAN,CCND1,G1/S-specific cyclin-D1,Miscellaneous,Miscellaneous;Cyclin,Established target
239,"arsenic trioxide,Trisenox",arsenic trioxide,antineoplastic agent,Small Molecule,approved,O14920,IKKB_HUMAN,IKBKB,Inhibitor of nuclear factor kappa-B kinase subunit beta OS=Homo sapiens GN=IKBKB PE=1 SV=1,Enzymes,EC:2.7.11.10,Established target
239,"arsenic trioxide,Trisenox",arsenic trioxide,antineoplastic agent,Small Molecule,approved,P05412,JUN_HUMAN,JUN,Transcription factor AP-1 (Activator protein 1) (AP1) (Proto-oncogene c-Jun) (V-jun avian sarcoma virus 17 oncogene homolog) (p39),Miscellaneous,Transcription factor,Established target
239,"arsenic trioxide,Trisenox",arsenic trioxide,antineoplastic agent,Small Molecule,approved,P28482,MK01_HUMAN,MAPK1,Mitogen-activated protein kinase 1 (MAP kinase 1) (MAPK 1) (EC 2.7.11.24) (ERT1) (Extracellular signal-regulated kinase 2) (ERK-2) (MAP kinase isoform p42) (p42-MAPK) (Mitogen-activated protein kinase 2) (MAP kinase 2) (MAPK 2),Enzymes,EC:2.7.11.24,Established target
239,"arsenic trioxide,Trisenox",arsenic trioxide,antineoplastic agent,Small Molecule,approved,P27361,MK03_HUMAN,MAPK3,Mitogen-activated protein kinase 3 (MAP kinase 3) (MAPK 3) (EC 2.7.11.24) (ERT2) (Extracellular signal-regulated kinase 1) (ERK-1) (Insulin-stimulated MAP2 kinase) (MAP kinase isoform p44) (p44-MAPK) (Microtubule-associated protein 2 kinase) (Mitogen-acti,Enzymes,EC:2.7.11.24,Established target
239,"arsenic trioxide,Trisenox",arsenic trioxide,antineoplastic agent,Small Molecule,approved,Q16881,TRXR1_HUMAN,TXNRD1,"Thioredoxin reductase 1, cytoplasmic (TR) (EC 1.8.1.9) (Gene associated with retinoic and interferon-induced mortality 12 protein) (GRIM-12) (Gene associated with retinoic and IFN-induced mortality 12 protein) (KM-102-derived reductase-like factor) (Thior",Enzymes,EC:1.8.1.9,Established target
240,"ART621, PN0621",ART621,"antiinflammatory agent,DMARD",antibody,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
241,"arverapamil, AGI-003,Rezular",arverapamil,for treatment of irritable bowel syndrome,Small molecule,not approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
241,"arverapamil, AGI-003,Rezular",arverapamil,for treatment of irritable bowel syndrome,Small molecule,not approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
241,"arverapamil, AGI-003,Rezular",arverapamil,for treatment of irritable bowel syndrome,Small molecule,not approved,O60840,CAC1F_HUMAN,CACNA1F,Voltage-dependent L-type calcium channel subunit alpha-1F OS=Homo sapiens GN=CACNA1F PE=1 SV=2,Transporters,TC:1.A.1.11.11,Established target
241,"arverapamil, AGI-003,Rezular",arverapamil,for treatment of irritable bowel syndrome,Small molecule,not approved,O43497,CAC1G_HUMAN,CACNA1G,Voltage-dependent T-type calcium channel subunit alpha-1G OS=Homo sapiens GN=CACNA1G PE=2 SV=3,Transporters,TC:1.A.1.11,Established target
241,"arverapamil, AGI-003,Rezular",arverapamil,for treatment of irritable bowel syndrome,Small molecule,not approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
241,"arverapamil, AGI-003,Rezular",arverapamil,for treatment of irritable bowel syndrome,Small molecule,not approved,Q02641,CACB1_HUMAN,CACNB1,Voltage-dependent L-type calcium channel subunit beta-1 OS=Homo sapiens GN=CACNB1 PE=1 SV=3,Transporters,TC:8.A.22.1.1,Established target
241,"arverapamil, AGI-003,Rezular",arverapamil,for treatment of irritable bowel syndrome,Small molecule,not approved,Q08289,CACB2_HUMAN,CACNB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
241,"arverapamil, AGI-003,Rezular",arverapamil,for treatment of irritable bowel syndrome,Small molecule,not approved,P54284,CACB3_HUMAN,CACNB3,Voltage-dependent L-type calcium channel subunit beta-3 OS=Homo sapiens GN=CACNB3 PE=1 SV=1,Transporters,TC:8.A.22.1.3,Established target
241,"arverapamil, AGI-003,Rezular",arverapamil,for treatment of irritable bowel syndrome,Small molecule,not approved,O00305,CACB4_HUMAN,CACNB4,Voltage-dependent L-type calcium channel subunit beta-4 OS=Homo sapiens GN=CACNB4 PE=1 SV=2,Transporters,TC:8.A.22.1.4,Established target
242,"ARX-01, sufentanil NanoTab",sufentanil,adjuvant to anesthesia,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",sufentanil,adjuvant to anesthesia,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",sufentanil,"analgesic,sedative",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
243,"ARX-03, sufentanil + triazolam NanoTab",triazolam,"analgesic,sedative",Small Molecule,approved,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
244,ARX201,ARX201,growth hormone replacement therapy,recombinant protein,not approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
245,"Arzoxifene, LY353381",Arzoxifene,"antineoplastic agent,antiosteoporotic agent",Small molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
246,"AS1402, R1550",AS1402,antineoplastic agent,monoclonal antibody,not approved,P15941,MUC1_HUMAN,MUC1,Mucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Carcinoma-associated mucin) (Episialin) (H23AG) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM) (Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associ,Miscellaneous,StructuralAndAdhesion;Mucin_1,Novel Target
247,AS1409,AS1409,antineoplastic agent,fusion protein,not approved,P02751,FINC_HUMAN,FN1,Fibronectin (FN) (Cold-insoluble globulin) (CIG) [Cleaved into: Anastellin; Ugl-Y1; Ugl-Y2; Ugl-Y3],Miscellaneous,Miscellaneous;Glycoprotein,Novel Target
247,AS1409,AS1409,antineoplastic agent,fusion protein,not approved,P42701,I12R1_HUMAN,IL12RB1,Interleukin-12 receptor subunit beta-1 (IL-12 receptor subunit beta-1) (IL-12R subunit beta-1) (IL-12R-beta-1) (IL-12RB1) (IL-12 receptor beta component) (CD antigen CD212),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
247,AS1409,AS1409,antineoplastic agent,fusion protein,not approved,Q99665,I12R2_HUMAN,IL12RB2,Interleukin-12 receptor subunit beta-2 (IL-12 receptor subunit beta-2) (IL-12R subunit beta-2) (IL-12R-beta-2) (IL-12RB2),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
248,"AS1411, AGRO100",AS1411,antineoplastic agent,aptamer,not approved,P19338,NUCL_HUMAN,NCL,Nucleolin (Protein C23),Miscellaneous,RNA Binding,Novel Target
249,ASC-J9,ASC-J9,dermatological agent,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P47898,5HT5A_HUMAN,HTR5A,5-hydroxytryptamine receptor 5A,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
250,Asenapine,Asenapine,antipsychotic agent,Small molecule,approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
252,ASG-22ME,ASG-22ME,antineoplastic agent,antibody-drug conjugate,not approved,Q96NY8,PVRL4_HUMAN,PVRL4,Poliovirus receptor-related protein 4 (Ig superfamily receptor LNIR) (Nectin-4) [Cleaved into: Processed poliovirus receptor-related protein 4],Receptors,StructureAndAdhesion; Nectin,Novel Target
253,asimadoline,asimadoline,analgesic,Small molecule,not approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
254,ASP1941,ipragliflozin,antidiabetic,Small molecule,not approved,P31639,SC5A2_HUMAN,SLC5A2,Sodium/glucose cotransporter 2 (Na(+)/glucose cotransporter 2) (Low affinity sodium-glucose cotransporter) (Solute carrier family 5 member 2),Transporters,TC:2.A.21.3.16,Established target
255,ASP2408,ASP2408,"antiinflammatory agent,DMARD",fusion protein,not approved,P33681,CD80_HUMAN,CD80,T-lymphocyte activation antigen CD80 OS=Homo sapiens GN=CD80 PE=1 SV=1,Receptors,Receptor; T-cell surface receptor,Established target
255,ASP2408,ASP2408,"antiinflammatory agent,DMARD",fusion protein,not approved,P42081,CD86_HUMAN,CD86,T-lymphocyte activation antigen CD86 OS=Homo sapiens GN=CD86 PE=1 SV=1,Other,T-lymphocyte activation antigen CD86,Established target
256,AT-101,AT-101,antineoplastic agent,Small molecule,not approved,Q92934,BAD_HUMAN,BAD,Bcl2 antagonist of cell death,Miscellaneous,regulator of apoptosis,Novel Target
256,AT-101,AT-101,antineoplastic agent,Small molecule,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
256,AT-101,AT-101,antineoplastic agent,Small molecule,not approved,Q07820,MCL1_HUMAN,MCL1,Induced myeloid leukemia cell differentiation protein Mcl-1 (Bcl-2-like protein 3) (Bcl2-L-3) (Bcl-2-related protein EAT/mcl1) (mcl1/EAT),Transporters,regulator of apoptosis,Novel Target
257,AT13387,AT13387,antineoplastic agent,Small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
257,AT13387,AT13387,antineoplastic agent,Small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
258,AT-1391,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
259,AT3022,fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
259,AT3022,fentanyl,analgesic,Small Molecule,approved,P41143,OPRM_HUMAN,OPRD1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
259,AT3022,fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
259,AT3022,fentanyl,"analgesic,opioid",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
260,AT7519,AT7519,antineoplastic agent,Small molecule,not approved,P24941,CDK2_HUMAN,CDK2,Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase),Enzymes,EC:2.7.11.22,Novel Target
261,AT9283,AT9283,antineoplastic agent,Small molecule,not approved,O14965,STK6_HUMAN,AURKA,Serine/threonine-protein kinase 6 (EC 2.7.11.1) (Aurora kinase A) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase aurora-A),Enzymes,EC:2.7.11.1,Novel Target
261,AT9283,AT9283,antineoplastic agent,Small molecule,not approved,Q96GD4,AURKB_HUMAN,AURKB,Serine/threonine-protein kinase 12 (EC 2.7.11.1) (Aurora kinase B) (Aurora- and IPL1-like midbody-associated protein 1) (AIM-1) (Aurora/IPL1-related kinase 2) (ARK-2) (Aurora-related kinase 2) (STK-1) (Serine/threonine-protein kinase aurora-B),Enzymes,EC:2.7.11.1,Novel Target
262,atamestane-plus-toremifene,atamestane,antineoplastic agent,Small molecule,not approved,P11511,CP19A_HUMAN,CYP19A1,Cytochrome P450 19A1 OS=Homo sapiens GN=CYP19A1 PE=1 SV=3,Enzymes,EC:1.14.14,Established target
262,atamestane-plus-toremifene,toremifene,antineoplastic agent,Small Molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
262,atamestane-plus-toremifene,toremifene,antineoplastic agent,Small Molecule,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
263,ATHX-105,ATHX-105,antiobesity agent,Small molecule,not approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
264,ATI-1123,docetaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
265,ATI-7505,ATI-7505,Parasympathomimetic,Small molecule,not approved,Q13639,5HT4R_HUMAN,HTR4,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
266,"ATL1102, TV-1102",ATL1102,antiinflammatory agent,siRNA,not approved,P13612,ITA4_HUMAN,ITGA4,Integrin alpha-4 OS=Homo sapiens GN=ITGA4 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
266,"ATL1102, TV-1102",ATL1102,antiinflammatory agent,siRNA,not approved,P05556,ITB1_HUMAN,ITGB1,Integrin beta-1 (Fibronectin receptor subunit beta) (VLA-4 subunit beta) (CD antigen CD29),Receptors,Receptors;Integrin,Established target
267,"ATL-2502,Colal-Pred",prednisone,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
268,"atomoxetine hydrochloride,Strattera",atomoxetine,for treatment of ADHD,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
269,"atorvastatin calcium,Lipitor",atorvastatin,antihypecholesterolemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
270,"atrasentan, ABT-627,Xinlay",atrasentan,antineoplastic agent,Small molecule,not approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
271,"Atryn, antithrombin",Antithrombin,antithrombotic,recombinant protein,approved,P09871,C1S_HUMAN,C1s,Complement C1s subcomponent,Miscellaneous,EC:3.4.21.42,Established target
271,"Atryn, antithrombin",Antithrombin,antithrombotic,recombinant protein,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
271,"Atryn, antithrombin",Antithrombin,antithrombotic,recombinant protein,approved,P03951,FA11_HUMAN,F11,Coagulation factor XI (FXI) (EC 3.4.21.27) (Plasma thromboplastin antecedent) (PTA) [Cleaved into: Coagulation factor XIa heavy chain; Coagulation factor XIa light chain],Enzymes,EC:3.4.21.27,Established target
271,"Atryn, antithrombin",Antithrombin,antithrombotic,recombinant protein,approved,P00748,FA12_HUMAN,F12,Coagulation factor XII,Enzymes,EC:3.4.21.38,Established target
271,"Atryn, antithrombin",Antithrombin,antithrombotic,recombinant protein,approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
271,"Atryn, antithrombin",Antithrombin,antithrombotic,recombinant protein,approved,P08709,FA7_HUMAN,F7,Coagulation factor VII OS=Homo sapiens GN=F7 PE=1 SV=1,Enzymes,EC:3.4.21.21,Established target
271,"Atryn, antithrombin",Antithrombin,antithrombotic,recombinant protein,approved,P00740,FA9_HUMAN,F9,Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2,Enzymes,EC:3.4.21.22,Established target
271,"Atryn, antithrombin",Antithrombin,antithrombotic,recombinant protein,approved,P03952,KLKB1_HUMAN,KLKB1,Plasma kallikrein,Enzymes,EC:3.4.21.34,Established target
271,"Atryn, antithrombin",Antithrombin,antithrombotic,recombinant protein,approved,P00747,FIBA_HUMAN,PLG,Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Established target
272,Atu027,Atu027,antineoplastic agent,siRNA,not approved,Q6P5Z2,PKN3_HUMAN,PKN3,Serine/threonine-protein kinase N3 (EC 2.7.11.13) (Protein kinase PKN-beta) (Protein-kinase C-related kinase 3),Enzymes,EC:2.7.11.13,Novel Target
273,ATX-MS-1467,ATX-MS-1467,vaccine for multiple sclerosis,vaccine,not approved,P02686,MBP_HUMAN,MBP,Myelin basic protein,Miscellaneous,Miscellaneous;StructureAndAdhesion,Novel Target
274,AUS-131,AUS-131,for treatment of menopausal symtpoms,Small molecule,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
275,autologous cell-based gene therapy,eNOS plasmid,antihypertensive agent,autologous cell-based gene-therapy,not approved,P29474,NOS3_HUMAN,NOS3,"Nitric oxide synthase, endothelial OS=Homo sapiens GN=NOS3 PE=1 SV=3",Enzymes,EC:1.14.13.39,Established target
276,"AV-299, SCH900105",ficlatuzumab,antineoplastic agent,monoclonal antibody,not approved,P14210,HGF_HUMAN,HGF,Hepatocyte growth factor (Hepatopoeitin-A) (Scatter factor) (SF) [Cleaved into: Hepatocyte growth factor alpha chain; Hepatocyte growth factor beta chain],Ligand,Ligand;HGF,Novel Target
277,AV-412,AV-412,antineoplastic agent,Small molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
277,AV-412,AV-412,antineoplastic agent,Small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
278,AV608,AV608,"antidepressant,for treatment of irritable bowel syndrome,antispasmodic",Small molecule,not approved,P25103,NK1R_HUMAN,TACR1,Substance-P receptor OS=Homo sapiens GN=TACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
279,AV-951,tivozanib,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
279,AV-951,tivozanib,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
279,AV-951,tivozanib,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
280,"avanafil, TA-1790",Avanafil,for treatment of erectile dysfunction,Small molecule,not approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
281,Avastin,bevacizumab,antineoplastic agent,monoclonal antibody,approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
282,AVE-0005,aflibercept,antineoplastic agent,fusion protein,not approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
283,"AVE0277, DiaPep277",DiaPep277,antidiabetic,vaccine,not approved,O60603,TLR2_HUMAN,TLR2,Toll-like receptor 2,Receptors,Receptors;TOLL,Novel Target
284,AVE-1625,AVE-1625,"antiobesity agent,for treatment for Alzheimer's disease",Small molecule,not approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
285,"AVI-4126, Resten-MP,Oncomyc-NG",AVI-4126,antineoplastic agent,antisense oligo,not approved,P01106,MYC_HUMAN,MYC,Myc proto-oncogene protein (Class E basic helix-loop-helix protein 39) (bHLHe39) (Proto-oncogene c-Myc) (Transcription factor p64),Miscellaneous,Transcription factor,Novel Target
286,"AVI-4557,N/",AVI-4557,drug efficacy enhancer,antisense oligo,not approved,P08684,CP3A4_HUMAN,CYP3A4,Cytochrome P450 3A4 (Albendazole monooxygenase) (EC 1.14.13.32) (Albendazole sulfoxidase) (CYPIIIA3) (CYPIIIA4) (Cytochrome P450 3A3) (Cytochrome P450 HLp) (Cytochrome P450 NF-25) (Cytochrome P450-PCN1) (Nifedipine oxidase) (Quinine 3-monooxygenase) (EC 1,Enzymes,EC:1.14.14,Novel Target
287,AVI-5126,AVI-5126,cardiovascular agent,antisense oligo,not approved,P01106,MYC_HUMAN,MYC,Myc proto-oncogene protein (Class E basic helix-loop-helix protein 39) (bHLHe39) (Proto-oncogene c-Myc) (Transcription factor p64),Miscellaneous,Transcription factor,Novel Target
288,"aviptadil,Invicorp",phentolamine ,for treatment of erectile dysfunction,small molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
288,"aviptadil,Invicorp",phentolamine ,for treatment of erectile dysfunction,small molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
288,"aviptadil,Invicorp",vasoactive intestinal peptide,for treatment of erectile dysfunction,peptide,not approved,P32241,VIPR1_HUMAN,VIPR1,Vasoactive intestinal polypeptide receptor 1,Receptors,GPCR;Secretin,Novel Target
288,"aviptadil,Invicorp",vasoactive intestinal peptide,for treatment of erectile dysfunction,peptide,not approved,P41587,VIPR2_HUMAN,VIPR2,Vasoactive intestinal polypeptide receptor 2,Receptors,GPCR;Rhodopsin,Novel Target
289,AVL-292,AVL-292,antineoplastic agent,Small molecule,not approved,Q06187,BTK_HUMAN,BTK,Tyrosine-protein kinase BTK (EC 2.7.10.2) (Agammaglobulinaemia tyrosine kinase) (ATK) (B-cell progenitor kinase) (BPK) (Bruton tyrosine kinase),Enzymes,EC:2.7.10.2,Novel Target
290,AVN-101,AVN-101,for treatment of alzheimer's disease,Small molecule,not approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
291,AVN-211,AVN-211,antipsychotic agent,Small molecule,not approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
292,AVN-322,AVN-322,for treatment of alzheimer's disease,Small molecule,not approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
293,AVN-944,AVN-944,antineoplastic agent,Small molecule,not approved,P20839,IMDH1_HUMAN,IMPDH1,Inosine-5'-monophosphate dehydrogenase 1 OS=Homo sapiens GN=IMPDH1 PE=1 SV=2,Enzymes,EC:1.1.1.205,Established target
293,AVN-944,AVN-944,antineoplastic agent,Small molecule,not approved,P12268,IMDH2_HUMAN,IMPDH2,Inosine-5'-monophosphate dehydrogenase 2 OS=Homo sapiens GN=IMPDH2 PE=1 SV=2,Enzymes,EC:1.1.1.205,Established target
294,Avonex,interferon beta-1a,for treatment of multiple sclerosis,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
294,Avonex,interferon beta-1a,for treatment of multiple sclerosis,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
295,"avosentan, SPP 301",avosentan,antihypertensive agent,Small molecule,not approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
296,AVP-923,dextromethorphan,antitussive agent,Small molecule,approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
296,AVP-923,dextromethorphan,antitussive agent,Small molecule,approved,Q99720,SGMR1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
297,AVT-02 UE,AVT-02 UE,antiinflammatory agent,oligonucleotide decoy,not approved,P42224,STAT1_HUMAN,STAT1,Signal transducer and activator of transcription 1-alpha/beta (Transcription factor ISGF-3 components p91/p84),Miscellaneous,Transcription factor,Novel Target
298,AX200,filgramstim,neuroprotectant agent for stroke victims,protein,approved,Q99062,CSF3R_HUMAN,CSF3R,Granulocyte colony-stimulating factor receptor OS=Homo sapiens GN=CSF3R PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
299,"axitinib, AG-013736",axitinib,antineoplastic agent,Small molecule,approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
299,"axitinib, AG-013736",axitinib,antineoplastic agent,Small molecule,approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
299,"axitinib, AG-013736",axitinib,antineoplastic agent,Small molecule,approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
299,"axitinib, AG-013736",axitinib,antineoplastic agent,Small molecule,approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
299,"axitinib, AG-013736",axitinib,antineoplastic agent,Small molecule,approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
299,"axitinib, AG-013736",axitinib,antineoplastic agent,Small molecule,approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
300,AXL1717,AXL1717,antineoplastic agent,Small molecule,not approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
301,"AZ-001, Staccato prochlorperazine",prochlorperazine,antimigraine agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
302,"AZ-002, Staccato alprazolam",alprazolam,"anxiolytic, sedative,hypnotic",Small Molecule,approved,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
303,"AZ-003, Staccato fentanyl",fentanyl,adjuvant to anesthesia,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
303,"AZ-003, Staccato fentanyl",fentanyl,adjuvant to anesthesia,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
304,AZ-004,loxapine,antipsychotic agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
304,AZ-004,loxapine,antipsychotic agent,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
305,"AZ-007, Staccato zaleplon",zaleplon,hypnotic,Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
305,"AZ-007, Staccato zaleplon",zaleplon,hypnotic,Small Molecule,approved,P30536,TSPOA_HUMAN,TSPO,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
306,"azacitidine,Vidaza",azacitidine,antineoplastic agent,Small Molecule,approved,P26358,DNMT1_HUMAN,DNMT1,DNA (cytosine-5)-methyltransferase 1 OS=Homo sapiens GN=DNMT1 PE=1 SV=2,Enzymes,EC:2.1.1.37,Established target
307,AZD-0837,AZD-0837,anticoagulant,Small molecule,not approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
308,AZD2066,AZD2066,"analgesic,for treatment of gastroesophageal reflux disease",Small molecule,not approved,P41594,GRM5_HUMAN,GRM5,Metabotropic glutamate receptor 5 (mGluR5),Receptors,GPCR;Glutamate,Established target
309,"AZD6244, ARRY-142886","AZD6244, ARRY-142886",antineoplastic agent,Small molecule,not approved,Q02750,MP2K1_HUMAN,MAP2K1,Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1),Enzymes,EC:2.7.12.2,Novel Target
309,"AZD6244, ARRY-142886","AZD6244, ARRY-142886",antineoplastic agent,Small molecule,not approved,P36507,MP2K2_HUMAN,MAP2K2,Dual specificity mitogen-activated protein kinase kinase 2 (MAP kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2) (MAPK/ERK kinase 2) (MEK 2),Enzymes,EC:2.7.12.2,Novel Target
310,AZD-6765,AZD-6765,antidepressant,unknown,not approved,Q05586,NMDZ1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo sapiens GN=GRIN1 PE=1 SV=1,Receptors,TC:1.A.10.1.6,Established target
310,AZD-6765,AZD-6765,antidepressant,unknown,not approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
310,AZD-6765,AZD-6765,antidepressant,unknown,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
310,AZD-6765,AZD-6765,antidepressant,unknown,not approved,Q14957,NMDE3_HUMAN,GRIN2C,Glutamate [NMDA] receptor subunit epsilon-3 (N-methyl D-aspartate receptor subtype 2C) (NMDAR2C) (NR2C),Receptors,TC:1.A.10.1.3,Novel Target
310,AZD-6765,AZD-6765,antidepressant,unknown,not approved,O15399,NMDE4_HUMAN,GRIN2D,Glutamate [NMDA] receptor subunit epsilon-4 OS=Homo sapiens GN=GRIN2D PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
310,AZD-6765,AZD-6765,antidepressant,unknown,not approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
310,AZD-6765,AZD-6765,antidepressant,unknown,not approved,O60391,NMD3B_HUMAN,GRIN3B,Glutamate [NMDA] receptor subunit 3B OS=Homo sapiens GN=GRIN3B PE=2 SV=2,Receptors,TC:1.A.10.1,Established target
311,AZD-8330,AZD-8330,antineoplastic agent,Small molecule,not approved,Q02750,MP2K1_HUMAN,MAP2K1,Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1),Enzymes,EC:2.7.12.2,Novel Target
312,AZD-8848,AZD-8848,antiallergy agent,Small molecule,not approved,Q9NYK1,TLR7_HUMAN,TLR7,Toll-like receptor 7 OS=Homo sapiens GN=TLR7 PE=1 SV=1,Receptors,Receptors;TOLL,Established target
313,Azelastine,azelastine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
314,"azelastine hydrochloride nasal spray,Astepro",azelastine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
315,"azilsartan medoxomil, TAK-491",azilsartan,antihypertensive agent,Small molecule,approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
316,"B27PD,Optiquel",B27PD,agent for hyposensibilization,peptide,not approved,P10523,ARRS_HUMAN,SAG,S-arrestin (48 kDa protein) (Retinal S-antigen) (S-AG) (Rod photoreceptor arrestin),Miscellaneous,Enzyme regulator,Novel Target
317,"balsalazide disodium,Colazal, Giazo",balsalazide,antiinflammatory agent,Small molecule,approved,P09917,LOX5_HUMAN,ALOX5,Arachidonate 5-lipoxygenase OS=Homo sapiens GN=ALOX5 PE=1 SV=2,Enzymes,EC:1.13.11.34,Established target
317,"balsalazide disodium,Colazal, Giazo",balsalazide,antiinflammatory agent,Small molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
317,"balsalazide disodium,Colazal, Giazo",balsalazide,antiinflammatory agent,Small molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
317,"balsalazide disodium,Colazal, Giazo",balsalazide,antiinflammatory agent,Small molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
318,"baminercept, BG-9924",baminercept,"antiinflammatory agent,DMARD",fusion protein,not approved,P01374,TNFB_HUMAN,LTA,Lymphotoxin-alpha (LT-alpha) (TNF-beta) (Tumor necrosis factor ligand superfamily member 1),Miscellaneous,Ligand;Cytokine,Novel Target
318,"baminercept, BG-9924",baminercept,"antiinflammatory agent,DMARD",fusion protein,not approved,Q06643,TNFC_HUMAN,LTB,Lymphotoxin-beta (LT-beta) (Tumor necrosis factor C) (TNF-C) (Tumor necrosis factor ligand superfamily member 3),Miscellaneous,Ligand;Cytokine,Novel Target
318,"baminercept, BG-9924",baminercept,"antiinflammatory agent,DMARD",fusion protein,not approved,O43557,TNF14_HUMAN,TNFSF14,Tumor necrosis factor ligand superfamily member 14,Ligand,Ligand; TNFSF14,Novel Target
319,BAN2401,BAN2401,for treatment of alzheimer's disease,monoclonal antibody,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
320,Bapineuzumab ,Bapineuzumab ,for treatment of alzheimer's disease,monoclonal antibody,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
321,"bardoxolone methyl, RTA 402",bardoxolone,antineoplastic agent,Small molecule,not approved,P19838,NFKB1_HUMAN,NFKB1,Nuclear factor NF-kappa-B p105 subunit OS=Homo sapiens GN=NFKB1 PE=1 SV=2,Transcription factor,Transcription factor,Established target
322,"basiliximab,Simulect",basiliximab,immunomodulatory agent,monoclonal antibody,approved,P01589,IL2RA_HUMAN,IL2RA,Interleukin-2 receptor alpha chain OS=Homo sapiens GN=IL2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
323,"bazedoxifene, bazedoxifene/conjugated estrogens, TSE-424,Viviant, Aprela, Conbriza",bazedoxifene,antiosteoporotic agent,Small molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
323,"bazedoxifene, bazedoxifene/conjugated estrogens, TSE-424,Viviant, Aprela, Conbriza",bazedoxifene,antiosteoporotic agent,Small molecule,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
324,"BCX-4208, R-3421",ulodesine,antiinflammatory agent,Small molecule,not approved,P00491,PNPH_HUMAN,PNP,Purine nucleoside phosphorylase (PNP) (EC 2.4.2.1) (Inosine phosphorylase),Enzymes,EC:2.4.2.1,Novel Target
325,"becaplermin,Regranex",becaplermin,for treatment of diabetic foot ulcers,recombinant protein,approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
325,"becaplermin,Regranex",becaplermin,for treatment of diabetic foot ulcers,recombinant protein,approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
326,"becatecarin, XL 119, rebeccamycin",becatecarin,antineoplastic agent,Small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
326,"becatecarin, XL 119, rebeccamycin",becatecarin,antineoplastic agent,Small molecule,not approved,Q02880,TOP2B_HUMAN,TOP2B,"DNA topoisomerase 2-beta (EC 5.99.1.3) (DNA topoisomerase II, beta isozyme)",Enzymes,EC:5.99.1.3,Established target
327,"beclometasone, CHF-1514, /",beclomethasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
328,"beclomethasone dipropionate, BDP HFA,Qvar, Qnaze",beclomethasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
329,"beclomethasone dipropionate,orBec",beclomethasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
330,"belagenpumatucel-L,Lucanix",belagenpumatucel-L,antineoplastic agent,vaccine,not approved,P61812,TGFB2_HUMAN,TGFB2,Transforming growth factor beta-2 (TGF-beta-2) (BSC-1 cell growth inhibitor) (Cetermin) (Glioblastoma-derived T-cell suppressor factor) (G-TSF) (Polyergin),Miscellaneous,Transforming growth factor,Novel Target
331,"belatacept, BMS-224818, LEA29y",belatacept,immunosuppressant,fusion protein,approved,P33681,CD80_HUMAN,CD80,T-lymphocyte activation antigen CD80 OS=Homo sapiens GN=CD80 PE=1 SV=1,Receptors,Receptor; T-cell surface receptor,Established target
331,"belatacept, BMS-224818, LEA29y",belatacept,immunosuppressant,fusion protein,approved,P42081,CD86_HUMAN,CD86,T-lymphocyte activation antigen CD86 OS=Homo sapiens GN=CD86 PE=1 SV=1,Miscellaneous,T-lymphocyte activation antigen CD86,Established target
332,Belimumab,Belimumab,"antiinflammatory agent,DMARD",monoclonal antibody,approved,Q9Y275,TN13B_HUMAN,TNFSF13B,Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved int,Miscellaneous,Ligand;Cytokine,Established target
333,"BEMA buprenorphine, buccal mucosa adhesive",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
333,"BEMA buprenorphine, buccal mucosa adhesive",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
334,"BEMA fentanyl,Onsolis, Breakyl",fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
334,"BEMA fentanyl,Onsolis, Breakyl",fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
335,"benazepril,Lotensin",benazepril,antihypertensive agent,Small Molecule,approved,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
336,"bepotastine besilate,Bepreve, Talion",bepotastine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
337,beraprost,beraprost,antihypertensive agent,Small molecule,not approved,P43119,PI2R_HUMAN,PTGIR,Prostacyclin receptor OS=Homo sapiens GN=PTGIR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
338,"betamethasone valerate 0.12% topical foam,BetMetFoam",betamethasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
339,"betamethasone valerate,Luxiq",betamethasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
340,"betrixaban, PRT054021, Factor Xa inhibitor",betrixaban,antithrombotic,Small molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
341,"bevasiranib, Cand5",bevasiranib,for treatment of wet age-related macular degeneration,siRNA,not approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
342,"bexarotene,Targretin",bexarotene,antineoplastic agent,Small Molecule,approved,P19793,RXRA_HUMAN,RXRA,Retinoic acid receptor RXR-alpha OS=Homo sapiens GN=RXRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
342,"bexarotene,Targretin",bexarotene,antineoplastic agent,Small Molecule,approved,P28702,RXRB_HUMAN,RXRB,Retinoic acid receptor RXR-beta OS=Homo sapiens GN=RXRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
342,"bexarotene,Targretin",bexarotene,antineoplastic agent,Small Molecule,approved,P48443,RXRG_HUMAN,RXRG,Retinoic acid receptor RXR-gamma OS=Homo sapiens GN=RXRG PE=1 SV=1,Receptors,Nuclear receptor,Established target
343,BF-1,BF-1,antimigraine agent,Small molecule,not approved,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
344,BF-Derm1,BF-Derm1,antiallergy agent,Small molecule,not approved,P19113,DCHS_HUMAN,HDC,Histidine decarboxylase (HDC) (EC 4.1.1.22),Enzymes,EC:4.1.1.22,Novel Target
345,BG-9928,BG-9928,for treatment of congestive heart failure,Small molecule,not approved,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
346,BGC20-0166,fluoxetine,for treatment of sleep apnea,Small Molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter,Transporter,TC:2.A.22.1.1,Established target
346,BGC20-0166,ondansetron,for treatment of sleep apnea,Small Molecule,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A,Receptors,TC:1.A.9.2.1,Established target
347,BGC20-1531,BGC20-1531 ,antimigraine agent,Small molecule,not approved,P35408,PE2R4_HUMAN,PTGER4,Prostaglandin E2 receptor EP4 subtype OS=Homo sapiens GN=PTGER4 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
348,BGG-492,BGG-492,"anticonvulsant,antimigraine agent",Small molecule,not approved,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
348,BGG-492,BGG-492,"anticonvulsant,antimigraine agent",Small molecule,not approved,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
348,BGG-492,BGG-492,"anticonvulsant,antimigraine agent",Small molecule,not approved,P42263,GRIA3_HUMAN,GRIA3,"Glutamate receptor 3 (GluR-3) (AMPA-selective glutamate receptor 3) (GluR-C) (GluR-K3) (Glutamate receptor ionotropic, AMPA 3) (GluA3)",Receptors,TC:1.A.10.1.4,Established target
348,BGG-492,BGG-492,"anticonvulsant,antimigraine agent",Small molecule,not approved,P48058,GRIA4_HUMAN,GRIA4,"Glutamate receptor 4 (GluR-4) (GluR4) (AMPA-selective glutamate receptor 4) (GluR-D) (Glutamate receptor ionotropic, AMPA 4) (GluA4)",Receptors,TC:1.A.10.1,Established target
349,BHR-100,progesterone,neuroprotectant for stroke victims,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
349,BHR-100,progesterone,neuroprotectant for stroke victims,Small Molecule,approved,P08235,MCR_HUMAN,NR3C2,Mineralocorticoid receptor OS=Homo sapiens GN=NR3C2 PE=1 SV=1,Receptors,Nuclear receptor,Established target
349,BHR-100,progesterone,neuroprotectant for stroke victims,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
350,BI-10773,BI-10773,antidiabetic,Small molecule,not approved,P31639,SC5A2_HUMAN,SLC5A2,Sodium/glucose cotransporter 2 (Na(+)/glucose cotransporter 2) (Low affinity sodium-glucose cotransporter) (Solute carrier family 5 member 2),Transporters,TC:2.A.21.3.16,Established target
351,BI-1744-CL,olodaterol,bronchodilator,Small molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
352,BI-204,BI-204,antiatherosclerotic agent,monoclonal antibody,not approved,P78380,OLR1_HUMAN,OLR1,Oxidized low-density lipoprotein receptor 1,Receptors,Miscellaneous;lipoprotein receptor,Novel Target
353,BI-505,BI-505,antineoplastic agent,antibody,not approved,P05362,ICAM1_HUMAN,ICAM1,Intercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
354,"BIBF-1120,Vargatef",Nintedanib,antineoplastic agent,Small molecule,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
354,"BIBF-1120,Vargatef",Nintedanib,antineoplastic agent,Small molecule,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
354,"BIBF-1120,Vargatef",Nintedanib,antineoplastic agent,Small molecule,not approved,P22607,FGFR3_HUMAN,FGFR3,Fibroblast growth factor receptor 3 OS=Homo sapiens GN=FGFR3 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
354,"BIBF-1120,Vargatef",Nintedanib,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
354,"BIBF-1120,Vargatef",Nintedanib,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
354,"BIBF-1120,Vargatef",Nintedanib,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
354,"BIBF-1120,Vargatef",Nintedanib,antineoplastic agent,Small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
354,"BIBF-1120,Vargatef",Nintedanib,antineoplastic agent,Small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
355,"bicalutimide,Casodex",Bicalutamide,antineoplastic agent,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
356,"bifeprunox, DU127090",bifeprunox,"antipsychotic agent,antiparkinson agent",Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
356,"bifeprunox, DU127090",bifeprunox,"antipsychotic agent,antiparkinson agent",Small molecule,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
356,"bifeprunox, DU127090",bifeprunox,"antipsychotic agent,antiparkinson agent",Small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
356,"bifeprunox, DU127090",bifeprunox,"antipsychotic agent,antiparkinson agent",Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
356,"bifeprunox, DU127090",bifeprunox,"antipsychotic agent,antiparkinson agent",Small molecule,not approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
356,"bifeprunox, DU127090",bifeprunox,"antipsychotic agent,antiparkinson agent",Small molecule,not approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
357,BIIB037,BIIB037,for treatment of alzheimer's disease,antibody,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
358,BIM23A760,BIM23A760,"antineoplastic agent,treatment for acromegaly",Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
358,BIM23A760,BIM23A760,"antineoplastic agent,treatment for acromegaly",Small molecule,not approved,P30874,SSR2_HUMAN,SSTR2,Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SRIF-1),Receptors,GPCR;Rhodopsin,Established target
358,BIM23A760,BIM23A760,"antineoplastic agent,treatment for acromegaly",Small molecule,not approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
359,"bimatoprost,  AGN 192024,Lumigan",bimatoprost,antiglaucomic agent,Small Molecule,approved,P34995,PE2R1_HUMAN,PTGER1,Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens GN=PTGER1 PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
359,"bimatoprost,  AGN 192024,Lumigan",bimatoprost,antiglaucomic agent,Small Molecule,approved,P43115,PE2R3_HUMAN,PTGER3,Prostaglandin E2 receptor EP3 subtype OS=Homo sapiens GN=PTGER3 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
359,"bimatoprost,  AGN 192024,Lumigan",bimatoprost,antiglaucomic agent,Small Molecule,approved,P43088,PF2R_HUMAN,PTGFR,Prostaglandin F2-alpha receptor OS=Homo sapiens GN=PTGFR PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
360,"bimoclomol, ABT-822",bimoclomol,for treatment of diabetic neuropathy,Small molecule,not approved,Q00613,HS90A_HUMAN,HSF1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
361,"bimosiamose, TBC 1269",bimosiamose,"antiinflammatory agent,antipsoriatic",Small molecule,not approved,P16581,LYAM2_HUMAN,SELE,E-selectin (CD62 antigen-like family member E) (Endothelial leukocyte adhesion molecule 1) (ELAM-1) (Leukocyte-endothelial cell adhesion molecule 2) (LECAM2) (CD antigen CD62E),Receptors,Receptors;Selectin,Novel Target
361,"bimosiamose, TBC 1269",bimosiamose,"antiinflammatory agent,antipsoriatic",Small molecule,not approved,P14151,LYAM1_HUMAN,SELL,L-selectin (CD62 antigen-like family member L) (Leukocyte adhesion molecule 1) (LAM-1) (Leukocyte surface antigen Leu-8) (Leukocyte-endothelial cell adhesion molecule 1) (LECAM1) (Lymph node homing receptor) (TQ1) (gp90-MEL) (CD antigen CD62L),Receptors,Receptors;Selectin,Novel Target
361,"bimosiamose, TBC 1269",bimosiamose,"antiinflammatory agent,antipsoriatic",Small molecule,not approved,P16109,LYAM3_HUMAN,SELP,P-selectin (CD62 antigen-like family member P) (Granule membrane protein 140) (GMP-140) (Leukocyte-endothelial cell adhesion molecule 3) (LECAM3) (Platelet activation dependent granule-external membrane protein) (PADGEM) (CD antigen CD62P),Receptors,Receptors;Selectin,Novel Target
362,BIND-014,docetaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
362,BIND-014,docetaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
363,"binodenoson, MRE 0470,CorVue",binodenoson,diagnostic agent,Small molecule,not approved,P29274,AA2AR_HUMAN,ADORA2A,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
364,"Bio-E-Gel, estradiol,Elestrin",estradiol,"hormone replacement,treatment for menopause",Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
364,"Bio-E-Gel, estradiol,Elestrin",estradiol,"hormone replacement,treatment for menopause",Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
365,Bio-T-Gel,testosterone,hormone replacement,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
366,BIW-8405,benralizumab,antiasthmatic agent,monoclonal antibody,not approved,Q01344,IL5RA_HUMAN,IL5RA,Interleukin-5 receptor subunit alpha (IL-5 receptor subunit alpha) (IL-5R subunit alpha) (IL-5R-alpha) (IL-5RA) (CDw125) (CD antigen CD125),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
367,"bivalirudin,Angiomax, Angiox",bivalirudin,antiplatelet agent,peptide,approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
368,BLX-883,interferon alpha-2b,for treatment of hepatitis,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
368,BLX-883,interferon alpha-2b,for treatment of hepatitis,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
369,"BMS 936564, MDX-1338",BMS 936564,antineoplastic agent,antibody,not approved,P61073,CXCR4_HUMAN,CXCR4,C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (Fusin) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD antigen CD184),Receptors,GPCR;Rhodopsin,Established target
370,"BMS-512148, dapagliflozin",dapagliflozin,antidiabetic,Small molecule,not approved,P31639,SC5A2_HUMAN,SLC5A2,Sodium/glucose cotransporter 2 (Na(+)/glucose cotransporter 2) (Low affinity sodium-glucose cotransporter) (Solute carrier family 5 member 2),Transporters,TC:2.A.21.3.16,Established target
371,BMS-582949,BMS-582949,"antiinflammatory agent,DMARD,antipsoriatic",Small molecule,not approved,Q15759,MK11_HUMAN,MAPK11,Mitogen-activated protein kinase 11 (MAP kinase 11) (MAPK 11) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 beta) (MAP kinase p38 beta) (p38b) (Stress-activated protein kinase 2) (p38-2),Enzymes,EC:2.7.11.24,Novel Target
371,BMS-582949,BMS-582949,"antiinflammatory agent,DMARD,antipsoriatic",Small molecule,not approved,P53778,MK12_HUMAN,MAPK12,Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3),Enzymes,EC:2.7.11.24,Novel Target
371,BMS-582949,BMS-582949,"antiinflammatory agent,DMARD,antipsoriatic",Small molecule,not approved,O15264,MK13_HUMAN,MAPK13,Mitogen-activated protein kinase 13 (MAP kinase 13) (MAPK 13) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 delta) (MAP kinase p38 delta) (Stress-activated protein kinase 4),Enzymes,EC:2.7.11.24,Novel Target
371,BMS-582949,BMS-582949,"antiinflammatory agent,DMARD,antipsoriatic",Small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
372,BMS-299897,BMS-299897,for treatment of alzheimer's disease,Small molecule,not approved,Q96BI3,APH1A_HUMAN,APH1A,Gamma-secretase subunit APH-1A (APH-1a) (Aph-1alpha) (Presenilin-stabilization factor),Enzymes,Miscellaneous:Gamma secretase subunit;APH-1 family,Novel Target
372,BMS-299897,BMS-299897,for treatment of alzheimer's disease,Small molecule,not approved,Q8WW43,APH1B_HUMAN,APH1B,Gamma-secretase subunit APH-1B,Enzymes,Miscellaneous:Gamma secretase subunit;APH-1 family,Novel Target
372,BMS-299897,BMS-299897,for treatment of alzheimer's disease,Small molecule,not approved,Q92542,NICA_HUMAN,NCSTN,Nicastrin,Miscellaneous,Miscellaneous;gamma secretase subunit,Novel Target
372,BMS-299897,BMS-299897,for treatment of alzheimer's disease,Small molecule,not approved,P49768,PSN1_HUMAN,PSEN1,Presenilin-1,Enzymes,EC:3.4.23.-,Novel Target
372,BMS-299897,BMS-299897,for treatment of alzheimer's disease,Small molecule,not approved,P49810,PSN2_HUMAN,PSEN2,Presenilin-2,Enzymes,EC:3.4.23.-,Novel Target
372,BMS-299897,BMS-299897,for treatment of alzheimer's disease,Small molecule,not approved,Q9NZ42,PEN2_HUMAN,PSENEN,Gamma-secretase subunit PEN-2 (Presenilin enhancer protein 2),Miscellaneous,Miscellaneous;Gamma secretase subunit,Novel Target
372,BMS-708163,BMS-708163,for treatment of alzheimer's disease,Small molecule,not approved,Q96BI3,APH1A_HUMAN,APH1A,Gamma-secretase subunit APH-1A (APH-1a) (Aph-1alpha) (Presenilin-stabilization factor),Enzymes,Miscellaneous:Gamma secretase subunit;APH-1 family,Novel Target
372,BMS-708163,BMS-708163,for treatment of alzheimer's disease,Small molecule,not approved,Q8WW43,APH1B_HUMAN,APH1B,Gamma-secretase subunit APH-1B,Enzymes,Miscellaneous:Gamma secretase subunit;APH-1 family,Novel Target
372,BMS-708163,BMS-708163,for treatment of alzheimer's disease,Small molecule,not approved,Q92542,NICA_HUMAN,NCSTN,Nicastrin,Miscellaneous,Miscellaneous;gamma secretase subunit,Novel Target
372,BMS-708163,BMS-708163,for treatment of alzheimer's disease,Small molecule,not approved,P49768,PSN1_HUMAN,PSEN1,Presenilin-1,Enzymes,EC:3.4.23.-,Novel Target
372,BMS-708163,BMS-708163,for treatment of alzheimer's disease,Small molecule,not approved,P49810,PSN2_HUMAN,PSEN2,Presenilin-2,Enzymes,EC:3.4.23.-,Novel Target
372,BMS-708163,BMS-708163,for treatment of alzheimer's disease,Small molecule,not approved,Q9NZ42,PEN2_HUMAN,PSENEN,Gamma-secretase subunit PEN-2 (Presenilin enhancer protein 2),Miscellaneous,Miscellaneous;Gamma secretase subunit,Novel Target
373,BMS-754807,BMS-754807,antineoplastic agent,Small molecule,not approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
374,"BMS-863233, XL-413",BMS-863233,antineoplastic agent,Small molecule,not approved,O00311,CDC7_HUMAN,CDC7,Cell division cycle 7-related protein kinase (CDC7-related kinase) (HsCdc7) (huCdc7) (EC 2.7.11.1),Enzymes,EC:2.7.11.1,Novel Target
375,"BMS-936558, ONO-4538, MDX-1106",MDX-1106,antineoplastic agent,monoclonal antibody,not approved,Q15116,PDCD1_HUMAN,PDCD1,Programmed cell death protein 1 (Protein PD-1) (hPD-1) (CD antigen CD279),Receptors,Miscellaneous;PDCD1,Novel Target
376,"BN-002,Capsitonin",calcitonin,antiosteoporotic agent,Small molecule,approved,P30988,CALCR_HUMAN,CALCR,Calcitonin receptor OS=Homo sapiens GN=CALCR PE=1 SV=1,Receptors,GPCR;Secretin,Established target
377,"BN-003,CaPTHymone",parathyroid hormone,antiosteoporotic agent,recombinant protein,not approved,Q03431,PTH1R_HUMAN,PTH1R,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
378,"BOL-303259-X, NCX 116, PF-03187207",NCX116,for treatment of glaucoma,Small molecule,not approved,P43088,PF2R_HUMAN,PTGFR,Prostaglandin F2-alpha receptor OS=Homo sapiens GN=PTGFR PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
379,bosutinib,bosutinib,antineoplastic agent,Small molecule,not approved,P00519,ABL1_HUMAN,ABL1,Proto-oncogene tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4,Enzymes,EC:2.7.10.2,Established target
379,bosutinib,bosutinib,antineoplastic agent,Small molecule,not approved,P12931,SRC_HUMAN,SRC,Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
380,botulinum toxin type A,botulinum toxin type A,"neuromuscular blocking agent,for treatment of wrinkles,antispasmodic",protein,approved,P60880,SNP25_HUMAN,SNAP25,Synaptosomal-associated protein 25 OS=Homo sapiens GN=SNAP25 PE=1 SV=1,Miscellaneous,SNAP25 family,Established target
380,botulinum toxin type A,botulinum toxin type A,"neuromuscular blocking agent,for treatment of wrinkles,antispasmodic",protein,approved,P60880,SNP25_HUMAN,SNAP25,Synaptosomal-associated protein 25 OS=Homo sapiens GN=SNAP25 PE=1 SV=1,Miscellaneous,SNAP25 family,Established target
381,"BP-100-1.01, liposomal Grb-2, L-Grb-2",liposomal Grb-2,antineoplastic agent,antisense oligo,not approved,P62993,GRB2_HUMAN,GRB2,Growth factor receptor-bound protein 2 (Adapter protein GRB2) (Protein Ash) (SH2/SH3 adapter GRB2),Receptors,Miscellaneous;GRB2/sem-5/DRK family,Novel Target
382,"BPX-101, BP-GMAX-CD1",BPX-101,antineoplastic agent,vaccine,not approved,P25942,TNR5_HUMAN,CD40,Tumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40) (Bp50) (CD40L receptor) (CDw40) (CD antigen CD40),Receptors,Receptors;TNFNGF,Novel Target
383,Bremelanotide,Bremelanotide,for treatment of sexual dysfunction,peptide,not approved,Q01726,MSHR_HUMAN,MC1R,Melanocyte-stimulating hormone receptor (MSH-R) (Melanocortin receptor 1) (MC1-R),Receptors,GPCR;Rhodopsin,Novel Target
383,Bremelanotide,Bremelanotide,for treatment of sexual dysfunction,peptide,not approved,P32245,MC4R_HUMAN,MC4R,Melanocortin receptor 4 (MC4-R),Receptors,GPCR;Rhodopsin,Novel Target
384,Briakinumab,Briakinumab,"antiinflammatory agent,for treatment of multiple sclerosis,antipsoriatic",monoclonal antibody,not approved,P29459,IL12A_HUMAN,IL12A,Interleukin-12 subunit alpha (IL-12A) (IL-12 subunit p35) (Cytotoxic lymphocyte maturation factor 35 kDa subunit) (CLMF p35) (NK cell stimulatory factor chain 1) (NKSF1),Miscellaneous,Ligand;Cytokine,Established target
384,Briakinumab,Briakinumab,"antiinflammatory agent,for treatment of multiple sclerosis,antipsoriatic",monoclonal antibody,not approved,P29460,IL12B_HUMAN,IL12B,Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2),Receptors,Receptor; Type 1 cytokine receptor,Established target
384,Briakinumab,Briakinumab,"antiinflammatory agent,for treatment of multiple sclerosis,antipsoriatic",monoclonal antibody,not approved,Q9NPF7,IL23A_HUMAN,IL23A,Interleukin-23 subunit alpha,Receptors,Receptor; Type 1 cytokine receptor,Established target
385,"brimonidine tartrate,Alphagan",brimonidine,for treatment of glaucoma,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
386,"brimonidine tartrate/timolol maleate,Combigan",brimonidine,for treatment of glaucoma,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
386,"brimonidine tartrate/timolol maleate,Combigan",timolol,for treatment of glaucoma,Small Molecule,approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
386,"brimonidine tartrate/timolol maleate,Combigan",timolol,for treatment of glaucoma,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
387,Brivaracetam (UCB 34714).,Brivaracetam,anticonvulsant,Small molecule,not approved,Q7L0J3,SV2A_HUMAN,SV2A,Synaptic vesicle glycoprotein 2A,Transporters,TC:2.A.1,Established target
388,Bromfenac,bromfenac,"opthalmological agent,NSAID",Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
388,Bromfenac,bromfenac,"opthalmological agent,NSAID",Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
389,"bromocriptine mesylate,Cycloset, Ergoset",bromocriptine,antidiabetic,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
389,"bromocriptine mesylate,Cycloset, Ergoset",bromocriptine,antidiabetic,Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,P17252,KPCA_HUMAN,PRKCA,Protein kinase C alpha type (PKC-A) (PKC-alpha) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,P05771,KPCB_HUMAN,PRKCB,Protein kinase C beta type (PKC-B) (PKC-beta) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,Q05655,KPCD_HUMAN,PRKCD,Protein kinase C delta type (EC 2.7.11.13) (nPKC-delta),Enzymes,EC:2.7.11.13,Established target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,Q02156,KPCE_HUMAN,PRKCE,Protein kinase C epsilon type (EC 2.7.11.13) (nPKC-epsilon),Enzymes,EC:2.7.11.13,Established target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,P05129,KPCG_HUMAN,PRKCG,Protein kinase C gamma type (PKC-gamma) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,P24723,KPCL_HUMAN,PRKCH,Protein kinase C eta type (EC 2.7.11.13) (PKC-L) (nPKC-eta),Enzymes,EC:2.7.11.13,Established target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,Q04759,KPCT_HUMAN,PRKCQ,Protein kinase C theta type (EC 2.7.11.13) (nPKC-theta),Enzymes,EC:2.7.11.13,Established target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,Q15139,KPCD1_HUMAN,PRKD1,Serine/threonine-protein kinase D1,Enzymes,EC:2.7.11.13,Novel Target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,Q9BZL6,KPCD2_HUMAN,PRKD2,Serine/threonine-protein kinase D2,Enzymes,EC:2.7.11.13,Novel Target
390,Bryostatin,Bryostatin,for treatment of alzheimer's disease,Small molecule,not approved,O94806,KPCD3_HUMAN,PRKD3,Serine/threonine-protein kinase D3,Enzymes,EC:2.7.11.13,Novel Target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,P17252,KPCA_HUMAN,PRKCA,Protein kinase C alpha type (PKC-A) (PKC-alpha) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,P05771,KPCB_HUMAN,PRKCB,Protein kinase C beta type (PKC-B) (PKC-beta) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,Q05655,KPCD_HUMAN,PRKCD,Protein kinase C delta type (EC 2.7.11.13) (nPKC-delta),Enzymes,EC:2.7.11.13,Established target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,Q02156,KPCE_HUMAN,PRKCE,Protein kinase C epsilon type (EC 2.7.11.13) (nPKC-epsilon),Enzymes,EC:2.7.11.13,Established target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,P05129,KPCG_HUMAN,PRKCG,Protein kinase C gamma type (PKC-gamma) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,P24723,KPCL_HUMAN,PRKCH,Protein kinase C eta type (EC 2.7.11.13) (PKC-L) (nPKC-eta),Enzymes,EC:2.7.11.13,Established target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,Q04759,KPCT_HUMAN,PRKCQ,Protein kinase C theta type (EC 2.7.11.13) (nPKC-theta),Enzymes,EC:2.7.11.13,Established target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,Q15139,KPCD1_HUMAN,PRKD1,Serine/threonine-protein kinase D1,Enzymes,EC:2.7.11.13,Novel Target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,Q9BZL6,KPCD2_HUMAN,PRKD2,Serine/threonine-protein kinase D2,Enzymes,EC:2.7.11.13,Novel Target
391,Bryostatin-1,Bryostatin-1,antineoplastic agent,Small molecule,not approved,O94806,KPCD3_HUMAN,PRKD3,Serine/threonine-protein kinase D3,Enzymes,EC:2.7.11.13,Novel Target
392,BT-061,BT-061,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P01730,CD4_HUMAN,CD4,T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4),Receptors,Receptor; T-cell surface receptor,Established target
393,"BTT-1023, VAP-1 monoclonal antibody",BTT-1023,"antiinflammatory agent,DMARD,antipsoriatic",antibody,not approved,Q16853,AOC3_HUMAN,AOC3,Membrane primary amine oxidase (EC 1.4.3.21) (Copper amine oxidase) (HPAO) (Semicarbazide-sensitive amine oxidase) (SSAO) (Vascular adhesion protein 1) (VAP-1),Enzymes,EC:1.4.3.21,Established target
394,buccal fentanyl,fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
394,buccal fentanyl,fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
395,"buccal prochlorperazine maleate,Emezine",prochlorperazine ,antiemetic,small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
396,"bucindolol hydrochloride,Gencaro",bucindolol,for treatment of heart failure,Small molecule,not approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
396,"bucindolol hydrochloride,Gencaro",bucindolol,for treatment of heart failure,Small molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
397,"budesonide + formoterol,Symbicort",budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
397,"budesonide + formoterol,Symbicort",Formoterol,bronchodilator,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
398,"budesonide inhalation suspension,Pulmicort Respules",budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
399,budesonide MMX,budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
400,"budesonide nasal spray,Rhinocort Aqua",budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
401,budesonide rectal foam,budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
402,"budesonide, oral viscous",budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
403,"budesonide,Entocort EC",budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
404,"budiodarone, ATI-2042",budiodarone,antiarrhytmic agent,Small molecule,not approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
404,"budiodarone, ATI-2042",budiodarone,antiarrhytmic agent,Small molecule,not approved,Q9NY47,CA2D2_HUMAN,CACNA2D2,Voltage-dependent calcium channel subunit alpha-2/delta-2 OS=Homo sapiens GN=CACNA2D2 PE=1 SV=1,Transporters,TC:8.A.18.2.1,Established target
404,"budiodarone, ATI-2042",budiodarone,antiarrhytmic agent,Small molecule,not approved,Q12809,KCNH2_HUMAN,KCNH2,Potassium voltage-gated channel subfamily H member 2 OS=Homo sapiens GN=KCNH2 PE=1 SV=1,Transporters,TC:1.A.1.20.1,Established target
405,"buprenorphine + naloxone capsule,NanoBUP",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
405,"buprenorphine + naloxone capsule,NanoBUP",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
405,"buprenorphine + naloxone capsule,NanoBUP",naloxone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
405,"buprenorphine + naloxone capsule,NanoBUP",naloxone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
406,"buprenorphine + naloxone,Suboxone",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
406,"buprenorphine + naloxone,Suboxone",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
406,"buprenorphine + naloxone,Suboxone",naloxone,for treatment of opioid addiction,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
406,"buprenorphine + naloxone,Suboxone",naloxone,for treatment of opioid addiction,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
407,"buprenorphine subcutaneous implant,Probuphine",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
407,"buprenorphine subcutaneous implant,Probuphine",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
408,"buprenorphine sublingual tablet,Subutex",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
408,"buprenorphine sublingual tablet,Subutex",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
409,"Butrans is a transdermal patch formulation of  buprenorphine, a partial agonist at mu opioid receptors and an antagonist at kappa opioid receptors. It is indicated as an analgesic to deliver continuous pain relief for seven days.  The efficacy of Butrans",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
409,"Butrans is a transdermal patch formulation of  buprenorphine, a partial agonist at mu opioid receptors and an antagonist at kappa opioid receptors. It is indicated as an analgesic to deliver continuous pain relief for seven days.  The efficacy of Butrans",buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
410,"BVF-033,Aplenzin",bupropion,"antidepressant,appetite suppressant,smoking-cessation agent",Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
410,"BVF-033,Aplenzin",bupropion,"antidepressant,appetite suppressant,smoking-cessation agent",Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
411,BVT.115959,BVT.115959,analgesic,Small molecule,not approved,P29274,AA2AR_HUMAN,ADORA2A,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
412,BVT.28949,BVT.28949,for treatment of glaucoma,Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
413,"C105, levo-amphetamine sulfate",amphetamine,"for treatment of cognitive dysfunction,for treatment of ADHD",Small Molecule,approved,Q16568,CART_HUMAN,CARTPT,Cocaine- and amphetamine-regulated transcript protein,Miscellaneous,Miscellaneous; CARTPT,Established target
413,"C105, levo-amphetamine sulfate",amphetamine,"for treatment of cognitive dysfunction,for treatment of ADHD",Small Molecule,approved,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
413,"C105, levo-amphetamine sulfate",amphetamine,"for treatment of cognitive dysfunction,for treatment of ADHD",Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
413,"C105, levo-amphetamine sulfate",amphetamine,"for treatment of cognitive dysfunction,for treatment of ADHD",Small Molecule,approved,Q96RJ0,TAAR1_HUMAN,TAAR1,Trace amine-associated receptor 1 (TaR-1) (Trace amine receptor 1),Receptors,GPCR;Rhodopsin,Established target
414,"C-1311, XLS-002,Symadex",C-1311,antineoplastic agent,Small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
414,"C-1311, XLS-002,Symadex",C-1311,antineoplastic agent,Small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
415,"C1-INH, Cinryze",C1-INH,for treatment of hereditary angioedema,protein,not approved,P05155,IC1_HUMAN,SERPING1,Plasma protease C1 inhibitor (C1 Inh) (C1Inh) (C1 esterase inhibitor) (C1-inhibiting factor) (Serpin G1),Miscellaneous,Protease_inhib_Serpin family,Novel Target
416,"cabazitaxel, XRP6258,Jevtana",cabazitaxel,antineoplastic agent,Small molecule,approved,P68366,TBA4A_HUMAN,TUBA4A,Tubulin alpha-4A chain (Alpha-tubulin 1) (Testis-specific alpha-tubulin) (Tubulin H2-alpha) (Tubulin alpha-1 chain),Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
416,"cabazitaxel, XRP6258,Jevtana",cabazitaxel,antineoplastic agent,Small molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
417,Caduet,amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
417,Caduet,amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
417,Caduet,amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
417,Caduet,amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
417,Caduet,amlodipine,"antihypertensive agent, cardiovascular agent",Small Molecule,approved,Q08289,CACB2_HUMAN,CACNB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
417,Caduet,atorvastatin,anticholesterolaemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
418,CAL-101,CAL-101,antineoplastic agent,Small molecule,not approved,O00329,PK3CD_HUMAN,PIK3CD,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3-kinase subunit delta) (PI3K-delta) (PtdIns-3-kinase subunit delta) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
419,"calcipotriene + betamethasone dipropionate, LEO-80185,Taclonex, Xamiol",betamethasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
419,"calcipotriene + betamethasone dipropionate, LEO-80185,Taclonex, Xamiol",calcipotriene,antipsoriatic agent,Small molecule,approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
420,"calcitriol, vitamin D3 derivative,Silkis, Vectical",calcitriol,antipsoriatic agent,Small Molecule,approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
421,CAM-2029,octreotide,antineoplastic agent,peptide,approved,P30872,SSR1_HUMAN,SSTR1,Somatostatin receptor type 1 OS=Homo sapiens GN=SSTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
421,CAM-2029,octreotide,antineoplastic agent,peptide,approved,P30874,SSR2_HUMAN,SSTR2,Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SRIF-1),Receptors,GPCR;Rhodopsin,Established target
421,CAM-2029,octreotide,antineoplastic agent,peptide,approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
422,CAM2038,buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
422,CAM2038,buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
423,CAM-3001,CAM-3001,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P15509,CSF2R_HUMAN,CSF2RA,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha OS=Homo sapiens GN=CSF2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
424,Campath,alemtuzumab,antineoplastic agent,monoclonal antibody,approved,P31358,CD52_HUMAN,CD52,CAMPATH-1 antigen OS=Homo sapiens GN=CD52 PE=1 SV=1,Miscellaneous,Unclassified,Established target
425,Canagliflozin,Canagliflozin,antidiabetic,Small molecule,not approved,P31639,SC5A2_HUMAN,SLC5A2,Sodium/glucose cotransporter 2 (Na(+)/glucose cotransporter 2) (Low affinity sodium-glucose cotransporter) (Solute carrier family 5 member 2),Transporters,TC:2.A.21.3.16,Established target
426,Canakinumab,Canakinumab,"antiinflammatory agent,DMARD",monoclonal antibody,approved,P01584,IL1B_HUMAN,IL1B,Interleukin-1 beta (IL-1 beta) (Catabolin),Miscellaneous,Ligand;Cytokine,Established target
427,"candesartan cilexetil,Atacand",candesartan,antihypertensive agent,Small Molecule,approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
428,"cangrelor, AR69931",cangrelor,antithrombotic,Small molecule,not approved,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
429,cannabinor,PRS-211375,analgesic,small molecule,not approved,P34972,CNR2_HUMAN,CNR2,Cannabinoid receptor 2 OS=Homo sapiens GN=CNR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
430,CAP7.1,CAP7.1,antineoplastic agent,Small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
431,"Caprospinol , SP-233",Caprospinol,for treatment of alzheimer's disease,Small molecule,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
432,Carfilzomib,Carfilzomib,antineoplastic agent,Small molecule,not approved,P20618,PSB1_HUMAN,PSMB1,Proteasome subunit beta type-1 OS=Homo sapiens GN=PSMB1 PE=1 SV=2,Enzymes,EC:3.4.25.1,Established target
432,Carfilzomib,Carfilzomib,antineoplastic agent,Small molecule,not approved,P49721,PSB2_HUMAN,PSMB2,Proteasome subunit beta type-2 OS=Homo sapiens GN=PSMB2 PE=1 SV=1,Enzymes,EC:3.4.25.1,Established target
432,Carfilzomib,Carfilzomib,antineoplastic agent,Small molecule,not approved,P28074,PSB5_HUMAN,PSMB5,Proteasome subunit beta type-5 OS=Homo sapiens GN=PSMB5 PE=1 SV=3,Enzymes,EC:3.4.25.1,Established target
433,"cariprazine, RGH-188",cariprazine,antipsychotic agent,Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
433,"cariprazine, RGH-188",cariprazine,antipsychotic agent,Small molecule,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
434,"carvedilol, Coreg",carvedilol,for treatment of congestive heart failure,Small Molecule,not approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
435,"carvedilol,Coreg",carvedilol,cardiovascular agent,Small Molecule,not approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
435,"carvedilol,Coreg",carvedilol,cardiovascular agent,Small Molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
436,"casopitant mesilate, 679769,Rezonic, Zunrisa",Casopitant,antiemetic,Small molecule,not approved,P25103,NK1R_HUMAN,TACR1,Substance-P receptor OS=Homo sapiens GN=TACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
437,"CAT-310 , Relivar",dronabinol,analgesic,Small molecule,approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
438,"CAT-310,Relivar",dronabinol,analgesic,Small molecule,approved,P34972,CNR2_HUMAN,CNR2,Cannabinoid receptor 2 OS=Homo sapiens GN=CNR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
439,CAT-354,tralokinumab,antiasthmatic agent,monoclonal antibody,not approved,P35225,IL13_HUMAN,IL13,Interleukin-13 (IL-13),Miscellaneous,Ligand;Cytokine,Novel Target
440,"catumaxomab,Removab",catumaxomab,antineoplastic agent,antibody,not approved,P04234,CD3D_HUMAN,CD3D,T-cell surface glycoprotein CD3 delta chain (T-cell receptor T3 delta chain) (CD antigen CD3d),Receptors,Receptor; T-cell receptor subunit,Established target
440,"catumaxomab,Removab",catumaxomab,antineoplastic agent,antibody,not approved,P07766,CD3E_HUMAN,CD3E,T-cell surface glycoprotein CD3 epsilon chain OS=Homo sapiens GN=CD3E PE=1 SV=2,Receptors,Receptor; T-cell receptor subunit,Established target
440,"catumaxomab,Removab",catumaxomab,antineoplastic agent,antibody,not approved,P09693,CD3G_HUMAN,CD3G,T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g),Receptors,Receptor; T-cell receptor subunit,Established target
440,"catumaxomab,Removab",catumaxomab,antineoplastic agent,antibody,not approved,P16422,EPCAM_HUMAN,EPCAM,Epithelial cell adhesion molecule (Ep-CAM) (Adenocarcinoma-associated antigen) (Cell surface glycoprotein Trop-1) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Epithelial glycoprotein 314) (EGP314) (hEGP314) (KS 1/4 antigen) (KSA) (Ma,Miscellaneous,StructuralAndAdhesion;,Novel Target
441,CB-03-01,CB-03-01,dermatological agent,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
442,"CB1954/EP-0152R, NQO2 prodrug therapy,Prolarix",caricotamide,antineoplastic agent,Small molecule,not approved,P16083,NQO2_HUMAN,NQO2,Ribosyldihydronicotinamide dehydrogenase [quinone] OS=Homo sapiens GN=NQO2 PE=1 SV=4,Enzymes,EC:1.10.99.2,Established target
442,"CB1954/EP-0152R, NQO2 prodrug therapy,Prolarix",tretazicar,antineoplastic agent,small molecule,not approved,DNA,DNA,DNA,DNA,DNA,DNA,Established target
443,CB7630,abiraterone,antineoplastic agent,Small molecule,approved,P05093,CP17A_HUMAN,CYP17A1,"Steroid 17-alpha-hydroxylase/17,20 lyase (EC 1.14.99.9) (CYPXVII) (Cytochrome P450 17A1) (Cytochrome P450-C17) (Cytochrome P450c17) (Steroid 17-alpha-monooxygenase)",Enzymes,EC:1.14.99.9,Established target
444,"CC-401, JNK-401",JNK-401,antineoplastic agent,Small molecule,not approved,P53779,MK10_HUMAN,MAPK10,Mitogen-activated protein kinase 10 (MAP kinase 10) (MAPK 10) (EC 2.7.11.24) (MAP kinase p49 3F12) (Stress-activated protein kinase JNK3) (c-Jun N-terminal kinase 3),Enzymes,EC:2.7.11.24,Novel Target
444,"CC-401, JNK-401",JNK-401,antineoplastic agent,Small molecule,not approved,P45983,MK08_HUMAN,MAPK8,Mitogen-activated protein kinase 8 (MAP kinase 8) (MAPK 8) (EC 2.7.11.24) (JNK-46) (Stress-activated protein kinase 1) (Stress-activated protein kinase JNK1) (c-Jun N-terminal kinase 1),Enzymes,EC:2.7.11.24,Novel Target
444,"CC-401, JNK-401",JNK-401,antineoplastic agent,Small molecule,not approved,P45984,MK09_HUMAN,MAPK9,Mitogen-activated protein kinase 9 (MAP kinase 9) (MAPK 9) (EC 2.7.11.24) (JNK-55) (Stress-activated protein kinase JNK2) (c-Jun N-terminal kinase 2),Enzymes,EC:2.7.11.24,Novel Target
445,CCL2-LPM,CCL2-LPM,antiinflammatory agent,fusion protein,not approved,P41597,CCR2_HUMAN,CCR2,C-C chemokine receptor type 2 (C-C CKR-2) (CC-CKR-2) (CCR-2) (CCR2) (Monocyte chemoattractant protein 1 receptor) (MCP-1-R) (CD antigen CD192),Receptors,GPCR;Rhodopsin,Novel Target
446,CCX025,CCX025,antiinflammatory agent,Small molecule,not approved,P51686,CCR9_HUMAN,CCR9,C-C chemokine receptor type 9 (C-C CKR-9) (CC-CKR-9) (CCR-9) (G-protein coupled receptor 28) (GPR-9-6) (CD antigen CDw199),Receptors,GPCR;Rhodopsin,Novel Target
447,CCX140,CCX140,"antiinflammatory agent,antidiabetic",Small molecule,not approved,P41597,CCR2_HUMAN,CCR2,C-C chemokine receptor type 2 (C-C CKR-2) (CC-CKR-2) (CCR-2) (CCR2) (Monocyte chemoattractant protein 1 receptor) (MCP-1-R) (CD antigen CD192),Receptors,GPCR;Rhodopsin,Novel Target
448,CCX168,CCX168,"antiinflammatory agent,for treatment for autoimmune disease",Small molecule,not approved,P21730,C5AR_HUMAN,C5AR1,C5a anaphylatoxin chemotactic receptor (C5a-R) (C5aR) (CD antigen CD88),Receptors,GPCR;Rhodopsin,Novel Target
449,"CCX282, Traficet-EN",CCX282,"antiinflammatory agent,for treatment of Chron's disease,for treatment of ulceraite colitis",Small molecule,not approved,P51686,CCR9_HUMAN,CCR9,C-C chemokine receptor type 9 (C-C CKR-9) (CC-CKR-9) (CCR-9) (G-protein coupled receptor 28) (GPR-9-6) (CD antigen CDw199),Receptors,GPCR;Rhodopsin,Novel Target
450,CCX354,CCX354,"antiinflammatory agent,DMARD",Small molecule,not approved,P32246,CCR1_HUMAN,CCR1,C-C chemokine receptor type 1 (C-C CKR-1) (CC-CKR-1) (CCR-1) (CCR1) (HM145) (LD78 receptor) (Macrophage inflammatory protein 1-alpha receptor) (MIP-1alpha-R) (RANTES-R) (CD antigen CD191),Receptors,GPCR;Rhodopsin,Novel Target
451,CCX832,CCX832,"antiinflammatory agent,for treatment for autoimmune disease",Small molecule,not approved,Q99788,CML1_HUMAN,CMKLR1,Chemokine-like receptor 1 (G-protein coupled receptor ChemR23) (G-protein coupled receptor DEZ),Receptors,GPCR;Rhodopsin,Novel Target
452,CD-NP,CD-NP,for treatment of heart failure,peptide,not approved,P20594,ANPRB_HUMAN,NPR2,Atrial natriuretic peptide receptor B OS=Homo sapiens GN=NPR2 PE=1 SV=1,Receptors,EC:4.6.1.2,Established target
453,CDP6038,CDP6038,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P05231,IL6_HUMAN,IL6,Interleukin-6 (IL-6) (B-cell stimulatory factor 2) (BSF-2) (CTL differentiation factor) (CDF) (Hybridoma growth factor) (Interferon beta-2) (IFN-beta-2),Miscellaneous,Ligand;Cytokine,Novel Target
454,CDT-fenofibrate,fenofibrate,anticholesterolaemic agent,Small Molecule,not approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
455,CDX-011,monomethyl-auristatin E ADC conjugate,antineoplastic agent,fusion protein,not approved,Q14956,GPNMB_HUMAN,GPNMB,Transmembrane glycoprotein NMB (Transmembrane glycoprotein HGFIN),Miscellaneous,PMEL/NMB family,Novel Target
456,"CDX-313, budesonide + azelastine nasal spray",azelastine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
456,"CDX-313, budesonide + azelastine nasal spray",budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
457,"CEA/MUC-1/VF/TRICOM,PANVAC-VF",CEA/MUC-1/VF/TRICOM,antineoplastic agent,vaccine,not approved,P06731,CEAM5_HUMAN,CEACAM5,Carcinoembryonic antigen-related cell adhesion molecule 5 (Carcinoembryonic antigen) (CEA) (Meconium antigen 100) (CD antigen CD66e),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Novel Target
457,"CEA/MUC-1/VF/TRICOM,PANVAC-VF",CEA/MUC-1/VF/TRICOM,antineoplastic agent,vaccine,not approved,P15941,MUC1_HUMAN,MUC1,Mucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Carcinoma-associated mucin) (Episialin) (H23AG) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM) (Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associ,Miscellaneous,StructuralAndAdhesion;Mucin_1,Novel Target
458,"cediranib, AZD2171,Recentin",cediranib,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
458,"cediranib, AZD2171,Recentin",cediranib,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
458,"cediranib, AZD2171,Recentin",cediranib,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
459,"celecoxib,Celebrex, Celecox",celecoxib,NSAID,Small molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
460,CellCept,mycophenolate mofetil,immunosuppressant,Small Molecule,approved,P20839,IMDH1_HUMAN,IMPDH1,Inosine-5'-monophosphate dehydrogenase 1 OS=Homo sapiens GN=IMPDH1 PE=1 SV=2,Enzymes,EC:1.1.1.205,Established target
460,CellCept,mycophenolate mofetil,immunosuppressant,Small Molecule,approved,P12268,IMDH2_HUMAN,IMPDH2,Inosine-5'-monophosphate dehydrogenase 2 OS=Homo sapiens GN=IMPDH2 PE=1 SV=2,Enzymes,EC:1.1.1.205,Established target
461,Cenestin,synthetic conjugated estrogens,for treatment of postmenopausal symptoms,small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
461,Cenestin,synthetic conjugated estrogens,for treatment of postmenopausal symptoms,small molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
462,CEP-37251,CEP-37251,antiosteoporotic agent,decoy receptor,not approved,O14788,TNF11_HUMAN,TNFSF11,Tumor necrosis factor ligand superfamily member 11 (Osteoclast differentiation factor) (ODF) (Osteoprotegerin ligand) (OPGL) (Receptor activator of nuclear factor kappa-B ligand) (RANKL) (TNF-related activation-induced cytokine) (TRANCE) (CD antigen CD254,Miscellaneous,Ligand;Cytokine,Established target
463,Ceplene,histamine,cytorprotective agent during cancer treatment ,Small molecule,not approved,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
464,CEQ508,CEQ508,antineoplastic agent,siRNA,not approved,P35222,CTNB1_HUMAN,CTNNB1,Catenin beta-1 (Beta-catenin),Miscellaneous,StructuralAndAdhesion;beta-Catenin,Novel Target
465,Cer-001,CER-001,antidyslipidaemic agent,fusion protein,not approved,P02647,APOA1_HUMAN,APOA1,Apolipoprotein A-I (Apo-AI) (ApoA-I) (Apolipoprotein A1) [Cleaved into: Apolipoprotein A-I(1-242)],Miscellaneous,Apolipoprotein A1/A4/E family,Novel Target
466,CER-002,CER-002 ,cardiovascular agent,Small molecule,not approved,Q03181,PPARD_HUMAN,PPARD,Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta),Receptors,Nuclear receptor,Established target
467,CER627,acetylsalicylic acid,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
467,CER627,acetylsalicylic acid,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
467,CER627,niacin,antidyslipidaemic agent,Small molecule,approved,Q8TDS4,NIAR1_HUMAN,GPR109A,Niacin receptor 1 OS=Homo sapiens GN=NIACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
467,CER627,niacin,antidyslipidaemic agent,Small molecule,approved,P49019,G109B_HUMAN,GPR109B,Niacin receptor 2 OS=Homo sapiens GN=NIACR2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
467,CER627,niacin,antidyslipidaemic agent,Small molecule,approved,P40261,NNMT_HUMAN,NNMT,Nicotinamide N-methyltransferase (EC 2.1.1.1),Enzymes,EC:2.1.1.1,Established target
467,CER627,niacin,antidyslipidaemic agent,Small molecule,approved,Q15274,NADC_HUMAN,QPRT,Nicotinate-nucleotide pyrophosphorylase [carboxylating] (EC 2.4.2.19) (Quinolinate phosphoribosyltransferase [decarboxylating]) (QAPRTase) (QPRTase),Enzymes,EC:2.4.2.19,Established target
468,CERE-110,CERE-110,for treatment of alzheimer's disease,adenoviral vector,not approved,P01138,NGF_HUMAN,NGF,Beta-nerve growth factor (Beta-NGF),Miscellaneous,Nerve Growth Factor;Neurotrophins,Novel Target
469,Cerimon,diclofenac,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
469,Cerimon,diclofenac,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
470,"cetilistat, ATL-962",cetilistat,antiobesity agent,Small molecule,not approved,P16233,LIPP_HUMAN,PNLIP,Pancreatic triacylglycerol lipase OS=Homo sapiens GN=PNLIP PE=1 SV=1,Enzymes,EC:3.1.1.3,Established target
471,"cetirizine HCl,Zyrtec",cetirizine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
472,"cetrorelix,Cetrotide",cetrorelix,antineoplastic agent,peptide,approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
473,CF-101,CF-101,"antiinflammatory agent,DMARD",Small molecule,not approved,P33765,AA3R_HUMAN,ADORA3,Adenosine receptor A3,Receptors,GPCR;Rhodopsin,Novel Target
474,CF-102,CF-102,antineoplastic agent,Small molecule,not approved,P33765,AA3R_HUMAN,ADORA3,Adenosine receptor A3,Receptors,GPCR;Rhodopsin,Novel Target
475,CG0070,CG0070,antineoplastic agent,adenoviral vector,not approved,P15509,CSF2R_HUMAN,CSF2RA,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha OS=Homo sapiens GN=CSF2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
476,CG100649,CG100649,NSAID,Small molecule,not approved,P00915,CAH1_HUMAN,CA1,Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
476,CG100649,CG100649,NSAID,Small molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
477,CGRP,CGRP,antiasthmatic agent,peptide,not approved,Q16602,CALRL_HUMAN,CALCRL,Calcitonin gene-related peptide type 1 receptor (CGRP type 1 receptor) (Calcitonin receptor-like receptor),Receptors,GPCR;Secretin,Novel Target
478,CGT-2168,clopidogrel,antiplatelet agent,Small Molecule,approved,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
478,CGT-2168,omeprazol,antiulcer agent,small molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
479,CH-1504,CH-1504,"antiinflammatory agent,DMARD",Small molecule,not approved,P00374,DYR_HUMAN,DHFR,Dihydrofolate reductase OS=Homo sapiens GN=DHFR PE=1 SV=2,Enzymes,EC:1.5.1.3,Established target
480,CHF 4227,CHF 4227,antiosteoporotic agent,Small molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
480,CHF 4227,CHF 4227,antiosteoporotic agent,Small molecule,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
481,"CHF-1535, beclomethasone dipropionate + formoterol fumarate",beclomethasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
481,"CHF-1535, beclomethasone dipropionate + formoterol fumarate",formoterol,antiasthmatic agent,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
482,"Chidamide, HBI-8000",chidamide,antineoplastic agent,Small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
482,"Chidamide, HBI-8000",chidamide,antineoplastic agent,Small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
482,"Chidamide, HBI-8000",chidamide,antineoplastic agent,Small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
482,"Chidamide, HBI-8000",chidamide,antineoplastic agent,Small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
483,CHIR-265,CHIR-265,antineoplastic agent,Small molecule,not approved,P15056,BRAF1_HUMAN,BRAF,B-Raf proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=BRAF PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
483,CHIR-265,CHIR-265,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
483,CHIR-265,CHIR-265,antineoplastic agent,Small molecule,not approved,P04049,RAF1_HUMAN,RAF1,RAF proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=RAF1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
484,Chiron,cyclosporine,immunosuppressant,Small molecule,approved,P49069,CAMLG_HUMAN,CAMLG,Calcium signal-modulating cyclophilin ligand (CAML),Miscellaneous,Miscellaneous:target for cyclosporine,Established target
484,Chiron,cyclosporine,immunosuppressant,Small molecule,approved,Q96LZ3,CANB2_HUMAN,PPP3R2,Calcineurin subunit B type 2 OS=Homo sapiens GN=PPP3R2 PE=2 SV=3,Miscellaneous,Enzyme regulator,Established target
485,Cialis,tadalafil,for treatment of erectile dysfunction,Small Molecule,approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
486,cilansetron,cilansetron,for treatment of irritable bowel syndrome,Small molecule,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
487,cilengitide. EMD-121974,cilengitide,antineoplastic agent,peptide,not approved,P08648,ITA5_HUMAN,ITGA5,Integrin alpha-5 (CD49 antigen-like family member E) (Fibronectin receptor subunit alpha) (Integrin alpha-F) (VLA-5) (CD antigen CD49e) [Cleaved into: Integrin alpha-5 heavy chain; Integrin alpha-5 light chain],Receptors,Receptors;Integrin,Novel Target
487,cilengitide. EMD-121974,cilengitide,antineoplastic agent,peptide,not approved,P06756,ITAV_HUMAN,ITGAV,Integrin alpha-V (Vitronectin receptor subunit alpha) (CD antigen CD51) [Cleaved into: Integrin alpha-V heavy chain; Integrin alpha-V light chain],Receptors,Receptors;Integrin,Established target
487,cilengitide. EMD-121974,cilengitide,antineoplastic agent,peptide,not approved,P05106,ITB3_HUMAN,ITGB3,Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
487,cilengitide. EMD-121974,cilengitide,antineoplastic agent,peptide,not approved,P18084,ITB5_HUMAN,ITGB5,Integrin beta-5,Miscellaneous,Receptor; integrin,Novel Target
488,Cimicoxib,cimicoxib,NSAID,Small molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
489,Cimzia,certolizumab pegol,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
490,Cintredekin,Cintredekin Besudotox ,antineoplastic agent,fusion protein,not approved,P78552,I13R1_HUMAN,IL13RA1,Interleukin-13 receptor subunit alpha-1 (IL-13 receptor subunit alpha-1) (IL-13R subunit alpha-1) (IL-13R-alpha-1) (IL-13RA1) (Cancer/testis antigen 19) (CT19) (CD antigen CD213a1),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
490,Cintredekin,Cintredekin Besudotox ,antineoplastic agent,fusion protein,not approved,Q14627,I13R2_HUMAN,IL13RA2,Interleukin-13 receptor subunit alpha-2 (IL-13 receptor subunit alpha-2) (IL-13R subunit alpha-2) (IL-13R-alpha-2) (IL-13RA2) (Interleukin-13-binding protein) (CD antigen CD213a2),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
490,Cintredekin,Cintredekin Besudotox ,antineoplastic agent,fusion protein,not approved,P24394,IL4RA_HUMAN,IL4R,Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL,Receptors,Receptor; Type 1 cytokine receptor,Novel Target
491,CIP-isotretinoin,isotretinoin,for treatment of acne,Small Molecule,approved,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
492,"Cipralex, escitalopram,Lexapro",escitalopram,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
493,"cixutumumab, IMC-A12",cixutumumab,antineoplastic agent,antibody,not approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
494,CK-2017357,tiramsetiv,for treatment of skeletal muscle disorders associated with aging and neuro-degenerative disorders.,Small molecule,not approved,P63316,TNNC1_HUMAN,TNNC1,"Troponin C, slow skeletal and cardiac muscles OS=Homo sapiens GN=TNNC1 PE=1 SV=1",Miscellaneous,Enzyme regulator,Established target
494,CK-2017357,tiramsetiv,for treatment of skeletal muscle disorders associated with aging and neuro-degenerative disorders.,Small molecule,not approved,P02585,TNNC2_HUMAN,TNNC2,"Troponin C, skeletal muscle",Miscellaneous,Enzyme regulator,Novel Target
494,CK-2017357,tiramsetiv,for treatment of skeletal muscle disorders associated with aging and neuro-degenerative disorders.,Small molecule,not approved,P19237,TNNI1_HUMAN,TNNI1,"Troponin I, slow skeletal muscle (Troponin I, slow-twitch isoform)",Miscellaneous,Enzyme regulator,Novel Target
494,CK-2017357,tiramsetiv,for treatment of skeletal muscle disorders associated with aging and neuro-degenerative disorders.,Small molecule,not approved,P48788,TNNI2_HUMAN,TNNI2,"Troponin I, fast skeletal muscle (Troponin I, fast-twitch isoform)",Miscellaneous,Enzyme regulator,Novel Target
494,CK-2017357,tiramsetiv,for treatment of skeletal muscle disorders associated with aging and neuro-degenerative disorders.,Small molecule,not approved,P19237,TNNI1_HUMAN,TNNT1,"Troponin I, slow skeletal muscle (Troponin I, slow-twitch isoform)",Miscellaneous,Enzyme regulator,Novel Target
494,CK-2017357,tiramsetiv,for treatment of skeletal muscle disorders associated with aging and neuro-degenerative disorders.,Small molecule,not approved,P45379,TNNT2_HUMAN,TNNT2,"Troponin T, cardiac muscle (TnTc) (Cardiac muscle troponin T) (cTnT)",Miscellaneous,Enzyme regulator,Novel Target
495,"clazosentan, AXV-343434,Pivlaz",clazosentan,for treatment and prevention of vasospasm,Small molecule,not approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
496,Clevelox,clevidipine,antihypertensive agent,Small molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
496,Clevelox,clevidipine,antihypertensive agent,Small molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
496,Clevelox,clevidipine,antihypertensive agent,Small molecule,approved,O60840,CAC1F_HUMAN,CACNA1F,Voltage-dependent L-type calcium channel subunit alpha-1F OS=Homo sapiens GN=CACNA1F PE=1 SV=2,Transporters,TC:1.A.1.11.11,Established target
496,Clevelox,clevidipine,antihypertensive agent,Small molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
497,Clobazam,clobazam,"anxiolytic,anticonvulsant",Small Molecule,approved,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
498,"clobetasol propionate,Olux Foam",clobetasol,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
499,"clodronate,Bonefos",clodronate,antineoplastic agent,Small Molecule,approved,P12235,ADT1_HUMAN,SLC25A4,"ADP/ATP translocase 1 (ADP,ATP carrier protein 1) (ADP,ATP carrier protein, heart/skeletal muscle isoform T1) (Adenine nucleotide translocator 1) (ANT 1) (Solute carrier family 25 member 4)",Transporters,TC:2.A.29.1.2,Established target
499,"clodronate,Bonefos",clodronate,antineoplastic agent,Small Molecule,approved,P05141,ADT2_HUMAN,SLC25A5,"ADP/ATP translocase 2 (ADP,ATP carrier protein 2) (ADP,ATP carrier protein, fibroblast isoform) (Adenine nucleotide translocator 2) (ANT 2) (Solute carrier family 25 member 5)",Transporters,TC:2.A.29.1.1,Established target
499,"clodronate,Bonefos",clodronate,antineoplastic agent,Small Molecule,approved,P12236,ADT3_HUMAN,SLC25A6,"ADP/ATP translocase 3 (ADP,ATP carrier protein 3) (ADP,ATP carrier protein, isoform T2) (ANT 2) (Adenine nucleotide translocator 3) (ANT 3) (Solute carrier family 25 member 6)",Transporters,TC:2.A.29.1.10,Established target
500,Clofarabine,Clofarabine,antineoplastic agent,Small Molecule,approved,P09884,DPOLA_HUMAN,POLA1,DNA polymerase alpha catalytic subunit OS=Homo sapiens GN=POLA1 PE=1 SV=2,Enzymes,EC:2.7.7.7,Established target
500,Clofarabine,Clofarabine,antineoplastic agent,Small Molecule,approved,P23921,RIR1_HUMAN,RRM1,Ribonucleoside-diphosphate reductase large subunit OS=Homo sapiens GN=RRM1 PE=1 SV=1,Enzymes,EC:1.17.4.1,Established target
501,"clonidine hydrochloride extended release,Kapvay, Jenloga XR (CloniBID)",clonidine,"for treatment of diabetic neuropathy,for treatment of ADHD,antimucositic",Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
501,"clonidine hydrochloride extended release,Kapvay, Jenloga XR (CloniBID)",clonidine,"for treatment of diabetic neuropathy,for treatment of ADHD,antimucositic",Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
501,"clonidine hydrochloride extended release,Kapvay, Jenloga XR (CloniBID)",clonidine,"for treatment of diabetic neuropathy,for treatment of ADHD,antimucositic",Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
502,"clonidine Lauriad, BA-028",clonidine,"for treatment of diabetic neuropathy,for treatment of ADHD,antimucositic",Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
502,"clonidine Lauriad, BA-028",clonidine,"for treatment of diabetic neuropathy,for treatment of ADHD,antimucositic",Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
502,"clonidine Lauriad, BA-028",clonidine,"for treatment of diabetic neuropathy,for treatment of ADHD,antimucositic",Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
503,CLX-0921,CLX-0921,antidiabetic,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
504,CM2489,CM2489,"antiinflammatory agent,antipsoriatic",Small molecule,not approved,Q96D31,CRCM1_HUMAN,ORA1,Calcium release-activated calcium channel protein 1 (Protein orai-1) (Transmembrane protein 142A),Transporters,TC:1.A.52,Novel Target
505,CMLVAX100,CMLVAX100,antineoplastic agent,vaccine,not approved,A1Z199,A1Z199_HUMAN,BCR/ABL fusion,BCR/ABL p210 fusion protein,Enzymes,miscellaneous;protein kinase,Established target
506,CNDO101,CNDO101 ,antineoplastic agent,Small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
507,CNF1010 ,CNF1010 ,antineoplastic agent,Small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
507,CNF1010 ,CNF1010 ,antineoplastic agent,Small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
508,CNS-5161,CNS-5161,analgesic,Small molecule,not approved,Q05586,NMDZ1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo sapiens GN=GRIN1 PE=1 SV=1,Receptors,TC:1.A.10.1.6,Established target
508,CNS-5161,CNS-5161,analgesic,Small molecule,not approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
508,CNS-5161,CNS-5161,analgesic,Small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
508,CNS-5161,CNS-5161,analgesic,Small molecule,not approved,Q14957,NMDE3_HUMAN,GRIN2C,Glutamate [NMDA] receptor subunit epsilon-3 (N-methyl D-aspartate receptor subtype 2C) (NMDAR2C) (NR2C),Receptors,TC:1.A.10.1.3,Novel Target
508,CNS-5161,CNS-5161,analgesic,Small molecule,not approved,O15399,NMDE4_HUMAN,GRIN2D,Glutamate [NMDA] receptor subunit epsilon-4 OS=Homo sapiens GN=GRIN2D PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
508,CNS-5161,CNS-5161,analgesic,Small molecule,not approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
508,CNS-5161,CNS-5161,analgesic,Small molecule,not approved,O60391,NMD3B_HUMAN,GRIN3B,Glutamate [NMDA] receptor subunit 3B OS=Homo sapiens GN=GRIN3B PE=2 SV=2,Receptors,TC:1.A.10.1,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P18507,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P48169,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P14867,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P24046,GBRR1_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,Q9UN88,GBRT_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,A8MPY1,GBRR3_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
509,CNS-7056,CNS-7056,sedative,Small molecule,not approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
510,CNTO 1275,CNTO 1275,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P29460,IL12B_HUMAN,IL12B,Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2),Receptors,Receptor; Type 1 cytokine receptor,Established target
510,CNTO 1275,CNTO 1275,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,Q9NPF7,IL23A_HUMAN,IL23A,Interleukin-23 subunit alpha (IL-23 subunit alpha) (IL-23-A) (Interleukin-23 subunit p19) (IL-23p19),Miscellaneous,Receptor; Type 1 cytokine receptor,Established target
511,CNTO 148,CNTO 148,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
512,CNTO-95,CNTO-95,antineoplastic agent,monoclonal antibody,not approved,P06756,ITAV_HUMAN,ITGAV,Integrin alpha-V (Vitronectin receptor subunit alpha) (CD antigen CD51) [Cleaved into: Integrin alpha-V heavy chain; Integrin alpha-V light chain],Receptors,Receptors;Integrin,Established target
512,CNTO-95,CNTO-95,antineoplastic agent,monoclonal antibody,not approved,P05106,ITB3_HUMAN,ITGB3,Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
512,CNTO-95,CNTO-95,antineoplastic agent,monoclonal antibody,not approved,P18084,ITB5_HUMAN,ITGB5,Integrin beta-5,Miscellaneous,Receptor; integrin,Novel Target
513,CNV2197944,CNV2197944,analgesic,Small molecule,not approved,Q00975,CAC1B_HUMAN,CACNA1B,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:1.A.1.11,Established target
514,"COL-003, sustained release oxycodone",oxycodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
514,"COL-003, sustained release oxycodone",oxycodone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
514,"COL-003, sustained release oxycodone",oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
515,"COL-172, extended-release oxycodone",oxycodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
515,"COL-172, extended-release oxycodone",oxycodone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
515,"COL-172, extended-release oxycodone",oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
516,"COL-3,Metastat",COL-3,antineoplastic agent,Small molecule,not approved,P08253,MMP2_HUMAN,MMP2,72 kDa type IV collagenase OS=Homo sapiens GN=MMP2 PE=1 SV=2,Enzymes,EC:3.4.24.24,Novel Target
516,"COL-3,Metastat",COL-3,antineoplastic agent,Small molecule,not approved,P14780,MMP9_HUMAN,MMP9,Matrix metalloproteinase-9 OS=Homo sapiens GN=MMP9 PE=1 SV=2,Enzymes,EC:3.4.24.35,Novel Target
517,"colchicine,Colcrys",colchicine,for treatment of gout,Small Molecule,approved,P07437,TBB5_HUMAN,TUBB,Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
518,"CollaRx bupivacaine topical, INN-LD-01, bupivacaine collagen sponge,XaraColl",bupivacaine,"local anestethic,analgesic,neuralgia",Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
519,"conivaptan, YM-087,Vaprisol",conivaptan,for treatment of hyponatremia,Small Molecule,approved,P37288,V1AR_HUMAN,AVPR1A,Vasopressin V1a receptor OS=Homo sapiens GN=AVPR1A PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
519,"conivaptan, YM-087,Vaprisol",conivaptan,for treatment of hyponatremia,Small Molecule,approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
520,"conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase",estrogen,for symptomatic treatment of menopausal symptoms,Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
520,"conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase",estrogen,for symptomatic treatment of menopausal symptoms,Small molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
520,"conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase",progesterone,for symptomatic treatment of menopausal symptoms,small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
520,"conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase",progesterone,for symptomatic treatment of menopausal symptoms,small molecule,approved,P08235,MCR_HUMAN,NR3C2,Mineralocorticoid receptor OS=Homo sapiens GN=NR3C2 PE=1 SV=1,Receptors,Nuclear receptor,Established target
520,"conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase",progesterone,for symptomatic treatment of menopausal symptoms,small molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
521,"contraceptive patch, ethinylestradiol + gestodene,FC Patch Fidencia",ethinyl estradiol,contraceptive,Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
521,"contraceptive patch, ethinylestradiol + gestodene,FC Patch Fidencia",gestodene,contraceptive,Small molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
522,Contrave,bupropion,"antidepressant,appetite suppressant,smoking-cessation agent",Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
522,Contrave,bupropion,"antidepressant,appetite suppressant,smoking-cessation agent",Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
522,Contrave,naltrexone,appetite suppressant,Small molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
522,Contrave,naltrexone,appetite suppressant,Small molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
522,Contrave,naltrexone,appetite suppressant,Small molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
523,Convivia,fomepizole,for treatment of ethanol intolerance,Small Molecule,approved,P07327,ADH1A_HUMAN,ADH1A,Alcohol dehydrogenase 1A OS=Homo sapiens GN=ADH1A PE=1 SV=2,Enzymes,EC:1.1.1.1,Established target
523,Convivia,fomepizole,for treatment of ethanol intolerance,Small Molecule,approved,P00325,ADH1B_HUMAN,ADH1B,Alcohol dehydrogenase 1B OS=Homo sapiens GN=ADH1B PE=1 SV=2,Enzymes,EC:1.1.1.1,Established target
523,Convivia,fomepizole,for treatment of ethanol intolerance,Small Molecule,approved,P00326,ADH1G_HUMAN,ADH1C,Alcohol dehydrogenase 1C OS=Homo sapiens GN=ADH1C PE=1 SV=2,Enzymes,EC:1.1.1.1,Established target
524,Cordase,collagenase,for treatment of Dupuytren's contracture,protein,approved,P03956,MMP1_HUMAN,MMP1,Interstitial collagenase,Enzymes,EC:3.4.24.7,Established target
524,Cordase,collagenase,for treatment of Dupuytren's contracture,protein,approved,P22894,MMP8_HUMAN,MMP8,Neutrophil collagenase (EC 3.4.24.34) (Matrix metalloproteinase-8) (MMP-8) (PMNL collagenase) (PMNL-CL),Enzymes,EC:3.4.24.34,Established target
525,cordycepin,cordycepin,antineoplastic agent,Small molecule,not approved,P04053,TDT_HUMAN,DNTT,DNA nucleotidylexotransferase (EC 2.7.7.31) (Terminal addition enzyme) (Terminal deoxynucleotidyltransferase) (Terminal transferase),Enzymes,EC:2.7.7.31,Novel Target
526,"corifollitropin alfa,Elonva",corifollitropin alfa,fertility agent,protein,not approved,P23945,FSHR_HUMAN,FSHR,Follicle-stimulating hormone receptor OS=Homo sapiens GN=FSHR PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
527,CORT 108297,CORT 108297,for prevention of weight gain during antipsychotic treatment,Small molecule,not approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
528,"corticotropin-releasing factor,Xerecept",corticotropin-releasing factor,for treatment of peritumoral brain edema,peptide,not approved,P34998,CRFR1_HUMAN,CRHR1,Corticotropin-releasing factor receptor 1 (CRF-R-1) (CRF-R1) (CRFR-1) (Corticotropin-releasing hormone receptor 1) (CRH-R-1) (CRH-R1),Receptors,GPCR;Secretin,Novel Target
528,"corticotropin-releasing factor,Xerecept",corticotropin-releasing factor,for treatment of peritumoral brain edema,peptide,not approved,Q13324,CRFR2_HUMAN,CRHR2,Corticotropin-releasing factor receptor 2 (CRF-R-2) (CRF-R2) (CRFR-2) (Corticotropin-releasing hormone receptor 2) (CRH-R-2) (CRH-R2),Receptors,GPCR;Secretin,Novel Target
529,"Coxsackievirus Type A21, CVA21,CAVATAK",coxsackievirus type A21,antineoplastic agent,virus,not approved,P08174,DAF_HUMAN,CD55,Complement decay-accelerating factor (CD antigen CD55),Miscellaneous,Receptors of complement activation (RCA) family,Novel Target
529,"Coxsackievirus Type A21, CVA21,CAVATAK",coxsackievirus type A21,antineoplastic agent,virus,not approved,P05362,ICAM1_HUMAN,ICAM1,Intercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
530,CP-4126,CP-4126 ,antineoplastic agent,Small molecule,not approved,DNA,DNA,DNA,DNA,DNA,DNA,Established target
531,CP-609,"CP-609,754",antineoplastic agent,Small molecule,not approved,P49354,FNTA_HUMAN,FNTA,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha (EC 2.5.1.58) (EC 2.5.1.59) (CAAX farnesyltransferase subunit alpha) (FTase-alpha) (Ras proteins prenyltransferase subunit alpha) (Type I protein geranyl-geranyltransferase subunit,Enzymes,EC:2.5.1.58; 2.5.1.59,Novel Target
531,CP-609,"CP-609,754",antineoplastic agent,Small molecule,not approved,P49356,FNTB_HUMAN,FNTB,Protein farnesyltransferase subunit beta (FTase-beta) (EC 2.5.1.58) (CAAX farnesyltransferase subunit beta) (Ras proteins prenyltransferase subunit beta),Enzymes,EC:2.5.1.58,Novel Target
532,"CPG 10101,Actilon",CPG 10101,immunostimulant,Small molecule,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
533,CPG 52364,CPG 52364,antiinflammatory agent,Small molecule,not approved,Q9NYK1,TLR7_HUMAN,TLR7,Toll-like receptor 7 OS=Homo sapiens GN=TLR7 PE=1 SV=1,Receptors,Receptors;TOLL,Established target
533,CPG 52364,CPG 52364,antiinflammatory agent,Small molecule,not approved,Q9NR97,TLR8_HUMAN,TLR8,Toll-like receptor 8 (CD antigen CD288),Receptors,Receptors;TOLL,Novel Target
533,CPG 52364,CPG 52364,antiinflammatory agent,Small molecule,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
534,CPI-613,CPI-613,antineoplastic agent,Small molecule,not approved,P08559,ODPA_HUMAN,PDHA1,"Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial (EC 1.2.4.1) (PDHE1-A type I)",Enzymes,EC:1.2.4.1,Novel Target
534,CPI-613,CPI-613,antineoplastic agent,Small molecule,not approved,P29803,ODPAT_HUMAN,PDHA2,"Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrial (EC 1.2.4.1) (PDHE1-A type II)",Enzymes,EC:1.2.4.1,Novel Target
534,CPI-613,CPI-613,antineoplastic agent,Small molecule,not approved,P11177,ODPB_HUMAN,PDHB,"Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHE1-B) (EC 1.2.4.1)",Enzymes,EC:1.2.4.1,Novel Target
534,CPI-613,CPI-613,antineoplastic agent,Small molecule,not approved,Q15118,PDK1_HUMAN,PDK1,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial (EC 2.7.11.2) (Pyruvate dehydrogenase kinase isoform 1)",Enzymes,EC:2.7.11.2,Novel Target
534,CPI-613,CPI-613,antineoplastic agent,Small molecule,not approved,Q15119,PDK2_HUMAN,PDK2,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial",Enzymes,EC:2.7.11.2,Novel Target
534,CPI-613,CPI-613,antineoplastic agent,Small molecule,not approved,Q15120,PDK3_HUMAN,PDK3,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial",Enzymes,EC:2.7.11.2,Novel Target
534,CPI-613,CPI-613,antineoplastic agent,Small molecule,not approved,Q16654,PDK4_HUMAN,PDK4,"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial",Enzymes,EC:2.7.11.2,Novel Target
535,CPSI-2364,semapimod,"antiinflammatory agent,for treatment of Chron's disease",small molecule,not approved,Q15759,MK11_HUMAN,MAPK11,Mitogen-activated protein kinase 11 (MAP kinase 11) (MAPK 11) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 beta) (MAP kinase p38 beta) (p38b) (Stress-activated protein kinase 2) (p38-2),Enzymes,EC:2.7.11.24,Novel Target
535,CPSI-2364,semapimod,"antiinflammatory agent,for treatment of Chron's disease",small molecule,not approved,P53778,MK12_HUMAN,MAPK12,Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3),Enzymes,EC:2.7.11.24,Novel Target
535,CPSI-2364,semapimod,"antiinflammatory agent,for treatment of Chron's disease",small molecule,not approved,O15264,MK13_HUMAN,MAPK13,Mitogen-activated protein kinase 13 (MAP kinase 13) (MAPK 13) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 delta) (MAP kinase p38 delta) (Stress-activated protein kinase 4),Enzymes,EC:2.7.11.24,Novel Target
535,CPSI-2364,semapimod,"antiinflammatory agent,for treatment of Chron's disease",small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
536,CPX-1,floxuridine,antineoplastic agent,Small Molecule,approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
536,CPX-1,irinotecan,antineoplastic agent,Small Molecule,approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
536,CPX-1,irinotecan,antineoplastic agent,Small Molecule,approved,Q969P6,TOP1M_HUMAN,TOP1MT,"DNA topoisomerase I, mitochondrial OS=Homo sapiens GN=TOP1MT PE=1 SV=1",Enzymes,EC:5.99.1.2,Established target
537,"CPX-351, cytarabine + daunorubicin",cytarabine,antineoplastic agent,Small Molecule,approved,P06746,DPOLB_HUMAN,POLB,DNA polymerase beta OS=Homo sapiens GN=POLB PE=1 SV=3,Enzymes,EC:2.7.7.7; 4.2.99.-,Established target
537,"CPX-351, cytarabine + daunorubicin",daunorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
537,"CPX-351, cytarabine + daunorubicin",daunorubicin,antineoplastic agent,Small Molecule,approved,Q02880,TOP2B_HUMAN,TOP2B,"DNA topoisomerase 2-beta (EC 5.99.1.3) (DNA topoisomerase II, beta isozyme)",Enzymes,EC:5.99.1.3,Established target
538,CR002,CR002 ,for treatment of IgA nephropathy,monoclonal antibody,not approved,Q9GZP0,PDGFD_HUMAN,PDGFD,"Platelet-derived growth factor D (PDGF-D) (Iris-expressed growth factor) (Spinal cord-derived growth factor B) (SCDGF-B) [Cleaved into: Platelet-derived growth factor D, latent form (PDGFD latent form); Platelet-derived growth factor D, receptor-binding f",Miscellaneous,Ligand;Growth factor,Novel Target
539,CR665,CR665,analgesic,Small molecule,not approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
540,CR845,CR845,analgesic,Small molecule,not approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
541,CRES pravastatin,pravastatin,antihypecholesterolemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
542,Crestor,rosuvastatin,antihypecholesterolemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
543,CRF-1 antagonist,561679,antidepressant,Small molecule,not approved,P34998,CRFR1_HUMAN,CRHR1,Corticotropin-releasing factor receptor 1 (CRF-R-1) (CRF-R1) (CRFR-1) (Corticotropin-releasing hormone receptor 1) (CRH-R-1) (CRH-R1),Receptors,GPCR;Secretin,Novel Target
544,"crizotinib, PF-02341066",crizotinib,antineoplastic agent,Small molecule,approved,Q9UM73,ALK_HUMAN,ALK,ALK tyrosine kinase receptor (EC 2.7.10.1) (Anaplastic lymphoma kinase) (CD antigen CD246),Receptors,EC:2.7.10.1,Established target
544,"crizotinib, PF-02341066",crizotinib,antineoplastic agent,Small molecule,approved,P08581,MET_HUMAN,MET,Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met),Receptors,EC:2.7.10.1,Established target
545,crofelemer,crofelemer,antidiarrhoeal agent,plant extract,not approved,P13569,CFTR_HUMAN,CFTR,Cystic fibrosis transmembrane conductance regulator (CFTR) (ATP-binding cassette sub-family C member 7) (Channel conductance-controlling ATPase) (EC 3.6.3.49) (cAMP-dependent chloride channel),Transporters,TC:3.A.1.202.1,Established target
546,CRTH2 receptor antagonist,CRTH2 receptor antagonist,antiallergy agent,Small molecule,not approved,Q9Y5Y4,GPR44_HUMAN,GPR44,Putative G-protein coupled receptor 44 (Chemoattractant receptor-homologous molecule expressed on Th2 cells) (CD antigen CD294),Receptors,GPCR;Rhodopsin,Novel Target
547,"CRx-102, prednisolone plus dipyridamole ,Synavive",prednisolone,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
548,"CRx-102, prednisolone plus dipyridamole,Synavive",dipyridamole,anticoagulant,Small Molecule,approved,P00813,ADA_HUMAN,ADA,Adenosine deaminase OS=Homo sapiens GN=ADA PE=1 SV=3,Enzymes,EC:3.5.4.4,Established target
548,"CRx-102, prednisolone plus dipyridamole,Synavive",dipyridamole,anticoagulant,Small Molecule,approved,Q9Y233,PDE10_HUMAN,PDE10A,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A OS=Homo sapiens GN=PDE10A PE=1 SV=1",Enzymes,EC:3.1.4.17; 3.1.4.35,Established target
548,"CRx-102, prednisolone plus dipyridamole,Synavive",dipyridamole,anticoagulant,Small Molecule,approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
548,"CRx-102, prednisolone plus dipyridamole,Synavive",dipyridamole,anticoagulant,Small Molecule,approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
549,CRx-119,amoxapine,antidepressant,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
549,CRx-119,amoxapine,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
549,CRx-119,prednisolone,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
550,CRx-139,paroxetine,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
550,CRx-139,prednisolone,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
551,"CRx-150, amoxapine plus dipyridamole",amoxapine,antidepressant,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
551,"CRx-150, amoxapine plus dipyridamole",amoxapine,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
551,"CRx-150, amoxapine plus dipyridamole",dipyridamole,antithrombotic,Small Molecule,approved,P00813,ADA_HUMAN,ADA,Adenosine deaminase OS=Homo sapiens GN=ADA PE=1 SV=3,Enzymes,EC:3.5.4.4,Established target
551,"CRx-150, amoxapine plus dipyridamole",dipyridamole,antithrombotic,Small Molecule,approved,Q9Y233,PDE10_HUMAN,PDE10A,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A OS=Homo sapiens GN=PDE10A PE=1 SV=1",Enzymes,EC:3.1.4.17; 3.1.4.35,Established target
551,"CRx-150, amoxapine plus dipyridamole",dipyridamole,antithrombotic,Small Molecule,approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
551,"CRx-150, amoxapine plus dipyridamole",dipyridamole,antithrombotic,Small Molecule,approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
552,CRx-170,budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
552,CRx-170,nortriptyline,antiasthmatic agent,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
552,CRx-170,nortriptyline,antiasthmatic agent,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
553,CRx-191,mometasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
553,CRx-191,nortriptyline,antidepressant,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
553,CRx-191,nortriptyline,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
554,CRx-401,bezafibrate,antidiabetic,Small Molecule,approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
554,CRx-401,diflunisal,antidiabetic,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
554,CRx-401,diflunisal,antidiabetic,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
555,CS-3030,CS-3030,anticoagulant,Small molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
556,CS-7017,CS-7017,antineoplastic agent,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
557,"CS-8663, amlodipine + olmesartan,Azor, Sevikar",amlodipine,antihypertensive agent,Small Molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
557,"CS-8663, amlodipine + olmesartan,Azor, Sevikar",amlodipine,antihypertensive agent,Small Molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
557,"CS-8663, amlodipine + olmesartan,Azor, Sevikar",amlodipine,antihypertensive agent,Small Molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
557,"CS-8663, amlodipine + olmesartan,Azor, Sevikar",amlodipine,antihypertensive agent,Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
557,"CS-8663, amlodipine + olmesartan,Azor, Sevikar",amlodipine,antihypertensive agent,Small Molecule,approved,Q08289,CACB2_HUMAN,CACNB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
557,"CS-8663, amlodipine + olmesartan,Azor, Sevikar",olmesartan,antihypertensive agent,Small Molecule,approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
558,CSL 360,CSL 360,antineoplastic agent,monoclonal antibody,not approved,P26951,IL3RA_HUMAN,IL3RA,Interleukin-3 receptor subunit alpha (IL-3 receptor subunit alpha) (IL-3R subunit alpha) (IL-3R-alpha) (IL-3RA) (CD antigen CD123),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
559,CT-011,CT-011,antineoplastic agent,monoclonal antibody,not approved,Q15116,PDCD1_HUMAN,PDCD1,Programmed cell death protein 1 (Protein PD-1) (hPD-1) (CD antigen CD279),Receptors,Miscellaneous;PDCD1,Novel Target
560,CT-322,CT-322,antineoplastic agent,recombinant protein,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
561,CTA018,CTA018 ,"antiinflammatory agent,antipsoriatic",Small molecule,not approved,Q07973,CP24A_HUMAN,CYP24A1,"1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (24-OHase) (Vitamin D(3) 24-hydroxylase) (EC 1.14.13.n4) (Cytochrome P450 24A1) (Cytochrome P450-CC24)",Enzymes,EC:1.14.13.126,Novel Target
562,CTLA4,RG-2077,immunosuppressant,protein,not approved,P33681,CD80_HUMAN,CD80,T-lymphocyte activation antigen CD80 OS=Homo sapiens GN=CD80 PE=1 SV=1,Receptors,Receptor; T-cell surface receptor,Established target
562,CTLA4,RG-2077,immunosuppressant,protein,not approved,P42081,CD86_HUMAN,CD86,T-lymphocyte activation antigen CD86 OS=Homo sapiens GN=CD86 PE=1 SV=1,Miscellaneous,T-lymphocyte activation antigen CD86,Established target
563,"CTP-37,Avicine",avicine,"antineoplastic agent,vaccine",vaccine,not approved,P22888,LSHR_HUMAN,LHCGR,Lutropin-choriogonadotropic hormone receptor OS=Homo sapiens GN=LHCGR PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
564,CTS-21166,CTS-21166,for treatment of Alzheimer's disease,Small molecule,not approved,P56817,BACE1_HUMAN,BACE1,Beta-secretase 1,Enzymes,EC:3.4.23.46,Novel Target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,Q96DB2,HDA11_HUMAN,HDAC11,Histone deacetylase 11 (HD11) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,P56524,HDAC4_HUMAN,HDAC4,Histone deacetylase 4 (HD4) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,Q9UQL6,HDAC5_HUMAN,HDAC5,Histone deacetylase 5 (HD5) (EC 3.5.1.98) (Antigen NY-CO-9),Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,Q8WUI4,HDAC7_HUMAN,HDAC7,Histone deacetylase 7 (HD7) (EC 3.5.1.98) (Histone deacetylase 7A) (HD7a),Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
565,CUDC-101,CUDC-101,antineoplastic agent,Small molecule,not approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
566,CVBT-141B,CVBT-141B,wound healing accelerant,protein,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
566,CVBT-141B,CVBT-141B,wound healing accelerant,protein,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
566,CVBT-141B,CVBT-141B,wound healing accelerant,protein,not approved,P22607,FGFR3_HUMAN,FGFR3,Fibroblast growth factor receptor 3 OS=Homo sapiens GN=FGFR3 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
566,CVBT-141B,CVBT-141B,wound healing accelerant,protein,not approved,P22455,FGFR4_HUMAN,FGFR4,Fibroblast growth factor receptor 4 OS=Homo sapiens GN=FGFR4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
567,"CVBT-141H, FGF-1, CVBT-141A,Cardio Vascu-Grow",CVBT-141H,for treatment of severe coronary artery disease,recombinant protein,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
567,"CVBT-141H, FGF-1, CVBT-141A,Cardio Vascu-Grow",CVBT-141H,for treatment of severe coronary artery disease,recombinant protein,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
567,"CVBT-141H, FGF-1, CVBT-141A,Cardio Vascu-Grow",CVBT-141H,for treatment of severe coronary artery disease,recombinant protein,not approved,P22607,FGFR3_HUMAN,FGFR3,Fibroblast growth factor receptor 3 OS=Homo sapiens GN=FGFR3 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
567,"CVBT-141H, FGF-1, CVBT-141A,Cardio Vascu-Grow",CVBT-141H,for treatment of severe coronary artery disease,recombinant protein,not approved,P22455,FGFR4_HUMAN,FGFR4,Fibroblast growth factor receptor 4 OS=Homo sapiens GN=FGFR4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
568,CVT-3619,CVT-3619,antihyperlipidemic agent,Small molecule,not approved,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
569,CVT-6883,CVT-6883,antiasthmatic agent,Small molecule,not approved,P29275,AA2BR_HUMAN,ADORA2B,Adenosine receptor A2b OS=Homo sapiens GN=ADORA2B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
570,"CX157,TriRima",CX157,antidepressant,Small molecule,not approved,P21397,AOFA_HUMAN,MAOA,Amine oxidase [flavin-containing] A OS=Homo sapiens GN=MAOA PE=1 SV=1,Enzymes,EC:1.4.3.4,Established target
571,"CX1632, S47445",CX1632/S 47445,for treatment of Alzheimer's disease,Small molecule,not approved,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
571,"CX1632, S47445",CX1632/S 47445,for treatment of Alzheimer's disease,Small molecule,not approved,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
571,"CX1632, S47445",CX1632/S 47445,for treatment of Alzheimer's disease,Small molecule,not approved,P42263,GRIA3_HUMAN,GRIA3,"Glutamate receptor 3 (GluR-3) (AMPA-selective glutamate receptor 3) (GluR-C) (GluR-K3) (Glutamate receptor ionotropic, AMPA 3) (GluA3)",Receptors,TC:1.A.10.1.4,Established target
571,"CX1632, S47445",CX1632/S 47445,for treatment of Alzheimer's disease,Small molecule,not approved,P48058,GRIA4_HUMAN,GRIA4,"Glutamate receptor 4 (GluR-4) (GluR4) (AMPA-selective glutamate receptor 4) (GluR-D) (Glutamate receptor ionotropic, AMPA 4) (GluA4)",Receptors,TC:1.A.10.1,Established target
572,CX-4945,CX-4945,antineoplastic agent,Small molecule,not approved,P68400,CSK21_HUMAN,CSNK2A1,Casein kinase II subunit alpha (CK II alpha) (EC 2.7.11.1),Enzymes,EC:2.7.11.1,Novel Target
573,CX717,CX717,for treatment of Alzheimer's disease,Small molecule,not approved,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
573,CX717,CX717,for treatment of Alzheimer's disease,Small molecule,not approved,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
573,CX717,CX717,for treatment of Alzheimer's disease,Small molecule,not approved,P42263,GRIA3_HUMAN,GRIA3,"Glutamate receptor 3 (GluR-3) (AMPA-selective glutamate receptor 3) (GluR-C) (GluR-K3) (Glutamate receptor ionotropic, AMPA 3) (GluA3)",Receptors,TC:1.A.10.1.4,Established target
573,CX717,CX717,for treatment of Alzheimer's disease,Small molecule,not approved,P48058,GRIA4_HUMAN,GRIA4,"Glutamate receptor 4 (GluR-4) (GluR4) (AMPA-selective glutamate receptor 4) (GluR-D) (Glutamate receptor ionotropic, AMPA 4) (GluA4)",Receptors,TC:1.A.10.1,Established target
574,CXB909,CXB909,for treatment of chemotherapy-induced peripheral neuropathy,Small molecule,not approved,P08138,TNR16_HUMAN,LNGFR,Tumor necrosis factor receptor superfamily member 16 (Gp80-LNGFR) (Low affinity neurotrophin receptor p75NTR) (Low-affinity nerve growth factor receptor) (NGF receptor) (p75 ICD) (CD antigen CD271),Receptors,Receptors;TNFNGF,Novel Target
574,CXB909,CXB909,for treatment of chemotherapy-induced peripheral neuropathy,Small molecule,not approved,P04629,NTRK1_HUMAN,NTRK1,High affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinase receptor type 1) (TRK1-transforming tyrosine kinase protein) (p140-TrkA) (Trk-A),Receptors,EC:2.7.10.1,Established target
575,CYC116,CYC116,antineoplastic agent,Small molecule,not approved,O14965,STK6_HUMAN,AURKA,Serine/threonine-protein kinase 6 (EC 2.7.11.1) (Aurora kinase A) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase aurora-A),Enzymes,EC:2.7.11.1,Novel Target
575,CYC116,CYC116,antineoplastic agent,Small molecule,not approved,Q96GD4,AURKB_HUMAN,AURKB,Serine/threonine-protein kinase 12 (EC 2.7.11.1) (Aurora kinase B) (Aurora- and IPL1-like midbody-associated protein 1) (AIM-1) (Aurora/IPL1-related kinase 2) (ARK-2) (Aurora-related kinase 2) (STK-1) (Serine/threonine-protein kinase aurora-B),Enzymes,EC:2.7.11.1,Novel Target
575,CYC116,CYC116,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
576,"cyclosporine,Restasis",cyclosporine,immunosuppressant,Small molecule,approved,P49069,CAMLG_HUMAN,CAMLG,Calcium signal-modulating cyclophilin ligand (CAML),Miscellaneous,Miscellaneous:target for cyclosporine,Established target
576,"cyclosporine,Restasis",cyclosporine,immunosuppressant,Small molecule,approved,Q96LZ3,CANB2_HUMAN,PPP3R2,Calcineurin subunit B type 2 OS=Homo sapiens GN=PPP3R2 PE=2 SV=3,Miscellaneous,Enzyme regulator,Established target
577,Cymbalta,duloxetine,antidepressant,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
577,Cymbalta,duloxetine,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
578,"cysteamine hydrochloride,Cystavision",cysteamine ,for treatment of corneal cystine accumulation,Small molecule,not approved,cystine,,cystine,,,,Novel Target
579,CYT006-AngQb,CYT006-AngQb,antihypertensive vaccine,vaccine,not approved,P01019,ANGT_HUMAN,AGT,Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1,Other,Ligand;Hormone,Novel Target
580,CYT007-TNFQb,CYT007-TNFQb,"antiinflammatory vaccine,antipsoriatic",vaccine,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
581,CYT-009-GhrQb,CYT-009-GhrQb,"appetite supressant,vaccine",vaccine,not approved,Q9UBU3,GHRL_HUMAN,GHRL,Appetite-regulating hormone (Growth hormone secretagogue) (Growth hormone-releasing peptide) (Motilin-related peptide) (Protein M46) [Cleaved into: Ghrelin-27; Ghrelin-28 (Ghrelin); Obestatin],Miscellaneous,Receptor; Type 1 cytokine receptor,Novel Target
582,CYT013-IL1bQb,CYT013-IL1bQb,antidiabetic vaccine,vaccine,not approved,P01584,IL1B_HUMAN,IL1B,Interleukin-1 beta (IL-1 beta) (Catabolin),Miscellaneous,Ligand;Cytokine,Established target
583,"CYT-107, CYT-99007, recombinant human interl/",CYT-107,immunosuppressant,recombinant protein,not approved,P31785,IL2RG_HUMAN,IL2RG,Cytokine receptor common gamma chain OS=Homo sapiens GN=IL2RG PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
583,"CYT-107, CYT-99007, recombinant human interl/",CYT-107,immunosuppressant,recombinant protein,not approved,P16871,IL7RA_HUMAN,IL7R,Interleukin-7 receptor subunit alpha (IL-7 receptor subunit alpha) (IL-7R subunit alpha) (IL-7R-alpha) (IL-7RA) (CDw127) (CD antigen CD127),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
584,CYT-6091,CYT-6091,antineoplastic agent,gold particle-fused protein,not approved,P19438,TNR1A_HUMAN,TNFRSF1A,Tumor necrosis factor receptor superfamily member 1A,Receptors,Receptor; TNFR,Novel Target
584,CYT-6091,CYT-6091,antineoplastic agent,gold particle-fused protein,not approved,P20333,TNR1B_HUMAN,TNFRSF1B,Tumor necrosis factor receptor superfamily member 1B,Miscellaneous,Miscellaneous;TNF,Novel Target
585,"cytarabine liposome injection,DepoCyt",cytarabine,antineoplastic agent,Small Molecule,approved,P06746,DPOLB_HUMAN,POLB,DNA polymerase beta OS=Homo sapiens GN=POLB PE=1 SV=3,Enzymes,EC:2.7.7.7; 4.2.99.-,Established target
586,CytoFab,CytoFab,for treatment of sepsis and septic shock,antibody,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
587,Cytolin,Cytolin,for treatment of HIV,monoclonal antibody,not approved,P20701,ITAL_HUMAN,ITGAL,Integrin alpha-L OS=Homo sapiens GN=ITGAL PE=1 SV=3,Receptors,Receptors;Integrin,Established target
588,D3263,D3263,antineoplastic agent,Small molecule,not approved,Q7Z2W7,TRPM8_HUMAN,TRPM8,Transient receptor potential cation channel subfamily M member 8 OS=Homo sapiens GN=TRPM8 PE=2 SV=2,Transporters,TC:1.A.4.5.7,Established target
589,Dabigatran,Dabigatran,anticoagulant,Small molecule,approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
590,"DAC:GLP-1, CJC-1131",DAC:GLP-1,antidiabetic,peptide,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
591,DAC:GRF,DAC:GRF,hormone replacement,peptide,not approved,Q02643,GHRHR_HUMAN,GHRHR,Growth hormone-releasing hormone receptor OS=Homo sapiens GN=GHRHR PE=1 SV=2,Receptors,GPCR;Secretin,Established target
592,"dacetuzumab, SGN-40",dacetuzumab,antineoplastic agent,monoclonal antibody,not approved,P25942,TNR5_HUMAN,CD40,Tumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40) (Bp50) (CD40L receptor) (CDw40) (CD antigen CD40),Receptors,Receptors;TNFNGF,Novel Target
593,"daclizumab,Zenapax",daclizumab,immunosuppressant,monoclonal antibody,approved,P01589,IL2RA_HUMAN,IL2RA,Interleukin-2 receptor alpha chain OS=Homo sapiens GN=IL2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
594,Dacogen/decitabine,decitabine,antineoplastic agent,Small Molecule,approved,P26358,DNMT1_HUMAN,DNMT1,DNA (cytosine-5)-methyltransferase 1 OS=Homo sapiens GN=DNMT1 PE=1 SV=2,Enzymes,EC:2.1.1.37,Established target
595,"dalotuzumab, MK-0646",dalotuzumab,antineoplastic agent,monoclonal antibody,not approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
596,"dapoxetine,Priligy",dapoxetine,for treatment of premature ejaculation,Small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
597,"darapladib, 480848",darapladib,"antiinflammatory agent,DMARD",Small molecule,not approved,Q13093,PAFA_HUMAN,PLA2G7,Platelet-activating factor acetylhydrolase (PAF acetylhydrolase) (EC 3.1.1.47) (1-alkyl-2-acetylglycerophosphocholine esterase) (2-acetyl-1-alkylglycerophosphocholine esterase) (Group-VIIA phospholipase A2) (gVIIA-PLA2) (LDL-associated phospholipase A2) (,Enzymes,EC:3.1.1.47,Novel Target
598,"darifenacin,Enablex, Emselex",darifenacin,for treatment of overactive bladder,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
599,darusentan,darusentan,antihypertensive agent,Small molecule,not approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P00519,ABL1_HUMAN,ABL1,Proto-oncogene tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4,Enzymes,EC:2.7.10.2,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P42684,ABL2_HUMAN,ABL2,Tyrosine-protein kinase ABL2 OS=Homo sapiens GN=ABL2 PE=1 SV=1,Enzymes,EC:2.7.10.2,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P29317,EPHA2_HUMAN,EPHA2,Ephrin type-A receptor 2 OS=Homo sapiens GN=EPHA2 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P06241,FYN_HUMAN,FYN,Proto-oncogene tyrosine-protein kinase Fyn OS=Homo sapiens GN=FYN PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P06239,LCK_HUMAN,LCK,Proto-oncogene tyrosine-protein kinase LCK OS=Homo sapiens GN=LCK PE=1 SV=6,Enzymes,EC:2.7.10.2,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P12931,SRC_HUMAN,SRC,Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P51692,STA5B_HUMAN,STAT5B,Signal transducer and activator of transcription 5B OS=Homo sapiens GN=STAT5B PE=1 SV=2,Miscellaneous,Transcription factor,Established target
600,"dasatinib, BMS-354825,Sprycel",dasatinib,antineoplastic agent,Small Molecule,approved,P07947,YES_HUMAN,YES1,Proto-oncogene tyrosine-protein kinase Yes OS=Homo sapiens GN=YES1 PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
601,Daytrana,methylphenidate,for treatment of ADHD,Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
602,DB-959,DB-959,antidiabetic,Small molecule,not approved,Q03181,PPARD_HUMAN,PPARD,Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta),Receptors,Nuclear receptor,Established target
602,DB-959,DB-959,antidiabetic,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
603,DCCR,diazoxide choline,antidyslipidaemic agent,Small molecule,not approved,Q09428,ABCC8_HUMAN,ABCC8,ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1),Transporters,TC:3.A.1.208.4,Established target
604,DC-RTS-IL-12,DC-RTS-IL-12,antineoplastic agent,adenoviral vector,not approved,P29459,IL12A_HUMAN,IL12A,Interleukin-12 subunit alpha (IL-12A) (IL-12 subunit p35) (Cytotoxic lymphocyte maturation factor 35 kDa subunit) (CLMF p35) (NK cell stimulatory factor chain 1) (NKSF1),Miscellaneous,Ligand;Cytokine,Established target
604,DC-RTS-IL-12,DC-RTS-IL-12,antineoplastic agent,adenoviral vector,not approved,P29460,IL12B_HUMAN,IL12B,Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2),Receptors,Receptor; Type 1 cytokine receptor,Established target
605,DCVax-Prostate,DCVax-Prostate ,antineoplastic agent,autologous cellular therapy,not approved,Q04609,FOLH1_HUMAN,FOLH1,Glutamate carboxypeptidase 2 OS=Homo sapiens GN=FOLH1 PE=1 SV=1,Enzymes,EC:3.4.17,Established target
606,DDP225,DDP225,for treatment of irritable bowel syndrome,Small molecule,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
606,DDP225,DDP225,for treatment of irritable bowel syndrome,Small molecule,not approved,O95264,5HT3B_HUMAN,HTR3B,5-hydroxytryptamine receptor 3B (5-HT3-B) (5-HT3B) (Serotonin receptor 3B),Receptors,TC:1.A.9,Established target
606,DDP225,DDP225,for treatment of irritable bowel syndrome,Small molecule,not approved,Q8WXA8,5HT3C_HUMAN,HTR3C,5-hydroxytryptamine receptor 3C (5-HT3-C) (5-HT3C) (Serotonin receptor 3C),Receptors,TC:1.A.9,Established target
606,DDP225,DDP225,for treatment of irritable bowel syndrome,Small molecule,not approved,Q70Z44,5HT3D_HUMAN,HTR3D,5-hydroxytryptamine receptor 3D (5-HT3-D) (5-HT3D) (Serotonin receptor 3D),Receptors,TC:1.A.9,Established target
606,DDP225,DDP225,for treatment of irritable bowel syndrome,Small molecule,not approved,A5X5Y0,5HT3E_HUMAN,HTR3E,5-hydroxytryptamine receptor 3E (5-HT3-E) (5-HT3E) (Serotonin receptor 3E),Receptors,TC:1.A.9,Established target
606,DDP225,DDP225,for treatment of irritable bowel syndrome,Small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
607,Debio 0932,Debio 0932,antineoplastic agent,Small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
607,Debio 0932,Debio 0932,antineoplastic agent,Small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
608,DEBIO-9902 SR,DEBIO-9902 SR,for treatment of Alzheimer's disease,Small molecule,not approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
610,Degarelix,Degarelix,antineoplastic agent,Small molecule,approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
610,Degarelix,Degarelix,antineoplastic agent,Small molecule,approved,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
611,Denenicokin,Denenicokin,antineoplastic agent,recombinant protein,not approved,Q9HBE5,IL21R_HUMAN,IL21R,Interleukin-21 receptor (IL-21 receptor) (IL-21R) (Novel interleukin receptor) (CD antigen CD360),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
612,Denileukin diftitox,Denileukin diftitox,antineoplastic agent,fusion protein,approved,P42701,I12R1_HUMAN,IL2RA,Interleukin-12 receptor subunit beta-1 (IL-12 receptor subunit beta-1) (IL-12R subunit beta-1) (IL-12R-beta-1) (IL-12RB1) (IL-12 receptor beta component) (CD antigen CD212),Receptors,Receptor; Type 1 cytokine receptor,Established target
612,Denileukin diftitox,Denileukin diftitox,antineoplastic agent,fusion protein,approved,Q99665,I12R2_HUMAN,IL2RB,Interleukin-12 receptor subunit beta-2 (IL-12 receptor subunit beta-2) (IL-12R subunit beta-2) (IL-12R-beta-2) (IL-12RB2),Receptors,Receptor; Type 1 cytokine receptor,Established target
613,Denosumab,Denosumab,antiosteoporotic agent,monoclonal antibody,approved,O14788,TNF11_HUMAN,TNFSF11,Tumor necrosis factor ligand superfamily member 11 (Osteoclast differentiation factor) (ODF) (Osteoprotegerin ligand) (OPGL) (Receptor activator of nuclear factor kappa-B ligand) (RANKL) (TNF-related activation-induced cytokine) (TRANCE) (CD antigen CD254,Miscellaneous,Ligand;Cytokine,Established target
614,"denufosol tetrasodium, INS37217 respiratory",denufosol,for treatment of cystic fibrosis,Small molecule,not approved,P41231,P2RY2_HUMAN,P2RY2,P2Y purinoceptor 2 (P2Y2) (ATP receptor) (P2U purinoceptor 1) (P2U1) (Purinergic receptor),Receptors,GPCR;Rhodopsin,Novel Target
615,"deoxynojirimycin hydrochloride, AT2220",deoxynojirimycin ,for treatment of Pompe disease,Small molecule,not approved,P10253,LYAG_HUMAN,GAA,Lysosomal alpha-glucosidase OS=Homo sapiens GN=GAA PE=1 SV=2,Enzymes,EC:3.2.1,Established target
616,"DepoBupivacaine, bupivacaine,Exparel",bupivacaine,"local anestethic,analgesic,neuralgia",Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
617,Depomed,gabapentin,for treatment of neuropathic pain,Small Molecule,approved,Q00975,CAC1B_HUMAN,CACNA1B,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:1.A.1.11,Established target
617,Depomed,gabapentin,for treatment of neuropathic pain,Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
617,Depomed,gabapentin,for treatment of neuropathic pain,Small Molecule,approved,Q9NY47,CA2D2_HUMAN,CACNA2D2,Voltage-dependent calcium channel subunit alpha-2/delta-2 OS=Homo sapiens GN=CACNA2D2 PE=1 SV=1,Transporters,TC:8.A.18.2.1,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,Q96DB2,HDA11_HUMAN,HDAC11,Histone deacetylase 11 (HD11) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,P56524,HDAC4_HUMAN,HDAC4,Histone deacetylase 4 (HD4) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,Q9UQL6,HDAC5_HUMAN,HDAC5,Histone deacetylase 5 (HD5) (EC 3.5.1.98) (Antigen NY-CO-9),Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,Q8WUI4,HDAC7_HUMAN,HDAC7A,Histone deacetylase 7 (HD7) (EC 3.5.1.98) (Histone deacetylase 7A) (HD7a),Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
618,Depsipeptide,romidepsin,antineoplastic agent,small molecule,approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
619,dersalazine sodium,dersalazine,"antiinflammatory agent,for treatment of ulcerative colitis",Small molecule,not approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
619,dersalazine sodium,dersalazine,"antiinflammatory agent,for treatment of ulcerative colitis",Small molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
619,dersalazine sodium,dersalazine,"antiinflammatory agent,for treatment of ulcerative colitis",Small molecule,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
620,"desloratadine , Clarinex",desloratadine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
621,desmoteplase,desmoteplase,anticoagulant,protein,approved,P00747,PLMN_HUMAN,PLG,Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2,Enzymes,StructuralAndAdhesion;Fibrinogen,Established target
622,"desonide,Desonate HydroGel",desonide,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
623,"dexamethasone intravitreal implant,Ozurdex, Posurdex",dexamethasone,"antiinflammatory agent,glucocorticoid,for treatment of Meniere's disease",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
624,"dexanabinol, HU-211",Dexanabinol,neuroprotectant,Small molecule,not approved,Q05586,NMDZ1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo sapiens GN=GRIN1 PE=1 SV=1,Receptors,TC:1.A.10.1.6,Established target
624,"dexanabinol, HU-211",Dexanabinol,neuroprotectant,Small molecule,not approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
624,"dexanabinol, HU-211",Dexanabinol,neuroprotectant,Small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
624,"dexanabinol, HU-211",Dexanabinol,neuroprotectant,Small molecule,not approved,O15399,NMDE4_HUMAN,GRIN2D,Glutamate [NMDA] receptor subunit epsilon-4 OS=Homo sapiens GN=GRIN2D PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
624,"dexanabinol, HU-211",Dexanabinol,neuroprotectant,Small molecule,not approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
624,"dexanabinol, HU-211",Dexanabinol,neuroprotectant,Small molecule,not approved,O60391,NMD3B_HUMAN,GRIN3B,Glutamate [NMDA] receptor subunit 3B OS=Homo sapiens GN=GRIN3B PE=2 SV=2,Receptors,TC:1.A.10.1,Established target
625,"dexlipotam, KRX-0701",dexlipotam,for treatment of diabetic neuropathy,Small molecule,not approved,P11177,ODPB_HUMAN,PDHB,"Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHE1-B) (EC 1.2.4.1)",Enzymes,EC:1.2.4.1,Novel Target
626,"dexloxiglumide, CR 2017",dexloxiglumide,motilitant,Small molecule,not approved,P32238,CCKAR_HUMAN,CCKAR,Cholecystokinin receptor type A OS=Homo sapiens GN=CCKAR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
627,"dexpramipexole, KNS-760704",dexpramipexole,for treatment of amyotrophic lateral sclerosis (ALS),Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
627,"dexpramipexole, KNS-760704",dexpramipexole,for treatment of amyotrophic lateral sclerosis (ALS),Small molecule,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
627,"dexpramipexole, KNS-760704",dexpramipexole,for treatment of amyotrophic lateral sclerosis (ALS),Small molecule,not approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
628,DG031,DG031,"antiinflammatory agent,myocardial infarction prophylaxis",Small molecule,not approved,P20292,AL5AP_HUMAN,ALOX5AP,Arachidonate 5-lipoxygenase-activating protein (FLAP) (MK-886-binding protein),Miscellaneous,Enzyme regulator,Novel Target
629,DG041,DG041,Platelet Aggregation Inhibitor,Small molecule,not approved,P43115,PE2R3_HUMAN,PTGER3,Prostaglandin E2 receptor EP3 subtype OS=Homo sapiens GN=PTGER3 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
630,DG051,DG051,"antiinflammatory agent,myocardial infarction prophylaxis",Small molecule,not approved,P09960,LKHA4_HUMAN,LTA4H,Leukotriene A-4 hydrolase (LTA-4 hydrolase) (EC 3.3.2.6) (Leukotriene A(4) hydrolase),Enzymes,EC:3.3.2.6,Novel Target
631,DG071,DG071,for treatment of alzheimer's disease,Small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
631,DG071,DG071,for treatment of alzheimer's disease,Small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
632,DG3173,DG3173,hormone replacement,Small molecule,not approved,P30872,SSR1_HUMAN,SSTR1,Somatostatin receptor type 1 OS=Homo sapiens GN=SSTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
632,DG3173,DG3173,hormone replacement,Small molecule,not approved,P30874,SSR2_HUMAN,SSTR2,Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SRIF-1),Receptors,GPCR;Rhodopsin,Established target
632,DG3173,DG3173,hormone replacement,Small molecule,not approved,P31391,SSR4_HUMAN,SSTR4,Somatostatin receptor type 4 (SS-4-R) (SS4-R) (SS4R),Receptors,GPCR;Rhodopsin,Novel Target
632,DG3173,DG3173,hormone replacement,Small molecule,not approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
633,diazepam rectal gel,diazepam,anticonvulsant,Small Molecule,approved,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
634,Diclofenac,diclofenac,analgesic,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
634,Diclofenac,diclofenac,analgesic,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
635,"diclofenac potassium, PRO-513,Cambia, Voltfast, Catafast",Diclofenac,analgesic,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
635,"diclofenac potassium, PRO-513,Cambia, Voltfast, Catafast",Diclofenac,analgesic,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
636,"diclofenac potassium,Zipsor, Lynxorb",Diclofenac,analgesic,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
636,"diclofenac potassium,Zipsor, Lynxorb",Diclofenac,analgesic,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
637,"diclofenac sodium topical solution,Pennsaid",Diclofenac,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
637,"diclofenac sodium topical solution,Pennsaid",Diclofenac,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
638,"diclofenac, ISV-205",Diclofenac,for treatment of glaucoma,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
638,"diclofenac, ISV-205",Diclofenac,for treatment of glaucoma,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
639,"difluprednate , ST-601,Durezol",difluprednate,"antiinflammatory agent,corticosteroid",Small molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
640,"diltiazem HCL,Cardizem, Cardizem CD, Cardizem LA",diltiazem,antihypertensive agent,Small Molecule,approved,Q06432,CCG1_HUMAN,CACNG1,Voltage-dependent calcium channel gamma-1 subunit OS=Homo sapiens GN=CACNG1 PE=2 SV=1,Transporters,TC:8.A.16.1.1,Established target
641,Dimebon,latrepirdine,neuroprotectant,Small molecule,not approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
641,Dimebon,latrepirdine,neuroprotectant,Small molecule,not approved,Q05586,NMDZ1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo sapiens GN=GRIN1 PE=1 SV=1,Receptors,TC:1.A.10.1.6,Established target
641,Dimebon,latrepirdine,neuroprotectant,Small molecule,not approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
641,Dimebon,latrepirdine,neuroprotectant,Small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
641,Dimebon,latrepirdine,neuroprotectant,Small molecule,not approved,Q14957,NMDE3_HUMAN,GRIN2C,Glutamate [NMDA] receptor subunit epsilon-3 (N-methyl D-aspartate receptor subtype 2C) (NMDAR2C) (NR2C),Receptors,TC:1.A.10.1.3,Novel Target
641,Dimebon,latrepirdine,neuroprotectant,Small molecule,not approved,O15399,NMDE4_HUMAN,GRIN2D,Glutamate [NMDA] receptor subunit epsilon-4 OS=Homo sapiens GN=GRIN2D PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
641,Dimebon,latrepirdine,neuroprotectant,Small molecule,not approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
641,Dimebon,latrepirdine,neuroprotectant,Small molecule,not approved,O60391,NMD3B_HUMAN,GRIN3B,Glutamate [NMDA] receptor subunit 3B OS=Homo sapiens GN=GRIN3B PE=2 SV=2,Receptors,TC:1.A.10.1,Established target
642,"dimiracetam, NT-11624",dimiracetam,nootropic,Small molecule,not approved,Q12879,NMDE1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
642,"dimiracetam, NT-11624",dimiracetam,nootropic,Small molecule,not approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
642,"dimiracetam, NT-11624",dimiracetam,nootropic,Small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
642,"dimiracetam, NT-11624",dimiracetam,nootropic,Small molecule,not approved,Q14957,NMDE3_HUMAN,GRIN2C,Glutamate [NMDA] receptor subunit epsilon-3 (N-methyl D-aspartate receptor subtype 2C) (NMDAR2C) (NR2C),Receptors,TC:1.A.10.1.3,Novel Target
642,"dimiracetam, NT-11624",dimiracetam,nootropic,Small molecule,not approved,O15399,NMDE4_HUMAN,GRIN2D,Glutamate [NMDA] receptor subunit epsilon-4 OS=Homo sapiens GN=GRIN2D PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
643,DIO-902,DIO-902,antidiabetic,Small molecule,not approved,P10613,CP51_CANAL,ERG11,Lanosterol 14-alpha demethylase (EC 1.14.13.70) (CYPLI) (Cytochrome P450 51) (Cytochrome P450-14DM) (Cytochrome P450-LIA1) (Sterol 14-alpha demethylase),Enzymes,EC:1.14.13.70,Established target
644,"diquafosol tetrasodium, INS365 ophthalmic,Prolacria",diquafosol,opthalmological agent,Small molecule,not approved,P41231,P2RY2_HUMAN,P2RY2,P2Y purinoceptor 2 (P2Y2) (ATP receptor) (P2U purinoceptor 1) (P2U1) (Purinergic receptor),Receptors,GPCR;Rhodopsin,Novel Target
645,DISC GM-CSF,GM-CSF,antineoplastic agent,protein,not approved,P15509,CSF2R_HUMAN,CSF2RA,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha OS=Homo sapiens GN=CSF2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
646,DM-1992,carbidopa,antiparkinson agent,Small Molecule,approved,P20711,DDC_HUMAN,DDC,Aromatic-L-amino-acid decarboxylase OS=Homo sapiens GN=DDC PE=1 SV=1,Enzymes,EC:4.1.1.28,Established target
646,DM-1992,levodopa,antiparkinson agent,Small Molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
646,DM-1992,levodopa,antiparkinson agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
647,"DM-3458, extended, controlled release omeprazole",omeprazole,antiulcer agent,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
648,DM-71,betanechol,antidiabetic,Small molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
649,"DN-101,Asentar",calcitriol,antineoplastic agent,Small Molecule,approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
650,Docetaxel,Docetaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
650,Docetaxel,Docetaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
651,"dolasetron mesylate, Anzemet",dolasetron,antiemetic,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
652,"dolasetron mesylate,Anzemet",dolasetron,antiemetic,Small Molecule,approved,O95264,5HT3B_HUMAN,HTR3B,5-hydroxytryptamine receptor 3B (5-HT3-B) (5-HT3B) (Serotonin receptor 3B),Receptors,TC:1.A.9,Established target
652,"dolasetron mesylate,Anzemet",dolasetron,antiemetic,Small Molecule,approved,Q8WXA8,5HT3C_HUMAN,HTR3C,5-hydroxytryptamine receptor 3C (5-HT3-C) (5-HT3C) (Serotonin receptor 3C),Receptors,TC:1.A.9,Established target
652,"dolasetron mesylate,Anzemet",dolasetron,antiemetic,Small Molecule,approved,Q70Z44,5HT3D_HUMAN,HTR3D,5-hydroxytryptamine receptor 3D (5-HT3-D) (5-HT3D) (Serotonin receptor 3D),Receptors,TC:1.A.9,Established target
652,"dolasetron mesylate,Anzemet",dolasetron,antiemetic,Small Molecule,approved,A5X5Y0,5HT3E_HUMAN,HTR3E,5-hydroxytryptamine receptor 3E (5-HT3-E) (5-HT3E) (Serotonin receptor 3E),Receptors,TC:1.A.9,Established target
653,"donepezil hydrochloride, E2020,Aricept",donepezil,for treatment of alzheimer's disease,Small Molecule,approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
654,"DOR201, delayed release beclomethasone dipropionate",beclomethasone dipropionate,"antiinflammatory agent,glucocorticoid",Small molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor,Receptors,Nuclear receptor,Established target
655,DOV 102,"DOV 102,677",antidepressant,Small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
655,DOV 102,"DOV 102,677",antidepressant,Small molecule,not approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
655,DOV 102,"DOV 102,677",antidepressant,Small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
656,DOV 216,"DOV 216,303",antidepressant,Small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
656,DOV 216,"DOV 216,303",antidepressant,Small molecule,not approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
656,DOV 216,"DOV 216,303",antidepressant,Small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
657,DOV 21947,DOV 21947,antidepressant,Small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
657,DOV 21947,DOV 21947,antidepressant,Small molecule,not approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
657,DOV 21947,DOV 21947,antidepressant,Small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
658,"dovitinib, TKI-258, CHIR-258",dovitinib,antineoplastic agent,Small molecule,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
658,"dovitinib, TKI-258, CHIR-258",dovitinib,antineoplastic agent,Small molecule,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
658,"dovitinib, TKI-258, CHIR-258",dovitinib,antineoplastic agent,Small molecule,not approved,P22607,FGFR3_HUMAN,FGFR3,Fibroblast growth factor receptor 3 OS=Homo sapiens GN=FGFR3 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
658,"dovitinib, TKI-258, CHIR-258",dovitinib,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
658,"dovitinib, TKI-258, CHIR-258",dovitinib,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
658,"dovitinib, TKI-258, CHIR-258",dovitinib,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
658,"dovitinib, TKI-258, CHIR-258",dovitinib,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
658,"dovitinib, TKI-258, CHIR-258",dovitinib,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
658,"dovitinib, TKI-258, CHIR-258",dovitinib,antineoplastic agent,Small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
659,"doxepin nasal solution,Dolorac",doxepin,antimigraine agent,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
659,"doxepin nasal solution,Dolorac",doxepin,antimigraine agent,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
660,"doxercalciferol , Hectorol",doxercalciferol,for treatment of secondary hyperparathyroidism,Small molecule,approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
661,"doxorubicin HCl,Doxil, Caelyx",doxorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
662,"doxorubicin TransDrug, BA-003",doxorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
663,"doxorubicin,Myocet",doxorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
664,"doxorubicin,Resmycin",doxorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
665,DP-VPA,DP-VPA,anticonvulsant,Small molecule,not approved,P80404,GABT_HUMAN,ABAT,"4-aminobutyrate aminotransferase, mitochondrial OS=Homo sapiens GN=ABAT PE=1 SV=3",Enzymes,EC:2.6.1.19; 2.6.1.22,Established target
666,DRF 10945,DRF 10945,antidyslipidaemic agent,Small molecule,not approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
667,"dronabinol ,Marinol",dronabinol,appetite stimulant,Small molecule,approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
668,"drospirenone plus estradiol,Angeliq",drospirenone,hormone replacement,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
668,"drospirenone plus estradiol,Angeliq",estradiol,hormone replacement,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
668,"drospirenone plus estradiol,Angeliq",estradiol,hormone replacement,Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
669,"drotrecogin alfa,Xigris",drotrecogin alfa,anticoagulant,recombinant protein,approved,P12259,FA5_HUMAN,F5,Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=3,Miscellaneous,Enzyme cofactor,Established target
669,"drotrecogin alfa,Xigris",drotrecogin alfa,anticoagulant,recombinant protein,approved,P00451,FA8_HUMAN,F8,Coagulation factor VIII OS=Homo sapiens GN=F8 PE=1 SV=1,Miscellaneous,Enzyme cofactor,Established target
670,DSC-103,DSC-103,antiosteoporotic agent,Small molecule,not approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
671,DTS-201,DTS-201,antineoplastic agent,Small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
672,"DUR-843,Eladur, Transdur-Bupivacaine",bupivacaine,"local anestethic,analgesic,neuralgia",Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
673,Durect,bupivacaine,"local anestethic,analgesic,neuralgia",Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
674,Duromist,sildenafil,for treatment of erectile dysfunction,Small Molecule,approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
675,"dutasteride + tamsulosin,Jalyn",dutasteride ,for treatment of benign prostate hyperplasia,Small molecule,approved,P18405,S5A1_HUMAN,SRD5A1,3-oxo-5-alpha-steroid 4-dehydrogenase 1 OS=Homo sapiens GN=SRD5A1 PE=1 SV=1,Enzymes,EC:1.3.99,Established target
675,"dutasteride + tamsulosin,Jalyn",dutasteride ,for treatment of benign prostate hyperplasia,Small molecule,approved,P31213,S5A2_HUMAN,SRD5A2,3-oxo-5-alpha-steroid 4-dehydrogenase 2 OS=Homo sapiens GN=SRD5A2 PE=1 SV=1,Enzymes,EC:1.3.99,Established target
675,"dutasteride + tamsulosin,Jalyn",tamsulosin,for treatment of benign prostatic hyperplasia,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
676,"dutasteride,Avodart",dutasteride ,for treatment of benign prostate hyperplasia,Small molecule,approved,P18405,S5A1_HUMAN,SRD5A1,3-oxo-5-alpha-steroid 4-dehydrogenase 1 OS=Homo sapiens GN=SRD5A1 PE=1 SV=1,Enzymes,EC:1.3.99,Established target
677,"dutogliptin, PHX1149",dutogliptin,antidiabetic,Small molecule,not approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
678,DV1179,DV1179,antiinflammatory agent,aptamer,not approved,Q9NYK1,TLR7_HUMAN,TLR7,Toll-like receptor 7 OS=Homo sapiens GN=TLR7 PE=1 SV=1,Receptors,Receptors;TOLL,Established target
678,DV1179,DV1179,antiinflammatory agent,aptamer,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
679,"Dymista, azelastine hydrochloride + fluticasone propionate, MP29-02",azelastine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
679,"Dymista, azelastine hydrochloride + fluticasone propionate, MP29-02",fluticasone,"antiinflammatory agent,glucocorticoid",Small molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
680,E-10030,E-10030,for treatment of age-related macular degeneration,recombinant protein,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
680,E-10030,E-10030,for treatment of age-related macular degeneration,recombinant protein,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
680,E-10030,E-10030,for treatment of age-related macular degeneration,recombinant protein,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
680,E-10030,E-10030,for treatment of age-related macular degeneration,recombinant protein,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
680,E-10030,E-10030,for treatment of age-related macular degeneration,recombinant protein,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
681,E2007,perampanel,anticonvulsant,Small molecule,not approved,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
681,E2007,perampanel,anticonvulsant,Small molecule,not approved,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
681,E2007,perampanel,anticonvulsant,Small molecule,not approved,P42263,GRIA3_HUMAN,GRIA3,"Glutamate receptor 3 (GluR-3) (AMPA-selective glutamate receptor 3) (GluR-C) (GluR-K3) (Glutamate receptor ionotropic, AMPA 3) (GluA3)",Receptors,TC:1.A.10.1.4,Established target
681,E2007,perampanel,anticonvulsant,Small molecule,not approved,P48058,GRIA4_HUMAN,GRIA4,"Glutamate receptor 4 (GluR-4) (GluR4) (AMPA-selective glutamate receptor 4) (GluR-D) (Glutamate receptor ionotropic, AMPA 4) (GluA4)",Receptors,TC:1.A.10.1,Established target
682,E2012,E2012,for treatment of Alzheimer's disease,Small molecule,not approved,P49768,PSN1_HUMAN,PSEN1,Presenilin-1,Enzymes,EC:3.4.23.-,Novel Target
683,E7080,lenvatinib,antineoplastic agent,Small molecule,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
683,E7080,lenvatinib,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
683,E7080,lenvatinib,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
683,E7080,lenvatinib,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
683,E7080,lenvatinib,antineoplastic agent,Small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
683,E7080,lenvatinib,antineoplastic agent,Small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
683,E7080,lenvatinib,antineoplastic agent,Small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
684,"E75,N/",E75,antineoplastic agent,vaccine,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
684,"E75,N/",GM-CSF,antineoplastic agent,protein,not approved,P15509,CSF2R_HUMAN,CSF2RA,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha OS=Homo sapiens GN=CSF2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
685,ecabet sodium,ecabet,antiulcer agent,Small molecule,not approved,P00790,PEPA_HUMAN,PGA3,Pepsin A (EC 3.4.23.1),Enzymes,EC:3.4.23.1,Established target
685,ecabet sodium,ecabet,antiulcer agent,Small molecule,not approved,P20142,PEPC_HUMAN,PGC,Gastricsin,Enzymes,EC:3.4.23.3,Established target
686,ecopipam,ecopipam,"for treatment of tourettes syndrome,for treatment of pathological gambling",Small molecule,not approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
687,"edoxaban, DU-176b",edoxaban,antithrombotic,Small molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
688,Effexor,venlafaxine,antidepressant,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
688,Effexor,venlafaxine,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
689,"eflornithine hydrochloride,Vaniqa",eflornithine,for treatment of unwanted facial hair in women,Small molecule,approved,P11926,DCOR_HUMAN,ODC1,Ornithine decarboxylase (ODC) (EC 4.1.1.17),Enzymes,EC:4.1.1.17,Established target
690,EGP-437,dexamethasone,"antiinflammatory agent,glucocorticoid,for treatment of Meniere's disease",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,Q08493,PDE4C_HUMAN,PDE4C,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C OS=Homo sapiens GN=PDE4C PE=1 SV=2",Enzymes,EC:3.1.4.17,Established target
691,EHT 0202,Etazolate,for treatment of alzheimer's disease,Small molecule,not approved,Q08499,PDE4D_HUMAN,PDE4D,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D OS=Homo sapiens GN=PDE4D PE=1 SV=2",Enzymes,EC:3.1.4.17,Established target
692,Elafin,Elafin,antiinflammatory agent,recombinant protein,not approved,P08246,ELNE_HUMAN,ELANE,Neutrophil elastase (EC 3.4.21.37) (Bone marrow serine protease) (Elastase-2) (Human leukocyte elastase) (HLE) (Medullasin) (PMN elastase),Enzymes,EC:3.4.21.37,Established target
692,Elafin,Elafin,antiinflammatory agent,recombinant protein,not approved,P24158,PRTN3_HUMAN,PRTN3,Myeloblastin (EC 3.4.21.76) (AGP7) (C-ANCA antigen) (Leukocyte proteinase 3) (PR-3) (PR3) (Neutrophil proteinase 4) (NP-4) (P29) (Wegener autoantigen),Enzymes,EC:3.4.21.76,Novel Target
693,ELB353,ronomilast,antiinflammatory agent,small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
693,ELB353,ronomilast,antiinflammatory agent,small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
694,"eldecalcitol, ED-71",ED-71,antiosteoporotic agent,Small molecule,not approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
695,ElectroImmunotherapy,DNA IL-12,antineoplastic agent,DNA plasmid,not approved,P29459,IL12A_HUMAN,IL12A,Interleukin-12 subunit alpha (IL-12A) (IL-12 subunit p35) (Cytotoxic lymphocyte maturation factor 35 kDa subunit) (CLMF p35) (NK cell stimulatory factor chain 1) (NKSF1),Miscellaneous,Ligand;Cytokine,Established target
695,ElectroImmunotherapy,DNA IL-12,antineoplastic agent,DNA plasmid,not approved,P29460,IL12B_HUMAN,IL12B,Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2),Receptors,Receptor; Type 1 cytokine receptor,Established target
696,"ELI-154, oxycodone (once daily)",oxycodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
696,"ELI-154, oxycodone (once daily)",oxycodone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
696,"ELI-154, oxycodone (once daily)",oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
697,Eligard,Leuprolide,antineoplastic agent,peptide,approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
698,eligen insulin (oral),insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
699,eligen PYY-3-36 + GLP-1,GLP,appetite suppressant,peptide,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
699,eligen PYY-3-36 + GLP-1,Peptide YY,appetite suppressant,peptide,not approved,P49146,NPY2R_HUMAN,NPY2R,Neuropeptide Y receptor type 2 (NPY2-R) (NPY-Y2 receptor) (Y2 receptor),Receptors,GPCR;Rhodopsin,Novel Target
699,eligen PYY-3-36 + GLP-1,Peptide YY,appetite suppressant,peptide,not approved,Q15761,NPY5R_HUMAN,NPY5R,Neuropeptide Y receptor type 5 (NPY5-R) (NPY-Y5 receptor) (NPYY5-R) (Y5 receptor),Receptors,GPCR;Rhodopsin,Novel Target
700,"eliglustat tartrate, Genz-112638",eliglustat,for treatment of Gaucher's disease,Small molecule,not approved,Q16739,CEGT_HUMAN,UGCG,Ceramide glucosyltransferase OS=Homo sapiens GN=UGCG PE=2 SV=1,Enzymes,EC:2.4.1,Established target
701,"elinogrel, PRT060128, ADP receptor antagonist",elinogrel,antiplatelet agent,Small molecule,not approved,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
702,Elocalcitol,Elocalcitol,for treatment of benign prostatic hyperplasia,Small molecule,not approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
703,"elotuzumab, HuLuc63",elotuzumab,antineoplastic agent,monoclonal antibody,not approved,Q9NQ25,SLAF7_HUMAN,SLAMF7,SLAM family member 7 (CD2 subset 1) (CD2-like receptor-activating cytotoxic cells) (CRACC) (Membrane protein FOAP-12) (Novel Ly9) (Protein 19A) (CD antigen CD319),Miscellaneous,StructureAndAdhesion:cell surface glycoprotein,Novel Target
704,Empatic,bupropion,"antidepressant,appetite suppressant,smoking-cessation agent",Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
704,Empatic,bupropion,"antidepressant,appetite suppressant,smoking-cessation agent",Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,O43497,CAC1G_HUMAN,CACNA1G,Voltage-dependent T-type calcium channel subunit alpha-1G OS=Homo sapiens GN=CACNA1G PE=2 SV=3,Transporters,TC:1.A.1.11,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,O95180,CAC1H_HUMAN,CACNA1H,Voltage-dependent T-type calcium channel subunit alpha-1H OS=Homo sapiens GN=CACNA1H PE=1 SV=4,Transporters,TC:1.A.1.11.5,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,Q9P0X4,CAC1I_HUMAN,CACNA1I,Voltage-dependent T-type calcium channel subunit alpha-1I OS=Homo sapiens GN=CACNA1I PE=1 SV=1,Transporters,TC:1.A.1.11.7,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,Q9UI33,SCNBA_HUMAN,SCN11A,Sodium channel protein type 11 subunit alpha OS=Homo sapiens GN=SCN11A PE=1 SV=2,Transporters,TC:1.A.1.10.9,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,Q07699,SCN1B_HUMAN,SCN1B,Sodium channel subunit beta-1,Transporters,TC:8.A.17,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,Q99250,SCN2A_HUMAN,SCN2A,Sodium channel protein type 2 subunit alpha (HBSC II) (Sodium channel protein brain II subunit alpha) (Sodium channel protein type II subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.2),Transporters,TC:1.A.1.10,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,O60939,SCN2B_HUMAN,SCN2B,Sodium channel subunit beta-2,Transporters,TC:8.A.17.2.1,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,Q9NY46,SCN3A_HUMAN,SCN3A,Sodium channel protein type 3 subunit alpha (Sodium channel protein brain III subunit alpha) (Sodium channel protein type III subunit alpha) (Voltage-gated sodium channel subtype III) (Voltage-gated sodium channel subunit alpha Nav1.3),Transporters,TC:1.A.1.10,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,Q9NY72,SCN3B_HUMAN,SCN3B,Sodium channel subunit beta-3,Transporters,TC:8.A.17,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,P35499,SCN4A_HUMAN,SCN4A,Sodium channel protein type 4 subunit alpha (SkM1) (Sodium channel protein skeletal muscle subunit alpha) (Sodium channel protein type IV subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.4),Transporters,TC:1.A.1.10.4,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,Q8IWT1,SCN4B_HUMAN,SCN4B,Sodium channel subunit beta-4,Transporters,TC:8.A.17.2.2,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
704,Empatic,zonisamide,appetite suppressant,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
705,"enalapril + felodipine,Lexxel",enalapril,antihypertensive agent,Small Molecule,approved,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
705,"enalapril + felodipine,Lexxel",felodipine,antihypertensive agent,Small Molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
705,"enalapril + felodipine,Lexxel",felodipine,antihypertensive agent,Small Molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
705,"enalapril + felodipine,Lexxel",felodipine,antihypertensive agent,Small Molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
705,"enalapril + felodipine,Lexxel",felodipine,antihypertensive agent,Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
705,"enalapril + felodipine,Lexxel",felodipine,antihypertensive agent,Small Molecule,approved,Q08289,CACB2_HUMAN,CACNANB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
706,Enbrel,etanercept,"antiinflammatory agent,DMARD",fusion protein,approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
707,EndoTAG-1,paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
707,EndoTAG-1,paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
708,eniluracil,eniluracil,antineoplastic agent,Small molecule,not approved,Q12882,DPYD_HUMAN,DPYD,Dihydropyrimidine dehydrogenase [NADP+] (DHPDHase) (DPD) (EC 1.3.1.2) (Dihydrothymine dehydrogenase) (Dihydrouracil dehydrogenase),Enzymes,EC:1.3.1.2,Novel Target
709,ENMD-1198,ENMD-1198,antineoplastic agent,Small molecule,not approved,Q16665,HIF1A_HUMAN,HIF1A,Hypoxia-inducible factor 1-alpha (HIF-1-alpha) (HIF1-alpha) (ARNT-interacting protein) (Basic-helix-loop-helix-PAS protein MOP1) (Class E basic helix-loop-helix protein 78) (bHLHe78) (Member of PAS protein 1) (PAS domain-containing protein 8),Miscellaneous,Transcription factor,Novel Target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P00519,ABL1_HUMAN,ABL1,Proto-oncogene tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4,Enzymes,EC:2.7.10.2,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,O14965,STK6_HUMAN,AURKA,Serine/threonine-protein kinase 6 (EC 2.7.11.1) (Aurora kinase A) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase aurora-A),Enzymes,EC:2.7.11.1,Novel Target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P51451,BLK_HUMAN,BLK,Tyrosine-protein kinase Blk,Enzymes,EC:2.7.10.2,Novel Target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P07333,CSF1R_HUMAN,CSF1R,Macrophage colony-stimulating factor 1 receptor OS=Homo sapiens GN=CSF1R PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P06241,FYN_HUMAN,FYN,Proto-oncogene tyrosine-protein kinase Fyn OS=Homo sapiens GN=FYN PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P06239,LCK_HUMAN,LCK,Proto-oncogene tyrosine-protein kinase LCK OS=Homo sapiens GN=LCK PE=1 SV=6,Enzymes,EC:2.7.10.2,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P04629,NTRK1_HUMAN,NTRK1,High affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinase receptor type 1) (TRK1-transforming tyrosine kinase protein) (p140-TrkA) (Trk-A),Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,Q05397,FAK1_HUMAN,PTK2,Focal adhesion kinase 1 (FADK 1) (EC 2.7.10.2) (Protein-tyrosine kinase 2) (pp125FAK),Enzymes,EC:2.7.10.2,Novel Target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P07949,RET_HUMAN,RET,Proto-oncogene tyrosine-protein kinase receptor ret OS=Homo sapiens GN=RET PE=1 SV=3,Receptors,EC:2.7.10.1,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P12931,SRC_HUMAN,SRC,Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
710,ENMD-2076,ENMD-2076,antineoplastic agent,Small molecule,not approved,P07947,YES_HUMAN,YES1,Proto-oncogene tyrosine-protein kinase Yes OS=Homo sapiens GN=YES1 PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
711,"entacapone, Comtan",entacapone,antiparkinson agent,Small Molecule,approved,P21964,COMT_HUMAN,COMT,Catechol O-methyltransferase OS=Homo sapiens GN=COMT PE=1 SV=2,Enzymes,EC:2.1.1.6,Established target
712,"entacapone/levodopa/carbidopa,Stalevo",carbidopa,antiparkinson agent,Small Molecule,approved,P20711,DDC_HUMAN,DDC,Aromatic-L-amino-acid decarboxylase OS=Homo sapiens GN=DDC PE=1 SV=1,Enzymes,EC:4.1.1.28,Established target
712,"entacapone/levodopa/carbidopa,Stalevo",entacapone,antiparkinson agent,Small Molecule,approved,P21964,COMT_HUMAN,COMT,Catechol O-methyltransferase OS=Homo sapiens GN=COMT PE=1 SV=2,Enzymes,EC:2.1.1.6,Established target
712,"entacapone/levodopa/carbidopa,Stalevo",levodopa,antiparkinson agent,Small Molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
712,"entacapone/levodopa/carbidopa,Stalevo",levodopa,antiparkinson agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
712,"entacapone/levodopa/carbidopa,Stalevo",levodopa,antiparkinson agent,Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
712,"entacapone/levodopa/carbidopa,Stalevo",levodopa,antiparkinson agent,Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
712,"entacapone/levodopa/carbidopa,Stalevo",levodopa,antiparkinson agent,Small Molecule,approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
713,"entinostat, SNDX-275, MS-275",entinostat,antineoplastic agent,Small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
713,"entinostat, SNDX-275, MS-275",entinostat,antineoplastic agent,Small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
714,"enzastaurin, LY317615",Enzastaurin,antineoplastic agent,Small molecule,not approved,P05771,KPCB_HUMAN,PRKCB,Protein kinase C beta type (PKC-B) (PKC-beta) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
715,EP-100,EP-100,antineoplastic agent,peptide,not approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
715,EP-100,EP-100,antineoplastic agent,peptide,not approved,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
716,EP217609,EP217609,anticoagulant,Small Molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
716,EP217609,EP217609,anticoagulant,Small Molecule,not approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
717,EP42675,EP42675,anticoagulant,Small Molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
717,EP42675,EP42675,anticoagulant,Small Molecule,not approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
718,EPI-743,EPI-743,"for treatment of Chron's disease,for treatment of ulcerative colitis",Small molecule,not approved,P15559,QOR_HUMAN,NQO1,Quinone oxidoreductase (EC 1.6.5.5) (NADPH:quinone reductase) (Zeta-crystallin),Enzymes,EC:1.6.5.5,Established target
719,epinastine,epinastine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
719,epinastine,epinastine,antiallergy agent,Small Molecule,approved,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
720,"eplerenone tablets,Inspra",eplerenone,antihypertensive agent,Small Molecule,approved,P08235,MCR_HUMAN,NR3C2,Mineralocorticoid receptor OS=Homo sapiens GN=NR3C2 PE=1 SV=1,Receptors,Nuclear receptor,Established target
721,"eplivanserine, SR 46349,Ciltyri",eplivanserine,for treatment of insomnia,Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
721,"eplivanserine, SR 46349,Ciltyri",eplivanserine,for treatment of insomnia,Small molecule,not approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
722,epoetin alpha,erythropoietin,erythropoietic agent,protein,approved,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
723,"epoetin delta, gene-activated erythropoietin,Dynepo",erythropoietin,erythropoietic agent,protein,approved,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
724,Epothilone D,Epothilone D,antineoplastic agent,Small molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
725,"eprotirome, KB2115",eprotirome,antidyslipidaemic agent,Small molecule,not approved,P10828,THB_HUMAN,THRB,Thyroid hormone receptor beta OS=Homo sapiens GN=THRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
726,"eptifibatide,Integrilin",eptifibatide,antiplatelet agent,peptide,approved,P08514,ITA2B_HUMAN,ITGA2B,"Integrin alpha-IIb (GPalpha IIb) (GPIIb) (Platelet membrane glycoprotein IIb) (CD antigen CD41) [Cleaved into: Integrin alpha-IIb heavy chain; Integrin alpha-IIb light chain, form 1; Integrin alpha-IIb light chain, form 2]",Receptors,Receptors;Integrin,Established target
726,"eptifibatide,Integrilin",eptifibatide,antiplatelet agent,peptide,approved,P05106,ITB3_HUMAN,ITGB3,Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
727,Erbitux,cetuximab,antineoplastic agent,monoclonal antibody,approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
728,erdosteine,erdosteine,for treatment of chronic obstructive pulmonary disorder (COPD),Small molecule,not approved,P08246,ELNE_HUMAN,ELANE,Leukocyte elastase OS=Homo sapiens GN=ELA2 PE=1 SV=1,Enzymes,EC:3.4.21.37,Established target
729,"eritoran tetrasodium, E5564",eritoran,for treatment of sepsis,Small molecule,not approved,O00206,TLR4_HUMAN,TLR4,Toll-like receptor 4 (hToll) (CD antigen CD284),Receptors,Receptors;TOLL,Novel Target
730,ESBA105,ESBA105 ,antiinflammatory agent,antibody fragment,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
731,Eslicarbazepine,Eslicarbazepine,anticonvulsant,Small molecule,not approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
732,"esmirtazapine, ORG-4420",esmirtazapine,"for treatment of insomnia,for treatment of menopausal symptoms",Small molecule,not approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
732,"esmirtazapine, ORG-4420",esmirtazapine,"for treatment of insomnia,for treatment of menopausal symptoms",Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
732,"esmirtazapine, ORG-4420",esmirtazapine,"for treatment of insomnia,for treatment of menopausal symptoms",Small molecule,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
733,"esomeprazole, Nexium",esomeprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
734,"estradiol , 17-beta,Estrogel",estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
735,"estradiol + norethisterone acetate,Estalis, Combipatch",estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
735,"estradiol + norethisterone acetate,Estalis, Combipatch",estradiol,contraceptive,Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
735,"estradiol + norethisterone acetate,Estalis, Combipatch",norethisterone,contraceptive,small molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
736,"estradiol MDTS,Evamist",estradiol ,for treatment of menopausal symptoms,Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
736,"estradiol MDTS,Evamist",estradiol ,for treatment of menopausal symptoms,Small molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
737,"estradiol transdermal, Estrasorb",estradiol ,for treatment of menopausal symptoms,Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
738,"estradiol transdermal,Estrasorb",estradiol ,for treatment of menopausal symptoms,Small molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
739,"estradiol valerate + dienogest, Natazia, Qlaira",estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
740,"estradiol valerate + dienogest,Natazia, Qlaira",dienogest,contraceptive,Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
740,"estradiol valerate + dienogest,Natazia, Qlaira",dienogest,contraceptive,Small molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
740,"estradiol valerate + dienogest,Natazia, Qlaira",estradiol,contraceptive,Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
741,"estradiol, 17-beta,Estrogel",estradiol,contraceptive,Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
742,"estradol/levonorgestrel,Menostar",estradiol,for treatment of menopausal symptoms,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
742,"estradol/levonorgestrel,Menostar",estradiol,for treatment of menopausal symptoms,Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
742,"estradol/levonorgestrel,Menostar",levonorgestrel,for treatment of menopausal symptoms,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
742,"estradol/levonorgestrel,Menostar",levonorgestrel,for treatment of menopausal symptoms,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
742,"estradol/levonorgestrel,Menostar",levonorgestrel,for treatment of menopausal symptoms,Small Molecule,approved,P18405,S5A1_HUMAN,SRD5A1,3-oxo-5-alpha-steroid 4-dehydrogenase 1 OS=Homo sapiens GN=SRD5A1 PE=1 SV=1,Enzymes,EC:1.3.99,Established target
743,"estrogen ,Vivelle, Menorest",estradiol,for treatment of menopausal symptoms,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
744,"estrogen,Vivelle, Menorest",estradiol,for treatment of menopausal symptoms,Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
745,"estrogen,Vivelle-Dot",estradiol,for treatment of menopausal symptoms,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
745,"estrogen,Vivelle-Dot",estradiol,for treatment of menopausal symptoms,Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
746,"ethinyl estradiol + drospirenone ,Yaz",drospirenone,contraceptive,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
747,"ethinyl estradiol + drospirenone,Yaz",drospirenone,contraceptive,Small Molecule,approved,P08235,MCR_HUMAN,NR3C2,Mineralocorticoid receptor OS=Homo sapiens GN=NR3C2 PE=1 SV=1,Receptors,Nuclear receptor,Established target
747,"ethinyl estradiol + drospirenone,Yaz",drospirenone,contraceptive,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
747,"ethinyl estradiol + drospirenone,Yaz",estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
747,"ethinyl estradiol + drospirenone,Yaz",estradiol,contraceptive,Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
748,"ethinyl estradiol + levonorgestrel,Seasonale, Lo Seasonale, Seasonique",ethinyl estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
748,"ethinyl estradiol + levonorgestrel,Seasonale, Lo Seasonale, Seasonique",levonorgestrel,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
748,"ethinyl estradiol + levonorgestrel,Seasonale, Lo Seasonale, Seasonique",levonorgestrel,contraceptive,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
749,"etilevodopa, TV-1203",etilevodopa,antiparkinson agent,Small molecule,not approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
749,"etilevodopa, TV-1203",etilevodopa,antiparkinson agent,Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
749,"etilevodopa, TV-1203",etilevodopa,antiparkinson agent,Small molecule,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
749,"etilevodopa, TV-1203",etilevodopa,antiparkinson agent,Small molecule,not approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
749,"etilevodopa, TV-1203",etilevodopa,antiparkinson agent,Small molecule,not approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
750,"etodolac,Lodine",etodolac,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
751,"etonogestrel implant,Implanon",etonogestrel,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
751,"etonogestrel implant,Implanon",etonogestrel,contraceptive,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
752,"etonogestrel/ethinyl estradiol vaginal ring,Nuvaring",ethinyl estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
752,"etonogestrel/ethinyl estradiol vaginal ring,Nuvaring",etonogestrel,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
752,"etonogestrel/ethinyl estradiol vaginal ring,Nuvaring",etonogestrel,contraceptive,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
753,"etoricoxib, MK-663,Arcoxia",etoricoxib,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
754,EV-077-3201-2TBS,EV-077-3201-2TBS ,antidiabetic,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
755,EW-A-401,EW-A-401,for treatment of intermittent claudication,protein,not approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
756,Everolimus,everolimus,immunosuppressant,Small Molecule,approved,P42345,FRAP_HUMAN,MTOR,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
757,Evista,raloxifen,for treatment of menopausal symptoms,small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
757,Evista,raloxifen,for treatment of menopausal symptoms,small molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
758,EVK-001,metoclopramide,for treatment of diabetic gastroparesis,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
758,EVK-001,metoclopramide,for treatment of diabetic gastroparesis,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
759,EVP-6124,EVP-6124,nootropic,Small molecule,not approved,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
760,EVT-101,EVT-101,antidepressant,Small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
761,EVT-103,EVT-103,antidepressant,Small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P18507,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P48169,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P14867,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P24046,GBRR1_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,Q9UN88,GBRT_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,A8MPY1,GBRR3_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
762,EVT-201,EVT-201,hypnotic,Small molecule,not approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
763,EVT-302,EVT-302,smoking-cessation agent,Small molecule,not approved,P27338,AOFB_HUMAN,MA0B,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3,Established target
764,EVT-401,EVT-401,antiinflammatory agent,Small molecule,not approved,Q99572,P2RX7_HUMAN,P2RX7,P2X purinoceptor 7 (P2X7) (ATP receptor) (P2Z receptor) (Purinergic receptor),Receptors,TC:1.A.7.1.3,Novel Target
765,Excellair,ACU-XSP-001,"antiinflammatory agent,antiasthmatic agent",siRNA,not approved,P43405,KSYK_HUMAN,SYK,Tyrosine-protein kinase SYK (EC 2.7.10.2) (Spleen tyrosine kinase),Enzymes,EC:2.7.10.2,Novel Target
766,Excellarate,adenoviral PDGF B,for treatment of diabetic foot ulcers,adenoviral vector,not approved,P01127,PDGFB_HUMAN,PDGFB,Platelet-derived growth factor subunit B,Ligand,Ligand;PDGF,Novel Target
767,Exebryl-1,Exebryl-1,for treatment of alzheimer's disease,Small molecule,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
767,Exebryl-1,Exebryl-1,for treatment of alzheimer's disease,Small molecule,not approved,P10636,TAU_HUMAN,MAPT,Microtubule-associated protein tau,Miscellaneous,Structureandadhesion,Novel Target
768,"exemestane ,Aromasin",exemestane,antineoplastic agent,Small Molecule,approved,P11511,CP19A_HUMAN,CYP19A1,Cytochrome P450 19A1 OS=Homo sapiens GN=CYP19A1 PE=1 SV=3,Enzymes,EC:1.14.14,Established target
769,Exenatide,exenatide,antidiabetic,peptide,approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
770,Exherin,ADH-1,antineoplastic agent,peptide,not approved,P19022,CADH2_HUMAN,CDH2,Cadherin-2 (CDw325) (Neural cadherin) (N-cadherin) (CD antigen CD325),Miscellaneous,StructuralAndAdhesion;Cadherin,Novel Target
771,"ezatiostat hydrochloride, TLK-199,Telintra",ezatiostat,for treatment of Myelodysplastic Syndrome,Small molecule,not approved,P09211,GSTP1_HUMAN,GSTP1,Glutathione S-transferase P (EC 2.5.1.18) (GST class-pi) (GSTP1-1),Enzymes,EC:2.5.1.18,Novel Target
772,"EZN-2208, PEG-SN38,",PEG-SN38,antineoplastic agent,small molecule,not approved,Q969P6,TOP1M_HUMAN,TOP1MT,"DNA topoisomerase I, mitochondrial OS=Homo sapiens GN=TOP1MT PE=1 SV=1",Enzymes,EC:5.99.1.2,Established target
772,"EZN-2208, PEG-SN38,",PEG-SN38 ,antineoplastic agent,small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
773,"EZN2968, SPC2968",SPC/ENZ2968 ,antineoplastic agent,antisense oligo,not approved,Q16665,HIF1A_HUMAN,HIF1A,Hypoxia-inducible factor 1-alpha (HIF-1-alpha) (HIF1-alpha) (ARNT-interacting protein) (Basic-helix-loop-helix-PAS protein MOP1) (Class E basic helix-loop-helix protein 78) (bHLHe78) (Member of PAS protein 1) (PAS domain-containing protein 8),Miscellaneous,Transcription factor,Novel Target
774,EZN-4176,EZN-4176,antineoplastic agent,antisense oligo,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
775,"FEBT,Fentora, Effentora",fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
775,"FEBT,Fentora, Effentora",fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
776,"febuxostat, TMX-67,Uloric, Adenuric, Feburic",febuxostat,for treatment of gout,Small molecule,not approved,P47989,XDH_HUMAN,XDH,Xanthine dehydrogenase/oxidase OS=Homo sapiens GN=XDH PE=1 SV=4,Enzymes,EC:1.17.1.4; 1.17.3.2,Established target
777,"felodipine ,Plendil",felodipine,antihypertensive agent,Small Molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
777,"felodipine ,Plendil",felodipine,antihypertensive agent,Small Molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
777,"felodipine ,Plendil",felodipine,antihypertensive agent,Small Molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
777,"felodipine ,Plendil",felodipine,antihypertensive agent,Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
777,"felodipine ,Plendil",felodipine,antihypertensive agent,Small Molecule,approved,Q08289,CACB2_HUMAN,CACNB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
778,"fenoldopam mesylate, SKF-82526,Corlopam",fenoldopam,antihypertensive agent,Small Molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
778,"fenoldopam mesylate, SKF-82526,Corlopam",fenoldopam,antihypertensive agent,Small Molecule,approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
779,"fenretinide, RT-101",fenretinide,antineoplastic agent,Small molecule,approved,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
779,"fenretinide, RT-101",fenretinide,antineoplastic agent,Small molecule,approved,P10826,RARB_HUMAN,RARB,Retinoic acid receptor beta OS=Homo sapiens GN=RARB PE=1 SV=2,Receptors,Nuclear receptor,Established target
779,"fenretinide, RT-101",fenretinide,antineoplastic agent,Small molecule,approved,P13631,RARG_HUMAN,RARG,Retinoic acid receptor gamma OS=Homo sapiens GN=RARG PE=1 SV=1,Receptors,Nuclear receptor,Established target
780,"fentanyl (sublingual), KW-2246,Abstral, Rapinyl",fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor (D-OR-1) (DOR-1),Receptors,GPCR;Rhodopsin,Established target
780,"fentanyl (sublingual), KW-2246,Abstral, Rapinyl",fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
781,"fentanyl citrate,PecFent, Nasalfent",fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
781,"fentanyl citrate,PecFent, Nasalfent",fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
782,"Fentanyl Lauriad, BA-041",fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
782,"Fentanyl Lauriad, BA-041",fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
783,Fentanyl MDTS,fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
783,Fentanyl MDTS,fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
784,"fentanyl spray, intranasal,Instanyl",fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor (D-OR-1) (DOR-1),Receptors,GPCR;Rhodopsin,Established target
784,"fentanyl spray, intranasal,Instanyl",fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
785,fentanyl sublingual spray,fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
785,fentanyl sublingual spray,fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
786,fentanyl TAIFUN,fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
786,fentanyl TAIFUN,fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
787,"fentanyl transdermal system,Duragesic, Ionsys",fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
787,"fentanyl transdermal system,Duragesic, Ionsys",fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
788,"fesoterodine fumarate, SPM 907,Toviaz",fesoterodine,for treatment of overactive bladder syndrome,Small molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
789,fexofenadine + ps/,fexofenadine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
789,fexofenadine + ps/,pseudoephedrine,antiallergy agent,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
789,fexofenadine + ps/,pseudoephedrine,antiallergy agent,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
789,fexofenadine + ps/,pseudoephedrine,antiallergy agent,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
789,fexofenadine + ps/,pseudoephedrine,antiallergy agent,Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
789,fexofenadine + ps/,pseudoephedrine,antiallergy agent,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
790,FG-2216,FG-2216 ,for treatment of anemia,Small molecule,not approved,Q9GZT9,EGLN1_HUMAN,EGLN1,Egl nine homolog 1 (EC 1.14.11.-) (Hypoxia-inducible factor prolyl hydroxylase 2) (HIF-PH2) (HIF-prolyl hydroxylase 2) (HPH-2) (Prolyl hydroxylase domain-containing protein 2) (PHD2) (SM-20),Enzymes,EC:1.14.11.29,Novel Target
790,FG-2216,FG-2216 ,for treatment of anemia,Small molecule,not approved,Q96KS0,EGLN2_HUMAN,EGLN2,Egl nine homolog 2 (EC 1.14.11.-) (Estrogen-induced tag 6) (HPH-3) (Hypoxia-inducible factor prolyl hydroxylase 1) (HIF-PH1) (HIF-prolyl hydroxylase 1) (HPH-1) (Prolyl hydroxylase domain-containing protein 1) (PHD1),Enzymes,EC:1.14.11.29,Novel Target
790,FG-2216,FG-2216 ,for treatment of anemia,Small molecule,not approved,Q9H6Z9,EGLN3_HUMAN,EGLN3,Egl nine homolog 3 (EC 1.14.11.-) (HPH-1) (Hypoxia-inducible factor prolyl hydroxylase 3) (HIF-PH3) (HIF-prolyl hydroxylase 3) (HPH-3) (Prolyl hydroxylase domain-containing protein 3) (PHD3),Enzymes,EC:1.14.11.29,Novel Target
791,"FG-3019 , anti-CTGF",FG-3019,antifibrogenic agent,monoclonal antibody,not approved,P29279,CTGF_HUMAN,CTGF,Connective tissue growth factor (CCN family member 2) (Hypertrophic chondrocyte-specific protein 24) (Insulin-like growth factor-binding protein 8) (IBP-8) (IGF-binding protein 8) (IGFBP-8),Miscellaneous,Ligand;growth factor,Novel Target
792,"FG-4592 , ASP1517",FG-4592,for treatment of anemia,Small molecule,not approved,Q9GZT9,EGLN1_HUMAN,EGLN1,Egl nine homolog 1 (EC 1.14.11.-) (Hypoxia-inducible factor prolyl hydroxylase 2) (HIF-PH2) (HIF-prolyl hydroxylase 2) (HPH-2) (Prolyl hydroxylase domain-containing protein 2) (PHD2) (SM-20),Enzymes,EC:1.14.11.29,Novel Target
792,"FG-4592 , ASP1517",FG-4592,for treatment of anemia,Small molecule,not approved,Q96KS0,EGLN2_HUMAN,EGLN2,Egl nine homolog 2 (EC 1.14.11.-) (Estrogen-induced tag 6) (HPH-3) (Hypoxia-inducible factor prolyl hydroxylase 1) (HIF-PH1) (HIF-prolyl hydroxylase 1) (HPH-1) (Prolyl hydroxylase domain-containing protein 1) (PHD1),Enzymes,EC:1.14.11.29,Novel Target
792,"FG-4592 , ASP1517",FG-4592,for treatment of anemia,Small molecule,not approved,Q9H6Z9,EGLN3_HUMAN,EGLN3,Egl nine homolog 3 (EC 1.14.11.-) (HPH-1) (Hypoxia-inducible factor prolyl hydroxylase 3) (HIF-PH3) (HIF-prolyl hydroxylase 3) (HPH-3) (Prolyl hydroxylase domain-containing protein 3) (PHD3),Enzymes,EC:1.14.11.29,Novel Target
793,"figitumumab, CP-751871",figitumumab,antineoplastic agent,monoclonal antibody,not approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
794,"fingolimod, FTY 720,Gilenia, Gilenya",fingolimod,for treatment of multiple sclerosis,Small molecule,approved,P21453,S1PR1_HUMAN,S1PR1,Sphingosine 1-phosphate receptor 1 (S1P receptor 1) (S1P1) (Endothelial differentiation G-protein coupled receptor 1) (Sphingosine 1-phosphate receptor Edg-1) (S1P receptor Edg-1) (CD antigen CD363),Receptors,GPCR;Rhodopsin,Established target
795,"fipamezole , JP-1730",fipamezole,antiparkinson agent,Small molecule,not approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
796,"fipamezole, JP-1730",fipamezole,antiparkinson agent,Small molecule,not approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
796,"fipamezole, JP-1730",fipamezole,antiparkinson agent,Small molecule,not approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
797,"Firazyr, icatibant, JE049",icatibant,for treatment of hereditary angioedema,Small Molecule,approved,P30411,BKRB2_HUMAN,BDKRB2,B2 bradykinin receptor OS=Homo sapiens GN=BDKRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
798,"fispemifene, HM-101",fispemifene,hormone replacement,Small molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
798,"fispemifene, HM-101",fispemifene,hormone replacement,Small molecule,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
799,FK352B,FK352B,antihypertensive agent,Small molecule,not approved,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,P06493,CDK1_HUMAN,CDC2,Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase),Enzymes,EC:2.7.11.22; 2.7.11.23,Novel Target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,Q15131,CDK10_HUMAN,CDK10,Cyclin-dependent kinase 10 (EC 2.7.11.22) (Cell division protein kinase 10) (Serine/threonine-protein kinase PISSLRE),Enzymes,EC:2.7.11.22,Novel Target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,P24941,CDK2_HUMAN,CDK2,Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase),Enzymes,EC:2.7.11.22,Novel Target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,Q00526,CDK3_HUMAN,CDK3,Cyclin-dependent kinase 3 (EC 2.7.11.22) (Cell division protein kinase 3),Enzymes,EC:2.7.11.22,Novel Target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,P11802,CDK4_HUMAN,CDK4,Cyclin-dependent kinase 4 (EC 2.7.11.22) (Cell division protein kinase 4) (PSK-J3),Enzymes,EC:2.7.11.22,Novel Target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,Q00535,CDK5_HUMAN,CDK5,Cyclin-dependent kinase 5 (EC 2.7.11.22) (Cell division protein kinase 5) (Serine/threonine-protein kinase PSSALRE) (Tau protein kinase II catalytic subunit) (TPKII catalytic subunit),Enzymes,EC:2.7.11.22,Novel Target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,Q00534,CDK6_HUMAN,CDK6,Cyclin-dependent kinase 6 (EC 2.7.11.22) (Cell division protein kinase 6) (Serine/threonine-protein kinase PLSTIRE),Enzymes,EC:2.7.11.22,Novel Target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,P50613,CDK7_HUMAN,CDK7,Cyclin-dependent kinase 7 (EC 2.7.11.22) (EC 2.7.11.23) (39 kDa protein kinase) (CAK1) (CDK-activating kinase) (CAK) (Cell division protein kinase 7) (STK1) (TFIIH basal transcription factor complex kinase subunit) (p39 Mo15),Enzymes,EC:2.7.11.22; 2.7.11.23,Novel Target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,P49336,CDK8_HUMAN,CDK8,Cyclin-dependent kinase 8 (EC 2.7.11.22) (EC 2.7.11.23) (Cell division protein kinase 8) (Mediator complex subunit CDK8) (Mediator of RNA polymerase II transcription subunit CDK8) (Protein kinase K35),Enzymes,EC:2.7.11.22; 2.7.11.23,Novel Target
800,"flavopiridol, alvocidib, HMR-1275",alvocidib,antineoplastic agent,Small molecule,not approved,P50750,CDK9_HUMAN,CDK9,Cyclin-dependent kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (C-2K) (Cell division cycle 2-like protein kinase 4) (Cell division protein kinase 9) (Serine/threonine-protein kinase PITALRE),Enzymes,EC:2.7.11.22; 2.7.11.23,Novel Target
801,Flibanserin,flibanserin,for treatment of female sexual dysfunction,Small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
801,Flibanserin,flibanserin,for treatment of female sexual dysfunction,Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
802,"flovagatran, TGN 255",flovagatran,anticoagulant,Small molecule,not approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
803,"fludarabine phosphate,Fludara",fludarabine,antineoplastic agent,Small Molecule,approved,P27707,DCK_HUMAN,DCK,Deoxycytidine kinase (dCK) (EC 2.7.1.74),Enzymes,EC:2.7.1.74,Established target
803,"fludarabine phosphate,Fludara",fludarabine,antineoplastic agent,Small Molecule,approved,P09884,DPOLA_HUMAN,POLA1,DNA polymerase alpha catalytic subunit OS=Homo sapiens GN=POLA1 PE=1 SV=2,Enzymes,EC:2.7.7.7,Established target
803,"fludarabine phosphate,Fludara",fludarabine,antineoplastic agent,Small Molecule,approved,P23921,RIR1_HUMAN,RRM1,Ribonucleoside-diphosphate reductase large subunit OS=Homo sapiens GN=RRM1 PE=1 SV=1,Enzymes,EC:1.17.4.1,Established target
804,"flunisolide HFA,Aerospan",flunisolide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
805,"flunisolide,Aerobid",flunisolide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
806,"fluocinonide,Vanos",fluocinonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
807,"fluoxetine HCl,Prozac",fluoxetine ,antidepressant,Small molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
808,"flupirtine,Effirma",flupirtine,analgesic,Small molecule,not approved,P48549,IRK3_HUMAN,KCNJ3,G protein-activated inward rectifier potassium channel 1,Transporters,TC:1.A.2.1,Novel Target
808,"flupirtine,Effirma",flupirtine,analgesic,Small molecule,not approved,P48544,IRK5_HUMAN,KCNJ5,G protein-activated inward rectifier potassium channel 4,Transporters,TC:1.A.2.1.3,Novel Target
808,"flupirtine,Effirma",flupirtine,analgesic,Small molecule,not approved,P48051,IRK6_HUMAN,KCNJ6,G protein-activated inward rectifier potassium channel 2,Transporters,TC:1.A.2.1.10,Novel Target
808,"flupirtine,Effirma",flupirtine,analgesic,Small molecule,not approved,Q92806,IRK9_HUMAN,KCNJ9,G protein-activated inward rectifier potassium channel 3,Transporter,TC:1.A.2.1,Novel Target
809,Fluticasone,fluticasone,"antiinflammatory agent,glucocorticoid",Small molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
810,"fluvastatin sodium,Lescol and Lescol XL",fluvastatin,antihypecholesterolemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
811,"fluvoxamine , fluvoxamine-CR,Luvox",fluvoxamine,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
812,Focalin,dexmethylphenidate,for treatment of ADHD,Small molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
812,Focalin,dexmethylphenidate,for treatment of ADHD,Small molecule,approved,P23975,SC6A2_HUMAN,SLCA2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
813,Fodosine,forodesine,antineoplastic agent,Small molecule,not approved,P00491,PNPH_HUMAN,PNP,Purine nucleoside phosphorylase (PNP) (EC 2.4.2.1) (Inosine phosphorylase),Enzymes,EC:2.4.2.1,Novel Target
814,"follitropin alpha ,Gonal-F",follitropin alpha,fertility agent,protein,approved,P23945,FSHR_HUMAN,FSHR,Follicle-stimulating hormone receptor OS=Homo sapiens GN=FSHR PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
815,"formoterol ,Foradil",formoterol,bronchodilator,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
816,"formoterol fumarate,Perforomist",formoterol,for treatment of chronic obstructive pulmonary disorder (COPD),Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
817,Fortical,salmon calcitonin,antiosteoporotic agent,peptide,approved,P30988,CALCR_HUMAN,CALCR,Calcitonin receptor OS=Homo sapiens GN=CALCR PE=1 SV=1,Receptors,GPCR;Secretin,Established target
818,"fosphenytoin sodium injection,Cerebyx",fosphenytoin,anticonvulsant,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
819,"fospropofol disodium, GPI-15715,Lusedra, Aquavan",fospropofol,hypnotic and sedative,Small molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
819,"fospropofol disodium, GPI-15715,Lusedra, Aquavan",fospropofol,hypnotic and sedative,Small molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
820,Fostamatinib,fostamatinib,"antiinflammatory agent,DMARD",Small molecule,not approved,P43405,KSYK_HUMAN,SYK,Tyrosine-protein kinase SYK (EC 2.7.10.2) (Spleen tyrosine kinase),Enzymes,EC:2.7.10.2,Novel Target
821,"FOV-1101,Prednisporin",cyclosporine,immunosuppressant,Small molecule,approved,P49069,CAMLG_HUMAN,CAMLG,Calcium signal-modulating cyclophilin ligand (CAML),Miscellaneous,Miscellaneous:target for cyclosporine,Established target
821,"FOV-1101,Prednisporin",cyclosporine,immunosuppressant,Small molecule,approved,Q96LZ3,CANB2_HUMAN,PPP3R2,Calcineurin subunit B type 2 OS=Homo sapiens GN=PPP3R2 PE=2 SV=3,Miscellaneous,Enzyme regulator,Established target
821,"FOV-1101,Prednisporin",prednisolone,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
822,FP-1039,FP-1039,antineoplastic agent,fusion protein,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
822,FP-1039,FP-1039,antineoplastic agent,fusion protein,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
822,FP-1039,FP-1039,antineoplastic agent,fusion protein,not approved,P22607,FGFR3_HUMAN,FGFR3,Fibroblast growth factor receptor 3 OS=Homo sapiens GN=FGFR3 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
822,FP-1039,FP-1039,antineoplastic agent,fusion protein,not approved,P22455,FGFR4_HUMAN,FGFR4,Fibroblast growth factor receptor 4 OS=Homo sapiens GN=FGFR4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
823,"frovatriptan,Frovelan, Frova",frovatriptan,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
823,"frovatriptan,Frovelan, Frova",frovatriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
824,fruquintinib,fruquintinib,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
824,fruquintinib,fruquintinib,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
824,fruquintinib,fruquintinib,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
825,FSH-GEX,FSH-GEX,fertility agent,protein,not approved,P23945,FSHR_HUMAN,FSHR,Follicle-stimulating hormone receptor OS=Homo sapiens GN=FSHR PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
826,FST-100,dexamethasone,"antiinflammatory agent,glucocorticoid,for treatment of Meniere's disease",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
827,FT-105,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
828,"fulvestrant,Faslodex",fulvestrant,antineoplastic agent,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
829,Fusilev ,leucovorin,adjuvant to chemotherapy,Small Molecule,approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
830,FX06,FX06,"antiinflammatory agent,for acute treatment of myocardial ischemia",peptide,not approved,P33151,CADH5_HUMAN,CDH5,Cadherin-5 (7B4 antigen) (Vascular endothelial cadherin) (VE-cadherin) (CD antigen CD144),Miscellaneous,StructuralAndAdhesion;Cadherin,Novel Target
831,FX125L,FX125L,antiasthmatic agent,Small molecule,not approved,P32246,CCR1_HUMAN,CCR1,C-C chemokine receptor type 1 (C-C CKR-1) (CC-CKR-1) (CCR-1) (CCR1) (HM145) (LD78 receptor) (Macrophage inflammatory protein 1-alpha receptor) (MIP-1alpha-R) (RANTES-R) (CD antigen CD191),Receptors,GPCR;Rhodopsin,Novel Target
831,FX125L,FX125L,antiasthmatic agent,Small molecule,not approved,P25024,CXCR1_HUMAN,CXCR1,C-X-C chemokine receptor type 1 (CXC-R1) (CXCR-1) (CDw128a) (High affinity interleukin-8 receptor A) (IL-8R A) (IL-8 receptor type 1) (CD antigen CD181),Receptors,GPCR;Rhodopsin,Novel Target
831,FX125L,FX125L,antiasthmatic agent,Small molecule,not approved,P25025,CXCR2_HUMAN,CXCR2,C-X-C chemokine receptor type 2 (CXC-R2) (CXCR-2) (CDw128b) (GRO/MGSA receptor) (High affinity interleukin-8 receptor B) (IL-8R B) (IL-8 receptor type 2) (CD antigen CD182),Receptors,GPCR;Rhodopsin,Novel Target
831,FX125L,FX125L,antiasthmatic agent,Small molecule,not approved,P61073,CXCR4_HUMAN,CXCR4,C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (Fusin) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD antigen CD184),Receptors,GPCR;Rhodopsin,Established target
832,"G17DT ,Insegia, Gastrimmune",G17DT,antineoplastic agent,vaccine,not approved,P01350,GAST_HUMAN,GAST,Gastrin [Cleaved into: Gastrin-71 (Gastrin component I); Gastrin-52 (G52); Big gastrin (Gastrin component II) (Gastrin-34) (G34); Gastrin (Gastrin component III) (Gastrin-17) (G17); Gastrin-14 (G14); Gastrin-6 (G6)],Ligand,Ligand;Gastrin,Novel Target
833,"G4460, LR3001",G4460,antineoplastic agent,antisense oligo,not approved,P10242,MYB_HUMAN,MYB,Transcriptional activator Myb (Proto-oncogene c-Myb),Miscellaneous,Transcription factor,Novel Target
834,"gabapentin ,N/",gabapentin,analgesic,Small Molecule,approved,Q00975,CAC1B_HUMAN,CACNA1B,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:1.A.1.11,Established target
835,"gabapentin,N/",gabapentin,analgesic,Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
835,"gabapentin,N/",gabapentin,analgesic,Small Molecule,approved,Q9NY47,CA2D2_HUMAN,CACNA2D2,Voltage-dependent calcium channel subunit alpha-2/delta-2 OS=Homo sapiens GN=CACNA2D2 PE=1 SV=1,Transporters,TC:8.A.18.2.1,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P18507,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P48169,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P14867,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
836,gaboxadol,gaboxadol,hypnotic,Small molecule,not approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
837,"galantamine hydrobromide,Razadyne, Reminyl",galantamine,for treatment of alzheimer's disease,Small Molecule,approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
838,galiximab,galiximab,antineoplastic agent,monoclonal antibody,not approved,P33681,CD80_HUMAN,CD80,T-lymphocyte activation antigen CD80 OS=Homo sapiens GN=CD80 PE=1 SV=1,Receptors,Receptor; T-cell surface receptor,Established target
839,"galsulfase ,Naglazyme",galsulfase,for treatment of mucopolysaccharidosis VI,protein,approved,O60664,M6PBP_HUMAN,M6PRBP1,Mannose-6-phosphate receptor-binding protein 1 OS=Homo sapiens GN=M6PRBP1 PE=1 SV=2,Miscellaneous,Vesicle transport,Established target
840,Ganaxolone,ganaxolone,anticonvulsant,Small molecule,not approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
840,Ganaxolone,ganaxolone,anticonvulsant,Small molecule,not approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
840,Ganaxolone,ganaxolone,anticonvulsant,Small molecule,not approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
840,Ganaxolone,ganaxolone,anticonvulsant,Small molecule,not approved,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
840,Ganaxolone,ganaxolone,anticonvulsant,Small molecule,not approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
840,Ganaxolone,ganaxolone,anticonvulsant,Small molecule,not approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
841,gantacurium chloride,gantacurium,"muscle relaxant,neuromuscular blocking agent",Small molecule,not approved,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
842,GDC-0068,GDC-0068,antineoplastic agent,Small molecule,not approved,P31749,AKT1_HUMAN,AKT1,RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Proto-oncogene c-Akt) (RAC-PK-alpha),Enzymes,EC:2.7.11.1,Novel Target
842,GDC-0068,GDC-0068,antineoplastic agent,Small molecule,not approved,P31751,AKT2_HUMAN,AKT2,RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta),Enzymes,EC:2.7.11.1,Novel Target
842,GDC-0068,GDC-0068,antineoplastic agent,Small molecule,not approved,Q9Y243,AKT3_HUMAN,AKT3,RAC-gamma serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-3) (Protein kinase B gamma) (PKB gamma) (RAC-PK-gamma) (STK-2),Enzymes,EC:2.7.11.1,Novel Target
843,"GDC-0973, XL518",GDC-0973,antineoplastic agent,Small molecule,not approved,Q02750,MP2K1_HUMAN,MAP2K1,Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1),Enzymes,EC:2.7.12.2,Novel Target
844,GED-aPC,GED-aPC,for treatment of cardiovascular disease,recombinant protein,not approved,Q9UNN8,EPCR_HUMAN,PROCR,Endothelial protein C receptor (Activated protein C receptor) (APC receptor) (Endothelial cell protein C receptor) (CD antigen CD201),Receptors,Miscellaneous;protein C receptor,Novel Target
845,"gemcitabine HCl,Gemzar",gemcitabine,antineoplastic agent,Small Molecule,approved,P23921,RIR1_HUMAN,RRM1,Ribonucleoside-diphosphate reductase large subunit OS=Homo sapiens GN=RRM1 PE=1 SV=1,Enzymes,EC:1.17.4.1,Established target
846,"gemtuzumab ozogamicin,Mylotarg",gemtuzumab ozogamicin,antineoplastic agent,monoclonal antibody,not approved,P20138,CD33_HUMAN,CD33,Myeloid cell surface antigen CD33 OS=Homo sapiens GN=CD33 PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
847,Genasense,oblimersen,antineoplastic agent,antisense oligo,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
848,Gepirone,gepirone,antidepressant,Small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
849,Gestiva,progesterone,for prevention of preterm delivery,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
850,GFT14,GFT14,antidyslipidaemic agent,unknown,not approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
851,GGF-2,GGF-2,for treatment of heart failure,recombinant protein,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
851,GGF-2,GGF-2,for treatment of heart failure,recombinant protein,not approved,P21860,ERBB3_HUMAN,ERBB3,Receptor tyrosine-protein kinase erbB-3 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-3) (Tyrosine kinase-type cell surface receptor HER3),Receptors,EC:2.7.10.1,Novel Target
851,GGF-2,GGF-2,for treatment of heart failure,recombinant protein,not approved,Q15303,ERBB4_HUMAN,ERBB4,Receptor tyrosine-protein kinase erbB-4 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-4) (Tyrosine kinase-type cell surface receptor HER4) (p180erbB4) [Cleaved into: ERBB4 intracellular domain (4ICD) (E4ICD) (s80HER4)],Receptors,EC:2.7.10.1,Novel Target
852,GGTI-2418,GGTI-2418,antineoplastic agent,Small molecule,not approved,P49354,FNTA_HUMAN,FNTA,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha (EC 2.5.1.58) (EC 2.5.1.59) (CAAX farnesyltransferase subunit alpha) (FTase-alpha) (Ras proteins prenyltransferase subunit alpha) (Type I protein geranyl-geranyltransferase subunit,Enzymes,EC:2.5.1.58; 2.5.1.59,Novel Target
852,GGTI-2418,GGTI-2418,antineoplastic agent,Small molecule,not approved,P53609,PGTB1_HUMAN,PGGT1B,Geranylgeranyl transferase type-1 subunit beta (EC 2.5.1.59) (Geranylgeranyl transferase type I subunit beta) (GGTase-I-beta) (Type I protein geranyl-geranyltransferase subunit beta),Enzymes,EC:2.5.1.59,Novel Target
853,GI-4000,GI-4000,"antineoplastic agent,vaccine",vaccine,not approved,P01116,RASK_HUMAN,KRAS,GTPase KRas,Miscellaneous,Miscellaneous;Hras,Novel Target
854,GL1001,GL1001,"for treatment of Chron's disease,for treatment of ulcerative colitis",Small molecule,not approved,Q9BYF1,ACE2_HUMAN,ACE2,Angiotensin-converting enzyme 2 (EC 3.4.17.23) (ACE-related carboxypeptidase) (Angiotensin-converting enzyme homolog) (ACEH) (Metalloprotease MPROT15) [Cleaved into: Processed angiotensin-converting enzyme 2],Enzymes,EC:3.4.17.23,Established target
855,"glimepiride ,Amaryl",glimepiride,antidiabetic,Small Molecule,approved,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
856,"glimepiride,Amaryl",glimepiride,antidiabetic,Small Molecule,approved,Q09428,ABCC8_HUMAN,ABCC8,ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1),Transporters,TC:3.A.1.208.4,Established target
856,"glimepiride,Amaryl",glimepiride,antidiabetic,Small Molecule,approved,Q14654,IRK11_HUMAN,KCNJ11,ATP-sensitive inward rectifier potassium channel 11 OS=Homo sapiens GN=KCNJ11 PE=1 SV=2,Transporters,TC:1.A.2.1,Established target
857,GLPG0187,GLPG0187,antineoplastic agent,Small molecule,not approved,P08648,ITA5_HUMAN,ITGA5,Integrin alpha-5 (CD49 antigen-like family member E) (Fibronectin receptor subunit alpha) (Integrin alpha-F) (VLA-5) (CD antigen CD49e) [Cleaved into: Integrin alpha-5 heavy chain; Integrin alpha-5 light chain],Receptors,Receptors;Integrin,Novel Target
857,GLPG0187,GLPG0187,antineoplastic agent,Small molecule,not approved,P06756,ITAV_HUMAN,ITGAV,Integrin alpha-V (Vitronectin receptor subunit alpha) (CD antigen CD51) [Cleaved into: Integrin alpha-V heavy chain; Integrin alpha-V light chain],Receptors,Receptors;Integrin,Established target
857,GLPG0187,GLPG0187,antineoplastic agent,Small molecule,not approved,P05556,ITB1_HUMAN,ITGB1,Integrin beta-1 (Fibronectin receptor subunit beta) (VLA-4 subunit beta) (CD antigen CD29),Receptors,Receptors;Integrin,Established target
857,GLPG0187,GLPG0187,antineoplastic agent,Small molecule,not approved,P05106,ITB3_HUMAN,ITGB3,Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
857,GLPG0187,GLPG0187,antineoplastic agent,Small molecule,not approved,P18084,ITB5_HUMAN,ITGB5,Integrin beta-5,Miscellaneous,Receptor; integrin,Novel Target
857,GLPG0187,GLPG0187,antineoplastic agent,Small molecule,not approved,P18564,ITB6_HUMAN,ITGB6,Integrin beta-6,Miscellaneous,Receptor; integrin,Novel Target
858,GLPG0259,GLPG0259,"antiinflammatory agent,DMARD",Small molecule,not approved,Q8IW41,MAPK5_HUMAN,MAPKAPK5,MAP kinase-activated protein kinase 5 (MAPK-activated protein kinase 5) (MAPKAP kinase 5) (MAPKAPK-5) (EC 2.7.11.1) (p38-regulated/activated protein kinase),Enzymes,EC:2.7.11.1,Novel Target
859,GLPG0492,GLPG0492,for treatment of cachexia,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
860,GLPG0634,GLPG0634,"antiinflammatory agent,DMARD",Small molecule,not approved,P23458,JAK1_HUMAN,JAK1,Tyrosine-protein kinase JAK1 (EC 2.7.10.2) (Janus kinase 1) (JAK-1),Enzymes,EC:2.7.10.2,Novel Target
860,GLPG0634,GLPG0634,"antiinflammatory agent,DMARD",Small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
861,Glufosfamide,Glufosfamide,antineoplastic agent,Small molecule,not approved,P11166,GTR1_HUMAN,SLC2A1,"Solute carrier family 2, facilitated glucose transporter member 1 (Glucose transporter type 1, erythrocyte/brain) (GLUT-1) (HepG2 glucose transporter)",Transporters,TC:2.A.1.1.28,Novel Target
861,Glufosfamide,Glufosfamide,antineoplastic agent,Small molecule,not approved,P11168,GTR2_HUMAN,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2 (Glucose transporter type 2, liver) (GLUT-2)",Transporters,TC:2.A.1.1.29,Novel Target
861,Glufosfamide,Glufosfamide,antineoplastic agent,Small molecule,not approved,P11169,GTR3_HUMAN,SLC2A3,"Solute carrier family 2, facilitated glucose transporter member 3 (Glucose transporter type 3, brain) (GLUT-3)",Transporters,TC:2.A.1.1.91,Novel Target
861,Glufosfamide,Glufosfamide,antineoplastic agent,Small molecule,not approved,P14672,GTR4_HUMAN,SLC2A4,"Solute carrier family 2, facilitated glucose transporter member 4 (Glucose transporter type 4, insulin-responsive) (GLUT-4)",Transporters,TC:2.A.1.1.80,Novel Target
861,Glufosfamide,Glufosfamide,antineoplastic agent,Small molecule,not approved,P22732,GTR5_HUMAN,SLC2A5,"Solute carrier family 2, facilitated glucose transporter member 5 (Fructose transporter) (Glucose transporter type 5, small intestine) (GLUT-5)",Transporters,TC:2.A.1.1.13,Novel Target
861,Glufosfamide,Glufosfamide,antineoplastic agent,Small molecule,not approved,P13866,SC5A1_HUMAN,SLC5A1,Sodium/glucose cotransporter 1,Transporters,TC:2.A.21.3.1,Novel Target
861,Glufosfamide,Glufosfamide,antineoplastic agent,Small molecule,not approved,P31639,SC5A2_HUMAN,SLC5A2,Sodium/glucose cotransporter 2 (Na(+)/glucose cotransporter 2) (Low affinity sodium-glucose cotransporter) (Solute carrier family 5 member 2),Transporters,TC:2.A.21.3.16,Established target
861,Glufosfamide,Glufosfamide,antineoplastic agent,Small molecule,not approved,Q9NY91,SC5A4_HUMAN,SLC5A4,Low affinity sodium-glucose cotransporter,Transporters,TC:2.A.21.3.18,Novel Target
862,"glyburide + metformin,Glucovance",glyburide,antidiabetic,Small molecule,approved,Q09428,ABCC8_HUMAN,ABCC8,ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1),Transporters,TC:3.A.1.208.4,Established target
862,"glyburide + metformin,Glucovance",metformin,antidiabetic,Small Molecule,approved,Q9Y478,AAKB1_HUMAN,PRKAB1,5'-AMP-activated protein kinase subunit beta-1 OS=Homo sapiens GN=PRKAB1 PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
863,GlycoPEG-GCSF,GlycoPEG-GCSF,for treatment of neutropenia,protein,not approved,Q99062,CSF3R_HUMAN,CSF3R,Granulocyte colony-stimulating factor receptor OS=Homo sapiens GN=CSF3R PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
864,"glycopyrrolate, FHPC-02,Cuvposa",glycopyrrolate,antineoplastic agent,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
865,GLYX-13,GLYX-13 ,antidepressant,peptide,not approved,Q05586,NMDZ1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo sapiens GN=GRIN1 PE=1 SV=1,Receptors,TC:1.A.10.1.6,Established target
866,GMI-1070,GMI-1070,for treatment of sickle-cell disease,Small molecule,not approved,P16581,LYAM2_HUMAN,SELE,E-selectin (CD62 antigen-like family member E) (Endothelial leukocyte adhesion molecule 1) (ELAM-1) (Leukocyte-endothelial cell adhesion molecule 2) (LECAM2) (CD antigen CD62E),Receptors,Receptors;Selectin,Novel Target
866,GMI-1070,GMI-1070,for treatment of sickle-cell disease,Small molecule,not approved,P14151,LYAM1_HUMAN,SELL,L-selectin (CD62 antigen-like family member L) (Leukocyte adhesion molecule 1) (LAM-1) (Leukocyte surface antigen Leu-8) (Leukocyte-endothelial cell adhesion molecule 1) (LECAM1) (Lymph node homing receptor) (TQ1) (gp90-MEL) (CD antigen CD62L),Receptors,Receptors;Selectin,Novel Target
866,GMI-1070,GMI-1070,for treatment of sickle-cell disease,Small molecule,not approved,P16109,LYAM3_HUMAN,SELP,P-selectin (CD62 antigen-like family member P) (Granule membrane protein 140) (GMP-140) (Leukocyte-endothelial cell adhesion molecule 3) (LECAM3) (Platelet activation dependent granule-external membrane protein) (PADGEM) (CD antigen CD62P),Receptors,Receptors;Selectin,Novel Target
867,GMX1777,GMX1777,antineoplastic agent,Small molecule,not approved,P43490,NAMPT_HUMAN,NAMPT,Nicotinamide phosphoribosyltransferase,Enzymes,EC:2.4.2.12,Novel Target
868,"GnRH pharmaccine,Gonadimmune",GnRH pharmaccine,antineoplastic agent,vaccine,not approved,P01148,GON1_HUMAN,GNRH1,Progonadoliberin-1 (Progonadoliberin I) [Cleaved into: Gonadoliberin-1 (Gonadoliberin I) (Gonadorelin) (Gonadotropin-releasing hormone I) (GnRH-I) (Luliberin I) (Luteinizing hormone-releasing hormone I) (LH-RH I); GnRH-associated peptide 1 (GnRH-associate,Ligand,Ligand;GnRH,Novel Target
869,"GnRH receptor antagonist, NBI-42902",NBI-42902,"for treatment of postmenopausal symptoms,antineoplastic agent",Small molecule,not approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
869,"GnRH receptor antagonist, NBI-42902",NBI-42902,"for treatment of postmenopausal symptoms,antineoplastic agent",Small molecule,not approved,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
870,GO-203-2c,GO-203-2c,antineoplastic agent,peptide,not approved,P15941,MUC1_HUMAN,MUC1,Mucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Carcinoma-associated mucin) (Episialin) (H23AG) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM) (Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associ,Miscellaneous,StructuralAndAdhesion;Mucin_1,Novel Target
871,GPI-1485,GPI-1485,antiparkinson agent ,Small molecule,not approved,P62942,FKB1A_HUMAN,FKBP1A,FKBP-type PPIase family. FKBP1 subfamily.,Enzymes,EC:5.2.1.8,Established target
872,GPX-100,GPX-100,antineoplastic agent,Small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
873,"granisetron (intranasal), TRG",granisetron,antiemetic,Small Molecule,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
873,"granisetron (intranasal), TRG",granisetron,antiemetic,Small Molecule,not approved,O95264,5HT3B_HUMAN,HTR3B,5-hydroxytryptamine receptor 3B (5-HT3-B) (5-HT3B) (Serotonin receptor 3B),Receptors,TC:1.A.9,Established target
873,"granisetron (intranasal), TRG",granisetron,antiemetic,Small Molecule,not approved,Q8WXA8,5HT3C_HUMAN,HTR3C,5-hydroxytryptamine receptor 3C (5-HT3-C) (5-HT3C) (Serotonin receptor 3C),Receptors,TC:1.A.9,Established target
873,"granisetron (intranasal), TRG",granisetron,antiemetic,Small Molecule,not approved,Q70Z44,5HT3D_HUMAN,HTR3D,5-hydroxytryptamine receptor 3D (5-HT3-D) (5-HT3D) (Serotonin receptor 3D),Receptors,TC:1.A.9,Established target
873,"granisetron (intranasal), TRG",granisetron,antiemetic,Small Molecule,not approved,A5X5Y0,5HT3E_HUMAN,HTR3E,5-hydroxytryptamine receptor 3E (5-HT3-E) (5-HT3E) (Serotonin receptor 3E),Receptors,TC:1.A.9,Established target
874,granisetron nasal spray,granisetron,antiemetic,Small Molecule,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
874,granisetron nasal spray,granisetron,antiemetic,Small Molecule,not approved,O95264,5HT3B_HUMAN,HTR3B,5-hydroxytryptamine receptor 3B (5-HT3-B) (5-HT3B) (Serotonin receptor 3B),Receptors,TC:1.A.9,Established target
874,granisetron nasal spray,granisetron,antiemetic,Small Molecule,not approved,Q8WXA8,5HT3C_HUMAN,HTR3C,5-hydroxytryptamine receptor 3C (5-HT3-C) (5-HT3C) (Serotonin receptor 3C),Receptors,TC:1.A.9,Established target
874,granisetron nasal spray,granisetron,antiemetic,Small Molecule,not approved,Q70Z44,5HT3D_HUMAN,HTR3D,5-hydroxytryptamine receptor 3D (5-HT3-D) (5-HT3D) (Serotonin receptor 3D),Receptors,TC:1.A.9,Established target
874,granisetron nasal spray,granisetron,antiemetic,Small Molecule,not approved,A5X5Y0,5HT3E_HUMAN,HTR3E,5-hydroxytryptamine receptor 3E (5-HT3-E) (5-HT3E) (Serotonin receptor 3E),Receptors,TC:1.A.9,Established target
875,GS-101,GS-101,for treatment of corneal neovascularisation,antisense oligo,not approved,P35568,IRS1_HUMAN,IRS1,Insulin receptor substrate 1 (IRS-1),Receptors,Insulin receptor substrate,Novel Target
876,"GS-9411, P-680",GS-9411,for treatment of pulmonary disease,Small molecule,not approved,P37088,SCNNA_HUMAN,SCNN1A,Amiloride-sensitive sodium channel subunit alpha OS=Homo sapiens GN=SCNN1A PE=1 SV=1,Transporters,TC:1.A.6.1.1,Established target
876,"GS-9411, P-680",GS-9411,for treatment of pulmonary disease,Small molecule,not approved,P51168,SCNNB_HUMAN,SCNN1B,Amiloride-sensitive sodium channel subunit beta OS=Homo sapiens GN=SCNN1B PE=1 SV=2,Transporters,TC:1.A.6.1.1,Established target
876,"GS-9411, P-680",GS-9411,for treatment of pulmonary disease,Small molecule,not approved,P51172,SCNND_HUMAN,SCNN1D,Amiloride-sensitive sodium channel subunit delta OS=Homo sapiens GN=SCNN1D PE=1 SV=2,Transporters,TC:1.A.6,Established target
876,"GS-9411, P-680",GS-9411,for treatment of pulmonary disease,Small molecule,not approved,P51170,SCNNG_HUMAN,SCNN1G,Amiloride-sensitive sodium channel subunit gamma OS=Homo sapiens GN=SCNN1G PE=1 SV=4,Transporters,TC:1.A.6.1.1,Established target
877,GSI-136,GSI-136,for treatment of Alzheimer's disease,Small molecule,not approved,Q96BI3,APH1A_HUMAN,APH1A,Gamma-secretase subunit APH-1A (APH-1a) (Aph-1alpha) (Presenilin-stabilization factor),Enzymes,Miscellaneous:Gamma secretase subunit;APH-1 family,Novel Target
877,GSI-136,GSI-136,for treatment of Alzheimer's disease,Small molecule,not approved,Q8WW43,APH1B_HUMAN,APH1B,Gamma-secretase subunit APH-1B,Enzymes,Miscellaneous:Gamma secretase subunit;APH-1 family,Novel Target
877,GSI-136,GSI-136,for treatment of Alzheimer's disease,Small molecule,not approved,Q92542,NICA_HUMAN,NCSTN,Nicastrin,Miscellaneous,Miscellaneous;gamma secretase subunit,Novel Target
877,GSI-136,GSI-136,for treatment of Alzheimer's disease,Small molecule,not approved,P49768,PSN1_HUMAN,PSEN1,Presenilin-1,Enzymes,EC:3.4.23.-,Novel Target
877,GSI-136,GSI-136,for treatment of Alzheimer's disease,Small molecule,not approved,P49810,PSN2_HUMAN,PSEN2,Presenilin-2,Enzymes,EC:3.4.23.-,Novel Target
877,GSI-136,GSI-136,for treatment of Alzheimer's disease,Small molecule,not approved,Q9NZ42,PEN2_HUMAN,PSENEN,Gamma-secretase subunit PEN-2 (Presenilin enhancer protein 2),Miscellaneous,Miscellaneous;Gamma secretase subunit,Novel Target
878,GSK-1004723,GSK-1004723,antiallergy agent,Small molecule,not approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
878,GSK-1004723,GSK-1004723,antiallergy agent,Small molecule,not approved,Q9Y5N1,HRH3_HUMAN,HRH3,Histamine H3 receptor (H3R) (HH3R) (G-protein coupled receptor 97),Receptors,GPCR;Rhodopsin,Novel Target
879,GSK1120212,trametinib,antineoplastic agent,Small molecule,not approved,Q02750,MP2K1_HUMAN,MAP2K1,Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1),Enzymes,EC:2.7.12.2,Novel Target
880,GSK2118436,GSK2118436,antineoplastic agent,Small molecule,not approved,P15056,BRAF1_HUMAN,BRAF,B-Raf proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=BRAF PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
881,GSK-961081,GSK-961081,bronchodilator,Small molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
881,GSK-961081,GSK-961081,bronchodilator,Small molecule,not approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
882,GT 389-255,GT 389-255,antiobesity agent,polymer,not approved,P49327,FAS_HUMAN,FASN,Fatty acid synthase,Enzymes,EC:2.3.1.85,Established target
882,GT 389-255,GT 389-255,antiobesity agent,polymer,not approved,P07098,LIPG_HUMAN,LIPF,Gastric triacylglycerol lipase (GL) (Gastric lipase) (EC 3.1.1.3),Enzymes,EC:3.1.1.3,Established target
882,GT 389-255,GT 389-255,antiobesity agent,polymer,not approved,P16233,LIPP_HUMAN,PNLIP,Pancreatic triacylglycerol lipase OS=Homo sapiens GN=PNLIP PE=1 SV=1,Enzymes,EC:3.1.1.3,Established target
883,GTF505,GTF505,"antidiabetic,antidyslipidaemic agent",unknown,not approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
883,GTF505,GTF505,"antidiabetic,antidyslipidaemic agent",unknown,not approved,Q03181,PPARD_HUMAN,PPARD,Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta),Receptors,Nuclear receptor,Established target
883,GTF505,GTF505,"antidiabetic,antidyslipidaemic agent",unknown,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
884,GTI-2501,GTI-2501,antineoplastic agent,antisense oligo,not approved,P23921,RIR1_HUMAN,RRM1,Ribonucleoside-diphosphate reductase large subunit OS=Homo sapiens GN=RRM1 PE=1 SV=1,Enzymes,EC:1.17.4.1,Established target
885,GTP-010,GTP-010,for treatment of irritable bowel syndrome,protein,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
886,GTP-200,GTP-200,appetite stimulant,peptide,not approved,Q92847,GHSR_HUMAN,GHSR,Growth hormone secretagogue receptor type 1 (GHS-R) (GH-releasing peptide receptor) (GHRP) (Ghrelin receptor),Receptors,GPCR;Rhodopsin,Novel Target
887,GTS-21,GTS-21,for treatment of schizophrenia,Small molecule,not approved,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
888,GTx-758,GTx-758,antineoplastic agent,Small molecule,not approved,P22888,LSHR_HUMAN,LHCGR,Lutropin-choriogonadotropic hormone receptor OS=Homo sapiens GN=LHCGR PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
889,"guanfacine, SPD 503,Intuniv",guanfacine,for treatment of ADHD,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
890,GV1001,GV1001,antineoplastic agent,vaccine,not approved,O14746,TERT_HUMAN,TERT,Telomerase reverse transcriptase (EC 2.7.7.49) (HEST2) (Telomerase catalytic subunit) (Telomerase-associated protein 2) (TP2),Enzymes,EC:2.7.7.49,Novel Target
891,GW501516,GW501516,antidyslipidaemic agent,Small molecule,not approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
891,GW501516,GW501516,antidyslipidaemic agent,Small molecule,not approved,Q03181,PPARD_HUMAN,PPARD,Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta),Receptors,Nuclear receptor,Established target
891,GW501516,GW501516,antidyslipidaemic agent,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
892,GW642444,GW642444,bronchodilator,Small molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
893,GVAX,GM-CSF,"antineoplastic agent,vaccine",protein,not approved,P04141,CSF2_HUMAN,CSF2,Granulocyte-macrophage colony-stimulating factor,ligand,Ligand; CSF2,Novel Target
894,"halofuginone ,Tempostatin",halofuginone,antineoplastic agent,Small molecule,not approved,P07814,SYEP_HUMAN,EPRS,Bifunctional glutamate/proline--tRNA ligase,Enzymes,EC:6.1.1,Novel Target
895,"HCT 1026, NO-flurbiprofen",flurbiprofen,"antiinflammatory agent,NSAID",Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
895,"HCT 1026, NO-flurbiprofen",nitric oxide,antiinflammatory agent,Small Molecule,approved,P33402,GCYA2_HUMAN,GUCY1A2,Guanylate cyclase soluble subunit alpha-2 (GCS-alpha-2) (EC 4.6.1.2),Enzymes,EC:4.6.1.2,Established target
896,"HE3235 ,Apotone",HE3235,antineoplastic agent,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
897,"heat-activated liposome technology,ThermoDox",doxorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
898,Hematide,hematide ,erythropoietic agent,peptide,not approved,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
899,heparin,heparin,anticoagulant,Small Molecule,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
899,heparin,heparin,anticoagulant,Small Molecule,approved,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Miscellaneous,Enzyme regulator,Established target
900,"heparin, oral, liquid",heparin,anticoagulant,Small Molecule,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
900,"heparin, oral, liquid",heparin,anticoagulant,Small Molecule,approved,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Miscellaneous,Enzyme regulator,Established target
901,Heplisav,ISS-1018,"for treatment of hepatitis B,vaccine",vaccine,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
902,HER-2 Protein AutoVac,PX 104.1 ,antineoplastic agent,vaccine,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
903,Herceptin,trastuzumab,antineoplastic agent,monoclonal antibody,approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
904,Herzyme,herzyme,antineoplastic agent,ribozyme,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
905,HF0220,HF0220,for treatment of alzheimer's disease,Small molecule,not approved,O60760,unknown,unknown,unknown,unknown,unknown,unknown
906,"HGF (Hepatocyte Growth Factor), AMG 0001,Collategene",AMG 0001,antiischemic agent,recombinant protein,not approved,P08581,MET_HUMAN,MET,Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met),Receptors,EC:2.7.10.1,Established target
907,HGS1029,HGS1029,antineoplastic agent,Small molecule,not approved,Q13490,BIRC2_HUMAN,BIRC2,Baculoviral IAP repeat-containing protein 2 (C-IAP1) (IAP homolog B) (Inhibitor of apoptosis protein 2) (IAP-2) (hIAP-2) (hIAP2) (RING finger protein 48) (TNFR2-TRAF-signaling complex protein 2),Miscellaneous,Inhibitor of apoptosis,Novel Target
907,HGS1029,HGS1029,antineoplastic agent,Small molecule,not approved,Q13489,BIRC3_HUMAN,BIRC3,Baculoviral IAP repeat-containing protein 3 (Apoptosis inhibitor 2) (API2) (C-IAP2) (IAP homolog C) (Inhibitor of apoptosis protein 1) (IAP-1) (hIAP-1) (hIAP1) (RING finger protein 49) (TNFR2-TRAF-signaling complex protein 1),Miscellaneous,Inhibitor of apoptosis,Novel Target
907,HGS1029,HGS1029,antineoplastic agent,Small molecule,not approved,O15392,BIRC5_HUMAN,BIRC5,Baculoviral IAP repeat-containing protein 5 (Apoptosis inhibitor 4) (Apoptosis inhibitor survivin),Miscellaneous,Inhibitor of apoptosis,Novel Target
907,HGS1029,HGS1029,antineoplastic agent,Small molecule,not approved,P98170,XIAP_HUMAN,XIAP,Baculoviral IAP repeat-containing protein 4 (EC 6.3.2.-) (E3 ubiquitin-protein ligase XIAP) (IAP-like protein) (ILP) (hILP) (Inhibitor of apoptosis protein 3) (IAP-3) (hIAP-3) (hIAP3) (X-linked inhibitor of apoptosis protein) (X-linked IAP),Miscellaneous,Inhibitor of apoptosis,Novel Target
908,HGS-ETR1,mapatumumab,antineoplastic agent,monoclonal antibody,not approved,O00220,TR10A_HUMAN,TNFRSF10A,Tumor necrosis factor receptor superfamily member 10A (Death receptor 4) (TNF-related apoptosis-inducing ligand receptor 1) (TRAIL receptor 1) (TRAIL-R1) (CD antigen CD261),Receptors,Receptors;TNFNGF,Novel Target
909,HGS-TR2J,HGS-TR2J,antineoplastic agent,monoclonal antibody,not approved,O14763,TR10B_HUMAN,TNFRSF10B,Tumor necrosis factor receptor superfamily member 10B (Death receptor 5) (TNF-related apoptosis-inducing ligand receptor 2) (TRAIL receptor 2) (TRAIL-R2) (CD antigen CD262),Receptors,Receptors;TNFNGF,Novel Target
910,HIF-1alpha,HIF-1alpha,antineoplastic agent,protein,not approved,Q16665,HIF1A_HUMAN,HIF1A,Hypoxia-inducible factor 1-alpha (HIF-1-alpha) (HIF1-alpha) (ARNT-interacting protein) (Basic-helix-loop-helix-PAS protein MOP1) (Class E basic helix-loop-helix protein 78) (bHLHe78) (Member of PAS protein 1) (PAS domain-containing protein 8),Miscellaneous,Transcription factor,Novel Target
911,HinsBet,insulin,for treatment of diabetic foot ulcers,protein,not approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
911,HinsBet,PDGF-BB,for treatment of diabetic foot ulcers,protein,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
911,HinsBet,PDGF-BB,for treatment of diabetic foot ulcers,protein,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
912,"HL 007, simvastatin + amlodipine",amlodipine,antihypertensive agent,Small molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
912,"HL 007, simvastatin + amlodipine",amlodipine,antihypertensive agent,Small molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
912,"HL 007, simvastatin + amlodipine",amlodipine,antihypertensive agent,Small molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
912,"HL 007, simvastatin + amlodipine",amlodipine,antihypertensive agent,Small molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
912,"HL 007, simvastatin + amlodipine",amlodipine,antihypertensive agent,Small molecule,approved,Q08289,CACB2_HUMAN,CACNAB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
912,"HL 007, simvastatin + amlodipine",simvastatin,antihypertensive agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
913,HMPL-004,HMPL-004,"antiinflammatory agent,for treatment of ulcerative colitis,for treatment of Chron's disease",plant extract,not approved,P19838,NFKB1_HUMAN,NFKB1,Nuclear factor NF-kappa-B p105 subunit OS=Homo sapiens GN=NFKB1 PE=1 SV=2,Transcription factor,Transcription factor,Established target
914,"hrBSSL, tgBSSL",Bile salt stimulated lipase,for treatment of pancreatitis,protein,not approved,P19835,CEL_HUMAN,CEL,Bile salt-activated lipase (BAL) (EC 3.1.1.13) (EC 3.1.1.3) (Bile salt-stimulated lipase) (BSSL) (Bucelipase) (Carboxyl ester lipase) (Cholesterol esterase) (Pancreatic lysophospholipase) (Sterol esterase),Enzymes,EC:3.1.1.13; 3.1.1.3,Novel Target
916,HTI-101,amiloride,antihypertensive agent,Small Molecule,approved,P37088,SCNNA_HUMAN,SCNN1A,Amiloride-sensitive sodium channel subunit alpha OS=Homo sapiens GN=SCNN1A PE=1 SV=1,Transporters,TC:1.A.6.1.1,Established target
916,HTI-101,amiloride,antihypertensive agent,Small Molecule,approved,P51168,SCNNB_HUMAN,SCNN1B,Amiloride-sensitive sodium channel subunit beta OS=Homo sapiens GN=SCNN1B PE=1 SV=2,Transporters,TC:1.A.6.1.1,Established target
916,HTI-101,amiloride,antihypertensive agent,Small Molecule,approved,P51172,SCNND_HUMAN,SCNN1D,Amiloride-sensitive sodium channel subunit delta OS=Homo sapiens GN=SCNN1D PE=1 SV=2,Transporters,TC:1.A.6,Established target
916,HTI-101,amiloride,antihypertensive agent,Small Molecule,approved,P51170,SCNNG_HUMAN,SCNN1G,Amiloride-sensitive sodium channel subunit gamma OS=Homo sapiens GN=SCNN1G PE=1 SV=4,Transporters,TC:1.A.6.1.1,Established target
916,HTI-101,spironolactone,antihypertensive agent,Small Molecule,approved,P08235,MCR_HUMAN,NR3C2,Mineralocorticoid receptor OS=Homo sapiens GN=NR3C2 PE=1 SV=1,Receptors,Nuclear receptor,Established target
917,"Hu Dreg 55,SMART Anti-L-Selectin",SMART Anti-L-Selectin,immunosuppressant,antibody,not approved,P14151,LYAM1_HUMAN,SELL,L-selectin (CD62 antigen-like family member L) (Leukocyte adhesion molecule 1) (LAM-1) (Leukocyte surface antigen Leu-8) (Leukocyte-endothelial cell adhesion molecule 1) (LECAM1) (Lymph node homing receptor) (TQ1) (gp90-MEL) (CD antigen CD62L),Receptors,Receptors;Selectin,Novel Target
918,HuCAL anti-beta amyloid monoclonal antibody,gantenerumab,for treatment of Alzheimer's disease,monoclonal antibody,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
919,humanized SMART Anti-IL-12 Antibody,humanized SMART Anti-IL-12 Antibody,antiinflammatory agent,antibody,not approved,P29459,IL12A_HUMAN,IL12A,Interleukin-12 subunit alpha (IL-12A) (IL-12 subunit p35) (Cytotoxic lymphocyte maturation factor 35 kDa subunit) (CLMF p35) (NK cell stimulatory factor chain 1) (NKSF1),Miscellaneous,Ligand;Cytokine,Established target
919,humanized SMART Anti-IL-12 Antibody,humanized SMART Anti-IL-12 Antibody,antiinflammatory agent,antibody,not approved,P29460,IL12B_HUMAN,IL12B,Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2),Receptors,Receptor; Type 1 cytokine receptor,Established target
920,HuMax-CD20,HuMax-CD20,antineoplastic agent,monoclonal antibody,not approved,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Miscellaneous,MS4A family,Established target
921,HuMax-CD38,HuMax-CD38,antineoplastic agent,monoclonal antibody,not approved,P28907,CD38_HUMAN,CD38,ADP-ribosyl cyclase 1 (EC 3.2.2.5) (Cyclic ADP-ribose hydrolase 1) (cADPr hydrolase 1) (T10) (CD antigen CD38),Enzymes,EC:3.2.2,Novel Target
922,HuMax-EGFr,HuMax-EGFr,antineoplastic agent,monoclonal antibody,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
923,Humira,adalimumab,"antiinflammatory agent,DMARD",monoclonal antibody,approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
924,Huperzine-A,huperzine-A,for treatment of Alzheimer's disease,Small molecule,not approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
925,HuZAF,fontolizumab,"antiinflammatory agent, for treatment of chron's disease, antipsoriatic",monoclonal antibody,not approved,P01579,IFNG_HUMAN,IFNG,Interferon gamma,Ligand,Ligand; interferon,Novel Target
926,HYC750,hyaluronan,antileukopenic agent,glycosaminoglycan,approved,P16070,CD44_HUMAN,CD44,CD44 antigen (CDw44) (Epican) (Extracellular matrix receptor III) (ECMR-III) (GP90 lymphocyte homing/adhesion receptor) (HUTCH-I) (Heparan sulfate proteoglycan) (Hermes antigen) (Hyaluronate receptor) (Phagocytic glycoprotein 1) (PGP-1) (Phagocytic glycop,Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
926,HYC750,hyaluronan,antileukopenic agent,glycosaminoglycan,approved,O75330,HMMR_HUMAN,HMMR,Hyaluronan mediated motility receptor,Receptors,Receptor; hyaluronan,Established target
926,HYC750,hyaluronan,antileukopenic agent,glycosaminoglycan,approved,P05362,ICAM1_HUMAN,ICAM1,Intercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
927,"hydralazine HCl/isosorbide,BiDil",hydralazine,antihypertensive agent,Small Molecule,approved,Q16853,AOC3_HUMAN,AOC3,Membrane primary amine oxidase (EC 1.4.3.21) (Copper amine oxidase) (HPAO) (Semicarbazide-sensitive amine oxidase) (SSAO) (Vascular adhesion protein 1) (VAP-1),Enzymes,EC:1.4.3.21,Established target
927,"hydralazine HCl/isosorbide,BiDil",isosorbide dinitrate,antihypertensive agent,Small Molecule,approved,P16066,ANPRA_HUMAN,NPR1,Atrial natriuretic peptide receptor A OS=Homo sapiens GN=NPR1 PE=2 SV=1,Receptors,EC:4.6.1.2,Established target
928,"hydroxytamoxifen ,Tamogel",hydroxytamoxifen,for treatment of cyclic mastalgia,Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
928,"hydroxytamoxifen ,Tamogel",hydroxytamoxifen,for treatment of cyclic mastalgia,Small molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
929,"HZT-501,  ibuprofen + famotidine,Duexa",famotidine,acid reducer,Small Molecule,approved,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
929,"HZT-501,  ibuprofen + famotidine,Duexa",famotidine,for treatment of gastric ulcer and gastroesophageal reflux,Small Molecule,approved,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
929,"HZT-501,  ibuprofen + famotidine,Duexa",ibuprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
929,"HZT-501,  ibuprofen + famotidine,Duexa",ibuprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
930,"IB1001, recombinant Factor IX",Factor IX,"coagulant,for treatment of hemophilia B",recombinant protein,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
931,"ibandronate, R484,Boniva, Bonviva, Bondronat",ibandronate,antiosteoporotic agent,Small Molecule,approved,P14324,FPPS_HUMAN,FDPS,Farnesyl pyrophosphate synthetase OS=Homo sapiens GN=FDPS PE=1 SV=4,Enzymes,EC:2.5.1.10,Established target
932,IBI-10090,dexamethasone,"antiinflammatory agent,glucocorticoid,for treatment of Meniere's disease",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
933,"ibudilast, MN-166, AV411",ibudilast,neuroprotectant,Small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
933,"ibudilast, MN-166, AV411",ibudilast,neuroprotectant,Small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
933,"ibudilast, MN-166, AV411",ibudilast,neuroprotectant,Small molecule,not approved,Q08493,PDE4C_HUMAN,PDE4C,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C OS=Homo sapiens GN=PDE4C PE=1 SV=2",Enzymes,EC:3.1.4.17,Established target
934,IC14,IC14,immunosuppressant,monoclonal antibody,not approved,P08571,CD14_HUMAN,CD14,"Monocyte differentiation antigen CD14 (Myeloid cell-specific leucine-rich glycoprotein) (CD antigen CD14) [Cleaved into: Monocyte differentiation antigen CD14, urinary form; Monocyte differentiation antigen CD14, membrane-bound form]",Miscellaneous,Miscellaneous;Glycoprotein,Novel Target
935,ICA-105665,ICA-105665,anticonvulsant,Small molecule,not approved,P51787,KCNQ1_HUMAN,KCNQ1,Potassium voltage-gated channel subfamily KQT member 1 OS=Homo sapiens GN=KCNQ1 PE=1 SV=3,Transporters,TC:1.A.1.15.6,Established target
935,ICA-105665,ICA-105665,anticonvulsant,Small molecule,not approved,O43526,KCNQ2_HUMAN,KCNQ2,Potassium voltage-gated channel subfamily KQT member 2 (KQT-like 2) (Neuroblastoma-specific potassium channel subunit alpha KvLQT2) (Voltage-gated potassium channel subunit Kv7.2),Transporters,TC:1.A.1.15.2,Established target
935,ICA-105665,ICA-105665,anticonvulsant,Small molecule,not approved,O43525,KCNQ3_HUMAN,KCNQ3,Potassium voltage-gated channel subfamily KQT member 3 (KQT-like 3) (Potassium channel subunit alpha KvLQT3) (Voltage-gated potassium channel subunit Kv7.3),Transporters,TC:1.A.1.15.3,Established target
935,ICA-105665,ICA-105665,anticonvulsant,Small molecule,not approved,P56696,KCNQ4_HUMAN,KCNQ4,Potassium voltage-gated channel subfamily KQT member 4 (KQT-like 4) (Potassium channel subunit alpha KvLQT4) (Voltage-gated potassium channel subunit Kv7.4),Transporters,TC.1.A.1.15.4,Established target
935,ICA-105665,ICA-105665,anticonvulsant,Small molecule,not approved,Q9NR82,KCNQ5_HUMAN,KCNQ5,Potassium voltage-gated channel subfamily KQT member 5 (KQT-like 5) (Potassium channel subunit alpha KvLQT5) (Voltage-gated potassium channel subunit Kv7.5),Transporters,TC:1.A.1.15,Established target
937,iCo-007,iCo-007,"for treatment of age-related macular degeneration,for treatment of diabetic retinopathy",antisense oligo,not approved,P04049,RAF1_HUMAN,RAF1,RAF proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=RAF1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
939,"idrabiotaparinux sodium, SSR-126517E",idrabiotaparinux,antithrombotic,Small molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
940,"idraparinux, SanOrg 34006",idraparinux,antithrombotic,Small molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
941,"iduronate-2 sulfatase ,Elaprase",iduronate-2 sulfatase,"enzyme replacement therapy for Hunter syndrome, mucopolysaccharidosis type 2",protein,not approved,P22304,IDS_HUMAN,IDS,Iduronate 2-sulfatase,Enzymes,EC:3.1.6.13,Novel Target
942,iferanserin ointment,iferanserin,antihemorrhoidal agent,Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
943,"IFN-alpha 2B-XL, Medusa interferon alpha-2b",interferon alpha-2b,for treatment of hepatitis B and C,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
943,"IFN-alpha 2B-XL, Medusa interferon alpha-2b",interferon alpha-2b,for treatment of hepatitis B and C,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon alpha/beta receptor 2 (IFN-R-2) (IFN-alpha binding protein) (IFN-alpha/beta receptor 2) (Interferon alpha binding protein) (Type I interferon receptor 2),Receptors,Receptor; Type 2 cytokine receptor,Established target
944,"IFN-alpha, interferon alpha ,Belerofon",modified IFN-alpha,for treatment of hepatitis C,recombinant protein,not approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
945,"IFN-alpha, interferon alpha,Belerofon",modified IFN-alpha,for treatment of hepatitis C,recombinant protein,not approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
946,"IFN-beta,Belerofon",modified IFN-beta,for treatment of hepatitis C,recombinant protein,not approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
946,"IFN-beta,Belerofon",modified IFN-beta,for treatment of hepatitis C,recombinant protein,not approved,P48551,INAR2_HUMAN,IFNAR1,Interferon alpha/beta receptor 2 (IFN-R-2) (IFN-alpha binding protein) (IFN-alpha/beta receptor 2) (Interferon alpha binding protein) (Type I interferon receptor 2),Receptors,Receptor; Type 2 cytokine receptor,Established target
947,IGN101,IGN101,"antineoplastic agent,cancer vaccine",vaccine,not approved,P16422,EPCAM_HUMAN,EPCAM,Epithelial cell adhesion molecule (Ep-CAM) (Adenocarcinoma-associated antigen) (Cell surface glycoprotein Trop-1) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Epithelial glycoprotein 314) (EGP314) (hEGP314) (KS 1/4 antigen) (KSA) (Ma,Miscellaneous,StructuralAndAdhesion;,Novel Target
949,IL-2 pDNA,interleukin-2 expressing plasmid,antineoplastic agent,DNA plasmid,not approved,P01589,IL2RA_HUMAN,IL2RA,Interleukin-2 receptor alpha chain OS=Homo sapiens GN=IL2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
949,IL-2 pDNA,interleukin-2 expressing plasmid,antineoplastic agent,DNA plasmid,not approved,P14784,IL2RB_HUMAN,IL2RB,Interleukin-2 receptor subunit beta OS=Homo sapiens GN=IL2RB PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
949,IL-2 pDNA,interleukin-2 expressing plasmid,antineoplastic agent,DNA plasmid,not approved,P31785,IL2RG_HUMAN,IL2RG,Cytokine receptor common gamma chain OS=Homo sapiens GN=IL2RG PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
950,"ilepatril, AVE-7688",ilepatril,antihypertensive agent,unknown,not approved,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
950,"ilepatril, AVE-7688",ilepatril,antihypertensive agent,unknown,not approved,P08473,NEP_HUMAN,MME,Neprilysin OS=Homo sapiens GN=MME PE=1 SV=2,Enzymes,EC:3.4.24,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
951,"iloperidone,Fanapt, Fiapta, Zomaril",iloperidone,"antipsychotic agent,atypical",Small molecule,approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
952,"iloprost,Ventavis",iloprost,antihypertensive agent,Small Molecule,approved,P34995,PE2R1_HUMAN,PTGER1,Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens GN=PTGER1 PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
952,"iloprost,Ventavis",iloprost,antihypertensive agent,Small Molecule,approved,P43119,PI2R_HUMAN,PTGIR,Prostacyclin receptor OS=Homo sapiens GN=PTGIR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
953,Iluvien,fluocinolone acetonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
954,"ILX-651, tasidotin,Synthadotin",tasidotin,antineoplastic agent,peptide,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
955,"imatinib mesylate, STI 571,Gleevec, Glivec",imatinib,antineoplastic agent,Small Molecule,approved,P00519,ABL1_HUMAN,ABL1,Proto-oncogene tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4,Enzymes,EC:2.7.10.2,Established target
955,"imatinib mesylate, STI 571,Gleevec, Glivec",imatinib,antineoplastic agent,Small Molecule,approved,P07333,CSF1R_HUMAN,CSF1R,Macrophage colony-stimulating factor 1 receptor OS=Homo sapiens GN=CSF1R PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
955,"imatinib mesylate, STI 571,Gleevec, Glivec",imatinib,antineoplastic agent,Small Molecule,approved,Q08345,DDR1_HUMAN,DDR1,Epithelial discoidin domain-containing receptor 1 (Epithelial discoidin domain receptor 1) (EC 2.7.10.1) (CD167 antigen-like family member A) (Cell adhesion kinase) (Discoidin receptor tyrosine kinase) (HGK2) (Mammary carcinoma kinase 10) (MCK-10) (Protei,Receptors,EC:2.7.10.1,Established target
955,"imatinib mesylate, STI 571,Gleevec, Glivec",imatinib,antineoplastic agent,Small Molecule,approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
955,"imatinib mesylate, STI 571,Gleevec, Glivec",imatinib,antineoplastic agent,Small Molecule,approved,P04629,NTRK1_HUMAN,NTRK1,High affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinase receptor type 1) (TRK1-transforming tyrosine kinase protein) (p140-TrkA) (Trk-A),Receptors,EC:2.7.10.1,Established target
955,"imatinib mesylate, STI 571,Gleevec, Glivec",imatinib,antineoplastic agent,Small Molecule,approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
955,"imatinib mesylate, STI 571,Gleevec, Glivec",imatinib,antineoplastic agent,Small Molecule,approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
955,"imatinib mesylate, STI 571,Gleevec, Glivec",imatinib,antineoplastic agent,Small Molecule,approved,P07949,RET_HUMAN,RET,Proto-oncogene tyrosine-protein kinase receptor ret OS=Homo sapiens GN=RET PE=1 SV=3,Receptors,EC:2.7.10.1,Established target
956,IMC-1121B,IMC-1121B,antineoplastic agent,antibody,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
957,IMC-3C5,IMC-3C5,antineoplastic agent,monoclonal antibody,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
958,IMC-3G3,IMC-3G3,antineoplastic agent,monoclonal antibody,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
959,Imetelstat,Imetelstat,antineoplastic agent,aptamer,not approved,RNA-sequence,TERC-201,TERC,Telomerase RNA component,Miscellaneous,Miscellaneous;Telomerase RNA-component,Novel Target
959,Imetelstat,Imetelstat,antineoplastic agent,aptamer,not approved,O14746,TERT_HUMAN,TERT,Telomerase reverse transcriptase (EC 2.7.7.49) (HEST2) (Telomerase catalytic subunit) (Telomerase-associated protein 2) (TP2),Enzymes,EC:2.7.7.49,Novel Target
960,Imiquimod,Imiquimod,"anti wart agent,antineoplastic agent",Small Molecule,approved,Q9NYK1,TLR7_HUMAN,TLR7,Toll-like receptor 7 OS=Homo sapiens GN=TLR7 PE=1 SV=1,Receptors,Receptors;TOLL,Established target
961,Immunomedics,anti-CD20 (hA20) monoclonal antibody,antineoplastic agent,monoclonal antibody,not approved,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Miscellaneous,MS4A family,Established target
962,IMO-3100,IMO-3100,immunosuppressant,aptamer,not approved,Q9NYK1,TLR7_HUMAN,TLR7,Toll-like receptor 7 OS=Homo sapiens GN=TLR7 PE=1 SV=1,Receptors,Receptors;TOLL,Established target
962,IMO-3100,IMO-3100,immunosuppressant,aptamer,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
963,"implitapide, AEGR427",implitapide,antiatherosclerotic agent,Small molecule,not approved,P55157,MTP_HUMAN,MTTP,Microsomal triglyceride transfer protein large subunit,Transporters,Miscellaneous;Lipid_transp,Novel Target
964,INCB13739,INCB13739,antidiabetic,Small molecule,not approved,P28845,DHI1_HUMAN,HSD11B1,Corticosteroid 11-beta-dehydrogenase isozyme 1 (EC 1.1.1.146) (11-beta-hydroxysteroid dehydrogenase 1) (11-DH) (11-beta-HSD1),Enzymes,EC:1.1.1.146,Novel Target
965,INCB18424,INCB18424,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,P23458,JAK1_HUMAN,JAK1,Tyrosine-protein kinase JAK1 (EC 2.7.10.2) (Janus kinase 1) (JAK-1),Enzymes,EC:2.7.10.2,Novel Target
965,INCB18424,INCB18424,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
966,INCB3284,INCB3284,"antiinflammatory agent,DMARD",Small molecule,not approved,P41597,CCR2_HUMAN,CCR2,C-C chemokine receptor type 2 (C-C CKR-2) (CC-CKR-2) (CCR-2) (CCR2) (Monocyte chemoattractant protein 1 receptor) (MCP-1-R) (CD antigen CD192),Receptors,GPCR;Rhodopsin,Novel Target
967,INCB7839,INCB7839,antineoplastic agent,Small molecule,not approved,O14672,ADA10_HUMAN,ADAM10,Disintegrin and metalloproteinase domain-containing protein 10 (ADAM 10) (EC 3.4.24.81) (CDw156) (Kuzbanian protein homolog) (Mammalian disintegrin-metalloprotease) (CD antigen CD156c),Enzymes,EC:3.4.24.81,Novel Target
967,INCB7839,INCB7839,antineoplastic agent,Small molecule,not approved,P78536,ADA17_HUMAN,ADAM17,Disintegrin and metalloproteinase domain-containing protein 17 (ADAM 17) (EC 3.4.24.86) (Snake venom-like protease) (TNF-alpha convertase) (TNF-alpha-converting enzyme) (CD antigen CD156b),Enzymes,EC:3.4.24.86,Novel Target
968,INcell-1001+ AD-1001,INcell-1001+ AD-1001,antineoplastic agent,autologous cell-based gene-therapy,not approved,P42701,I12R1_HUMAN,IL12RB1,Interleukin-12 receptor subunit beta-1 (IL-12 receptor subunit beta-1) (IL-12R subunit beta-1) (IL-12R-beta-1) (IL-12RB1) (IL-12 receptor beta component) (CD antigen CD212),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
968,INcell-1001+ AD-1001,INcell-1001+ AD-1001,antineoplastic agent,autologous cell-based gene-therapy,not approved,Q99665,I12R2_HUMAN,IL12RB2,Interleukin-12 receptor subunit beta-2 (IL-12 receptor subunit beta-2) (IL-12R subunit beta-2) (IL-12R-beta-2) (IL-12RB2),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
969,Indacaterol,indacaterol,bronchodilator,Small molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
970,Indaflex,indomethacin,NSAID,Small Molecule,approved,P15382,KCNE1_HUMAN,KCNE1,Potassium voltage-gated channel subfamily E member 1 OS=Homo sapiens GN=KCNE1 PE=1 SV=1,Transporters,TC:8.A.10.1.1,Established target
970,Indaflex,indomethacin,NSAID,Small Molecule,approved,P51787,KCNQ1_HUMAN,KCNQ1,Potassium voltage-gated channel subfamily KQT member 1 OS=Homo sapiens GN=KCNQ1 PE=1 SV=3,Transporters,TC:1.A.1.15.6,Established target
971,Indiplon,Indiplon,hypnotic,Small molecule,not approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
972,"inecalcitol, TX-522",inecalcitol,"antineoplastic agent,prostate cancer",Small molecule,not approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
973,"infliximab ,Remicade",infliximab,"antiinflammatory agent,DMARD",monoclonal antibody,approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
974,ING-1,ING-1,antineoplastic agent,antibody,not approved,P16642,EPCAM_HUMAN,EPCAM,Epithelial cell adhesion molecule (Ep-CAM) (Adenocarcinoma-associated antigen) (Cell surface glycoprotein Trop-1) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Epithelial glycoprotein 314) (EGP314) (hEGP314) (KS 1/4 antigen) (KSA) (Ma,Miscellaneous,StructuralAndAdhesion;,Novel Target
975,INGN,INGN 242,antineoplastic agent,adenoviral vector,not approved,Q13007,IL24_HUMAN,IL24,Interleukin-24 (IL-24) (Melanoma differentiation-associated gene 7 protein) (MDA-7) (Suppression of tumorigenicity 16 protein),Miscellaneous,Ligand;Cytokine,Novel Target
976,"inhaled apomorphine hydrochloride, VR004, VR-040, VR-400",apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
976,"inhaled apomorphine hydrochloride, VR004, VR-040, VR-400",apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
976,"inhaled apomorphine hydrochloride, VR004, VR-040, VR-400",apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
977,inhaled atropine,atropine,nerve agent antidote,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
977,inhaled atropine,atropine,nerve agent antidote,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
977,inhaled atropine,atropine,nerve agent antidote,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
977,inhaled atropine,atropine,nerve agent antidote,Small Molecule,approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
977,inhaled atropine,atropine,nerve agent antidote,Small Molecule,approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
978,inhaled insulin product,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
979,"inhaled insulin,Exubera",insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
980,"iniparib, SAR240550, BSI-201",iniparib,antineoplastic agent,Small molecule,not approved,P09874,PARP1_HUMAN,PARP1,Poly [ADP-ribose] polymerase 1 (PARP-1) (EC 2.4.2.30) (NAD(+) ADP-ribosyltransferase 1) (ADPRT 1) (Poly[ADP-ribose] synthase 1),Enzymes,EC:2.4.2.30,Novel Target
981,"injectable octreotide acetate,Sandostatin LAR",octreotide,antineoplastic agent,peptide,approved,P30872,SSR1_HUMAN,SSTR1,Somatostatin receptor type 1 OS=Homo sapiens GN=SSTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
981,"injectable octreotide acetate,Sandostatin LAR",octreotide,antineoplastic agent,peptide,approved,P30874,SSR2_HUMAN,SSTR2,Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SRIF-1),Receptors,GPCR;Rhodopsin,Established target
981,"injectable octreotide acetate,Sandostatin LAR",octreotide,antineoplastic agent,peptide,approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
982,INK128,INK128,antineoplastic agent,Small molecule,not approved,Q6UUV9,CRTC1_HUMAN,CRTC1,CREB-regulated transcription coactivator 1 (Mucoepidermoid carcinoma translocated protein 1) (Transducer of regulated cAMP response element-binding protein 1) (TORC-1) (Transducer of CREB protein 1),Miscellaneous,Miscellaneous;TORC family,Novel Target
982,INK128,INK128,antineoplastic agent,Small molecule,not approved,Q53ET0,CRTC2_HUMAN,CRTC2,CREB-regulated transcription coactivator 2 (Transducer of regulated cAMP response element-binding protein 2) (TORC-2) (Transducer of CREB protein 2),Miscellaneous,Miscellaneous;TORC family,Novel Target
983,"INN-00835, nemifitide",nemifitide,antidepressant,peptide,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
984,INNO-206,INNO-206,antineoplastic agent,Small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
985,INO-8875,INO-8875,for treatment of glaucoma,Small molecule,not approved,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
986,"inotuzumab ozogamicin, CMC-544",inotuzumab ozogamicin,antineoplastic agent,fusion protein,not approved,P20273,CD22_HUMAN,CD22,B-cell receptor CD22 OS=Homo sapiens GN=CD22 PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
987,INS117548,INS117548,for treatment of glaucoma,unknown,not approved,Q13464,ROCK1_HUMAN,ROCK1,"Rho-associated protein kinase 1 (EC 2.7.11.1) (Renal carcinoma antigen NY-REN-35) (Rho-associated, coiled-coil-containing protein kinase 1) (p160 ROCK-1) (p160ROCK)",Enzymes,EC:2.7.11.1,Novel Target
987,INS117548,INS117548,for treatment of glaucoma,unknown,not approved,O75116,ROCK2_HUMAN,ROCK2,"Rho-associated protein kinase 2 (EC 2.7.11.1) (Rho kinase 2) (Rho-associated, coiled-coil-containing protein kinase 2) (p164 ROCK-2)",Enzymes,EC:2.7.11.1,Novel Target
988,INS-19,INS-19,for treatment of neutropenia,recombinant protein,not approved,Q99062,CSF3R_HUMAN,CSF3R,Granulocyte colony-stimulating factor receptor OS=Homo sapiens GN=CSF3R PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
989,INS-20,INS-20,for treatment of neutropenia,recombinant protein,not approved,Q99062,CSF3R_HUMAN,CSF3R,Granulocyte colony-stimulating factor receptor OS=Homo sapiens GN=CSF3R PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
990,INS37217,INS37217,for treatment of rhegmatogenous retinal detachment,Small molecule,not approved,P41231,P2RY2_HUMAN,P2RY2,P2Y purinoceptor 2 (P2Y2) (ATP receptor) (P2U purinoceptor 1) (P2U1) (Purinergic receptor),Receptors,GPCR;Rhodopsin,Novel Target
991,INS37217 Intranasal,INS37217,"for treatment of cystic fibrosis,for treatment of perennial allergic rhinitis",Small molecule,not approved,P41231,P2RY2_HUMAN,P2RY2,P2Y purinoceptor 2 (P2Y2) (ATP receptor) (P2U purinoceptor 1) (P2U1) (Purinergic receptor),Receptors,GPCR;Rhodopsin,Novel Target
992,INS-50589,INS-50589,antithrombotic,unknown,not approved,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
993,INSM-18,INSM-18,"antineoplastic agent,prostate cancer",Small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
993,INSM-18,INSM-18,"antineoplastic agent,prostate cancer",Small molecule,not approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
994,"insulin aspart,NovoRapid, NovoLog",insulin aspart,antidiabetic,recombinant protein,not approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
995,"insulin glargine [rDNA origin] injection,Lantus",insulin glargine,antidiabetic,recombinant protein,not approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
996,"insulin glulisine, 1964,Apidra",insulin glulisine,antidiabetic,recombinant protein,not approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
997,"INT-131, AMG-131, T131",AMG-131,antidiabetic,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
998,"interferon alfa-n3, Alferon N Injection, Alferon LDO",interferon alfa-n3,"antiviral agent,antineoplastic agent",protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
999,"interferon alfa-n3,Alferon N Injection, Alferon LDO",interferon alfa-n3,"antiviral agent,antineoplastic agent",protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1000,interferon alpha,interferon alpha,"antiviral agent,antineoplastic agent",protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1000,interferon alpha,interferon alpha,"antiviral agent,antineoplastic agent",protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1001,interferon beta (intranasal),interferon beta ,for treatment of multiple sclerosis,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1001,interferon beta (intranasal),interferon beta ,for treatment of multiple sclerosis,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1002,"interferon beta-1a ,Biferonex",interferon beta-1a,for treatment of multiple sclerosis,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1003,"interferon beta-1a,Biferonex",interferon beta-1a,for treatment of multiple sclerosis,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1004,"interferon beta-1a,Rebif",interferon beta-1a,for treatment of multiple sclerosis,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1004,"interferon beta-1a,Rebif",interferon beta-1a,for treatment of multiple sclerosis,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1005,Interferon beta-1b,Interferon beta-1b,for treatment of multiple sclerosis,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1005,Interferon beta-1b,Interferon beta-1b,for treatment of multiple sclerosis,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1006,"interferon gamma-1b,Actimmune, Imukin",interferon gamma-1b,antiosteoporotic agent,protein,approved,P15260,INGR1_HUMAN,IFNGR1,Interferon-gamma receptor alpha chain OS=Homo sapiens GN=IFNGR1 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1006,"interferon gamma-1b,Actimmune, Imukin",interferon gamma-1b,antiosteoporotic agent,protein,approved,P38484,INGR2_HUMAN,IFNGR2,Interferon-gamma receptor beta chain OS=Homo sapiens GN=IFNGR2 PE=1 SV=2,Receptors,Receptor; Type 2 cytokine receptor,Established target
1007,interleukin-1 (IL-1) trap,rilonacept,"antiinflammatory agent,DMARD",fusion protein,not approved,P01583,IL1A_HUMAN,IL1A,Interleukin-1 alpha (IL-1 alpha) (Hematopoietin-1),Miscellaneous,Ligand;Cytokine,Established target
1009,intranasal apomorphine,apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1009,intranasal apomorphine,apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1009,intranasal apomorphine,apomorphine,"for treatment of sexual dysfunction in women,for treatment of erectile dysfunction,antiparkinson agent ",Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1010,intranasal insulin,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1011,"intranasal insulin,Nasulin",insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1012,"intranasal ketorolac tromethamine, ROX-888,Sprix",ketorolac,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1013,"intranasal morphine,Rylomine",morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1013,"intranasal morphine,Rylomine",morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1013,"intranasal morphine,Rylomine",morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1014,"IPI-493, oral retaspimycin",retaspimycin,antineoplastic agent,small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
1014,"IPI-493, oral retaspimycin",retaspimycin,antineoplastic agent,small molecule,not approved,Q14568,HS902_HUMAN,HSP90AA2,Putative heat shock protein HSP 90-alpha A2,Miscellaneous,Miscellaneous;heat shock protein,Novel Target
1014,"IPI-493, oral retaspimycin",retaspimycin,antineoplastic agent,small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
1015,IPI-504,IPI-504,antineoplastic agent,Small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
1015,IPI-504,IPI-504,antineoplastic agent,Small molecule,not approved,Q14568,HS902_HUMAN,HSP90AA2,Putative heat shock protein HSP 90-alpha A2,Miscellaneous,Miscellaneous;heat shock protein,Novel Target
1015,IPI-504,IPI-504,antineoplastic agent,Small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
1016,IPI-940,IPI-940,analgesic,Small molecule,not approved,O00519,FAAH1_HUMAN,FAAH,Fatty-acid amide hydrolase 1 (EC 3.5.1.99) (Anandamide amidohydrolase 1) (Oleamide hydrolase 1),Enzymes,EC:3.5.1.99,Novel Target
1017,Ipilimumab,Ipilimumab,antineoplastic agent,monoclonal antibody,approved,P16410,CTLA4_HUMAN,CTLA4,Cytotoxic T-lymphocyte protein 4 (Cytotoxic T-lymphocyte-associated antigen 4) (CTLA-4) (CD antigen CD152),Receptors,Miscellaneous;CTLA4,Established target
1018,IPL455,IPL455,nootropic,unknown,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
1018,IPL455,IPL455,nootropic,unknown,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
1019,iPlex,mecasermin rinfibate,"antidiabetic,hormone replacement,for treatment of HIV treatment-related lipodystrophy,anabolic",recombinant protein,approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1020,IPP-204106,IPP-204106,antineoplastic agent,pseudopeptide,not approved,P19338,NUCL_HUMAN,NCL,Nucleolin (Protein C23),Miscellaneous,RNA Binding,Novel Target
1021,"ipratropium bromide + albuterol sulfate,DuoNeb",ipratropium,for treatment of chronic obstructive pulmonary disorder (COPD),Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1021,"ipratropium bromide + albuterol sulfate,DuoNeb",ipratropium,for treatment of chronic obstructive pulmonary disorder (COPD),Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1021,"ipratropium bromide + albuterol sulfate,DuoNeb",salbutamol,for treatment of chronic obstructive pulmonary disorder (COPD),Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1022,IPX066,IPX066,antiparkinson agent,Small molecule,not approved,P20711,DDC_HUMAN,DDC,Aromatic-L-amino-acid decarboxylase OS=Homo sapiens GN=DDC PE=1 SV=1,Enzymes,EC:4.1.1.28,Established target
1023,"irbesartan,Avapro, Irbetan",irbesartan,antihypertensive agent,Small Molecule,approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1024,Iressa,gefitinib,antineoplastic agent,Small Molecule,approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1025,"irinotecan hydrochloride injection,Camptosar",irinotecan,antineoplastic agent,Small Molecule,approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
1026,IRX-2,IFN-gamma,antineoplastic agent,protein,approved,P15260,INGR1_HUMAN,IFNGR1,Interferon-gamma receptor alpha chain OS=Homo sapiens GN=IFNGR1 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1026,IRX-2,IFN-gamma,antineoplastic agent,protein,approved,P38484,INGR2_HUMAN,IFNGR2,Interferon-gamma receptor beta chain OS=Homo sapiens GN=IFNGR2 PE=1 SV=2,Receptors,Receptor; Type 2 cytokine receptor,Established target
1026,IRX-2,IL-1,antineoplastic agent,protein,not approved,P14778,IL1R1_HUMAN,IL1R1,Interleukin-1 receptor type I OS=Homo sapiens GN=IL1R1 PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1026,IRX-2,IL-1,antineoplastic agent,protein,not approved,P27930,IL1R2_HUMAN,IL1R2,Interleukin-1 receptor type II OS=Homo sapiens GN=IL1R2 PE=2 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1026,IRX-2,IL-2,antineoplastic agent,protein,not approved,P01589,IL2RA_HUMAN,IL2RA,Interleukin-2 receptor alpha chain OS=Homo sapiens GN=IL2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1026,IRX-2,IL-2,antineoplastic agent,protein,not approved,P14784,IL2RB_HUMAN,IL2RB,Interleukin-2 receptor subunit beta OS=Homo sapiens GN=IL2RB PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1026,IRX-2,IL-2,antineoplastic agent,protein,not approved,P31785,IL2RG_HUMAN,IL2RG,Cytokine receptor common gamma chain OS=Homo sapiens GN=IL2RG PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1027,ISF35,ISF35,antineoplastic agent,recombinant protein,not approved,P25942,TNR5_HUMAN,CD40,Tumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40) (Bp50) (CD40L receptor) (CDw40) (CD antigen CD40),Receptors,Receptors;TNFNGF,Novel Target
1028,ISIS 113715,ISIS 113715,antidiabetic,antisense oligo,not approved,P18031,PTN1_HUMAN,PTPN1,Tyrosine-protein phosphatase non-receptor type 1 OS=Homo sapiens GN=PTPN1 PE=1 SV=1,Enzymes,EC:3.1.3,Established target
1029,ISIS 301012 ,mipomersen,anticholesterolaemic agent,antisense oligo,not approved,P04114,APOB_HUMAN,APOB,Apolipoprotein B-100 (Apo B-100) [Cleaved into: Apolipoprotein B-48 (Apo B-48)],Miscellaneous,Enzyme cofactor ,Novel Target
1030,ISIS 325568,ISIS 325568,antidiabetic,antisense oligo,not approved,P47871,GLR_HUMAN,GCGR,Glucagon receptor OS=Homo sapiens GN=GCGR PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1031,ISIS 353512,ISIS 353512,antiinflammatory agent,antisense oligo,not approved,P02741,CRP_HUMAN,CRP,C-reactive protein [Cleaved into: C-reactive protein(1-205)],Miscellaneous,Miscellaneous;Pentaxin family,Novel Target
1032,ISIS-104838,ISIS-104838,"antiinflammatory agent,DMARD",antisense oligo,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
1033,ISIS-2302,alicaforsen,"antiinflammatory agent,for treatment of ulcerative colitis,for treatment of Chron's disease",antisense oligo,not approved,P05362,ICAM1_HUMAN,ICAM1,Intercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
1034,ISIS-2503,ISIS-2503,antineoplastic agent,antisense oligo,not approved,P01112,RASH_HUMAN,HRAS,"GTPase HRas (H-Ras-1) (Ha-Ras) (Transforming protein p21) (c-H-ras) (p21ras) [Cleaved into: GTPase HRas, N-terminally processed]",Miscellaneous,Miscellaneous;Hras,Novel Target
1035,ISIS-CRPRx,ISIS-CRPRx,"antiinflammatory agent,DMARD,antineoplastic agent",antisense oligo,not approved,P02741,CRP_HUMAN,CRP,C-reactive protein [Cleaved into: C-reactive protein(1-205)],Miscellaneous,Miscellaneous;Pentaxin family,Novel Target
1036,ISIS-FXIRx,ISIS-FXIRx,antithrombotic,antisense oligo,not approved,P03951,FA11_HUMAN,F11,Coagulation factor XI (FXI) (EC 3.4.21.27) (Plasma thromboplastin antecedent) (PTA) [Cleaved into: Coagulation factor XIa heavy chain; Coagulation factor XIa light chain],Enzymes,EC:3.4.21.27,Established target
1037,ISIS-SGLT2Rx,ISIS-SGLT2Rx,antidiabetic,antisense oligo,not approved,P31639,SC5A2_HUMAN,SLC5A2,Sodium/glucose cotransporter 2 (Na(+)/glucose cotransporter 2) (Low affinity sodium-glucose cotransporter) (Solute carrier family 5 member 2),Transporters,TC:2.A.21.3.16,Established target
1038,ISIS-SOD1Rx,ISIS-SOD1Rx,for treatment of ALS,antisense oligo,not approved,P00441,SODC_HUMAN,SOD1,Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) (Superoxide dismutase 1) (hSod1),Enzymes,EC:1.15.1.1,Novel Target
1039,"isofagomine tartrate, AT2101,Plicera",isofagomine,for treatment of Gaucher's disease,Small molecule,not approved,P04062,GLCM_HUMAN,GBA,Glucosylceramidase (EC 3.2.1.45) (Acid beta-glucosidase) (Alglucerase) (Beta-glucocerebrosidase) (D-glucosyl-N-acylsphingosine glucohydrolase) (Imiglucerase),Enzymes,EC:3.2.1.45,Novel Target
1040,ispinesib,ispinesib,antineoplastic agent,Small molecule,not approved,P52732,KIF11_HUMAN,KIF11,Kinesin-like protein KIF11 (Kinesin-like protein 1) (Kinesin-like spindle protein HKSP) (Kinesin-related motor protein Eg5) (Thyroid receptor-interacting protein 5) (TR-interacting protein 5) (TRIP-5),Miscellaneous,Miscellaneous;motor protein,Novel Target
1041,"ISS-1018, immunostimulatory phosphorothiolate oligodeoxyribonucleotide",ISS-1018,immunostimulant,vaccine,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
1042,"istaroxime, Debio 0614, ST-2744",istaroxime,for treatment of heart failure,Small molecule,not approved,P05023,AT1A1_HUMAN,ATP1A1,Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1,transporter,TC:3.A.3.1.1,Established target
1042,"istaroxime, Debio 0614, ST-2744",istaroxime,for treatment of heart failure,Small molecule,not approved,P16615,AT2A2_HUMAN,ATP2A2,Sarcoplasmic/endoplasmic reticulum calcium ATPase 2,Enzymes,TC:3.A.3.2.7,Novel Target
1043,"istradefylline, KW-6002",istradefylline,antiparkinson agent,Small molecule,not approved,P29274,AA2AR_HUMAN,ADORA2A,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1044,ISV-101,bromfenac,"opthalmological agent,NSAID",Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1044,ISV-101,bromfenac,"opthalmological agent,NSAID",Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1045,ISV-303,bromfenac,"opthalmological agent,NSAID",Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1045,ISV-303,bromfenac,"opthalmological agent,NSAID",Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1046,ITCA 650,exenatide,antidiabetic,peptide,approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,P56524,HDAC4_HUMAN,HDAC4,Histone deacetylase 4 (HD4) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,Q9UQL6,HDAC5_HUMAN,HDAC5,Histone deacetylase 5 (HD5) (EC 3.5.1.98) (Antigen NY-CO-9),Enzymes,EC:3.5.1.98,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,Q8WUI4,HDAC7_HUMAN,HDAC7,Histone deacetylase 7 (HD7) (EC 3.5.1.98) (Histone deacetylase 7A) (HD7a),Enzymes,EC:3.5.1.98,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1047,"ITF2357,Givinostat",Givinostat,"antineoplastic agent,antiinflammatory agent",Small molecule,not approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
1048,"ITI-007, ITI-722",ITI-007,antipsychotic agent,Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1048,"ITI-007, ITI-722",ITI-007,antipsychotic agent,Small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1048,"ITI-007, ITI-722",ITI-007,antipsychotic agent,Small molecule,not approved,Q9UD71,PPR1B_HUMAN,PPP1R1B,Protein phosphatase 1 regulatory subunit 1B,Miscellaneous,Miscellaneous;protein phosphatase 1 regulatory subunit,Novel Target
1048,"ITI-007, ITI-722",ITI-007,antipsychotic agent,Small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1049,"itopride,Itax",itopride,motilitant,Small molecule,not approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
1049,"itopride,Itax",itopride,motilitant,Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1050,"IW-6118, ICP-109-201",IW-6118,analgesic,Small molecule,not approved,O00519,FAAH1_HUMAN,FAAH,Fatty-acid amide hydrolase 1 (EC 3.5.1.99) (Anandamide amidohydrolase 1) (Oleamide hydrolase 1),Enzymes,EC:3.5.1.99,Novel Target
1052,"ixabepilone,  BMS-247550,Ixempra",ixabepilone,antineoplastic agent,Small molecule,not approved,Q13509,TBB3_HUMAN,TUBB3,Tubulin beta-3 chain,Miscellaneous,StructuralAndAdhesion;Tubulin,Established target
1053,JB991,JB991,"antiinflammatory agent,dermatologic agent",Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1054,JNJ-37822681,JNJ-37822681,antipsychotic agent,Small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1055,JSM 6427,JSM 6427,for treatment of age-related macular degeneration,Small molecule,not approved,P08648,ITA5_HUMAN,ITGA5,Integrin alpha-5 (CD49 antigen-like family member E) (Fibronectin receptor subunit alpha) (Integrin alpha-F) (VLA-5) (CD antigen CD49e) [Cleaved into: Integrin alpha-5 heavy chain; Integrin alpha-5 light chain],Receptors,Receptors;Integrin,Novel Target
1055,JSM 6427,JSM 6427,for treatment of age-related macular degeneration,Small molecule,not approved,P05556,ITB1_HUMAN,ITGB1,Integrin beta-1 (Fibronectin receptor subunit beta) (VLA-4 subunit beta) (CD antigen CD29),Receptors,Receptors;Integrin,Established target
1056,JVS-100,JVS-100,cardioprotectant,DNA plasmid,not approved,P61073,CXCR4_HUMAN,CXCR4,C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (Fusin) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD antigen CD184),Receptors,GPCR;Rhodopsin,Established target
1057,JZP-7,ropinirole,for treatment of restlegs legs syndrome,Small Molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1057,JZP-7,ropinirole,for treatment of restlegs legs syndrome,Small Molecule,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1057,JZP-7,ropinirole,for treatment of restlegs legs syndrome,Small Molecule,not approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P18507,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P48169,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P14867,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P24046,GBRR1_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,Q9UN88,GBRT_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,A8MPY1,GBRR3_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1058,JZP-8,clonazepam,anticonvulsant,Small Molecule,approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1059,KAI-1455,KAI-1455,cardioprotectant,unknown,not approved,Q02156,KPCE_HUMAN,PRKCE,Protein kinase C epsilon type (EC 2.7.11.13) (nPKC-epsilon),Enzymes,EC:2.7.11.13,Established target
1060,KAI-1678,KAI-1678,analgesic,peptide,not approved,Q02156,KPCE_HUMAN,PRKCE,Protein kinase C epsilon type (EC 2.7.11.13) (nPKC-epsilon),Enzymes,EC:2.7.11.13,Established target
1061,KAI-9803,KAI-9803,cardioprotectant,peptide,not approved,Q05655,KPCD_HUMAN,PRKCD,Protein kinase C delta type (EC 2.7.11.13) (nPKC-delta),Enzymes,EC:2.7.11.13,Established target
1062,"kappaproct, DIMS-0150",kappaproct,"antiinflammatory agent,for treatment of ulcerative colitis",antisense oligo,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
1063,"Karenitecin, BNP 1350",Karenitecin,antineoplastic agent,Small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
1064,KB002,KB002,"antiinflammatory agent,DMARD,antiasthmatic agent",monoclonal antibody,not approved,P04141,CSF2_HUMAN,CSF2,Granulocyte-macrophage colony-stimulating factor,ligand,Ligand; CSF2,Novel Target
1065,KB004,KB004,antineoplastic agent,antibody,not approved,P29320,EPHA3_HUMAN,EPHA3,Ephrin type-A receptor 3 (EC 2.7.10.1) (EPH-like kinase 4) (EK4) (hEK4) (HEK) (Tyrosine-protein kinase TYRO4) (Tyrosine-protein kinase receptor ETK1),Receptors,EC:2.7.10.1,Novel Target
1066,KB3305,KB3305,antidiabetic,unknown,not approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1067,KC706,KC706,"antiinflammatory agent,DMARD",Small molecule,not approved,Q15759,MK11_HUMAN,MAPK11,Mitogen-activated protein kinase 11 (MAP kinase 11) (MAPK 11) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 beta) (MAP kinase p38 beta) (p38b) (Stress-activated protein kinase 2) (p38-2),Enzymes,EC:2.7.11.24,Novel Target
1067,KC706,KC706,"antiinflammatory agent,DMARD",Small molecule,not approved,P53778,MK12_HUMAN,MAPK12,Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3),Enzymes,EC:2.7.11.24,Novel Target
1067,KC706,KC706,"antiinflammatory agent,DMARD",Small molecule,not approved,O15264,MK13_HUMAN,MAPK13,Mitogen-activated protein kinase 13 (MAP kinase 13) (MAPK 13) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 delta) (MAP kinase p38 delta) (Stress-activated protein kinase 4),Enzymes,EC:2.7.11.24,Novel Target
1067,KC706,KC706,"antiinflammatory agent,DMARD",Small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
1068,KD3010,KD3010,"antiobesity agent,for treatment of metabolic disorders",Small molecule,not approved,Q03181,PPARD_HUMAN,PPARD,Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta),Receptors,Nuclear receptor,Established target
1069,KD7040,KD7040,"analgesic,neuropathic pain",unknown,not approved,P35228,NOS2_HUMAN,NOS2,"Nitric oxide synthase, inducible (EC 1.14.13.39) (Hepatocyte NOS) (HEP-NOS) (Inducible NO synthase) (Inducible NOS) (iNOS) (NOS type II) (Peptidyl-cysteine S-nitrosylase NOS2)",Enzymes,EC:1.14.13.39,Novel Target
1071,"ketoprofen in Transfersome gel, IDEA-033,Diractin",ketoprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1071,"ketoprofen in Transfersome gel, IDEA-033,Diractin",ketoprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1072,"ketoprofen transdermal patch, EN3269",ketoprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1072,"ketoprofen transdermal patch, EN3269",ketoprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1072,"ketoprofen transdermal patch, EN3269",ketoprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1072,"ketoprofen transdermal patch, EN3269",ketoprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1073,"ketorolac tromethamine ophthalmic solution,Acuvail",ketorolac,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1073,"ketorolac tromethamine ophthalmic solution,Acuvail",ketorolac,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1074,"ketotifen fumarate,Zaditen, Zaditor",ketotifen,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1075,"Ketotransdel, TDLP-110",ketoprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1075,"Ketotransdel, TDLP-110",ketoprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1075,"Ketotransdel, TDLP-110",ketoprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1075,"Ketotransdel, TDLP-110",ketoprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1076,KN38-7271,KN38-7271,neuroprotectant,Small molecule,not approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1076,KN38-7271,KN38-7271,neuroprotectant,Small molecule,not approved,P34972,CNR2_HUMAN,CNR2,Cannabinoid receptor 2 OS=Homo sapiens GN=CNR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1077,Kogenate,factor VIII,"coagulant,for treatment of hemophilia A",recombinant protein,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1078,KOS-2187,KOS-2187,for treatment of gastrointestinal motility disorders,Small molecule,not approved,O43193,MTLR_HUMAN,MLNR,Motilin receptor (G-protein coupled receptor 38),Receptors,GPCR;Rhodopsin,Novel Target
1079,KP201 (prodrug of hydrocodone),kp201,analgesic,Small molecule,not approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1079,KP201 (prodrug of hydrocodone),kp201,analgesic,Small molecule,not approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1079,KP201 (prodrug of hydrocodone),kp201,analgesic,Small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1080,KRN-330,KRN-330,antineoplastic agent,monoclonal antibody,not approved,Q99795,GPA33_HUMAN,GPA33,Cell surface A33 antigen (Glycoprotein A33),Miscellaneous,Cell surface antigen,Novel Target
1081,KRP-104,KRP-104,antidiabetic,Small molecule,not approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
1082,KUC-7483,KUC-7483,for treatment of overactive bladder,Small molecule,not approved,P13945,ADRB3_HUMAN,ADRB3,Beta-3 adrenergic receptor (Beta-3 adrenoreceptor) (Beta-3 adrenoceptor),Receptors,GPCR;Rhodopsin,Novel Target
1083,"KUR-212, I-020502, fibrin Tg-PDGF.AB",platelet-derived growth factor (PDGF) ,wound healing accelerant,protein,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1083,"KUR-212, I-020502, fibrin Tg-PDGF.AB",platelet-derived growth factor (PDGF) ,wound healing accelerant,protein,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1084,KX2-391,KX2-391,antineoplastic agent,Small molecule,not approved,P12931,SRC_HUMAN,SRC,Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
1085,Kytril,granisetron,antiemetic,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1086,Lacosamide,Lacosamide,"anticonvulsant,analgesic,neuropathic pain",Small molecule,approved,Q16555,DPYL2_HUMAN,DPYSL2,Dihydropyrimidinase-related protein 2 (DRP-2) (Collapsin response mediator protein 2) (CRMP-2) (N2A3) (Unc-33-like phosphoprotein 2) (ULIP-2),Miscellaneous,Miscellaneous; DPYSL2,Established target
1087,Lamictal,lamotrigine,anticonvulsant,Small Molecule,approved,Q99250,SCN2A_HUMAN,SCN2A,Sodium channel protein type 2 subunit alpha (HBSC II) (Sodium channel protein brain II subunit alpha) (Sodium channel protein type II subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.2),Transporters,TC:1.A.1.10,Established target
1088,"lanreotide ,Somatuline Autogel, Somatuline Depot",lanreotide,for treatment of acromegaly,Small molecule,approved,P30872,SSR1_HUMAN,SSTR1,Somatostatin receptor type 1 OS=Homo sapiens GN=SSTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1089,"lanreotide,Somatuline Autogel, Somatuline Depot",lanreotide,for treatment of acromegaly,Small molecule,approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1090,"lansoprazole , AG 1749,Prevacid, Takepron",lansoprazole,antiulcer agent,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1091,"lansoprazole,PrevOnco",lansoprazole,antiulcer agent,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1092,LAS-100977,LAS-100977,bronchodilator,Small molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1093,"lasmiditan, COL-144, LY-573144",lasmiditan,antimigraine agent,Small molecule,not approved,P30939,5HT1F_HUMAN,HTR1F,5-hydroxytryptamine receptor 1F OS=Homo sapiens GN=HTR1F PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1094,"lasofoxifene,Fablyn, Oporia",lasofoxifene,"antiosteoporotic agent,hormone replacement therapy",Small molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1095,"latanoprost + timolol,Xalcom, Xalacom",latanoprost,for treatment of glaucoma,Small Molecule,approved,P43088,PF2R_HUMAN,PTGFR,Prostaglandin F2-alpha receptor OS=Homo sapiens GN=PTGFR PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1095,"latanoprost + timolol,Xalcom, Xalacom",timolol,for treatment of glaucoma,Small Molecule,approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1095,"latanoprost + timolol,Xalcom, Xalacom",timolol,for treatment of glaucoma,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1096,"latanoprost, (sustained release, Punctal Plug delivery system)",latanoprost,for treatment of glaucoma,Small Molecule,approved,P43088,PF2R_HUMAN,PTGFR,Prostaglandin F2-alpha receptor OS=Homo sapiens GN=PTGFR PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1097,"latanoprost,Xalatan Fixed Flow Device",latanoprost,for treatment of glaucoma,Small Molecule,approved,P43088,PF2R_HUMAN,PTGFR,Prostaglandin F2-alpha receptor OS=Homo sapiens GN=PTGFR PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1098,"LCP-AtorFen, atorvastatin + fenofibrate",atorvastatin,anticholesterolaemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
1098,"LCP-AtorFen, atorvastatin + fenofibrate",fenofibrate,anticholesterolaemic agent,Small Molecule,approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1099,LCP-Feno,fenofibrate,anticholesterolaemic agent,Small Molecule,approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1100,"LCP-Siro, sirolimus",sirolimus,immunosuppressant,Small Molecule,approved,P09038,FGF2_HUMAN,FGF2,Heparin-binding growth factor 2 OS=Homo sapiens GN=FGF2 PE=1 SV=2,Miscellaneous,Ligand;Growth factor,Established target
1100,"LCP-Siro, sirolimus",sirolimus,immunosuppressant,Small Molecule,approved,P62942,FKB1A_HUMAN,FKBP1A,Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Homo sapiens GN=FKBP1A PE=1 SV=2,Enzymes,EC:5.2.1.8,Established target
1100,"LCP-Siro, sirolimus",sirolimus,immunosuppressant,Small Molecule,approved,P42345,FRAP_HUMAN,FRAP1,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1101,LDE225,Erismodegib,antineoplastic agent,Small molecule,not approved,Q99835,SMO_HUMAN,SMO,Smoothened homolog (SMO) (Protein Gx),Receptors,GPCR;Frizzled,Novel Target
1102,LEE011,LEE011,antineoplastic agent,Small molecule,not approved,P11802,CDK4_HUMAN,CDK4,Cyclin-dependent kinase 4 (EC 2.7.11.22) (Cell division protein kinase 4) (PSK-J3),Enzymes,EC:2.7.11.22,Novel Target
1102,LEE011,LEE011,antineoplastic agent,Small molecule,not approved,Q00534,CDK6_HUMAN,CDK6,Cyclin-dependent kinase 6 (EC 2.7.11.22) (Cell division protein kinase 6) (Serine/threonine-protein kinase PLSTIRE),Enzymes,EC:2.7.11.22,Novel Target
1103,"lepirudin (rDNA) for injection,Refludan",lepirudin,antithrombotic,recombinant protein,approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
1104,LErafAON,c-raf antisense oligonucleotide,antineoplastic agent,antisense oligo,not approved,P04049,RAF1_HUMAN,RAF1,RAF proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=RAF1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1105,"lercanidipine ,Lastolic, Zanidip",lercanidipine,antihypertensive agent,Small Molecule,approved,Q06432,CCG1_HUMAN,CACNG1,Voltage-dependent calcium channel gamma-1 subunit OS=Homo sapiens GN=CACNG1 PE=2 SV=1,Transporters,TC:8.A.16.1.1,Established target
1106,"lerdelimumab, CAT-152,Trabio",lerdelimumab,"opthalmological agent,for treatment of glaucoma",monoclonal antibody,not approved,P61812,TGFB2_HUMAN,TGFB2,Transforming growth factor beta-2 (TGF-beta-2) (BSC-1 cell growth inhibitor) (Cetermin) (Glioblastoma-derived T-cell suppressor factor) (G-TSF) (Polyergin),Miscellaneous,Transforming growth factor,Novel Target
1107,LE-SN38,LE-SN38,antineoplastic agent,Small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
1107,LE-SN38,LE-SN38,antineoplastic agent,Small molecule,not approved,Q969P6,TOP1M_HUMAN,TOP1MT,"DNA topoisomerase I, mitochondrial OS=Homo sapiens GN=TOP1MT PE=1 SV=1",Enzymes,EC:5.99.1.2,Established target
1108,"lesogaberan, AZD-3355",lesogaberan,for treatment of gastrointestinal reflux disease,Small molecule,not approved,Q9UBS5,GABR1_HUMAN,GABBR1,Gamma-aminobutyric acid type B receptor subunit 1 OS=Homo sapiens GN=GABBR1 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
1108,"lesogaberan, AZD-3355",lesogaberan,for treatment of gastrointestinal reflux disease,Small molecule,not approved,O75899,GABR2_HUMAN,GABBR2,Gamma-aminobutyric acid type B receptor subunit 2 OS=Homo sapiens GN=GABBR2 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
1109,"lestaurtinib , CEP-701",lestaurtinib,antineoplastic agent,Small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1109,"lestaurtinib , CEP-701",lestaurtinib,antineoplastic agent,Small molecule,not approved,P04629,NTRK1_HUMAN,NTRK1,High affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinase receptor type 1) (TRK1-transforming tyrosine kinase protein) (p140-TrkA) (Trk-A),Receptors,EC:2.7.10.1,Established target
1109,"lestaurtinib , CEP-701",lestaurtinib,antineoplastic agent,Small molecule,not approved,Q16620,NTRK2_HUMAN,NTRK2,BDNF/NT-3 growth factors receptor (EC 2.7.10.1) (GP145-TrkB) (Trk-B) (Neurotrophic tyrosine kinase receptor type 2) (TrkB tyrosine kinase),Receptors,EC:2.7.10.1,Novel Target
1109,"lestaurtinib , CEP-701",lestaurtinib,antineoplastic agent,Small molecule,not approved,Q16288,NTRK3_HUMAN,NTRK3,NT-3 growth factor receptor,Receptors,EC:2.7.10.1,Novel Target
1110,"lestaurtinib, CEP-701",lestaurtinib,antineoplastic agent,Small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
1111,Letairis,ambrisentan,antihypertensive agent,Small molecule,approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1111,Letairis,ambrisentan,antihypertensive agent,Small molecule,approved,P24530,EDNRB_HUMAN,EDNRB,Endothelin B receptor OS=Homo sapiens GN=EDNRB PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1112,"letrozole ,Femara",letrozole,antineoplastic agent,Small Molecule,approved,P11511,CP19A_HUMAN,CYP19A1,Cytochrome P450 19A1 OS=Homo sapiens GN=CYP19A1 PE=1 SV=3,Enzymes,EC:1.14.14,Established target
1113,leuprolide,leuprolide,"antineoplastic agent,for treatment of endometriosis",peptide,approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1114,"Leuprolide acetate, TAP-144 SR",leuprolide,"antineoplastic agent,for treatment of endometriosis",peptide,approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1115,LeuProMaxx,leuprolide,"antineoplastic agent,for treatment of endometriosis",peptide,approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1116,Levalbuterol,salbutamol,bronchodilator,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1117,"levetiracetam ,Keppra, Keppra XR",levetiracetam,anticonvulsant,Small Molecule,approved,Q00975,CAC1B_HUMAN,CACNA1B,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:1.A.1.11,Established target
1117,"levetiracetam ,Keppra, Keppra XR",levetiracetam,anticonvulsant,Small Molecule,approved,Q7L0J3,SV2A_HUMAN,SV2A,Synaptic vesicle glycoprotein 2A,Transporters,TC:2.A.1,Established target
1118,"levocetirizine dihydrochloride,Xusal, Xyzal",levocetirizine,antiallergy agent,Small molecule,not approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1119,"levodopa + carbidopa,Duodopa",levodopa,antiparkinson agent,Small Molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1119,"levodopa + carbidopa,Duodopa",levodopa,antiparkinson agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1119,"levodopa + carbidopa,Duodopa",levodopa,antiparkinson agent,Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1119,"levodopa + carbidopa,Duodopa",levodopa,antiparkinson agent,Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1119,"levodopa + carbidopa,Duodopa",levodopa,antiparkinson agent,Small Molecule,approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1122,"levomilnacipran, F2695",levomilnacipran,antidepressant,Small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1122,"levomilnacipran, F2695",levomilnacipran,antidepressant,Small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1123,"levonorgestrel/ethinyl estradiol,Alesse",ethinyl estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1123,"levonorgestrel/ethinyl estradiol,Alesse",levonorgestrel,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1123,"levonorgestrel/ethinyl estradiol,Alesse",levonorgestrel,contraceptive,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
1123,"levonorgestrel/ethinyl estradiol,Alesse",levonorgestrel,contraceptive,Small Molecule,approved,P18405,S5A1_HUMAN,SRD5A1,3-oxo-5-alpha-steroid 4-dehydrogenase 1 OS=Homo sapiens GN=SRD5A1 PE=1 SV=1,Enzymes,EC:1.3.99,Established target
1124,Levosimendan,Levosimendan,for treatment of heart failure,Small Molecule,approved,Q14654,IRK11_HUMAN,KCNJ11,ATP-sensitive inward rectifier potassium channel 11 OS=Homo sapiens GN=KCNJ11 PE=1 SV=2,Transporters,TC:1.A.2.1,Established target
1124,Levosimendan,Levosimendan,for treatment of heart failure,Small Molecule,approved,P63316,TNNC1_HUMAN,TNNC1,"Troponin C, slow skeletal and cardiac muscles OS=Homo sapiens GN=TNNC1 PE=1 SV=1",Miscellaneous,Enzyme regulator,Established target
1125,"levothyroxine sodium,Unithroid",levothyroxine,hormone replacement,Small Molecule,approved,P10827,THA_HUMAN,THRA,Thyroid hormone receptor alpha OS=Homo sapiens GN=THRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
1125,"levothyroxine sodium,Unithroid",levothyroxine,hormone replacement,Small Molecule,approved,P10828,THB_HUMAN,THRB,Thyroid hormone receptor beta OS=Homo sapiens GN=THRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1126,"levothyroxine,Levoxyl",levothyroxine,hormone replacement,Small Molecule,approved,P10827,THA_HUMAN,THRA,Thyroid hormone receptor alpha OS=Homo sapiens GN=THRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
1126,"levothyroxine,Levoxyl",levothyroxine,hormone replacement,Small Molecule,approved,P10828,THB_HUMAN,THRB,Thyroid hormone receptor beta OS=Homo sapiens GN=THRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1127,"lexatumumab, HGS-ETR2, TRAIL-R2",lexatumumab,antineoplastic agent,monoclonal antibody,not approved,O14763,TR10B_HUMAN,TNFRSF10B,Tumor necrosis factor receptor superfamily member 10B (Death receptor 5) (TNF-related apoptosis-inducing ligand receptor 2) (TRAIL receptor 2) (TRAIL-R2) (CD antigen CD262),Receptors,Receptors;TNFNGF,Novel Target
1128,LFB-R603,LFB-R603,antineoplastic agent,fusion protein,not approved,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Miscellaneous,MS4A family,Established target
1129,LGD-1550,LGD-1550,antineoplastic agent,Small molecule,not approved,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1129,LGD-1550,LGD-1550,antineoplastic agent,Small molecule,not approved,P10826,RARB_HUMAN,RARB,Retinoic acid receptor beta OS=Homo sapiens GN=RARB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1129,LGD-1550,LGD-1550,antineoplastic agent,Small molecule,not approved,P13631,RARG_HUMAN,RARG,Retinoic acid receptor gamma OS=Homo sapiens GN=RARG PE=1 SV=1,Receptors,Nuclear receptor,Established target
1130,LGD-2941,LGD-2941,antiosteoporotic agent,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1131,LGD-4033,LGD-4033,hormone replacement,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1132,LGD-4665,LGD-4665,thrombopoietic agent,Small molecule,not approved,P40238,TPOR_HUMAN,MPL,Thrombopoietin receptor (TPO-R) (Myeloproliferative leukemia protein) (Proto-oncogene c-Mpl) (CD antigen CD110),Receptors,Receptor; Type 1 cytokine receptor,Established target
1133,Liarozole,Liarozole,"dermatological agent,for treatment of ichtyosis",Small molecule,not approved,O43174,CP26A_HUMAN,CYP26A1,Cytochrome P450 26A1 (EC 1.14.-.-) (Cytochrome P450 retinoic acid-inactivating 1) (Cytochrome P450RAI) (hP450RAI) (Retinoic acid 4-hydroxylase) (Retinoic acid-metabolizing cytochrome),Enzymes,EC:1.14.-.-,Novel Target
1134,"licarbazepine , LIC-477",licarbazepine,for treatment of bipolar disorder,Small molecule,not approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1135,"licofelone, ML3000",licofelone,antiinflammatory agent,Small molecule,not approved,P09917,LOX5_HUMAN,ALOX5,Arachidonate 5-lipoxygenase OS=Homo sapiens GN=ALOX5 PE=1 SV=2,Enzymes,EC:1.13.11.34,Established target
1135,"licofelone, ML3000",licofelone,antiinflammatory agent,Small molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1136,"lidocaine hydrochloride, piroxicam,  AK1015, Akten",lidocaine,anestethic,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
1137,"lidocaine hydrochloride, piroxicam,  AK1015,Akten",lidocaine,anestethic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
1137,"lidocaine hydrochloride, piroxicam,  AK1015,Akten",lidocaine,anestethic,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1137,"lidocaine hydrochloride, piroxicam,  AK1015,Akten",piroxicam,"antiinflammatory agent,NSAID",Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1138,"lidocaine patch,Lidoderm, Versatis",lidocaine,anestethic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
1138,"lidocaine patch,Lidoderm, Versatis",lidocaine,anestethic,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1138,"lidocaine patch,Lidoderm, Versatis",lidocaine,anestethic,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
1139,"lidocaine patch,LidoPain SP",lidocaine,anestethic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
1139,"lidocaine patch,LidoPain SP",lidocaine,anestethic,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1139,"lidocaine patch,LidoPain SP",lidocaine,anestethic,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
1140,lidocaine vaginal gel,lidocaine,anestethic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
1140,lidocaine vaginal gel,lidocaine,anestethic,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1140,lidocaine vaginal gel,lidocaine,anestethic,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
1141,LIM-0705,LIM-0705,for improving pharmacokinetics of tacrolimus,Small molecule,not approved,Q8WWZ7,ABCA5_HUMAN,ABCA5,ATP-binding cassette sub-family A member 5,transporter,TC:3.A.1.211.9,Novel Target
1141,LIM-0705,LIM-0705,for improving pharmacokinetics of tacrolimus,Small molecule,not approved,P08183,MDR1_HUMAN,ABCB1,Multidrug resistance protein 1 OS=Homo sapiens GN=ABCB1 PE=1 SV=3,Transporters,TC:3.A.1.201.1,Novel Target
1142,Linaclotide,Linaclotide,"motilitant,for treatment of irritable bowel syndrome",peptide,not approved,P25092,GUC2C_HUMAN,GUCY2C,Heat-stable enterotoxin receptor (STA receptor) (hSTAR) (EC 4.6.1.2) (Guanylyl cyclase C) (GC-C) (Intestinal guanylate cyclase),Receptors,EC:4.6.1.2,Novel Target
1143,Linaglipton,Linaglipton,antidiabetic,Small molecule,not approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
1144,Linjeta,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1145,"lintuzumab, SGN-33",lintuzumab,antineoplastic agent,monoclonal antibody,not approved,P20138,CD33_HUMAN,CD33,Myeloid cell surface antigen CD33 OS=Homo sapiens GN=CD33 PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
1146,"LIPO-102, salmeterol xinafoate + fluticasone propionate",fluticasone propionate,for treatment of symptomatic exophthalmos associated with thyroid-related eye disease,Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1146,"LIPO-102, salmeterol xinafoate + fluticasone propionate",salbutamol,for treatment of symptomatic exophthalmos associated with thyroid-related eye disease,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1147,liposomal encapsulated docetaxel (LE-DT),docetaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1147,liposomal encapsulated docetaxel (LE-DT),docetaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1148,liposomal encapsulated doxorubicin (LED),doxorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
1149,liposomal encapsulated paclitaxel (LEP),paclitaxel,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
1150,"Liposomal lurtotecan, OSI-211",lurtotecan,antineoplastic agent,Small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
1151,liposome encapsulated mitoxantrone  (LEM),mitoxantrone,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
1152,"liposome encapsulated prednisolone,Nanocort",prednisolone,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1153,"Lipotecan , TLC388 HCl for Injection",Lipotecan,antineoplastic agent,Small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
1154,Liraglutide,Liraglutide,antidiabetic,protein,approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1155,"lisinopril ,Zestril, Prinivil",lisinopril,antihypertensive agent,Small Molecule,approved,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
1156,Lisofylline,Lisofylline,antidiabetic,Small molecule,not approved,Q14765,STAT4_HUMAN,STAT4,Signal transducer and activator of transcription 4,Miscellaneous,Miscellaneous;activator of transcription,Novel Target
1157,lixivaptan,lixivaptan,for treatment of hyponatremia,Small molecule,not approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1158,Lobeline,Lobeline,for treatment of metamphetamine addicton,Small molecule,not approved,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
1159,"lofexidine,BritLofex",lofexidine,for treatment of opiate withdrawal,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1159,"lofexidine,BritLofex",lofexidine,for treatment of opiate withdrawal,Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1159,"lofexidine,BritLofex",lofexidine,for treatment of opiate withdrawal,Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1160,"lomitapide , AEGR-733, BMS-201038",lomitapide,anticholesterolaemic agent,Small molecule,not approved,P55157,MTP_HUMAN,MTTP,Microsomal triglyceride transfer protein large subunit,Transporters,Miscellaneous;Lipid_transp,Novel Target
1161,LOR-2040,LOR-2040,antineoplastic agent,antisense oligo,not approved,P31350,RIR2_HUMAN,RRM2,Ribonucleoside-diphosphate reductase subunit M2 (EC 1.17.4.1) (Ribonucleotide reductase small chain) (Ribonucleotide reductase small subunit),Enzymes,EC:1.17.4.1,Novel Target
1161,LOR-2040,LOR-2040,antineoplastic agent,antisense oligo,not approved,Q7LG56,RIR2B_HUMAN,RRM2B,Ribonucleoside-diphosphate reductase subunit M2 B (EC 1.17.4.1) (TP53-inducible ribonucleotide reductase M2 B) (p53-inducible ribonucleotide reductase small subunit 2-like protein) (p53R2),Enzymes,EC:1.17.4.1,Novel Target
1162,LOR-253,LOR-253,antineoplastic agent,Small molecule,not approved,Q14872,MTF1_HUMAN,MTF1,Metal regulatory transcription factor 1 (MRE-binding transcription factor) (Transcription factor MTF-1),Miscellaneous,Transcription factor,Novel Target
1163,"loratadine + montelukast sodium,Claritin + Singulair",loratadine,antiasthmatic agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1163,"loratadine + montelukast sodium,Claritin + Singulair",montelukast,antiasthmatic agent,Small Molecule,approved,Q9Y271,CLTR1_HUMAN,CYSLTR1,Cysteinyl leukotriene receptor 1 OS=Homo sapiens GN=CYSLTR1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1164,Lorcaserin,Lorcaserin,antiobesity agent,Small molecule,not approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1165,Lorvotuzumab,Lorvotuzumab,antineoplastic agent,monoclonal antibody,not approved,P13591,NCAM1_HUMAN,NCAM1,Neural cell adhesion molecule 1 (N-CAM-1) (NCAM-1) (CD antigen CD56),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Novel Target
1166,"loteprednol etabonate,Lotemax, Alrex",loteprednol etabonate,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,P21397,AOFA_HUMAN,MAOA,Amine oxidase [flavin-containing] A OS=Homo sapiens GN=MAOA PE=1 SV=1,Enzymes,EC:1.4.3.4,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,P27338,AOFB_HUMAN,MAOB,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,P54219,VMAT1_HUMAN,SLC18A1,Chromaffin granule amine transporter (Solute carrier family 18 member 1) (Vesicular amine transporter 1) (VAT1),Transporters,TC:2.A.1.2.12,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1167,low dose intravenous methamphetamine,methamphetamine,neuroprotectant,Small Molecule,approved,Q96RJ0,TAAR1_HUMAN,TAAR1,Trace amine-associated receptor 1 (TaR-1) (Trace amine receptor 1),Receptors,GPCR;Rhodopsin,Established target
1168,"lovastatin,Mevacor, Altocor, Altoprev",lovastatin,anticholesterolaemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
1169,Lovenox,enoxaparin,anticoagulant,Small Molecule,approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
1170,Lu 02-750,Lu 02-750,antiparkinson agent,unknown,not approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1170,Lu 02-750,Lu 02-750,antiparkinson agent,unknown,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1170,Lu 02-750,Lu 02-750,antiparkinson agent,unknown,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1170,Lu 02-750,Lu 02-750,antiparkinson agent,unknown,not approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1170,Lu 02-750,Lu 02-750,antiparkinson agent,unknown,not approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1171,Lu AA21004,vortioxetine,antidepressant,small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1171,Lu AA21004,vortioxetine,antidepressant,small molecule,not approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1171,Lu AA21004,vortioxetine,antidepressant,small molecule,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1171,Lu AA21004,vortioxetine,antidepressant,small molecule,not approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1171,Lu AA21004,vortioxetine,antidepressant,small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1172,Lu AA24493,Lu AA24493,neuroprotectant,protein,not approved,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1173,Lu AA24530,Tedatioxetine,antidepressant,small molecule,not approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1173,Lu AA24530,Tedatioxetine,antidepressant,small molecule,not approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1173,Lu AA24530,Tedatioxetine,antidepressant,small molecule,not approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1173,Lu AA24530,Tedatioxetine,antidepressant,small molecule,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1173,Lu AA24530,Tedatioxetine,antidepressant,small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1173,Lu AA24530,Tedatioxetine,antidepressant,small molecule,not approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1173,Lu AA24530,Tedatioxetine,antidepressant,small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1175,Lu AE04621,Lu AE04621,antiparkinson agent,unknown,not approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1175,Lu AE04621,Lu AE04621,antiparkinson agent,unknown,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1175,Lu AE04621,Lu AE04621,antiparkinson agent,unknown,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1175,Lu AE04621,Lu AE04621,antiparkinson agent,unknown,not approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1175,Lu AE04621,Lu AE04621,antiparkinson agent,unknown,not approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1176,LU-31130,zicronapine,antipsychotic agent,small molecule,not approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1177,"Lu-AE58054 , LY-483518, SGS518",Lu-AE58054,antipsychotic agent,Small molecule,not approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1178,Lubiprostone,Lubiprostone,"motilitant,for treatment of irritable bowel disorder",Small Molecule,approved,P51788,CLCN2_HUMAN,CLCN2,Chloride channel protein 2 OS=Homo sapiens GN=CLCN2 PE=1 SV=1,Transporters,TC:2.A.49,Established target
1179,"lucatumumab , HCD122, CHIR-12.12",lucatumumab ,antineoplastic agent,monoclonal antibody,not approved,P25942,TNR5_HUMAN,CD40,Tumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40) (Bp50) (CD40L receptor) (CDw40) (CD antigen CD40),Receptors,Receptors;TNFNGF,Novel Target
1180,Lucentis,ranibizumab,for treatment of age-related macular degeneration,antibody fragment,approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
1181,"lumiliximab , IDEC-152",lumiliximab,"antineoplastic agent,antiinflammatory agent",monoclonal antibody,not approved,P06734,FCER2_HUMAN,FCER2,Low affinity immunoglobulin epsilon Fc receptor (BLAST-2) (C-type lectin domain family 4 member J) (Fc-epsilon-RII) (Immunoglobulin E-binding factor) (Lymphocyte IgE receptor) (CD antigen CD23) [Cleaved into: Low affinity immunoglobulin epsilon Fc recepto,Receptors,Receptor;immunoglobulin,Novel Target
1182,"lumiracoxib, COX 189,Prexige",lumiracoxib,NSAID,Small Molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1183,Lunesta,eszopiclone,hypnotic,Small molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
1183,Lunesta,eszopiclone,hypnotic,Small molecule,approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
1183,Lunesta,eszopiclone,hypnotic,Small molecule,approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1183,Lunesta,eszopiclone,hypnotic,Small molecule,approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1183,Lunesta,eszopiclone,hypnotic,Small molecule,approved,P30536,TSPOA_HUMAN,TSPO,Translocator protein (Mitochondrial benzodiazepine receptor) (PKBS) (Peripheral-type benzodiazepine receptor) (PBR),Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
1184,"lurasidone, SM-13496,Latuda",lurasidone,antipsychotic agent,Small molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1184,"lurasidone, SM-13496,Latuda",lurasidone,antipsychotic agent,Small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1184,"lurasidone, SM-13496,Latuda",lurasidone,antipsychotic agent,Small molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1184,"lurasidone, SM-13496,Latuda",lurasidone,antipsychotic agent,Small molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1184,"lurasidone, SM-13496,Latuda",lurasidone,antipsychotic agent,Small molecule,approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1185,LX1031,LX1031,for treatment of irritable bowel syndrome,Small molecule,not approved,P17752,TPH1_HUMAN,TPH1,Tryptophan 5-hydroxylase 1 OS=Homo sapiens GN=TPH1 PE=1 SV=4,Enzymes,EC:1.14.16.4,Established target
1186,LX1032,LX1032,for treatment of carcinoid syndrome,Small molecule,not approved,P17752,TPH1_HUMAN,TPH1,Tryptophan 5-hydroxylase 1 OS=Homo sapiens GN=TPH1 PE=1 SV=4,Enzymes,EC:1.14.16.4,Established target
1187,"LX201, cyclosporine A implant,Lumitect",cyclosporine A,"immunosuppressant,opthalmological agent",Small molecule,approved,P49069,CAMLG_HUMAN,CAMLG,Calcium signal-modulating cyclophilin ligand (CAML),Miscellaneous,Miscellaneous:target for cyclosporine,Established target
1187,"LX201, cyclosporine A implant,Lumitect",cyclosporine A,"immunosuppressant,opthalmological agent",Small molecule,approved,Q96LZ3,CANB2_HUMAN,PPP3R2,Calcineurin subunit B type 2 OS=Homo sapiens GN=PPP3R2 PE=2 SV=3,Miscellaneous,Enzyme regulator,Established target
1188,LX4211,LX4211,antidiabetic,Small molecule,not approved,P13866 ,SC5A1_HUMAN,SLC5A1,Sodium/glucose cotransporter 1,Transporters,TC:2.A.21.3.16,Novel Target
1188,LX4211,LX4211,antidiabetic,Small molecule,not approved,P31639,SC5A2_HUMAN,SLC5A2,Sodium/glucose cotransporter 2 (Na(+)/glucose cotransporter 2) (Low affinity sodium-glucose cotransporter) (Solute carrier family 5 member 2),Transporters,TC:2.A.21.3.16,Established target
1189,LY2127399,LY2127399,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,Q9Y275,TN13B_HUMAN,TNFSF13B,Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved int,Miscellaneous,Ligand;Cytokine,Established target
1190,LY2140023,LY2140023,antipsychotic agent,Small molecule,not approved,Q14416,GRM2_HUMAN,GRM2,Metabotropic glutamate receptor 2 (mGluR2),Receptors,GPCR;Glutamate,Novel Target
1190,LY2140023,LY2140023,antipsychotic agent,Small molecule,not approved,Q14832,GRM3_HUMAN,GRM3,Metabotropic glutamate receptor 3 (mGluR3),Receptors,GPCR;Glutamate,Novel Target
1191,LY2181308,LY2181308,antineoplastic agent,antisense oligo,not approved,O15392,BIRC5_HUMAN,BIRC5,Baculoviral IAP repeat-containing protein 5 (Apoptosis inhibitor 4) (Apoptosis inhibitor survivin),Miscellaneous,Inhibitor of apoptosis,Novel Target
1192,LY-2189265,LY-2189265,antidiabetic,peptide,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1193,LY-2216684,LY-2216684,"antidepressant,for treatment of ADHD",unknown,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1194,LY2275796,LY2275796,antineoplastic agent,antisense oligo,not approved,P06730,IF4E_HUMAN,EIF4E,Eukaryotic translation initiation factor 4E (eIF-4E) (eIF4E) (eIF-4F 25 kDa subunit) (mRNA cap-binding protein),Miscellaneous,TIF_eIF4e,Novel Target
1195,"LY-2599506, PSN-010",LY-2599506,antidiabetic,unknown,not approved,P35557,HXK4_HUMAN,GCK,Glucokinase (EC 2.7.1.2) (Hexokinase type IV) (HK IV) (Hexokinase-4) (HK4) (Hexokinase-D),Enzymes,EC:2.7.1.2,Novel Target
1196,"LY3009104, INCB28050",LY3009104,"antiinflammatory agent,DMARD",Small molecule,not approved,P23458,JAK1_HUMAN,JAK1,Tyrosine-protein kinase JAK1 (EC 2.7.10.2) (Janus kinase 1) (JAK-1),Enzymes,EC:2.7.10.2,Novel Target
1196,"LY3009104, INCB28050",LY3009104,"antiinflammatory agent,DMARD",Small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
1197,LY-450139,semagacestat,for treatment of Alzheimer's disease,small molecule,not approved,P46976,PSN1_HUMAN,PSEN1,Presenilin-1,Enzymes,EC:3.4.23.-,Novel Target
1197,LY-450139,semagacestat,for treatment of Alzheimer's disease,small molecule,not approved,P49810,PSN2_HUMAN,PSEN2,Presenilin-2,Enzymes,EC:3.4.23.-,Novel Target
1198,LY-517717,LY-517717,anticoagulant,Small molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1199,"LY519818 , LY818",naveglitazar ,antidiabetic,Small molecule,not approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1199,"LY519818 , LY818",naveglitazar ,antidiabetic,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1200,LY-674,LY-674,anticholesterolaemic agent,Small molecule,not approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1201,LymphoCide,epratuzumab,antineoplastic agent,monoclonal antibody,not approved,P20273,CD22_HUMAN,CD22,B-cell receptor CD22 OS=Homo sapiens GN=CD22 PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
1202,LymphoRad,LymphoRad,antineoplastic agent,protein,not approved,O14836,TR13B_HUMAN,TNFRSF13B,Tumor necrosis factor receptor superfamily member 13B,,Receptors;TNFNGF,Novel Target
1202,LymphoRad,LymphoRad,antineoplastic agent,protein,not approved,Q96RJ3,TR13C_HUMAN,TNFRSF13C,Tumor necrosis factor receptor superfamily member 13C,Receptors,Miscellaneous;TNFR,Novel Target
1202,LymphoRad,LymphoRad,antineoplastic agent,protein,not approved,Q02223,TNR17_HUMAN,TNFRSF17,Tumor necrosis factor receptor superfamily member 17,Miscellaneous,Miscellaneous;TNF,Novel Target
1204,M0002,M0002,for treatemnt of ascites,Small molecule,not approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1205,M118 ,heparin,anticoagulant,Small Molecule,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1205,M118 ,heparin,anticoagulant,Small Molecule,approved,Q9Y251,HPSE_HUMAN,HPSE,Heparanase (EC 3.2.-.-) (Endo-glucoronidase) (Heparanase-1) (Hpa1) [Cleaved into: Heparanase 8 kDa subunit; Heparanase 50 kDa subunit],Enzymes,EC:3.2.-.-,Established target
1205,M118 ,heparin,anticoagulant,Small Molecule,approved,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Miscellaneous,Enzyme regulator,Established target
1207,"M6G, CEE 04-410",morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1207,"M6G, CEE 04-410",morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1207,"M6G, CEE 04-410",morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1208,MABT5102A,MABT5102A,for treatment of Alzheimer's disease,monoclonal antibody,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
1209,"macitentan , ACT-064992",macitentan,cardiovascular agent,Small molecule,not approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1210,"macitentan, ACT-064992",macitentan,cardiovascular agent,Small molecule,not approved,P24530,EDNRB_HUMAN,EDNRB,Endothelin B receptor OS=Homo sapiens GN=EDNRB PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1211,Macugen,pegaptanib,for treatment of age-related macular degeneration,aptamer,approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
1212,"MAGE-A3 ASCI, SB-249553, antigen specific cancer immunMiscellaneousap/",MAGE-A3,antineoplastic agent,vaccine,not approved,P43357,MAGA3_HUMAN,MAGEA3,Melanoma-associated antigen 3 (Antigen MZ2-D) (Cancer/testis antigen 1.3) (CT1.3) (MAGE-3 antigen),Miscellaneous,Troponin,Novel Target
1214,"MAP-0004, TEMPO Migraine,Levadex",dihydroergotamine,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1214,"MAP-0004, TEMPO Migraine,Levadex",dihydroergotamine,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1215,MAP-0005,budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1215,MAP-0005,formoterol,bronchodilator,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1216,"MAP-0010, Unit Dose Budesonide",budesonide,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1217,MAR701,MAR701,antidiabetic,peptide,not approved,P48546,GIPR_HUMAN,GIPR,Gastric inhibitory polypeptide receptor (GIP-R) (Glucose-dependent insulinotropic polypeptide receptor),Receptors,GPCR;Secretin,Novel Target
1217,MAR701,MAR701,antidiabetic,peptide,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1218,"masitinib, AB1010",masitinib,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P00519,ABL1_HUMAN,ABL1,Proto-oncogene tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4,Enzymes,EC:2.7.10.2,Established target
1218,"masitinib, AB1010",masitinib,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P07333,CSF1R_HUMAN,CSF1R,Macrophage colony-stimulating factor 1 receptor OS=Homo sapiens GN=CSF1R PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1218,"masitinib, AB1010",masitinib,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P08631,HCK_HUMAN,HCK,Tyrosine-protein kinase HCK,Enzymes,EC:2.7.10.2,Novel Target
1218,"masitinib, AB1010",masitinib,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1218,"masitinib, AB1010",masitinib,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P07948,LYN_HUMAN,LYN,Tyrosine-protein kinase Lyn,Enzymes,EC:2.7.10.2,Novel Target
1218,"masitinib, AB1010",masitinib,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1218,"masitinib, AB1010",masitinib,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1218,"masitinib, AB1010",masitinib,"antiinflammatory agent,DMARD,antineoplastic agent",Small molecule,not approved,P12931,SRC_HUMAN,SRC,Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
1219,MAX-002,mesalazine,for treatment of ulcerative proctitis,Small Molecule,approved,P09917,LOX5_HUMAN,ALOX5,Arachidonate 5-lipoxygenase OS=Homo sapiens GN=ALOX5 PE=1 SV=2,Enzymes,EC:1.13.11.34,Established target
1219,MAX-002,mesalazine,for treatment of ulcerative proctitis,Small Molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1219,MAX-002,mesalazine,for treatment of ulcerative proctitis,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1219,MAX-002,mesalazine,for treatment of ulcerative proctitis,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1220,Max-AD Factor VIII,Max-AD Factor VIII,for treatment of hemophilia A,adenoviral vector,not approved,P00451,FA8_HUMAN,F8,Coagulation factor VIII OS=Homo sapiens GN=F8 PE=1 SV=1,Miscellaneous,Enzyme cofactor,Established target
1221,Maxy-G34,Maxy-G34,for treatment of chemotherapy-induced neutropenia,protein,not approved,Q99062,CSF3R_HUMAN,CSF3R,Granulocyte colony-stimulating factor receptor OS=Homo sapiens GN=CSF3R PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1222,MB07803,MB07803,antidiabetic,unknown,not approved,P09467,F16P1_HUMAN,FBP1,"Fructose-1,6-bisphosphatase 1 (FBPase 1) (EC 3.1.3.11) (D-fructose-1,6-bisphosphate 1-phosphohydrolase 1)",Enzymes,EC:3.1.3.11,Novel Target
1222,MB07803,MB07803,antidiabetic,unknown,not approved,O00757 ,F16P2_HUMAN,FBP2,"Fructose-1,6-bisphosphatase isozyme 2",Enzymes,EC:3.1.3.11,Novel Target
1223,MB07811 ,MB07811 ,antidyslipidaemic agent,Small molecule,not approved,P10828,THB_HUMAN,THRB,Thyroid hormone receptor beta OS=Homo sapiens GN=THRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1224,MBX-2044,MBX-2044,antidiabetic,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1225,MBX-2982,MBX-2982,antidiabetic,Small molecule,not approved,Q8TDV5,GP119_HUMAN,GPR119,Glucose-dependent insulinotropic receptor (G-protein coupled receptor 119),Receptors,GPCR;Rhodopsin,Novel Target
1226,MBX-8025,MBX-8025,antidyslipidaemic agent,Small molecule,not approved,Q03181,PPARD_HUMAN,PPARD,Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta),Receptors,Nuclear receptor,Established target
1227,MC-4232,lisinopril,antihypertensive agent,Small Molecule,approved,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
1227,MC-4232,lisinopril,antihypertensive agent,Small Molecule,approved,Q9BYF1,ACE2_HUMAN,ACE2,Angiotensin-converting enzyme 2 (EC 3.4.17.23) (ACE-related carboxypeptidase) (Angiotensin-converting enzyme homolog) (ACEH) (Metalloprotease MPROT15) [Cleaved into: Processed angiotensin-converting enzyme 2],Enzymes,EC:3.4.17.23,Established target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,Q99677,LPAR4_HUMAN,LPAR4,Lysophosphatidic acid receptor 4,Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,P43657,LPAR6_HUMAN,LPAR6,Lysophosphatidic acid receptor 6,Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,P47900,P2RY1_HUMAN,P2RY1,P2Y purinoceptor 1,Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,O00398,P2Y10_HUMAN,P2RY10,Putative P2Y purinoceptor 10,Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,Q96G91,P2Y11_HUMAN,P2RY11,P2Y purinoceptor 11,Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,Q9BPV8,P2Y13_HUMAN,P2RY13,P2Y purinoceptor 13,Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,Q15391,P2Y14_HUMAN,P2RY14,P2Y purinoceptor 14,Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,P41231,P2RY2_HUMAN,P2RY2,P2Y purinoceptor 2 (P2Y2) (ATP receptor) (P2U purinoceptor 1) (P2U1) (Purinergic receptor),Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,P51582,P2RY4_HUMAN,P2RY4,P2Y purinoceptor 4,Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,Q15077,P2RY6_HUMAN,P2RY6,P2Y purinoceptor 6,Receptors,GPCR;Rhodopsin,Novel Target
1227,MC-4232,MC-1,cardioprotectant,Small molecule,not approved,Q86VZ1,P2RY8_HUMAN,P2RY8,P2Y purinoceptor 8,Receptors,GPCR;Rhodopsin,Novel Target
1228,MCD-386,MCD-386,for treatment of Alzheimer's disease,Small molecule,not approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1229,MDAM (y-methylene-10-deazaaminopterin),MDAM,antineoplastic agent,Small molecule,not approved,P00374,DYR_HUMAN,DHFR,Dihydrofolate reductase OS=Homo sapiens GN=DHFR PE=1 SV=2,Enzymes,EC:1.5.1.3,Established target
1230,MDV3100,MDV3100,antineoplastic agent,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1231,MDX-060,MDX-060,antineoplastic agent,monoclonal antibody,not approved,P28908,TNR8_HUMAN,TNFRSF8,Tumor necrosis factor receptor superfamily member 8 (CD30L receptor) (Ki-1 antigen) (Lymphocyte activation antigen CD30) (CD antigen CD30),Receptors,Receptors;TNFNGF,Novel Target
1232,MDX-1100,MDX-1100,"antiinflammatory agent,DMARD,for treatment of ulcerative colitis",monoclonal antibody,not approved,P02778,CXL10_HUMAN,CXCL10,C-X-C motif chemokine 10 (10 kDa interferon gamma-induced protein) (Gamma-IP10) (IP-10) (Small-inducible cytokine B10) [Cleaved into: CXCL10(1-73)],Ligand,Ligand;Chemokine,Novel Target
1233,MDX-1203,MDX-1203,antineoplastic agent,fusion protein,not approved,P32970,CD70_HUMAN,CD70,CD70 antigen (CD27 ligand) (CD27-L) (Tumor necrosis factor ligand superfamily member 7) (CD antigen CD70),Miscellaneous,Ligand;Cytokine;TNFR,Novel Target
1234,MDX-1342,MDX-1342,antineoplastic agent,monoclonal antibody,not approved,P15391,CD19_HUMAN,CD19,B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigen CD19) (T-cell surface antigen Leu-12) (CD antigen CD19),Miscellaneous,Miscellaneous;CD19,Novel Target
1235,MDX-1401,MDX-1401,antineoplastic agent,monoclonal antibody,not approved,P28908,TNR8_HUMAN,TNFRSF8,Tumor necrosis factor receptor superfamily member 8 (CD30L receptor) (Ki-1 antigen) (Lymphocyte activation antigen CD30) (CD antigen CD30),Receptors,Receptors;TNFNGF,Novel Target
1236,MDX-1411,MDX-1411,antineoplastic agent,monoclonal antibody,not approved,P32970,CD70_HUMAN,CD70,CD70 antigen (CD27 ligand) (CD27-L) (Tumor necrosis factor ligand superfamily member 7) (CD antigen CD70),Miscellaneous,Ligand;Cytokine;TNFR,Novel Target
1237,MDX-214,MDX-214,antineoplastic agent,fusion protein,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1238,Mebendazole,Mebendazole,antineoplastic agent,Small molecule,approved,Q71U36,TBA1A_HUMAN,TUBA1A,Tubulin alpha-1A chain (Alpha-tubulin 3) (Tubulin B-alpha-1) (Tubulin alpha-3 chain),Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1238,Mebendazole,Mebendazole,antineoplastic agent,Small molecule,approved,P68371,TBB2C_HUMAN,TUBB2C,Tubulin beta-2C chain (Tubulin beta-2 chain),Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1239,"mecamylamine HCl , TC-5231",mecamylamine,for treatment of ADHD,Small Molecule,approved,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1240,"mecasermin, rhIGF-1,Increlex",mecasermin,hormone replacement,recombinant protein,approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1241,MEDI-528,MEDI-528,antiasthmatic agent,monoclonal antibody,not approved,P15248,IL9_HUMAN,IL9,Interleukin-9 (IL-9) (Cytokine P40) (T-cell growth factor P40),Miscellaneous,Ligand;Cytokine,Novel Target
1242,"MEDI-563, Anti-IL-5 Receptor Mab",benralizumab,antiasthmatic agent,monoclonal antibody,not approved,Q01344,IL5RA_HUMAN,IL5RA,Interleukin-5 receptor subunit alpha (IL-5 receptor subunit alpha) (IL-5R subunit alpha) (IL-5R-alpha) (IL-5RA) (CDw125) (CD antigen CD125),Receptors,Receptor; Type 1 cytokine receptor,Novel Target
1243,Medusa IL-2,interleukin 2,antineoplastic agent,protein,not approved,P01589,IL2RA_HUMAN,IL2RA,Interleukin-2 receptor alpha chain OS=Homo sapiens GN=IL2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1243,Medusa IL-2,interleukin 2,antineoplastic agent,protein,not approved,P14784,IL2RB_HUMAN,IL2RB,Interleukin-2 receptor subunit beta OS=Homo sapiens GN=IL2RB PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1243,Medusa IL-2,interleukin 2,antineoplastic agent,protein,not approved,P31785,IL2RG_HUMAN,IL2RG,Cytokine receptor common gamma chain OS=Homo sapiens GN=IL2RG PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1244,"melogliptin, GRC 8200",melogliptin,antidiabetic,Small molecule,not approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
1245,MEM 1003,MEM 1003,for treatment of Alzheimer's disease,Small molecule,not approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
1245,MEM 1003,MEM 1003,for treatment of Alzheimer's disease,Small molecule,not approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
1245,MEM 1003,MEM 1003,for treatment of Alzheimer's disease,Small molecule,not approved,O60840,CAC1F_HUMAN,CACNA1F,Voltage-dependent L-type calcium channel subunit alpha-1F OS=Homo sapiens GN=CACNA1F PE=1 SV=2,Transporters,TC:1.A.1.11.11,Established target
1245,MEM 1003,MEM 1003,for treatment of Alzheimer's disease,Small molecule,not approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
1246,MEM 1414,MEM 1414,for treatment of Alzheimer's disease,Small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
1246,MEM 1414,MEM 1414,for treatment of Alzheimer's disease,Small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
1247,"MEM 63908, R4996",MEM 63908,for treatment of Alzheimer's disease,Small molecule,not approved,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
1248,"MEM3454, R3487",MEM3454,for treatment of Alzheimer's disease,Small molecule,not approved,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
1249,memantine,memantine,for treatment of glaucoma,Small Molecule,approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
1249,memantine,memantine,for treatment of glaucoma,Small Molecule,approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
1249,memantine,memantine,for treatment of glaucoma,Small Molecule,approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
1250,Memryte,leuprolide,for treatment of Alzheimer's disease,peptide,approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1251,"mepolizumab, 240563,Bosatria",mepolizumab,"antiinflammatory agent,antiasthmatic agent",monoclonal antibody,not approved,P05113,IL5_HUMAN,IL5,Interleukin-5 (IL-5) (B-cell differentiation factor I) (Eosinophil differentiation factor) (T-cell replacing factor) (TRF),Miscellaneous,Ligand;Cytokine,Novel Target
1252,Merck,vorinostat,antineoplastic agent,Small Molecule,approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
1252,Merck,vorinostat,antineoplastic agent,Small Molecule,approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1252,Merck,vorinostat,antineoplastic agent,Small Molecule,approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1252,Merck,vorinostat,antineoplastic agent,Small Molecule,approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1254,"mesalamine,Pentasa, Canasa, Asacol",mesalamine,antiinflammatory agent,Small molecule,approved,P09917,LOX5_HUMAN,ALOX5,Arachidonate 5-lipoxygenase OS=Homo sapiens GN=ALOX5 PE=1 SV=2,Enzymes,EC:1.13.11.34,Established target
1254,"mesalamine,Pentasa, Canasa, Asacol",mesalamine,antiinflammatory agent,Small molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1254,"mesalamine,Pentasa, Canasa, Asacol",mesalamine,antiinflammatory agent,Small molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1254,"mesalamine,Pentasa, Canasa, Asacol",mesalamine,antiinflammatory agent,Small molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1255,"Mesupron, WX-671",WX-671,antineoplastic agent,small molecule,not approved,P00749,UROK_HUMAN,PLAU,Urokinase-type plasminogen activator (U-plasminogen activator) (uPA) (EC 3.4.21.73) [Cleaved into: Urokinase-type plasminogen activator long chain A; Urokinase-type plasminogen activator short chain A; Urokinase-type plasminogen activator chain B],Enzymes,EC:3.4.21.73,Established target
1256,"metabolite of allopurinol, Oxypurinol",Oxypurinol,"for treatment of heart failure,for treatment of gout",small molecule,not approved,P47989,XDH_HUMAN,XDH,Xanthine dehydrogenase/oxidase OS=Homo sapiens GN=XDH PE=1 SV=4,Enzymes,EC:1.17.1.4; 1.17.3.2,Established target
1257,"metaglidasen, JNJ-39659100, MBX-102",metaglidasen,antidiabetic,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1258,"metformin GR,Glumetza",metformin ,antidiabetic,Small molecule,approved,Q9Y478,AAKB1_HUMAN,PRKAB1,5'-AMP-activated protein kinase subunit beta-1 OS=Homo sapiens GN=PRKAB1 PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
1259,"metformin HCl,Glucophage XR",metformin ,antidiabetic,Small molecule,approved,Q9Y478,AAKB1_HUMAN,PRKAB1,5'-AMP-activated protein kinase subunit beta-1 OS=Homo sapiens GN=PRKAB1 PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
1260,"metformin,MetControl",metformin ,antidiabetic,Small molecule,approved,Q9Y478,AAKB1_HUMAN,PRKAB1,5'-AMP-activated protein kinase subunit beta-1 OS=Homo sapiens GN=PRKAB1 PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
1262,Methylnaltrexone,Methylnaltrexone,for treatment of opioid-induced constipation,Small molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1263,"methylphenidate HCl,Concerta",methylphenidate,for treatment of ADHD,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1263,"methylphenidate HCl,Concerta",methylphenidate,for treatment of ADHD,Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1263,"methylphenidate HCl,Concerta",methylphenidate,for treatment of ADHD,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1264,"methylphenidate HCl,Metadate CD, Equasym",methylphenidate,for treatment of ADHD,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1264,"methylphenidate HCl,Metadate CD, Equasym",methylphenidate,for treatment of ADHD,Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1264,"methylphenidate HCl,Metadate CD, Equasym",methylphenidate,for treatment of ADHD,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1265,"methylphenidate HCl,Ritalin LA",methylphenidate,for treatment of ADHD,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1265,"methylphenidate HCl,Ritalin LA",methylphenidate,for treatment of ADHD,Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1265,"methylphenidate HCl,Ritalin LA",methylphenidate,for treatment of ADHD,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1266,methyltestosterone,methyltestosterone,for treatment of dysfunctional libido in women,Small molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1267,MetMAb,MetMAb,antineoplastic agent,monoclonal antibody,not approved,P08581,MET_HUMAN,MET,Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met),Receptors,EC:2.7.10.1,Established target
1268,"metoclopramide HCl,Metzoliv ODT",metoclopramide,"motilitant,for treatment of gastroesophageal reflux disease ",Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1268,"metoclopramide HCl,Metzoliv ODT",metoclopramide,"motilitant,for treatment of gastroesophageal reflux disease ",Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1269,"metoclopramide,Emitasol, Pramidin",metoclopramide,antiemetic,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1269,"metoclopramide,Emitasol, Pramidin",metoclopramide,antiemetic,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1270,"metoprolol succinate,Toprol-XL",metoprolol ,antihypertensive agent,Small molecule,approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1272,"MF101 ,Menerba",MF101,for treatment of menopausal symptoms,Small molecule,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1273,MG98,MG98,antineoplastic agent,antisense oligo,not approved,P26358,DNMT1_HUMAN,DNMT1,DNA (cytosine-5)-methyltransferase 1 OS=Homo sapiens GN=DNMT1 PE=1 SV=2,Enzymes,EC:2.1.1.37,Established target
1274,MGAH22,MGAH22,antineoplastic agent,monoclonal antibody,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,Q96DB2,HDA11_HUMAN,HDAC11,Histone deacetylase 11 (HD11) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,P56524,HDAC4_HUMAN,HDAC4,Histone deacetylase 4 (HD4) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,Q9UQL6,HDAC5_HUMAN,HDAC5,Histone deacetylase 5 (HD5) (EC 3.5.1.98) (Antigen NY-CO-9),Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,Q8WUI4,HDAC7_HUMAN,HDAC7A,Histone deacetylase 7 (HD7) (EC 3.5.1.98) (Histone deacetylase 7A) (HD7a),Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1275,MGCD-0103,MGCD-0103,antineoplastic agent,Small molecule,not approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
1276,MGCD265,MGCD265,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1276,MGCD265,MGCD265,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1276,MGCD265,MGCD265,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1276,MGCD265,MGCD265,antineoplastic agent,Small molecule,not approved,P08581,MET_HUMAN,MET,Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met),Receptors,EC:2.7.10.1,Established target
1276,MGCD265,MGCD265,antineoplastic agent,Small molecule,not approved,Q04912,RON_HUMAN,MST1R,Macrophage-stimulating protein receptor,Enzymes,EC:2.7.10.1,Novel Target
1276,MGCD265,MGCD265,antineoplastic agent,Small molecule,not approved,Q02763,TIE2_HUMAN,TEK,Angiopoietin-1 receptor (EC 2.7.10.1) (Tunica interna endothelial cell kinase) (Tyrosine-protein kinase receptor TEK) (Tyrosine-protein kinase receptor TIE-2) (hTIE2) (p140 TEK) (CD antigen CD202b),Receptors,EC:2.7.10.1,Novel Target
1278,MGN1703,MGN1703,antineoplastic agent,DNA-based immuno-therapy,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
1279,"MH-200, TAK-453 SR, morphine HCl,ANPEC",morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1279,"MH-200, TAK-453 SR, morphine HCl,ANPEC",morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1279,"MH-200, TAK-453 SR, morphine HCl,ANPEC",morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1280,"micellar paclitaxel,Paxceed",paclitaxel,"antiinflammatory agent,DMARD",Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1280,"micellar paclitaxel,Paxceed",paclitaxel,"antiinflammatory agent,DMARD",Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1282,"Midostaurin, PKC 412",Midostaurin,antineoplastic agent,Small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1283,"Mifepristone, RU486",Mifepristone,"opthalmological agent,for lowering intraocular pressure",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1283,"Mifepristone, RU486",Mifepristone,"opthalmological agent,for lowering intraocular pressure",Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
1284,"mifepristone,Corlux",Mifepristone,"antipsychotic,antidepressant",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1284,"mifepristone,Corlux",Mifepristone,"antipsychotic,antidepressant",Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
1285,"migalastat ,Amigal",migalastat,"enzyme replacement therapy,for treatment of Fabry disease",Small molecule,not approved,P06280,AGAL_HUMAN,GLA,Alpha-galactosidase A (EC 3.2.1.22) (Alpha-D-galactosidase A) (Alpha-D-galactoside galactohydrolase) (Melibiase) (Agalsidase),Enzymes,EC:3.2.1.22,Novel Target
1286,"miglustat, OGT 918,Zavesca",miglustat,for treatment of Gaucher's disease,Small Molecule,approved,Q16739,CEGT_HUMAN,UGCG,Ceramide glucosyltransferase OS=Homo sapiens GN=UGCG PE=2 SV=1,Enzymes,EC:2.4.1,Established target
1287,"milataxel, MAC-321",milataxel,antineoplastic agent,Small molecule,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1287,"milataxel, MAC-321",milataxel,antineoplastic agent,Small molecule,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1288,milatuzumab,milatuzumab,antineoplastic agent,monoclonal antibody,not approved,P04233,HG2A_HUMAN,CD74,HLA class II histocompatibility antigen gamma chain (HLA-DR antigens-associated invariant chain) (Ia antigen-associated invariant chain) (Ii) (p33) (CD antigen CD74),Miscellaneous,StructuralAndAdhesion;MHC claas II,Novel Target
1289,Milnacipran,Milnacipran,for treatment of fibromyalgia syndrome,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1289,Milnacipran,Milnacipran,for treatment of fibromyalgia syndrome,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1290,"milveterol. TD-3327, GSK-159797",milveterol,bronchodilator,Small molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1291,MIM-D3,MIM-D3,opthalmological agent,Small molecule,not approved,P04629,NTRK1_HUMAN,NTRK1,High affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinase receptor type 1) (TRK1-transforming tyrosine kinase protein) (p140-TrkA) (Trk-A),Receptors,EC:2.7.10.1,Established target
1292,"minodronate, YM-529,Bonoteo, Recalbon",minodronate,antineoplastic agent,Small molecule,not approved,P14324,FPPS_HUMAN,FDPS,Farnesyl pyrophosphate synthetase OS=Homo sapiens GN=FDPS PE=1 SV=4,Enzymes,EC:2.5.1.10,Established target
1293,Mirapex,pramipexole,antiparkinson agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1293,Mirapex,pramipexole,antiparkinson agent,Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1293,Mirapex,pramipexole,antiparkinson agent,Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1294,Mircera,METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,erythropoietic agent,protein,approved,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1295,"mirtazapine,Remeron, Remeron SolTab, Reflex",mirtazapine,antidepressant,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1295,"mirtazapine,Remeron, Remeron SolTab, Reflex",mirtazapine,antidepressant,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1295,"mirtazapine,Remeron, Remeron SolTab, Reflex",mirtazapine,antidepressant,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1296,"mitemcinal, GM-611",mitemcinal,for treatment of gastroparesis,Small molecule,not approved,O43193,MTLR_HUMAN,MLNR,Motilin receptor (G-protein coupled receptor 38),Receptors,GPCR;Rhodopsin,Novel Target
1297,"mitiglinide, KAD-1229,Glufast, Glinsuna, Metgluna",mitiglinide,antidiabetic,Small Molecule,approved,Q09428,ABCC8_HUMAN,ABCC8,ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1),Transporters,TC:3.A.1.208.4,Established target
1298,"mitoxantrone hydrochloride,Novantrone",mitoxantrone ,antineoplastic agent,Small molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
1299,MIV-701,MIV-701,for treatment of osteoporosis,Small molecule,not approved,P43235,CATK_HUMAN,CTSK,Cathepsin K (EC 3.4.22.38) (Cathepsin O) (Cathepsin O2) (Cathepsin X),Enzymes,EC:3.4.22.38,Novel Target
1300,"MK-0524A, ER niacin/laropiprant,Tredaptive, Trevaclyn, Pelzont",laropiprant,for counteracting niacin-induced flushing,Small molecule,not approved,Q13258,PD2R_HUMAN,PTGDR,Prostaglandin D2 receptor (PGD receptor) (PGD2 receptor) (Prostanoid DP receptor),Receptors,GPCR;Rhodopsin,Established target
1300,"MK-0524A, ER niacin/laropiprant,Tredaptive, Trevaclyn, Pelzont",niacin,antidyslipidaemic agent,Small molecule,approved,Q8TDS4,NIAR1_HUMAN,GPR109A,Niacin receptor 1 OS=Homo sapiens GN=NIACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1300,"MK-0524A, ER niacin/laropiprant,Tredaptive, Trevaclyn, Pelzont",niacin,antidyslipidaemic agent,Small molecule,approved,P49019,G109B_HUMAN,GPR109B,Niacin receptor 2 OS=Homo sapiens GN=NIACR2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1300,"MK-0524A, ER niacin/laropiprant,Tredaptive, Trevaclyn, Pelzont",niacin,antidyslipidaemic agent,Small molecule,approved,P40261,NNMT_HUMAN,NNMT,Nicotinamide N-methyltransferase (EC 2.1.1.1),Enzymes,EC:2.1.1.1,Established target
1300,"MK-0524A, ER niacin/laropiprant,Tredaptive, Trevaclyn, Pelzont",niacin,antidyslipidaemic agent,Small molecule,approved,Q15274,NADC_HUMAN,QPRT,Nicotinate-nucleotide pyrophosphorylase [carboxylating] (EC 2.4.2.19) (Quinolinate phosphoribosyltransferase [decarboxylating]) (QAPRTase) (QPRTase),Enzymes,EC:2.4.2.19,Established target
1301,"MK-0542B, extended release niacin + laropiprant +simvastatin",laropiprant,for counteracting niacin-induced flushing,Small molecule,not approved,Q13258,PD2R_HUMAN,PTGDR,Prostaglandin D2 receptor (PGD receptor) (PGD2 receptor) (Prostanoid DP receptor),Receptors,GPCR;Rhodopsin,Established target
1301,"MK-0542B, extended release niacin + laropiprant +simvastatin",niacin,antidyslipidaemic agent,Small molecule,approved,Q8TDS4,NIAR1_HUMAN,GPR109A,Niacin receptor 1 OS=Homo sapiens GN=NIACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1301,"MK-0542B, extended release niacin + laropiprant +simvastatin",niacin,antidyslipidaemic agent,Small molecule,approved,P49019,G109B_HUMAN,GPR109B,Niacin receptor 2 OS=Homo sapiens GN=NIACR2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1301,"MK-0542B, extended release niacin + laropiprant +simvastatin",niacin,antidyslipidaemic agent,Small molecule,approved,P40261,NNMT_HUMAN,NNMT,Nicotinamide N-methyltransferase (EC 2.1.1.1),Enzymes,EC:2.1.1.1,Established target
1301,"MK-0542B, extended release niacin + laropiprant +simvastatin",niacin,antidyslipidaemic agent,Small molecule,approved,Q15274,NADC_HUMAN,QPRT,Nicotinate-nucleotide pyrophosphorylase [carboxylating] (EC 2.4.2.19) (Quinolinate phosphoribosyltransferase [decarboxylating]) (QAPRTase) (QPRTase),Enzymes,EC:2.4.2.19,Established target
1301,"MK-0542B, extended release niacin + laropiprant +simvastatin",simvastatin,anticholesterolaemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
1302,MK-1775,MK-1775,antineoplastic agent,Small molecule,not approved,P30291,WEE1_HUMAN,WEE1,Wee1-like protein kinase (WEE1hu) (EC 2.7.10.2) (Wee1A kinase),Enzymes,EC:2.7.10.2,Novel Target
1303,MK-2206,MK-2206,antineoplastic agent,Small molecule,not approved,P31749,AKT1_HUMAN,AKT1,RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Proto-oncogene c-Akt) (RAC-PK-alpha),Enzymes,EC:2.7.11.1,Novel Target
1303,MK-2206,MK-2206,antineoplastic agent,Small molecule,not approved,P31751,AKT2_HUMAN,AKT2,RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta),Enzymes,EC:2.7.11.1,Novel Target
1303,MK-2206,MK-2206,antineoplastic agent,Small molecule,not approved,Q9Y243,AKT3_HUMAN,AKT3,RAC-gamma serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-3) (Protein kinase B gamma) (PKB gamma) (RAC-PK-gamma) (STK-2),Enzymes,EC:2.7.11.1,Novel Target
1304,MK-4305,suvorexant,hypnotic,small molecule,not approved,O43613,OX1R_HUMAN,HCRTR1,Orexin receptor type 1 (Ox-1-R) (Ox1-R) (Ox1R) (Hypocretin receptor type 1),Receptors,GPCR;Rhodopsin,Novel Target
1304,MK-4305,suvorexant,hypnotic,small molecule,not approved,O43614,OX2R_HUMAN,HCRTR2,Orexin receptor type 2 (Ox-2-R) (Ox2-R) (Ox2R) (Hypocretin receptor type 2),Receptors,GPCR;Rhodopsin,Novel Target
1305,MK-4827,MK-4827,antineoplastic agent,Small molecule,not approved,P09874,PARP1_HUMAN,PARP1,Poly [ADP-ribose] polymerase 1 (PARP-1) (EC 2.4.2.30) (NAD(+) ADP-ribosyltransferase 1) (ADPRT 1) (Poly[ADP-ribose] synthase 1),Enzymes,EC:2.4.2.30,Novel Target
1305,MK-4827,MK-4827,antineoplastic agent,Small molecule,not approved,Q9UGN5,PARP2_HUMAN,PARP2,Poly [ADP-ribose] polymerase 2 (PARP-2) (hPARP-2) (EC 2.4.2.30) (NAD(+) ADP-ribosyltransferase 2) (ADPRT-2) (Poly[ADP-ribose] synthase 2) (pADPRT-2),Enzymes,EC:2.4.2.30,Novel Target
1306,MK-6913,MK-6913,for treatment of menopausal symptoms,unknown,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1306,MK-6913,MK-6913,for treatment of menopausal symptoms,unknown,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1307,MKC-1,MKC-1,antineoplastic agent,Small molecule,not approved,Q9UI26,IPO11_HUMAN,IPO11,Importin-11,Miscellaneous,Miscellaneous;importin,Novel Target
1307,MKC-1,MKC-1,antineoplastic agent,Small molecule,not approved,O94829,IPO13_HUMAN,IPO13,Importin-13,Miscellaneous,Miscellaneous; importin,Novel Target
1307,MKC-1,MKC-1,antineoplastic agent,Small molecule,not approved,Q8TEX9,IPO4_HUMAN,IPO4,Importin-4,Miscellaneous,Miscellaneous;importin,Novel Target
1307,MKC-1,MKC-1,antineoplastic agent,Small molecule,not approved,O95373,IPO7_HUMAN,IPO7,Importin-7,Miscellaneous,Miscellaneous; importin,Novel Target
1307,MKC-1,MKC-1,antineoplastic agent,Small molecule,not approved,O15397,IPO8_HUMAN,IPO8,Importin-8,Miscellaneous,Miscellaneous; importin,Novel Target
1307,MKC-1,MKC-1,antineoplastic agent,Small molecule,not approved,Q96P70,IPO9_HUMAN,IPO9,Importin-9,Miscellaneous,Miscellaneous;importin,Novel Target
1307,MKC-1,MKC-1,antineoplastic agent,Small molecule,not approved,P07437,TBB5_HUMAN,TUBB,Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1307,MKC-1,MKC-1,antineoplastic agent,Small molecule,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1308,MKC-253,MKC-253,antidiabetic,protein,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1309,MLN-0415,MLN-0415,antiinflammatory agent,Small molecule,not approved,O14920,IKKB_HUMAN,IKBKB,Inhibitor of nuclear factor kappa-B kinase subunit beta OS=Homo sapiens GN=IKBKB PE=1 SV=1,Enzymes,EC:2.7.11.10,Established target
1310,MLN-1202,MLN-1202,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P41597,CCR2_HUMAN,CCR2,C-C chemokine receptor type 2 (C-C CKR-2) (CC-CKR-2) (CCR-2) (CCR2) (Monocyte chemoattractant protein 1 receptor) (MCP-1-R) (CD antigen CD192),Receptors,GPCR;Rhodopsin,Novel Target
1311,MLN-4924,MLN-4924,antineoplastic agent,Small molecule,not approved,Q8TBC4,UBA3_HUMAN,UBA3,NEDD8-activating enzyme E1 catalytic subunit (EC 6.3.2.-) (NEDD8-activating enzyme E1C) (Ubiquitin-activating enzyme E1C) (Ubiquitin-like modifier-activating enzyme 3) (Ubiquitin-activating enzyme 3),Miscellaneous,EC:6.3.2.-,Novel Target
1312,MLN-8054,MLN-8054,antineoplastic agent,Small molecule,not approved,Q683C9,AUR2_ARATH,AUR2,Serine/threonine-protein kinase Aurora-2 (AtAur2) (EC 2.7.11.1) (Aurora-like kinase 2),Enzymes,EC:2.7.11.1,Novel Target
1313,MLN-8237,MLN-8237,antineoplastic agent,Small molecule,not approved,O14965,STK6_HUMAN,AURKA,Serine/threonine-protein kinase 6 (EC 2.7.11.1) (Aurora kinase A) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase aurora-A),Enzymes,EC:2.7.11.1,Novel Target
1314,MLN-9708,MLN-9708,antineoplastic agent,Small molecule,not approved,P20618,PSB1_HUMAN,PSMB1,Proteasome subunit beta type-1 OS=Homo sapiens GN=PSMB1 PE=1 SV=2,Enzymes,EC:3.4.25.1,Established target
1314,MLN-9708,MLN-9708,antineoplastic agent,Small molecule,not approved,P49721,PSB2_HUMAN,PSMB2,Proteasome subunit beta type-2 OS=Homo sapiens GN=PSMB2 PE=1 SV=1,Enzymes,EC:3.4.25.1,Established target
1314,MLN-9708,MLN-9708,antineoplastic agent,Small molecule,not approved,P28074,PSB5_HUMAN,PSMB5,Proteasome subunit beta type-5 OS=Homo sapiens GN=PSMB5 PE=1 SV=3,Enzymes,EC:3.4.25.1,Established target
1314,MLN-9708,MLN-9708,antineoplastic agent,Small molecule,not approved,Q99460,PSMD1_HUMAN,PSMD1,26S proteasome non-ATPase regulatory subunit 1 OS=Homo sapiens GN=PSMD1 PE=1 SV=2,Miscellaneous,Enzyme regulator,Established target
1314,MLN-9708,MLN-9708,antineoplastic agent,Small molecule,not approved,Q13200,PSMD2_HUMAN,PSMD2,26S proteasome non-ATPase regulatory subunit 2 OS=Homo sapiens GN=PSMD2 PE=1 SV=3,Miscellaneous,Enzyme regulator,Established target
1315,MM-111,MM-111,antineoplastic agent,monoclonal antibody,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1315,MM-111,MM-111,antineoplastic agent,monoclonal antibody,not approved,P21860,ERBB3_HUMAN,ERBB3,Receptor tyrosine-protein kinase erbB-3 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-3) (Tyrosine kinase-type cell surface receptor HER3),Receptors,EC:2.7.10.1,Novel Target
1316,MN-201,MN-201,antineoplastic agent,Small molecule,not approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
1317,MN-221,MN-221,antiasthmatic agent,unknown,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1318,MN-246,MN-246,for treatment of overactive bladder,Small molecule,not approved,P13945,ADRB3_HUMAN,ADRB3,Beta-3 adrenergic receptor (Beta-3 adrenoreceptor) (Beta-3 adrenoceptor),Receptors,GPCR;Rhodopsin,Novel Target
1319,MN-305,MN-305,"antidepressant,hypnotic",Small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1320,"moclobemide ,Aurorix",moclobemide,antidepressant,Small Molecule,approved,P21397,AOFA_HUMAN,MAOA,Amine oxidase [flavin-containing] A OS=Homo sapiens GN=MAOA PE=1 SV=1,Enzymes,EC:1.4.3.4,Established target
1321,"MOD-4023, hGH-CTP",MOD-4023,hormone replacement,recombinant protein,not approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1322,"modafinil,Provigil, Sparlon",modafinil,central nervous system stimulant,Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1323,Modufolin,Modufolin,antineoplastic agent,Small molecule,approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
1324,"molecular iodine,IoGen",iodine,for treatment of fibrocystic breast disease (FBD),mineral,mineral,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1325,"mometasone furoate + formoterol fumarate dihydrate,Dulera",formoterol,antiasthmatic agent,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1325,"mometasone furoate + formoterol fumarate dihydrate,Dulera",mometasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1326,"monoclonal antibody ,BrevaRex MAb",BrevaRex MAb,antineoplastic agent,monoclonal antibody,not approved,P15941,MUC1_HUMAN,MUC1,Mucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Carcinoma-associated mucin) (Episialin) (H23AG) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM) (Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associ,Miscellaneous,StructuralAndAdhesion;Mucin_1,Novel Target
1327,"montelukast sodium,Singulair",montelukast,antiasthmatic agent,Small Molecule,approved,Q9Y271,CLTR1_HUMAN,CYSLTR1,Cysteinyl leukotriene receptor 1 OS=Homo sapiens GN=CYSLTR1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1328,MOR103,MOR103,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P04141,CSF2_HUMAN,CSF2,Granulocyte-macrophage colony-stimulating factor,ligand,Ligand; CSF2,Novel Target
1329,MOR208,MOR208,antineoplastic agent,monoclonal antibody,not approved,P28908,TNR8_HUMAN,TNFRSF8,Tumor necrosis factor receptor superfamily member 8 (CD30L receptor) (Ki-1 antigen) (Lymphocyte activation antigen CD30) (CD antigen CD30),Receptors,Receptors;TNFNGF,Novel Target
1330,"MORAb-003, farletuzumab",farletuzumab,antineoplastic agent,monoclonal antibody,not approved,P15328,FOLR1_HUMAN,FOLR1,"Folate receptor alpha (FR-alpha) (Adult folate-binding protein) (FBP) (Folate receptor 1) (Folate receptor, adult) (KB cells FBP) (Ovarian tumor-associated antigen MOv18)",Receptors,Receptors;Folate,Novel Target
1331,MORAb-004,MORAb-004,antineoplastic agent,antibody,not approved,Q9HCU0,CD248_HUMAN,CD248,Endosialin (Tumor endothelial marker 1) (CD antigen CD248),Receptors,SCAR;Class_E,Novel Target
1332,"moroctocog alfa ,ReFacto, Xyntha, ReFacto AF",factor VIII,for treatment of hemophilia A,recombinant protein,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1332,"moroctocog alfa ,ReFacto, Xyntha, ReFacto AF",factor VIII,for treatment of hemophilia A,recombinant protein,approved,P00740,FA9_HUMAN,F9,Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2,Enzymes,EC:3.4.21.22,Established target
1332,"moroctocog alfa ,ReFacto, Xyntha, ReFacto AF",factor VIII,for treatment of hemophilia A,recombinant protein,approved,P04275,VWF_HUMAN,VWF,von Willebrand factor (vWF) [Cleaved into: von Willebrand antigen 2 (von Willebrand antigen II)],Miscellaneous,StructuralAndAdhesion;Collagen;F8;F2,Established target
1333,"morphine sulfate,Avinza",morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1333,"morphine sulfate,Avinza",morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1333,"morphine sulfate,Avinza",morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1334,"morphine sulfate,DepoDur, DepoMorphine",morphine,analgesic,Small molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1334,"morphine sulfate,DepoDur, DepoMorphine",morphine,analgesic,Small molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1334,"morphine sulfate,DepoDur, DepoMorphine",morphine,analgesic,Small molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1335,"morphine/dextromethorphan,MorphiDex",dextromethorphan,analgesic,Small molecule,approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
1335,"morphine/dextromethorphan,MorphiDex",dextromethorphan,analgesic,Small molecule,approved,Q99720,SGMR1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
1335,"morphine/dextromethorphan,MorphiDex",morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1335,"morphine/dextromethorphan,MorphiDex",morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1335,"morphine/dextromethorphan,MorphiDex",morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1336,MorViva,morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1336,MorViva,morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1336,MorViva,morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1336,MorViva,naltrexone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1336,MorViva,naltrexone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1336,MorViva,naltrexone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1336,MorViva,naltrexone,analgesic,Small Molecule,approved,Q99720 ,OPRS1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
1337,"mosapride citrate, TAK-370,Gasmotin",mosapride,for treatment of Gastrointestinal reflux disease (GERD),Small molecule,not approved,Q13639,5HT4R_HUMAN,HTR4,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1338,"motesanib diphosphate, AMG 706",motesanib ,antineoplastic agent,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1338,"motesanib diphosphate, AMG 706",motesanib ,antineoplastic agent,Small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1338,"motesanib diphosphate, AMG 706",motesanib ,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1338,"motesanib diphosphate, AMG 706",motesanib ,antineoplastic agent,Small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1338,"motesanib diphosphate, AMG 706",motesanib ,antineoplastic agent,Small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1338,"motesanib diphosphate, AMG 706",motesanib ,antineoplastic agent,Small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1339,"motexafin gadolinium ,Xcytrin",motexafin gadolinium,antineoplastic agent,Small molecule,not approved,P23921,RIR1_HUMAN,RRM1,Ribonucleoside-diphosphate reductase large subunit OS=Homo sapiens GN=RRM1 PE=1 SV=1,Enzymes,EC:1.17.4.1,Established target
1340,"motexafin gadolinium,Xcytrin",motexafin gadolinium,antineoplastic agent,Small molecule,not approved,P31350,RIR2_HUMAN,RRM2,Ribonucleoside-diphosphate reductase subunit M2 (EC 1.17.4.1) (Ribonucleotide reductase small chain) (Ribonucleotide reductase small subunit),Enzymes,EC:1.17.4.1,Novel Target
1340,"motexafin gadolinium,Xcytrin",motexafin gadolinium,antineoplastic agent,Small molecule,not approved,Q7LG56,RIR2B_HUMAN,RRM2B,Ribonucleoside-diphosphate reductase subunit M2 B (EC 1.17.4.1) (TP53-inducible ribonucleotide reductase M2 B) (p53-inducible ribonucleotide reductase small subunit 2-like protein) (p53R2),Enzymes,EC:1.17.4.1,Novel Target
1340,"motexafin gadolinium,Xcytrin",motexafin gadolinium,antineoplastic agent,Small molecule,not approved,Q16881,TRXR1_HUMAN,TXNRD1,"Thioredoxin reductase 1, cytoplasmic (TR) (EC 1.8.1.9) (Gene associated with retinoic and interferon-induced mortality 12 protein) (GRIM-12) (Gene associated with retinoic and IFN-induced mortality 12 protein) (KM-102-derived reductase-like factor) (Thior",Enzymes,EC:1.8.1.9,Established target
1340,"motexafin gadolinium,Xcytrin",motexafin gadolinium,antineoplastic agent,Small molecule,not approved,Q9NNW7,TRXR2_HUMAN,TXNRD2,"Thioredoxin reductase 2, mitochondrial (EC 1.8.1.9) (Selenoprotein Z) (SelZ) (TR-beta) (Thioredoxin reductase TR3)",Enzymes,EC:1.8.1.9,Novel Target
1340,"motexafin gadolinium,Xcytrin",motexafin gadolinium,antineoplastic agent,Small molecule,not approved,Q86VQ6,TRXR3_HUMAN,TXNRD3,Thioredoxin reductase 3 (EC 1.8.1.9) (Thioredoxin and glutathione reductase) (Thioredoxin reductase TR2) (Fragment),Enzymes,EC:1.8.1.9,Novel Target
1341,MoxDuo,morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor (D-OR-1) (DOR-1),Receptors,GPCR;Rhodopsin,Established target
1341,MoxDuo,morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1341,MoxDuo,morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1341,MoxDuo,oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1341,MoxDuo,oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1341,MoxDuo,oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1342,Mozobil,plerixafor,antineoplastic agent,small molecule,approved,P61073,CXCR4_HUMAN,CXCR4,C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (Fusin) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD antigen CD184),Receptors,GPCR;Rhodopsin,Established target
1343,MP0112,MP0112,for treatment of diabetic retinopathy,Small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1343,MP0112,MP0112,for treatment of diabetic retinopathy,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1344,MP-470,amuvatinib,antineoplastic agent,Small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1344,MP-470,amuvatinib,antineoplastic agent,Small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1344,MP-470,amuvatinib,antineoplastic agent,Small molecule,not approved,P08581,MET_HUMAN,MET,Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met),Receptors,EC:2.7.10.1,Established target
1344,MP-470,amuvatinib,antineoplastic agent,Small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1344,MP-470,amuvatinib,antineoplastic agent,Small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1344,MP-470,amuvatinib,antineoplastic agent,Small molecule,not approved,Q06609,RAD51_HUMAN,RAD51,DNA repair protein RAD51 homolog 1,Miscellaneous,Miscellaneous;RecA,Novel Target
1344,MP-470,amuvatinib,antineoplastic agent,Small molecule,not approved,P07949,RET_HUMAN,RET,Proto-oncogene tyrosine-protein kinase receptor ret OS=Homo sapiens GN=RET PE=1 SV=3,Receptors,EC:2.7.10.1,Established target
1345,"MPC-0920 is an orally available direct thrombin inhibitor, under investigation by Myriad Genetics for the treatment of thrombosis. In May 2006, Myriad initiated a phase I /",MPC-0920,antithrombotic,Small molecule,not approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
1346,"MPI-674 ,Femathina",MPI-674,for treatment of abnormal uterine bleeding (AUB),Small molecule,not approved,P11511,CP19A_HUMAN,CYP19A1,Cytochrome P450 19A1 OS=Homo sapiens GN=CYP19A1 PE=1 SV=3,Enzymes,EC:1.14.14,Established target
1347,MPI-676,MPI-676,for treatment of endometriosis,Small molecule,not approved,P11511,CP19A_HUMAN,CYP19A1,Cytochrome P450 19A1 OS=Homo sapiens GN=CYP19A1 PE=1 SV=3,Enzymes,EC:1.14.14,Established target
1348,"MQX-503, nitroglycerin 0.9% topical cream,Vascana",nitroglycerin,for treatment of Raynaud's disease,Small Molecule,approved,P16066,ANPRA_HUMAN,NPR1,Atrial natriuretic peptide receptor A OS=Homo sapiens GN=NPR1 PE=2 SV=1,Receptors,EC:4.6.1.2,Established target
1349,MRX-4,MRX-4,antiinflammatory agent,Small molecule,not approved,Q9NZ20,PA2G3_HUMAN,PLA2G3,Group 3 secretory phospholipase A2,Enzymes,EC:3.1.1.4,Novel Target
1350,MRX-6,MRX-6,antiinflammatory agent,Small molecule,not approved,Q9NZ20,PA2G3_HUMAN,PLA2G3,Group 3 secretory phospholipase A2,Enzymes,EC:3.1.1.4,Novel Target
1351,"MRX-801 ,SonoLysis Prolyse",MRX-801,for diagnosing and disolving blood clots,recombinant protein,not approved,P00749,UROK_HUMAN,PLAU,Urokinase-type plasminogen activator (U-plasminogen activator) (uPA) (EC 3.4.21.73) [Cleaved into: Urokinase-type plasminogen activator long chain A; Urokinase-type plasminogen activator short chain A; Urokinase-type plasminogen activator chain B],Enzymes,EC:3.4.21.73,Established target
1352,MSDC-0160,mitoglitazone,antidiabetic,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1353,"MSI-1995, talniflumate,Lomucin",talniflumate,for treatment of cystic fibrosis,small molecule,not approved,A8K7I4,CLCA1_HUMAN,CLCA1,Calcium-activated chloride channel regulator 1 (Calcium-activated chloride channel family member 1) (hCLCA1) (Calcium-activated chloride channel protein 1) (CaCC-1) (hCaCC-1),Transporters,TC:1.A.13,Novel Target
1354,MSX-122,MSX-122,antineoplastic agent,Small molecule,not approved,P61073,CXCR4_HUMAN,CXCR4,C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (Fusin) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD antigen CD184),Receptors,GPCR;Rhodopsin,Established target
1355,MT 100,metoclopramide,antimigraine agent,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1355,MT 100,metoclopramide,antimigraine agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1355,MT 100,naproxen,antimigraine agent,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1355,MT 100,naproxen,antimigraine agent,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1356,MT 300,dihydroergotamine,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1356,MT 300,dihydroergotamine,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1357,"MT 400,Treximet",naproxen,antimigraine agent,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1357,"MT 400,Treximet",naproxen,antimigraine agent,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1357,"MT 400,Treximet",sumatriptan,antimigraine agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1357,"MT 400,Treximet",sumatriptan,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1357,"MT 400,Treximet",sumatriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1357,"MT 400,Treximet",sumatriptan,antimigraine agent,Small Molecule,approved,P30939,5HT1F_HUMAN,HTR1F,5-hydroxytryptamine receptor 1F OS=Homo sapiens GN=HTR1F PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1358,MT-103,MT-103,antineoplastic agent,antibody,not approved,P15391,CD19_HUMAN,CD19,B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigen CD19) (T-cell surface antigen Leu-12) (CD antigen CD19),Miscellaneous,Miscellaneous;CD19,Novel Target
1358,MT-103,MT-103,antineoplastic agent,antibody,not approved,P20963,CD3Z_HUMAN,CD247,T-cell surface glycoprotein CD3 zeta chain,Miscellaneous,Miscellaneous;T-cell surface glycoprotein,Established target
1358,MT-103,MT-103,antineoplastic agent,antibody,not approved,P04234,CD3D_HUMAN,CD3D,T-cell surface glycoprotein CD3 delta chain (T-cell receptor T3 delta chain) (CD antigen CD3d),Receptors,Receptor; T-cell receptor subunit,Established target
1358,MT-103,MT-103,antineoplastic agent,antibody,not approved,P07766,CD3E_HUMAN,CD3E,T-cell surface glycoprotein CD3 epsilon chain OS=Homo sapiens GN=CD3E PE=1 SV=2,Receptors,Receptor; T-cell receptor subunit,Established target
1358,MT-103,MT-103,antineoplastic agent,antibody,not approved,P09693,CD3G_HUMAN,CD3G,T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g),Receptors,Receptor; T-cell receptor subunit,Established target
1359,MT110,MT110,antineoplastic agent,antibody,not approved,P04234,CD3D_HUMAN,CD3D,T-cell surface glycoprotein CD3 delta chain (T-cell receptor T3 delta chain) (CD antigen CD3d),Receptors,Receptor; T-cell receptor subunit,Established target
1359,MT110,MT110,antineoplastic agent,antibody,not approved,P07766,CD3E_HUMAN,CD3E,T-cell surface glycoprotein CD3 epsilon chain OS=Homo sapiens GN=CD3E PE=1 SV=2,Receptors,Receptor; T-cell receptor subunit,Established target
1359,MT110,MT110,antineoplastic agent,antibody,not approved,P09693,CD3G_HUMAN,CD3G,T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g),Receptors,Receptor; T-cell receptor subunit,Established target
1359,MT110,MT110,antineoplastic agent,antibody,not approved,P16422,EPCAM_HUMAN,EPCAM,Epithelial cell adhesion molecule (Ep-CAM) (Adenocarcinoma-associated antigen) (Cell surface glycoprotein Trop-1) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Epithelial glycoprotein 314) (EGP314) (hEGP314) (KS 1/4 antigen) (KSA) (Ma,Miscellaneous,StructuralAndAdhesion;,Novel Target
1360,MT203,MT203,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P04141,CSF2_HUMAN,CSF2,Granulocyte-macrophage colony-stimulating factor,ligand,Ligand; CSF2,Novel Target
1361,"MTC-DOX, MTC-doxorubicin",doxorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
1362,"MTR 105, MTR106, MTR107",isothiourea,antihypertensive agent,Small molecule,not approved,P29475,NOS1_HUMAN,NOS1,"Nitric oxide synthase, brain (EC 1.14.13.39) (Constitutive NOS) (NC-NOS) (NOS type I) (Neuronal NOS) (N-NOS) (nNOS) (Peptidyl-cysteine S-nitrosylase NOS1) (bNOS)",Enzymes,EC:1.14.13.39,Novel Target
1362,"MTR 105, MTR106, MTR107",isothiourea,antihypertensive agent,Small molecule,not approved,P35228,NOS2_HUMAN,NOS2,"Nitric oxide synthase, inducible (EC 1.14.13.39) (Hepatocyte NOS) (HEP-NOS) (Inducible NO synthase) (Inducible NOS) (iNOS) (NOS type II) (Peptidyl-cysteine S-nitrosylase NOS2)",Enzymes,EC:1.14.13.39,Novel Target
1362,"MTR 105, MTR106, MTR107",isothiourea,antihypertensive agent,Small molecule,not approved,P29474,NOS3_HUMAN,NOS3,"Nitric oxide synthase, endothelial OS=Homo sapiens GN=NOS3 PE=1 SV=3",Enzymes,EC:1.14.13.39,Established target
1363,Mu Delta,Mu Delta,for treatment of irritable bowel syndrome,unknown,not approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1363,Mu Delta,Mu Delta,for treatment of irritable bowel syndrome,unknown,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1364,Muparfostat,PI-88,antineoplastic agent,polysaccharide,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
1364,Muparfostat,PI-88,antineoplastic agent,polysaccharide,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1364,Muparfostat,PI-88,antineoplastic agent,polysaccharide,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1364,Muparfostat,PI-88,antineoplastic agent,polysaccharide,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1364,Muparfostat,PI-88,antineoplastic agent,polysaccharide,not approved,Q9Y251,HPSE_HUMAN,HPSE,Heparanase (EC 3.2.-.-) (Endo-glucoronidase) (Heparanase-1) (Hpa1) [Cleaved into: Heparanase 8 kDa subunit; Heparanase 50 kDa subunit],Enzymes,EC:3.2.-.-,Established target
1364,Muparfostat,PI-88,antineoplastic agent,polysaccharide,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1365,"muraglitazar, BMS-298585",muraglitazar,antidiabetic,Small molecule,not approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1365,"muraglitazar, BMS-298585",muraglitazar,antidiabetic,Small molecule,not approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1366,MVA-BN Prostate,MVA-BN,antineoplastic agent,vaccine,not approved,P15309,PPAP_HUMAN,ACPP,Prostatic acid phosphatase (EC 3.1.3.2),Enzymes,EC:3.1.3.2,Novel Target
1366,MVA-BN Prostate,MVA-BN,antineoplastic agent,vaccine,not approved,P07288,KLK3_HUMAN,KLK3,Prostate-specific antigen (PSA) (EC 3.4.21.77) (Gamma-seminoprotein) (Seminin) (Kallikrein-3) (P-30 antigen) (Semenogelase),Enzymes,EC:3.4.21.77,Novel Target
1367,MVA-BN-HER-2,MVA-BN-HER-2,antineoplastic agent,vaccine,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1368,"Mx-dnG1,Rexin-G",Mx-dnG1,antineoplastic agent,retroviral vector,not approved,P51959,CCNG1_HUMAN,CCNG1,Cyclin-G1 (Cyclin-G),Miscellaneous,Miscellaneous;Cyclin,Novel Target
1369,"mycophenolic acid delayed-release,Myfortic",mycophenolic acid,immunosuppressant,Small Molecule,approved,P20839,IMDH1_HUMAN,IMPDH1,Inosine-5'-monophosphate dehydrogenase 1 OS=Homo sapiens GN=IMPDH1 PE=1 SV=2,Enzymes,EC:1.1.1.205,Established target
1369,"mycophenolic acid delayed-release,Myfortic",mycophenolic acid,immunosuppressant,Small Molecule,approved,P12268,IMDH2_HUMAN,IMPDH2,Inosine-5'-monophosphate dehydrogenase 2 OS=Homo sapiens GN=IMPDH2 PE=1 SV=2,Enzymes,EC:1.1.1.205,Established target
1370,Myocell SDF-1 (Stromal Derived Factor - 1),Myocell SDF-1 ,for treatment of heart failure,autologous cell-based gene-therapy,not approved,P48061,SDF1_HUMAN,CXCL12,Stromal cell-derived factor 1,Ligand,Ligand;Chemokine,Novel Target
1371,"Myrexis, Inc/MPC-3100",MPC-3100 ,antineoplastic agent,Small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
1371,"Myrexis, Inc/MPC-3100",MPC-3100 ,antineoplastic agent,Small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
1372,"nab-docetaxel, ABI-008",docetaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1372,"nab-docetaxel, ABI-008",docetaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1373,"nabilone,Cesamet",nabilone,antiemetic,Small Molecule,approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1373,"nabilone,Cesamet",nabilone,antiemetic,Small Molecule,approved,P34972,CNR2_HUMAN,CNR2,Cannabinoid receptor 2 OS=Homo sapiens GN=CNR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1374,"nalbuphine hydrochloride,  PW-4142",nalbuphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1374,"nalbuphine hydrochloride,  PW-4142",nalbuphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1374,"nalbuphine hydrochloride,  PW-4142",nalbuphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1375,"nalmefene, CPH-101",nalmefene,"smoking-cessation agent,for treatment of addiction",Small molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1375,"nalmefene, CPH-101",nalmefene,"smoking-cessation agent,for treatment of addiction",Small molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1375,"nalmefene, CPH-101",nalmefene,"smoking-cessation agent,for treatment of addiction",Small molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1376,Namenda,memantine,for treatment of Alzheimer's disease,Small Molecule,approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
1376,Namenda,memantine,for treatment of Alzheimer's disease,Small Molecule,approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
1376,Namenda,memantine,for treatment of Alzheimer's disease,Small Molecule,approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
1377,NanoEmulsion (diclofenac),diclofenac,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1377,NanoEmulsion (diclofenac),diclofenac,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1378,Naproxcinod,Naproxcinod,NSAID,Small molecule,not approved,P33402,GCYA2_HUMAN,GUCY1A2,Guanylate cyclase soluble subunit alpha-2 (GCS-alpha-2) (EC 4.6.1.2),Enzymes,EC:4.6.1.2,Established target
1378,Naproxcinod,Naproxcinod,NSAID,Small molecule,not approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1378,Naproxcinod,Naproxcinod,NSAID,Small molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1379,"naproxen + esomeprazole, PN-400,Vimovo",esomeprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1379,"naproxen + esomeprazole, PN-400,Vimovo",naproxen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1379,"naproxen + esomeprazole, PN-400,Vimovo",naproxen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1380,"naproxen etemesil, LT-NS001, MX-1094",naproxen etemesil,NSAID,Small molecule,not approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1380,"naproxen etemesil, LT-NS001, MX-1094",naproxen etemesil,NSAID,Small molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1381,"naratriptan,Naramig, Amerge",naratriptan,antimigraine agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1381,"naratriptan,Naramig, Amerge",naratriptan,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1381,"naratriptan,Naramig, Amerge",naratriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1381,"naratriptan,Naramig, Amerge",naratriptan,antimigraine agent,Small Molecule,approved,P30939,5HT1F_HUMAN,HTR1F,5-hydroxytryptamine receptor 1F OS=Homo sapiens GN=HTR1F PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1382,"nasal ketamine,Ereska",ketamine,analgesic,Small Molecule,approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
1382,"nasal ketamine,Ereska",ketamine,analgesic,Small Molecule,approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
1383,"natalizumab ,Tysabri",natalizumab,"antiinflammatory agent,for treatment of Crohn's disease",monoclonal antibody,approved,P13612,ITA4_HUMAN,ITGA4,Integrin alpha-4 OS=Homo sapiens GN=ITGA4 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
1384,"natural alpha interferon ,Multiferon",interferon alpha,antineoplastic agent,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1385,"natural alpha interferon,Multiferon",interferon alpha,antineoplastic agent,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1386,Nav 1.7 blocker,Nav 1.7 blocker,analgesic,Small molecule,not approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
1387,"NB1011,Thymectacin",NB-1011,antineoplastic agent,Small molecule,not approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
1388,NBI-56418,NBI-56418,antineoplastic agent,Small molecule,not approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1389,NBI-98854,NBI-98854,antipsychotic agent,Small molecule,not approved,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
1390,"NCX 1510, OX-NLA",NCX 1510,antiallergy agent,Small molecule,not approved,P33402,GCYA2_HUMAN,GUCY1A2,Guanylate cyclase soluble subunit alpha-2 (GCS-alpha-2) (EC 4.6.1.2),Enzymes,EC:4.6.1.2,Established target
1390,"NCX 1510, OX-NLA",NCX 1510,antiallergy agent,Small molecule,not approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1391,NCX 4016,NCX 4016,antithrombotic,Small molecule,not approved,P33402,GCYA2_HUMAN,GUCY1A2,Guanylate cyclase soluble subunit alpha-2 (GCS-alpha-2) (EC 4.6.1.2),Enzymes,EC:4.6.1.2,Established target
1391,NCX 4016,NCX 4016,antithrombotic,Small molecule,not approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1391,NCX 4016,NCX 4016,antithrombotic,Small molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1392,ND0611,carbidopa,antiparkinson agent,Small Molecule,approved,P20711,DDC_HUMAN,DDC,Aromatic-L-amino-acid decarboxylase OS=Homo sapiens GN=DDC PE=1 SV=1,Enzymes,EC:4.1.1.28,Established target
1393,NE-180,erythropoietin,for treatment of anemia,protein,approved,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1394,"nebivolol ,Bystolic",nebivolol,antihypertensive agent,Small Molecule,approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1395,"necitumumab , IMC-11F8",necitumumab,antineoplastic agent,monoclonal antibody,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1396,"nelarabine, GW-506U78,Arranon, Atriance",nelarabine,antineoplastic agent,Small Molecule,approved,P09884,DPOLA_HUMAN,POLA1,DNA polymerase alpha catalytic subunit OS=Homo sapiens GN=POLA1 PE=1 SV=2,Enzymes,EC:2.7.7.7,Established target
1397,"nepicastat, SYN-117",nepicastat,"for treatment of addiction,for treatment of post-traumatic stress disorder",Small molecule,not approved,P09172,DOPO_HUMAN,DBH,Dopamine beta-hydroxylase (EC 1.14.17.1) (Dopamine beta-monooxygenase) [Cleaved into: Soluble dopamine beta-hydroxylase],Enzymes,EC:1.14.17,Novel Target
1398,neramexane mesylate,neramexane,for treatment of Alzheimer's disease,Small molecule,not approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
1398,neramexane mesylate,neramexane,for treatment of Alzheimer's disease,Small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
1398,neramexane mesylate,neramexane,for treatment of Alzheimer's disease,Small molecule,not approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
1399,"neratinib, HKI-272",neratinib,antineoplastic agent,Small molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1399,"neratinib, HKI-272",neratinib,antineoplastic agent,Small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1400,"nesiritide ,Natrecor",nesiritide,for treatment of congestive heart failure,recombinant peptide,approved,P16066,ANPRA_HUMAN,NPR1,Atrial natriuretic peptide receptor A OS=Homo sapiens GN=NPR1 PE=2 SV=1,Receptors,EC:4.6.1.2,Established target
1401,"nesiritide,Natrecor",nesiritide,cardiovascular agent,recombinant peptide,approved,P20594,ANPRB_HUMAN,NPR2,Atrial natriuretic peptide receptor B OS=Homo sapiens GN=NPR2 PE=1 SV=1,Receptors,EC:4.6.1.2,Established target
1401,"nesiritide,Natrecor",nesiritide,cardiovascular agent,recombinant peptide,approved,P17342,ANPRC_HUMAN,NPR3,Atrial natriuretic peptide clearance receptor OS=Homo sapiens GN=NPR3 PE=1 SV=2,Receptors,Receptor;NPR3,Established target
1402,Nestorone (progestin) + ethinyl estradiol,ethinyl estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1402,Nestorone (progestin) + ethinyl estradiol,progestin,contraceptive,small molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
1403,Neu-2000,Neu-2000,cardioprotectant,Small molecule,not approved,Q05586,NMDZ1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo sapiens GN=GRIN1 PE=1 SV=1,Receptors,TC:1.A.10.1.6,Established target
1403,Neu-2000,Neu-2000,cardioprotectant,Small molecule,not approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
1403,Neu-2000,Neu-2000,cardioprotectant,Small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
1403,Neu-2000,Neu-2000,cardioprotectant,Small molecule,not approved,Q14957,NMDE3_HUMAN,GRIN2C,Glutamate [NMDA] receptor subunit epsilon-3 (N-methyl D-aspartate receptor subtype 2C) (NMDAR2C) (NR2C),Receptors,TC:1.A.10.1.3,Novel Target
1403,Neu-2000,Neu-2000,cardioprotectant,Small molecule,not approved,O15399,NMDE4_HUMAN,GRIN2D,Glutamate [NMDA] receptor subunit epsilon-4 OS=Homo sapiens GN=GRIN2D PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
1403,Neu-2000,Neu-2000,cardioprotectant,Small molecule,not approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
1403,Neu-2000,Neu-2000,cardioprotectant,Small molecule,not approved,O60391,NMD3B_HUMAN,GRIN3B,Glutamate [NMDA] receptor subunit 3B OS=Homo sapiens GN=GRIN3B PE=2 SV=2,Receptors,TC:1.A.10.1,Established target
1404,Neupro,rotigotine,antiparkinson agent ,small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1404,Neupro,rotigotine,antiparkinson agent ,small molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1404,Neupro,rotigotine,antiparkinson agent ,small molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1405,Nexavar,sorafenib,antineoplastic agent,Small Molecule,approved,P15056,RAF1_HUMAN,BRAF,RAF proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=RAF1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1405,Nexavar,sorafenib,antineoplastic agent,Small Molecule,approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1405,Nexavar,sorafenib,antineoplastic agent,Small Molecule,approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1405,Nexavar,sorafenib,antineoplastic agent,Small Molecule,approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1405,Nexavar,sorafenib,antineoplastic agent,Small Molecule,approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1405,Nexavar,sorafenib,antineoplastic agent,Small Molecule,approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1405,Nexavar,sorafenib,antineoplastic agent,Small Molecule,approved,P04049,RAF1_HUMAN,RAF1,RAF proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=RAF1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1406,"NF-KB Decoy,Avrina",NF-KB Decoy,antiinflammatory agent,fusion protein,not approved,P19838,NFKB1_HUMAN,NFKB1,Nuclear factor NF-kappa-B p105 subunit OS=Homo sapiens GN=NFKB1 PE=1 SV=2,Transcription factor,Transcription factor,Established target
1406,"NF-KB Decoy,Avrina",NF-KB Decoy,antiinflammatory agent,fusion protein,not approved,Q00653,NFKB2_HUMAN,NFKB2,Nuclear factor NF-kappa-B p100 subunit (DNA-binding factor KBF2) (H2TF1) (Lymphocyte translocation chromosome 10 protein) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2) (Oncogene Lyt-10) (Lyt10) [Cleaved into: Nuclear factor NF-kap,Transcription factor,Transcription factor,Novel Target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P18507,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P48169,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P14867,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P24046,GBRR1_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,Q9UN88,GBRT_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,A8MPY1,GBRR3_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1407,NG2-73,NG2-73,hypnotic,Small molecule,not approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1408,NGD-4715,NGD-4715,appetite suppressant,Small molecule,not approved,Q99705,MCHR1_HUMAN,MCHR1,Melanin-concentrating hormone receptor 1 (MCH receptor 1) (MCH-R1) (MCHR-1) (G-protein coupled receptor 24) (MCH-1R) (MCH1R) (MCHR) (SLC-1) (Somatostatin receptor-like protein),Receptors,GPCR;Rhodopsin,Novel Target
1409,"NGD-8243, MK-2295",NGD-8243,analgesic,Small molecule,not approved,Q8NER1,TRPV1_HUMAN,TRPV1,Transient receptor potential cation channel subfamily V member 1 (TrpV1) (Capsaicin receptor) (Osm-9-like TRP channel 1) (OTRPC1) (Vanilloid receptor 1),Transporters,TC:1.A.4,Established target
1410,NGX267,NGX267,for treatment of dry mouth,Small molecule,not approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1411,NI-0401,NI-0401,"antiinflammatory agent,for treatment of Chron's disease",monoclonal antibody,not approved,P04234,CD3D_HUMAN,CD3D,T-cell surface glycoprotein CD3 delta chain (T-cell receptor T3 delta chain) (CD antigen CD3d),Receptors,Receptor; T-cell receptor subunit,Established target
1411,NI-0401,NI-0401,"antiinflammatory agent,for treatment of Chron's disease",monoclonal antibody,not approved,P07766,CD3E_HUMAN,CD3E,T-cell surface glycoprotein CD3 epsilon chain OS=Homo sapiens GN=CD3E PE=1 SV=2,Receptors,Receptor; T-cell receptor subunit,Established target
1411,NI-0401,NI-0401,"antiinflammatory agent,for treatment of Chron's disease",monoclonal antibody,not approved,P09693,CD3G_HUMAN,CD3G,T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g),Receptors,Receptor; T-cell receptor subunit,Established target
1412,niacin receptor agonist,niacin receptor agonist,antiatherosclerotic agent,Small molecule,not approved,Q8TDS4,NIAR1_HUMAN,HCAR2,Niacin receptor 1 OS=Homo sapiens GN=NIACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1412,niacin receptor agonist,niacin receptor agonist,antiatherosclerotic agent,Small molecule,not approved,P49019,G109B_HUMAN,HCAR3,Niacin receptor 2 OS=Homo sapiens GN=NIACR2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1413,NIC5-15,NIC5-15,for treatment of Alzheimer's disease,Small molecule,not approved,Q96BI3,APH1A_HUMAN,APH1A,Gamma-secretase subunit APH-1A (APH-1a) (Aph-1alpha) (Presenilin-stabilization factor),Enzymes,Miscellaneous:Gamma secretase subunit;APH-1 family,Novel Target
1413,NIC5-15,NIC5-15,for treatment of Alzheimer's disease,Small molecule,not approved,Q9NZ42,PEN2_HUMAN,PSENEN,Gamma-secretase subunit PEN-2 (Presenilin enhancer protein 2),Miscellaneous,Miscellaneous;Gamma secretase subunit,Novel Target
1414,"nilotinib , AMN-107,Tasigna",nilotinib,antineoplastic agent,Small molecule,approved,P00519,ABL1_HUMAN,ABL1,Proto-oncogene tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4,Enzymes,EC:2.7.10.2,Established target
1415,Nimotuzumab,nimotuzumab,antineoplastic agent,monoclonal antibody,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1416,"nitisinone,Orfadin",nitisinone,"for treatment of restlegs legs syndrome,for treatment of hereditary tyrosinemia type 1 (HT-1)",Small Molecule,approved,P32754,HPPD_HUMAN,HPD,4-hydroxyphenylpyruvate dioxygenase OS=Homo sapiens GN=HPD PE=1 SV=2,Enzymes,EC:1.13.11.27,Established target
1417,"NKTR-102, PEG-irinotecan",PEG-irinotecan,antineoplastic agent,small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
1417,"NKTR-102, PEG-irinotecan",PEG-irinotecan,antineoplastic agent,small molecule,not approved,Q969P6,TOP1M_HUMAN,TOP1MT,"DNA topoisomerase I, mitochondrial OS=Homo sapiens GN=TOP1MT PE=1 SV=1",Enzymes,EC:5.99.1.2,Established target
1418,NKTR-105,PEG-docetaxel,antineoplastic agent,small molecule,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1418,NKTR-105,PEG-docetaxel,antineoplastic agent,small molecule,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1419,NKTR-118,PEG-naloxol,for treatment of opioid-induced constipation,small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1420,NKTR-181,NKTR-181,analgesic,Small molecule polymer conjugate,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1421,NM-702,NM-702,for treatment of intermittent claudication,small molecule,not approved,Q14432,PDE3A_HUMAN,PDE3A,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A OS=Homo sapiens GN=PDE3A PE=1 SV=3",Enzymes,EC:3.1.4,Established target
1421,NM-702,NM-702,for treatment of intermittent claudication,small molecule,not approved,Q13370,PDE3B_HUMAN,PDE3B,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B (EC 3.1.4.17) (CGIPDE1) (CGIP1) (Cyclic GMP-inhibited phosphodiesterase B) (CGI-PDE B)",Enzymes,EC:3.1.4.17,Novel Target
1422,"NMED-1077,Exalgo, Jurnista, Dilaudid",hydromorphone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor (D-OR-1) (DOR-1),Receptors,GPCR;Rhodopsin,Established target
1422,"NMED-1077,Exalgo, Jurnista, Dilaudid",hydromorphone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1422,"NMED-1077,Exalgo, Jurnista, Dilaudid",hydromorphone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1423,NMS-1116354,NMS-1116354,antineoplastic agent,small molecule,not approved,O00311,CDC7_HUMAN,CDC7,Cell division cycle 7-related protein kinase (CDC7-related kinase) (HsCdc7) (huCdc7) (EC 2.7.11.1),Enzymes,EC:2.7.11.1,Novel Target
1424,"NN 304, insulin detemir,Levemir",insulin detemir,antidiabetic,recombinant protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1425,"NN-1215,Basulin",insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1426,"NN1250,Degludec",insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1427,"NN1952, oral insulin analogue",NN1952,antidiabetic,protein,not approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1428,"NN5401,DegludecPlus",insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1429,NN9924,NN9924,antidiabetic,protein,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1430,NNZ-2566,NNZ-2566,neuroprotectant,small molecule,not approved,P05019,IGF1_HUMAN,IGF1,Insulin-like growth factor I (IGF-I) (Mechano growth factor) (MGF) (Somatomedin-C),Ligand,Ligand;Growth factor,Novel Target
1431,"nonacog alfa,BeneFIX",nonacog alfa,anticoagulant,recombinant protein,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1432,Norditropin,somatropin recombinant,"For treatment of growth disorders,for treatment of spinal muscular atrophy",recombinant protein,approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1432,Norditropin,somatropin recombinant,"For treatment of growth disorders,for treatment of spinal muscular atrophy",recombinant protein,approved,P16471,PRLR_HUMAN,PRLR,Prolactin receptor (PRL-R),Receptors,Receptor; Type 1 cytokine receptor,Established target
1433,"norelgestromin/ethinyl estradiol,Ortho Evra",ethinyl estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1433,"norelgestromin/ethinyl estradiol,Ortho Evra",norelgestromin,contraceptive,Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1433,"norelgestromin/ethinyl estradiol,Ortho Evra",norelgestromin,contraceptive,Small molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
1434,Norelin,Norelin,antineoplastic agent,vaccine,not approved,P01148,GON1_HUMAN,GNRH1,Progonadoliberin-1 (Progonadoliberin I) [Cleaved into: Gonadoliberin-1 (Gonadoliberin I) (Gonadorelin) (Gonadotropin-releasing hormone I) (GnRH-I) (Luliberin I) (Luteinizing hormone-releasing hormone I) (LH-RH I); GnRH-associated peptide 1 (GnRH-associate,Ligand,Ligand;GnRH,Novel Target
1435,"noscapine, CB3304",noscapine,antineoplastic agent,small molecule,not approved,Q16665,HIF1A_HUMAN,HIF1A,Hypoxia-inducible factor 1-alpha (HIF-1-alpha) (HIF1-alpha) (ARNT-interacting protein) (Basic-helix-loop-helix-PAS protein MOP1) (Class E basic helix-loop-helix protein 78) (bHLHe78) (Member of PAS protein 1) (PAS domain-containing protein 8),Miscellaneous,Transcription factor,Novel Target
1436,"Nova21027,Catioprost",latanoprost,for treatment of glaucoma,Small Molecule,approved,P43088,PF2R_HUMAN,PTGFR,Prostaglandin F2-alpha receptor OS=Homo sapiens GN=PTGFR PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1437,"NOVA-22007,Vekacia, Cyclokat",Cyclosporine A,"immunosuppressant,opthalmological agent",Small molecule,approved,P49069,CAMLG_HUMAN,CAMLG,Calcium signal-modulating cyclophilin ligand (CAML),Miscellaneous,Miscellaneous:target for cyclosporine,Established target
1437,"NOVA-22007,Vekacia, Cyclokat",Cyclosporine A,"immunosuppressant,opthalmological agent",Small molecule,approved,Q96LZ3,CANB2_HUMAN,PPP3R2,Calcineurin subunit B type 2 OS=Homo sapiens GN=PPP3R2 PE=2 SV=3,Miscellaneous,Enzyme regulator,Established target
1438,"NP101,Zelrix",sumatriptan,antimigraine agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1438,"NP101,Zelrix",sumatriptan,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1438,"NP101,Zelrix",sumatriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1438,"NP101,Zelrix",sumatriptan,antimigraine agent,Small Molecule,approved,P30939,5HT1F_HUMAN,HTR1F,5-hydroxytryptamine receptor 1F OS=Homo sapiens GN=HTR1F PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1439,"NP-50301,iDESTRIN",17-beta estradiol,opthalmological agent,Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1439,"NP-50301,iDESTRIN",17-beta estradiol,opthalmological agent,Small molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1440,"NPL-2008, Fluoxetine",Fluoxetine,for treatment of autism,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1440,"NPL-2008, Fluoxetine",Fluoxetine,for treatment of autism,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1441,NPS-2143,NPS-2143,antiosteoporotic agent,small molecule,not approved,P41180,CASR_HUMAN,CASR,Extracellular calcium-sensing receptor OS=Homo sapiens GN=CASR PE=1 SV=2,Receptors,GPCR;Glutamate,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1442,NRL-01,diazepam,anticonvulsant,Small Molecule,approved,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1443,"NRM8499, tramiprosate prodrug",NRM8499,for treatment of Alzheimer's disease,small molecule,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
1444,NRP290,NRP290,analgesic,small molecule,not approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1444,NRP290,NRP290,analgesic,small molecule,not approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1444,NRP290,NRP290,analgesic,small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1445,NRP409,triiodothyronine (T3),hormone replacement,small molecule,not approved,P10827,THA_HUMAN,THRA,Thyroid hormone receptor alpha OS=Homo sapiens GN=THRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
1445,NRP409,triiodothyronine (T3),hormone replacement,small molecule,not approved,P10828,THB_HUMAN,THRB,Thyroid hormone receptor beta OS=Homo sapiens GN=THRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1446,"NRX-5183, VTP-195183",NRX-5183,hematopoietic agent,small molecule,not approved,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1447,"NS-1209, SPD-502",NS-1209,neuroprotectant,unknown,not approved,P39086,GRIK1_HUMAN,GRIK1,GRIK1 108 kDa protein,Receptors,TC:1.A.10.1,Established target
1448,NS-304,NS-304,antihypertensive agent,small molecule,not approved,P43119,PI2R_HUMAN,PTGIR,Prostacyclin receptor OS=Homo sapiens GN=PTGIR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1449,NSD-644,NSD-644,"analgesic,antidepressant",small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1449,NSD-644,NSD-644,"analgesic,antidepressant",small molecule,not approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1449,NSD-644,NSD-644,"analgesic,antidepressant",small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1450,NSD-788,NSD-788,antidepressant,small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1450,NSD-788,NSD-788,antidepressant,small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1451,"NU1618, tranilast + allopurinol",allopurinol,for treatment of gout,Small Molecule,approved,P47989,XDH_HUMAN,XDH,Xanthine dehydrogenase/oxidase OS=Homo sapiens GN=XDH PE=1 SV=4,Enzymes,EC:1.17.1.4; 1.17.3.2,Established target
1452,"NU172,",NU172,anticoagulant,aptamer,not approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
1453,NuLeusin,interleukin-2,antineoplastic agent,protein,not approved,P01589,IL2RA_HUMAN,IL2RA,Interleukin-2 receptor alpha chain OS=Homo sapiens GN=IL2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1453,NuLeusin,interleukin-2,antineoplastic agent,protein,not approved,P14784,IL2RB_HUMAN,IL2RB,Interleukin-2 receptor subunit beta OS=Homo sapiens GN=IL2RB PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1453,NuLeusin,interleukin-2,antineoplastic agent,protein,not approved,P31785,IL2RG_HUMAN,IL2RG,Cytokine receptor common gamma chain OS=Homo sapiens GN=IL2RG PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1454,NuPIAO,erythropoiesis-stimulating agent,for treatment of anemia,protein,not approved,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1455,Nuvion,visilizumab,"antiinflammatory agent,immunosuppressant,for treatment of Chron's disease,for treatment of ulcerative colitis",monoclonal antibody,not approved,P04234,CD3D_HUMAN,CD3D,T-cell surface glycoprotein CD3 delta chain (T-cell receptor T3 delta chain) (CD antigen CD3d),Receptors,Receptor; T-cell receptor subunit,Established target
1455,Nuvion,visilizumab,"antiinflammatory agent,immunosuppressant,for treatment of Chron's disease,for treatment of ulcerative colitis",monoclonal antibody,not approved,P07766,CD3E_HUMAN,CD3E,T-cell surface glycoprotein CD3 epsilon chain OS=Homo sapiens GN=CD3E PE=1 SV=2,Receptors,Receptor; T-cell receptor subunit,Established target
1455,Nuvion,visilizumab,"antiinflammatory agent,immunosuppressant,for treatment of Chron's disease,for treatment of ulcerative colitis",monoclonal antibody,not approved,P09693,CD3G_HUMAN,CD3G,T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g),Receptors,Receptor; T-cell receptor subunit,Established target
1456,NV-52,NV-52,antiinflammatory agent,small molecule,not approved,P24557,THAS_HUMAN,TBXAS1,Thromboxane-A synthase,Enzymes,EC:5.3.99.5,Novel Target
1457,"NVA237, inhaled glycopyrronium bromide",glycopyrronium,for treatment of chronic obstructive pulmonary disease (COPD),Small molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1458,"NVD-422, tizanidine oral spray",tizanidine,for treatment of skeletal muscular spasticity,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1458,"NVD-422, tizanidine oral spray",tizanidine,for treatment of skeletal muscular spasticity,Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1458,"NVD-422, tizanidine oral spray",tizanidine,for treatment of skeletal muscular spasticity,Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1460,NXN-188,NXN-188,antimigraine agent,small molecule,not approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1460,NXN-188,NXN-188,antimigraine agent,small molecule,not approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1460,NXN-188,NXN-188,antimigraine agent,small molecule,not approved,P29475,NOS1_HUMAN,NOS1,"Nitric oxide synthase, brain (EC 1.14.13.39) (Constitutive NOS) (NC-NOS) (NOS type I) (Neuronal NOS) (N-NOS) (nNOS) (Peptidyl-cysteine S-nitrosylase NOS1) (bNOS)",Enzymes,EC:1.14.13.39,Novel Target
1461,o/Zuplenz,ondansetron,antiemetic,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1462,"OAS-PAC-100,Paclical, Pacliex",paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1462,"OAS-PAC-100,Paclical, Pacliex",paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1463,"obatoclax, GX15-070",obatoclax,antineoplastic agent,small molecule,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1464,"OBE101,Histalean",betahistine,antiobesity agent,Small molecule,not approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1464,"OBE101,Histalean",betahistine,antiobesity agent,Small molecule,not approved,Q9Y5N1,HRH3_HUMAN,HRH3,Histamine H3 receptor (H3R) (HH3R) (G-protein coupled receptor 97),Receptors,GPCR;Rhodopsin,Novel Target
1465,"obeticholic acid, INT-747",obeticholic acid,"for treatment of non-alcoholic fatty liver disease (NAFLD),for treatment of Primary Biliary Cirrhosis (PBC)",small molecule,approved,Q96RI1,NR1H4_HUMAN,NR1H4,Bile acid receptor (Farnesoid X-activated receptor) (Farnesol receptor HRR-1) (Nuclear receptor subfamily 1 group H member 4) (Retinoid X receptor-interacting protein 14) (RXR-interacting protein 14),Receptors,Nuclear receptor,Established target
1466,OC000459,OC000459 ,antiallergy agent,small molecule,not approved,Q9Y5Y4,GPR44_HUMAN,PD2R2,Putative G-protein coupled receptor 44 (Chemoattractant receptor-homologous molecule expressed on Th2 cells) (CD antigen CD294),Receptors,GPCR;Rhodopsin,Novel Target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P18507,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P48169,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P14867,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P24046,GBRR1_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,Q9UN88,GBRT_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,A8MPY1,GBRR3_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1467,ocinaplon,ocinaplon,anxiolytic,small molecule,not approved,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
1468,ocrelizumab,ocrelizumab,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Miscellaneous,MS4A family,Established target
1469,"octaparine, AVE-5026",heparin,antithrombotic,Small Molecule,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1469,"octaparine, AVE-5026",heparin,antithrombotic,Small Molecule,approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
1470,"octrotide,Atrigel",octreotide,antineoplastic agent,peptide,approved,P30872,SSR1_HUMAN,SSTR1,Somatostatin receptor type 1 OS=Homo sapiens GN=SSTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1470,"octrotide,Atrigel",octreotide,antineoplastic agent,peptide,approved,P30874,SSR2_HUMAN,SSTR2,Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SRIF-1),Receptors,GPCR;Rhodopsin,Established target
1470,"octrotide,Atrigel",octreotide,antineoplastic agent,peptide,approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1471,"odanacatib, MK-0822",odanacatib,antiosteoporotic agent,small molecule,not approved,P43235,CATK_HUMAN,CTSK,Cathepsin K (EC 3.4.22.38) (Cathepsin O) (Cathepsin O2) (Cathepsin X),Enzymes,EC:3.4.22.38,Novel Target
1472,"Oglemilast, GRC 3886",Oglemilast,antiasthmatic agent,small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
1472,"Oglemilast, GRC 3886",Oglemilast,antiasthmatic agent,small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
1473,OGX-011,OGX-011,antineoplastic agent,antisense oligo,not approved,P51788,CLUS_HUMAN,CLU,"Clusterin (Aging-associated gene 4 protein) (Apolipoprotein J) (Apo-J) (Complement cytolysis inhibitor) (CLI) (Complement-associated protein SP-40,40) (Ku70-binding protein 1) (NA1/NA2) (Testosterone-repressed prostate message 2) (TRPM-2) [Cleaved into: C",Miscellaneous,Miscellaneous;Clusterin family,Novel Target
1474,OGX-427,OGX-427,antineoplastic agent,antisense oligo,not approved,P04792,HSPB1_HUMAN,HSPB1,Heat shock protein beta-1 (HspB1) (28 kDa heat shock protein) (Estrogen-regulated 24 kDa protein) (Heat shock 27 kDa protein) (HSP 27) (Stress-responsive protein 27) (SRP27),Miscellaneous,HSP20-like_chaperon,Novel Target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P28566,5HT1E_HUMAN,HTR1E,5-hydroxytryptamine receptor 1E,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1475,"olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv",olanzapine,antipsychotic agent,Small Molecule,approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",fluoxetine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P28566,5HT1E_HUMAN,HTR1E,5-hydroxytryptamine receptor 1E,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1476,"Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)",olanzapine,"antidepressant,for treatment of bipolar disorder",Small Molecule,approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1477,"olesoxime, TRO19622",olesoxime,for treatment of motor neuron disease,small molecule,not approved,P30536,TSPOA_HUMAN,TSPO,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
1477,"olesoxime, TRO19622",olesoxime,for treatment of motor neuron disease,small molecule,not approved,P21796,VDAC1_HUMAN,VDAC1,Voltage-dependent anion-selective channel protein 1,Transporters,TC:1.B.8,Novel Target
1477,"olesoxime, TRO19622",olesoxime,for treatment of motor neuron disease,small molecule,not approved,P45880,VDAC2_HUMAN,VDAC2,Voltage-dependent anion-selective channel protein 2,Transporters,TC:1.B.8,Novel Target
1477,"olesoxime, TRO19622",olesoxime,for treatment of motor neuron disease,small molecule,not approved,Q9Y277,VDAC3_HUMAN,VDAC3,Voltage-dependent anion-selective channel protein 3,Transporters,TC:1.B.8,Novel Target
1478,"olmesartan medoxomil (CS-866),Benicar",olmesartan,antihypertensive agent,Small Molecule,approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1479,"olmesartan, DE-092",olmesartan,for treatment of glaucoma,Small Molecule,approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1480,"olopatadine hydrochloride,Patanase",olopatadine,antiallergy agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1481,Omacetaxine,omacetaxine mepesuccinate,antineoplastic agent,small molecule,not approved,Ribosome A-site,Ribosome A-site,Ribosome A-site,Ribosome A-site,Miscellaneous,Miscellaneous;Ribosome A-site,Novel Target
1482,ombrabulin,ombrabulin,antineoplastic agent,small molecule,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1483,Omecamtiv,omecamtiv mecarbil,for treatment of heart failure,small molecule,not approved,Cardiac Mysoin,Cardiac Mysoin,Cardiac Mysoin,Cardiac Mysoin,Cardiac Mysoin,Cardiac Mysoin,Novel Target
1484,"omeprazole + sodium bicarbonate,Acitrel",omeprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1485,"omeprazole, SAN-05,Zegerid, Rapinex",omeprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1486,"omeprazole,Prilosec, Losec, Omeprazon, Omepral",omeprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1487,"omigapil, SNT-317",omigapil,"antiparkinson agent,for treatment of amyotrophic lateral sclerosis (ALS)",small molecule,not approved,P04406,G3P_HUMAN,GAPDA,Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) (Peptidyl-cysteine S-nitrosylase GAPDH) (EC 2.6.99.-),Enzymes,EC:1.2.1.12; 2.6.99.-,Novel Target
1487,"omigapil, SNT-317",omigapil,"antiparkinson agent,for treatment of amyotrophic lateral sclerosis (ALS)",small molecule,not approved,Q8IUQ4,SIAH1_HUMAN,SIAH1,E3 ubiquitin-protein ligase SIAH1,Enzymes,EC:6.3.2.-,Novel Target
1488,Omnitarg,pertuzumab,antineoplastic agent,monoclonal antibody,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1489,OMP-21M18,demcizumab,antineoplastic agent,antibody,not approved,Q9NR61,DLL4_HUMAN,DLL4,Delta-like protein 4 (Drosophila Delta homolog 4) (Delta4),Miscellaneous,Ligand;Delta,Novel Target
1490,OMP-59R5,OMP-59R5,antineoplastic agent,monoclonal antibody,not approved,Q04721,NOTC2_HUMAN,NOTCH2,Neurogenic locus notch homolog protein 2 (Notch 2) (hN2) [Cleaved into: Notch 2 extracellular truncation; Notch 2 intracellular domain],Receptors,Receptors;Notch,Novel Target
1490,OMP-59R5,OMP-59R5,antineoplastic agent,monoclonal antibody,not approved,Q9UM47,NOTC3_HUMAN,NOTCH3,Neurogenic locus notch homolog protein 3 (Notch 3) [Cleaved into: Notch 3 extracellular truncation; Notch 3 intracellular domain],Receptors,Receptors;Notch,Novel Target
1491,OMS-103HP,amitriptyline,analgesic,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1491,OMS-103HP,amitriptyline,analgesic,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1491,OMS-103HP,amitriptyline,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1491,OMS-103HP,amitriptyline,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1491,OMS-103HP,amitriptyline,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1491,OMS-103HP,amitriptyline,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1491,OMS-103HP,ketoprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1491,OMS-103HP,ketoprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1491,OMS-103HP,ketoprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1491,OMS-103HP,ketoprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1491,OMS-103HP,oxymetazoline,analgesic,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1491,OMS-103HP,oxymetazoline,analgesic,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1491,OMS-103HP,oxymetazoline,analgesic,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1491,OMS-103HP,oxymetazoline,analgesic,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1492,"ON 01910.Na,Estybon",rigosertib,antineoplastic agent,small molecule,not approved,P42336,PK3CA_HUMAN,PIK3CA,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PI3-kinase subunit alpha) (PI3K-alpha) (PtdIns-3-kinase subunit alpha) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
1492,"ON 01910.Na,Estybon",rigosertib,antineoplastic agent,small molecule,not approved,P42338,PK3CB_HUMAN,PIK3CB,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Enzymes,EC:2.7.1.153,Novel Target
1492,"ON 01910.Na,Estybon",rigosertib,antineoplastic agent,small molecule,not approved,O00329,PK3CD_HUMAN,PIK3CD,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3-kinase subunit delta) (PI3K-delta) (PtdIns-3-kinase subunit delta) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
1492,"ON 01910.Na,Estybon",rigosertib,antineoplastic agent,small molecule,not approved,P53350,PLK1_HUMAN,PLK1,Serine/threonine-protein kinase PLK1 (EC 2.7.11.21) (Polo-like kinase 1) (PLK-1) (Serine/threonine-protein kinase 13) (STPK13),Enzymes,EC:2.7.11.21,Novel Target
1493,OncoGel,paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1493,OncoGel,paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1494,OncoVEX,OncoVEX GM-CSF,antineoplastic agent,virus,not approved,P15509,CSF2R_HUMAN,CSF2RA,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha OS=Homo sapiens GN=CSF2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1495,ondansetron,ondansetron,antiemetic,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1496,"ONX 0801, BCG945",ONX 0801,antineoplastic agent,unknown,not approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
1497,ONX 0912,oprozomib,antineoplastic agent,small molecule,not approved,P20618,PSB1_HUMAN,PSMB1,Proteasome subunit beta type-1 OS=Homo sapiens GN=PSMB1 PE=1 SV=2,Enzymes,EC:3.4.25.1,Established target
1497,ONX 0912,oprozomib,antineoplastic agent,small molecule,not approved,P49721,PSB2_HUMAN,PSMB2,Proteasome subunit beta type-2 OS=Homo sapiens GN=PSMB2 PE=1 SV=1,Enzymes,EC:3.4.25.1,Established target
1497,ONX 0912,oprozomib,antineoplastic agent,small molecule,not approved,P28074,PSB5_HUMAN,PSMB5,Proteasome subunit beta type-5 OS=Homo sapiens GN=PSMB5 PE=1 SV=3,Enzymes,EC:3.4.25.1,Established target
1497,ONX 0912,oprozomib,antineoplastic agent,small molecule,not approved,Q99460,PSMD1_HUMAN,PSMD1,26S proteasome non-ATPase regulatory subunit 1 OS=Homo sapiens GN=PSMD1 PE=1 SV=2,Miscellaneous,Enzyme regulator,Established target
1497,ONX 0912,oprozomib,antineoplastic agent,small molecule,not approved,Q13200,PSMD2_HUMAN,PSMD2,26S proteasome non-ATPase regulatory subunit 2 OS=Homo sapiens GN=PSMD2 PE=1 SV=3,Miscellaneous,Enzyme regulator,Established target
1498,Opaxio,paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1498,Opaxio,paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1499,OPB-51602,OPB-51602,antineoplastic agent,small molecule,not approved,P40763,STAT3_HUMAN,STAT3,Signal transducer and activator of transcription 3 (Acute-phase response factor),Miscellaneous,Transcription factor,Novel Target
1501,OPC-28326,OPC-28326,vasodilator,small molecule,not approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1501,OPC-28326,OPC-28326,vasodilator,small molecule,not approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1502,OPC-34712,OPC-34712,antidepressant,small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1502,OPC-34712,OPC-34712,antidepressant,small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1502,OPC-34712,OPC-34712,antidepressant,small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1502,OPC-34712,OPC-34712,antidepressant,small molecule,not approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1503,OPC-51803,OPC-51803,for treatment of incontinence,small molecule,not approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1504,"oprelvekin, YM 294, recombinant human interl/",oprelvekin,thrombopoietic,protein,approved,Q14626,I11RA_HUMAN,IL11RA,IL11RA Isoform HCR1 of Interleukin-11 receptor alpha chain precursor,Receptors,Receptor; Type 1 cytokine receptor,Established target
1505,Oracea,doxycyklin,for treatment of dental disease,Small molecule,approved,P22894,MMP8_HUMAN,MMP8,Neutrophil collagenase (EC 3.4.24.34) (Matrix metalloproteinase-8) (MMP-8) (PMNL collagenase) (PMNL-CL),Enzymes,EC:3.4.24.34,Established target
1506,"oral contraceptive,Pill-Plus",estrogen,"contraceptive,for treatment of female sexual dysfunction",Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1506,"oral contraceptive,Pill-Plus",estrogen,"contraceptive,for treatment of female sexual dysfunction",Small molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1506,"oral contraceptive,Pill-Plus",progestogen,"contraceptive,for treatment of female sexual dysfunction",small molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
1507,"oral estriol,Trimesta",estriol E3,for treatment of multiple sclerosis,Small molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1507,"oral estriol,Trimesta",estriol E3,for treatment of multiple sclerosis,Small molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1508,"oral octreotide actetate ,Octreolin",octreotide,antihypertensive agent,peptide,approved,P30872,SSR1_HUMAN,SSTR1,Somatostatin receptor type 1 OS=Homo sapiens GN=SSTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1509,"oral octreotide actetate,Octreolin",octreotide,antihypertensive agent,peptide,approved,P30874,SSR2_HUMAN,SSTR2,Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SRIF-1),Receptors,GPCR;Rhodopsin,Established target
1509,"oral octreotide actetate,Octreolin",octreotide,antihypertensive agent,peptide,approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1510,oral paclitaxel,paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1510,oral paclitaxel,paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1511,Oral-lyn,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1512,Oraqix,lidocaine,anesthetic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
1512,Oraqix,lidocaine,anesthetic,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1512,Oraqix,lidocaine,anesthetic,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
1512,Oraqix,prilocaine,anesthetic,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1513,"oregovamab,OvaRex",oregovamab,antineoplastic agent,monoclonal antibody,not approved,Q8WXI7,MUC16_HUMAN,MUC16,Mucin-16 (MUC-16) (Ovarian cancer-related tumor marker CA125) (CA-125) (Ovarian carcinoma antigen CA125),Miscellaneous,StructuralAndAdhesion;Mucin_16,Novel Target
1514,Orencia,abatacept,"antiinflammatory agent,DMARD",fusion protein,approved,P33681,CD80_HUMAN,CD80,T-lymphocyte activation antigen CD80 OS=Homo sapiens GN=CD80 PE=1 SV=1,Receptors,Receptor; T-cell surface receptor,Established target
1514,Orencia,abatacept,"antiinflammatory agent,DMARD",fusion protein,approved,P42081,CD86_HUMAN,CD86,T-lymphocyte activation antigen CD86 OS=Homo sapiens GN=CD86 PE=1 SV=1,Miscellaneous,T-lymphocyte activation antigen CD86,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Transporters,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P28566,5HT1E_HUMAN,HTR1E,5-hydroxytryptamine receptor 1E,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",olanzapine,antipsychotic agent,Small Molecule,approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,O43497,CAC1H_HUMAN,CACNA1G,Voltage-dependent T-type calcium channel subunit alpha-1H OS=Homo sapiens GN=CACNA1H PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,O95180,CAC1H_HUMAN,CACNA1H,Voltage-dependent T-type calcium channel subunit alpha-1H OS=Homo sapiens GN=CACNA1H PE=1 SV=4,Transporters,TC:1.A.1.11.5,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,Q9P0X4,CAC1I_HUMAN,CACNA1I,Voltage-dependent T-type calcium channel subunit alpha-1I OS=Homo sapiens GN=CACNA1I PE=1 SV=1,Transporters,TC:1.A.1.11.7,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,Q9UI33,SCNBA_HUMAN,SCN11A,Sodium channel protein type 11 subunit alpha OS=Homo sapiens GN=SCN11A PE=1 SV=2,Transporters,TC:1.A.1.10.9,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,Q07699,SCN1B_HUMAN,SCN1B,Sodium channel subunit beta-1,Transporters,TC:8.A.17,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,Q99250,SCN2A_HUMAN,SCN2A,Sodium channel protein type 2 subunit alpha (HBSC II) (Sodium channel protein brain II subunit alpha) (Sodium channel protein type II subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.2),Transporters,TC:1.A.1.10,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,O60939,SCN2B_HUMAN,SCN2B,Sodium channel subunit beta-2,Transporters,TC:8.A.17.2.1,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,Q9NY46,SCN3A_HUMAN,SCN3A,Sodium channel protein type 3 subunit alpha (Sodium channel protein brain III subunit alpha) (Sodium channel protein type III subunit alpha) (Voltage-gated sodium channel subtype III) (Voltage-gated sodium channel subunit alpha Nav1.3),Transporters,TC:1.A.1.10,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,Q9NY72,SCN3B_HUMAN,SCN3B,Sodium channel subunit beta-3,Transporters,TC:8.A.17,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,P35499,SCN4A_HUMAN,SCN4A,Sodium channel protein type 4 subunit alpha (SkM1) (Sodium channel protein skeletal muscle subunit alpha) (Sodium channel protein type IV subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.4),Transporters,TC:1.A.1.10.4,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,Q8IWT1,SCN4B_HUMAN,SCN4B,Sodium channel subunit beta-4,Transporters,TC:8.A.17.2.2,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1515,"OREX-003, olanzapine plus zonisamide SR",zonisamide,antipsychotic agent,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
1516,"orlistat,Xenical",orlistat,antiobesity agent,Small Molecule,approved,P49327,FAS_HUMAN,FASN,Fatty acid synthase,Enzymes,EC:2.3.1.85,Established target
1516,"orlistat,Xenical",orlistat,antiobesity agent,Small Molecule,approved,P06858,LIPL_HUMAN,LPL,Lipoprotein lipase OS=Homo sapiens GN=LPL PE=1 SV=1,Enzymes,EC:3.1.1.34,Established target
1516,"orlistat,Xenical",orlistat,antiobesity agent,Small Molecule,approved,P16233,LIPP_HUMAN,PNLIP,Pancreatic triacylglycerol lipase OS=Homo sapiens GN=PNLIP PE=1 SV=1,Enzymes,EC:3.1.1.3,Established target
1517,"ORMD-0801, oral insulin",insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1518,"ORMD-0802, insulin suppository",insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1519,"ORMD-0901, oral GLP-1 Analog",ORMD-0901,antidiabetic,peptide,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1520,ortataxel,ortataxel,antineoplastic agent,small molecule,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1520,ortataxel,ortataxel,antineoplastic agent,small molecule,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1521,"orteronel, TAK-700",orteronel,antineoplastic agent,small molecule,not approved,P05093,CP17A_HUMAN,CYP17A1,"Steroid 17-alpha-hydroxylase/17,20 lyase (EC 1.14.99.9) (CYPXVII) (Cytochrome P450 17A1) (Cytochrome P450-C17) (Cytochrome P450c17) (Steroid 17-alpha-monooxygenase)",Enzymes,EC:1.14.99.9,Established target
1522,Orthokine,Orthokine serum,"antiinflammatory agent,DMARD",autologous cell therapy,not approved,not applicable,not applicable,not applicable,not applicable,not applicable,not applicable,not applicable
1524,OSI-027,OSI-027,antineoplastic agent,small molecule,not approved,P42345,FRAP_HUMAN,MTOR,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1525,OSI-461,OSI-461,antineoplastic agent,small molecule,not approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
1526,OSI-7904L,OSI-7904L,antineoplastic agent,small molecule,not approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
1527,OSI-906,OSI-906,antineoplastic agent,small molecule,not approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1528,OSI-930,OSI-930,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1529,"ospemifene,Ophena",ospemifene,for treatment of postmenopausal vaginal atrophy,small molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1529,"ospemifene,Ophena",ospemifene,for treatment of postmenopausal vaginal atrophy,small molecule,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1530,"Ostabolin-C,  ZT-031",Ostabolin-C,antiosteoporotic agent,peptide,not approved,Q03431,PTH1R_HUMAN,PTH1R,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1530,"Ostabolin-C,  ZT-031",Ostabolin-C,antiosteoporotic agent,peptide,not approved,P49190,PTH2R_HUMAN,PTH2R,Parathyroid hormone 2 receptor (PTH2 receptor),Receptors,GPCR;Secretin,Established target
1531,"ostarine, GTx-024",enobosarm,hormone replacement,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1533,OT-730,OT-730,for treatment of glaucoma,small molecule,not approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1533,OT-730,OT-730,for treatment of glaucoma,small molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1534,"otamixaban, XRP0673",otamixaban,antithrombotic,small molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1535,"otelixizumab, TRX4, GSK2136525",otelixizumab,"antidiabetic,antiinflammatory agent,DMARD",monoclonal antibody,not approved,P04234,CD3D_HUMAN,CD3D,T-cell surface glycoprotein CD3 delta chain (T-cell receptor T3 delta chain) (CD antigen CD3d),Receptors,Receptor; T-cell receptor subunit,Established target
1535,"otelixizumab, TRX4, GSK2136525",otelixizumab,"antidiabetic,antiinflammatory agent,DMARD",monoclonal antibody,not approved,P07766,CD3E_HUMAN,CD3E,T-cell surface glycoprotein CD3 epsilon chain OS=Homo sapiens GN=CD3E PE=1 SV=2,Receptors,Receptor; T-cell receptor subunit,Established target
1535,"otelixizumab, TRX4, GSK2136525",otelixizumab,"antidiabetic,antiinflammatory agent,DMARD",monoclonal antibody,not approved,P09693,CD3G_HUMAN,CD3G,T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g),Receptors,Receptor; T-cell receptor subunit,Established target
1536,OTO-104,dexamethasone,"antiinflammatory agent,glucocorticoid,for treatment of Meniere's disease",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1537,"OX 19, sublingual desmopressin",desmopressin,for treatment of incontinence,peptide,approved,P37288,V1AR_HUMAN,AVPR1A,Vasopressin V1a receptor OS=Homo sapiens GN=AVPR1A PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1537,"OX 19, sublingual desmopressin",desmopressin,for treatment of incontinence,peptide,approved,P47901,V1BR_HUMAN,AVPR1B,Vasopressin V1b receptor OS=Homo sapiens GN=AVPR1B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1537,"OX 19, sublingual desmopressin",desmopressin,for treatment of incontinence,peptide,approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1539,OX17,famotidine,acid reducer,Small Molecule,approved,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1539,OX17,omeprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1540,"OX-22, zolpidem sublingual,Edluar, Sublinox",zolpidem,hypnotic,Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
1540,"OX-22, zolpidem sublingual,Edluar, Sublinox",zolpidem,hypnotic,Small Molecule,approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
1540,"OX-22, zolpidem sublingual,Edluar, Sublinox",zolpidem,hypnotic,Small Molecule,approved,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1541,OX914,OX914,antiallergy agent,small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
1541,OX914,OX914,antiallergy agent,small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
1542,"oxandrolone ,Oxandrin",oxandrolone,anabolic agent,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1543,"oxcarbazepine controlled release, SPN804,Epliga",oxcarbazepine,anticonvulsant,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1544,OXi4503,combretastatin A1 di-phosphate,antineoplastic agent,Small molecule,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1545,"oxycodone ART, ELI216,OxyNal",oxycodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor (D-OR-1) (DOR-1),Receptors,GPCR;Rhodopsin,Established target
1545,"oxycodone ART, ELI216,OxyNal",oxycodone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1545,"oxycodone ART, ELI216,OxyNal",oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1546,"oxycodone HCl + niacin,Acurox, OxyADF",niacin,substance abuse deterrant,Small molecule,approved,Q8TDS4,NIAR1_HUMAN,GPR109A,Niacin receptor 1 OS=Homo sapiens GN=NIACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1546,"oxycodone HCl + niacin,Acurox, OxyADF",niacin,substance abuse deterrant,Small molecule,approved,P49019,G109B_HUMAN,GPR109B,Niacin receptor 2 OS=Homo sapiens GN=NIACR2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1546,"oxycodone HCl + niacin,Acurox, OxyADF",niacin,substance abuse deterrant,Small molecule,approved,P40261,NNMT_HUMAN,NNMT,Nicotinamide N-methyltransferase (EC 2.1.1.1),Enzymes,EC:2.1.1.1,Established target
1546,"oxycodone HCl + niacin,Acurox, OxyADF",niacin,substance abuse deterrant,Small molecule,approved,Q15274,NADC_HUMAN,QPRT,Nicotinate-nucleotide pyrophosphorylase [carboxylating] (EC 2.4.2.19) (Quinolinate phosphoribosyltransferase [decarboxylating]) (QAPRTase) (QPRTase),Enzymes,EC:2.4.2.19,Established target
1546,"oxycodone HCl + niacin,Acurox, OxyADF",oxycodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor (D-OR-1) (DOR-1),Receptors,GPCR;Rhodopsin,Established target
1546,"oxycodone HCl + niacin,Acurox, OxyADF",oxycodone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1546,"oxycodone HCl + niacin,Acurox, OxyADF",oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1547,"oxycodone, PTI-821,Remoxy",oxycodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1547,"oxycodone, PTI-821,Remoxy",oxycodone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1547,"oxycodone, PTI-821,Remoxy",oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1548,"oxymorphone hydrochloride, EN3202,Opana, Opana ER",oxymorphone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1548,"oxymorphone hydrochloride, EN3202,Opana, Opana ER",oxymorphone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1549,ozoralizumab,ozoralizumab,"antiinflammatory agent,DMARD",antibody fragment,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
1551,P-552-02,P-552,for treatment of dry mouth,small molecule,not approved,P78348,ACCN2_HUMAN,ACCN2,"Amiloride-sensitive cation channel 2, neuronal (Acid-sensing ion channel 1) (ASIC1) (Brain sodium channel 2) (BNaC2)",transporter,TC:1.A.6,Established target
1551,P-552-02,P-552,for treatment of dry mouth,small molecule,not approved,Q9UHC3,ASIC3_HUMAN,ACCN3,Acid-sensing ion channel 3,transporter,TC:1.A.6.1.2,Established target
1551,P-552-02,P-552,for treatment of dry mouth,small molecule,not approved,Q96FT7,ASIC3_HUMAN,ACCN4,Acid-sensing ion channel 3,transporter,TC:1.A.6,Established target
1551,P-552-02,P-552,for treatment of dry mouth,small molecule,not approved,Q16515,ASIC2_HUMAN,ASIC2,Acid-sensing ion channel 2,transporter,TC:1.A.6.1.8,Established target
1551,P-552-02,P-552,for treatment of dry mouth,small molecule,not approved,P37088,SCNNA_HUMAN,SCNN1A,Amiloride-sensitive sodium channel subunit alpha OS=Homo sapiens GN=SCNN1A PE=1 SV=1,Transporters,TC:1.A.6.1.1,Established target
1551,P-552-02,P-552,for treatment of dry mouth,small molecule,not approved,P51168,SCNNB_HUMAN,SCNN1B,Amiloride-sensitive sodium channel subunit beta OS=Homo sapiens GN=SCNN1B PE=1 SV=2,Transporters,TC:1.A.6.1.1,Established target
1551,P-552-02,P-552,for treatment of dry mouth,small molecule,not approved,P51172,SCNND_HUMAN,SCNN1D,Amiloride-sensitive sodium channel subunit delta OS=Homo sapiens GN=SCNN1D PE=1 SV=2,Transporters,TC:1.A.6,Established target
1551,P-552-02,P-552,for treatment of dry mouth,small molecule,not approved,P51170,SCNNG_HUMAN,SCNN1G,Amiloride-sensitive sodium channel subunit gamma OS=Homo sapiens GN=SCNN1G PE=1 SV=4,Transporters,TC:1.A.6.1.1,Established target
1552,"PA32540, immediate-release omeprazole + enteric-coated aspirin",acetylsalicylic acid,NSAID,Small molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1552,"PA32540, immediate-release omeprazole + enteric-coated aspirin",acetylsalicylic acid,NSAID,Small molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1552,"PA32540, immediate-release omeprazole + enteric-coated aspirin",omeprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1553,"PA-401, PA04-001",PA-401,"antiinflammatory agent,immunosuppressant",recombinant protein,not approved,P25024,CXCR1_HUMAN,CXCR1,C-X-C chemokine receptor type 1 (CXC-R1) (CXCR-1) (CDw128a) (High affinity interleukin-8 receptor A) (IL-8R A) (IL-8 receptor type 1) (CD antigen CD181),Receptors,GPCR;Rhodopsin,Novel Target
1553,"PA-401, PA04-001",PA-401,"antiinflammatory agent,immunosuppressant",recombinant protein,not approved,P25025,CXCR2_HUMAN,CXCR2,C-X-C chemokine receptor type 2 (CXC-R2) (CXCR-2) (CDw128b) (GRO/MGSA receptor) (High affinity interleukin-8 receptor B) (IL-8R B) (IL-8 receptor type 2) (CD antigen CD182),Receptors,GPCR;Rhodopsin,Novel Target
1554,Paclimer,paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1554,Paclimer,paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1555,"paclitaxel, oral,Xorane",paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1555,"paclitaxel, oral,Xorane",paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1556,"paclitaxel,Vascular Wrap",paclitaxel,for treatment of peripheral arterial disease (PAD),Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1556,"paclitaxel,Vascular Wrap",paclitaxel,for treatment of peripheral arterial disease (PAD),Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1557,pagoclone,pagoclone,"for treatment of premature ejaculation,for treatment of persistant stuttering",small molecule,not approved,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
1557,pagoclone,pagoclone,"for treatment of premature ejaculation,for treatment of persistant stuttering",small molecule,not approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
1558,"paliperidone ER, paliperidone palmitate",paliperidone,antipsychotic agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1558,"paliperidone ER, paliperidone palmitate",paliperidone,antipsychotic agent,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1559,"Palomid 529, P529",Palomid 529,for treatment of age-related macular degeneration,small molecule,not approved,P42345,FRAP_HUMAN,MTOR,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1560,Palonosetron,Palonosetron,antiemetic,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,Q96DB2,HDA11_HUMAN,HDAC11,Histone deacetylase 11 (HD11) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,P56524,HDAC4_HUMAN,HDAC4,Histone deacetylase 4 (HD4) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,Q9UQL6,HDAC5_HUMAN,HDAC5,Histone deacetylase 5 (HD5) (EC 3.5.1.98) (Antigen NY-CO-9),Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,Q8WUI4,HDAC7_HUMAN,HDAC7A,Histone deacetylase 7 (HD7) (EC 3.5.1.98) (Histone deacetylase 7A) (HD7a),Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1561,Panobinostat,Panobinostat,antineoplastic agent,small molecule,not approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
1562,"pantoprazole sodium,Protonix, Simac, Pantozol, Pantoloc, Panteca",pantoprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1563,"pardoprunox, SLV 308",pardoprunox,antiparkinson agent,small molecule,not approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1563,"pardoprunox, SLV 308",pardoprunox,antiparkinson agent,small molecule,not approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1563,"pardoprunox, SLV 308",pardoprunox,antiparkinson agent,small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1563,"pardoprunox, SLV 308",pardoprunox,antiparkinson agent,small molecule,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1563,"pardoprunox, SLV 308",pardoprunox,antiparkinson agent,small molecule,not approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1563,"pardoprunox, SLV 308",pardoprunox,antiparkinson agent,small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1563,"pardoprunox, SLV 308",pardoprunox,antiparkinson agent,small molecule,not approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1564,"parecoxib sodium,Dynastat",parecoxib,"antiinflammatory agent,NSAID",small molecule,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1565,"paricalcitol , Zemplar",paricalcitol,for treatment of hyperparathyroidism,Small Molecule,not approved,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
1566,"paroxetine hydrochloride,Paxil, Seroxat",paroxetine,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1567,"pasireotide, SOM230",pasireotide,"antineoplastic agent,for treatment of acromegaly",peptide,not approved,P30872,SSR1_HUMAN,SSTR1,Somatostatin receptor type 1 OS=Homo sapiens GN=SSTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1567,"pasireotide, SOM230",pasireotide,"antineoplastic agent,for treatment of acromegaly",peptide,not approved,P30874,SSR2_HUMAN,SSTR2,Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SRIF-1),Receptors,GPCR;Rhodopsin,Established target
1567,"pasireotide, SOM230",pasireotide,"antineoplastic agent,for treatment of acromegaly",peptide,not approved,P32745,SSR3_HUMAN,SSTR3,Somatostatin receptor type 3 (SS-3-R) (SS3-R) (SS3R) (SSR-28),Receptors,GPCR;Rhodopsin,Novel Target
1567,"pasireotide, SOM230",pasireotide,"antineoplastic agent,for treatment of acromegaly",peptide,not approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1568,Pazopanib,Pazopanib,antineoplastic agent,small molecule,approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1568,Pazopanib,Pazopanib,antineoplastic agent,small molecule,approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1568,Pazopanib,Pazopanib,antineoplastic agent,small molecule,approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1569,"PB1023, GLP-1-ELP-120,Glymera",PB1023,antidiabetic,protein,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1571,PC-A11,bleomycin,antineoplastic agent,Small Molecule,approved,P18858,DNLI1_HUMAN,LIG1,DNA ligase 1 (EC 6.5.1.1) (DNA ligase I) (Polydeoxyribonucleotide synthase [ATP] 1),Enzymes,EC:6.5.1.1,Established target
1572,PC-DAC:Exendin-4,exendin-4,antidiabetic,peptide,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor (GLP-1 receptor) (GLP-1-R) (GLP-1R),Receptors,GPCR;Secretin,Established target
1573,"PCI-27483, CRA-024781",CRA-024781,antineoplastic agent,Small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
1573,"PCI-27483, CRA-024781",CRA-024781,antineoplastic agent,Small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1573,"PCI-27483, CRA-024781",CRA-024781,antineoplastic agent,Small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1573,"PCI-27483, CRA-024781",CRA-024781,antineoplastic agent,Small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1573,"PCI-27483, CRA-024781",CRA-024781,antineoplastic agent,Small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1574,PCI-32765,ibrutinib,antineoplastic agent,small molecule,not approved,Q06187,BTK_HUMAN,BTK,Tyrosine-protein kinase BTK (EC 2.7.10.2) (Agammaglobulinaemia tyrosine kinase) (ATK) (B-cell progenitor kinase) (BPK) (Bruton tyrosine kinase),Enzymes,EC:2.7.10.2,Novel Target
1575,"PD-6735, LY-156735",PD-6735,hypnotic,small molecule,not approved,P48039,MTR1A_HUMAN,MTNR1A,Melatonin receptor type 1A OS=Homo sapiens GN=MTNR1A PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1575,"PD-6735, LY-156735",PD-6735,hypnotic,small molecule,not approved,P49286,MTR1B_HUMAN,MTNR1B,Melatonin receptor type 1B OS=Homo sapiens GN=MTNR1B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1576,PDX,10-propargyl-10-deazaaminopterin,antineoplastic agent,Small molecule,not approved,P00374,DYR_HUMAN,DHFR,Dihydrofolate reductase OS=Homo sapiens GN=DHFR PE=1 SV=2,Enzymes,EC:1.5.1.3,Established target
1577,"PEG-camptothecin,Prothecan",PEG-camptothecin,antineoplastic agent,small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
1578,"pegfilgrastim,N/",Pegfilgrastim ,for treatment of neutropenia,protein,approved,Q99062,CSF3R_HUMAN,CSF3R,Granulocyte colony-stimulating factor receptor OS=Homo sapiens GN=CSF3R PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1579,"PEG-Infergen,PEG-Alfacon",PEG-Interferon alfacon-1,for treatment of hepatitis C,protein,not approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1579,"PEG-Infergen,PEG-Alfacon",PEG-Interferon alfacon-1,for treatment of hepatitis C,protein,not approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1580,PEG-Interferon,PEG-Interferon lamba,for treatment of hepatitis C,protein,not approved,Q08334,I10R2_HUMAN,IL10RB,Interleukin-10 receptor subunit beta,Receptors,Receptor; Type 2 cytokine receptor,Established target
1580,PEG-Interferon,PEG-Interferon lamba,for treatment of hepatitis C,protein,not approved,Q8IU57,I28RA_HUMAN,IL28RA,Interleukin-28 receptor subunit alpha,Receptors,Receptor; Type 2 cytokine receptor,Established target
1581,"peginterferon alfa-2a,Pegasys",peginterferon alfa-2a,for treatment of hepatitis B and C,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1581,"peginterferon alfa-2a,Pegasys",peginterferon alfa-2a,for treatment of hepatitis B and C,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1582,PEG-Intron,recombinant interferon alfa-2b,for treatment of hepatitis C,recombinant protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1582,PEG-Intron,recombinant interferon alfa-2b,for treatment of hepatitis C,recombinant protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1583,"pegvisomant,Somavert",pegvisomant,for treatment of acromegaly,recombinant protein,approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1584,"pentosan polysulfate sodium,Elmiron",pentosan polysulfate,for symptomatic treatment of bladder pain or discomfort associated with interstitial cystitis,Small Molecule,approved,P05230,FGF1_HUMAN,FGF1,Heparin-binding growth factor 1 OS=Homo sapiens GN=FGF1 PE=1 SV=1,Miscellaneous,Ligand;Growth factor,Established target
1584,"pentosan polysulfate sodium,Elmiron",pentosan polysulfate,for symptomatic treatment of bladder pain or discomfort associated with interstitial cystitis,Small Molecule,approved,P09038,FGF2_HUMAN,FGF2,Heparin-binding growth factor 2 OS=Homo sapiens GN=FGF2 PE=1 SV=2,Miscellaneous,Ligand;Growth factor,Established target
1584,"pentosan polysulfate sodium,Elmiron",pentosan polysulfate,for symptomatic treatment of bladder pain or discomfort associated with interstitial cystitis,Small Molecule,approved,P08620,FGF4_HUMAN,FGF4,Fibroblast growth factor 4 OS=Homo sapiens GN=FGF4 PE=1 SV=1,Miscellaneous,Ligand;Growth factor,Established target
1585,"pentostatin,Nipent",pentostatin,antineoplastic agent,Small Molecule,approved,P00813,ADA_HUMAN,ADA,Adenosine deaminase OS=Homo sapiens GN=ADA PE=1 SV=3,Enzymes,EC:3.5.4.4,Established target
1586,"pentoxifylline, EHT0201",pentoxifylline,for treatment of amyotrophic lateral sclerosis (ALS),Small Molecule,approved,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1586,"pentoxifylline, EHT0201",pentoxifylline,for treatment of amyotrophic lateral sclerosis (ALS),Small Molecule,approved,P29274,AA2AR_HUMAN,ADORA2B,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1586,"pentoxifylline, EHT0201",pentoxifylline,for treatment of amyotrophic lateral sclerosis (ALS),Small Molecule,approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
1586,"pentoxifylline, EHT0201",pentoxifylline,for treatment of amyotrophic lateral sclerosis (ALS),Small Molecule,approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
1586,"pentoxifylline, EHT0201",pentoxifylline,for treatment of amyotrophic lateral sclerosis (ALS),Small Molecule,approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,Q16512,PKN1_HUMAN,PKN1,Serine/threonine-protein kinase N1 (EC 2.7.11.13) (Protease-activated kinase 1) (PAK-1) (Protein kinase C-like 1) (Protein kinase C-like PKN) (Protein kinase PKN-alpha) (Protein-kinase C-related kinase 1) (Serine-threonine protein kinase N),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,Q16513,PKN2_HUMAN,PKN2,Serine/threonine-protein kinase N2 (EC 2.7.11.13) (Protein kinase C-like 2) (Protein-kinase C-related kinase 2),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,P17252,KPCA_HUMAN,PRKCA,Protein kinase C alpha type (PKC-A) (PKC-alpha) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,P05771,KPCB_HUMAN,PRKCB1,Protein kinase C beta type (PKC-B) (PKC-beta) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,Q05655,KPCD_HUMAN,PRKCD,Protein kinase C delta type (EC 2.7.11.13) (nPKC-delta),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,Q02156,KPCE_HUMAN,PRKCE,Protein kinase C epsilon type (EC 2.7.11.13) (nPKC-epsilon),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,P05129,KPCG_HUMAN,PRKCG,Protein kinase C gamma type (PKC-gamma) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,P24723,KPCL_HUMAN,PRKCH,Protein kinase C eta type (EC 2.7.11.13) (PKC-L) (nPKC-eta),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,P41743,KPCI_HUMAN,PRKCI,Protein kinase C iota type (EC 2.7.11.13) (Atypical protein kinase C-lambda/iota) (PRKC-lambda/iota) (aPKC-lambda/iota) (nPKC-iota),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,Q04759,KPCT_HUMAN,PRKCQ,Protein kinase C theta type (EC 2.7.11.13) (nPKC-theta),Enzymes,EC:2.7.11.13,Established target
1587,PEP005,ingenol Mebutate,"for treatment of actinic keratosis,antineoplastic agent",Small molecule,approved,Q05513,KPCZ_HUMAN,PRKCZ,Protein kinase C zeta type (EC 2.7.11.13) (nPKC-zeta),Enzymes,EC:2.7.11.13,Established target
1588,PEP-02,irinotecan,antineoplastic agent,Small Molecule,approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
1588,PEP-02,irinotecan,antineoplastic agent,Small Molecule,approved,Q969P6,TOP1M_HUMAN,TOP1MT,"DNA topoisomerase I, mitochondrial OS=Homo sapiens GN=TOP1MT PE=1 SV=1",Enzymes,EC:5.99.1.2,Established target
1589,"perifosine, KRX-0401",perifosine,antineoplastic agent,small molecule,not approved,P31749,AKT1_HUMAN,AKT1,RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Proto-oncogene c-Akt) (RAC-PK-alpha),Enzymes,EC:2.7.11.1,Novel Target
1589,"perifosine, KRX-0401",perifosine,antineoplastic agent,small molecule,not approved,P31751,AKT2_HUMAN,AKT2,RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta),Enzymes,EC:2.7.11.1,Novel Target
1589,"perifosine, KRX-0401",perifosine,antineoplastic agent,small molecule,not approved,Q9Y243,AKT3_HUMAN,AKT3,RAC-gamma serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-3) (Protein kinase B gamma) (PKB gamma) (RAC-PK-gamma) (STK-2),Enzymes,EC:2.7.11.1,Novel Target
1591,PF-00610355,PF-00610355,bronchodilator,small molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1592,PF-04236921,PF-04236921,"antiinflammatory agent,for treatment of Chron's disease",monoclonal antibody,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
1593,PF-04554878,PF-04554878,antineoplastic agent,small molecule,not approved,Q05397,FAK1_HUMAN,PTK2,Focal adhesion kinase 1 (FADK 1) (EC 2.7.10.2) (Protein-tyrosine kinase 2) (pp125FAK),Enzymes,EC:2.7.10.2,Novel Target
1594,PF-299804,Dacomitinib,antineoplastic agent,small molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1594,PF-299804,Dacomitinib,antineoplastic agent,small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1594,PF-299804,Dacomitinib,antineoplastic agent,small molecule,not approved,Q15303,ERBB4_HUMAN,ERBB4,Receptor tyrosine-protein kinase erbB-4 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-4) (Tyrosine kinase-type cell surface receptor HER4) (p180erbB4) [Cleaved into: ERBB4 intracellular domain (4ICD) (E4ICD) (s80HER4)],Receptors,EC:2.7.10.1,Novel Target
1595,"PF-3512676 , CpG 7909,Promune",PF-3512676,antineoplastic agent,aptamer,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
1596,PG102,PG102,antiinflammatory agent,monoclonal antibody,not approved,P25942,TNR5_HUMAN,CD40,Tumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40) (Bp50) (CD40L receptor) (CDw40) (CD antigen CD40),Receptors,Receptors;TNFNGF,Novel Target
1597,PG110,PG110,analgesic,monoclonal antibody,not approved,P01138,NGF_HUMAN,NGF,Beta-nerve growth factor (Beta-NGF),Miscellaneous,Nerve Growth Factor;Neurotrophins,Novel Target
1598,"PG-490-88 ,Uknown",PG-490-88,antineoplastic agent,small molecule,not approved,P19838,NFKB1_HUMAN,NFKB1,Nuclear factor NF-kappa-B p105 subunit OS=Homo sapiens GN=NFKB1 PE=1 SV=2,Transcription factor,Transcription factor,Established target
1599,"PG-490-88,Uknown",PG-490-88,antineoplastic agent,small molecule,not approved,Q00653,NFKB2_HUMAN,NFKB2,Nuclear factor NF-kappa-B p100 subunit (DNA-binding factor KBF2) (H2TF1) (Lymphocyte translocation chromosome 10 protein) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2) (Oncogene Lyt-10) (Lyt10) [Cleaved into: Nuclear factor NF-kap,Transcription factor,Transcription factor,Novel Target
1600,PG545,PG545,antineoplastic agent,small molecule,not approved,Q9Y251,HPSE_HUMAN,HPSE,Heparanase (EC 3.2.-.-) (Endo-glucoronidase) (Heparanase-1) (Hpa1) [Cleaved into: Heparanase 8 kDa subunit; Heparanase 50 kDa subunit],Enzymes,EC:3.2.-.-,Established target
1601,PGL2001,PGL2001,for treatment of endometriosis,unknown,not approved,P08842,STS_HUMAN,STS,Steryl-sulfatase (EC 3.1.6.2) (Arylsulfatase C) (ASC) (Steroid sulfatase) (Steryl-sulfate sulfohydrolase),Enzymes,EC:3.1.6,Novel Target
1602,PGX-100,"2-O, 3-O desulfated heparin",for prevention of cardiac and cerebral reperfusion injury,protein,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1602,PGX-100,"2-O, 3-O desulfated heparin",for prevention of cardiac and cerebral reperfusion injury,protein,not approved,Q9Y251,HPSE_HUMAN,HPSE,Heparanase (EC 3.2.-.-) (Endo-glucoronidase) (Heparanase-1) (Hpa1) [Cleaved into: Heparanase 8 kDa subunit; Heparanase 50 kDa subunit],Enzymes,EC:3.2.-.-,Established target
1602,PGX-100,"2-O, 3-O desulfated heparin",for prevention of cardiac and cerebral reperfusion injury,protein,not approved,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Miscellaneous,Enzyme regulator,Established target
1603,PH20 hyaluronidase enzyme + insulin,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1604,PH-797804,PH-797804,"antiinflammatory agent,DMARD",small molecule,not approved,Q15759,MK11_HUMAN,MAPK11,Mitogen-activated protein kinase 11 (MAP kinase 11) (MAPK 11) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 beta) (MAP kinase p38 beta) (p38b) (Stress-activated protein kinase 2) (p38-2),Enzymes,EC:2.7.11.24,Novel Target
1604,PH-797804,PH-797804,"antiinflammatory agent,DMARD",small molecule,not approved,P53778,MK12_HUMAN,MAPK12,Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3),Enzymes,EC:2.7.11.24,Novel Target
1604,PH-797804,PH-797804,"antiinflammatory agent,DMARD",small molecule,not approved,O15264,MK13_HUMAN,MAPK13,Mitogen-activated protein kinase 13 (MAP kinase 13) (MAPK 13) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 delta) (MAP kinase p38 delta) (Stress-activated protein kinase 4),Enzymes,EC:2.7.11.24,Novel Target
1604,PH-797804,PH-797804,"antiinflammatory agent,DMARD",small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
1606,Phenoxodiol,phenoxodiol,antineoplastic agent,small molecule,not approved,Q9NYA1,SPHK1_HUMAN,SPHK1,Sphingosine kinase 1 (SK 1) (SPK 1) (EC 2.7.1.91),Enzymes,EC:2.7.1.91,Novel Target
1606,Phenoxodiol,phenoxodiol,antineoplastic agent,small molecule,not approved,Q9NRA0,SPHK2_HUMAN,SPHK2,Sphingosine kinase 2 (SK 2) (SPK 2) (EC 2.7.1.91),Enzymes,EC:2.7.1.91,Novel Target
1607,Phenserine,phenserine,for treatment of Alzheimer's disease,small molecule,not approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
1608,"physostigmine ,Xalieve",physostigmine,for treatment of dry mouth,Small Molecule,approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
1609,PI-0824,desmoglein-3,for treatment of pemphigus vulgaris,peptide,not approved,P32926 ,DSG3_HUMAN,DSG3,Desmoglein-3,Miscellaneous,"Miscellaneous;Cell structure, desmosome",Novel Target
1610,Pimavanserin,Pimavanserin,antiparkinson agent,small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1611,"pimecrolimus, ASM 981,Elidel",pimecrolimus,antiinflammatory agent,Small Molecule,approved,P42345,FRAP_HUMAN,MTOR,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1612,"pioglitazone HCl,Actos",pioglitazone,antidiabetic,Small Molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1613,"pioglitazone/metformin,Actoplus Met, Competact",metformin,antidiabetic,Small Molecule,approved,Q9Y478,AAKB1_HUMAN,PRKAB1,5'-AMP-activated protein kinase subunit beta-1 OS=Homo sapiens GN=PRKAB1 PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
1613,"pioglitazone/metformin,Actoplus Met, Competact",pioglitazone,antidiabetic,Small Molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1614,"pirfenidone,Esbriet , Deskar, Pirespa",pirfenidone,for treatment of fibrotic conditions,small molecule,not approved,Q15759,MK11_HUMAN,MAPK11,Mitogen-activated protein kinase 11 (MAP kinase 11) (MAPK 11) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 beta) (MAP kinase p38 beta) (p38b) (Stress-activated protein kinase 2) (p38-2),Enzymes,EC:2.7.11.24,Novel Target
1614,"pirfenidone,Esbriet , Deskar, Pirespa",pirfenidone,for treatment of fibrotic conditions,small molecule,not approved,P53778,MK12_HUMAN,MAPK12,Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3),Enzymes,EC:2.7.11.24,Novel Target
1614,"pirfenidone,Esbriet , Deskar, Pirespa",pirfenidone,for treatment of fibrotic conditions,small molecule,not approved,O15264,MK13_HUMAN,MAPK13,Mitogen-activated protein kinase 13 (MAP kinase 13) (MAPK 13) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 delta) (MAP kinase p38 delta) (Stress-activated protein kinase 4),Enzymes,EC:2.7.11.24,Novel Target
1614,"pirfenidone,Esbriet , Deskar, Pirespa",pirfenidone,for treatment of fibrotic conditions,small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
1615,"pitavastatin , NK-104,Livalo",pitavastatin,anticholesterolaemic agent,small molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,,EC:1.1.1.34,Established target
1616,"PL37, Debio 0827",PL37 ,"analgesic,neuropathic pain",small molecule,not approved,P15144,AMPN_HUMAN,ANPEP,Aminopeptidase N (AP-N) (hAPN) (EC 3.4.11.2) (Alanyl aminopeptidase) (Aminopeptidase M) (AP-M) (Microsomal aminopeptidase) (Myeloid plasma membrane glycoprotein CD13) (gp150) (CD antigen CD13),Enzymes,EC:3.4.11.2,Novel Target
1616,"PL37, Debio 0827",PL37 ,"analgesic,neuropathic pain",small molecule,not approved,P08473,NEP_HUMAN,MME,Neprilysin OS=Homo sapiens GN=MME PE=1 SV=2,Enzymes,EC:3.4.24,Established target
1617,PL-3994,PL-3994,antihypertensive agent,peptide,not approved,P16066,ANPRA_HUMAN,NPR1,Atrial natriuretic peptide receptor A OS=Homo sapiens GN=NPR1 PE=2 SV=1,Receptors,EC:4.6.1.2,Established target
1618,Plasmin,Plasmin,thrombolytic agent,protein,not approved,P00747,PLMN_HUMAN,PLG,Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2,Enzymes,StructuralAndAdhesion;Fibrinogen,Established target
1619,Plavix,clopidogrel,antithrombotic,Small Molecule,approved,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1620,"plecanatide , SP-304",plecanatide,motilitant,peptide,not approved,P25092,GUC2C_HUMAN,GUCY2C,Heat-stable enterotoxin receptor (STA receptor) (hSTAR) (EC 4.6.1.2) (Guanylyl cyclase C) (GC-C) (Intestinal guanylate cyclase),Receptors,EC:4.6.1.2,Novel Target
1622,PLK-1 inhibitor,PLK-1 inhibitor,antineoplastic agent,small molecule,not approved,P53350,PLK1_HUMAN,PLK1,Serine/threonine-protein kinase PLK1 (EC 2.7.11.21) (Polo-like kinase 1) (PLK-1) (Serine/threonine-protein kinase 13) (STPK13),Enzymes,EC:2.7.11.21,Novel Target
1623,"PLX4032, RG7204",vemurafenib,antineoplastic agent,small molecule,not approved,P15056,BRAF1_HUMAN,BRAF,B-Raf proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=BRAF PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
1624,PMI-001,PMI-001,"antiinflammatory agent,DMARD",small molecule,not approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1626,"PN 200, immediate release omeprazole + enteric coated naproxen",naproxen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1626,"PN 200, immediate release omeprazole + enteric coated naproxen",naproxen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1626,"PN 200, immediate release omeprazole + enteric coated naproxen",omeprazole,Proton pump inhibitor,Small Molecule,approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1627,"polifeprosan 20/carmustine,Gliadel",carmustine,antineoplastic agent,Small Molecule,approved,P00390,GSHR_HUMAN,GSR,"Glutathione reductase, mitochondrial OS=Homo sapiens GN=GSR PE=1 SV=2",Enzymes,EC:1.8.1.7,Established target
1629,"ponatinib, AP24534",ponatinib,antineoplastic agent,small molecule,not approved,P00519,ABL1_HUMAN,ABL1,Proto-oncogene tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4,Enzymes,EC:2.7.10.2,Established target
1629,"ponatinib, AP24534",ponatinib,antineoplastic agent,small molecule,not approved,P12931,SRC_HUMAN,SRC,Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
1630,ponesimod,ponesimod,"antiinflammatory agent,for treatment of multiple sclerosis",small molecule,not approved,P21453,S1PR1_HUMAN,S1PR1,Sphingosine 1-phosphate receptor 1 (S1P receptor 1) (S1P1) (Endothelial differentiation G-protein coupled receptor 1) (Sphingosine 1-phosphate receptor Edg-1) (S1P receptor Edg-1) (CD antigen CD363),Receptors,GPCR;Rhodopsin,Established target
1631,"ponezumab, PF-04360365",ponezumab,for treatment of Alzheimer's disease,monoclonal antibody,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
1633,Posiphen,Posiphen,for treatment of Alzheimer's disease,small molecule,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
1633,Posiphen,Posiphen,for treatment of Alzheimer's disease,small molecule,not approved,P56817,BACE1_HUMAN,BACE1,Beta-secretase 1,Enzymes,EC:3.4.23.46,Novel Target
1633,Posiphen,Posiphen,for treatment of Alzheimer's disease,small molecule,not approved,Q9Y5Z0,BACE2_HUMAN,BACE2,Beta-secretase 2 (EC 3.4.23.45) (Aspartic-like protease 56 kDa) (Aspartyl protease 1) (ASP1) (Asp 1) (Beta-site amyloid precursor protein cleaving enzyme 2) (Beta-site APP cleaving enzyme 2) (Down region aspartic protease) (DRAP) (Memapsin-1) (Membrane-as,Enzymes,EC:3.4.23.45,Novel Target
1634,POT-4,POT-4,for treatment of age-related macular degeneration,peptide,not approved,P01024,CO3_HUMAN,C3,Complement C3 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1) [Cleaved into: Complement C3 beta chain; Complement C3 alpha chain; C3a anaphylatoxin; Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg f,Miscellaneous,Immune response;Complement system,Novel Target
1635,"pozanicline , ABT-089",pozanicline,for treatment of Alzheimer's disease,small molecule,not approved,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1635,"pozanicline , ABT-089",pozanicline,for treatment of Alzheimer's disease,small molecule,not approved,P17787,ACHB2_HUMAN,CHRNB2,Neuronal acetylcholine receptor subunit beta-2 OS=Homo sapiens GN=CHRNB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1636,PPC-5650,PPC-5650,analgesic,small molecule,not approved,P78348,ACCN2_HUMAN,ACCN2,"Amiloride-sensitive cation channel 2, neuronal (Acid-sensing ion channel 1) (ASIC1) (Brain sodium channel 2) (BNaC2)",transporter,TC:1.A.6,Established target
1637,PPI-2458,PPI-2458,antineoplastic agent,small molecule,not approved,P50579,AMPM2_HUMAN,METAP2,Methionine aminopeptidase 2 (MAP 2) (MetAP 2) (EC 3.4.11.18) (Initiation factor 2-associated 67 kDa glycoprotein) (Peptidase M 2) (p67eIF2) (p67),Enzymes,EC:3.4.11.18,Novel Target
1638,PR-15,PR-15,antithrombotic,small molecule,not approved,Q9HCN6,GPVI_HUMAN,GP6,Platelet glycoprotein VI (GPVI) (Glycoprotein 6),Receptors,Miscellaneous;platelet glycoprotein,Novel Target
1639,"prasterone, GL-701,Prestara",prasterone,hormone supplement for increasing bone mineral density in patients with systemic lupus erythematosus,small molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1640,"prasugrel, CS-747,Efient",prasugrel,antithrombotic,small molecule,approved,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1641,"pravastatin and fenofibrate,PravaFen",fenofibrate,anticholesterolaemic agent,Small Molecule,approved,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1641,"pravastatin and fenofibrate,PravaFen",pravastatin,anticholesterolaemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
1642,"prednisolone sodium phosphate,Orapred syrup",prednisolone,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1643,"prednisone,Lodotra",prednisolone,"antiinflammatory agent,corticosteroid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1644,"pregabalin,Lyrica",pregabalin,"analgesic,neuropathic pain,for treatment of restlegs legs syndrome",Small Molecule,approved,O00555,CAC1A_HUMAN,CACNA1A,Voltage-dependent P/Q-type calcium channel subunit alpha-1A OS=Homo sapiens GN=CACNA1A PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
1645,"preladenant, SCH-420814",preladenant,antiparkinson agent,small molecule,not approved,P29274,AA2AR_HUMAN,ADORA2A,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1646,PREOS,ALX1-11,antiosteoporotic agent,recombinant protein,not approved,Q03431,PTH1R_HUMAN,PTH1R,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1646,PREOS,ALX1-11,antiosteoporotic agent,recombinant protein,not approved,P49190,PTH2R_HUMAN,PTH2R,Parathyroid hormone 2 receptor (PTH2 receptor),Receptors,GPCR;Secretin,Established target
1647,"pridopidine, ACR-16,Huntexil",pridopidine,for treatment of Huntington's disease,small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1648,Pristiq,desvenlafaxine,"for treatment of menopausal symptoms,antidepressant",Small molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter (Norepinephrine transporter) (NET) (Solute carrier family 6 member 2),Transporters,TC:2.A.22.1.2,Established target
1648,Pristiq,desvenlafaxine,"for treatment of menopausal symptoms,antidepressant",Small molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1649,PRO 140,PRO 140,"antiviral agent,HIV",monoclonal antibody,not approved,P51681,CCR5_HUMAN,CCR5,C-C chemokine receptor type 5 OS=Homo sapiens GN=CCR5 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1650,PRO044,PRO044,for treatment of Duchenne muscular dystrophy,RNA based therapy,not approved,P11532,DMD_HUMAN,DMD,Dystrophin,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Novel Target
1651,"PRO-571, diclofenac potassium",diclofenac,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1651,"PRO-571, diclofenac potassium",diclofenac,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1652,Proellex,telapristone,for treatment of uterin fibroids and endometriosis,small molecule,not approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
1653,ProFibrix B.V/,thrombin,topical tissue sealant,protein,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1653,ProFibrix B.V/,thrombin,topical tissue sealant,protein,not approved,P12259,FA5_HUMAN,F5,Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=3,Miscellaneous,Enzyme cofactor,Established target
1653,ProFibrix B.V/,thrombin,topical tissue sealant,protein,not approved,P00451,FA8_HUMAN,F8,Coagulation factor VIII OS=Homo sapiens GN=F8 PE=1 SV=1,Miscellaneous,Enzyme cofactor,Established target
1654,"progesterone gel,Crinone, Prochieve",progesterone,for reducing the risk of pre-term birth for women with short cervix a mid-pregnancy,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
1655,"progressive hydration buccal tablet,Striant",testosterone,hormone replacement,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1656,Proleukin IL-2,aldesleukin,antineoplastic agent,recombinant protein,approved,P01589,IL2RA_HUMAN,IL2RA,Interleukin-2 receptor alpha chain OS=Homo sapiens GN=IL2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1656,Proleukin IL-2,aldesleukin,antineoplastic agent,recombinant protein,approved,P14784,IL2RB_HUMAN,IL2RB,Interleukin-2 receptor subunit beta OS=Homo sapiens GN=IL2RB PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1656,Proleukin IL-2,aldesleukin,antineoplastic agent,recombinant protein,approved,P31785,IL2RG_HUMAN,IL2RG,Cytokine receptor common gamma chain OS=Homo sapiens GN=IL2RG PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1657,Promacta,eltrombopag,thrombopoietic,Small molecule,approved,P40238,TPOR_HUMAN,MPL,Thrombopoietin receptor (TPO-R) (Myeloproliferative leukemia protein) (Proto-oncogene c-Mpl) (CD antigen CD110),Receptors,Receptor; Type 1 cytokine receptor,Established target
1658,"propafenone hydrochloride,Rythmol",propafenone,antiarrythmic agent,Small Molecule,approved,Q12809,KCNH2_HUMAN,KCNH2,Potassium voltage-gated channel subfamily H member 2 OS=Homo sapiens GN=KCNH2 PE=1 SV=1,Transporters,TC:1.A.1.20.1,Established target
1658,"propafenone hydrochloride,Rythmol",propafenone,antiarrythmic agent,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1659,"propionyl-L-carnitine, ST-261",propionyl-L-carnitine,for treatment of intermittent claudication,small molecule,not approved,P50416,CPT1A_HUMAN,CPT1A,"Carnitine O-palmitoyltransferase 1, liver isoform OS=Homo sapiens GN=CPT1A PE=1 SV=2",Enzymes,EC:2.3.1,Established target
1659,"propionyl-L-carnitine, ST-261",propionyl-L-carnitine,for treatment of intermittent claudication,small molecule,not approved,P23786,CPT2_HUMAN,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial OS=Homo sapiens GN=CPT2 PE=1 SV=2",Enzymes,EC:2.3.1.21,Established target
1659,"propionyl-L-carnitine, ST-261",propionyl-L-carnitine,for treatment of intermittent claudication,small molecule,not approved,P43155,CACP_HUMAN,CRAT,Carnitine O-acetyltransferase (Carnitine acetylase) (EC 2.3.1.7) (Carnitine acetyltransferase) (CAT) (CrAT),Enzymes,EC:2.1.1.37,Novel Target
1659,"propionyl-L-carnitine, ST-261",propionyl-L-carnitine,for treatment of intermittent claudication,small molecule,not approved,Q9UKG9,OCTC_HUMAN,CROT,Peroxisomal carnitine O-octanoyltransferase (COT) (EC 2.3.1.137),Enzymes,EC:2.3.1.137,Novel Target
1659,"propionyl-L-carnitine, ST-261",propionyl-L-carnitine,for treatment of intermittent claudication,small molecule,not approved,Q9H015,S22A4_HUMAN,SLC22A4,Solute carrier family 22 member 4 (Ergothioneine transporter) (ET transporter) (Organic cation/carnitine transporter 1),Transporters,TC:2.A.1.19.26,Novel Target
1659,"propionyl-L-carnitine, ST-261",propionyl-L-carnitine,for treatment of intermittent claudication,small molecule,not approved,O76082,S22A5_HUMAN,SLC22A5,Solute carrier family 22 member 5 (High-affinity sodium-dependent carnitine cotransporter) (Organic cation/carnitine transporter 2),Transporters,TC:2.A.1.19.3,Novel Target
1659,"propionyl-L-carnitine, ST-261",propionyl-L-carnitine,for treatment of intermittent claudication,small molecule,not approved,O43772,MCAT_HUMAN,SLC25A20,Mitochondrial carnitine/acylcarnitine carrier protein (Carnitine/acylcarnitine translocase) (CAC) (Solute carrier family 25 member 20),Transporters,TC:2.A.29.8.3,Novel Target
1659,"propionyl-L-carnitine, ST-261",propionyl-L-carnitine,for treatment of intermittent claudication,small molecule,not approved,Q8N8R3,MCATL_HUMAN,SLC25A29,Mitochondrial carnitine/acylcarnitine carrier protein CACL (CACT-like) (Solute carrier family 25 member 29),Transporters,TC:2.A.29.8.9,Novel Target
1660,propofol lingual spray,propofol,sedative,small molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
1660,propofol lingual spray,propofol,sedative,small molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1660,propofol lingual spray,propofol,sedative,small molecule,approved,Q99250,SCN2A_HUMAN,SCN2A,Sodium channel protein type 2 subunit alpha (HBSC II) (Sodium channel protein brain II subunit alpha) (Sodium channel protein type II subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.2),Transporters,TC:1.A.1.10,Established target
1660,propofol lingual spray,propofol,sedative,small molecule,approved,P35499,SCN4A_HUMAN,SCN4A,Sodium channel protein type 4 subunit alpha (SkM1) (Sodium channel protein skeletal muscle subunit alpha) (Sodium channel protein type IV subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.4),Transporters,TC:1.A.1.10.4,Established target
1661,"propofol,Diprivan",propofol,sedative,small molecule,approved,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
1661,"propofol,Diprivan",propofol,sedative,small molecule,approved,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1661,"propofol,Diprivan",propofol,sedative,small molecule,approved,Q99250,SCN2A_HUMAN,SCN2A,Sodium channel protein type 2 subunit alpha (HBSC II) (Sodium channel protein brain II subunit alpha) (Sodium channel protein type II subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.2),Transporters,TC:1.A.1.10,Established target
1661,"propofol,Diprivan",propofol,sedative,small molecule,approved,P35499,SCN4A_HUMAN,SCN4A,Sodium channel protein type 4 subunit alpha (SkM1) (Sodium channel protein skeletal muscle subunit alpha) (Sodium channel protein type IV subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.4),Transporters,TC:1.A.1.10.4,Established target
1662,"PRS-013, OPC-14523",OPC-14523,antidepressant,small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1662,"PRS-013, OPC-14523",OPC-14523,antidepressant,small molecule,not approved,O00264,PGRC1_HUMAN,PGRMC1,Membrane-associated progesterone receptor component 1,Receptors,GPCR;Rhodopsin,Novel Target
1662,"PRS-013, OPC-14523",OPC-14523,antidepressant,small molecule,not approved,Q99720,OPRS1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
1662,"PRS-013, OPC-14523",OPC-14523,antidepressant,small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1663,PRT062607,PRT062607,antiinflammatory agent,small molecule,not approved,P43405,KSYK_HUMAN,SYK,Tyrosine-protein kinase SYK (EC 2.7.10.2) (Spleen tyrosine kinase),Enzymes,EC:2.7.10.2,Novel Target
1664,PRT-201,PRT-201,to improve vascular access during surgery,recombinant protein,not approved,P15502,ELN_HUMAN,ELN,Elastin,Miscellaneous,StructuralAndAdhesion;,Novel Target
1665,"prucalopride ,Resolor",prucalopride,motilitant,small molecule,not approved,Q13639,5HT4R_HUMAN,HTR4,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1666,PRX-00023,PRX-00023,"antidepressant,anxiolytic",small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1667,PRX-07034,PRX-07034,"antiobesity agent,nootropic",small molecule,not approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1668,PRX-08066,PRX-08066,antihypertensive agent,small molecule,not approved,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1669,"PRX-105, acetylcholinesterase",recombinant pegylated acetylcholinesterase,nerve gas antidote,recombinant protein,not approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
1670,PRX302,PRX302,antineoplastic agent,fusion protein,not approved,P07288,KLK3_HUMAN,KLK3,Prostate-specific antigen (PSA) (EC 3.4.21.77) (Gamma-seminoprotein) (Seminin) (Kallikrein-3) (P-30 antigen) (Semenogelase),Enzymes,EC:3.4.21.77,Novel Target
1671,PRX-3140,PRX-3140,for treatment of Alzheimer's disease,small molecule,not approved,Q13639,5HT4R_HUMAN,HTR4,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1672,PRX-321,PRX-321,antineoplastic agent,fusion protein,not approved,P24394,IL4RA_HUMAN,IL4R,Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL,Receptors,Receptor; Type 1 cytokine receptor,Novel Target
1673,PS433540,PS433540,antihypertensive agent,small molecule,not approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1673,PS433540,PS433540,antihypertensive agent,small molecule,not approved,P50052,AGTR2_HUMAN,AGTR2,Type-2 angiotensin II receptor,receptor,GPCR;Rhodopsin,Novel Target
1673,PS433540,PS433540,antihypertensive agent,small molecule,not approved,P25101 ,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1674,"PSD502, lidocaine + prilocaine",lidocaine,for treatment of premature ejaculation,Small Molecule,approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1674,"PSD502, lidocaine + prilocaine",lidocaine,for treatment of premature ejaculation,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
1674,"PSD502, lidocaine + prilocaine",lidocaine,for treatment of premature ejaculation,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1674,"PSD502, lidocaine + prilocaine",prilocaine,for treatment of premature ejaculation,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1675,"PSD-503, phenylephrine",phenylephrine,for treatment of incontinence,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1675,"PSD-503, phenylephrine",phenylephrine,for treatment of incontinence,Small Molecule,approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
1675,"PSD-503, phenylephrine",phenylephrine,for treatment of incontinence,Small Molecule,approved,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1676,PSD-506,PSD-506,for treatment of overactive bladder,small molecule,not approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1676,PSD-506,PSD-506,for treatment of overactive bladder,small molecule,not approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1677,PSN357,PSN357,antidiabetic,small molecule,not approved,P11216,PYGB_HUMAN,PYGB,"Glycogen phosphorylase, brain form (EC 2.4.1.1)",Enzymes,EC:2.4.1.1,Novel Target
1677,PSN357,PSN357,antidiabetic,small molecule,not approved,P06737,PYGL_HUMAN,PYGL,"Glycogen phosphorylase, liver form (EC 2.4.1.1)",Enzymes,EC:2.4.1.1,Novel Target
1677,PSN357,PSN357,antidiabetic,small molecule,not approved,P11217,PYGM_HUMAN,PYGM,"Glycogen phosphorylase, muscle form (EC 2.4.1.1) (Myophosphorylase)",Enzymes,EC:2.4.1.1,Novel Target
1678,PSN602,PSN602,antiobesity agent,small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1678,PSN602,PSN602,antiobesity agent,small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1678,PSN602,PSN602,antiobesity agent,small molecule,not approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1678,PSN602,PSN602,antiobesity agent,small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1679,PSN821,PSN821,antidiabetic,small molecule,not approved,Q8TDV5,GP119_HUMAN,GPR119,Glucose-dependent insulinotropic receptor (G-protein coupled receptor 119),Receptors,GPCR;Rhodopsin,Novel Target
1680,PT001,glycopyrrolate,for treatment of chronic obstructive pulmonary disorder (COPD),Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1681,"PT003, glycopyrrolate + formoterol inhalation aerosol",formoterol,for treatment of chronic obstructive pulmonary disorder (COPD),Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1681,"PT003, glycopyrrolate + formoterol inhalation aerosol",glycopyrrolate,for treatment of chronic obstructive pulmonary disorder (COPD),Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1682,"PT005, formoterol fumarate hydrofluoroalkane metered dose inhaler",formoterol,for treatment of chronic obstructive pulmonary disorder (COPD),Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1683,PTC299,PTC299,antineoplastic agent,small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1683,PTC299,PTC299,antineoplastic agent,small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1683,PTC299,PTC299,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1684,PTI-202,not disclosed,analgesic,unknown,not disclosed,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1684,PTI-202,not disclosed,analgesic,unknown,not disclosed,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1684,PTI-202,not disclosed,analgesic,unknown,not disclosed,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,naltrexone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,naltrexone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,naltrexone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,naltrexone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,naltrexone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,naltrexone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,naltrexone,analgesic,Small Molecule,approved,Q99720 ,OPRS1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
1685,PTI-601,tramadol,analgesic,Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,tramadol,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,tramadol,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,tramadol,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,tramadol,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1685,PTI-601,tramadol,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1685,PTI-601,tramadol,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1685,PTI-601,tramadol,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1686,PTI-701,acetaminophen,analgesic,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1686,PTI-701,acetaminophen,analgesic,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1686,PTI-701,acetaminophen,analgesic,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1686,PTI-701,acetaminophen,analgesic,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1686,PTI-701,hydrocodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,hydrocodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,hydrocodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,hydrocodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,naltrexone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,naltrexone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,naltrexone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,naltrexone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,naltrexone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,naltrexone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1686,PTI-701,naltrexone,analgesic,Small Molecule,approved,Q99720 ,OPRS1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
1686,PTI-701,naltrexone,analgesic,Small Molecule,approved,Q99720 ,OPRS1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
1687,"PTI-801,Oxytrex",naltrexone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1687,"PTI-801,Oxytrex",naltrexone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1687,"PTI-801,Oxytrex",naltrexone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1687,"PTI-801,Oxytrex",oxycodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1687,"PTI-801,Oxytrex",oxycodone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1687,"PTI-801,Oxytrex",oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1688,PTI-901,naltrexone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1688,PTI-901,naltrexone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1688,PTI-901,naltrexone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1689,Pumosetrag,Pumosetrag,motilitant,small molecule,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1689,Pumosetrag,Pumosetrag,motilitant,small molecule,not approved,O95264,5HT3B_HUMAN,HTR3B,5-hydroxytryptamine receptor 3B (5-HT3-B) (5-HT3B) (Serotonin receptor 3B),Receptors,TC:1.A.9,Established target
1689,Pumosetrag,Pumosetrag,motilitant,small molecule,not approved,Q8WXA8,5HT3C_HUMAN,HTR3C,5-hydroxytryptamine receptor 3C (5-HT3-C) (5-HT3C) (Serotonin receptor 3C),Receptors,TC:1.A.9,Established target
1689,Pumosetrag,Pumosetrag,motilitant,small molecule,not approved,Q70Z44,5HT3D_HUMAN,HTR3D,5-hydroxytryptamine receptor 3D (5-HT3-D) (5-HT3D) (Serotonin receptor 3D),Receptors,TC:1.A.9,Established target
1689,Pumosetrag,Pumosetrag,motilitant,small molecule,not approved,A5X5Y0,5HT3E_HUMAN,HTR3E,5-hydroxytryptamine receptor 3E (5-HT3-E) (5-HT3E) (Serotonin receptor 3E),Receptors,TC:1.A.9,Established target
1690,PW2101,PW2101,antihypertensive agent,small molecule,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1691,PWT33597,PWT33597,antineoplastic agent,unknown,not approved,P42345,FRAP_HUMAN,FRAP1,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1691,PWT33597,PWT33597,antineoplastic agent,unknown,not approved,P42336,PK3CA_HUMAN,PIK3CA,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PI3-kinase subunit alpha) (PI3K-alpha) (PtdIns-3-kinase subunit alpha) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
1692,PX-12,PX-12,antineoplastic agent,small molecule,not approved,P10599,THIO_HUMAN,TXN,Thioredoxin (Trx) (ATL-derived factor) (ADF) (Surface-associated sulphydryl protein) (SASP),Miscellaneous,Thioredoxin family,Novel Target
1693,PX-478,PX-478,antineoplastic agent,small molecule,not approved,Q16665,HIF1A_HUMAN,HIF1A,Hypoxia-inducible factor 1-alpha (HIF-1-alpha) (HIF1-alpha) (ARNT-interacting protein) (Basic-helix-loop-helix-PAS protein MOP1) (Class E basic helix-loop-helix protein 78) (bHLHe78) (Member of PAS protein 1) (PAS domain-containing protein 8),Miscellaneous,Transcription factor,Novel Target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,Q96DB2,HDA11_HUMAN,HDAC11,Histone deacetylase 11 (HD11) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,P56524,HDAC4_HUMAN,HDAC4,Histone deacetylase 4 (HD4) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,Q9UQL6,HDAC5_HUMAN,HDAC5,Histone deacetylase 5 (HD5) (EC 3.5.1.98) (Antigen NY-CO-9),Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,Q8WUI4,HDAC7_HUMAN,HDAC7A,Histone deacetylase 7 (HD7) (EC 3.5.1.98) (Histone deacetylase 7A) (HD7a),Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1694,PXD101,belinostat,antineoplastic agent,Small molecule,not approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
1696,"PYM50028,Cogane",PYM50028,antiparkinson agent ,small molecule,not approved,P56159,GFRA1_HUMAN,GFRA1,GDNF family receptor alpha-1 (GDNF receptor alpha-1) (GDNFR-alpha-1) (GFR-alpha-1) (RET ligand 1) (TGF-beta-related neurotrophic factor receptor 1),Receptors,Receptor;GDNF,Novel Target
1696,"PYM50028,Cogane",PYM50028,antiparkinson agent ,small molecule,not approved,P08138,TNR16_HUMAN,NGFR,Tumor necrosis factor receptor superfamily member 16 (Gp80-LNGFR) (Low affinity neurotrophin receptor p75NTR) (Low-affinity nerve growth factor receptor) (NGF receptor) (p75 ICD) (CD antigen CD271),Receptors,Receptors;TNFNGF,Novel Target
1696,"PYM50028,Cogane",PYM50028,antiparkinson agent ,small molecule,not approved,P04629,NTRK1_HUMAN,NTRK1,High affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinase receptor type 1) (TRK1-transforming tyrosine kinase protein) (p140-TrkA) (Trk-A),Receptors,EC:2.7.10.1,Established target
1696,"PYM50028,Cogane",PYM50028,antiparkinson agent ,small molecule,not approved,Q16620,NTRK2_HUMAN,NTRK2,BDNF/NT-3 growth factors receptor (EC 2.7.10.1) (GP145-TrkB) (Trk-B) (Neurotrophic tyrosine kinase receptor type 2) (TrkB tyrosine kinase),Receptors,EC:2.7.10.1,Novel Target
1698,PYY3-36,PYY3-36,antiobesity agent,peptide,not approved,P49146,NPY2R_HUMAN,NPY2R,Neuropeptide Y receptor type 2 (NPY2-R) (NPY-Y2 receptor) (Y2 receptor),Receptors,GPCR;Rhodopsin,Novel Target
1698,PYY3-36,PYY3-36,antiobesity agent,peptide,not approved,Q15761,NPY5R_HUMAN,NPY5R,Neuropeptide Y receptor type 5 (NPY5-R) (NPY-Y5 receptor) (NPYY5-R) (Y5 receptor),Receptors,GPCR;Rhodopsin,Novel Target
1698,PYY3-36,PYY3-36,antiobesity agent,peptide,not approved,P50391,NPY4R_HUMAN,PPYR1,Neuropeptide Y receptor type 4 (NPY4-R) (Pancreatic polypeptide receptor 1) (PP1),Receptors,GPCR;Rhodopsin,Novel Target
1699,QAX576,QAX576,"antiinflammatory agent,for treatment of Chron's disease",monoclonal antibody,not approved,P35225,IL13_HUMAN,IL13,Interleukin-13 (IL-13),Miscellaneous,Ligand;Cytokine,Novel Target
1701,"quinapril hydrochloride,Accupril",quinapril,antihypertensive agent,Small Molecule,approved,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
1702,"QVA149, glycopyrronium bromide + i/",glycopyrronium bromide,for treatment of chronic obstructive pulmonary disorder (COPD),Small molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1702,"QVA149, glycopyrronium bromide + i/",indacaterol,for treatment of chronic obstructive pulmonary disorder (COPD),Small molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1703,R112,R112,antiallergy agent,small molecule,not approved,P12319,FCERA_HUMAN,FCER1A,High affinity immunoglobulin epsilon receptor subunit alpha OS=Homo sapiens GN=FCER1A PE=1 SV=1,Receptors,Receptor;immunoglobulin,Established target
1703,R112,R112,antiallergy agent,small molecule,not approved,P30273,FCERG_HUMAN,FCER1G,High affinity immunoglobulin epsilon receptor subunit gamma OS=Homo sapiens GN=FCER1G PE=1 SV=1,Receptors,Receptor; Fc receptor,Established target
1703,R112,R112,antiallergy agent,small molecule,not approved,Q01362,FCERB_HUMAN,MS4A2,High affinity immunoglobulin epsilon receptor subunit beta (FcERI) (Fc epsilon receptor I beta-chain) (IgE Fc receptor subunit beta) (Membrane-spanning 4-domains subfamily A member 2),Miscellaneous,MS4A family,Established target
1704,R1295,R1295,antiinflammatory agent,unknown,not approved,P13612,ITA4_HUMAN,ITGA4,Integrin alpha-4 OS=Homo sapiens GN=ITGA4 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
1704,R1295,R1295,antiinflammatory agent,unknown,not approved,P05556,ITB1_HUMAN,ITGB1,Integrin beta-1 (Fibronectin receptor subunit beta) (VLA-4 subunit beta) (CD antigen CD29),Receptors,Receptors;Integrin,Established target
1704,R1295,R1295,antiinflammatory agent,unknown,not approved,P26010,ITB7_HUMAN,ITGB7,Integrin beta-7 (Gut homing receptor beta subunit),Receptors,Receptors;Integrin,Novel Target
1705,R343,R343,antiallergy agent,small molecule,not approved,P43405,KSYK_HUMAN,SYK,Tyrosine-protein kinase SYK (EC 2.7.10.2) (Spleen tyrosine kinase),Enzymes,EC:2.7.10.2,Novel Target
1706,R348,R348,antiinflammatory agent,small molecule,not approved,P52333,JAK3_HUMAN,JAK3,Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK),Enzymes,EC:2.7.10.2,Novel Target
1707,R667,R667,for treatment of emphysema,small molecule,not approved,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1707,R667,R667,for treatment of emphysema,small molecule,not approved,P10826,RARB_HUMAN,RARB,Retinoic acid receptor beta OS=Homo sapiens GN=RARB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1707,R667,R667,for treatment of emphysema,small molecule,not approved,P13631,RARG_HUMAN,RARG,Retinoic acid receptor gamma OS=Homo sapiens GN=RARG PE=1 SV=1,Receptors,Nuclear receptor,Established target
1708,"R763, AS703569",R763,antineoplastic agent,small molecule,not approved,O14965,STK6_HUMAN,AURKA,Serine/threonine-protein kinase 6 (EC 2.7.11.1) (Aurora kinase A) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase aurora-A),Enzymes,EC:2.7.11.1,Novel Target
1708,"R763, AS703569",R763,antineoplastic agent,small molecule,not approved,Q96GD4,AURKB_HUMAN,AURKB,Serine/threonine-protein kinase 12 (EC 2.7.11.1) (Aurora kinase B) (Aurora- and IPL1-like midbody-associated protein 1) (AIM-1) (Aurora/IPL1-related kinase 2) (ARK-2) (Aurora-related kinase 2) (STK-1) (Serine/threonine-protein kinase aurora-B),Enzymes,EC:2.7.11.1,Novel Target
1708,"R763, AS703569",R763,antineoplastic agent,small molecule,not approved,Q9UQB9,AURKC_HUMAN,AURKC,Serine/threonine-protein kinase 13 (EC 2.7.11.1) (Aurora kinase C) (Aurora/IPL1-related kinase 3) (ARK-3) (Aurora-related kinase 3) (Aurora/IPL1/Eg2 protein 2) (Serine/threonine-protein kinase aurora-C),Enzymes,EC:2.7.11.1,Novel Target
1709,"rAAT,Dermolastin",Dermolastin,dermatological agent,protein,not approved,P08311,CATG_HUMAN,CTSG,Cathepsin G (CG) (EC 3.4.21.20),Enzymes,EC:3.4.21.20,Novel Target
1709,"rAAT,Dermolastin",Dermolastin,dermatological agent,protein,not approved,P08246,ELNE_HUMAN,ELA2,Leukocyte elastase OS=Homo sapiens GN=ELA2 PE=1 SV=1,Enzymes,EC:3.4.21.37,Established target
1709,"rAAT,Dermolastin",Dermolastin,dermatological agent,protein,not approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
1709,"rAAT,Dermolastin",Dermolastin,dermatological agent,protein,not approved,P07477,TRY1_HUMAN,PRSS1,Trypsin-1 (EC 3.4.21.4) (Beta-trypsin) (Cationic trypsinogen) (Serine protease 1) (Trypsin I) [Cleaved into: Alpha-trypsin chain 1; Alpha-trypsin chain 2],Enzymes,EC:3.4.21.4,Novel Target
1709,"rAAT,Dermolastin",Dermolastin,dermatological agent,protein,not approved,P07478,TRY2_HUMAN,PRSS2,Trypsin-2 (EC 3.4.21.4) (Anionic trypsinogen) (Serine protease 2) (Trypsin II),Enzymes,EC:3.4.21.4,Novel Target
1709,"rAAT,Dermolastin",Dermolastin,dermatological agent,protein,not approved,P35030,TRY3_HUMAN,PRSS3,Trypsin-3 (EC 3.4.21.4) (Brain trypsinogen) (Mesotrypsinogen) (Serine protease 3) (Serine protease 4) (Trypsin III) (Trypsin IV),Enzymes,EC:3.4.21.4,Novel Target
1710,RAD1901,RAD1901,for treatment of postmenopausal symptoms,small molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1711,"rAHF-PFM,Advate",Recombinant Antihemophilic Factor ,for treatment of hemophilia A,recombinant protein,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1711,"rAHF-PFM,Advate",Recombinant Antihemophilic Factor ,for treatment of hemophilia A,recombinant protein,approved,P00740,FA9_HUMAN,F9,Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2,Enzymes,EC:3.4.21.22,Established target
1711,"rAHF-PFM,Advate",Recombinant Antihemophilic Factor ,for treatment of hemophilia A,recombinant protein,approved,P04275,VWF_HUMAN,VWF,von Willebrand factor (vWF) [Cleaved into: von Willebrand antigen 2 (von Willebrand antigen II)],Miscellaneous,StructuralAndAdhesion;Collagen;F8;F2,Established target
1712,"raltitrexed, ZD-1694,Tomudex",raltitrexed,antineoplastic agent,Small Molecule,not approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
1713,"ramelteon, TAK-375,Rozerem",ramelteon,for treatment of insomnia,Small Molecule,approved,P48039,MTR1A_HUMAN,MTNR1A,Melatonin receptor type 1A OS=Homo sapiens GN=MTNR1A PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1713,"ramelteon, TAK-375,Rozerem",ramelteon,for treatment of insomnia,Small Molecule,approved,P49286,MTR1B_HUMAN,MTNR1B,Melatonin receptor type 1B OS=Homo sapiens GN=MTNR1B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1714,Ranexa,ranolazine,antiallergy agent,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1714,Ranexa,ranolazine,antiallergy agent,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
1715,"ranirestat, AS-3201",ranirestat,for treatment of diabetic neuropathy,small molecule,not approved,P15121,ALDR_HUMAN,AKR1B1,Aldose reductase (AR) (EC 1.1.1.21) (Aldehyde reductase) (Aldo-keto reductase family 1 member B1),Enzymes,EC:1.1.1.21,Novel Target
1716,"ranitidine bismuth citrate,Tritec",ranitidine,antiulcer agent,Small Molecule,approved,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1717,Raptiva,efalizumab,"antiinflammatory agent,DMARD",monoclonal antibody,approved,P20701,ITAL_HUMAN,ITGAL,Integrin alpha-L OS=Homo sapiens GN=ITGAL PE=1 SV=3,Receptors,Receptors;Integrin,Established target
1718,"rasagiline mesylate, TVP-1012,Agilect",rasagiline,antiparkinson agent ,Small Molecule,approved,P27338,AOFB_HUMAN,MAOB,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3,Established target
1720,RC-8800,RC-8800,for improving the antiproliferative and apoptotic properties of vitamin D3 ,small molecule,not approved,Q9Y6A2,CP46A_HUMAN,CYP46A1,Cholesterol 24-hydroxylase (CH24H) (EC 1.14.13.98) (Cytochrome P450 46A1),Enzymes,EC:1.14.13.98,Novel Target
1721,RDEA119,RDEA119,antineoplastic agent,small molecule,not approved,P28482,MK01_HUMAN,MAPK1,Mitogen-activated protein kinase 1 (MAP kinase 1) (MAPK 1) (EC 2.7.11.24) (ERT1) (Extracellular signal-regulated kinase 2) (ERK-2) (MAP kinase isoform p42) (p42-MAPK) (Mitogen-activated protein kinase 2) (MAP kinase 2) (MAPK 2),Enzymes,EC:2.7.11.24,Established target
1721,RDEA119,RDEA119,antineoplastic agent,small molecule,not approved,P27361,MK03_HUMAN,MAPK3,Mitogen-activated protein kinase 3 (MAP kinase 3) (MAPK 3) (EC 2.7.11.24) (ERT2) (Extracellular signal-regulated kinase 1) (ERK-1) (Insulin-stimulated MAP2 kinase) (MAP kinase isoform p44) (p44-MAPK) (Microtubule-associated protein 2 kinase) (Mitogen-acti,Enzymes,EC:2.7.11.24,Established target
1723,"recombinant human GM-CSF,L/",recombinant GM-CSF,for treatment of leukopenia,recombinant protein,not approved,P15509,CSF2R_HUMAN,CSF2RA,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha OS=Homo sapiens GN=CSF2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1724,REG1,pegnivacogin,antithrombotic,aptamer,not approved,P00740,FA9_HUMAN,F9,Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2,Enzymes,EC:3.4.21.22,Established target
1725,"REG2, pegnivacogin SC + anivamersen IV, RB006 SC + RB007 IV",pegnivacogin,antithrombotic,aptamer,not approved,P00740,FA9_HUMAN,F9,Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2,Enzymes,EC:3.4.21.22,Established target
1726,"regadenoson,Lexiscan",regadenoson,diagnostic agent,small molecule,approved,P29274,AA2AR_HUMAN,ADORA2A,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1727,REGN727,REGN727 ,anticholesterolaemic agent,antibody,not approved,Q8NBP7,PCSK9_HUMAN,PCSK9,Proprotein convertase subtilisin/kexin type 9 (EC 3.4.21.-) (Neural apoptosis-regulated convertase 1) (NARC-1) (Proprotein convertase 9) (PC9) (Subtilisin/kexin-like protease PC9),Enzymes,EC:3.4.21.-,Novel Target
1728,REGN910,REGN910,antineoplastic agent,antibody,not approved,O15123 ,ANGP2_HUMAN,ANGPT2,,Ligand,Ligand;Serpin-family,Novel Target
1729,"regorafenib, BAY 73-4506",regorafenib,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1729,"regorafenib, BAY 73-4506",regorafenib,antineoplastic agent,small molecule,not approved,Q02763,TIE2_HUMAN,TEK,Angiopoietin-1 receptor (EC 2.7.10.1) (Tunica interna endothelial cell kinase) (Tyrosine-protein kinase receptor TEK) (Tyrosine-protein kinase receptor TIE-2) (hTIE2) (p140 TEK) (CD antigen CD202b),Receptors,EC:2.7.10.1,Novel Target
1730,"relacatib, SB 462795",relacatib,antiosteoporotic agent,small molecule,not approved,P43235,CATK_HUMAN,CTSK,Cathepsin K (EC 3.4.22.38) (Cathepsin O) (Cathepsin O2) (Cathepsin X),Enzymes,EC:3.4.22.38,Novel Target
1731,Relpax,eletriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1732,"remifentanil,Ultiva",remifentanil,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1733,REN-213,Nalbuphine,analgesic,Small Molecule,approved ,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1733,REN-213,Nalbuphine,analgesic,Small Molecule,approved ,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1733,REN-213,Nalbuphine,analgesic,Small Molecule,approved ,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1733,REN-213,naloxone,analgesic,Small Molecule,approved ,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1733,REN-213,naloxone,analgesic,Small Molecule,approved ,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1733,REN-213,naloxone,analgesic,Small Molecule,approved ,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1734,renzapride,renzapride,for treatment of irritable bowel syndrome,small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1734,renzapride,renzapride,for treatment of irritable bowel syndrome,small molecule,not approved,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1734,renzapride,renzapride,for treatment of irritable bowel syndrome,small molecule,not approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1734,renzapride,renzapride,for treatment of irritable bowel syndrome,small molecule,not approved,Q13639,5HT4R_HUMAN,HTR3A,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1734,renzapride,renzapride,for treatment of irritable bowel syndrome,small molecule,not approved,Q13639,5HT4R_HUMAN,HTR4,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1735,Reolysin,Reolysin,antineoplastic agent,reovirus,not approved,P01112,RASH_HUMAN,HRAS,"GTPase HRas (H-Ras-1) (Ha-Ras) (Transforming protein p21) (c-H-ras) (p21ras) [Cleaved into: GTPase HRas, N-terminally processed]",Miscellaneous,Miscellaneous;Hras,Novel Target
1735,Reolysin,Reolysin,antineoplastic agent,reovirus,not approved,P01111,RASN_HUMAN,NRAS,GTPase NRas (Transforming protein N-Ras),Miscellaneous,Miscellaneous;Hras,Novel Target
1736,"repaglinide,Prandin, NovoNorm, PrandiMet",repaglinide,antidiabetic,Small Molecule,approved,Q09428,ABCC8_HUMAN,ABCC8,ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1),Transporters,TC:3.A.1.208.4,Established target
1737,ReQuip,ropinirol,antiparkinson agent,small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1737,ReQuip,ropinirol,antiparkinson agent,small molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1738,"resiniferatoxin, RTX",resiniferatoxin,"for treatment of interstitial cystitis,antiincontinence agent",small molecule,not approved,Q8NER1,TRPV1_HUMAN,TRPV1,Transient receptor potential cation channel subfamily V member 1 (TrpV1) (Capsaicin receptor) (Osm-9-like TRP channel 1) (OTRPC1) (Vanilloid receptor 1),Transporters,TC:1.A.4,Established target
1739,"reslizumab ,Cinquil",reslizumab,"antiinflammatory agent,anti asthmatic",monoclonal antibody,not approved,P05113,IL5_HUMAN,IL5,Interleukin-5 (IL-5) (B-cell differentiation factor I) (Eosinophil differentiation factor) (T-cell replacing factor) (TRF),Miscellaneous,Ligand;Cytokine,Novel Target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,Q96DB2,HDA11_HUMAN,HDAC11,Histone deacetylase 11 (HD11) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,P56524,HDAC4_HUMAN,HDAC4,Histone deacetylase 4 (HD4) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,Q9UQL6,HDAC5_HUMAN,HDAC5,Histone deacetylase 5 (HD5) (EC 3.5.1.98) (Antigen NY-CO-9),Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,Q8WUI4,HDAC7_HUMAN,HDAC7A,Histone deacetylase 7 (HD7) (EC 3.5.1.98) (Histone deacetylase 7A) (HD7a),Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1740,Resminostat,Resminostat,antineoplastic agent,small molecule,not approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
1741,Resveratrol,Resveratrol,for treatment of herpes simplex virus 1,small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
1741,Resveratrol,Resveratrol,for treatment of herpes simplex virus 1,small molecule,not approved,Q08499,PDE4D_HUMAN,PDE4D,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D OS=Homo sapiens GN=PDE4D PE=1 SV=2",Enzymes,EC:3.1.4.17,Established target
1743,"reteplase,Retavase, Rapilysin",reteplase,thrombolytic agent,recombinant protein,approved,P02671,FIBA_HUMAN,FGA,Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Established target
1743,"reteplase,Retavase, Rapilysin",reteplase,thrombolytic agent,recombinant protein,approved,P00747,PLMN_HUMAN,PLG,Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2,Enzymes,StructuralAndAdhesion;Fibrinogen,Established target
1744,"retigabine, ezogabine,Potiga",retigabine,anticonvulsant,small molecule,approved,P51787,KCNQ1_HUMAN,KCNQ1,Potassium voltage-gated channel subfamily KQT member 1 OS=Homo sapiens GN=KCNQ1 PE=1 SV=3,Transporters,TC:1.A.1.15.6,Established target
1744,"retigabine, ezogabine,Potiga",retigabine,anticonvulsant,small molecule,approved,O43526,KCNQ2_HUMAN,KCNQ2,Potassium voltage-gated channel subfamily KQT member 2 (KQT-like 2) (Neuroblastoma-specific potassium channel subunit alpha KvLQT2) (Voltage-gated potassium channel subunit Kv7.2),Transporters,TC:1.A.1.15.2,Established target
1744,"retigabine, ezogabine,Potiga",retigabine,anticonvulsant,small molecule,approved,O43525,KCNQ3_HUMAN,KCNQ3,Potassium voltage-gated channel subfamily KQT member 3 (KQT-like 3) (Potassium channel subunit alpha KvLQT3) (Voltage-gated potassium channel subunit Kv7.3),Transporters,TC:1.A.1.15.3,Established target
1744,"retigabine, ezogabine,Potiga",retigabine,anticonvulsant,small molecule,approved,P56696,KCNQ4_HUMAN,KCNQ4,Potassium voltage-gated channel subfamily KQT member 4 (KQT-like 4) (Potassium channel subunit alpha KvLQT4) (Voltage-gated potassium channel subunit Kv7.4),Transporters,TC.1.A.1.15.4,Established target
1744,"retigabine, ezogabine,Potiga",retigabine,anticonvulsant,small molecule,approved,Q9NR82,KCNQ5_HUMAN,KCNQ5,Potassium voltage-gated channel subfamily KQT member 5 (KQT-like 5) (Potassium channel subunit alpha KvLQT5) (Voltage-gated potassium channel subunit Kv7.5),Transporters,TC:1.A.1.15,Established target
1745,rEV131,rEV131,antiallergy agent,small molecule,not approved,Q9H3N8,HRH4_HUMAN,HRH4,Histamine H4 receptor OS=Homo sapiens GN=HRH4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1746,Revlimid,lenalidomide,antineoplastic agent,Small Molecule,approved,O14788,TNF11_HUMAN,TNFSF11,Tumor necrosis factor ligand superfamily member 11,Ligand,Ligand;Cytokine,Established target
1747,"rFIXFc, recombinant Factor IX Fc fusion protein",recombinant Factor IX Fc fusion protein,for treatment of hemophilia B,protein,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1748,r-FV/,recombinant Factor VIIa,coagulant,recombinant protein,approved,P00451,FA8_HUMAN,F8,Coagulation factor VIII OS=Homo sapiens GN=F8 PE=1 SV=1,Miscellaneous,Enzyme cofactor,Established target
1749,"RG1068, synthetic secretin,SecreFlo",RG1068,for treatment of autism,peptide,not approved,P47872,SCTR_HUMAN,SCTR,Secretin receptor OS=Homo sapiens GN=SCTR PE=2 SV=2,Receptors,GPCR;Secretin,Established target
1750,RG2833,RG2833,for treatment of Friedrich's ataxia,small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1751,RG3039,RG3039,for treatment of spinal muscular atrophy,small molecule,not approved,Q96C86,DCPS_HUMAN,DCPS,m7GpppX diphosphatase,Enzymes,EC:3.6.1.59,Novel Target
1752,"RGN-137, topical thymosin beta 4, Tá4",Thymosin beta-4,wound healing accelerant,peptide,not approved,P68133,ACTS_HUMAN,ACTA1,"Actin, alpha skeletal muscle (Alpha-actin-1)",Miscellaneous,StructureAndAdhesion:Actin,Novel Target
1752,"RGN-137, topical thymosin beta 4, Tá4",Thymosin beta-4,wound healing accelerant,peptide,not approved,P63261,ACTG_HUMAN,ACTG1,"Actin, cytoplasmic 2 (Gamma-actin) [Cleaved into: Actin, cytoplasmic 2, N-terminally processed]",Miscellaneous,StructureAndAdhesion:Actin,Novel Target
1752,"RGN-137, topical thymosin beta 4, Tá4",Thymosin beta-4,wound healing accelerant,peptide,not approved,P19838,NFKB1_HUMAN,NFKB1,Nuclear factor NF-kappa-B p105 subunit OS=Homo sapiens GN=NFKB1 PE=1 SV=2,Transcription factor,Transcription factor,Established target
1752,"RGN-137, topical thymosin beta 4, Tá4",Thymosin beta-4,wound healing accelerant,peptide,not approved,Q00653,NFKB2_HUMAN,NFKB2,Nuclear factor NF-kappa-B p100 subunit (DNA-binding factor KBF2) (H2TF1) (Lymphocyte translocation chromosome 10 protein) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2) (Oncogene Lyt-10) (Lyt10) [Cleaved into: Nuclear factor NF-kap,Transcription factor,Transcription factor,Novel Target
1753,"RGN-259, eye-drop thymosin beta 4, TB4",Thymosin beta-4,wound healing accelerant,peptide,not approved,P68133,ACTS_HUMAN,ACTA1,"Actin, alpha skeletal muscle (Alpha-actin-1)",Miscellaneous,StructureAndAdhesion:Actin,Novel Target
1753,"RGN-259, eye-drop thymosin beta 4, TB4",Thymosin beta-4,wound healing accelerant,peptide,not approved,P63261,ACTG_HUMAN,ACTG1,"Actin, cytoplasmic 2 (Gamma-actin) [Cleaved into: Actin, cytoplasmic 2, N-terminally processed]",Miscellaneous,StructureAndAdhesion:Actin,Novel Target
1753,"RGN-259, eye-drop thymosin beta 4, TB4",Thymosin beta-4,wound healing accelerant,peptide,not approved,P19838,NFKB1_HUMAN,NFKB1,Nuclear factor NF-kappa-B p105 subunit OS=Homo sapiens GN=NFKB1 PE=1 SV=2,Transcription factor,Transcription factor,Established target
1753,"RGN-259, eye-drop thymosin beta 4, TB4",Thymosin beta-4,wound healing accelerant,peptide,not approved,Q00653,NFKB2_HUMAN,NFKB2,Nuclear factor NF-kappa-B p100 subunit (DNA-binding factor KBF2) (H2TF1) (Lymphocyte translocation chromosome 10 protein) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2) (Oncogene Lyt-10) (Lyt10) [Cleaved into: Nuclear factor NF-kap,Transcription factor,Transcription factor,Novel Target
1754,"RGN-352, injectable thymosin beta 4, TB4",Thymosin beta-4,for restoring cardiac tissue following infarction,peptide,not approved,P68133,ACTS_HUMAN,ACTA1,"Actin, alpha skeletal muscle (Alpha-actin-1)",Miscellaneous,StructureAndAdhesion:Actin,Novel Target
1754,"RGN-352, injectable thymosin beta 4, TB4",Thymosin beta-4,for restoring cardiac tissue following infarction,peptide,not approved,P63261,ACTG_HUMAN,ACTG1,"Actin, cytoplasmic 2 (Gamma-actin) [Cleaved into: Actin, cytoplasmic 2, N-terminally processed]",Miscellaneous,StructureAndAdhesion:Actin,Novel Target
1754,"RGN-352, injectable thymosin beta 4, TB4",Thymosin beta-4,for restoring cardiac tissue following infarction,peptide,not approved,P19838,NFKB1_HUMAN,NFKB1,Nuclear factor NF-kappa-B p105 subunit OS=Homo sapiens GN=NFKB1 PE=1 SV=2,Transcription factor,Transcription factor,Established target
1754,"RGN-352, injectable thymosin beta 4, TB4",Thymosin beta-4,for restoring cardiac tissue following infarction,peptide,not approved,Q00653,NFKB2_HUMAN,NFKB2,Nuclear factor NF-kappa-B p100 subunit (DNA-binding factor KBF2) (H2TF1) (Lymphocyte translocation chromosome 10 protein) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2) (Oncogene Lyt-10) (Lyt10) [Cleaved into: Nuclear factor NF-kap,Transcription factor,Transcription factor,Novel Target
1755,RH/,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1756,"r-hCG,Ovidrel",recombinant human chorionic gonadotropin,antineoplastic agent,recombinant protein,approved,P22888,LSHR_HUMAN,LHCGR,Lutropin-choriogonadotropic hormone receptor OS=Homo sapiens GN=LHCGR PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1757,rhIGFBP-3,recombinant human insulin-like growth factor binding protein-3,antineoplastic agent,recombinant protein,not approved,P05019,IGF1_HUMAN,IGF1,Insulin-like growth factor I (IGF-I) (Mechano growth factor) (MGF) (Somatomedin-C),Ligand,Ligand;Growth factor,Novel Target
1758,Rhucin,recombinant human C1 esterase inhibitor,for treatment of hereditary angioedema,recombinant protein,not approved,P05155,IC1_HUMAN,SERPING1,Plasma protease C1 inhibitor (C1 Inh) (C1Inh) (C1 esterase inhibitor) (C1-inhibiting factor) (Serpin G1),Miscellaneous,Protease_inhib_Serpin family,Novel Target
1759,RhuDex,AV1142742,"antiinflammatory agent,DMARD",unknown,not approved,P33681,CD80_HUMAN,CD80,T-lymphocyte activation antigen CD80 OS=Homo sapiens GN=CD80 PE=1 SV=1,Receptors,Receptor; T-cell surface receptor,Established target
1760,"rHu-KGF, keratinocyte growth factor (KGF),Kepivance",palifermin,for treatment of antineoplasty-induced oral mucositis ,recombinant protein,approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
1760,"rHu-KGF, keratinocyte growth factor (KGF),Kepivance",palifermin,for treatment of antineoplasty-induced oral mucositis ,recombinant protein,approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1760,"rHu-KGF, keratinocyte growth factor (KGF),Kepivance",palifermin,for treatment of antineoplasty-induced oral mucositis ,recombinant protein,approved,P22607,FGFR3_HUMAN,FGFR3,Fibroblast growth factor receptor 3 OS=Homo sapiens GN=FGFR3 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1760,"rHu-KGF, keratinocyte growth factor (KGF),Kepivance",palifermin,for treatment of antineoplasty-induced oral mucositis ,recombinant protein,approved,P22455,FGFR4_HUMAN,FGFR4,Fibroblast growth factor receptor 4 OS=Homo sapiens GN=FGFR4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1760,"rHu-KGF, keratinocyte growth factor (KGF),Kepivance",palifermin,for treatment of antineoplasty-induced oral mucositis ,recombinant protein,approved,P98160,PGBM_HUMAN,HSPG2,Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG) (Perlecan) (PLC) [Cleaved into: Endorepellin; LG3 peptide],Miscellaneous,Miscellaneous;mebrane protein,Established target
1760,"rHu-KGF, keratinocyte growth factor (KGF),Kepivance",palifermin,for treatment of antineoplasty-induced oral mucositis ,recombinant protein,approved,O14786,NRP1_HUMAN,NRP1,Neuropilin-1 (Vascular endothelial cell growth factor 165 receptor) (CD antigen CD304),Receptors,Receptors;Neuropilin,Established target
1761,Ridaforolimus,Ridaforolimus,antineoplastic agent,small molecule,not approved,P42345,FRAP_HUMAN,MTOR,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1762,r-IFNá-1a,interferon beta-1a,antineoplastic agent,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1762,r-IFNá-1a,interferon beta-1a,antineoplastic agent,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
1764,"riluzole,Rilutek",riluzole,for treatment of ALS,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1764,"riluzole,Rilutek",riluzole,for treatment of ALS,Small Molecule,approved,Q9UPY5,XCT_HUMAN,SLC7A11,Cystine/glutamate transporter,Transporters,TC:2.A.3.8.18,Established target
1765,rimcazole,rimcazole,antineoplastic agent,small molecule,not approved,Q99720,SGMR1_HUMAN,SIGMAR1,Sigma non-opioid intracellular receptor 1 (Aging-associated gene 8 protein) (SR31747-binding protein) (SR-BP) (Sigma 1-type opioid receptor) (SIG-1R) (Sigma1-receptor) (Sigma1R) (hSigmaR1),Receptors,Miscellaneous;SIGMAR,Established target
1766,Rimonabant,Rimonabant,antiobesity agent,Small Molecule,not approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1767,"rindopepimut, CDX-110",rindopepimut,antineoplastic agent,vaccine,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1768,"riociguat, BAY-63-2521",riociguat,antihypertensive agent,small molecule,not approved,P33402,GCYA2_HUMAN,GUCY1A2,Guanylate cyclase soluble subunit alpha-2 (GCS-alpha-2) (EC 4.6.1.2),Enzymes,EC:4.6.1.2,Established target
1768,"riociguat, BAY-63-2521",riociguat,antihypertensive agent,small molecule,not approved,Q02108,GCYA3_HUMAN,GUCY1A3,Guanylate cyclase soluble subunit alpha-3 (GCS-alpha-3) (EC 4.6.1.2) (GCS-alpha-1) (Soluble guanylate cyclase large subunit),Enzymes,EC:4.6.1.2,Novel Target
1768,"riociguat, BAY-63-2521",riociguat,antihypertensive agent,small molecule,not approved,O75343,GCYB2_HUMAN,GUCY1B2,Guanylate cyclase soluble subunit beta-2,Enzymes,EC:4.6.1.2,Novel Target
1768,"riociguat, BAY-63-2521",riociguat,antihypertensive agent,small molecule,not approved,Q02153,GCYB1_HUMAN,GUCY1B3,Guanylate cyclase soluble subunit beta-1 (GCS-beta-1) (EC 4.6.1.2) (Guanylate cyclase soluble subunit beta-3) (GCS-beta-3) (Soluble guanylate cyclase small subunit),Enzymes,EC:4.6.1.2,Novel Target
1769,"risedronate sodium, NE-58095,Actonel, Benet, Atelvia",risedronate ,antiosteoporotic agent,small molecule,approved,P14324,FPPS_HUMAN,FDPS,Farnesyl pyrophosphate synthetase OS=Homo sapiens GN=FDPS PE=1 SV=4,Enzymes,EC:2.5.1.10,Established target
1770,Risperdal,Risperdal,antipsychotic agent,small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1770,Risperdal,Risperdal,antipsychotic agent,small molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1771,Rituxan,rituximab,antineoplastic agent,monoclonal antibody,approved,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Miscellaneous,MS4A family,Established target
1772,"rivaroxaban, BAY 59-7939,Xarelto",rivaroxaban,antithrombotic,small molecule,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1773,"rivastigmine,Exelon",rivastigmine,for treatment of Alzheimer's disease,Small Molecule,approved,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
1773,"rivastigmine,Exelon",rivastigmine,for treatment of Alzheimer's disease,Small Molecule,approved,P06276,CHLE_HUMAN,BCHE,Cholinesterase OS=Homo sapiens GN=BCHE PE=1 SV=1,Enzymes,EC:3.1.1.8,Established target
1774,rNAPc2,Recombinant Nematode Anticoagulant Protein c2,antithrombotic,recombinant protein,not approved,P17326,AT1A_ARTSF,F3,Sodium/potassium-transporting ATPase subunit alpha-A (Na(+)/K(+) ATPase alpha-A subunit) (EC 3.6.3.9) (Sodium pump subunit alpha-A),Enzymes,EC:3.6.3.9,Novel Target
1774,rNAPc2,Recombinant Nematode Anticoagulant Protein c2,antithrombotic,recombinant protein,not approved,P08709,FA7_HUMAN,F7,Coagulation factor VII OS=Homo sapiens GN=F7 PE=1 SV=1,Enzymes,EC:3.4.21.21,Established target
1775,Rob 803,Rob 803,"antiinflammatory agent,DMARD",small molecule,not approved,unknown,unknown,unknown,unknown,unknown,unknown,unknown
1776,"rocuronium bromide,Esmeron, Zemuron, Eslax",rocuronium,muscle relaxant,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1776,"rocuronium bromide,Esmeron, Zemuron, Eslax",rocuronium,muscle relaxant,Small Molecule,approved,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1776,"rocuronium bromide,Esmeron, Zemuron, Eslax",rocuronium,muscle relaxant,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
1777,"rofecoxib,Vioxx",rofecoxib,NSAID,small molecule,withdrawn,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1778,"roflumilast, Daxas",roflumilast,for treatment of chronic obstructive pulmonary disorder (COPD),small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
1779,"roflumilast,Daxas",roflumilast,for treatment of chronic obstructive pulmonary disorder (COPD),small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
1780,"rolofylline, MK-7418, KW-3902",rolofylline,for treatment of congestive heart failure,small molecule,not approved,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1781,"romiplostim, AMG 531,Nplate",romiplostim,for treatment of thrombocytopenia,fusion protein,approved,P40238,TPOR_HUMAN,MPL,Thrombopoietin receptor (TPO-R) (Myeloproliferative leukemia protein) (Proto-oncogene c-Mpl) (CD antigen CD110),Receptors,Receptor; Type 1 cytokine receptor,Established target
1782,"ronacaleret, 751689",ronacaleret,antiiosteoporotic agent,small molecule,not approved,P41180,CASR_HUMAN,CASR,Extracellular calcium-sensing receptor OS=Homo sapiens GN=CASR PE=1 SV=2,Receptors,GPCR;Glutamate,Established target
1783,"ropivacaine HCl,Naropin",ropivacaine,anestethic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
1784,"rosiglitazone + glimepiride,Avandaryl",glimepiride,antidiabetic,Small Molecule,approved,Q09428,ABCC8_HUMAN,ABCC8,ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1),Transporters,TC:3.A.1.208.4,Established target
1784,"rosiglitazone + glimepiride,Avandaryl",glimepiride,antidiabetic,Small Molecule,approved,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
1784,"rosiglitazone + glimepiride,Avandaryl",glimepiride,antidiabetic,Small Molecule,approved,Q14654,IRK11_HUMAN,KCNJ11,ATP-sensitive inward rectifier potassium channel 11 OS=Homo sapiens GN=KCNJ11 PE=1 SV=2,Transporters,TC:1.A.2.1,Established target
1784,"rosiglitazone + glimepiride,Avandaryl",rosiglitazone,antidiabetic,Small Molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1785,"rosiglitazone maleate + metformin HCl,Ava/",metformin,antidiabetic,Small Molecule,approved,Q9Y478,AAKB1_HUMAN,PRKAB1,5'-AMP-activated protein kinase subunit beta-1 OS=Homo sapiens GN=PRKAB1 PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
1785,"rosiglitazone maleate + metformin HCl,Ava/",rosiglitazone,antidiabetic,Small Molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1786,"rosiglitazone,Avandia",rosiglitazone,"for treatment of Alzheimer's disease,antidiabetic",Small Molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1787,ROX-828,ketorolac,antimigraine agent,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1787,ROX-828,ketorolac,antimigraine agent,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1789,RP101,bromovinyl deoxyuridine,antineoplastic agent,Small molecule,not approved,P09884,DPOLA_HUMAN,POLA1,DNA polymerase alpha catalytic subunit OS=Homo sapiens GN=POLA1 PE=1 SV=2,Enzymes,EC:2.7.7.7,Established target
1790,RPC1063,RPC1063,for treatment of multiple sclerosis,small molecule,not approved,P21453,S1PR1_HUMAN,S1PR1,Sphingosine 1-phosphate receptor 1 (S1P receptor 1) (S1P1) (Endothelial differentiation G-protein coupled receptor 1) (Sphingosine 1-phosphate receptor Edg-1) (S1P receptor Edg-1) (CD antigen CD363),Receptors,GPCR;Rhodopsin,Established target
1791,RPL-554,RPL-554,bronchodilator,small molecule,not approved,Q14432,PDE3A_HUMAN,PDE3A,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A OS=Homo sapiens GN=PDE3A PE=1 SV=3",Enzymes,EC:3.1.4,Established target
1791,RPL-554,RPL-554,bronchodilator,small molecule,not approved,Q13370,PDE3B_HUMAN,PDE3B,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B (EC 3.1.4.17) (CGIPDE1) (CGIP1) (Cyclic GMP-inhibited phosphodiesterase B) (CGI-PDE B)",Enzymes,EC:3.1.4.17,Novel Target
1791,RPL-554,RPL-554,bronchodilator,small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
1791,RPL-554,RPL-554,bronchodilator,small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
1792,"RT001, botulinum toxin type A gel",botulinum toxin type A,"neuromuscular blocking agent,for treatment of wrinkles,antispasmodic",protein,approved,P60880,SNP25_HUMAN,SNAP25,Synaptosomal-associated protein 25 OS=Homo sapiens GN=SNAP25 PE=1 SV=1,Miscellaneous,SNAP25 family,Established target
1793,RTA,RTA 744,antineoplastic agent,small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
1793,RTA,RTA 744,antineoplastic agent,small molecule,not approved,Q02880,TOP2B_HUMAN,TOP2B,"DNA topoisomerase 2-beta (EC 5.99.1.3) (DNA topoisomerase II, beta isozyme)",Enzymes,EC:5.99.1.3,Established target
1794,"rubitecan, RF-2000,Orathecin",rubitecan,antineoplastic agent,small molecule,not approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
1795,"ruboxistaurin mesylate, LY 333531,Arxxant",ruboxistaurin,for treatment of diabetic neuropathy,small molecule,not approved,P05771,KPCB_HUMAN,PRKCB1,Protein kinase C beta type (PKC-B) (PKC-beta) (EC 2.7.11.13),Enzymes,EC:2.7.11.13,Established target
1797,RVX-208,RVX-208,antiatherosclerotic agent,small molecule,not approved,P02647,APOA1_HUMAN,APOA1,Apolipoprotein A-I (Apo-AI) (ApoA-I) (Apolipoprotein A1) [Cleaved into: Apolipoprotein A-I(1-242)],Miscellaneous,Apolipoprotein A1/A4/E family,Novel Target
1798,"RX-0201 ,Archexin",RX-0201,antineoplastic agent,antisense oligo,not approved,P31749,AKT1_HUMAN,AKT1,RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Proto-oncogene c-Akt) (RAC-PK-alpha),Enzymes,EC:2.7.11.1,Novel Target
1799,"RX-0201,Archexin",RX-0201,antineoplastic agent,antisense oligo,not approved,P31751,AKT2_HUMAN,AKT2,RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta),Enzymes,EC:2.7.11.1,Novel Target
1799,"RX-0201,Archexin",RX-0201,antineoplastic agent,antisense oligo,not approved,Q9Y243,AKT3_HUMAN,AKT3,RAC-gamma serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-3) (Protein kinase B gamma) (PKB gamma) (RAC-PK-gamma) (STK-2),Enzymes,EC:2.7.11.1,Novel Target
1800,"S-1, TS1",gimestat,antineoplastic agent,Small molecule,not approved,Q12882,DPYD_HUMAN,DPYD,Dihydropyrimidine dehydrogenase [NADP+] (DHPDHase) (DPD) (EC 1.3.1.2) (Dihydrothymine dehydrogenase) (Dihydrouracil dehydrogenase),Enzymes,EC:1.3.1.2,Novel Target
1800,"S-1, TS1",tegafur,antineoplastic agent,small molecule,not approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
1801,"S-8184,TOCOSOL paclitaxel",paclitaxel,antineoplastic agent,Small Molecule,approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1801,"S-8184,TOCOSOL paclitaxel",paclitaxel,antineoplastic agent,Small Molecule,approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1802,"SA4503, Msc-1",SA4503,"antidepressant,neuroprotectant",small molecule,not approved,Q99720,OPRS1_HUMAN,SIGMAR1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q00975,CAC1B_HUMAN,CACNA1B,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:1.A.1.11,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q9NY47,CA2D2_HUMAN,CACNA2D2,Voltage-dependent calcium channel subunit alpha-2/delta-2 OS=Homo sapiens GN=CACNA2D2 PE=1 SV=1,Transporters,TC:8.A.18.2.1,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,P54284,CACB3_HUMAN,CACNB3,Voltage-dependent L-type calcium channel subunit beta-3 OS=Homo sapiens GN=CACNB3 PE=1 SV=1,Transporters,TC:8.A.22.1.3,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,O00305,CACB4_HUMAN,CACNB4,Voltage-dependent L-type calcium channel subunit beta-4 OS=Homo sapiens GN=CACNB4 PE=1 SV=2,Transporters,TC:8.A.22.1.4,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,P27338,AOFB_HUMAN,MAOB,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q9UI33,SCNBA_HUMAN,SCN11A,Sodium channel protein type 11 subunit alpha OS=Homo sapiens GN=SCN11A PE=1 SV=2,Transporters,TC:1.A.1.10.9,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q9UI33,SCNBA_HUMAN,SCN11A,Sodium channel protein type 11 subunit alpha OS=Homo sapiens GN=SCN11A PE=1 SV=2,Transporters,TC:1.A.1.10.9,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q99250,SCN2A_HUMAN,SCN2A,Sodium channel protein type 2 subunit alpha (HBSC II) (Sodium channel protein brain II subunit alpha) (Sodium channel protein type II subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.2),Transporters,TC:1.A.1.10,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q9NY46,SCN3A_HUMAN,SCN3A,Sodium channel protein type 3 subunit alpha (Sodium channel protein brain III subunit alpha) (Sodium channel protein type III subunit alpha) (Voltage-gated sodium channel subtype III) (Voltage-gated sodium channel subunit alpha Nav1.3),Transporters,TC:1.A.1.10,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,P35499,SCN4A_HUMAN,SCN4A,Sodium channel protein type 4 subunit alpha (SkM1) (Sodium channel protein skeletal muscle subunit alpha) (Sodium channel protein type IV subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.4),Transporters,TC:1.A.1.10.4,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q01118,SCN7A_HUMAN,SCN7A,Sodium channel protein type 7 subunit alpha,Transporters,TC:1.A.1.10,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q9UQD0,SCN8A_HUMAN,SCN8A,Sodium channel protein type 8 subunit alpha (Sodium channel protein type VIII subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.6),Transporters,TC:1.A.1.10.8,Established target
1803,Safinamide,Safinamide,antiparkinson agent ,small molecule,not approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
1804,SAN-300,SAN-300,"antiinflammatory agent,DMARD",antibody,not approved,P56199,ITA1_HUMAN,ITGA1,Integrin alpha-1 (CD49 antigen-like family member A) (Laminin and collagen receptor) (VLA-1) (CD antigen CD49a),Receptors,Receptors;Integrin,Novel Target
1804,SAN-300,SAN-300,"antiinflammatory agent,DMARD",antibody,not approved,P05556,ITB1_HUMAN,ITGB1,Integrin beta-1 (Fibronectin receptor subunit beta) (VLA-4 subunit beta) (CD antigen CD29),Receptors,Receptors;Integrin,Established target
1805,Sapropterin,tetrahydrobiopterin,for treatment of phenolketonuria (PKU),Small Molecule,approved,P29474,NOS3_HUMAN,NOS3,"Nitric oxide synthase, endothelial OS=Homo sapiens GN=NOS3 PE=1 SV=3",Enzymes,EC:1.14.13.39,Established target
1805,Sapropterin,tetrahydrobiopterin,for treatment of phenolketonuria (PKU),Small Molecule,approved,P00439,PH4H_HUMAN,PAH,Phenylalanine-4-hydroxylase OS=Homo sapiens GN=PAH PE=1 SV=1,Enzymes,EC:1.14.16.1,Established target
1805,Sapropterin,tetrahydrobiopterin,for treatment of phenolketonuria (PKU),Small Molecule,approved,P07101,TY3H_HUMAN,TH,Tyrosine 3-monooxygenase OS=Homo sapiens GN=TH PE=1 SV=4,Enzymes,EC:1.14.16.2,Established target
1805,Sapropterin,tetrahydrobiopterin,for treatment of phenolketonuria (PKU),Small Molecule,approved,P17752,TPH1_HUMAN,TPH1,Tryptophan 5-hydroxylase 1 OS=Homo sapiens GN=TPH1 PE=1 SV=4,Enzymes,EC:1.14.16.4,Established target
1806,SAR 1118,SAR 1118,antiinflammatory agent,small molecule,not approved,P05362,ICAM1_HUMAN,ICAM1,Intercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
1806,SAR 1118,SAR 1118,antiinflammatory agent,small molecule,not approved,P20701,ITAL_HUMAN,ITGAL,Integrin alpha-L OS=Homo sapiens GN=ITGAL PE=1 SV=3,Receptors,Receptors;Integrin,Established target
1806,SAR 1118,SAR 1118,antiinflammatory agent,small molecule,not approved,P05107,ITB2_HUMAN,ITGB2,Integrin beta-2,Receptors,Receptors;Integrin,Novel Target
1807,SAR3419,SAR3419,antineoplastic agent,fusion protein,not approved,P15391,CD19_HUMAN,CD19,B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigen CD19) (T-cell surface antigen Leu-12) (CD antigen CD19),Miscellaneous,Miscellaneous;CD19,Novel Target
1808,SAR566658,SAR566658,antineoplastic agent,monoclonal antibody,not approved,P23280,CAH6_HUMAN,CA6,Carbonic anhydrase 6 (EC 4.2.1.1) (Carbonate dehydratase VI) (Carbonic anhydrase VI) (CA-VI) (Salivary carbonic anhydrase) (Secreted carbonic anhydrase),Enzymes,EC:4.2.1.1,Novel Target
1809,SAR650984,SAR650984,antineoplastic agent,monoclonal antibody,not approved,P28907,CD38_HUMAN,CD38,ADP-ribosyl cyclase 1 (EC 3.2.2.5) (Cyclic ADP-ribose hydrolase 1) (cADPr hydrolase 1) (T10) (CD antigen CD38),Enzymes,EC:3.2.2,Novel Target
1810,"Saredutant, SR 48968",saredutant,"antidepressant,anxiolytic",small molecule,not approved,P21452,NK2R_HUMAN,TACR2,Substance-K receptor (SKR) (NK-2 receptor) (NK-2R) (Neurokinin A receptor) (Tachykinin receptor 2),Receptors,GPCR;Rhodopsin,Novel Target
1811,"sargramostim,L/",sargramostim,for treatment of Chron's disease,recombinant protein,approved,P15509,CSF2R_HUMAN,CSF2RA,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha OS=Homo sapiens GN=CSF2RA PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1811,"sargramostim,L/",sargramostim,for treatment of Chron's disease,recombinant protein,approved,P32927,IL3RB_HUMAN,CSF2RB,Cytokine receptor common subunit beta OS=Homo sapiens GN=CSF2RB PE=1 SV=2,Receptors,Receptor; Type 1 cytokine receptor,Established target
1812,Sativex,nabilone,"analgesic,neuropathic pain,for treatment of restlegs legs syndrome",Small Molecule,approved,P34972,CNR2_HUMAN,CNR2,Cannabinoid receptor 2 OS=Homo sapiens GN=CNR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1812,Sativex,nabilone,"analgesic,neuropathic pain,for treatment of restlegs legs syndrome",Small Molecule,approved,P34972,CNR2_HUMAN,CNR2,Cannabinoid receptor 2 OS=Homo sapiens GN=CNR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1812,Sativex,tetrahydrocannabinol,"analgesic,neuropathic pain,for treatment of restlegs legs syndrome",plant extract,approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1812,Sativex,tetrahydrocannabinol,"analgesic,neuropathic pain,for treatment of restlegs legs syndrome",plant extract,approved,P34972,CNR2_HUMAN,CNR2,Cannabinoid receptor 2 OS=Homo sapiens GN=CNR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1813,Saxagliptin,Saxagliptin,antidiabetic,small molecule,approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
1814,"SB1518, ONX 0803",SB1518,antineoplastic agent,small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
1815,SB-509,SB-509,for treatment of diabetic neuropathy,DNA plasmid,not approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
1816,SB-559448,SB-559448,thrombopoietic agent,small molecule,not approved,P40238,TPOR_HUMAN,MPL,Thrombopoietin receptor (TPO-R) (Myeloproliferative leukemia protein) (Proto-oncogene c-Mpl) (CD antigen CD110),Receptors,Receptor; Type 1 cytokine receptor,Established target
1817,SB-681323,SB-681323,"antiinflammatory agent,DMARD",small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
1818,"SB-683699, T-0047",firategrast,antiinflammatory agent,Small molecule,not approved,P13612,ITA4_HUMAN,ITGA4,Integrin alpha-4 OS=Homo sapiens GN=ITGA4 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
1818,"SB-683699, T-0047",firategrast,antiinflammatory agent,Small molecule,not approved,P05556,ITB1_HUMAN,ITGB1,Integrin beta-1 (Fibronectin receptor subunit beta) (VLA-4 subunit beta) (CD antigen CD29),Receptors,Receptors;Integrin,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,Q13547,HDAC1_HUMAN,HDAC1,Histone deacetylase 1 OS=Homo sapiens GN=HDAC1 PE=1 SV=1,Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,Q969S8,HDA10_HUMAN,HDAC10,Histone deacetylase 10 (HD10) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,Q96DB2,HDA11_HUMAN,HDAC11,Histone deacetylase 11 (HD11) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,Q92769,HDAC2_HUMAN,HDAC2,Histone deacetylase 2 OS=Homo sapiens GN=HDAC2 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,O15379,HDAC3_HUMAN,HDAC3,Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,P56524,HDAC4_HUMAN,HDAC4,Histone deacetylase 4 (HD4) (EC 3.5.1.98),Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,Q9UQL6,HDAC5_HUMAN,HDAC5,Histone deacetylase 5 (HD5) (EC 3.5.1.98) (Antigen NY-CO-9),Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,Q9UBN7,HDAC6_HUMAN,HDAC6,Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,Q8WUI4,HDAC7_HUMAN,HDAC7A,Histone deacetylase 7 (HD7) (EC 3.5.1.98) (Histone deacetylase 7A) (HD7a),Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,Q9BY41,HDAC8_HUMAN,HDAC8,Histone deacetylase 8 OS=Homo sapiens GN=HDAC8 PE=1 SV=2,Enzymes,EC:3.5.1.98,Established target
1819,SB939,pracinostat,antineoplastic agent,small molecule,not approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
1820,"SBI-087, PF-05230895",SBI-087,"antiinflammatory agent,DMARD",protein,not approved,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Miscellaneous,MS4A family,Established target
1821,"SBS-1000, safflower-produced insulin",insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1822,"SCH-527123, PS-291822, PS-938285",SCH-527123,for treatment of chronic obstructive pulmonary disorder (COPD),small molecule,not approved,P25024,CXCR1_HUMAN,CXCR1,C-X-C chemokine receptor type 1 (CXC-R1) (CXCR-1) (CDw128a) (High affinity interleukin-8 receptor A) (IL-8R A) (IL-8 receptor type 1) (CD antigen CD181),Receptors,GPCR;Rhodopsin,Novel Target
1822,"SCH-527123, PS-291822, PS-938285",SCH-527123,for treatment of chronic obstructive pulmonary disorder (COPD),small molecule,not approved,P25025,CXCR2_HUMAN,CXCR2,C-X-C chemokine receptor type 2 (CXC-R2) (CXCR-2) (CDw128b) (GRO/MGSA receptor) (High affinity interleukin-8 receptor B) (IL-8R B) (IL-8 receptor type 2) (CD antigen CD182),Receptors,GPCR;Rhodopsin,Novel Target
1823,SCIO-469,talmapimod,"antiinflammatory agent,DMARD",small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
1825,SCY-635,SCY-635,for treatment of hepatitis C,small molecule,not approved,P62937 ,PPIA_HUMAN,PP1A,Peptidyl-prolyl cis-trans isomerase A,Enzymes,EC:5.2.1.8,Novel Target
1825,SCY-635,SCY-635,for treatment of hepatitis C,small molecule,not approved,Q08752,PPID_HUMAN,PP1D,Peptidyl-prolyl cis-trans isomerase D (PPIase D) (EC 5.2.1.8) (40 kDa peptidyl-prolyl cis-trans isomerase) (Cyclophilin-40) (CYP-40) (Cyclophilin-related protein) (Rotamase D),Enzymes,EC:5.2.1.8,Novel Target
1826,"Scyllo-inositol, ELND005, AZD-103",scyllo-inositol,for treatment of Alzheimer's disease,small molecule,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
1827,"SDX-101, R-etodolac",R-etodolac,antineoplastic agent,small molecule,not approved,P19793,RXRA_HUMAN,RXRA,Retinoic acid receptor RXR-alpha OS=Homo sapiens GN=RXRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
1828,"selegiline transdermal,Emsam",selegiline,antidepressant,Small Molecule,approved,P27338,AOFB_HUMAN,MAOB,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3,Established target
1829,"selegiline,Zelapar",selegiline,antiparkinson agent ,Small Molecule,approved,P27338,AOFB_HUMAN,MAOB,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3,Established target
1830,"seletracetam, UCB 44212",seletracetam,anticonvulsant,small molecule,not approved,Q7L0J3,SV2A_HUMAN,SV2A,Synaptic vesicle glycoprotein 2A,Transporters,TC:2.A.1,Established target
1831,"selexipag, ACT-293987",selexipag,antihypertensive agent,small molecule,not approved,P43119,PI2R_HUMAN,PTGIR,Prostacyclin receptor OS=Homo sapiens GN=PTGIR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1832,SelG1,SelG1,for treatment of sickle-cell disease,monoclonal antibody,not approved,P16109,LYAM3_HUMAN,SELP,P-selectin (CD62 antigen-like family member P) (Granule membrane protein 140) (GMP-140) (Leukocyte-endothelial cell adhesion molecule 3) (LECAM3) (Platelet activation dependent granule-external membrane protein) (PADGEM) (CD antigen CD62P),Receptors,Receptors;Selectin,Novel Target
1833,"seliciclib, R-roscovitine, CYC202",seliciclib,antineoplastic agent,small molecule,not approved,P24941,CDK2_HUMAN,CDK2,Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase),Enzymes,EC:2.7.11.22,Novel Target
1833,"seliciclib, R-roscovitine, CYC202",seliciclib,antineoplastic agent,small molecule,not approved,P50613,CDK7_HUMAN,CDK7,Cyclin-dependent kinase 7 (EC 2.7.11.22) (EC 2.7.11.23) (39 kDa protein kinase) (CAK1) (CDK-activating kinase) (CAK) (Cell division protein kinase 7) (STK1) (TFIIH basal transcription factor complex kinase subunit) (p39 Mo15),Enzymes,EC:2.7.11.22; 2.7.11.23,Novel Target
1833,"seliciclib, R-roscovitine, CYC202",seliciclib,antineoplastic agent,small molecule,not approved,P50750,CDK9_HUMAN,CDK9,Cyclin-dependent kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (C-2K) (Cell division cycle 2-like protein kinase 4) (Cell division protein kinase 9) (Serine/threonine-protein kinase PITALRE),Enzymes,EC:2.7.11.22; 2.7.11.23,Novel Target
1834,Selzentry,maraviroc,"antiviral agent,HIV",Small Molecule,approved,P51681,CCR5_HUMAN,CCR5,C-C chemokine receptor type 5 OS=Homo sapiens GN=CCR5 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1835,"SEN0014196, EX-527",SEN0014196,for treatment of Huntington's disease,unknown,not approved,Q96EB6,SIRT1_HUMAN,SIRT1,NAD-dependent deacetylase sirtuin-1 (hSIRT1) (EC 3.5.1.-) (SIR2-like protein 1) (hSIR2),Enzymes,EC:3.5.1.-,Novel Target
1836,SEP-225289,eszopiclone,anxiolytic,Small molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
1837,Serdaxin,clavulanic acid,antidepressant,Small molecule,approved,Q04609,FOLH1_HUMAN,FOLH1,Glutamate carboxypeptidase 2 OS=Homo sapiens GN=FOLH1 PE=1 SV=1,Enzymes,EC:3.4.17,Established target
1838,Serdolect,SERTINDOLE,antipsychotic agent,small molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1838,Serdolect,SERTINDOLE,antipsychotic agent,small molecule,approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
1838,Serdolect,SERTINDOLE,antipsychotic agent,small molecule,approved,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1838,Serdolect,SERTINDOLE,antipsychotic agent,small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1838,Serdolect,SERTINDOLE,antipsychotic agent,small molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1838,Serdolect,SERTINDOLE,antipsychotic agent,small molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1838,Serdolect,SERTINDOLE,antipsychotic agent,small molecule,approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1838,Serdolect,SERTINDOLE,antipsychotic agent,small molecule,approved,Q12809,KCNH2_HUMAN,KCNH2,Potassium voltage-gated channel subfamily H member 2 OS=Homo sapiens GN=KCNH2 PE=1 SV=1,Transporters,TC:1.A.1.20.1,Established target
1839,Serevent,salmeterol,bronchodilator,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1840,Seroquel,Quetiapine,"antipsychotic agent,antidepressant",Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1840,Seroquel,Quetiapine,"antipsychotic agent,antidepressant",Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1840,Seroquel,Quetiapine,"antipsychotic agent,antidepressant",Small Molecule,approved,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1840,Seroquel,Quetiapine,"antipsychotic agent,antidepressant",Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1840,Seroquel,Quetiapine,"antipsychotic agent,antidepressant",Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,P42345,FRAP_HUMAN,MTOR,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,Q8NEB9,PK3C3_HUMAN,PIK3C3,Phosphatidylinositol 3-kinase catalytic subunit type 3,Enzymes,EC:2.7.1.137,Novel Target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,P42336,PK3CA_HUMAN,PIK3CA,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PI3-kinase subunit alpha) (PI3K-alpha) (PtdIns-3-kinase subunit alpha) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,P42336,PK3CA_HUMAN,PIK3CA,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PI3-kinase subunit alpha) (PI3K-alpha) (PtdIns-3-kinase subunit alpha) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,P42338,PK3CB_HUMAN,PIK3CB,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Enzymes,EC:2.7.1.153,Novel Target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,O00329,PK3CD_HUMAN,PIK3CD,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3-kinase subunit delta) (PI3K-delta) (PtdIns-3-kinase subunit delta) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,O00329,PK3CD_HUMAN,PIK3CD,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3-kinase subunit delta) (PI3K-delta) (PtdIns-3-kinase subunit delta) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,P48736,PK3CG_HUMAN,PIK3CG,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3-kinase subunit gamma) (PI3K-gamma) (PtdIns-3-kinase subunit gamma) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,P48736,PK3CG_HUMAN,PIK3CG,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3-kinase subunit gamma) (PI3K-gamma) (PtdIns-3-kinase subunit gamma) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
1841,SF1126,SF1126,antineoplastic agent,small molecule,not approved,P78527,PRKDC_HUMAN,PRKDC,DNA-dependent protein kinase catalytic subunit,Enzymes,EC:2.7.11.1,Novel Target
1842,SGI-1776,SGI-1776,antineoplastic agent,small molecule,not approved,P11309,PIM1_HUMAN,PIM1,Proto-oncogene serine/threonine-protein kinase pim-1 (EC 2.7.11.1),Enzymes,EC:2.7.11.1,Novel Target
1842,SGI-1776,SGI-1776,antineoplastic agent,small molecule,not approved,Q9P1W9,PIM2_HUMAN,PIM2,Serine/threonine-protein kinase pim-2 (EC 2.7.11.1) (Pim-2h),Enzymes,EC:2.7.11.1,Novel Target
1842,SGI-1776,SGI-1776,antineoplastic agent,small molecule,not approved,Q86V86,PIM3_HUMAN,PIM3,Serine/threonine-protein kinase pim-3 (EC 2.7.11.1),Enzymes,EC:2.7.11.1,Novel Target
1843,SGN-35,brentuximab vedotin,antineoplastic agent,fusion protein,not approved,P28908,TNR8_HUMAN,TNFRSF8,Tumor necrosis factor receptor superfamily member 8 (CD30L receptor) (Ki-1 antigen) (Lymphocyte activation antigen CD30) (CD antigen CD30),Receptors,Receptors;TNFNGF,Novel Target
1844,SGN-70,SGN-70,antiinflammatory agent,monoclonal antibody,not approved,P32970,CD70_HUMAN,CD70,CD70 antigen (CD27 ligand) (CD27-L) (Tumor necrosis factor ligand superfamily member 7) (CD antigen CD70),Miscellaneous,Ligand;Cytokine;TNFR,Novel Target
1845,SGN-75,SGN-75,antineoplastic agent,monoclonal antibody,not approved,P32970,CD70_HUMAN,CD70,CD70 antigen (CD27 ligand) (CD27-L) (Tumor necrosis factor ligand superfamily member 7) (CD antigen CD70),Miscellaneous,Ligand;Cytokine;TNFR,Novel Target
1846,SGX201,beclomethasone,"antiinflammatory agent,glucocorticoid",Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1847,SGX523,SGX523,antineoplastic agent,small molecule,not approved,P08581,MET_HUMAN,MET,Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met),Receptors,EC:2.7.10.1,Established target
1848,"sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium",sibutramine,appetite suppressant,Small Molecule,withdrawn,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1848,"sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium",sibutramine,appetite suppressant,Small Molecule,withdrawn,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1848,"sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium",sibutramine,appetite suppressant,Small Molecule,withdrawn,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1849,"sifalimumab, MEDI-545, MDX-1103",sifalimumab,for treatment of systemic lupues erythematosus,monoclonal antibody,not approved,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
1850,"sildenafil citrate,Revatio, Viagra",sildenafil,"for treatment of erectile dysfucntion,antihypertensive agent",Small Molecule,approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1851,Silenor (SO-101),doxepin,hypnotic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1852,Silodosin,Silodosin,for treatment of BPH-related urinary symptoms,small molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1853,"siplizumab, MEDI-507",siplizumab,antineoplastic agent,monoclonal antibody,not approved,P06729,CD2_HUMAN,CD2,T-cell surface antigen CD2 OS=Homo sapiens GN=CD2 PE=1 SV=2,Miscellaneous,StructuralAndAdhesion,Established target
1854,"sirolimus, rapamycin,Perceiva",sirolimus,for treatment of wet age-related macular degeneration,Small Molecule,approved,P62942,FKB1A_HUMAN,FKBP1A,Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Homo sapiens GN=FKBP1A PE=1 SV=2,Enzymes,EC:5.2.1.8,Established target
1854,"sirolimus, rapamycin,Perceiva",sirolimus,for treatment of wet age-related macular degeneration,Small Molecule,approved,P42345,FRAP_HUMAN,MTOR,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1855,"sirolimus,Rapamune",sirolimus,immunosuppressant,Small Molecule,approved,P62942,FKB1A_HUMAN,FKBP1A,Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Homo sapiens GN=FKBP1A PE=1 SV=2,Enzymes,EC:5.2.1.8,Established target
1855,"sirolimus,Rapamune",sirolimus,immunosuppressant,Small Molecule,approved,P42345,FRAP_HUMAN,MTOR,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1856,sirukumab,sirukumab,"antiinflammatory agent,DMARD",antibody,not approved,P08887,IL6RA_HUMAN,IL6R,Interleukin-6 receptor subunit alpha (IL-6 receptor subunit alpha) (IL-6R subunit alpha) (IL-6R-alpha) (IL-6RA) (IL-6R 1) (Membrane glycoprotein 80) (gp80) (CD antigen CD126),Receptors,Receptor; Type 1 cytokine receptor,Established target
1857,Sitagliptin,Sitagliptin,antidiabetic,Small Molecule,not approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
1858,"sivelestat sodium hydrate,Elaspol",sivelestat ,for treatment of acute lung injury associated with systemic inflammatory response syndrome (SIRS),small molecule,not approved,P08246,ELNE_HUMAN,ELA2,Leukocyte elastase OS=Homo sapiens GN=ELA2 PE=1 SV=1,Enzymes,EC:3.4.21.37,Established target
1860,"SKP-1041, delayed-release zaleplon",zaleplon,hypnotic,Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
1860,"SKP-1041, delayed-release zaleplon",zaleplon,hypnotic,Small Molecule,approved,P30536,TSPOA_HUMAN,TSPO,Translocator protein (Mitochondrial benzodiazepine receptor) (PKBS) (Peripheral-type benzodiazepine receptor) (PBR),Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
1861,"SkyePharma,FlutiForm",fluticasone,"antiinflammatory agent,glucocorticoid",Small molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
1861,"SkyePharma,FlutiForm",formoterol,bronchodilator,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1862,"SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR",amphetamine,"for treatment of cognitive dysfunction,for treatment of ADHD",Small Molecule,approved,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
1862,"SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR",amphetamine,"for treatment of cognitive dysfunction,for treatment of ADHD",Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1862,"SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR",amphetamine,"for treatment of cognitive dysfunction,for treatment of ADHD",Small Molecule,approved,Q96RJ0,TAAR1_HUMAN,TAAR1,Trace amine-associated receptor 1 (TaR-1) (Trace amine receptor 1),Receptors,GPCR;Rhodopsin,Established target
1862,"SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR",dextroamphetamine,for treatment of ADHD,Small Molecule,approved,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
1862,"SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR",dextroamphetamine,for treatment of ADHD,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1862,"SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR",dextroamphetamine,for treatment of ADHD,Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
1863,SLx-2101,SLx-2101,"antihypertensive agent,for treatment of erectile dysfunction",small molecule,not approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
1864,SLx-4090,SLx-4090,antidyslipidaemic agent,small molecule,not approved,P55157,MTP_HUMAN,MTTP,Microsomal triglyceride transfer protein large subunit,Transporters,Miscellaneous;Lipid_transp,Novel Target
1865,SM101,SM101,"antiinflammatory agent,DMARD",fusion protein,not approved,P31994,FCG2B_HUMAN,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b (IgG Fc receptor II-b) (CDw32) (Fc-gamma RII-b) (Fc-gamma-RIIb) (FcRII-b) (CD antigen CD32),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
1866,SNS01-T,SNS01-T,antineoplastic agent,siRNA,not approved,P63241,IF5A1_HUMAN,EIF5A,Eukaryotic translation initiation factor 5A-1 (eIF-5A-1) (eIF-5A1) (Eukaryotic initiation factor 5A isoform 1) (eIF-5A) (Rev-binding factor) (eIF-4D),Miscellaneous,Miscellaneous; translation initiation factor,Novel Target
1867,SNS-032,SNS-032,antineoplastic agent,small molecule,not approved,P24941,CDK2_HUMAN,CDK2,Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase),Enzymes,EC:2.7.11.22,Novel Target
1867,SNS-032,SNS-032,antineoplastic agent,small molecule,not approved,P50613,CDK7_HUMAN,CDK7,Cyclin-dependent kinase 7 (EC 2.7.11.22) (EC 2.7.11.23) (39 kDa protein kinase) (CAK1) (CDK-activating kinase) (CAK) (Cell division protein kinase 7) (STK1) (TFIIH basal transcription factor complex kinase subunit) (p39 Mo15),Enzymes,EC:2.7.11.22; 2.7.11.23,Novel Target
1867,SNS-032,SNS-032,antineoplastic agent,small molecule,not approved,P50750,CDK9_HUMAN,CDK9,Cyclin-dependent kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (C-2K) (Cell division cycle 2-like protein kinase 4) (Cell division protein kinase 9) (Serine/threonine-protein kinase PITALRE),Enzymes,EC:2.7.11.22; 2.7.11.23,Novel Target
1868,SNS-314,SNS-314,antineoplastic agent,small molecule,not approved,O14695,STK6_HUMAN,AURKA,Serine/threonine-protein kinase 6 (EC 2.7.11.1) (Aurora kinase A) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase aurora-A),Enzymes,EC:2.7.11.1,Novel Target
1868,SNS-314,SNS-314,antineoplastic agent,small molecule,not approved,Q96GD4,AURKB_HUMAN,AURKB,Serine/threonine-protein kinase 12 (EC 2.7.11.1) (Aurora kinase B) (Aurora- and IPL1-like midbody-associated protein 1) (AIM-1) (Aurora/IPL1-related kinase 2) (ARK-2) (Aurora-related kinase 2) (STK-1) (Serine/threonine-protein kinase aurora-B),Enzymes,EC:2.7.11.1,Novel Target
1869,SNX-5422,SNX-5422,antineoplastic agent,small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
1869,SNX-5422,SNX-5422,antineoplastic agent,small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
1870,"sobetirome, QRX-431",sobetirome,antihypecholesterolemic agent,small molecule,not approved,P10828,THB_HUMAN,THRB,Thyroid hormone receptor beta OS=Homo sapiens GN=THRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1871,Sodium oxybate,gamma hydroxybutyric acid,hypnotic,Small molecule,approved,Q9UBS5,GABR1_HUMAN,GABBR1,Gamma-aminobutyric acid type B receptor subunit 1 OS=Homo sapiens GN=GABBR1 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
1871,Sodium oxybate,gamma hydroxybutyric acid,hypnotic,Small molecule,approved,O75899,GABR2_HUMAN,GABBR2,Gamma-aminobutyric acid type B receptor subunit 2 OS=Homo sapiens GN=GABBR2 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
1871,Sodium oxybate,gamma hydroxybutyric acid,hypnotic,Small molecule,approved,Q9HAB3,S52A2_HUMAN,SLC5A2,Riboflavin transporter 3 (hRFT3) (Porcine endogenous retrovirus A receptor 1) (PERV-A receptor 1) (Protein GPR172A),Transporter,TC:9.A.53.1.3,Established target
1872,"sodium stibogluconate,Lenocta",stibogluconate,antineoplastic agent,small molecule,not approved,Q06124,PTN11_HUMAN,PTPN11,Tyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48) (Protein-tyrosine phosphatase 1D) (PTP-1D) (Protein-tyrosine phosphatase 2C) (PTP-2C) (SH-PTP2) (SHP-2) (Shp2) (SH-PTP3),Enzymes,EC:3.1.3.48,Novel Target
1873,"SOH-075,NorLevo",levonorgestrel,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1873,"SOH-075,NorLevo",levonorgestrel,contraceptive,Small Molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
1873,"SOH-075,NorLevo",levonorgestrel,contraceptive,Small Molecule,approved,P18405,S5A1_HUMAN,SRD5A1,3-oxo-5-alpha-steroid 4-dehydrogenase 1 OS=Homo sapiens GN=SRD5A1 PE=1 SV=1,Enzymes,EC:1.3.99,Established target
1874,"solabegron, GW 427353",solabegron,"antidiabetic,for treatment of irritable bowel syndrome,antiincontinence agent",small molecule,not approved,P13945,ADRB3_HUMAN,ADRB3,Beta-3 adrenergic receptor (Beta-3 adrenoreceptor) (Beta-3 adrenoceptor),Receptors,GPCR;Rhodopsin,Novel Target
1875,"Solanezumab, LY-2062430",Solanezumab,for treatment of Alzheimer's disease,monoclonal antibody,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
1876,"Solifenacin succinate, YM-905,Vesicare",Solifenacin,for treatment of incontinence,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1876,"Solifenacin succinate, YM-905,Vesicare",Solifenacin,for treatment of incontinence,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1876,"Solifenacin succinate, YM-905,Vesicare",Solifenacin,for treatment of incontinence,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1876,"Solifenacin succinate, YM-905,Vesicare",Solifenacin,for treatment of incontinence,Small Molecule,approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1876,"Solifenacin succinate, YM-905,Vesicare",Solifenacin,for treatment of incontinence,Small Molecule,approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1877,Soliris,eculizumab,"antiinflammatory agent,DMARD",monoclonal antibody,approved,P01031,CO5_HUMAN,C5,Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4,Miscellaneous,Immune response;Complement system,Established target
1878,Solulin,recombinant thrombomodulin,anticoagulant,recombinant protein,not approved,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
1879,somatropin (intranasal),somatropin ,growth hormone replacement therapy,recombinant protein,approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1879,somatropin (intranasal),somatropin ,growth hormone replacement therapy,recombinant protein,approved,P16471,PRLR_HUMAN,PRLR,Prolactin receptor (PRL-R),Receptors,Receptor; Type 1 cytokine receptor,Established target
1880,"somatropin,Genotropin",somatropin,growth hormone replacement therapy,recombinant protein,approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1880,"somatropin,Genotropin",somatropin,growth hormone replacement therapy,recombinant protein,approved,P16471,PRLR_HUMAN,PRLR,Prolactin receptor (PRL-R),Receptors,Receptor; Type 1 cytokine receptor,Established target
1881,"SOU-001, DRP-001",SOU-001,for treatment of incontinence,small molecule,not approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1881,"SOU-001, DRP-001",SOU-001,for treatment of incontinence,small molecule,not approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
1881,"SOU-001, DRP-001",SOU-001,for treatment of incontinence,small molecule,not approved,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1882,"SOU-003, OPC-51803",SOU-003,for treatment of incontinence,small molecule,not approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1883,SP1049C,doxorubicin,antineoplastic agent,Small Molecule,approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
1884,SPC-2996,SPC-2996,antineoplastic agent,antisense oligo,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1885,"SPC-3042, EZN-3042",SPC-3042,antineoplastic agent,antisense oligo,not approved,O15392,BIRC5_HUMAN,BIRC5,Baculoviral IAP repeat-containing protein 5 (Apoptosis inhibitor 4) (Apoptosis inhibitor survivin),Miscellaneous,Inhibitor of apoptosis,Novel Target
1886,SPC4955,SPC4955,antidyslipidaemic agent,antisense oligo,not approved,P04114,APOB_HUMAN,APOB,Apolipoprotein B-100 (Apo B-100) [Cleaved into: Apolipoprotein B-48 (Apo B-48)],Miscellaneous,Enzyme cofactor ,Novel Target
1887,SPC5001,SPC5001,antidyslipidaemic agent,antisense oligo,not approved,Q8NBP7,PCSK9_HUMAN,PCSK9,Proprotein convertase subtilisin/kexin type 9 (EC 3.4.21.-) (Neural apoptosis-regulated convertase 1) (NARC-1) (Proprotein convertase 9) (PC9) (Subtilisin/kexin-like protease PC9),Enzymes,EC:3.4.21.-,Novel Target
1888,"SPD 417, carbamazepine,Equetro, Carbatrol",carbamazepine,for treatment of bipolar disorder,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1889,"SPD476,Lialda",mesalamine,for treatment of ulcerative colitis,Small molecule,approved,P09917,LOX5_HUMAN,ALOX5,Arachidonate 5-lipoxygenase OS=Homo sapiens GN=ALOX5 PE=1 SV=2,Enzymes,EC:1.13.11.34,Established target
1889,"SPD476,Lialda",mesalamine,for treatment of ulcerative colitis,Small molecule,approved,O15111,IKKA_HUMAN,CHUK,Inhibitor of nuclear factor kappa-B kinase subunit alpha (I-kappa-B kinase alpha) (IKK-A) (IKK-alpha) (IkBKA) (IkappaB kinase) (EC 2.7.11.10) (Conserved helix-loop-helix ubiquitous kinase) (I-kappa-B kinase 1) (IKK1) (Nuclear factor NF-kappa-B inhibitor k,Enzymes,EC:2.7.11.10,Established target
1889,"SPD476,Lialda",mesalamine,for treatment of ulcerative colitis,Small molecule,approved,O14920,IKKB_HUMAN,IKBKB,Inhibitor of nuclear factor kappa-B kinase subunit beta OS=Homo sapiens GN=IKBKB PE=1 SV=1,Enzymes,EC:2.7.11.10,Established target
1889,"SPD476,Lialda",mesalamine,for treatment of ulcerative colitis,Small molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1889,"SPD476,Lialda",mesalamine,for treatment of ulcerative colitis,Small molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1889,"SPD476,Lialda",mesalamine,for treatment of ulcerative colitis,Small molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 (EC 1.14.99.1) (Cyclooxygenase-2) (COX-2) (PHS II) (Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (Prostaglandin-endoperoxide synthase 2),Enzymes,EC:1.14.99.1,Established target
1891,"SPI-153, D-63153,Ozarelix",Ozarelix,antineoplastic agent,peptide,not approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1891,"SPI-153, D-63153,Ozarelix",Ozarelix,antineoplastic agent,peptide,not approved,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
1892,SPI-1620,SPI-1620,adjuvant to chemotherapy,peptide,not approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1892,SPI-1620,SPI-1620,adjuvant to chemotherapy,peptide,not approved,P24530,EDNRB_HUMAN,EDNRB,Endothelin B receptor OS=Homo sapiens GN=EDNRB PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1893,"SPI-3005, ebselen + allopurinol",allopurinol,antiuricemic agent,Small Molecule,approved,P47989,XDH_HUMAN,XDH,Xanthine dehydrogenase/oxidase OS=Homo sapiens GN=XDH PE=1 SV=4,Enzymes,EC:1.17.1.4; 1.17.3.2,Established target
1894,Spiegelmer NOX-E36,NOX-E36 ,for treatment of kidney disease,aptamer,not approved,P13500,CCL2_HUMAN,CCL2,C-C motif chemokine 2 (HC11) (Monocyte chemoattractant protein 1) (Monocyte chemotactic and activating factor) (MCAF) (Monocyte chemotactic protein 1) (MCP-1) (Monocyte secretory protein JE) (Small-inducible cytokine A2),Miscellaneous,Ligand;Cytokine,Novel Target
1895,SPP635,SPP635,antihypertensive agent,unknown,not approved,P00797,RENI_HUMAN,REN,Renin OS=Homo sapiens GN=REN PE=1 SV=1,Enzymes,EC:3.4.23.15,Established target
1896,SPP676,SPP676,antihypertensive agent,small molecule,not approved,P00797,RENI_HUMAN,REN,Renin OS=Homo sapiens GN=REN PE=1 SV=1,Enzymes,EC:3.4.23.15,Established target
1897,SRT501,Resveratrol,"antidiabetic,antineoplastic agent",small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
1897,SRT501,Resveratrol,"antidiabetic,antineoplastic agent",small molecule,not approved,Q08499,PDE4D_HUMAN,PDE4D,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D OS=Homo sapiens GN=PDE4D PE=1 SV=2",Enzymes,EC:3.1.4.17,Established target
1898,SS1(dsFv)-PE38,SS1(dsFv)-PE38,antineoplastic agent,fusion protein,not approved,P13639,EF2_HUMAN,EEF2,Elongation factor 2 (EF-2),Miscellaneous,Miscellaneous;elongation factor,Novel Target
1898,SS1(dsFv)-PE38,SS1(dsFv)-PE38,antineoplastic agent,fusion protein,not approved,Q13421,MSLN_HUMAN,MSLN,"Mesothelin (CAK1 antigen) (Pre-pro-megakaryocyte-potentiating factor) [Cleaved into: Megakaryocyte-potentiating factor (MPF); Mesothelin, cleaved form]",Miscellaneous,Mesothelin family,Novel Target
1899,STA-9090,ganetespib,antineoplastic agent,Small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
1899,STA-9090,ganetespib,antineoplastic agent,Small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
1900,"stannsoporfin,Stanate",stannsoporfin,for prevention of hyperbilirubinemia,small molecule,not approved,P09601,HMOX1_HUMAN,HMOX1,Heme oxygenase 1 (HO-1) (EC 1.14.99.3),Enzymes,EC:1.14.99,Novel Target
1900,"stannsoporfin,Stanate",stannsoporfin,for prevention of hyperbilirubinemia,small molecule,not approved,P30519,HMOX2_HUMAN,HMOX2,Heme oxygenase 2 (HO-2) (EC 1.14.99.3),Enzymes,EC:1.14.99,Novel Target
1901,StarGen,StarGen,for treatment of Stargardt macular dystrophy,LentiVector gene delivery,not approved,P78363,ABCA4_HUMAN,ABCA4,Retinal-specific ATP-binding cassette transporter (ATP-binding cassette sub-family A member 4) (RIM ABC transporter) (RIM protein) (RmP) (Stargardt disease protein),Transporters,TC:3.A.1.211.2,Novel Target
1902,Starlix,nateglinide,antidiabetic,Small Molecule,approved,Q09428,ABCC8_HUMAN,ABCC8,ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1),Transporters,TC:3.A.1.208.4,Established target
1903,Statex,morphine,analgesic,Small molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1903,Statex,morphine,analgesic,Small molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1903,Statex,morphine,analgesic,Small molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1904,"Stem,NTx-265",erythropoietin,for treatment of stroke,protein,approved,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
1904,"Stem,NTx-265",gonadotropin,for treatment of stroke,protein,approved,P22888,LSHR_HUMAN,LHCGR,Lutropin-choriogonadotropic hormone receptor OS=Homo sapiens GN=LHCGR PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1905,"strontium ranelate, S12911",strontium ranelate,antiosteoporotic agent,small molecule,not approved,P41180,CASR_HUMAN,CASR,Extracellular calcium-sensing receptor OS=Homo sapiens GN=CASR PE=1 SV=2,Receptors,GPCR;Glutamate,Established target
1906,STX107,STX107,for treatment of Fragile X symptoms,small molecule,not approved,P41594,GRM5_HUMAN,GRM5,Metabotropic glutamate receptor 5 (mGluR5),Receptors,GPCR;Glutamate,Established target
1907,"substance P,Homspera, Radilex, Viprovex",Homspera,for treatment of idiopathic pulmonary fibrosis,recombinant protein,not approved,P25103,NK1R_HUMAN,TACR1,Substance-P receptor OS=Homo sapiens GN=TACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1908,"sucralfate,Ulcermin",sucralfate,antiulcer agent,Small Molecule,approved,P00790,PEPA_HUMAN,PGA3,Pepsin A (EC 3.4.23.1),Enzymes,EC:3.4.23.1,Established target
1909,"sufentanil transdermal patch,Transdur-sufentanil",sufentanil,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1909,"sufentanil transdermal patch,Transdur-sufentanil",sufentanil,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor (K-OR-1) (KOR-1),Receptors,GPCR;Rhodopsin,Established target
1909,"sufentanil transdermal patch,Transdur-sufentanil",sufentanil,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1910,"sufentanil,Chronogesic",sufentanil,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1910,"sufentanil,Chronogesic",sufentanil,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1910,"sufentanil,Chronogesic",sufentanil,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1912,"sulfasalazine,Azulfidine, Salazopyrin",sulfasalazine,"antiinflammatory agent,DMARD",Small Molecule,approved,P24752,THIL_HUMAN,ACAT1,"Acetyl-CoA acetyltransferase, mitochondrial OS=Homo sapiens GN=ACAT1 PE=1 SV=1",Enzymes,EC:2.3.1.9,Established target
1912,"sulfasalazine,Azulfidine, Salazopyrin",sulfasalazine,"antiinflammatory agent,DMARD",Small Molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
1912,"sulfasalazine,Azulfidine, Salazopyrin",sulfasalazine,"antiinflammatory agent,DMARD",Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
1912,"sulfasalazine,Azulfidine, Salazopyrin",sulfasalazine,"antiinflammatory agent,DMARD",Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
1913,"sulodexide, KRX-101,Sulonex",sulodexide,for treatment of diabetic nephropathy,Small Molecule,approved,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Miscellaneous,Enzyme regulator,Established target
1913,"sulodexide, KRX-101,Sulonex",sulodexide,for treatment of diabetic nephropathy,Small Molecule,approved,P05546,HEP2_HUMAN,SERPIND1,Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 SV=3,Miscellaneous,Enzyme regulator,Established target
1914,Sumatriptan,Sumatriptan,antimigraine agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1914,Sumatriptan,Sumatriptan,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1914,Sumatriptan,Sumatriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1914,Sumatriptan,Sumatriptan,antimigraine agent,Small Molecule,approved,P30939,5HT1F_HUMAN,HTR1F,5-hydroxytryptamine receptor 1F OS=Homo sapiens GN=HTR1F PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1915,"sumatriptan, triptan",Sumatriptan,antimigraine agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1915,"sumatriptan, triptan",Sumatriptan,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1915,"sumatriptan, triptan",Sumatriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1915,"sumatriptan, triptan",Sumatriptan,antimigraine agent,Small Molecule,approved,P30939,5HT1F_HUMAN,HTR1F,5-hydroxytryptamine receptor 1F OS=Homo sapiens GN=HTR1F PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1916,"sumatriptan,Imitrex",Sumatriptan,antimigraine agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
1916,"sumatriptan,Imitrex",Sumatriptan,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1916,"sumatriptan,Imitrex",Sumatriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1916,"sumatriptan,Imitrex",Sumatriptan,antimigraine agent,Small Molecule,approved,P30939,5HT1F_HUMAN,HTR1F,5-hydroxytryptamine receptor 1F OS=Homo sapiens GN=HTR1F PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1917,"surinabant, SR 147778",surinabant,smoking-cessation agent,small molecule,not approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1918,sustained release latanoprost,latanoprost,for treatment of glaucoma,Small Molecule,approved,P43088,PF2R_HUMAN,PTGFR,Prostaglandin F2-alpha receptor (PGF receptor) (PGF2-alpha receptor) (Prostanoid FP receptor),Receptors,GPCR;Rhodopsin,Established target
1919,Sutent,sunitinib,antineoplastic agent,Small Molecule,approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1919,Sutent,sunitinib,antineoplastic agent,Small Molecule,approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1919,Sutent,sunitinib,antineoplastic agent,Small Molecule,approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1919,Sutent,sunitinib,antineoplastic agent,Small Molecule,approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1919,Sutent,sunitinib,antineoplastic agent,Small Molecule,approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1919,Sutent,sunitinib,antineoplastic agent,Small Molecule,approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1919,Sutent,sunitinib,antineoplastic agent,Small Molecule,approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1919,Sutent,sunitinib,antineoplastic agent,Small Molecule,approved,P07949,RET_HUMAN,RET,Proto-oncogene tyrosine-protein kinase receptor ret OS=Homo sapiens GN=RET PE=1 SV=3,Receptors,EC:2.7.10.1,Established target
1920,SUVN-502,SUVN-502,for treatment of Alzheimer's disease,small molecule,not approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1921,SVT-40776,SVT-40776,for treatment of incontinence,small molecule,not approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1922,SYL040012,SYL040012,for treatment of glaucoma,siRNA,not approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1923,Sym004,Sym004,antineoplastic agent,monoclonal antibody,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1924,Symlin,pramlintide,"antidiabetic,antiobesity agent",peptide,approved,P30988,CALCR_HUMAN,CALCR,Calcitonin receptor OS=Homo sapiens GN=CALCR PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1924,Symlin,pramlintide,"antidiabetic,antiobesity agent",peptide,approved,O60894,RAMP1_HUMAN,RAMP1,Receptor activity-modifying protein 1 OS=Homo sapiens GN=RAMP1 PE=1 SV=1,Receptors,Receptors;RAMP,Established target
1924,Symlin,pramlintide,"antidiabetic,antiobesity agent",peptide,approved,O60895,RAMP2_HUMAN,RAMP2,Receptor activity-modifying protein 2 OS=Homo sapiens GN=RAMP2 PE=2 SV=2,Receptors,Receptors;RAMP,Established target
1924,Symlin,pramlintide,"antidiabetic,antiobesity agent",peptide,approved,O60896,RAMP3_HUMAN,RAMP3,Receptor activity-modifying protein 3 OS=Homo sapiens GN=RAMP3 PE=2 SV=1,Receptors,Receptors;RAMP,Established target
1925,"SYN-101, interferon beta (inhaled)",interferon beta,antiasthmatic agent,protein,approved,P17181,INAR1_HUMAN,IFNAR1,Interferon alpha/beta receptor 1 (IFN-R-1) (IFN-alpha/beta receptor 1) (Cytokine receptor class-II member 1) (Cytokine receptor family 2 member 1) (CRF2-1) (Type I interferon receptor 1),Receptors,Receptor; Type 2 cytokine receptor,Established target
1925,"SYN-101, interferon beta (inhaled)",interferon beta,antiasthmatic agent,protein,approved,P48551,INAR2_HUMAN,IFNAR2,Interferon alpha/beta receptor 2 (IFN-R-2) (IFN-alpha binding protein) (IFN-alpha/beta receptor 2) (Interferon alpha binding protein) (Type I interferon receptor 2),Receptors,Receptor; Type 2 cytokine receptor,Established target
1926,SYN-115,tozadenant,antiparkinson agent,small molecule,not approved,P29274,AA2AR_HUMAN,ADORA2A,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1927,SYN-118,nitisinone,antiparkinson agent,small molecule,not approved,P32754,HPPD_HUMAN,HPD,4-hydroxyphenylpyruvate dioxygenase OS=Homo sapiens GN=HPD PE=1 SV=2,Enzymes,EC:1.13.11.27,Established target
1929,T-5224,T-5224,"antiinflammatory agent,DMARD",small molecule,not approved,P05412,JUN_HUMAN,JUN,Transcription factor AP-1 (Activator protein 1) (AP1) (Proto-oncogene c-Jun) (V-jun avian sarcoma virus 17 oncogene homolog) (p39),Miscellaneous,Transcription factor,Established target
1930,T-62,T-62,analgesic,small molecule,not approved,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1932,"taberminogene vadenovec, EG004,Trinam",taberminogene vadenovec,for prevention of blood vessel-blocking in kidney dialysis patients who have undergone vascular access graft surgery,adenoviral vector,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1932,"taberminogene vadenovec, EG004,Trinam",taberminogene vadenovec,for prevention of blood vessel-blocking in kidney dialysis patients who have undergone vascular access graft surgery,adenoviral vector,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1932,"taberminogene vadenovec, EG004,Trinam",taberminogene vadenovec,for prevention of blood vessel-blocking in kidney dialysis patients who have undergone vascular access graft surgery,adenoviral vector,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1933,TACI-Ig,TACI-Ig,"antiinflammatory agent,DMARD",antibody,not approved,O75888,TNF13_HUMAN,TNFSF13,Tumor necrosis factor ligand superfamily member 13 (A proliferation-inducing ligand) (APRIL) (TNF- and APOL-related leukocyte expressed ligand 2) (TALL-2) (TNF-related death ligand 1) (TRDL-1) (CD antigen CD256),Miscellaneous,Ligand;Cytokine,Established target
1933,TACI-Ig,TACI-Ig,"antiinflammatory agent,DMARD",antibody,not approved,Q9Y275,TN13B_HUMAN,TNFSF13B,Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved int,Miscellaneous,Ligand;Cytokine,Established target
1934,"tacrolimus hydrate,Prograf, Advagraf, Graceptor",tacrolimus ,immunosuppressant,small molecule,not approved,P62942,FKB1A_HUMAN,FKBP1A,Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Homo sapiens GN=FKBP1A PE=1 SV=2,Enzymes,EC:5.2.1.8,Established target
1935,"tacrolimus,LCP-Tacro",tacrolimus,immunosuppressant,Small Molecule,not approved,P62942,FKB1A_HUMAN,FKBP1A,Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Homo sapiens GN=FKBP1A PE=1 SV=2,Enzymes,EC:5.2.1.8,Established target
1936,TAFA-93,TAFA-93,immunosuppressant,small molecule,not approved,P42345,FRAP_HUMAN,FRAP1,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1937,TAK-242,TAK-242,for treatment of sepsis,small molecule,not approved,O00206,TLR4_HUMAN,TLR4,Toll-like receptor 4 (hToll) (CD antigen CD284),Receptors,Receptors;TOLL,Novel Target
1938,"TAK-390MR, dexlansoprazole,Dexilant, Kapidex",dexlansoprazole,Proton pump inhibitor,Small molecule,not approved,P20648,ATP4A_HUMAN,ATP4A,Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=2 SV=5,Transporters,TC:3.A.3.1.2,Established target
1939,TAK-442,TAK-442,antithrombotic,small molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
1940,Talabostat,Talabostat,for treatment of neutropenia,small molecule,not approved,P09919,CSF3_HUMAN,CSF3,Granulocyte colony-stimulating factor (G-CSF) (Pluripoietin) (Filgrastim) (Lenograstim),Miscellaneous,Ligand;Cytokine,Novel Target
1941,talampanel,talampanel,"antiparkinson agent,antineoplastic agent",small molecule,not approved,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
1941,talampanel,talampanel,"antiparkinson agent,antineoplastic agent",small molecule,not approved,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
1941,talampanel,talampanel,"antiparkinson agent,antineoplastic agent",small molecule,not approved,P42263,GRIA3_HUMAN,GRIA3,"Glutamate receptor 3 (GluR-3) (AMPA-selective glutamate receptor 3) (GluR-C) (GluR-K3) (Glutamate receptor ionotropic, AMPA 3) (GluA3)",Receptors,TC:1.A.10.1.4,Established target
1941,talampanel,talampanel,"antiparkinson agent,antineoplastic agent",small molecule,not approved,P48058,GRIA4_HUMAN,GRIA4,"Glutamate receptor 4 (GluR-4) (GluR4) (AMPA-selective glutamate receptor 4) (GluR-D) (Glutamate receptor ionotropic, AMPA 4) (GluA4)",Receptors,TC:1.A.10.1,Established target
1942,"talarozole, R-115866,Rambazole",talarozole,"antipsoriatic agent,for treatment of acne",small molecule,not approved,O43174,CP26A_HUMAN,CYP26A1,Cytochrome P450 26A1 (EC 1.14.-.-) (Cytochrome P450 retinoic acid-inactivating 1) (Cytochrome P450RAI) (hP450RAI) (Retinoic acid 4-hydroxylase) (Retinoic acid-metabolizing cytochrome),Enzymes,EC:1.14.-.-,Novel Target
1942,"talarozole, R-115866,Rambazole",talarozole,"antipsoriatic agent,for treatment of acne",small molecule,not approved,Q9NR63,CP26B_HUMAN,CYP26B1,Cytochrome P450 26B1 (EC 1.14.-.-) (Cytochrome P450 26A2) (Cytochrome P450 retinoic acid-inactivating 2) (Cytochrome P450RAI-2) (Retinoic acid-metabolizing cytochrome),Enzymes,EC:1.14.-.-,Novel Target
1942,"talarozole, R-115866,Rambazole",talarozole,"antipsoriatic agent,for treatment of acne",small molecule,not approved,Q6V0L0,CP26C_HUMAN,CYP26C1,Cytochrome P450 26C1 (EC 1.14.-.-),Enzymes,EC:1.14.-.-,Novel Target
1943,"talnetant, SB 223412",talnetant,antipsychotic agent,small molecule,not approved,P29371,NK3R_HUMAN,TACR3,Neuromedin-K receptor (NKR) (NK-3 receptor) (NK-3R) (Neurokinin B receptor) (Tachykinin receptor 3),Receptors,GPCR;Rhodopsin,Novel Target
1944,"talotrexin, PT-523,Talvesta",talotrexin,antineoplastic agent,small molecule,not approved,P00374,DYR_HUMAN,DHFR,Dihydrofolate reductase OS=Homo sapiens GN=DHFR PE=1 SV=2,Enzymes,EC:1.5.1.3,Established target
1945,"Tamibarotene, Z-208, INNO-507",Tamibarotene,antineoplastic agent,Small Molecule,not approved,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1945,"Tamibarotene, Z-208, INNO-507",Tamibarotene,antineoplastic agent,Small Molecule,not approved,P10826,RARB_HUMAN,RARB,Retinoic acid receptor beta OS=Homo sapiens GN=RARB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1946,"tamsulosin, YM-617,Harnal, Flomax",tamsulosin,for treatment of urinary symptoms associated with BPH,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1946,"tamsulosin, YM-617,Harnal, Flomax",tamsulosin,for treatment of urinary symptoms associated with BPH,Small Molecule,approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
1946,"tamsulosin, YM-617,Harnal, Flomax",tamsulosin,for treatment of urinary symptoms associated with BPH,Small Molecule,approved,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1947,"tandutinib, MLN-518",tandutinib,antineoplastic agent,small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1948,Tanespimycin,Tanespimycin,antineoplastic agent,small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
1948,Tanespimycin,Tanespimycin,antineoplastic agent,small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
1949,"tanezumab, PF-4383119, RI 624",tanezumab,analgesic,monoclonal antibody,not approved,P01138,NGF_HUMAN,NGF,Beta-nerve growth factor (Beta-NGF),Miscellaneous,Nerve Growth Factor;Neurotrophins,Novel Target
1950,tapentadol,tapentadol,analgesic,small molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1950,tapentadol,tapentadol,analgesic,small molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1951,"tapentadol hydrochloride, CG-5503, R331333",tapentadol,"analgesic,opioid",small molecule,not approved,P35372,OPRM_HUMAN,MOR,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1952,"taranabant, MK-0364",Taranabant,"antiobesity agent,smoking-cessation agent",small molecule,not approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1953,Tarceva,erlotinib,antineoplastic agent,Small Molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1954,tariquidar,tariquidar,adjuvant to chemotherapy,small molecule,not approved,P08183,MDR1_HUMAN,ABCB1,Multidrug resistance protein 1 OS=Homo sapiens GN=ABCB1 PE=1 SV=3,Transporters,TC:3.A.1.201.1,Novel Target
1955,TAS-108,TAS-108,antineoplastic agent,small molecule,not approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1955,TAS-108,TAS-108,antineoplastic agent,small molecule,not approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
1956,"tasimelteon, VEC-162",tasimelteon,hypnotic,small molecule,not approved,P48039,MTR1A_HUMAN,MTNR1A,Melatonin receptor type 1A OS=Homo sapiens GN=MTNR1A PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1956,"tasimelteon, VEC-162",tasimelteon,hypnotic,small molecule,not approved,P49286,MTR1B_HUMAN,MTNR1B,Melatonin receptor type 1B OS=Homo sapiens GN=MTNR1B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1957,Tasocitinib,Tasocitinib,"antiinflammatory agent,DMARD",small molecule,not approved,P52333,JAK3_HUMAN,JAK3,Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK),Enzymes,EC:2.7.10.2,Novel Target
1958,"taspoglutide, ITM-077, R1583, BIM-51077",taspoglutide,antidiabetic,protein,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1959,"tazarotene,Tazorac",tazarotene,"antipsoriatic agent,for treatment of acne",Small Molecule,approved,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
1959,"tazarotene,Tazorac",tazarotene,"antipsoriatic agent,for treatment of acne",Small Molecule,approved,P10826,RARB_HUMAN,RARB,Retinoic acid receptor beta OS=Homo sapiens GN=RARB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1959,"tazarotene,Tazorac",tazarotene,"antipsoriatic agent,for treatment of acne",Small Molecule,approved,P13631,RARG_HUMAN,RARG,Retinoic acid receptor gamma OS=Homo sapiens GN=RARG PE=1 SV=1,Receptors,Nuclear receptor,Established target
1959,"tazarotene,Tazorac",tazarotene,"antipsoriatic agent,for treatment of acne",Small Molecule,approved,P28702,RXRB_HUMAN,RXRB,Retinoic acid receptor RXR-beta OS=Homo sapiens GN=RXRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
1960,TB-402,TB-402,anticoagulant,monoclonal antibody,not approved,P00451,FA8_HUMAN,F8,Coagulation factor VIII OS=Homo sapiens GN=F8 PE=1 SV=1,Miscellaneous,Enzyme cofactor,Established target
1961,"TB-403, RG7334",TB-403,antineoplastic agent,monoclonal antibody,not approved,P49763,PLGF_HUMAN,PGF,Placenta growth factor (PlGF),Ligand,Ligand;Growth factor,Novel Target
1962,"TBR-652, TAK-652",TBR-652,"antiviral agent,HIV",small molecule,not approved,P51681,CCR5_HUMAN,CCR5,C-C chemokine receptor type 5 OS=Homo sapiens GN=CCR5 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1963,"TC-1734, AZD-3480, ispronicline",ispronicline,nootropic,Small molecule,not approved,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1963,"TC-1734, AZD-3480, ispronicline",ispronicline,nootropic,Small molecule,not approved,P17787,ACHB2_HUMAN,CHRNB2,Neuronal acetylcholine receptor subunit beta-2 OS=Homo sapiens GN=CHRNB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1964,TC-2403-12,TC-2403-12,for treatment of ulcerative colitis,small molecule,not approved,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1964,TC-2403-12,TC-2403-12,for treatment of ulcerative colitis,small molecule,not approved,P17787,ACHB2_HUMAN,CHRNB2,Neuronal acetylcholine receptor subunit beta-2 OS=Homo sapiens GN=CHRNB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1965,TC-2696,TC-2696,analgesic,small molecule,not approved,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1965,TC-2696,TC-2696,analgesic,small molecule,not approved,P17787,ACHB2_HUMAN,CHRNB2,Neuronal acetylcholine receptor subunit beta-2 OS=Homo sapiens GN=CHRNB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1966,TC-5214,TC-5214,antidepressant,small molecule,not approved,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1966,TC-5214,TC-5214,antidepressant,small molecule,not approved,P17787,ACHB2_HUMAN,CHRNB2,Neuronal acetylcholine receptor subunit beta-2 OS=Homo sapiens GN=CHRNB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1967,TC-5619,TC-5619,neuroprotectant,small molecule,not approved,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
1968,TC-6499,TC-6499,"analgesic,neuropathic pain",small molecule,not approved,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
1968,TC-6499,TC-6499,"analgesic,neuropathic pain",small molecule,not approved,P17787,ACHB2_HUMAN,CHRNB2,Neuronal acetylcholine receptor subunit beta-2 OS=Homo sapiens GN=CHRNB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
1969,TC-6987ÿby Targacept forÿasthmaÿandÿtype II diabetes,TC-6987,"antiasthmatic agent,antidiabetic",small molecule,not approved,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
1970,TD101,TD101,for treatment of pachyonychia congenita,siRNA,not approved,P02538,K2C6A_HUMAN,KRT6A,"Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Cytokeratin-6D) (CK-6D) (Keratin-6A) (K6A) (Type-II keratin Kb6) (allergen Hom s 5)",Miscellaneous,Intermediate filament family; keratin,Novel Target
1971,TD-1211,TD-1211,for treatment of opioid-induced gastrointestinal side-effects,small molecule,not approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1972,TD-2749,TD-2749,motilitant,unknown,not approved,Q13639,5HT4R_HUMAN,HTR4,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1973,tecadenoson,tecadenoson,antiarrhytmic agent,small molecule,not approved,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1974,"tecarfarin, ATI-5923",tecarfarin,antithrombotic,small molecule,not approved,Q9BQB6,VKOR1_HUMAN,VKORC1,Vitamin K epoxide reductase complex subunit 1 OS=Homo sapiens GN=VKORC1 PE=1 SV=1,Enzymes,EC:1.1.4.1,Established target
1975,"tegaserod,Zelnorm, Zelmac",tegaserod,motilitant,small molecule,approved,Q13639,5HT4R_HUMAN,HTR4,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
1976,telatinib,telatinib,antineoplastic agent,small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1976,telatinib,telatinib,antineoplastic agent,small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1976,telatinib,telatinib,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
1976,telatinib,telatinib,antineoplastic agent,small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1976,telatinib,telatinib,antineoplastic agent,small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
1977,"telmisartan,Micardis, Micardis HCT",telmisartan,antihypertensive agent,Small Molecule,not approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1978,"temsirolimus, CCI-779,Torisel",temsirolimus,antineoplastic agent,Small Molecule,approved,P42345,FRAP_HUMAN,FRAP1,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
1979,"teplizumab, MGA03",teplizumab,antidiabetic,monoclonal antibody,not approved,P07766,CD3E_HUMAN,CD3E,T-cell surface glycoprotein CD3 epsilon chain OS=Homo sapiens GN=CD3E PE=1 SV=2,Receptors,Receptor; T-cell receptor subunit,Established target
1981,terguride,terguride,for treatment of pulmonary arterial hypertension,small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
1981,terguride,terguride,for treatment of pulmonary arterial hypertension,small molecule,not approved,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1982,"teriflunomide, HMR1726",teriflunomide,for treatment of multiple sclerosis,small molecule,not approved,Q02127,PYRD_HUMAN,DHODH,"Dihydroorotate dehydrogenase, mitochondrial OS=Homo sapiens GN=DHODH PE=1 SV=3",Enzymes,EC:1.3.3,Established target
1983,"teriparatide, inhaled AIR",teriparatide,antiosteoporotic agent,recombinant peptide,approved,Q03431,PTH1R_HUMAN,PTHR1,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1984,"teriparatide, PTH1-34 nasal spray",teriparatide,antiosteoporotic agent,recombinant peptide,approved,Q03431,PTH1R_HUMAN,PTHR1,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1985,"teriparatide,Forteo, Forsteo",teriparatide,antiosteoporotic agent,recombinant peptide,approved,Q03431,PTH1R_HUMAN,PTHR1,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
1986,"terlipressin,Lucassin",terlipressin,for treatment of hepatorenal syndrome,Small Molecule,approved,P37288,V1AR_HUMAN,AVPR1A,Vasopressin V1a receptor OS=Homo sapiens GN=AVPR1A PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1986,"terlipressin,Lucassin",terlipressin,for treatment of hepatorenal syndrome,Small Molecule,approved,P47901,V1BR_HUMAN,AVPR1B,Vasopressin V1b receptor OS=Homo sapiens GN=AVPR1B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
1986,"terlipressin,Lucassin",terlipressin,for treatment of hepatorenal syndrome,Small Molecule,approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
1987,Tesamorelin,Tesamorelin,for treatment of HIV-associated lipodystrophy,peptide,approved,Q02643,GHRHR_HUMAN,GHRHR,Growth hormone-releasing hormone receptor OS=Homo sapiens GN=GHRHR PE=1 SV=2,Receptors,GPCR;Secretin,Established target
1988,tesetaxel,tesetaxel,antineoplastic agent,small molecule,not approved,P10415,BCL2_HUMAN,BCL2,Apoptosis regulator Bcl-2,other,regulator of apoptosis,Established target
1988,tesetaxel,tesetaxel,antineoplastic agent,small molecule,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
1989,tesmilifene,tesmilifene,adjuvant to chemotherapy,small molecule,not approved,P08183,MDR1_HUMAN,ABCB1,Multidrug resistance protein 1 OS=Homo sapiens GN=ABCB1 PE=1 SV=3,Transporters,TC:3.A.1.201.1,Novel Target
1989,tesmilifene,tesmilifene,adjuvant to chemotherapy,small molecule,not approved,P08684,CP3A4_HUMAN,CYP3A4,Cytochrome P450 3A4 (Albendazole monooxygenase) (EC 1.14.13.32) (Albendazole sulfoxidase) (CYPIIIA3) (CYPIIIA4) (Cytochrome P450 3A3) (Cytochrome P450 HLp) (Cytochrome P450 NF-25) (Cytochrome P450-PCN1) (Nifedipine oxidase) (Quinine 3-monooxygenase) (EC 1,Enzymes,EC:1.14.14,Novel Target
1989,tesmilifene,tesmilifene,adjuvant to chemotherapy,small molecule,not approved,P20815,CP3A5_HUMAN,CYP3A5,Cytochrome P450 3A5,Enzymes,EC:1.14.14.1,Novel Target
1989,tesmilifene,tesmilifene,adjuvant to chemotherapy,small molecule,not approved,P24462,CP3A7_HUMAN,CYP3A7,Cytochrome P450 3A7,Enzymes,EC:1.14.14.1,Novel Target
1990,"tesofensine, NS-2330",tesofensine,antiobesity agent,small molecule,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
1990,"tesofensine, NS-2330",tesofensine,antiobesity agent,small molecule,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
1991,testosterone cream,testosterone,"hormone replacement,for treatment of female sexual dysfunction",Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1992,"testosterone gel,LibiGel",testosterone,for treatment of female sexual dysfunction,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1993,"Testosterone MD-Lotion,Axiron",testosterone,hormone replacement,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1994,"testosterone MDTS,Luramist",testosterone,for treatment of female sexual dysfunction,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1995,"testosterone undecanoate,Nebido, Aveed",testosterone,hormone replacement,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1996,"testosterone,AndroGel",testosterone,hormone replacement,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1997,"testosterone,Androsorb",testosterone,for treatment of female sexual dysfunction,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
1998,"tetrabenazine,Nitoman",tetrabenazine,for treatment of Huntington's disease,Small Molecule,approved,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
1999,"tetrodotoxin,Tectin, Tetrodin",tetrodotoxin,analgesic,small molecule,not approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
1999,"tetrodotoxin,Tectin, Tetrodin",tetrodotoxin,analgesic,small molecule,not approved,Q9UI33,SCNBA_HUMAN,SCN11A,Sodium channel protein type 11 subunit alpha OS=Homo sapiens GN=SCN11A PE=1 SV=2,Transporters,TC:1.A.1.10.9,Established target
1999,"tetrodotoxin,Tectin, Tetrodin",tetrodotoxin,analgesic,small molecule,not approved,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
1999,"tetrodotoxin,Tectin, Tetrodin",tetrodotoxin,analgesic,small molecule,not approved,Q99250,SCN2A_HUMAN,SCN2A,Sodium channel protein type 2 subunit alpha (HBSC II) (Sodium channel protein brain II subunit alpha) (Sodium channel protein type II subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.2),Transporters,TC:1.A.1.10,Established target
1999,"tetrodotoxin,Tectin, Tetrodin",tetrodotoxin,analgesic,small molecule,not approved,Q9NY46,SCN3A_HUMAN,SCN3A,Sodium channel protein type 3 subunit alpha (Sodium channel protein brain III subunit alpha) (Sodium channel protein type III subunit alpha) (Voltage-gated sodium channel subtype III) (Voltage-gated sodium channel subunit alpha Nav1.3),Transporters,TC:1.A.1.10,Established target
1999,"tetrodotoxin,Tectin, Tetrodin",tetrodotoxin,analgesic,small molecule,not approved,P35499,SCN4A_HUMAN,SCN4A,Sodium channel protein type 4 subunit alpha (SkM1) (Sodium channel protein skeletal muscle subunit alpha) (Sodium channel protein type IV subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.4),Transporters,TC:1.A.1.10.4,Established target
1999,"tetrodotoxin,Tectin, Tetrodin",tetrodotoxin,analgesic,small molecule,not approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
1999,"tetrodotoxin,Tectin, Tetrodin",tetrodotoxin,analgesic,small molecule,not approved,Q9UQD0,SCN8A_HUMAN,SCN8A,Sodium channel protein type 8 subunit alpha (Sodium channel protein type VIII subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.6),Transporters,TC:1.A.1.10.8,Established target
1999,"tetrodotoxin,Tectin, Tetrodin",tetrodotoxin,analgesic,small molecule,not approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
2000,"tezampanel, NGX424,NGX426",tezampanel,"antimigraine agent,analgesic",small molecule,not approved,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
2000,"tezampanel, NGX424,NGX426",tezampanel,"antimigraine agent,analgesic",small molecule,not approved,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
2000,"tezampanel, NGX424,NGX426",tezampanel,"antimigraine agent,analgesic",small molecule,not approved,P42263,GRIA3_HUMAN,GRIA3,"Glutamate receptor 3 (GluR-3) (AMPA-selective glutamate receptor 3) (GluR-C) (GluR-K3) (Glutamate receptor ionotropic, AMPA 3) (GluA3)",Receptors,TC:1.A.10.1.4,Established target
2000,"tezampanel, NGX424,NGX426",tezampanel,"antimigraine agent,analgesic",small molecule,not approved,P48058,GRIA4_HUMAN,GRIA4,"Glutamate receptor 4 (GluR-4) (GluR4) (AMPA-selective glutamate receptor 4) (GluR-D) (Glutamate receptor ionotropic, AMPA 4) (GluA4)",Receptors,TC:1.A.10.1,Established target
2000,"tezampanel, NGX424,NGX426",tezampanel,"antimigraine agent,analgesic",small molecule,not approved,P39086,GRIK1_HUMAN,GRIK1,GRIK1 108 kDa protein,Receptors,TC:1.A.10.1,Established target
2000,"tezampanel, NGX424,NGX426",tezampanel,"antimigraine agent,analgesic",small molecule,not approved,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
2000,"tezampanel, NGX424,NGX426",tezampanel,"antimigraine agent,analgesic",small molecule,not approved,Q13003,GRIK3_HUMAN,GRIK3,"Glutamate receptor, ionotropic kainate 3 (Excitatory amino acid receptor 5) (EAA5) (Glutamate receptor 7) (GluR-7) (GluR7)",Receptors,TC:1.A.10.1,Novel Target
2000,"tezampanel, NGX424,NGX426",tezampanel,"antimigraine agent,analgesic",small molecule,not approved,Q16099,GRIK4_HUMAN,GRIK4,"Glutamate receptor, ionotropic kainate 4 (Excitatory amino acid receptor 1) (EAA1) (Glutamate receptor KA-1) (KA1)",Receptors,TC:1.A.10.1.9,Novel Target
2000,"tezampanel, NGX424,NGX426",tezampanel,"antimigraine agent,analgesic",small molecule,not approved,Q16478,GRIK5_HUMAN,GRIK5,"Glutamate receptor, ionotropic kainate 5 (Excitatory amino acid receptor 2) (EAA2) (Glutamate receptor KA-2) (KA2)",Receptors,TC:1.A.10.1,Novel Target
2001,TF2,TF2,antineoplastic agent,antibody,not approved,P06731,CEAM5_HUMAN,CEACAM5,Carcinoembryonic antigen-related cell adhesion molecule 5 (Carcinoembryonic antigen) (CEA) (Meconium antigen 100) (CD antigen CD66e),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Novel Target
2002,TG-0054,TG-0054,adjuvant to stem cell transplantation,small molecule,not approved,P61073,CXCR4_HUMAN,CXCR4,C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (Fusin) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD antigen CD184),Receptors,GPCR;Rhodopsin,Established target
2003,"TG02, SB1317","TG02, SB1317",antineoplastic agent,small molecule,not approved,P24941,CDK2_HUMAN,CDK2,Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase),Enzymes,EC:2.7.11.22,Novel Target
2003,"TG02, SB1317","TG02, SB1317",antineoplastic agent,small molecule,not approved,Q13164,MK07_HUMAN,ERK5,Mitogen-activated protein kinase 7 (MAP kinase 7) (MAPK 7) (EC 2.7.11.24) (Big MAP kinase 1) (BMK-1) (Extracellular signal-regulated kinase 5) (ERK-5),Enzymes,EC:2.7.11.24,Novel Target
2003,"TG02, SB1317","TG02, SB1317",antineoplastic agent,small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2003,"TG02, SB1317","TG02, SB1317",antineoplastic agent,small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
2004,TG101348,TG101348,antineoplastic agent,small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
2005,tgAAC94,tgAAC94,"antiinflammatory agent,DMARD",adenoviral vector,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
2006,TG-C,TG-C,for treatment of degenerative joint disease,protein,not approved,P36897,TGFR1_HUMAN,TGFBR1,TGF-beta receptor type-1 (TGFR-1) (EC 2.7.11.30) (Activin receptor-like kinase 5) (ALK-5) (Serine/threonine-protein kinase receptor R4) (SKR4) (TGF-beta type I receptor) (Transforming growth factor-beta receptor type I) (TGF-beta receptor type I) (TbetaR-,Receptors,EC:2.7.11.30,Novel Target
2006,TG-C,TG-C,for treatment of degenerative joint disease,protein,not approved,P37173,TGFR2_HUMAN,TGFBR2,TGF-beta receptor type-2 (TGFR-2) (EC 2.7.11.30) (TGF-beta type II receptor) (Transforming growth factor-beta receptor type II) (TGF-beta receptor type II) (TbetaR-II),Receptors,EC:2.7.11.30,Novel Target
2006,TG-C,TG-C,for treatment of degenerative joint disease,protein,not approved,Q03167,TGBR3_HUMAN,TGFBR3,Transforming growth factor beta receptor type 3 (TGF-beta receptor type 3) (TGFR-3) (Betaglycan) (Transforming growth factor beta receptor III) (TGF-beta receptor type III),Receptors,Receptor;TGFR,Novel Target
2007,TGN 1412,TGN 1412,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P10747,CD28_HUMAN,CD28,T-cell-specific surface glycoprotein CD28 (TP44) (CD antigen CD28),Receptors,Receptor; T-cell surface receptor,Novel Target
2008,TH0318,TH0318,antidiabetic,peptide,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2009,Thalomid,thalidomide,antineoplastic agent,Small Molecule,approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2009,Thalomid,thalidomide,antineoplastic agent,Small Molecule,approved,P19838,NFKB1_HUMAN,NFKB1,Nuclear factor NF-kappa-B p105 subunit OS=Homo sapiens GN=NFKB1 PE=1 SV=2,Transcription factor,Transcription factor,Established target
2009,Thalomid,thalidomide,antineoplastic agent,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
2009,Thalomid,thalidomide,antineoplastic agent,Small Molecule,approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
2010,Thelin,sitaxsentan,for treatment of pulmonary arterial hypertension,small molecule,approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2011,ThermoProfen,ketoprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
2011,ThermoProfen,ketoprofen,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
2011,ThermoProfen,ketoprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
2011,ThermoProfen,ketoprofen,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
2012,ThPTH,parathyroid hormone,antiosteoporotic agent,recombinant protein,approved,Q03431,PTH1R_HUMAN,PTH1R,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2012,ThPTH,parathyroid hormone,antiosteoporotic agent,recombinant protein,approved,P49190,PTH2R_HUMAN,PTH2R,Parathyroid hormone 2 receptor (PTH2 receptor),Receptors,GPCR;Secretin,Established target
2013,THVD-201,pilocarpine,for treatment of incontinence,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2013,THVD-201,pilocarpine,for treatment of incontinence,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2013,THVD-201,pilocarpine,for treatment of incontinence,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2013,THVD-201,tolterodine,for treatment of incontinence,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2013,THVD-201,tolterodine,for treatment of incontinence,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2013,THVD-201,tolterodine,for treatment of incontinence,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2013,THVD-201,tolterodine,for treatment of incontinence,Small Molecule,approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2013,THVD-201,tolterodine,for treatment of incontinence,Small Molecule,approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2014,"TI-001, intranasal oxytocin",oxytocin,analgesic,peptide,approved,P30559,OXYR_HUMAN,OXTR,Oxytocin receptor OS=Homo sapiens GN=OXTR PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2015,Ticagrelor,Ticagrelor,antithrombotic,small molecule,approved,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2016,"tideglusib, NP-12,Nypta",tideglusib,for treatment of Alzheimer's disease,small molecule,not approved,P49840,GSK3A_HUMAN,GSK3A,Glycogen synthase kinase-3 alpha (GSK-3 alpha) (EC 2.7.11.26),Enzymes,EC:2.7.11.26,Novel Target
2016,"tideglusib, NP-12,Nypta",tideglusib,for treatment of Alzheimer's disease,small molecule,not approved,P49841,GSK3B_HUMAN,GSK3B,Glycogen synthase kinase-3 beta (GSK-3 beta) (EC 2.7.11.26),Enzymes,EC:2.7.11.26,Novel Target
2017,tilarginine acetate,tilarginine ,for treatment of cardiogenic shock,small molecule,not approved,P35228,NOS2_HUMAN,NOS2,"Nitric oxide synthase, inducible (EC 1.14.13.39) (Hepatocyte NOS) (HEP-NOS) (Inducible NO synthase) (Inducible NOS) (iNOS) (NOS type II) (Peptidyl-cysteine S-nitrosylase NOS2)",Enzymes,EC:1.14.13.39,Novel Target
2018,"tinzaparin sodium injection,Innohep",tinzaparin ,anticoagulant,polysaccharide,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
2018,"tinzaparin sodium injection,Innohep",tinzaparin ,anticoagulant,polysaccharide,approved,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Miscellaneous,Enzyme regulator,Established target
2019,"tiotropium bromide,Spiriva",tiotropium,"for treatment of cystic fibrosis,for treatment of chronic obstructive pulmonary disorder (COPD)",Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2019,"tiotropium bromide,Spiriva",tiotropium,"for treatment of cystic fibrosis,for treatment of chronic obstructive pulmonary disorder (COPD)",Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2019,"tiotropium bromide,Spiriva",tiotropium,"for treatment of cystic fibrosis,for treatment of chronic obstructive pulmonary disorder (COPD)",Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2020,"tipifarnib, R115777,Zarnestra",tipifarnib,antineoplastic agent,small molecule,not approved,P49354,FNTA_HUMAN,FNTA,Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha (EC 2.5.1.58) (EC 2.5.1.59) (CAAX farnesyltransferase subunit alpha) (FTase-alpha) (Ras proteins prenyltransferase subunit alpha) (Type I protein geranyl-geranyltransferase subunit,Enzymes,EC:2.5.1.58; 2.5.1.59,Novel Target
2020,"tipifarnib, R115777,Zarnestra",tipifarnib,antineoplastic agent,small molecule,not approved,P49356,FNTB_HUMAN,FNTB,Protein farnesyltransferase subunit beta (FTase-beta) (EC 2.5.1.58) (CAAX farnesyltransferase subunit beta) (Ras proteins prenyltransferase subunit beta),Enzymes,EC:2.5.1.58,Novel Target
2021,"tizanidine hydrochloride,Zanaflex",tizanidine,muscle relaxant,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2021,"tizanidine hydrochloride,Zanaflex",tizanidine,muscle relaxant,Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2021,"tizanidine hydrochloride,Zanaflex",tizanidine,muscle relaxant,Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2022,TKM-PLK1,TKM-PLK1,antineoplastic agent,siRNA,not approved,P53350,PLK1_HUMAN,PLK1,Serine/threonine-protein kinase PLK1 (EC 2.7.11.21) (Polo-like kinase 1) (PLK-1) (Serine/threonine-protein kinase 13) (STPK13),Enzymes,EC:2.7.11.21,Novel Target
2023,TLK286,canfosfamide,antineoplastic agent,Small molecule,not approved,P09211,GSTP1_HUMAN,GSTP1,Glutathione S-transferase P (EC 2.5.1.18) (GST class-pi) (GSTP1-1),Enzymes,EC:2.5.1.18,Novel Target
2024,"TLN-232, CAP-232, TT-232",TLN-232,antineoplastic agent,peptide,not approved,P14618,KPYM_HUMAN,PKM2,Pyruvate kinase isozymes M1/M2 (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (p58),Enzymes,EC:2.7.1.40,Novel Target
2025,"TLN-4601, ECO-4601",TLN-4601,antineoplastic agent,small molecule,not approved,P30536,TSPOA_HUMAN,TSPO,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
2027,"TM30338,Obinepitide",obinepitide,antiobesity agent,small molecule,not approved,P49146,NPY2R_HUMAN,NPY2R,Neuropeptide Y receptor type 2 (NPY2-R) (NPY-Y2 receptor) (Y2 receptor),Receptors,GPCR;Rhodopsin,Novel Target
2027,"TM30338,Obinepitide",obinepitide,antiobesity agent,small molecule,not approved,P50391,NPY4R_HUMAN,PPYR1,Neuropeptide Y receptor type 4 (NPY4-R) (Pancreatic polypeptide receptor 1) (PP1),Receptors,GPCR;Rhodopsin,Novel Target
2028,TM30339,TM30339,antiobesity agent,small molecule,not approved,P50391,NPY4R_HUMAN,PPYR1,Neuropeptide Y receptor type 4 (NPY4-R) (Pancreatic polypeptide receptor 1) (PP1),Receptors,GPCR;Rhodopsin,Novel Target
2029,TM38837,TM38837,antiobesity agent,small molecule,not approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2030,TNFerade,TNF-alpha adenovector,antineoplastic agent,adenoviral vector,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Miscellaneous,Ligand;Cytokine,Established target
2031,TNX-650,TNX-650,antineoplastic agent,monoclonal antibody,not approved,P35225,IL13_HUMAN,IL13,Interleukin-13 (IL-13),Miscellaneous,Ligand;Cytokine,Novel Target
2032,TO-2061,ondansetron,for treatment of obsessive compulsive disorder (OCD),Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
2033,Tocilizumab,Tocilizumab,"antiinflammatory agent,DMARD",monoclonal antibody,approved,P08887,IL6RA_HUMAN,IL6R,Interleukin-6 receptor subunit alpha (IL-6 receptor subunit alpha) (IL-6R subunit alpha) (IL-6R-alpha) (IL-6RA) (IL-6R 1) (Membrane glycoprotein 80) (gp80) (CD antigen CD126),Receptors,Receptor; Type 1 cytokine receptor,Established target
2034,TOK-001,galeterone,antineoplastic agent,Small molecule,not approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
2034,TOK-001,galeterone,antineoplastic agent,Small molecule,not approved,P05093,CP17A_HUMAN,CYP17A1,"Steroid 17-alpha-hydroxylase/17,20 lyase (EC 1.14.99.9) (CYPXVII) (Cytochrome P450 17A1) (Cytochrome P450-C17) (Cytochrome P450c17) (Steroid 17-alpha-monooxygenase)",Enzymes,EC:1.14.99.9,Established target
2036,"tolterodine extended release capsules,Detrol LA",tolterodine ,for treatment of incontinence,small molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2036,"tolterodine extended release capsules,Detrol LA",tolterodine ,for treatment of incontinence,small molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2036,"tolterodine extended release capsules,Detrol LA",tolterodine ,for treatment of incontinence,small molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2036,"tolterodine extended release capsules,Detrol LA",tolterodine ,for treatment of incontinence,small molecule,approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2036,"tolterodine extended release capsules,Detrol LA",tolterodine ,for treatment of incontinence,small molecule,approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2037,"tolvaptan, OPC-41061,Samsca",tolvaptan,antihypertensive agent,small molecule,approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2038,Tonabersat,Tonabersat,antimigraine agent,small molecule,not approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2039,"topical alprostadil cream,Alprox-TD, Befar, Vitaros",alprostadil,"for treatment of erectile dysfunction,for treatment of sexual dysfunction in women",Small Molecule,approved,P34995,PE2R1_HUMAN,PTGER1,Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens GN=PTGER1 PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
2039,"topical alprostadil cream,Alprox-TD, Befar, Vitaros",alprostadil,"for treatment of erectile dysfunction,for treatment of sexual dysfunction in women",Small Molecule,approved,P43116,PE2R2_HUMAN,PTGER2,Prostaglandin E2 receptor EP2 subtype OS=Homo sapiens GN=PTGER2 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2040,"topical filgrastim, Nupen",filgrastim,for treatment of neutropenia,recombinant protein,approved,Q99062,CSF3R_HUMAN,CSF3R,Granulocyte colony-stimulating factor receptor OS=Homo sapiens GN=CSF3R PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
2041,topical menadione lotion,menadione,for reducing EGFR-inhibitor-induced dermatological side effects,Small Molecule,approved,P38435,VKGC_HUMAN,GGCX,Vitamin K-dependent gamma-carboxylase OS=Homo sapiens GN=GGCX PE=1 SV=2,Enzymes,EC:4.1.1.90,Established target
2041,topical menadione lotion,menadione,for reducing EGFR-inhibitor-induced dermatological side effects,Small Molecule,approved,Q9BQB6,VKOR1_HUMAN,VKORC1,Vitamin K epoxide reductase complex subunit 1 OS=Homo sapiens GN=VKORC1 PE=1 SV=1,Enzymes,EC:1.1.4.1,Established target
2041,topical menadione lotion,menadione,for reducing EGFR-inhibitor-induced dermatological side effects,Small Molecule,approved,Q8N0U8,VKORL_HUMAN,VKORC1L1,Vitamin K epoxide reductase complex subunit 1-like protein 1 OS=Homo sapiens GN=VKORC1L1 PE=1 SV=2,Enzymes,EC:1.1.4.1,Established target
2042,"topical testosterone gel AA2500,Testim",testosterone,hormone replacement,Small Molecule,approved,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
2043,"topiramate controlled release,Trokesa",topiramate ,anticonvulsant,small molecule,approved,P00918,CAH2_HUMAN,CA2,Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
2043,"topiramate controlled release,Trokesa",topiramate ,anticonvulsant,small molecule,approved,P22748,CAH4_HUMAN,CA4,Carbonic anhydrase 4 OS=Homo sapiens GN=CA4 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
2043,"topiramate controlled release,Trokesa",topiramate ,anticonvulsant,small molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
2043,"topiramate controlled release,Trokesa",topiramate ,anticonvulsant,small molecule,approved,P39086,GRIK1_HUMAN,GRIK1,GRIK1 108 kDa protein,Receptors,TC:1.A.10.1,Established target
2043,"topiramate controlled release,Trokesa",topiramate ,anticonvulsant,small molecule,approved,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
2044,"topiramate tablet,Topamax",topiramate ,"anticonvulsant,antimigraine agent",small molecule,approved,P00918,CAH2_HUMAN,CA2,Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
2044,"topiramate tablet,Topamax",topiramate ,"anticonvulsant,antimigraine agent",small molecule,approved,P22748,CAH4_HUMAN,CA4,Carbonic anhydrase 4 OS=Homo sapiens GN=CA4 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
2044,"topiramate tablet,Topamax",topiramate ,"anticonvulsant,antimigraine agent",small molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
2044,"topiramate tablet,Topamax",topiramate ,"anticonvulsant,antimigraine agent",small molecule,approved,P39086,GRIK1_HUMAN,GRIK1,GRIK1 108 kDa protein,Receptors,TC:1.A.10.1,Established target
2044,"topiramate tablet,Topamax",topiramate ,"anticonvulsant,antimigraine agent",small molecule,approved,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
2045,"topotecan,Hycamtin",topotecan,antineoplastic agent,Small Molecule,approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
2046,Torcetrapib,Torcetrapib,antidyslipidaemic agent,small molecule,not approved,P11597,CETP_HUMAN,CETP,Cholesteryl ester transfer protein (Lipid transfer protein I),Miscellaneous,BLI/LBP/Plunc superfamily,Novel Target
2047,"tositumomab,Bexxar",tositumomab,antineoplastic agent,monoclonal antibody,approved,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Miscellaneous,MS4A family,Established target
2048,"TP-508,Chrysalin",rusalatide,for treatment of diabetic foot ulcers,peptide,not approved,P25116,PAR1_HUMAN,F2R,Proteinase-activated receptor 1 (PAR-1) (Coagulation factor II receptor) (Thrombin receptor),Receptors,GPCR;Rhodopsin,Novel Target
2048,"TP-508,Chrysalin",rusalatide,for treatment of diabetic foot ulcers,peptide,not approved,O00254,PAR3_HUMAN,F2RL2,Proteinase-activated receptor 3 (PAR-3) (Coagulation factor II receptor-like 2) (Thrombin receptor-like 2),Receptors,GPCR;Rhodopsin,Novel Target
2048,"TP-508,Chrysalin",rusalatide,for treatment of diabetic foot ulcers,peptide,not approved,Q96RI0,PAR4_HUMAN,F2RL3,Proteinase-activated receptor 4 (PAR-4) (Coagulation factor II receptor-like 3) (Thrombin receptor-like 3),Receptors,GPCR;Rhodopsin,Novel Target
2049,TPI-ASM8,TPI-ASM8,antiasthmatic agent,antisense oligo,not approved,P51677,CCR3_HUMAN,CCR3,C-C chemokine receptor type 3 (C-C CKR-3) (CC-CKR-3) (CCR-3) (CCR3) (CKR3) (Eosinophil eotaxin receptor) (CD antigen CD193),Receptors,GPCR;Rhodopsin,Novel Target
2049,TPI-ASM8,TPI-ASM8,antiasthmatic agent,antisense oligo,not approved,P32927,IL3RB_HUMAN,CSF2RB,Cytokine receptor common subunit beta OS=Homo sapiens GN=CSF2RB PE=1 SV=2,Receptors,Receptor; Type 1 cytokine receptor,Established target
2050,TPM-02/Insulin,insulin,antidiabetic,protein,approved,P06213,INSR_HUMAN,INSR,Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2051,TPM-1/Morphine,morphine,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2051,TPM-1/Morphine,morphine,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2051,TPM-1/Morphine,morphine,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2052,"trabedersen, AP-12009",trabedersen,antineoplastic agent,antisense oligo,not approved,P61812,TGFB2_HUMAN,TGFB2,Transforming growth factor beta-2 (TGF-beta-2) (BSC-1 cell growth inhibitor) (Cetermin) (Glioblastoma-derived T-cell suppressor factor) (G-TSF) (Polyergin),Miscellaneous,Transforming growth factor,Novel Target
2053,Tracleer,bosentan,for treatment of pulmonary arterial hypertension,Small Molecule,approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2053,Tracleer,bosentan,for treatment of pulmonary arterial hypertension,Small Molecule,approved,P24530,EDNRB_HUMAN,EDNRB,Endothelin B receptor OS=Homo sapiens GN=EDNRB PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2054,"trafermin, fibro/",trafermin,"for treatment of periodontitis,for treatment of diabetic foot ulcers",protein,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
2054,"trafermin, fibro/",trafermin,"for treatment of periodontitis,for treatment of diabetic foot ulcers",protein,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2054,"trafermin, fibro/",trafermin,"for treatment of periodontitis,for treatment of diabetic foot ulcers",protein,not approved,P22607,FGFR3_HUMAN,FGFR3,Fibroblast growth factor receptor 3 OS=Homo sapiens GN=FGFR3 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2054,"trafermin, fibro/",trafermin,"for treatment of periodontitis,for treatment of diabetic foot ulcers",protein,not approved,P22455,FGFR4_HUMAN,FGFR4,Fibroblast growth factor receptor 4 OS=Homo sapiens GN=FGFR4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2055,"tramadol extended-release,Raliva ER",tramadol,analgesic,Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2055,"tramadol extended-release,Raliva ER",tramadol,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2055,"tramadol extended-release,Raliva ER",tramadol,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2055,"tramadol extended-release,Raliva ER",tramadol,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2055,"tramadol extended-release,Raliva ER",tramadol,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
2055,"tramadol extended-release,Raliva ER",tramadol,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
2055,"tramadol extended-release,Raliva ER",tramadol,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
2055,"tramadol extended-release,Raliva ER",tramadol,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
2056,"tramadol hydrochloride,Ultram",tramadol,analgesic,Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2056,"tramadol hydrochloride,Ultram",tramadol,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2056,"tramadol hydrochloride,Ultram",tramadol,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2056,"tramadol hydrochloride,Ultram",tramadol,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2056,"tramadol hydrochloride,Ultram",tramadol,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
2056,"tramadol hydrochloride,Ultram",tramadol,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
2056,"tramadol hydrochloride,Ultram",tramadol,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
2056,"tramadol hydrochloride,Ultram",tramadol,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
2057,"tramadol,Tridural, Ryzolt",tramadol,analgesic,Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2057,"tramadol,Tridural, Ryzolt",tramadol,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2057,"tramadol,Tridural, Ryzolt",tramadol,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2057,"tramadol,Tridural, Ryzolt",tramadol,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2057,"tramadol,Tridural, Ryzolt",tramadol,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
2057,"tramadol,Tridural, Ryzolt",tramadol,analgesic,Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
2057,"tramadol,Tridural, Ryzolt",tramadol,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
2057,"tramadol,Tridural, Ryzolt",tramadol,analgesic,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
2058,"tramiprosate, NC-531,Alzhemed",homotaurine,for treatment of Alzheimer's disease,Small molecule,not approved,P05067,A4_HUMAN,APP,Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-,Miscellaneous,Miscellaneous:Amyloid beta 4,Novel Target
2059,"trandolapril,Gopten, Mavik, Odrik",trandolapril,antihypertensive agent,Small Molecule,approved,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
2060,"tranexamic acid,Lysteda",tranexamic acid,antimenorrhagic agent,Small Molecule,approved,P00750,TPA_HUMAN,PLAT,Tissue-type plasminogen activator OS=Homo sapiens GN=PLAT PE=1 SV=1,Enzymes,EC:3.4.21.68,Established target
2061,Transacin,capsaicin,analgesic,Small molecule,approved,Q8NER1,TRPV1_HUMAN,TRPV1,Transient receptor potential cation channel subfamily V member 1 (TrpV1) (Capsaicin receptor) (Osm-9-like TRP channel 1) (OTRPC1) (Vanilloid receptor 1),Transporters,TC:1.A.4,Established target
2062,transdermal diclofenac,diclofenac,NSAID,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
2062,transdermal diclofenac,diclofenac,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
2063,"transdermal estradiol,Divigel",estradiol,hormone replacement,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
2063,"transdermal estradiol,Divigel",estradiol,hormone replacement,Small Molecule,approved,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
2064,"transdermal granisetron,Sancuso",granisetron,antiemetic,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
2065,"transdermal lidocaine, TPM/lidocaine",lidocaine,anestethic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
2065,"transdermal lidocaine, TPM/lidocaine",lidocaine,anestethic,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
2065,"transdermal lidocaine, TPM/lidocaine",lidocaine,anestethic,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",epinephrine,anestethic,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",epinephrine,anestethic,Small Molecule,approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",epinephrine,anestethic,Small Molecule,approved,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",epinephrine,anestethic,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",epinephrine,anestethic,Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",epinephrine,anestethic,Small Molecule,approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",epinephrine,anestethic,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",lidocaine,anestethic,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",lidocaine,anestethic,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
2066,"transdermal lidocaine/epinephrine patch,Lidosite",lidocaine,anestethic,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
2067,"transdermal oxybutynin patch, oxybutynin topical gel,Oxytrol, Kentera, Gelnique",oxybutynin,for treatment of incontinence,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2067,"transdermal oxybutynin patch, oxybutynin topical gel,Oxytrol, Kentera, Gelnique",oxybutynin,for treatment of incontinence,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2067,"transdermal oxybutynin patch, oxybutynin topical gel,Oxytrol, Kentera, Gelnique",oxybutynin,for treatment of incontinence,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2068,transdermal oxycodone,oxycodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2068,transdermal oxycodone,oxycodone,analgesic,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2068,transdermal oxycodone,oxycodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2069,"transmucosal fentanyl,Actiq",fentanyl,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2069,"transmucosal fentanyl,Actiq",fentanyl,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2070,"trastuzumab-DM1, T-DM1",Trastuzumab emtansine,antineoplastic agent,monoclonal antibody,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2070,"trastuzumab-DM1, T-DM1",Trastuzumab emtansine,antineoplastic agent,monoclonal antibody,not approved,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
2071,"travoprost + timolol,Extravan, Duotrav",timolol,for treatment of glaucoma,Small Molecule,approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2071,"travoprost + timolol,Extravan, Duotrav",timolol,for treatment of glaucoma,Small Molecule,approved,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2071,"travoprost + timolol,Extravan, Duotrav",travoprost,for treatment of glaucoma,Small Molecule,approved,P43088,PF2R_HUMAN,PTGFR,Prostaglandin F2-alpha receptor (PGF receptor) (PGF2-alpha receptor) (Prostanoid FP receptor),Receptors,GPCR;Rhodopsin,Established target
2072,"trazodone extended release, DDS-04A,Oleptro",trazodone,antidepressant,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2072,"trazodone extended release, DDS-04A,Oleptro",trazodone,antidepressant,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2072,"trazodone extended release, DDS-04A,Oleptro",trazodone,antidepressant,Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2072,"trazodone extended release, DDS-04A,Oleptro",trazodone,antidepressant,Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter (5HT transporter) (5HTT) (Solute carrier family 6 member 4),Transporters,TC:2.A.22.1.1,Established target
2073,TRC105,TRC105,antineoplastic agent,monoclonal antibody,not approved,P17813,EGLN_HUMAN,ENG,Endoglin (CD antigen CD105),Miscellaneous,Miscellaneous;Glycoprotein,Novel Target
2074,"trelanserin, SL 65.0472",trelanserin,for treatment of intermittent claudication,small molecule,not approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2074,"trelanserin, SL 65.0472",trelanserin,for treatment of intermittent claudication,small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2075,Tremelimumab,Tremelimumab,antineoplastic agent,monoclonal antibody,not approved,P16410,CTLA4_HUMAN,CTLA4,Cytotoxic T-lymphocyte protein 4 (Cytotoxic T-lymphocyte-associated antigen 4) (CTLA-4) (CD antigen CD152),Receptors,Miscellaneous;CTLA4,Established target
2076,"tretinoin microsponge,Retin-A",tretinoin,for treatment of acne,Small Molecule,approved,P13631,RARG_HUMAN,RARG,Retinoic acid receptor gamma OS=Homo sapiens GN=RARG PE=1 SV=1,Receptors,Nuclear receptor,Established target
2076,"tretinoin microsponge,Retin-A",tretinoin,for treatment of acne,Small Molecule,approved,P28702,RXRB_HUMAN,RXRB,Retinoic acid receptor RXR-beta OS=Homo sapiens GN=RXRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
2076,"tretinoin microsponge,Retin-A",tretinoin,for treatment of acne,Small Molecule,approved,P48443,RXRG_HUMAN,RXRG,Retinoic acid receptor RXR-gamma OS=Homo sapiens GN=RXRG PE=1 SV=1,Receptors,Nuclear receptor,Established target
2077,TriAb/TriGem,Triab,antineoplastic agent,monoclonal antibody,not approved,Q08431,MFGM_HUMAN,MFGE8,Lactadherin (Breast epithelial antigen BA46) (HMFG) (MFGM) (Milk fat globule-EGF factor 8) (MFG-E8) (SED1) [Cleaved into: Lactadherin short form; Medin],Miscellaneous,Milk fat globule,Novel Target
2078,"triamcinolone acetonide implant,I-vation",triamcinolone,for treatment of diabetic macular edema,Small Molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
2079,Triapine,Triapine,antineoplastic agent,small molecule,not approved,P31350,RIR2_HUMAN,RRM2,Ribonucleoside-diphosphate reductase subunit M2 (EC 1.17.4.1) (Ribonucleotide reductase small chain) (Ribonucleotide reductase small subunit),Enzymes,EC:1.17.4.1,Novel Target
2080,Tribenzor,amlodipine,antihypertensive agent,Small Molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
2080,Tribenzor,amlodipine,antihypertensive agent,Small Molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
2080,Tribenzor,amlodipine,antihypertensive agent,Small Molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
2080,Tribenzor,amlodipine,antihypertensive agent,Small Molecule,approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
2080,Tribenzor,amlodipine,antihypertensive agent,Small Molecule,approved,Q08289,CACB2_HUMAN,CACNB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
2080,Tribenzor,hydrochlorothiazide,antihypertensive agent,Small molecule,approved,P55017,S12A3_HUMAN,SLC12A3,Solute carrier family 12 member 3 OS=Homo sapiens GN=SLC12A3 PE=1 SV=2,Transporters,TC:2.A.30.4.2,Established target
2080,Tribenzor,olmesartan,antihypertensive agent,Small Molecule,approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2081,"triciribine-phosphate, TCN-P, VQD-002",triciribine,antineoplastic agent,small molecule,not approved,P31749,AKT1_HUMAN,AKT1,RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Proto-oncogene c-Akt) (RAC-PK-alpha),Enzymes,EC:2.7.11.1,Novel Target
2081,"triciribine-phosphate, TCN-P, VQD-002",triciribine,antineoplastic agent,small molecule,not approved,P31751,AKT2_HUMAN,AKT2,RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta),Enzymes,EC:2.7.11.1,Novel Target
2081,"triciribine-phosphate, TCN-P, VQD-002",triciribine,antineoplastic agent,small molecule,not approved,Q9Y243,AKT3_HUMAN,AKT3,RAC-gamma serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-3) (Protein kinase B gamma) (PKB gamma) (RAC-PK-gamma) (STK-2),Enzymes,EC:2.7.11.1,Novel Target
2082,Triolex,HE3286,"antiinflammatory agent,DMARD",Small molecule,not approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
2084,"triptorelin pamoate,Trelstar, Decapeptyl, Salvacyl, Moapar, Pamorelin",triptorelin pamoate,"antineoplastic agent,chemical castration agent",peptide,approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2084,"triptorelin pamoate,Trelstar, Decapeptyl, Salvacyl, Moapar, Pamorelin",triptorelin pamoate,"antineoplastic agent,chemical castration agent",peptide,approved,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
2085,"trodusquemine, MSI-1436",trodusquemine,antiobesity agent,small molecule,not approved,P18031,PTN1_HUMAN,PTPN1,Tyrosine-protein phosphatase non-receptor type 1 OS=Homo sapiens GN=PTPN1 PE=1 SV=1,Enzymes,EC:3.1.3,Established target
2086,"trospium chloride,Sanctura",trospium,for treatment of incontinence,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1,Receptors,GPCR;Rhodopsin,Established target
2087,TRU-016,TRU-016,antineoplastic agent,antibody fragment,not approved,P11049,CD37_HUMAN,CD37,Leukocyte antigen CD37 (Tetraspanin-26) (Tspan-26) (CD antigen CD37),Miscellaneous,Miscellaneous;Tetraspanin,Novel Target
2088,TRX1,TRX1,antiinflammatory agent,monoclonal antibody,not approved,P01730,CD4_HUMAN,CD4,T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4),Receptors,Receptor; T-cell surface receptor,Established target
2089,TRX518,TRX518,antineoplastic agent,monoclonal antibody,not approved,Q9Y5U5,TNR18_HUMAN,TNFRSF18,Tumor necrosis factor receptor superfamily member 18 (Activation-inducible TNFR family receptor) (Glucocorticoid-induced TNFR-related protein) (CD antigen CD357),Receptors,Receptors;TNFNGF,Novel Target
2090,"TS-032, PF-4802540","TS-032, PF-4802540",antipsychotic agent,unknown,not approved,Q14416,GRM2_HUMAN,GRM2,Metabotropic glutamate receptor 2 (mGluR2),Receptors,GPCR;Glutamate,Novel Target
2090,"TS-032, PF-4802540","TS-032, PF-4802540",antipsychotic agent,unknown,not approved,Q14832,GRM3_HUMAN,GRM3,Metabotropic glutamate receptor 3 (mGluR3),Receptors,GPCR;Glutamate,Novel Target
2091,TST10088,TST10088,antineoplastic agent,recombinant protein,not approved,P08253,MMP2_HUMAN,MMP2,72 kDa type IV collagenase OS=Homo sapiens GN=MMP2 PE=1 SV=2,Enzymes,EC:3.4.24.24,Novel Target
2091,TST10088,TST10088,antineoplastic agent,recombinant protein,not approved,P14780,MMP9_HUMAN,MMP9,Matrix metalloproteinase-9 OS=Homo sapiens GN=MMP9 PE=1 SV=2,Enzymes,EC:3.4.24.35,Novel Target
2092,TT-223,TT-223,"antidiabetic,injectable islet neogenesis therapy for diabetes",injectible islet neogenesis therapy,not approved,P32239,GASR_HUMAN,CCKBR,Gastrin/cholecystokinin type B receptor OS=Homo sapiens GN=CCKBR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2092,TT-223,TT-223,"antidiabetic,injectable islet neogenesis therapy for diabetes",injectible islet neogenesis therapy,not approved,P01133,EGF_HUMAN,EGF,Pro-epidermal growth factor (EGF) [Cleaved into: Epidermal growth factor (Urogastrone)],Receptors,Receptor;LDLR,Novel Target
2092,TT-223,TT-223,"antidiabetic,injectable islet neogenesis therapy for diabetes",injectible islet neogenesis therapy,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2093,TTP889,TTP889,anticoagulant,small molecule,not approved,P00740,FA9_HUMAN,F9,Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2,Enzymes,EC:3.4.21.22,Established target
2094,Tykerb,lapatinib,antineoplastic agent,Small Molecule,approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2094,Tykerb,lapatinib,antineoplastic agent,Small Molecule,approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2095,TZP-101,TZP-101,for treatment of gastroparesis,small molecule,not approved,Q92847,GHSR_HUMAN,GHSR,Growth hormone secretagogue receptor type 1 (GHS-R) (GH-releasing peptide receptor) (GHRP) (Ghrelin receptor),Receptors,GPCR;Rhodopsin,Novel Target
2096,TZP-102,TZP-102,for treatment of gastroparesis,small molecule,not approved,Q92847,GHSR_HUMAN,GHSR,Growth hormone secretagogue receptor type 1 (GHS-R) (GH-releasing peptide receptor) (GHRP) (Ghrelin receptor),Receptors,GPCR;Rhodopsin,Novel Target
2097,"TZTX-001,Teverelix LA",luteinizing hormone-releasing hormone,antineoplastic agent,peptide,not approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2097,"TZTX-001,Teverelix LA",luteinizing hormone-releasing hormone,antineoplastic agent,peptide,not approved,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
2098,U-101,heparin,for treatment of pelvic pain of bladder origin and interstitital cystitis,Small Molecule,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
2098,U-101,heparin,for treatment of pelvic pain of bladder origin and interstitital cystitis,Small Molecule,approved,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Miscellaneous,Enzyme regulator,Established target
2098,U-101,lidocaine,for treatment of pelvic pain of bladder origin and interstitital cystitis,Small Molecule,approved,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
2098,U-101,lidocaine,for treatment of pelvic pain of bladder origin and interstitital cystitis,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
2098,U-101,lidocaine,for treatment of pelvic pain of bladder origin and interstitital cystitis,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
2099,"udenafil,Zydena",udenafil,for treatment of erectile dysfunction,Small Molecule,approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
2100,UFT,tegafur,antineoplastic agent,small molecule,not approved,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
2101,ularitide,cardiodilatin,for treatment of congestive heart failure,peptide,not approved,P16066,ANPRA_HUMAN,NPR1,Atrial natriuretic peptide receptor A OS=Homo sapiens GN=NPR1 PE=2 SV=1,Receptors,EC:4.6.1.2,Established target
2101,ularitide,cardiodilatin,for treatment of congestive heart failure,peptide,not approved,P20594,ANPRB_HUMAN,NPR2,Atrial natriuretic peptide receptor B OS=Homo sapiens GN=NPR2 PE=1 SV=1,Receptors,EC:4.6.1.2,Established target
2101,ularitide,cardiodilatin,for treatment of congestive heart failure,peptide,not approved,P17342,ANPRC_HUMAN,NPR3,Atrial natriuretic peptide clearance receptor OS=Homo sapiens GN=NPR3 PE=1 SV=2,Receptors,Receptor;NPR3,Established target
2102,Ulipristal,Ulipristal,contraceptive,small molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
2103,UltiMAb IgG1 antibody,IgG1 antibody,antineoplastic agent,monoclonal antibody,not approved,P01857,IGHG1_HUMAN,IGHG1,Ig gamma-1 chain C region,Miscellaneous,IgG1,Novel Target
2104,unfractionated heparin tablets,heparin,antithrombotic,Small Molecule,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
2104,unfractionated heparin tablets,heparin,antithrombotic,Small Molecule,approved,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Miscellaneous,Enzyme regulator,Established target
2105,"urocortin 2, 358-086-15",urocortin 2,for treatment of congestive heart failure,peptide,not approved,Q13324,CRFR2_HUMAN,CRHR2,Corticotropin-releasing factor receptor 2 (CRF-R-2) (CRF-R2) (CRFR-2) (Corticotropin-releasing hormone receptor 2) (CRH-R-2) (CRH-R2),Receptors,GPCR;Secretin,Novel Target
2106,"urokinase for injection,Kinlytic",urokinase ,thrombolytic agent,protein,approved,P00750,TPA_HUMAN,PLAT,Tissue-type plasminogen activator OS=Homo sapiens GN=PLAT PE=1 SV=1,Enzymes,EC:3.4.21.68,Established target
2106,"urokinase for injection,Kinlytic",urokinase ,thrombolytic agent,protein,approved,P00749,UROK_HUMAN,PLAU,Urokinase-type plasminogen activator (U-plasminogen activator) (uPA) (EC 3.4.21.73) [Cleaved into: Urokinase-type plasminogen activator long chain A; Urokinase-type plasminogen activator short chain A; Urokinase-type plasminogen activator chain B],Enzymes,EC:3.4.21.73,Established target
2106,"urokinase for injection,Kinlytic",urokinase ,thrombolytic agent,protein,approved,Q03405,UPAR_HUMAN,PLAUR,Urokinase plasminogen activator surface receptor (U-PAR) (uPAR) (Monocyte activation antigen Mo3) (CD antigen CD87),Receptors,Receptor; Ly-6 antigen / uPA receptor -like,Established target
2106,"urokinase for injection,Kinlytic",urokinase ,thrombolytic agent,protein,approved,P00747,PLMN_HUMAN,PLG,Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2,Enzymes,StructuralAndAdhesion;Fibrinogen,Established target
2106,"urokinase for injection,Kinlytic",urokinase ,thrombolytic agent,protein,approved,P05120,PAI2_HUMAN,SERPINB2,Plasminogen activator inhibitor 2 (PAI-2) (Monocyte Arg-serpin) (Placental plasminogen activator inhibitor) (Serpin B2) (Urokinase inhibitor),Miscellaneous,Protease_inhib_Serpin family,Established target
2106,"urokinase for injection,Kinlytic",urokinase ,thrombolytic agent,protein,approved,P05121,PAI1_HUMAN,SERPINE1,Plasminogen activator inhibitor 1 (PAI) (PAI-1) (Endothelial plasminogen activator inhibitor) (Serpin E1),Miscellaneous,Protease_inhib_Serpin family,Established target
2107,"ursodiol, ursodeoxycholic acid,Urso, Urso Forte",ursodeoxycholic acid,for prevention of recurrence of colorectal polyps,Small Molecule,approved,P52895,AK1C2_HUMAN,AKR1C2,"Aldo-keto reductase family 1 member C2 (EC 1.-.-.-) (3-alpha-HSD3) (Chlordecone reductase homolog HAKRD) (Dihydrodiol dehydrogenase 2) (DD-2) (DD2) (Dihydrodiol dehydrogenase/bile acid-binding protein) (DD/BABP) (Trans-1,2-dihydrobenzene-1,2-diol dehydrog",Enzymes,EC:1.-.-.-; 1.3.1.20; 1.1.1.213,Established target
2108,USL255,topiramate ,anticonvulsant,small molecule,approved,P00918,CAH2_HUMAN,CA2,Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
2108,USL255,topiramate ,anticonvulsant,small molecule,approved,P22748,CAH4_HUMAN,CA4,Carbonic anhydrase 4 OS=Homo sapiens GN=CA4 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
2108,USL255,topiramate ,anticonvulsant,small molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
2108,USL255,topiramate ,anticonvulsant,small molecule,approved,P39086,GRIK1_HUMAN,GRIK1,GRIK1 108 kDa protein,Receptors,TC:1.A.10.1,Established target
2108,USL255,topiramate ,anticonvulsant,small molecule,approved,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
2109,V1003,buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2109,V1003,buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2109,V1003,buprenorphine,"antidepressant,analgesic,for treatment of opioid addiction",Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2110,"V-1512, CHF-1512,Levomet Complex, Sirio",carbidopa,antiparkinson agent,Small Molecule,approved,P20711,DDC_HUMAN,DDC,Aromatic-L-amino-acid decarboxylase OS=Homo sapiens GN=DDC PE=1 SV=1,Enzymes,EC:4.1.1.28,Established target
2110,"V-1512, CHF-1512,Levomet Complex, Sirio",melevodopa,antiparkinson agent,Small molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2110,"V-1512, CHF-1512,Levomet Complex, Sirio",melevodopa,antiparkinson agent,Small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2110,"V-1512, CHF-1512,Levomet Complex, Sirio",melevodopa,antiparkinson agent,Small molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2110,"V-1512, CHF-1512,Levomet Complex, Sirio",melevodopa,antiparkinson agent,Small molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2110,"V-1512, CHF-1512,Levomet Complex, Sirio",melevodopa,antiparkinson agent,Small molecule,approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2111,V158866,V158866,analgesic,small molecule,not approved,O00519,FAAH1_HUMAN,FAAH,Fatty-acid amide hydrolase 1 (EC 3.5.1.99) (Anandamide amidohydrolase 1) (Oleamide hydrolase 1),Enzymes,EC:3.5.1.99,Novel Target
2112,V24343,V24343,antiobesity agent,small molecule,not approved,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2113,V3381,V3381,"analgesic,neuropathic pain",small molecule,not approved,Q05586,NMDZ1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo sapiens GN=GRIN1 PE=1 SV=1,Receptors,TC:1.A.10.1.6,Established target
2113,V3381,V3381,"analgesic,neuropathic pain",small molecule,not approved,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
2113,V3381,V3381,"analgesic,neuropathic pain",small molecule,not approved,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
2113,V3381,V3381,"analgesic,neuropathic pain",small molecule,not approved,Q14957,NMDE3_HUMAN,GRIN2C,Glutamate [NMDA] receptor subunit epsilon-3 (N-methyl D-aspartate receptor subtype 2C) (NMDAR2C) (NR2C),Receptors,TC:1.A.10.1.3,Novel Target
2113,V3381,V3381,"analgesic,neuropathic pain",small molecule,not approved,O15399,NMDE4_HUMAN,GRIN2D,Glutamate [NMDA] receptor subunit epsilon-4 OS=Homo sapiens GN=GRIN2D PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
2113,V3381,V3381,"analgesic,neuropathic pain",small molecule,not approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
2113,V3381,V3381,"analgesic,neuropathic pain",small molecule,not approved,O60391,NMD3B_HUMAN,GRIN3B,Glutamate [NMDA] receptor subunit 3B OS=Homo sapiens GN=GRIN3B PE=2 SV=2,Receptors,TC:1.A.10.1,Established target
2113,V3381,V3381,"analgesic,neuropathic pain",small molecule,not approved,P21397,AOFA_HUMAN,MAOA,Amine oxidase [flavin-containing] A OS=Homo sapiens GN=MAOA PE=1 SV=1,Enzymes,EC:1.4.3.4,Established target
2113,V3381,V3381,"analgesic,neuropathic pain",small molecule,not approved,P27338,AOFB_HUMAN,MAOB,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3,Established target
2114,V934/V935,V934/V935,antineoplastic agent,vaccine,not approved,O60832,DKC1_HUMAN,DKC1,H/ACA ribonucleoprotein complex subunit 4 (EC 5.4.99.-) (CBF5 homolog) (Dyskerin) (Nopp140-associated protein of 57 kDa) (Nucleolar protein NAP57) (Nucleolar protein family A member 4) (snoRNP protein DKC1),Enzymes,EC:5.4.99.-,Novel Target
2114,V934/V935,V934/V935,antineoplastic agent,vaccine,not approved,Q99973,TEP1_HUMAN,TEP1,Telomerase protein component 1 (Telomerase-associated protein 1) (Telomerase protein 1) (p240) (p80 telomerase homolog),Miscellaneous,MHC class II transactivator,Novel Target
2114,V934/V935,V934/V935,antineoplastic agent,vaccine,not approved,O14746,TERT_HUMAN,TERT,Telomerase reverse transcriptase (EC 2.7.7.49) (HEST2) (Telomerase catalytic subunit) (Telomerase-associated protein 2) (TP2),Enzymes,EC:2.7.7.49,Novel Target
2115,VA106483,VA106483,for treatment of BPH-related urinary symptoms,small molecule,not approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2116,VA111913,VA111913,for treatment of dysmenorrhea,small molecule,not approved,P37288,V1AR_HUMAN,AVPR1A,Vasopressin V1a receptor OS=Homo sapiens GN=AVPR1A PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2116,VA111913,VA111913,for treatment of dysmenorrhea,small molecule,not approved,P47901,V1BR_HUMAN,AVPR1B,Vasopressin V1b receptor OS=Homo sapiens GN=AVPR1B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2116,VA111913,VA111913,for treatment of dysmenorrhea,small molecule,not approved,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2117,"vaccine, EGF cancer",nimotuzumab,antineoplastic agent,monoclonal antibody,not approved,P01133,EGF_HUMAN,EGF,Pro-epidermal growth factor (EGF) [Cleaved into: Epidermal growth factor (Urogastrone)],Receptors,Receptor;LDLR,Novel Target
2119,Vadimezan,Vadimezan ,antineoplastic agent,small molecule,not approved,Q9H2X6,HIPK2_HUMAN,HIPK2,Homeodomain-interacting protein kinase 2,Enzymes,EC:2.7.11.1,Novel Target
2119,Vadimezan,Vadimezan ,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2119,Vadimezan,Vadimezan ,antineoplastic agent,small molecule,not approved,Q86V86,PIM3_HUMAN,PIM3,Serine/threonine-protein kinase pim-3 (EC 2.7.11.1),Enzymes,EC:2.7.11.1,Novel Target
2120,"valproic acid delayed release capsules,Stavzor",valproic acid ,anticonvulsant,small molecule,approved,P80404,GABT_HUMAN,ABAT,"4-aminobutyrate aminotransferase, mitochondrial OS=Homo sapiens GN=ABAT PE=1 SV=3",Enzymes,EC:2.6.1.19; 2.6.1.22,Established target
2120,"valproic acid delayed release capsules,Stavzor",valproic acid ,anticonvulsant,small molecule,approved,P45954,ACDSB_HUMAN,ACADSB,"Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial (SBCAD) (EC 1.3.99.-) (2-methyl branched chain acyl-CoA dehydrogenase) (2-MEBCAD) (2-methylbutyryl-coenzyme A dehydrogenase) (2-methylbutyryl-CoA dehydrogenase)",Enzymes,EC:1.3.99.-,Established target
2120,"valproic acid delayed release capsules,Stavzor",valproic acid ,anticonvulsant,small molecule,approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
2121,"valproic acid,Avugane, Baceca",valproic acid ,for treatment of basal cell carcinoma,small molecule,approved,P80404,GABT_HUMAN,ABAT,"4-aminobutyrate aminotransferase, mitochondrial OS=Homo sapiens GN=ABAT PE=1 SV=3",Enzymes,EC:2.6.1.19; 2.6.1.22,Established target
2121,"valproic acid,Avugane, Baceca",valproic acid ,for treatment of basal cell carcinoma,small molecule,approved,P45954,ACDSB_HUMAN,ACADSB,"Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial (SBCAD) (EC 1.3.99.-) (2-methyl branched chain acyl-CoA dehydrogenase) (2-MEBCAD) (2-methylbutyryl-coenzyme A dehydrogenase) (2-methylbutyryl-CoA dehydrogenase)",Enzymes,EC:1.3.99.-,Established target
2121,"valproic acid,Avugane, Baceca",valproic acid ,for treatment of basal cell carcinoma,small molecule,approved,Q9UKV0,HDAC9_HUMAN,HDAC9,Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR),Enzymes,EC:3.5.1.98,Established target
2122,"valsartan,Diovan",valsartan,antihypertensive agent,Small Molecule,approved,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2123,"vapitadine dihydrochloride,Hivenyl",vapitadine,antiallergy agent,small molecule,not approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2124,"vapreotide, Debio 8609,Sanvar, Docrised",vapreotide,for treatment of liver cirrhosis-related variceal bleeding,Small Molecule,approved,P30874,SSR2_HUMAN,SSTR2,Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SRIF-1),Receptors,GPCR;Rhodopsin,Established target
2124,"vapreotide, Debio 8609,Sanvar, Docrised",vapreotide,for treatment of liver cirrhosis-related variceal bleeding,Small Molecule,approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2125,"vardenafil HCL,Levitra, Staxyn",vardenafil,for treatment of erectile dysfunction,Small Molecule,not approved,O76074,PDE5A_HUMAN,PDE5A,"cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A PE=1 SV=1",Enzymes,EC:3.1.4.35,Established target
2126,"varenicline, CP-526",varenicline,smoking-cessation agent,Small Molecule,approved,P32297,ACHA3_HUMAN,CHRNA3,Neuronal acetylcholine receptor subunit alpha-3,Receptors,TC:1.A.9,Established target
2126,"varenicline, CP-526",varenicline,smoking-cessation agent,Small Molecule,approved,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
2126,"varenicline, CP-526",varenicline,smoking-cessation agent,Small Molecule,approved,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
2126,"varenicline, CP-526",varenicline,smoking-cessation agent,Small Molecule,approved,P17787,ACHB2_HUMAN,CHRNB2,Neuronal acetylcholine receptor subunit beta-2 OS=Homo sapiens GN=CHRNB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
2126,"varenicline, CP-526",varenicline,smoking-cessation agent,Small Molecule,approved,P30926,ACHB4_HUMAN,CHRNB4,Neuronal acetylcholine receptor subunit beta-4,Transporters,TC:1.A.9,Established target
2127,"varespladib sodium, A-001",varespladib,antiinflammatory agent,small molecule,not approved,O15496,PA2GX_HUMAN,PLA2G10,Group 10 secretory phospholipase A2,Enzymes,EC:3.1.1.4,Novel Target
2127,"varespladib sodium, A-001",varespladib,antiinflammatory agent,small molecule,not approved,P14555,PA2GA_HUMAN,PLA2G2A,"Phospholipase A2, membrane associated",Enzymes,EC:3.1.1.4,Novel Target
2127,"varespladib sodium, A-001",varespladib,antiinflammatory agent,small molecule,not approved,P39877,PA2G5_HUMAN,PLA2G5,Calcium-dependent phospholipase A2,Enzymes,EC:3.1.1.4,Novel Target
2128,"varespladib, A-002",varespladib,antiinflammatory agent,small molecule,not approved,O15496,PA2GX_HUMAN,PLA2G10,Group 10 secretory phospholipase A2,Enzymes,EC:3.1.1.4,Novel Target
2128,"varespladib, A-002",varespladib,antiinflammatory agent,small molecule,not approved,P14555,PA2GA_HUMAN,PLA2G2A,"Phospholipase A2, membrane associated",Enzymes,EC:3.1.1.4,Novel Target
2128,"varespladib, A-002",varespladib,antiinflammatory agent,small molecule,not approved,P39877,PA2G5_HUMAN,PLA2G5,Calcium-dependent phospholipase A2,Enzymes,EC:3.1.1.4,Novel Target
2129,Warner,ethinyl estradiol,contraceptive,Small Molecule,approved,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
2129,Warner,norethindrone ,contraceptive,small molecule,approved,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
2130,"vascular endothelial growth factor-121,BioBypass",VEGF-121,cardiovascular agent,peptide,not approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
2131,Vatalanib,Vatalanib,antineoplastic agent,small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2131,Vatalanib,Vatalanib,antineoplastic agent,small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2131,Vatalanib,Vatalanib,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2131,Vatalanib,Vatalanib,antineoplastic agent,small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2131,Vatalanib,Vatalanib,antineoplastic agent,small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2131,Vatalanib,Vatalanib,antineoplastic agent,small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2132,"vatalanib, PTK 787",Vatalanib,antineoplastic agent,small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2132,"vatalanib, PTK 787",Vatalanib,antineoplastic agent,small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2132,"vatalanib, PTK 787",Vatalanib,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2132,"vatalanib, PTK 787",Vatalanib,antineoplastic agent,small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2132,"vatalanib, PTK 787",Vatalanib,antineoplastic agent,small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2132,"vatalanib, PTK 787",Vatalanib,antineoplastic agent,small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2133,VB-201,VB-201,antipsoriatic agent,unknown,not approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
2133,VB-201,VB-201,antipsoriatic agent,unknown,not approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
2134,"VB4-845,Proxinium, Vicinium",VB4-845,antineoplastic agent,antibody,not approved,P13639,EF2_HUMAN,EEF2,Elongation factor 2 (EF-2),Miscellaneous,Miscellaneous;elongation factor,Novel Target
2134,"VB4-845,Proxinium, Vicinium",VB4-845,antineoplastic agent,antibody,not approved,P16422,EPCAM_HUMAN,EPCAM,Epithelial cell adhesion molecule (Ep-CAM) (Adenocarcinoma-associated antigen) (Cell surface glycoprotein Trop-1) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Epithelial glycoprotein 314) (EGP314) (hEGP314) (KS 1/4 antigen) (KSA) (Ma,Miscellaneous,StructuralAndAdhesion;,Novel Target
2135,VB6-845,VB6-845,antineoplastic agent,monoclonal antibody,not approved,P16422,EPCAM_HUMAN,EPCAM,Epithelial cell adhesion molecule (Ep-CAM) (Adenocarcinoma-associated antigen) (Cell surface glycoprotein Trop-1) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Epithelial glycoprotein 314) (EGP314) (hEGP314) (KS 1/4 antigen) (KSA) (Ma,Miscellaneous,StructuralAndAdhesion;,Novel Target
2136,Vectibix,panitumumab,antineoplastic agent,monoclonal antibody,approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2137,"vedolizumab, MLN-02",vedolizumab,"for treatment of Chron's disease,for treatment of ulcerative colitis",monoclonal antibody,not approved,P13612,ITA4_HUMAN,ITGA4,Integrin alpha-4 OS=Homo sapiens GN=ITGA4 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
2137,"vedolizumab, MLN-02",vedolizumab,"for treatment of Chron's disease,for treatment of ulcerative colitis",monoclonal antibody,not approved,P26010,ITB7_HUMAN,ITGB7,Integrin beta-7 (Gut homing receptor beta subunit),Receptors,Receptors;Integrin,Novel Target
2138,VEGF gene therapy,VEGF gene therapy,cardiovascular agent,peptide,not approved,P15692,VEGFA_HUMAN,VEGFA,Vascular endothelial growth factor A OS=Homo sapiens GN=VEGFA PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
2139,VEGF-2 gene therapy,VEGF-2,cardiovascular agent,protein,not approved,P49765,VEGFB_HUMAN,VEGFB,Vascular endothelial growth factor B,Ligand,Ligand;Growth factor,Novel Target
2140,"VEGF-AS,Veglin",Veglin,antineoplastic agent,antisense oligo,not approved,P15692,VGFR1_HUMAN,VEGFA,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Ligand,Ligand;Growth factor,Established target
2141,VEL-0230,VEL-0230,antirheumatic agent,small molecule,not approved,P43235,CATK_HUMAN,CTSK,Cathepsin K (EC 3.4.22.38) (Cathepsin O) (Cathepsin O2) (Cathepsin X),Enzymes,EC:3.4.22.38,Novel Target
2142,Velcade,bortezomib,antineoplastic agent,Small Molecule,approved,P20618,PSB1_HUMAN,PSMB1,Proteasome subunit beta type-1 OS=Homo sapiens GN=PSMB1 PE=1 SV=2,Enzymes,EC:3.4.25.1,Established target
2142,Velcade,bortezomib,antineoplastic agent,Small Molecule,approved,P49721,PSB2_HUMAN,PSMB2,Proteasome subunit beta type-2 OS=Homo sapiens GN=PSMB2 PE=1 SV=1,Enzymes,EC:3.4.25.1,Established target
2142,Velcade,bortezomib,antineoplastic agent,Small Molecule,approved,P28074,PSB5_HUMAN,PSMB5,Proteasome subunit beta type-5 OS=Homo sapiens GN=PSMB5 PE=1 SV=3,Enzymes,EC:3.4.25.1,Established target
2142,Velcade,bortezomib,antineoplastic agent,Small Molecule,approved,Q99460,PSMD1_HUMAN,PSMD1,26S proteasome non-ATPase regulatory subunit 1 (26S proteasome regulatory subunit RPN2) (26S proteasome regulatory subunit S1) (26S proteasome subunit p112),Miscellaneous,Enzyme regulator,Established target
2142,Velcade,bortezomib,antineoplastic agent,Small Molecule,approved,Q13200,PSMD2_HUMAN,PSMD2,26S proteasome non-ATPase regulatory subunit 2 OS=Homo sapiens GN=PSMD2 PE=1 SV=3,Miscellaneous,Enzyme regulator,Established target
2143,Wellbutrin,bupropion,"antidepressant,appetite suppressant,smoking-cessation agent",Small Molecule,approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
2143,Wellbutrin,bupropion,"antidepressant,appetite suppressant,smoking-cessation agent",Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
2144,"velneperit, S-2367",velneperit,antiobesity agent,small molecule,not approved,Q15761,NPY5R_HUMAN,NPY5R,Neuropeptide Y receptor type 5 (NPY5-R) (NPY-Y5 receptor) (NPYY5-R) (Y5 receptor),Receptors,GPCR;Rhodopsin,Novel Target
2145,"velusetrag, TD-5108",velusetrag,motilitant,small molecule,not approved,Q13639,5HT4R_HUMAN,HTR4,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2146,Veramyst,fluticasone furoate,"antiinflammatory agent,glucocorticoid",Small molecule,approved,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
2147,"Verapamil,Calan, Covera-HS",verapamil,antihypertensive agent,Small Molecule,approved,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
2147,"Verapamil,Calan, Covera-HS",verapamil,antihypertensive agent,Small Molecule,approved,Q01668,CAC1D_HUMAN,CACNA1D,Voltage-dependent L-type calcium channel subunit alpha-1D OS=Homo sapiens GN=CACNA1D PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
2147,"Verapamil,Calan, Covera-HS",verapamil,antihypertensive agent,Small Molecule,approved,O60840,CAC1F_HUMAN,CACNA1F,Voltage-dependent L-type calcium channel subunit alpha-1F OS=Homo sapiens GN=CACNA1F PE=1 SV=2,Transporters,TC:1.A.1.11.11,Established target
2147,"Verapamil,Calan, Covera-HS",verapamil,antihypertensive agent,Small Molecule,approved,Q13698,CAC1S_HUMAN,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4,Transporters,TC:1.A.1.11,Established target
2147,"Verapamil,Calan, Covera-HS",verapamil,antihypertensive agent,Small Molecule,approved,Q02641,CACB1_HUMAN,CACNB1,Voltage-dependent L-type calcium channel subunit beta-1 OS=Homo sapiens GN=CACNB1 PE=1 SV=3,Transporters,TC:8.A.22.1.1,Established target
2147,"Verapamil,Calan, Covera-HS",verapamil,antihypertensive agent,Small Molecule,approved,Q08289,CACB2_HUMAN,CACNB2,Voltage-dependent L-type calcium channel subunit beta-2 OS=Homo sapiens GN=CACNB2 PE=1 SV=3,Transporters,TC:8.A.22.1.2,Established target
2147,"Verapamil,Calan, Covera-HS",verapamil,antihypertensive agent,Small Molecule,approved,P54284,CACB3_HUMAN,CACNB3,Voltage-dependent L-type calcium channel subunit beta-3 OS=Homo sapiens GN=CACNB3 PE=1 SV=1,Transporters,TC:8.A.22.1.3,Established target
2147,"Verapamil,Calan, Covera-HS",verapamil,antihypertensive agent,Small Molecule,approved,O00305,CAC1I_HUMAN,CACNB4,Voltage-dependent T-type calcium channel subunit alpha-1I OS=Homo sapiens GN=CACNA1I PE=1 SV=1,Transporters,TC:8.A.22.1.4,Established target
2148,"vestipitant, GW 597599",vestipitant,"for treatment of tinnitus,hypnotic",small molecule,not approved,P25103,NK1R_HUMAN,TACR1,Substance-P receptor OS=Homo sapiens GN=TACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2149,VGX-1027,VGX-1027,"antiinflammatory agent,DMARD",small molecule,not approved,unknown,unknown,unknown,unknown,unknown,unknown,unknown
2150,VI-0134,VI-0134,for prevention of premature ejaculation,unknown,not approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
2150,VI-0134,VI-0134,for prevention of premature ejaculation,unknown,not approved,O95264,5HT3B_HUMAN,HTR3B,5-hydroxytryptamine receptor 3B (5-HT3-B) (5-HT3B) (Serotonin receptor 3B),Receptors,TC:1.A.9,Established target
2150,VI-0134,VI-0134,for prevention of premature ejaculation,unknown,not approved,Q8WXA8,5HT3C_HUMAN,HTR3C,5-hydroxytryptamine receptor 3C (5-HT3-C) (5-HT3C) (Serotonin receptor 3C),Receptors,TC:1.A.9,Established target
2150,VI-0134,VI-0134,for prevention of premature ejaculation,unknown,not approved,Q70Z44,5HT3D_HUMAN,HTR3D,5-hydroxytryptamine receptor 3D (5-HT3-D) (5-HT3D) (Serotonin receptor 3D),Receptors,TC:1.A.9,Established target
2150,VI-0134,VI-0134,for prevention of premature ejaculation,unknown,not approved,A5X5Y0,5HT3E_HUMAN,HTR3E,5-hydroxytryptamine receptor 3E (5-HT3-E) (5-HT3E) (Serotonin receptor 3E),Receptors,TC:1.A.9,Established target
2151,VIA-2291,VIA-2291,antiatherosclerotic agent,small molecule,not approved,P09917,LOX5_HUMAN,ALOX5,Arachidonate 5-lipoxygenase OS=Homo sapiens GN=ALOX5 PE=1 SV=2,Enzymes,EC:1.13.11.34,Established target
2152,VIA-3196,VIA-3196,antidyslipidaemic agent,small molecule,not approved,P10828,THB_HUMAN,THRB,Thyroid hormone receptor beta OS=Homo sapiens GN=THRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
2153,ViaDerm hPTH 1-34,h-PTH 1-34,antiosteoporotic agent,peptide,approved,Q03431,PTH1R_HUMAN,PTH1R,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2153,ViaDerm hPTH 1-34,h-PTH 1-34,antiosteoporotic agent,peptide,not approved,P49190,PTH2R_HUMAN,PTH2R,Parathyroid hormone 2 receptor (PTH2 receptor),Receptors,GPCR;Secretin,Established target
2154,ViaDerm-Calcitonin,Calcitonin,antiosteoporotic agent,Small molecule,approved,P30988,CALCR_HUMAN,CALCR,Calcitonin receptor OS=Homo sapiens GN=CALCR PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2155,ViaDerm-GLP1 agonist,GLP1 agonist ,antidiabetic,unknown,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2156,VIBEX MTX,methotrexate,DMARD,Small molecule,approved,P00374,DYR_HUMAN,DHFR,Dihydrofolate reductase OS=Homo sapiens GN=DHFR PE=1 SV=2,Enzymes,EC:1.5.1.3,Established target
2157,Vicriviroc,vicriviroc,"antiviral agent,HIV",small molecule,not approved,P51681,CCR5_HUMAN,CCR5,C-C chemokine receptor type 5 OS=Homo sapiens GN=CCR5 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2158,"vidofludimus, 4SC101, SC12267",vidofludimus,"antiinflammatory agent,DMARD",small molecule,not approved,Q02127,PYRD_HUMAN,DHODH,"Dihydroorotate dehydrogenase, mitochondrial OS=Homo sapiens GN=DHODH PE=1 SV=3",Enzymes,EC:1.3.3,Established target
2158,"vidofludimus, 4SC101, SC12267",vidofludimus,"antiinflammatory agent,DMARD",small molecule,not approved,Q16552,IL17_HUMAN,IL17A,Interleukin-17A (IL-17) (IL-17A) (Cytotoxic T-lymphocyte-associated antigen 8) (CTLA-8),Miscellaneous,Ligand;Cytokine,Novel Target
2158,"vidofludimus, 4SC101, SC12267",vidofludimus,"antiinflammatory agent,DMARD",small molecule,not approved,Q9UHF5,IL17B_HUMAN,IL17B,Interleukin-17B (IL-17B) (Cytokine Zcyto7) (Interleukin-20) (IL-20) (Neuronal interleukin-17-related factor),Miscellaneous,Ligand;Cytokine,Novel Target
2158,"vidofludimus, 4SC101, SC12267",vidofludimus,"antiinflammatory agent,DMARD",small molecule,not approved,Q9P0M4,IL17C_HUMAN,IL17C,Interleukin-17C (IL-17C) (Cytokine CX2),Miscellaneous,Ligand;Cytokine,Novel Target
2158,"vidofludimus, 4SC101, SC12267",vidofludimus,"antiinflammatory agent,DMARD",small molecule,not approved,Q9P0M4,IL17C_HUMAN,IL17D,Interleukin-17C (IL-17C) (Cytokine CX2),Miscellaneous,Ligand;Cytokine,Novel Target
2158,"vidofludimus, 4SC101, SC12267",vidofludimus,"antiinflammatory agent,DMARD",small molecule,not approved,Q9H293,IL25_HUMAN,IL17E,Interleukin-25 (IL-25) (Interleukin-17E) (IL-17E),Miscellaneous,Ligand;Cytokine,Novel Target
2159,"Vigabatrin is a selective, irreversible enzyme-activated GABA transaminase inhibitor. GABA (gamma-aminobutyric acid) is a n/",Vigabatrin,for treatment of addiction,Small Molecule,approved,P80404,GABT_HUMAN,ABAT,"4-aminobutyrate aminotransferase, mitochondrial OS=Homo sapiens GN=ABAT PE=1 SV=3",Enzymes,EC:2.6.1.19; 2.6.1.22,Established target
2159,"Vigabatrin is a selective, irreversible enzyme-activated GABA transaminase inhibitor. GABA (gamma-aminobutyric acid) is a n/",Vigabatrin,for treatment of addiction,Small Molecule,approved,Q9UBS5,GABR1_HUMAN,GABBR1,Gamma-aminobutyric acid type B receptor subunit 1 OS=Homo sapiens GN=GABBR1 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
2160,"vilazodone hydrochloride, SB 659746A",vilazodone ,antidepressant,small molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2161,"vildagliptin, LAF 237,Galvus, Equa",vildagliptin,antidiabetic,small molecule,approved,P27487,DPP4_HUMAN,DPP4,Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2,Enzymes,EC:3.4.14.5,Established target
2162,"vincristine sulfate liposomes injection, Onco TCS,Marqibo",vincristine,antineoplastic agent,Small Molecule,approved,P68366,TBA4A_HUMAN,TUBA4A,Tubulin alpha-4A chain (Alpha-tubulin 1) (Testis-specific alpha-tubulin) (Tubulin H2-alpha) (Tubulin alpha-1 chain),Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
2162,"vincristine sulfate liposomes injection, Onco TCS,Marqibo",vincristine,antineoplastic agent,Small Molecule,approved,P07437,TBB5_HUMAN,TUBB,Tubulin beta chain (Tubulin beta-5 chain),Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
2163,"vinorelbine,Navelbine",vinorelbine,antineoplastic agent,Small Molecule,approved,P07437,TBB5_HUMAN,TUBB,Tubulin beta chain (Tubulin beta-5 chain),Miscellaneous,StructuralAndAdhesion;Cytoskeleton,Established target
2164,Vipadenantis,BIIB014,antiparkinson agent,Small molecule,not approved,P29274,AA2AR_HUMAN,ADORA2A,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2165,virosome-based breast cancer vaccine ,virosome-based breast cancer vaccine ,antineoplastic agent,vaccine,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2166,Virulizin,Virulizin,antineoplastic agent,small molecule,not approved,P29459,IL12A_HUMAN,IL12A,Interleukin-12 subunit alpha (IL-12A) (IL-12 subunit p35) (Cytotoxic lymphocyte maturation factor 35 kDa subunit) (CLMF p35) (NK cell stimulatory factor chain 1) (NKSF1),Miscellaneous,Ligand;Cytokine,Established target
2166,Virulizin,Virulizin,antineoplastic agent,small molecule,not approved,P29460,IL12B_HUMAN,IL12B,Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2),Receptors,Receptor; Type 1 cytokine receptor,Established target
2167,"VIT-100,VitrenASE, ChelASE",VIT-100,for treatment of proliferative vitreoretinopathy,ribozyme,not approved,P12004,PCNA_HUMAN,PCNA,Proliferating cell nuclear antigen (PCNA) (Cyclin),Miscellaneous,Enzyme regulator,Novel Target
2168,Vivitrol,naltrexone,for treatment of substance abuse,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2168,Vivitrol,naltrexone,for treatment of substance abuse,Small Molecule,approved,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2168,Vivitrol,naltrexone,for treatment of substance abuse,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2169,Voclosporin,Voclosporin,"antiinflammatory agent,DMARD,immunosuppressant",small molecule,not approved,Q3KQW3,Q3KQW3_HUMAN,PPIA,Merged into P62937.,Enzymes,EC:5.2.1.8,Established target
2169,Voclosporin,Voclosporin,"antiinflammatory agent,DMARD,immunosuppressant",small molecule,not approved,Q08209,PP2BA_HUMAN,PPP3CA,Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform,Enzymes,EC:3.1.3.16,Established target
2169,Voclosporin,Voclosporin,"antiinflammatory agent,DMARD,immunosuppressant",small molecule,not approved,P16298,PP2BB_HUMAN,PPP3CB,Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform,Enzymes,EC:3.1.3.16,Established target
2169,Voclosporin,Voclosporin,"antiinflammatory agent,DMARD,immunosuppressant",small molecule,not approved,P48454,PP2BC_HUMAN,PPP3CC,Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform,Enzymes,EC:3.1.3.16,Established target
2170,"vofopitant, GR-205171",vofopitant,"for treatment of post-traumatic stress disorder,hypnotic",small molecule,not approved,P25103,NK1R_HUMAN,TACR1,Substance-P receptor OS=Homo sapiens GN=TACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2171,"voglibose,Basen",voglibose,antidiabetic,Small Molecule,approved,O43451,MGA_HUMAN,MGAM,"Maltase-glucoamylase, intestinal OS=Homo sapiens GN=MGAM PE=1 SV=5",Enzymes,EC:3.2.1,Established target
2172,volinanserin,volinanserin,hypnotic,small molecule,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2173,"volociximab, E10030, Eos200-4",volociximab,antineoplastic agent,monoclonal antibody,not approved,P06756,ITAV_HUMAN,ITGAV,Integrin alpha-V (Vitronectin receptor subunit alpha) (CD antigen CD51) [Cleaved into: Integrin alpha-V heavy chain; Integrin alpha-V light chain],Receptors,Receptors;Integrin,Established target
2173,"volociximab, E10030, Eos200-4",volociximab,antineoplastic agent,monoclonal antibody,not approved,P05556,ITB1_HUMAN,ITGB1,Integrin beta-1 (Fibronectin receptor subunit beta) (VLA-4 subunit beta) (CD antigen CD29),Receptors,Receptors;Integrin,Established target
2174,von Willebrand Factor/Coagulation Factor V/,von Willebrand Factor (VWF)/Coagulation Factor VIII Complex,for treatment of bleeding in von Willebrand disease patients,protein,not approved,P00451,FA8_HUMAN,F8,Coagulation factor VIII OS=Homo sapiens GN=F8 PE=1 SV=1,Miscellaneous,Enzyme cofactor,Established target
2175,"vorapaxar , SCH-530348",vorapaxar,cardiovascular agent,small molecule,not approved,P25116,PAR1_HUMAN,F2R,Proteinase-activated receptor 1 (PAR-1) (Coagulation factor II receptor) (Thrombin receptor),Receptors,GPCR;Rhodopsin,Novel Target
2175,"vorapaxar , SCH-530348",vorapaxar,cardiovascular agent,small molecule,not approved,O00254,PAR3_HUMAN,F2RL2,Proteinase-activated receptor 3 (PAR-3) (Coagulation factor II receptor-like 2) (Thrombin receptor-like 2),Receptors,GPCR;Rhodopsin,Novel Target
2175,"vorapaxar , SCH-530348",vorapaxar,cardiovascular agent,small molecule,not approved,Q96RI0,PAR4_HUMAN,F2RL3,Proteinase-activated receptor 4 (PAR-4) (Coagulation factor II receptor-like 3) (Thrombin receptor-like 3),Receptors,GPCR;Rhodopsin,Novel Target
2176,Voreloxin,Voreloxin,antineoplastic agent,small molecule,not approved,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
2176,Voreloxin,Voreloxin,antineoplastic agent,small molecule,not approved,Q02880,TOP2B_HUMAN,TOP2B,"DNA topoisomerase 2-beta (EC 5.99.1.3) (DNA topoisomerase II, beta isozyme)",Enzymes,EC:5.99.1.3,Established target
2177,"VP 002, histrelin implant,Vantas, Supprelin",Histrelin,antineoplastic agent,Small molecule,approved,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2177,"VP 002, histrelin implant,Vantas, Supprelin",Histrelin,antineoplastic agent,Small molecule,approved,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
2178,VR1 antagonist,TRPV1 antagonist,analgesic,small molecule,not approved,Q8NER1,TRPV1_HUMAN,TRPV1,Transient receptor potential cation channel subfamily V member 1 (TrpV1) (Capsaicin receptor) (Osm-9-like TRP channel 1) (OTRPC1) (Vanilloid receptor 1),Transporters,TC:1.A.4,Established target
2179,VR-147,VR-147,antimigraine agent,small molecule,not approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2179,VR-147,VR-147,antimigraine agent,small molecule,not approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2180,VR496,heparin,for treatment of cystic fibrosis,Small Molecule,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
2180,VR496,heparin,for treatment of cystic fibrosis,Small Molecule,not approved,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Miscellaneous,Enzyme regulator,Established target
2181,VRS-317,recombinant human growth hormone,hormone replacement,recombinant protein,not approved,P10912,GHR_HUMAN,GHR,Growth hormone receptor OS=Homo sapiens GN=GHR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
2182,VRS-859,VRS-859,antidiabetic,peptide,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2183,VT-122,etodolac,for treatment of cancer cachexia,Small Molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
2183,VT-122,etodolac,NSAID,Small Molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
2183,VT-122,propranolol,for treatment of cancer cachexia,Small Molecule,approved,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2184,VTP-27999,VTP-27999,antihypertensive agent,small molecule,not approved,P00797,RENI_HUMAN,REN,Renin OS=Homo sapiens GN=REN PE=1 SV=1,Enzymes,EC:3.4.23.15,Established target
2185,VTX-1463,VTX-1463,antiallergy agent,small molecule,not approved,Q9NR97,TLR8_HUMAN,TLR8,Toll-like receptor 8 (CD antigen CD288),Receptors,Receptors;TOLL,Novel Target
2186,VTX-2337,VTX-2337,antineoplastic agent,small molecule,not approved,Q9NR97,TLR8_HUMAN,TLR8,Toll-like receptor 8 (CD antigen CD288),Receptors,Receptors;TOLL,Novel Target
2187,VX15/2503 vaccine,VX15/2503 vaccine,antineoplastic agent,monoclonal antibody,not approved,Q92854,SEM4D_HUMAN,SEMA4D,Semaphorin-4D (A8) (BB18) (GR3) (CD antigen CD100),Miscellaneous,Ligand;Semaphorins,Novel Target
2188,VX-509,VX-509,"antiinflammatory agent,DMARD",small molecule,not approved,P52333,JAK3_HUMAN,JAK3,Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK),Enzymes,EC:2.7.10.2,Novel Target
2189,WX-554,WX-554,antineoplastic agent,small molecule,not approved,Q02750,MP2K1_HUMAN,MAP2K1,Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1),Enzymes,EC:2.7.12.2,Novel Target
2189,WX-554,WX-554,antineoplastic agent,small molecule,not approved,P36507,MP2K2_HUMAN,MAP2K2,Dual specificity mitogen-activated protein kinase kinase 2 (MAP kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2) (MAPK/ERK kinase 2) (MEK 2),Enzymes,EC:2.7.12.2,Novel Target
2189,WX-554,WX-554,antineoplastic agent,small molecule,not approved,P46734,MP2K3_HUMAN,MAP2K3,Dual specificity mitogen-activated protein kinase kinase 3 (MAP kinase kinase 3) (MAPKK 3) (EC 2.7.12.2) (MAPK/ERK kinase 3) (MEK 3),Enzymes,EC:2.7.12.2,Novel Target
2189,WX-554,WX-554,antineoplastic agent,small molecule,not approved,P45985,MP2K4_HUMAN,MAP2K4,Dual specificity mitogen-activated protein kinase kinase 4 (MAP kinase kinase 4) (MAPKK 4) (EC 2.7.12.2) (JNK-activating kinase 1) (MAPK/ERK kinase 4) (MEK 4) (SAPK/ERK kinase 1) (SEK1) (c-Jun N-terminal kinase kinase 1) (JNKK),Enzymes,EC:2.7.12.2,Novel Target
2189,WX-554,WX-554,antineoplastic agent,small molecule,not approved,Q13163,MP2K5_HUMAN,MAP2K5,Dual specificity mitogen-activated protein kinase kinase 5 (MAP kinase kinase 5) (MAPKK 5) (EC 2.7.12.2) (MAPK/ERK kinase 5) (MEK 5),Enzymes,EC:2.7.12.2,Novel Target
2189,WX-554,WX-554,antineoplastic agent,small molecule,not approved,P52564,MP2K6_HUMAN,MAP2K6,Dual specificity mitogen-activated protein kinase kinase 6 (MAP kinase kinase 6) (MAPKK 6) (EC 2.7.12.2) (MAPK/ERK kinase 6) (MEK 6) (SAPKK3),Enzymes,EC:2.7.12.2,Novel Target
2189,WX-554,WX-554,antineoplastic agent,small molecule,not approved,O14733,MP2K7_HUMAN,MAP2K7,Dual specificity mitogen-activated protein kinase kinase 7 (MAP kinase kinase 7) (MAPKK 7) (EC 2.7.12.2) (JNK-activating kinase 2) (MAPK/ERK kinase 7) (MEK 7) (c-Jun N-terminal kinase kinase 2) (JNK kinase 2) (JNKK 2),Enzymes,EC:2.7.12.2,Novel Target
2190,"VX-680, MK-0457",tozasertib,antineoplastic agent,small molecule,not approved,O14965,STK6_HUMAN,AURKA,Serine/threonine-protein kinase 6 (EC 2.7.11.1) (Aurora kinase A) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase aurora-A),Enzymes,EC:2.7.11.1,Novel Target
2190,"VX-680, MK-0457",tozasertib,antineoplastic agent,small molecule,not approved,Q96GD4,AURKB_HUMAN,AURKB,Serine/threonine-protein kinase 12 (EC 2.7.11.1) (Aurora kinase B) (Aurora- and IPL1-like midbody-associated protein 1) (AIM-1) (Aurora/IPL1-related kinase 2) (ARK-2) (Aurora-related kinase 2) (STK-1) (Serine/threonine-protein kinase aurora-B),Enzymes,EC:2.7.11.1,Novel Target
2190,"VX-680, MK-0457",tozasertib,antineoplastic agent,small molecule,not approved,Q9UQB9,AURKC_HUMAN,AURKC,Serine/threonine-protein kinase 13 (EC 2.7.11.1) (Aurora kinase C) (Aurora/IPL1-related kinase 3) (ARK-3) (Aurora-related kinase 3) (Aurora/IPL1/Eg2 protein 2) (Serine/threonine-protein kinase aurora-C),Enzymes,EC:2.7.11.1,Novel Target
2191,VX-702,VX-702,"antiinflammatory agent,cardiovascular agent",small molecule,not approved,Q15759,MK11_HUMAN,MAPK11,Mitogen-activated protein kinase 11 (MAP kinase 11) (MAPK 11) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 beta) (MAP kinase p38 beta) (p38b) (Stress-activated protein kinase 2) (p38-2),Enzymes,EC:2.7.11.24,Novel Target
2191,VX-702,VX-702,"antiinflammatory agent,cardiovascular agent",small molecule,not approved,P53778,MK12_HUMAN,MAPK12,Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3),Enzymes,EC:2.7.11.24,Novel Target
2191,VX-702,VX-702,"antiinflammatory agent,cardiovascular agent",small molecule,not approved,O15264,MK13_HUMAN,MAPK13,Mitogen-activated protein kinase 13 (MAP kinase 13) (MAPK 13) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 delta) (MAP kinase p38 delta) (Stress-activated protein kinase 4),Enzymes,EC:2.7.11.24,Novel Target
2191,VX-702,VX-702,"antiinflammatory agent,cardiovascular agent",small molecule,not approved,Q16539,MK14_HUMAN,MAPK14,Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a,Enzymes,EC:2.7.11.24,Novel Target
2192,VX-765,VX-765,"antipsoriatic agent,anticonvulsant",small molecule,not approved,P29466,CASP1_HUMAN,CASP1,Caspase-1,Enzymes,EC:3.4.22.36,Novel Target
2193,VX-770,ivacaftor,for treatment of cystic fibrosis,Small molecule,approved,P13569,CFTR_HUMAN,CFTR,Cystic fibrosis transmembrane conductance regulator (CFTR) (ATP-binding cassette sub-family C member 7) (Channel conductance-controlling ATPase) (EC 3.6.3.49) (cAMP-dependent chloride channel),Transporters,TC:3.A.1.202.1,Established target
2194,VX-809,VX-809,for treatment of cystic fibrosis,small molecule,not approved,P13569,CFTR_HUMAN,CFTR,Cystic fibrosis transmembrane conductance regulator (CFTR) (ATP-binding cassette sub-family C member 7) (Channel conductance-controlling ATPase) (EC 3.6.3.49) (cAMP-dependent chloride channel),Transporters,TC:3.A.1.202.1,Established target
2195,VX-809 + VX-770,ivacaftor,for treatment of cystic fibrosis,Small molecule,approved,P13569,CFTR_HUMAN,CFTR,Cystic fibrosis transmembrane conductance regulator (CFTR) (ATP-binding cassette sub-family C member 7) (Channel conductance-controlling ATPase) (EC 3.6.3.49) (cAMP-dependent chloride channel),Transporters,TC:3.A.1.202.1,Established target
2195,VX-809 + VX-770,VX-809,for treatment of cystic fibrosis,small molecule,not approved,P13569,CFTR_HUMAN,CFTR,Cystic fibrosis transmembrane conductance regulator (CFTR) (ATP-binding cassette sub-family C member 7) (Channel conductance-controlling ATPase) (EC 3.6.3.49) (cAMP-dependent chloride channel),Transporters,TC:3.A.1.202.1,Established target
2196,"WX-G250,Rencarex",WX-G250,antineoplastic agent,monoclonal antibody,not approved,P06028,GLPB_HUMAN,GPYB,Glycophorin-B (PAS-3) (SS-active sialoglycoprotein) (Sialoglycoprotein delta) (CD antigen CD235b),Miscellaneous,Miscellaneous;Glycoprotein,Novel Target
2196,"WX-G250,Rencarex",WX-G250,antineoplastic agent,monoclonal antibody,not approved,P02724,GLPA_HUMAN,GYPA,Glycophorin-A (MN sialoglycoprotein) (PAS-2) (Sialoglycoprotein alpha) (CD antigen CD235a),Miscellaneous,Miscellaneous; membrane protein,Novel Target
2197,WX-UK1,WX-UK1,antineoplastic agent,small molecule,not approved,P00749,UROK_HUMAN,PLAU,Urokinase-type plasminogen activator (U-plasminogen activator) (uPA) (EC 3.4.21.73) [Cleaved into: Urokinase-type plasminogen activator long chain A; Urokinase-type plasminogen activator short chain A; Urokinase-type plasminogen activator chain B],Enzymes,EC:3.4.21.73,Established target
2198,Vytorin,emzetibe,antidyslipidaemic agent,Small molecule,approved,Q9UHC9,NPCL1_HUMAN,NPC1L1,Niemann-Pick C1-like protein 1 OS=Homo sapiens GN=NPC1L1 PE=2 SV=1,Receptors,Miscellaneous;Patched,Established target
2198,Vytorin,emzetibe,antidyslipidaemic agent,Small molecule,approved,P35610,SOAT1_HUMAN,SOAT1,Sterol O-acyltransferase 1 (EC 2.3.1.26) (Acyl-coenzyme A:cholesterol acyltransferase 1) (ACAT-1) (Cholesterol acyltransferase 1),Enzymes,EC:2.3.1.26,Established target
2198,Vytorin,simvastatin,antidyslipidaemic agent,Small Molecule,approved,P04035,HMDH_HUMAN,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase OS=Homo sapiens GN=HMGCR PE=1 SV=1,Enzymes,EC:1.1.1.34,Established target
2199,Vyvanse,NRP104,for treatment of ADHD,small molecule,not approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor (Alpha-1B adrenoreceptor) (Alpha-1B adrenoceptor),Receptors,GPCR;Rhodopsin,Established target
2199,Vyvanse,NRP104,for treatment of ADHD,small molecule,not approved,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
2199,Vyvanse,NRP104,for treatment of ADHD,small molecule,not approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
2200,"xaliproden, SR 57746A",xaliproden,neuroprotectant,small molecule,not approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2201,Xen2174,Xen2174,analgesic,peptide,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
2202,XEN402,XEN402,analgesic,unknown,not approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
2203,Xeomin,botulinum toxin type A,"neuromuscular blocking agent,for treatment of wrinkles,antispasmodic",protein,approved,P60880,SNP25_HUMAN,SNAP25,Synaptosomal-associated protein 25 OS=Homo sapiens GN=SNAP25 PE=1 SV=1,Miscellaneous,SNAP25 family,Established target
2204,XL019,XL019,antineoplastic agent,small molecule,not approved,O60674,JAK2_HUMAN,JAK2,Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2),Enzymes,EC:2.7.10.2,Novel Target
2205,XL184,cabozantinib,antineoplastic agent,Small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2205,XL184,cabozantinib,antineoplastic agent,Small molecule,not approved,P08581,MET_HUMAN,MET,Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met),Receptors,EC:2.7.10.1,Established target
2206,XL228,XL228,antineoplastic agent,small molecule,not approved,P00519,ABL1_HUMAN,ABL1,Proto-oncogene tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4,Enzymes,EC:2.7.10.2,Established target
2206,XL228,XL228,antineoplastic agent,small molecule,not approved,O14965,STK6_HUMAN,AURKA,Serine/threonine-protein kinase 6 (EC 2.7.11.1) (Aurora kinase A) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase aurora-A),Enzymes,EC:2.7.11.1,Novel Target
2206,XL228,XL228,antineoplastic agent,small molecule,not approved,P08069,IGF1R_HUMAN,IGF1R,Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2206,XL228,XL228,antineoplastic agent,small molecule,not approved,P12931,SRC_HUMAN,SRC,Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3,Enzymes,EC:2.7.10.2,Established target
2207,XL281,XL281,antineoplastic agent,small molecule,not approved,P10398,ARAF_HUMAN,ARAF,Serine/threonine-protein kinase A-Raf,Enzymes,EC:2.7.11.1,Novel Target
2207,XL281,XL281,antineoplastic agent,small molecule,not approved,P15056,BRAF1_HUMAN,BRAF,B-Raf proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=BRAF PE=1 SV=4,Enzymes,EC:2.7.11.1,Established target
2207,XL281,XL281,antineoplastic agent,small molecule,not approved,P04049,RAF1_HUMAN,RAF1,RAF proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=RAF1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
2208,XL418,XL418,antineoplastic agent,small molecule,not approved,P31749,AKT1_HUMAN,AKT1,RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Proto-oncogene c-Akt) (RAC-PK-alpha),Enzymes,EC:2.7.11.1,Novel Target
2208,XL418,XL418,antineoplastic agent,small molecule,not approved,P31751,AKT2_HUMAN,AKT2,RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta),Enzymes,EC:2.7.11.1,Novel Target
2208,XL418,XL418,antineoplastic agent,small molecule,not approved,Q9Y243,AKT3_HUMAN,AKT3,RAC-gamma serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-3) (Protein kinase B gamma) (PKB gamma) (RAC-PK-gamma) (STK-2),Enzymes,EC:2.7.11.1,Novel Target
2208,XL418,XL418,antineoplastic agent,small molecule,not approved,P23443,KS6B1_HUMAN,RPS6KB1,Ribosomal protein S6 kinase beta-1 (S6K-beta-1) (S6K1) (EC 2.7.11.1) (70 kDa ribosomal protein S6 kinase 1) (P70S6K1) (p70-S6K 1) (Ribosomal protein S6 kinase I) (Serine/threonine-protein kinase 14A) (p70 ribosomal S6 kinase alpha) (p70 S6 kinase alpha) (,Enzymes,EC:2.7.11.1,Novel Target
2209,XL647,XL647,antineoplastic agent,small molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2209,XL647,XL647,antineoplastic agent,small molecule,not approved,P54760,EPHB4_HUMAN,EPHB4,Ephrin type-B receptor 4 (EC 2.7.10.1) (Tyrosine-protein kinase TYRO11) (Tyrosine-protein kinase receptor HTK),Receptors,EC:2.7.10.1,Novel Target
2209,XL647,XL647,antineoplastic agent,small molecule,not approved,P04626,ERBB2_HUMAN,ERBB2,Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2209,XL647,XL647,antineoplastic agent,small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2209,XL647,XL647,antineoplastic agent,small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2209,XL647,XL647,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2210,XL765,XL765,antineoplastic agent,small molecule,not approved,P42345,FRAP_HUMAN,MTOR,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.11.1,Established target
2210,XL765,XL765,antineoplastic agent,small molecule,not approved,P42336,FRAP_HUMAN,PIK3CA,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.1.153,Novel Target
2210,XL765,XL765,antineoplastic agent,small molecule,not approved,O00329,PK3CD_HUMAN,PIK3CD,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3-kinase subunit delta) (PI3K-delta) (PtdIns-3-kinase subunit delta) (EC 2.7.1.153) (Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta) (PtdIns-",Enzymes,EC:2.7.1.153,Novel Target
2210,XL765,XL765,antineoplastic agent,small molecule,not approved,P48736,FRAP_HUMAN,PIK3CG,FKBP12-rapamycin complex-associated protein OS=Homo sapiens GN=FRAP1 PE=1 SV=1,Enzymes,EC:2.7.1.153,Novel Target
2211,XL820,XL820,antineoplastic agent,small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2211,XL820,XL820,antineoplastic agent,small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2211,XL820,XL820,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2211,XL820,XL820,antineoplastic agent,small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2211,XL820,XL820,antineoplastic agent,small molecule,not approved,P16234,PGFRA_HUMAN,PDGFRA,Alpha-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRA PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2211,XL820,XL820,antineoplastic agent,small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2212,XL844,XL844,antineoplastic agent,small molecule,not approved,O14757,CHK1_HUMAN,CHEK1,Serine/threonine-protein kinase Chk1 (EC 2.7.11.1),Enzymes,EC:2.7.11.1,Novel Target
2212,XL844,XL844,antineoplastic agent,small molecule,not approved,O96017,CHK2_HUMAN,CHEK2,Serine/threonine-protein kinase Chk2 (EC 2.7.11.1) (Cds1),Enzymes,EC:2.7.11.1,Novel Target
2213,XL880,XL880,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2213,XL880,XL880,antineoplastic agent,small molecule,not approved,P08581,MET_HUMAN,MET,Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met),Receptors,EC:2.7.10.1,Established target
2214,XL888,XL888,antineoplastic agent,small molecule,not approved,P07900,HS90A_HUMAN,HSP90AA1,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Renal carcinoma antigen NY-REN-38),Miscellaneous,HSP90-like_chaperon,Novel Target
2214,XL888,XL888,antineoplastic agent,small molecule,not approved,P08238,HS90B_HUMAN,HSP90AB1,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),Miscellaneous,HSP90-like_chaperon,Novel Target
2215,XL999,XL999,antineoplastic agent,small molecule,not approved,P30530,UFO_HUMAN,AXL,Tyrosine-protein kinase receptor UFO,Receptors,EC:2.7.10.1,Novel Target
2215,XL999,XL999,antineoplastic agent,small molecule,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
2215,XL999,XL999,antineoplastic agent,small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2215,XL999,XL999,antineoplastic agent,small molecule,not approved,P36888,FLT3_HUMAN,FLT3,FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2215,XL999,XL999,antineoplastic agent,small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2215,XL999,XL999,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2215,XL999,XL999,antineoplastic agent,small molecule,not approved,P10721,KIT_HUMAN,KIT,Mast/stem cell growth factor receptor OS=Homo sapiens GN=KIT PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2215,XL999,XL999,antineoplastic agent,small molecule,not approved,P09619,PGFRB_HUMAN,PDGFRB,Beta-type platelet-derived growth factor receptor OS=Homo sapiens GN=PDGFRB PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
2216,XMT-1001,camptothecin,antineoplastic agent,Small molecule,approved,P11387,TOP1_HUMAN,TOP1,DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2,Enzymes,EC:5.99.1.2,Established target
2217,XMT-1107,XMT-1107,antineoplastic agent,small molecule,not approved,P50579,AMPM2_HUMAN,METAP2,Methionine aminopeptidase 2 (MAP 2) (MetAP 2) (EC 3.4.11.18) (Initiation factor 2-associated 67 kDa glycoprotein) (Peptidase M 2) (p67eIF2) (p67),Enzymes,EC:3.4.11.18,Novel Target
2218,Xolair,omalizumab,antiasthmatic agent,monoclonal antibody,approved,P12319,FCERA_HUMAN,FCER1A,High affinity immunoglobulin epsilon receptor subunit alpha OS=Homo sapiens GN=FCER1A PE=1 SV=1,Receptors,Receptor;immunoglobulin,Established target
2218,Xolair,omalizumab,antiasthmatic agent,monoclonal antibody,approved,Q01362,FCERB_HUMAN,MS4A2,High affinity immunoglobulin epsilon receptor subunit beta (FcERI) (Fc epsilon receptor I beta-chain) (IgE Fc receptor subunit beta) (Membrane-spanning 4-domains subfamily A member 2),Miscellaneous,MS4A family,Established target
2219,XOMA,gevokizumab,antidiabetic,monoclonal antibody,not approved,P01584,IL1B_HUMAN,IL1B,Interleukin-1 beta (IL-1 beta) (Catabolin),Miscellaneous,Ligand;Cytokine,Established target
2220,"XP12B, tranexamic acid MR",tranexamic acid ,for treatment of menorrhagia,small molecule,approved,P00747,PLMN_HUMAN,PLG,Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2,Enzymes,StructuralAndAdhesion;Fibrinogen,Established target
2221,XP13512,XP13512,for treatment of restless legs syndrome,small molecule,not approved,Q00975,CAC1B_HUMAN,CACNA1B,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:1.A.1.11,Established target
2221,XP13512,XP13512,for treatment of restless legs syndrome,small molecule,not approved,P54289,CAC1B_HUMAN,CACNA2D1,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:8.A.18.1.1,Established target
2221,XP13512,XP13512,for treatment of restless legs syndrome,small molecule,not approved,Q9NY47,CA2D2_HUMAN,CACNA2D2,Voltage-dependent calcium channel subunit alpha-2/delta-2 OS=Homo sapiens GN=CACNA2D2 PE=1 SV=1,Transporters,TC:8.A.18.2.1,Established target
2222,XP19986,R-baclofen,for treatment of gastrointestinal reflux disease,small molecule,approved,Q9UBS5,GABR1_HUMAN,GABBR1,Gamma-aminobutyric acid type B receptor subunit 1 OS=Homo sapiens GN=GABBR1 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
2222,XP19986,R-baclofen,for treatment of gastrointestinal reflux disease,small molecule,approved,O75899,GABR2_HUMAN,GABBR2,Gamma-aminobutyric acid type B receptor subunit 2 OS=Homo sapiens GN=GABBR2 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
2223,XP21279,XP21279,antiparkinson agent,small molecule,not approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2223,XP21279,XP21279,antiparkinson agent,small molecule,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2223,XP21279,XP21279,antiparkinson agent,small molecule,not approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2223,XP21279,XP21279,antiparkinson agent,small molecule,not approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2223,XP21279,XP21279,antiparkinson agent,small molecule,not approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2224,"Y-90 clivatuzumab tetraxetan, hPAM4",Yttrium (90Y) clivatuzumab tetraxetan,antineoplastic agent,monoclonal antibody,not approved,P15941,MUC1_HUMAN,MUC1,Mucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Carcinoma-associated mucin) (Episialin) (H23AG) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM) (Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associ,Miscellaneous,StructuralAndAdhesion;Mucin_1,Novel Target
2225,YKP-10A,YKP-10A,antidepressant,unknown,not approved,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
2225,YKP-10A,YKP-10A,antidepressant,unknown,not approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
2226,YKP-1358,YKP-1358,antipsychotic agent,unknown,not approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2226,YKP-1358,YKP-1358,antipsychotic agent,unknown,not approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2227,"YM-028, gantofiban",gantofiban,"antithrombotic,antiatherosclerotic agent",Small molecule,not approved,P08514,ITA2B_HUMAN,ITGA2B,"Integrin alpha-IIb (GPalpha IIb) (GPIIb) (Platelet membrane glycoprotein IIb) (CD antigen CD41) [Cleaved into: Integrin alpha-IIb heavy chain; Integrin alpha-IIb light chain, form 1; Integrin alpha-IIb light chain, form 2]",Receptors,Receptors;Integrin,Established target
2227,"YM-028, gantofiban",gantofiban,"antithrombotic,antiatherosclerotic agent",Small molecule,not approved,P05106,ITB3_HUMAN,ITGB3,Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
2228,"YM-152, finasteride",finasteride,antineoplastic agent,Small Molecule,approved,P51857,AK1D1_HUMAN,AKR1D1,3-oxo-5-beta-steroid 4-dehydrogenase (EC 1.3.1.3) (Aldo-keto reductase family 1 member D1) (Delta(4)-3-ketosteroid 5-beta-reductase) (Delta(4)-3-oxosteroid 5-beta-reductase),Enzymes,EC:1.3.1.3,Established target
2228,"YM-152, finasteride",finasteride,antineoplastic agent,Small Molecule,approved,P18405,S5A1_HUMAN,SRD5A1,3-oxo-5-alpha-steroid 4-dehydrogenase 1 OS=Homo sapiens GN=SRD5A1 PE=1 SV=1,Enzymes,EC:1.3.99,Established target
2228,"YM-152, finasteride",finasteride,antineoplastic agent,Small Molecule,approved,P31213,S5A2_HUMAN,SRD5A2,3-oxo-5-alpha-steroid 4-dehydrogenase 2 OS=Homo sapiens GN=SRD5A2 PE=1 SV=1,Enzymes,EC:1.3.99,Established target
2229,YM-178,YM-178,for treatment of overactive bladder,small molecule,not approved,P13945,ADRB3_HUMAN,ADRB3,Beta-3 adrenergic receptor (Beta-3 adrenoreceptor) (Beta-3 adrenoceptor),Receptors,GPCR;Rhodopsin,Novel Target
2230,YM-598,YM-598,antineoplastic agent,small molecule,not approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2231,"YSPSL, TS-1",YSPSL,anticoagulant,fusion protein,not approved,P16109,LYAM3_HUMAN,SELP,P-selectin (CD62 antigen-like family member P) (Granule membrane protein 140) (GMP-140) (Leukocyte-endothelial cell adhesion molecule 3) (LECAM3) (Platelet activation dependent granule-external membrane protein) (PADGEM) (CD antigen CD62P),Receptors,Receptors;Selectin,Novel Target
2232,"Yttrium-90 edotreotide,Onalta",Yttrium-90 edotreotide,antineoplastic agent,peptide,not approved,P30872,SSR1_HUMAN,SSTR1,Somatostatin receptor type 1 OS=Homo sapiens GN=SSTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2232,"Yttrium-90 edotreotide,Onalta",Yttrium-90 edotreotide,antineoplastic agent,peptide,not approved,P30874,SSR2_HUMAN,SSTR2,Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SRIF-1),Receptors,GPCR;Rhodopsin,Established target
2232,"Yttrium-90 edotreotide,Onalta",Yttrium-90 edotreotide,antineoplastic agent,peptide,not approved,P35346,SSR5_HUMAN,SSTR5,Somatostatin receptor type 5 OS=Homo sapiens GN=SSTR5 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2233,Zactima,vandetanib,antineoplastic agent,small molecule,not approved,P00533,EGFR_HUMAN,EGFR,Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2233,Zactima,vandetanib,antineoplastic agent,small molecule,not approved,P17948,VGFR1_HUMAN,FLT1,Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2233,Zactima,vandetanib,antineoplastic agent,small molecule,not approved,P35916,VGFR3_HUMAN,FLT4,Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2233,Zactima,vandetanib,antineoplastic agent,small molecule,not approved,P35968,VGFR2_HUMAN,KDR,Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2,Receptors,EC:2.7.10.1,Established target
2233,Zactima,vandetanib,antineoplastic agent,small molecule,not approved,P07949,RET_HUMAN,RET,Proto-oncogene tyrosine-protein kinase receptor ret OS=Homo sapiens GN=RET PE=1 SV=3,Receptors,EC:2.7.10.1,Established target
2234,Zadaxin,thymalfasin,immunostimulant,peptide,approved,P06454,PTMA_HUMAN,PTMA,Prothymosin alpha,Miscellaneous,Miscellaneous; prothymosin,Established target
2235,"zafirlukast,Accolate",zafirlukast,antiasthmatic agent,Small Molecule,approved,Q9Y271,CLTR1_HUMAN,CYSLTR1,Cysteinyl leukotriene receptor 1 OS=Homo sapiens GN=CYSLTR1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2236,"zaleplon,Sonata",zaleplon,hypnotic,Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
2236,"zaleplon,Sonata",zaleplon,hypnotic,Small Molecule,approved,P30536,TSPOA_HUMAN,TSPO,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
2237,"zanolimumab, HuMax-CD4",zanolimumab,"antiinflammatory agent,DMARD",monoclonal antibody,not approved,P01730,CD4_HUMAN,CD4,T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4),Receptors,Receptor; T-cell surface receptor,Established target
2238,"Zantac,ranitidine hydrochloride",ranitidine,antiulcer agent,Small Molecule,approved,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2239,Zevalin,ibritumomab tiuxetan,antineoplastic agent,monoclonal antibody,approved,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Miscellaneous,MS4A family,Established target
2240,ZGN-433,beloranib,antiobesity agent,small molecule,not approved,P50579,AMPM2_HUMAN,METAP2,Methionine aminopeptidase 2 (MAP 2) (MetAP 2) (EC 3.4.11.18) (Initiation factor 2-associated 67 kDa glycoprotein) (Peptidase M 2) (p67eIF2) (p67),Enzymes,EC:3.4.11.18,Novel Target
2241,"zibotentan, ZD-4054, AZD-4054",zibotentan,antineoplastic agent,small molecule,not approved,P25101,EDNRA_HUMAN,EDNRA,Endothelin-1 receptor OS=Homo sapiens GN=EDNRA PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2242,"ziconotide,Prialt",ziconotide,analgesic,small molecule,approved,Q00975,CAC1B_HUMAN,CACNA1B,Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo sapiens GN=CACNA1B PE=1 SV=1,Transporters,TC:1.A.1.11,Established target
2243,"ziprasidone HCl, ziprasidone mesylate,Geodon, Zeldox",ziprasidone ,antipsychotic agent,small molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2243,"ziprasidone HCl, ziprasidone mesylate,Geodon, Zeldox",ziprasidone ,antipsychotic agent,small molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
2244,Zofran,ondansetron,antiemetic,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
2245,Zoledronic,zoledronate,antiosteoporotic agent,Small Molecule,approved,P14324,FPPS_HUMAN,FDPS,Farnesyl pyrophosphate synthetase OS=Homo sapiens GN=FDPS PE=1 SV=4,Enzymes,EC:2.5.1.10,Established target
2245,Zoledronic,zoledronate,antiosteoporotic agent,Small Molecule,approved,O95749,GGPPS_HUMAN,GGPS1,"Geranylgeranyl pyrophosphate synthase (GGPP synthase) (GGPPSase) ((2E,6E)-farnesyl diphosphate synthase) (Dimethylallyltranstransferase) (EC 2.5.1.1) (Farnesyl diphosphate synthase) (Farnesyltranstransferase) (EC 2.5.1.29) (Geranylgeranyl diphosphate synt",Enzymes,EC:2.5.1.1; 2.5.1.29; 2.5.1.10,Established target
2246,"zolmitriptan,Zomig",zolmitriptan,antimigraine agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2246,"zolmitriptan,Zomig",zolmitriptan,antimigraine agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
2246,"zolmitriptan,Zomig",zolmitriptan,antimigraine agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2246,"zolmitriptan,Zomig",zolmitriptan,antimigraine agent,Small Molecule,approved,P30939,5HT1F_HUMAN,HTR1F,5-hydroxytryptamine receptor 1F OS=Homo sapiens GN=HTR1F PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
2247,Zoloft,sertraline,"antidepressant,for treatment of obsessive compulsive disorder (OCD)",Small Molecule,approved,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
2247,Zoloft,sertraline,"antidepressant,for treatment of obsessive compulsive disorder (OCD)",Small Molecule,approved,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
2248,"zolpidem,Intermezzo",zolpidem,hypnotic,Small Molecule,approved,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,O43497,CAC1G_HUMAN,CACNA1G,Voltage-dependent T-type calcium channel subunit alpha-1G OS=Homo sapiens GN=CACNA1G PE=2 SV=3,Transporters,TC:1.A.1.11,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,O95180,CAC1H_HUMAN,CACNA1H,Voltage-dependent T-type calcium channel subunit alpha-1H OS=Homo sapiens GN=CACNA1H PE=1 SV=4,Transporters,TC:1.A.1.11.5,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,Q9P0X4,CAC1I_HUMAN,CACNA1I,Voltage-dependent T-type calcium channel subunit alpha-1I OS=Homo sapiens GN=CACNA1I PE=1 SV=1,Transporters,TC:1.A.1.11.7,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,Q9UI33,SCNBA_HUMAN,SCN11A,Sodium channel protein type 11 subunit alpha OS=Homo sapiens GN=SCN11A PE=1 SV=2,Transporters,TC:1.A.1.10.9,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,Q07699,SCN1B_HUMAN,SCN1B,Sodium channel subunit beta-1,Transporters,TC:8.A.17,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,Q99250,SCN2A_HUMAN,SCN2A,Sodium channel protein type 2 subunit alpha (HBSC II) (Sodium channel protein brain II subunit alpha) (Sodium channel protein type II subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.2),Transporters,TC:1.A.1.10,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,O60939,SCN2B_HUMAN,SCN2B,Sodium channel subunit beta-2,Transporters,TC:8.A.17.2.1,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,Q9NY46,SCN3A_HUMAN,SCN3A,Sodium channel protein type 3 subunit alpha (Sodium channel protein brain III subunit alpha) (Sodium channel protein type III subunit alpha) (Voltage-gated sodium channel subtype III) (Voltage-gated sodium channel subunit alpha Nav1.3),Transporters,TC:1.A.1.10,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,Q9NY72,SCN3B_HUMAN,SCN3B,Sodium channel subunit beta-3,Transporters,TC:8.A.17,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,P35499,SCN4A_HUMAN,SCN4A,Sodium channel protein type 4 subunit alpha (SkM1) (Sodium channel protein skeletal muscle subunit alpha) (Sodium channel protein type IV subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.4),Transporters,TC:1.A.1.10.4,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,Q8IWT1,SCN4B_HUMAN,SCN4B,Sodium channel subunit beta-4,Transporters,TC:8.A.17.2.2,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
2249,"zonisamide,Zonegran, Trerief",zonisamide,anticonvulsant,Small Molecule,approved,Q15858,SCN9A_HUMAN,SCN9A,Sodium channel protein type 9 subunit alpha OS=Homo sapiens GN=SCN9A PE=1 SV=2,Transporters,TC:1.A.1.10.5,Established target
2250,"zosuquidar, LY335979",zosuquidar,adjuvant to chemotherapy,small molecule,not approved,P08183,MDR1_HUMAN,ABCB1,Multidrug resistance protein 1 OS=Homo sapiens GN=ABCB1 PE=1 SV=3,Transporters,TC:3.A.1.201.1,Novel Target
2251,ZP1848,ZP1848,for treatment of Chron's disease,peptide,not approved,O95838,GLP2R_HUMAN,GLP2R,Glucagon-like peptide 2 receptor (GLP-2 receptor) (GLP-2-R) (GLP-2R),Receptors,GPCR;Secretin,Novel Target
2252,"ZT-034, teriparatide nasal spray",teriparatide,antiosteoporotic agent,recombinant peptide,approved,Q03431,PTH1R_HUMAN,PTH1R,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2252,"ZT-034, teriparatide nasal spray",teriparatide,antiosteoporotic agent,recombinant peptide,approved,Q03431,PTH1R_HUMAN,PTHR1,Parathyroid hormone/parathyroid hormone-related peptide receptor OS=Homo sapiens GN=PTH1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2253,"zucapsaicin, civamide, WL-1002,,Civanex",zucapsaicin,analgesic,small molecule,not approved,Q8NER1,TRPV1_HUMAN,TRPV1,Transient receptor potential cation channel subfamily V member 1 (TrpV1) (Capsaicin receptor) (Osm-9-like TRP channel 1) (OTRPC1) (Vanilloid receptor 1),Transporters,TC:1.A.4,Established target
2254,"ZX002, hydrocodone bitartrate",hydrocodone,analgesic,Small Molecule,approved,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
2254,"ZX002, hydrocodone bitartrate",hydrocodone,analgesic,Small Molecule,approved,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
2255,ZYC300,ZYC300,antineoplastic agent,vaccine,not approved,Q16678,CP1B1_HUMAN,CYP1B1,Cytochrome P450 1B1 (EC 1.14.14.1) (CYPIB1),Enzymes,EC:1.14.14.1,Novel Target
2256,ZYD1,ZYD1,antidiabetic,peptide,not approved,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
2257,Zyflo,zileuton,antiinflammatory agent,Small Molecule,approved,P09917,LOX5_HUMAN,ALOX5,Arachidonate 5-lipoxygenase OS=Homo sapiens GN=ALOX5 PE=1 SV=2,Enzymes,EC:1.13.11.34,Established target
2258,ZymoGenetics,recombinant Factor IX Fc fusion protein,for treatment of factor XIII deficiency,protein,not approved,P02671,FIBA_HUMAN,FGA,Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Established target
2258,ZymoGenetics,recombinant Factor IX Fc fusion protein,for treatment of factor XIII deficiency,protein,not approved,P02675,FIBB_HUMAN,FGB,Fibrinogen beta chain,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Novel Target
2258,ZymoGenetics,recombinant Factor IX Fc fusion protein,for treatment of factor XIII deficiency,protein,not approved,P02679,FIBG_HUMAN,FGG,Fibrinogen gamma chain,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Novel Target
2258,ZymoGenetics,recombinant human Thrombin,"coagulant,surgical homeostat",recombinant protein,not approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
2258,ZymoGenetics,recombinant human Thrombin,"coagulant,surgical homeostat",recombinant protein,not approved,P12259,FA5_HUMAN,F5,Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=3,Miscellaneous,Enzyme cofactor,Established target
2258,ZymoGenetics,recombinant human Thrombin,"coagulant,surgical homeostat",recombinant protein,not approved,P00451,FA8_HUMAN,F8,Coagulation factor VIII OS=Homo sapiens GN=F8 PE=1 SV=1,Miscellaneous,Enzyme cofactor,Established target
APR13_0001,bl-8040,bl-8040,antineoplastic agent,peptide,not approved,P61073,CXCR4_HUMAN,CXCR4,C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (Fusin) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD antigen CD184),Receptors,GPCR;Rhodopsin,Established target
APR13_0002,Anti-MIF monoclonal antibody,Anti-MIF monoclonal antibody,antineoplastic agent,monoclonal antibody,not approved,P14174 ,MIF_HUMAN,MIF,Macrophage migration inhibitory factor,Ligand,Ligand;cytokine,Novel Target
APR13_0003,rFIX,rFIX,for treatment of hemophilia B,recombinant proetin,approved,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
APR13_0004,Alpha-1 HC aerosol,alpha 1 proteinase inhibitor,for treatment of cystic fibrosis,recombinant proetin,approved,not specified,not specified,not specified,not specified,not specified,not specified,not specified
APR13_0005,ASP015K,ASP015K,for treatment of rheumatoid arthritis,small molecule,not approved,P23458,JAK1_HUMAN,JAK1,Tyrosine-protein kinase JAK1 (EC 2.7.10.2) (Janus kinase 1) (JAK-1),Enzymes,EC:2.7.10.2,Novel Target
APR13_0005,ASP015K,ASP015K,for treatment of rheumatoid arthritis,small molecule,not approved,P52333,JAK3_HUMAN,JAK3,Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK),Enzymes,EC:2.7.10.2,Novel Target
APR13_0006,CHF 6001,CHF 6001,antiasthmatic; for treatment of chronic obstructive pulmonary disease,small molecule,not approved,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
APR13_0006,CHF 6001,CHF 6001,antiasthmatic; for treatment of chronic obstructive pulmonary disease,small molecule,not approved,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
APR13_0007,AVX-470,AVX-470,for treatment of ulcerative colitis,bovine polyclonal antibody,not approved,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Other,Ligand;Cytokine,Established target
APR13_0008,AZD1419,AZD1419,antiasthmatic,immunostimulatory short DNA-sequences,not approved,Q9NR96,TLR9_HUMAN,TLR9,Toll-like receptor 9 (CD antigen CD289),Receptors,Receptors;TOLL,Established target
APR13_0009,CUDC-427,CUDC-427,antineoplastic agent,small molecule,not approved,P98170,XIAP_HUMAN,XIAP,Baculoviral IAP repeat-containing protein 4 (EC 6.3.2.-) (E3 ubiquitin-protein ligase XIAP) (IAP-like protein) (ILP) (hILP) (Inhibitor of apoptosis protein 3) (IAP-3) (hIAP-3) (hIAP3) (X-linked inhibitor of apoptosis protein) (X-linked IAP),Miscellaneous,Inhibitor of apoptosis,Novel Target
APR13_0010,AMT-021,rAAV5-PBGD,for treatment of acute intermittent porphyria,adenoviral gene delivery,not approved,P08397 ,HEM3_HUMAN,HMBS,Porphobilinogen deaminase,Enzymes,EC:2.5.1.61,Novel Target
APR13_0011,ARQ 087,ARQ 087,antineoplastic agent,small molecule,not approved,P11362,FGFR1_HUMAN,FGFR1,Basic fibroblast growth factor receptor 1 (FGFR-1) (bFGF-R-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 2) (FLT-2) (Proto-oncogene c-Fgr) (CD antigen CD331),Receptors,EC:2.7.10.1,Established target
APR13_0011,ARQ 087,ARQ 087,antineoplastic agent,small molecule,not approved,P21802,FGFR2_HUMAN,FGFR2,Fibroblast growth factor receptor 2 OS=Homo sapiens GN=FGFR2 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
APR13_0011,ARQ 087,ARQ 087,antineoplastic agent,small molecule,not approved,P22607,FGFR3_HUMAN,FGFR3,Fibroblast growth factor receptor 3 OS=Homo sapiens GN=FGFR3 PE=1 SV=1,Receptors,EC:2.7.10.1,Established target
APR13_0012,AVP-786,deuterated dextromethorphan,for treatment of neurologic and psychiatric disorders,small molecule,not approved,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
APR13_0012,AVP-786,deuterated dextromethorphan,for treatment of neurologic and psychiatric disorders,small molecule,not approved,Q99720,OPRS1_HUMAN,OPRS1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P28566,5HT1E_HUMAN,HTR1E,5-hydroxytryptamine receptor 1E,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P46098,5HT3A_HUMAN,HTR3A,5-hydroxytryptamine receptor 3A OS=Homo sapiens GN=HTR3A PE=1 SV=1,Receptors,TC:1.A.9.2.1,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P50406,5HT6R_HUMAN,HTR6,5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,olanzapine,antipsychotic agent,Small Molecule,approved,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0013,ALKS 3831,samidoprhan,for treatment of addiction,small molecule,not approved,P35372,OPRM_HUMAN,MOR,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
APR13_0014,ALN-TTRsc,ALN-TTR,for treatment of TTR-mediated amyloidosis,siRNA,not approved,P02766 ,TTHY_HUMAN,TTR,Transthyretin,Miscellaneous,Miscellaneous;carrier protein,Novel Target
APR13_0015,AMR102,Ethyl eicosapentaenoic acid,for treatment of cardiovascular disorders,small molecule,approved,Q03181,PPARD_HUMAN,PPARD,Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta),Receptors,Nuclear receptor,Established target
APR13_0015,AMR102,Ethyl eicosapentaenoic acid,for treatment of cardiovascular disorders,small molecule,approved,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
APR13_0015,AMR102,Ethyl eicosapentaenoic acid,for treatment of cardiovascular disorders,small molecule,approved,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
APR13_0015,AMR102,Ethyl eicosapentaenoic acid,for treatment of cardiovascular disorders,small molecule,approved,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
APR13_0016,AVO113,AVO113,antineoplastic agent,autologous dendritic cell therapy,not approved,not applicable,not applicable,not applicable,not applicable,not applicable,not applicable,not applicable
APR13_0017,BCX4161,BCX4161,for treatment of hereditary angioedema,small molecule,not approved,P03952,KLKB1_HUMAN,KLKB1,Plasma kallikrein,Enzymes,EC:3.4.21.34,Established target
APR13_0018,BL-8020,BL-8020,for treatment of hepatitis C,undisclosed,not approved,non-human target,non-human target,non-human target,non-human target,non-human target,non-human target,non-human target
NRDD001,-,ACEBUTOLOL,Antihypertensive Agents,small molecule,1984,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD002,-,ACENOCOUMAROL,Anticoagulants,small molecule,not approved by the FDA,Q9BQB6,VKOR1_HUMAN,VKORC1,Vitamin K epoxide reductase complex subunit 1 OS=Homo sapiens GN=VKORC1 PE=1 SV=1,Enzymes,EC:1.1.4.1,Established target
NRDD003,-,ACEPROMETAZINE,Hypnotics and Sedatives,small molecule,not approved by the FDA,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD004,-,ACETAZOLAMIDE,Anticonvulsants; Diuretics; antiglaucomic agent,small molecule,1953,P00915,CAH1_HUMAN,CA1,Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD004,-,ACETAZOLAMIDE,Anticonvulsants; Diuretics; antiglaucomic agent,small molecule,1953,O43570,CAH12_HUMAN,CA12,Carbonic anhydrase 12 OS=Homo sapiens GN=CA12 PE=1 SV=1,Enzymes,EC:4.2.1,Established target
NRDD004,-,ACETAZOLAMIDE,Anticonvulsants; Diuretics; antiglaucomic agent,small molecule,1953,P00918,CAH2_HUMAN,CA2,Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD005,-,ACETOHEXAMIDE,Hypoglycemic Agents,small molecule,1964,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
NRDD006,-,ACETOPHENAZINE,Antipsychotic Agents,small molecule,1961,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD006,-,ACETOPHENAZINE,Antipsychotic Agents,small molecule,1961,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD007,-,ACETYLDIGITOXIN,Anti-Arrhythmia Agents,small molecule,Approved before 1982,P05023,AT1A1_HUMAN,ATP1A1,Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1,Transporters,TC:3.A.3.1.1,Established target
NRDD008,-,ACITRETIN,Keratolytic Agents,small molecule,1996,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD009,-,ADAPALENE,Dermatologic Agents,small molecule,1996,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD009,-,ADAPALENE,Dermatologic Agents,small molecule,1996,P10826,RARB_HUMAN,RARB,Retinoic acid receptor beta OS=Homo sapiens GN=RARB PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD009,-,ADAPALENE,Dermatologic Agents,small molecule,1996,P13631,RARG_HUMAN,RARG,Retinoic acid receptor gamma OS=Homo sapiens GN=RARG PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD009,-,ADAPALENE,Dermatologic Agents,small molecule,1996,P19793,RXRA_HUMAN,RXRA,Retinoic acid receptor RXR-alpha OS=Homo sapiens GN=RXRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD009,-,ADAPALENE,Dermatologic Agents,small molecule,1996,P28702,RXRB_HUMAN,RXRB,Retinoic acid receptor RXR-beta OS=Homo sapiens GN=RXRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD009,-,ADAPALENE,Dermatologic Agents,small molecule,1996,P48443,RXRG_HUMAN,RXRG,Retinoic acid receptor RXR-gamma OS=Homo sapiens GN=RXRG PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD010,-,ADINAZOLAM,Anti-anxiety Agents; anticonvulsant,small molecule,not approved by the FDA,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD011,-,ALCAFTADINE,Anti-Allergic Agents,small molecule,2010,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD012,-,ALCLOMETASONE,"Anti-Inflammatory Agents; Anti-pruritics; Corticosteroids, topical",small molecule,1982,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor,Receptors,Nuclear receptor,Established target
NRDD013,-,ALEFACEPT,Immunosuppressive Agents,fusion protein,2003,P06729,CD2_HUMAN,CD2,T-cell surface antigen CD2 OS=Homo sapiens GN=CD2 PE=1 SV=2,Other,StructuralAndAdhesion,Established target
NRDD014,-,ALENDRONATE,Bisphosphonates,small molecule,1995,P14324,FPPS_HUMAN,FDPS,Farnesyl pyrophosphate synthetase OS=Homo sapiens GN=FDPS PE=1 SV=4,Enzymes,EC:2.5.1.-,Established target
NRDD015,-,ALFENTANIL,"Analgesics, Opioid",small molecule,1986,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD016,-,Alitretionine,Antineoplastic Agents,small molecule,1999,P10276,RARA_HUMAN,RARA,Retinoic acid receptor alpha OS=Homo sapiens GN=RARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD016,-,Alitretionine,Antineoplastic Agents,small molecule,1999,P10826,RARB_HUMAN,RARB,Retinoic acid receptor beta OS=Homo sapiens GN=RARB PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD016,-,Alitretionine,Antineoplastic Agents,small molecule,1999,P13631,RARG_HUMAN,RARG,Retinoic acid receptor gamma OS=Homo sapiens GN=RARG PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD016,-,Alitretionine,Antineoplastic Agents,small molecule,1999,P19793,RXRA_HUMAN,RXRA,Retinoic acid receptor RXR-alpha OS=Homo sapiens GN=RXRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD016,-,Alitretionine,Antineoplastic Agents,small molecule,1999,P28702,RXRB_HUMAN,RXRB,Retinoic acid receptor RXR-beta OS=Homo sapiens GN=RXRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD016,-,Alitretionine,Antineoplastic Agents,small molecule,1999,P48443,RXRG_HUMAN,RXRG,Retinoic acid receptor RXR-gamma OS=Homo sapiens GN=RXRG PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD017,-,ALMITRINE,Respiratory Stimulant Agents,small molecule,not approved by the FDA,P05023,AT1A1_HUMAN,ATP1A1,Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1,Transporters,TC:3.A.3.1.1,Established target
NRDD018,-,ALPHA-1-PROTEINASE INHIBITOR,Enzyme Replacement Agents,recombinant protein,2002,P08246,ELNE_HUMAN,ELA2,Leukocyte elastase OS=Homo sapiens GN=ELA2 PE=1 SV=1,Enzymes,EC:3.4.21.37,Established target
NRDD019,-,ALPRENOLOL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,not approved by the FDA,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD019,-,ALPRENOLOL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,not approved by the FDA,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD020,-,ALSEROXYLON,Antipsychotic Agents; Antihypertensive Agents,small molecule,not approved by the FDA,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
NRDD021,-,ALVIMOPAN,Opiate Antagonists,small molecule,2008,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD022,-,AMBENONIUM,Antimyasthenics,small molecule,1956,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
NRDD023,-,AMCINONIDE,"Anti-Inflammatory Agents; Anti-pruritics; Corticosteroids, topical",small molecule,not approved by the FDA,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD024,-,AMINOCAPROIC ACID,Antifibrinolytic Agents,small molecule,1964,P00747,PLMN_HUMAN,PLG,Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2,Enzymes,EC:3.4.21.7,Established target
NRDD025,-,AMINOGLUTETHIMIDE,Antineoplastic agents,small molecule,1980,P11511,CP19A_HUMAN,CYP19A1,Cytochrome P450 19A1 OS=Homo sapiens GN=CYP19A1 PE=1 SV=3,Enzymes,EC:1.14.14,Established target
NRDD026,-,AMRINONE,Cardiotonic Agents; Phosphodiesterase Inhibitors,small molecule,1984,Q14432,PDE3A_HUMAN,PDE3A,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A OS=Homo sapiens GN=PDE3A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
NRDD026,-,AMRINONE,Cardiotonic Agents; Phosphodiesterase Inhibitors,small molecule,1984,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
NRDD027,-,ANILERIDINE,Analgesics; Narcotics,small molecule,Approved before 1982,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD028,-,ANISINDIONE,Anticoagulants,small molecule,1957,P38435,VKGC_HUMAN,GGCX,Vitamin K-dependent gamma-carboxylase OS=Homo sapiens GN=GGCX PE=1 SV=2,Enzymes,EC:6.4.-.-,Established target
NRDD029,-,ANISOTROPINE METHYLBROMIDE,Antispasmodics; Anti-ulcer Agents,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD029,-,ANISOTROPINE METHYLBROMIDE,Antispasmodics; Anti-ulcer Agents,small molecule,Approved before 1982,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD029,-,ANISOTROPINE METHYLBROMIDE,Antispasmodics; Anti-ulcer Agents,small molecule,Approved before 1982,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD030,-,ANISTREPLASE,Thrombolytic Agents,protein,not approved by the FDA,P02671 ,FIBA_HUMAN,FGA,Fibrinogen alpha chain,Miscellaneous,StructuralAndAdhesion;Fibrinogen,Established target
NRDD030,-,ANISTREPLASE,Thrombolytic Agents,protein,not approved by the FDA,P00747,PLMN_HUMAN,PLG,Plasminogen,Enzymes,EC:3.4.21.7,Established target
NRDD031,-,ANTITHYMOCYTE GLOBULIN,Immunomodulatory Agents,protein,approved,P01730,CD4_HUMAN,CD4,T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4),Receptors,Receptor; T-cell surface receptor,Established target
NRDD031,-,ANTITHYMOCYTE GLOBULIN,Immunomodulatory Agents,protein,approved,P42081,CD86_HUMAN,CD86,T-lymphocyte activation antigen CD86 OS=Homo sapiens GN=CD86 PE=1 SV=1,Other,T-lymphocyte activation antigen CD86,Established target
NRDD031,-,ANTITHYMOCYTE GLOBULIN,Immunomodulatory Agents,protein,approved,P31994,FCG2B_HUMAN,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b (IgG Fc receptor II-b) (CDw32) (Fc-gamma RII-b) (Fc-gamma-RIIb) (FcRII-b) (CD antigen CD32),Miscellaneous,StructuralAndAdhesion;IG_AdhesionProteins,Established target
NRDD031,-,ANTITHYMOCYTE GLOBULIN,Immunomodulatory Agents,protein,approved,P20701,ITAL_HUMAN,ITGAL,Integrin alpha-L,Receptors,Receptors;Integrin,Established target
NRDD031,-,ANTITHYMOCYTE GLOBULIN,Immunomodulatory Agents,protein,approved,P06756,ITAV_HUMAN,ITGAV,Integrin alpha-V (Vitronectin receptor subunit alpha) (CD antigen CD51) [Cleaved into: Integrin alpha-V heavy chain; Integrin alpha-V light chain],Receptors,Receptors;Integrin,Established target
NRDD031,-,ANTITHYMOCYTE GLOBULIN,Immunomodulatory Agents,protein,approved,P05556,ITB1_HUMAN,ITGB1,Integrin beta-1 (Fibronectin receptor subunit beta) (VLA-4 subunit beta) (CD antigen CD29),Receptors,Receptors;Integrin,Established target
NRDD031,-,ANTITHYMOCYTE GLOBULIN,Immunomodulatory Agents,protein,approved,P05106,ITB3_HUMAN,ITGB3,Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
NRDD031,-,ANTITHYMOCYTE GLOBULIN,Immunomodulatory Agents,protein,approved,Q95460,HMR1_HUMAN,MR1,Major histocompatibility complex class I-related gene protein,Miscellaneous,Miscellaneous;MHC class I,Established target
NRDD032,-,APRACLONIDINE,Antiglaucomic Agents,small molecule,1987,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD033,-,APRINDINE,Anti-Arrhythmia Agents,small molecule,not approved by the FDA,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD034,-,ARBUTAMINE,Cardiotonic Agents,small molecule,1997,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD035,-,ARDEPARIN,Anticoagulants,small molecule,1997,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Other,Enzyme regulator,Established target
NRDD035,-,ARDEPARIN,Anticoagulants,small molecule,1997,P05546,HEP2_HUMAN,SERPIND1,Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 SV=3,Other,Enzyme regulator,Established target
NRDD036,-,ARFORMOTEROL,Bronchodilator Agents,small molecule,2006,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD037,-,ASTEMIZOLE,Anti-Allergic Agents,small molecule,1988,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD038,-,ATENOLOL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1981,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD039,-,ATRACURIUM,Muscle Relaxants,small molecule,1983,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD040,-,AURANOFIN,Antirheumatic Agents,small molecule,1985,O14920,IKKB_HUMAN,IKBKB,Inhibitor of nuclear factor kappa-B kinase subunit beta OS=Homo sapiens GN=IKBKB PE=1 SV=1,Enzymes,EC:2.7.11.10,Established target
NRDD041,-,AZATADINE,Anti-Allergic Agents,small molecule,1977,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD042,-,BENDROFLUMETHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,Approved before 1982,P55017,S12A3_HUMAN,SLC12A3,Solute carrier family 12 member 3 OS=Homo sapiens GN=SLC12A3 PE=1 SV=2,Transporters,TC:2.A.30.4.2,Established target
NRDD043,-,BENTIROMIDE,Diagnostic Agents,small molecule,1983,P05981,HEPS_HUMAN,HPN ,Serine protease hepsin OS=Homo sapiens GN=HPN PE=1 SV=1,Enzymes,EC:3.4.21.106,Established target
NRDD043,-,BENTIROMIDE,Diagnostic Agents,small molecule,1983,P05981,HEPS_HUMAN,HPN ,Serine protease hepsin OS=Homo sapiens GN=HPN PE=1 SV=1,Enzymes,EC:3.4.21.106,Established target
NRDD044,-,BENZOCAINE,"Anesthetics, Local",small molecule,not approved by the FDA,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD045,-,BENZONATATE,Antitussive Agents,small molecule,1958,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD046,-,BENZPHETAMINE,Central Nervous System Stimulants,small molecule,1960,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD046,-,BENZPHETAMINE,Central Nervous System Stimulants,small molecule,1960,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD047,-,BENZQUINAMIDE,Antiemetics; Antipsychotic Agents,small molecule,1974,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD047,-,BENZQUINAMIDE,Antiemetics; Antipsychotic Agents,small molecule,1974,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD047,-,BENZQUINAMIDE,Antiemetics; Antipsychotic Agents,small molecule,1974,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD047,-,BENZQUINAMIDE,Antiemetics; Antipsychotic Agents,small molecule,1974,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD047,-,BENZQUINAMIDE,Antiemetics; Antipsychotic Agents,small molecule,1974,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD047,-,BENZQUINAMIDE,Antiemetics; Antipsychotic Agents,small molecule,1974,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD048,-,BENZTHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,not approved by the FDA,P55017,S12A3_HUMAN,SLC12A3,Solute carrier family 12 member 3 OS=Homo sapiens GN=SLC12A3 PE=1 SV=2,Transporters,TC:2.A.30.4.2,Established target
NRDD049,-,BENZTROPINE,Antiparkinson Agents,small molecule,1954,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD049,-,BENZTROPINE,Antiparkinson Agents,small molecule,1954,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
NRDD050,-,BENZYLPENICILLOYL POLYLYSINE,Diagnostic Agents,small molecule,1974,P12319,FCERA_HUMAN,FCER1A,High affinity immunoglobulin epsilon receptor subunit alpha OS=Homo sapiens GN=FCER1A PE=1 SV=1,Receptors,Receptor;immunoglobulin,Established target
NRDD050,-,BENZYLPENICILLOYL POLYLYSINE,Diagnostic Agents,small molecule,1974,P30273,FCERG_HUMAN,FCER1G,High affinity immunoglobulin epsilon receptor subunit gamma OS=Homo sapiens GN=FCER1G PE=1 SV=1,Receptors,Receptor; Fc receptor,Established target
NRDD051,-,BEPRIDIL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1990,P05023,AT1A1_HUMAN,ATP1A1,Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1,Transporters,TC:3.A.3.1.1,Established target
NRDD051,-,BEPRIDIL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1990,O00555,CAC1A_HUMAN,CACNA1A,Voltage-dependent P/Q-type calcium channel subunit alpha-1A OS=Homo sapiens GN=CACNA1A PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
NRDD051,-,BEPRIDIL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1990,P51787,KCNQ1_HUMAN,KCNQ1,Potassium voltage-gated channel subfamily KQT member 1 OS=Homo sapiens GN=KCNQ1 PE=1 SV=3,Transporters,TC:1.A.1.15.6,Established target
NRDD051,-,BEPRIDIL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1990,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD051,-,BEPRIDIL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1990,P63316,TNNC1_HUMAN,TNNC1,"Troponin C, slow skeletal and cardiac muscles OS=Homo sapiens GN=TNNC1 PE=1 SV=1",Other,Enzyme regulator,Established target
NRDD052,-,BETAXOLOL,Antihypertensive Agents,small molecule,1985,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD053,-,BETAZOLE,Diagnostic Agents,small molecule,Approved before 1982,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD054,-,BETHANECHOL,Parasympathomimetics,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD055,-,BETHANIDINE,Antihypertensive Agents,small molecule,Approved before 1982,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD055,-,BETHANIDINE,Antihypertensive Agents,small molecule,Approved before 1982,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD055,-,BETHANIDINE,Antihypertensive Agents,small molecule,Approved before 1982,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD055,-,BETHANIDINE,Antihypertensive Agents,small molecule,Approved before 1982,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD055,-,BETHANIDINE,Antihypertensive Agents,small molecule,Approved before 1982,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD055,-,BETHANIDINE,Antihypertensive Agents,small molecule,Approved before 1982,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD055,-,BETHANIDINE,Antihypertensive Agents,small molecule,Approved before 1982,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD056,-,BEVANTOLOL,Antihypertensive Agents,small molecule,not approved by the FDA,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD057,-,BIPERIDEN,Antidyskinetics,small molecule,1959,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD057,-,BIPERIDEN,Antidyskinetics,small molecule,1959,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD058,-,BISOPROLOL,Antihypertensive Agents,small molecule,1992,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD059,-,BOTULINUM TOXIN TYPE B,Neuromuscular Blocking Agents,protein,2000,Q8N9I0,SYT2_HUMAN,SYT2,Synaptotagmin-2 OS=Homo sapiens GN=SYT2 PE=1 SV=2,Other,Miscellaneous;Synaptotagmin,Established target
NRDD059,-,BOTULINUM TOXIN TYPE B,Neuromuscular Blocking Agents,protein,2000,P23763,VAMP1_HUMAN,VAMP1,Vesicle-associated membrane protein 1 OS=Homo sapiens GN=VAMP1 PE=1 SV=1,Transporters,TC:1.F.1.1.1,Established target
NRDD059,-,BOTULINUM TOXIN TYPE B,Neuromuscular Blocking Agents,protein,2000,P63027,VAMP2_HUMAN,VAMP2,Vesicle-associated membrane protein 2 OS=Homo sapiens GN=VAMP2 PE=1 SV=2,Transporters,TC:1.F.1.1.1,Established target
NRDD060,-,BRINZOLAMIDE,Antiglaucomic Agents,small molecule,1998,P00918,CAH2_HUMAN,CA2,Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD061,-,BROMAZEPAM,Hypnotics and Sedatives,small molecule,Approved before 1982,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD062,-,BROMODIPHENHYDRAMINE,Anti-Allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD063,-,BROMPHENIRAMINE,Anti-Allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD064,-,BUCLIZINE,Antiemetics,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD064,-,BUCLIZINE,Antiemetics,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD065,-,BUMETANIDE,Antihypertensive Agents; Diuretics,small molecule,1983,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD065,-,BUMETANIDE,Antihypertensive Agents; Diuretics,small molecule,1983,P55011,S12A2_HUMAN,SLC12A2,Solute carrier family 12 member 2 OS=Homo sapiens GN=SLC12A2 PE=1 SV=1,Transporters,TC:2.A.30.3.1,Established target
NRDD065,-,BUMETANIDE,Antihypertensive Agents; Diuretics,small molecule,1983,Q9UP95,S12A4_HUMAN,SLC12A4,Solute carrier family 12 member 4 OS=Homo sapiens GN=SLC12A4 PE=1 SV=2,Transporters,TC:2.A.30.5.5,Established target
NRDD065,-,BUMETANIDE,Antihypertensive Agents; Diuretics,small molecule,1983,Q9H2X9,S12A5_HUMAN,SLC12A5,Solute carrier family 12 member 5 OS=Homo sapiens GN=SLC12A5 PE=2 SV=3,Transporters,TC:2.A.30.5.6,Established target
NRDD066,-,BUSPIRONE,Anti-anxiety Agents,small molecule,1986,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD066,-,BUSPIRONE,Anti-anxiety Agents,small molecule,1986,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD067,-,BUTABARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD068,-,BUTALBITAL,Analgesics,small molecule,not approved by the FDA,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD069,-,BUTETHAL,Hypnotics and Sedatives,small molecule,not approved by the FDA,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD070,-,BUTORPHANOL,"Analgesics, Opioid",small molecule,1978,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD070,-,BUTORPHANOL,"Analgesics, Opioid",small molecule,1978,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD070,-,BUTORPHANOL,"Analgesics, Opioid",small molecule,1978,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD071,-,CABERGOLINE,Antiparkinson Agents,small molecule,1996,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD072,-,CAFFEINE,Central Nervous System Stimulants,small molecule,not approved by the FDA,P30542,AA1R_HUMAN,ADORA1,Adenosine receptor A1 OS=Homo sapiens GN=ADORA1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD072,-,CAFFEINE,Central Nervous System Stimulants,small molecule,not approved by the FDA,P29274,AA2AR_HUMAN,ADORA2A,Adenosine receptor A2a OS=Homo sapiens GN=ADORA2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD072,-,CAFFEINE,Central Nervous System Stimulants,small molecule,not approved by the FDA,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
NRDD073,-,CALCIPOTRIOL,Dermatologic Agents,small molecule,1993,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD074,-,CANDOXATRIL,Antihypertensive Agents,small molecule,1995,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
NRDD074,-,CANDOXATRIL,Antihypertensive Agents,small molecule,1995,P08473,NEP_HUMAN,MME,Neprilysin OS=Homo sapiens GN=MME PE=1 SV=2,Enzymes,EC:3.4.24,Established target
NRDD075,-,CAPROMAB,Diagnostic Agents,monoclonal antibody,1996,Q04609,FOLH1_HUMAN,PSMA,Glutamate carboxypeptidase 2 OS=Homo sapiens GN=FOLH1 PE=1 SV=1,Enzymes,EC:3.4.17,Established target
NRDD076,-,CAPTOPRIL,Antihypertensive Agents,small molecule,1981,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
NRDD077,-,CARBACHOL,Antiglaucomic Agents,small molecule,1972,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD077,-,CARBACHOL,Antiglaucomic Agents,small molecule,1972,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD077,-,CARBACHOL,Antiglaucomic Agents,small molecule,1972,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD078,-,CARBETOCIN,Labor Inducing Agents,small molecule,not approved by the FDA,P30559,OXYR_HUMAN,OXTR,Oxytocin receptor OS=Homo sapiens GN=OXTR PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD079,-,CARBIMAZOLE,Antithyroid Agents,small molecule,not approved by the FDA,P07202,PERT_HUMAN,TPO,Thyroid peroxidase OS=Homo sapiens GN=TPO PE=1 SV=4,Enzymes,EC:1.11.1.8,Established target
NRDD080,-,CARBINOXAMINE,Anti-Allergic Agents,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD080,-,CARBINOXAMINE,Anti-Allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD081,-,CARBOPROST TROMETHAMINE,Abortifacient Agents,small molecule,1979,P34995,PE2R1_HUMAN,PTGER1,Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens GN=PTGER1 PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD082,-,CARPHENAZINE,Antipsychotic Agents,small molecule,Approved before 1982,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD082,-,CARPHENAZINE,Antipsychotic Agents,small molecule,Approved before 1982,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD082,-,CARPHENAZINE,Antipsychotic Agents,small molecule,Approved before 1982,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD083,-,CARPROFEN,"Anti-Inflammatory Agents, Non-Steroidal",small molecule,1987,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD084,-,CARTEOLOL,Antiglaucomic Agents,small molecule,1988,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD084,-,CARTEOLOL,Antiglaucomic Agents,small molecule,1988,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD085,-,CERULETIDE,Diagnostic Agents,small molecule,Approved before 1982,P32238,CCKAR_HUMAN,CCKAR,Cholecystokinin receptor type A OS=Homo sapiens GN=CCKAR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD086,-,CEVIMELINE,Parasympathomimetics,small molecule,2000,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD086,-,CEVIMELINE,Parasympathomimetics,small molecule,2000,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD087,-,CHLOPHEDIANOL,Antitussive Agents,small molecule,not approved by the FDA,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD088,-,CHLORDIAZEPOXIDE,Hypnotics and Sedatives,small molecule,Approved before 1982,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD089,-,CHLORMERODRIN,Antihypertensive Agents; Diuretics,small molecule,Approved before 1982,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD090,-,CHLORMEZANONE,Anti-anxiety Agents; Muscle Relaxants,small molecule,1960,P30536,TSPOA_HUMAN,BZRP,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
NRDD091,-,CHLOROPROCAINE,"Anesthetics, Local",small molecule,1955,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD092,-,CHLOROTHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,Approved before 1982,P00915,CAH1_HUMAN,CA1,Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD092,-,CHLOROTHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,Approved before 1982,P00918,CAH2_HUMAN,CA2,Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD092,-,CHLOROTHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,Approved before 1982,P22748,CAH4_HUMAN,CA4,Carbonic anhydrase 4 OS=Homo sapiens GN=CA4 PE=1 SV=2,Enzymes,EC:4.2.1,Established target
NRDD092,-,CHLOROTHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,Approved before 1982,P55017,S12A3_HUMAN,SLC12A3,Solute carrier family 12 member 3 OS=Homo sapiens GN=SLC12A3 PE=1 SV=2,Transporters,TC:2.A.30.4.2,Established target
NRDD093,-,CHLOROTRIANISENE,Hormone Replacement Agents,small molecule,Approved before 1982,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD094,-,CHLORPHENIRAMINE,Anti-Allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD095,-,CHLORPROPAMIDE,Hypoglycemic Agents,small molecule,1958,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
NRDD096,-,CHLORPROTHIXENE,Antipsychotic Agents,small molecule,Approved before 1982,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD096,-,CHLORPROTHIXENE,Antipsychotic Agents,small molecule,Approved before 1982,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD096,-,CHLORPROTHIXENE,Antipsychotic Agents,small molecule,Approved before 1982,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD096,-,CHLORPROTHIXENE,Antipsychotic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD096,-,CHLORPROTHIXENE,Antipsychotic Agents,small molecule,Approved before 1982,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD096,-,CHLORPROTHIXENE,Antipsychotic Agents,small molecule,Approved before 1982,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD096,-,CHLORPROTHIXENE,Antipsychotic Agents,small molecule,Approved before 1982,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD097,-,CHLORTHALIDONE,Antihypertensive Agents; Diuretics,small molecule,1960,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD098,-,CHLORZOXAZONE,Muscle Relaxants,small molecule,Approved before 1982,Q12791,KCMA1_HUMAN,KCNMA1,Calcium-activated potassium channel subunit alpha-1 OS=Homo sapiens GN=KCNMA1 PE=1 SV=2,Transporters,TC:1.A.1.3,Established target
NRDD099,-,CHORIOGONADOTROPIN ALFA,Fertility Agents,protein,2000,P23945,FSHR_HUMAN,FSHR,Follicle-stimulating hormone receptor OS=Homo sapiens GN=FSHR PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD099,-,CHORIOGONADOTROPIN ALFA,Fertility Agents,protein,2000,P22888,LSHR_HUMAN,LHCGR,Lutropin-choriogonadotropic hormone receptor OS=Homo sapiens GN=LHCGR PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD100,-,CICLESONIDE,Anti-Inflammatory Agents; Anti-allergic agents; Glucocorticoids,small molecule,2006,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD101,-,CILASTATIN,"Adjuvants, enzyme inhibitors",small molecule,1985,P16444,DPEP1_HUMAN,DPEP1,Dipeptidase 1 OS=Homo sapiens GN=DPEP1 PE=1 SV=3,Enzymes,EC:3.4.13,Established target
NRDD102,-,CILAZAPRIL,Antihypertensive Agents,small molecule,not approved by the FDA,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme,Other,EC:3.4.15,Established target
NRDD103,-,CILOSTAZOL,Platelet Aggregation Inhibitors,small molecule,1999,Q14432,PDE3A_HUMAN,PDE3A,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A OS=Homo sapiens GN=PDE3A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
NRDD104,-,CIMETIDINE,"GI Anti-Ulcer Agents, antihistamines",small molecule,1979,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD105,-,CINACALCET,Calcimimetics,small molecule,2004,P41180,CASR_HUMAN,CASR,Extracellular calcium-sensing receptor OS=Homo sapiens GN=CASR PE=1 SV=2,Receptors,GPCR;Glutamate,Established target
NRDD106,-,CINALUKAST,Anti-Asthmatic Agents,small molecule,not approved by the FDA,Q9Y271,CLTR1_HUMAN,CYSLTR1,Cysteinyl leukotriene receptor 1 OS=Homo sapiens GN=CYSLTR1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD107,-,CINNARIZINE,Anti-Allergic Agents,small molecule,not approved by the FDA,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD108,-,CINOLAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD109,-,CISAPRIDE,Parasympathomimetics,small molecule,1993,Q13639,5HT4R_HUMAN,HTR4,5-hydroxytryptamine receptor 4 OS=Homo sapiens GN=HTR4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD110,-,CISATRACURIUM BESYLATE,Neuromuscular Blocking Agents,small molecule,1995,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD111,-,CITALOPRAM,"Antidepressive Agents, Second-Generation",small molecule,1998,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD112,-,CLEMASTINE,Anti-Allergic Agents,small molecule,1977,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD113,-,CLENBUTEROL,Bronchodilator Agents,small molecule,not approved by the FDA,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD114,-,CLIDINIUM,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD115,-,CLOCORTOLONE,"Anti-Inflammatory Agents; Anti-pruritics; Corticosteroids, topical",small molecule,1977,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor,Receptors,Nuclear receptor,Established target
NRDD116,-,CLOFIBRATE,Anticholesteremic Agents,small molecule,1967,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD117,-,CLOMIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,1989,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD117,-,CLOMIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,1989,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P30536,TSPOA_HUMAN,BZRP,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD118,-,CLORAZEPATE,Hypnotics and Sedatives,small molecule,1972,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD119,-,CLOTIAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD120,-,CLOZAPINE,Antipsychotic Agents,small molecule,1989,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD120,-,CLOZAPINE,Antipsychotic Agents,small molecule,1989,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD120,-,CLOZAPINE,Antipsychotic Agents,small molecule,1989,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD120,-,CLOZAPINE,Antipsychotic Agents,small molecule,1989,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD120,-,CLOZAPINE,Antipsychotic Agents,small molecule,1989,Q9H3N8,HRH4_HUMAN,HRH4,Histamine H4 receptor OS=Homo sapiens GN=HRH4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD120,-,CLOZAPINE,Antipsychotic Agents,small molecule,1989,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD120,-,CLOZAPINE,Antipsychotic Agents,small molecule,1989,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD120,-,CLOZAPINE,Antipsychotic Agents,small molecule,1989,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD121,-,COAGULATION FACTOR IX,Coagulants,recombinant protein,not approved by the FDA,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
NRDD122,-,COAGULATION FACTOR VIIA,Coagulants,recombinant protein,not approved by the FDA,P00742,FA10_HUMAN,F10,Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2,Enzymes,EC:3.4.21.6,Established target
NRDD122,-,COAGULATION FACTOR VIIA,Coagulants,recombinant protein,not approved by the FDA,P08709,FA7_HUMAN,F9,Coagulation factor VII OS=Homo sapiens GN=F7 PE=1 SV=1,Enzymes,EC:3.4.21.21,Established target
NRDD123,-,COCAINE,local anesthetic,small molecule,Approved before 1982,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD123,-,COCAINE,local anesthetic,small molecule,Approved before 1982,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD123,-,COCAINE,local anesthetic,small molecule,Approved before 1982,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD123,-,COCAINE,local anesthetic,small molecule,Approved before 1982,Q9UI33,SCNBA_HUMAN,SCN11A,Sodium channel protein type 11 subunit alpha OS=Homo sapiens GN=SCN11A PE=1 SV=2,Transporters,TC:1.A.1.10.9,Established target
NRDD123,-,COCAINE,local anesthetic,small molecule,Approved before 1982,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD123,-,COCAINE,local anesthetic,small molecule,Approved before 1982,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD123,-,COCAINE,local anesthetic,small molecule,Approved before 1982,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
NRDD123,-,COCAINE,local anesthetic,small molecule,Approved before 1982,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD124,-,CODEINE,"Analgesics, Opioid; Antitussive Agents",small molecule,Approved before 1982,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD124,-,CODEINE,"Analgesics, Opioid; Antitussive Agents",small molecule,Approved before 1982,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD124,-,CODEINE,"Analgesics, Opioid; Antitussive Agents",small molecule,Approved before 1982,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD125,-,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,for treatment of Dupuytren's contracture,protein,2010,P02452,CO1A1_HUMAN,COL1A1,Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=4,Other,StructuralAndAdhesion;Collagen,Established target
NRDD125,-,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,for treatment of Dupuytren's contracture,protein,2010,P08123,CO1A2_HUMAN,COL1A2,Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=6,Other,StructuralAndAdhesion;Collagen,Established target
NRDD125,-,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,for treatment of Dupuytren's contracture,protein,2010,P02458,CO2A1_HUMAN,COL2A1,Collagen alpha-1(II) chain OS=Homo sapiens GN=COL2A1 PE=1 SV=3,Other,StructuralAndAdhesion;Collagen,Established target
NRDD125,-,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,for treatment of Dupuytren's contracture,protein,2010,P02461,CO3A1_HUMAN,COL3A1,Collagen alpha-1(III) chain OS=Homo sapiens GN=COL3A1 PE=1 SV=4,Other,StructuralAndAdhesion;Collagen,Established target
NRDD126,-,CONJUGATED ESTROGENS,Hormone Replacement Agents,small molecule,not approved by the FDA,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD127,-,CORTICOTROPIN,Diagnostic Agents,protein,1950,Q01718,ACTHR_HUMAN,MC2R,Adrenocorticotropic hormone receptor OS=Homo sapiens GN=MC2R PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD128,-,COSYNTROPIN,Diagnostic Agents,peptide,1970,Q01718,ACTHR_HUMAN,MC2R,Adrenocorticotropic hormone receptor OS=Homo sapiens GN=MC2R PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD129,-,CROMOGLICATE,Anti-Asthmatic Agents,small molecule,Approved before 1982,Q12791,KCMA1_HUMAN,KCNMA1,Calcium-activated potassium channel subunit alpha-1 OS=Homo sapiens GN=KCNMA1 PE=1 SV=2,Transporters,TC:1.A.1.3,Established target
NRDD130,-,CYCLIZINE,Antiemetics,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD131,-,CYCLOBENZAPRINE,"Antidepressive Agents, Tricyclic",small molecule,1977,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD132,-,CYCLOPENTOLATE,Mydriatics,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD133,-,CYCLOTHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,Approved before 1982,P54710,ATNG_HUMAN,FXYD2,Sodium/potassium-transporting ATPase gamma chain OS=Homo sapiens GN=FXYD2 PE=1 SV=3,Transporters,TC:1.A.27.2.1,Established target
NRDD134,-,CYCRIMINE,Antiparkinson Agents,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD135,-,CYPROHEPTADINE,Anti-Allergic Agents; Appetite Stimulant,small molecule,1961,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD135,-,CYPROHEPTADINE,Anti-Allergic Agents; Appetite Stimulant,small molecule,1961,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD136,-,CYPROTERONE,Hypersexuality-inhibiting agents; Antihirsutism agents,small molecule,Approved before 1982,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD137,-,DACARBAZINE,Antineoplastic Agents,small molecule,1975,Q14181,DPOA2_HUMAN,POLA2,DNA polymerase alpha subunit B OS=Homo sapiens GN=POLA2 PE=1 SV=2,Other,DNA Binding;DNA polymerase,Established target
NRDD138,-,DALFAMPRIDINE,MS-treatment,small molecule,2010,Q09470,KCNA1_HUMAN,KCNA1,Potassium voltage-gated channel subfamily A member 1 OS=Homo sapiens GN=KCNA1 PE=1 SV=2,Transporters,TC:1.A.1.2.12,Established target
NRDD139,-,DANAZOL,"Antiendometriosis Agent, Antineoplastic Agent",small molecule,1976,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD139,-,DANAZOL,"Antiendometriosis Agent, Antineoplastic Agent",small molecule,1976,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD139,-,DANAZOL,"Antiendometriosis Agent, Antineoplastic Agent",small molecule,1976,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD140,-,DANTROLENE,Muscle Relaxants,small molecule,2005,P21817,RYR1_HUMAN,RYR1,Ryanodine receptor 1 OS=Homo sapiens GN=RYR1 PE=1 SV=3,Transporters,TC:1.A.3.1.2,Established target
NRDD141,-,DAPIPRAZOLE,ophthalmological agent,small molecule,1990,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD141,-,DAPIPRAZOLE,ophthalmological agent,small molecule,1990,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD141,-,DAPIPRAZOLE,ophthalmological agent,small molecule,1990,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD142,-,DARBEPOETIN ALFA,Antianemic Agents,protein,2001,P19235,EPOR_HUMAN,EPOR,Erythropoietin receptor OS=Homo sapiens GN=EPOR PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
NRDD143,-,DEBRISOQUIN,Antihypertensive Agents,small molecule,not approved by the FDA,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD143,-,DEBRISOQUIN,Antihypertensive Agents,small molecule,not approved by the FDA,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD143,-,DEBRISOQUIN,Antihypertensive Agents,small molecule,not approved by the FDA,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD143,-,DEBRISOQUIN,Antihypertensive Agents,small molecule,not approved by the FDA,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD143,-,DEBRISOQUIN,Antihypertensive Agents,small molecule,not approved by the FDA,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD143,-,DEBRISOQUIN,Antihypertensive Agents,small molecule,not approved by the FDA,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD144,-,DECAMETHONIUM,Muscle Relaxants,small molecule,Approved before 1982,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD145,-,DEMECARIUM BROMIDE,Antiglaucomic Agents,small molecule,1959,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
NRDD145,-,DEMECARIUM BROMIDE,Antiglaucomic Agents,small molecule,1959,P06276,CHLE_HUMAN,BCHE,Cholinesterase OS=Homo sapiens GN=BCHE PE=1 SV=1,Enzymes,EC:3.1.1.8,Established target
NRDD146,-,DESERPIDINE,Antihypertensive Agents,small molecule,1957,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
NRDD147,-,DESFLURANE,inhalation anesthetics,small molecule,1992,P98194,AT2C1_HUMAN,ATP2C1,Calcium-transporting ATPase type 2C member 1 OS=Homo sapiens GN=ATP2C1 PE=1 SV=3,Transporters,TC:3.A.3.2.5,Established target
NRDD147,-,DESFLURANE,inhalation anesthetics,small molecule,1992,P30049,ATPD_HUMAN,ATP5D,"ATP synthase subunit delta, mitochondrial OS=Homo sapiens GN=ATP5D PE=1 SV=2",Enzymes,EC:3.6.3.14,Established target
NRDD147,-,DESFLURANE,inhalation anesthetics,small molecule,1992,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD147,-,DESFLURANE,inhalation anesthetics,small molecule,1992,P23415,GLRA1_HUMAN,GLRA1,Glycine receptor subunit alpha-1 OS=Homo sapiens GN=GLRA1 PE=1 SV=2,Receptors,TC:1.A.9.3.1,Established target
NRDD147,-,DESFLURANE,inhalation anesthetics,small molecule,1992,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD147,-,DESFLURANE,inhalation anesthetics,small molecule,1992,Q09470,KCNA1_HUMAN,KCNA1,Potassium voltage-gated channel subfamily A member 1 OS=Homo sapiens GN=KCNA1 PE=1 SV=2,Transporters,TC:1.A.1.2.12,Established target
NRDD147,-,DESFLURANE,inhalation anesthetics,small molecule,1992,P03886,NU1M_HUMAN,MT-ND1,NADH-ubiquinone oxidoreductase chain 1 OS=Homo sapiens GN=MT-ND1 PE=1 SV=1,Enzymes,EC:1.6.5.3,Established target
NRDD148,-,DESIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,Approved before 1982,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD148,-,DESIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,Approved before 1982,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD148,-,DESIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD148,-,DESIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,Approved before 1982,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD148,-,DESIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD148,-,DESIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,Approved before 1982,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD148,-,DESIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,Approved before 1982,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD149,-,DESLANOSIDE,Antiarrhythmia Agents; Cardiotonic Agents,small molecule,Approved before 1982,P05023,AT1A1_HUMAN,ATP1A1,Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1,Transporters,TC:3.A.3.1.1,Established target
NRDD150,-,DESOGESTREL,"Contraceptives, Oral",small molecule,1992,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD150,-,DESOGESTREL,"Contraceptives, Oral",small molecule,1992,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
NRDD151,-,DESOXIMETASONE,Anti-Inflammatory Agents; Glucocorticoids,small molecule,1977,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor,Receptors,Nuclear receptor,Established target
NRDD152,-,DESOXYCORTICOSTERONE PIVALATE,"Hormone Replacement Agents, anti-addison agent",small molecule,Approved before 1982,P08235,MCR_HUMAN,NR3C2,Mineralocorticoid receptor OS=Homo sapiens GN=NR3C2 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD153,-,DEXBROMPHENIRAMINE,Anti-Allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD154,-,DEXFENFLURAMINE,Appetite Depressants,small molecule,1996,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD155,-,DEXMEDETOMIDINE,Analgesics; Hypnotics and Sedatives,small molecule,1999,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD156,-,DEXTROMETHORPHAN,Antitussive Agents,small molecule,Approved before 1982,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD156,-,DEXTROMETHORPHAN,Antitussive Agents,small molecule,Approved before 1982,Q99720,OPRS1_HUMAN,OPRS1,"Opioid receptor, sigma 1 OS=Homo sapiens GN=OPRS1 PE=2 SV=1",Receptors,Miscellaneous;SIGMAR,Established target
NRDD157,-,DEZOCINE,"Analgesics, Opioid",small molecule,1989,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD157,-,DEZOCINE,"Analgesics, Opioid",small molecule,1989,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD158,-,DIAZOXIDE,Antihypertensive Agents; Vasodilator Agents,small molecule,1973,P55017,S12A3_HUMAN,SLC12A3,Solute carrier family 12 member 3 OS=Homo sapiens GN=SLC12A3 PE=1 SV=2,Transporters,TC:2.A.30.4.2,Established target
NRDD159,-,DIBUCAINE,"Anesthetics, Local",small molecule,Approved before 1982,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD159,-,DIBUCAINE,"Anesthetics, Local",small molecule,Approved before 1982,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD160,-,DICHLORPHENAMIDE,Antiglaucomic Agents,small molecule,1958,P00915,CAH1_HUMAN,CA1,Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD161,-,DICUMAROL,Anticoagulants,small molecule,Approved before 1982,Q9BQB6,VKOR1_HUMAN,VKORC1,Vitamin K epoxide reductase complex subunit 1 OS=Homo sapiens GN=VKORC1 PE=1 SV=1,Enzymes,EC:1.1.4.1,Established target
NRDD162,-,DICYCLOMINE,Antispasmodics,small molecule,1950,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD163,-,DIENESTROL,Hormone Replacement Agents,small molecule,Approved before 1982,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD164,-,DIETHYLPROPION,Appetite Depressants,small molecule,1959,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD164,-,DIETHYLPROPION,Appetite Depressants,small molecule,1959,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
NRDD165,-,DIETHYLSTILBESTROL,Hormone Replacement Agents,small molecule,Approved before 1982,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD166,-,DIFLORASONE,Anti-Inflammatory Agents; Glucocorticoids,small molecule,1977,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor ,Receptors,Nuclear receptor,Established target
NRDD167,-,DIGITOXIN,Anti-Arrhythmia Agents; Cardiotonic Agents,small molecule,Approved before 1982,P05023,AT1A1_HUMAN,ATP1A1,Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1,Transporters,TC:3.A.3.1.1,Established target
NRDD168,-,DIGOXIN,Anti-Arrhythmia Agents; Cardiotonic Agents,small molecule,Approved before 1982,P05023,AT1A1_HUMAN,ATP1A1,Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1,Transporters,TC:3.A.3.1.1,Established target
NRDD169,-,DIHYDROTACHYSTEROL,Anti-migraine Agents,small molecule,not approved by the FDA,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD170,-,DIMENHYDRINATE,Antiemetics,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD171,-,DINOPROST TROMETHAMINE,Abortifacient Agents,small molecule,Approved before 1982,P43119,PI2R_HUMAN,PTGIR,Prostacyclin receptor OS=Homo sapiens GN=PTGIR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD172,-,DINOPROSTONE,Abortifacient Agents,small molecule,1977,P34995,PE2R1_HUMAN,PTGER1,Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens GN=PTGER1 PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD172,-,DINOPROSTONE,Abortifacient Agents,small molecule,1977,P43116,PE2R2_HUMAN,PTGER2,Prostaglandin E2 receptor EP2 subtype OS=Homo sapiens GN=PTGER2 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD172,-,DINOPROSTONE,Abortifacient Agents,small molecule,1977,P43115,PE2R3_HUMAN,PTGER3,Prostaglandin E2 receptor EP3 subtype OS=Homo sapiens GN=PTGER3 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD172,-,DINOPROSTONE,Abortifacient Agents,small molecule,1977,P35408,PE2R4_HUMAN,PTGER4,Prostaglandin E2 receptor EP4 subtype OS=Homo sapiens GN=PTGER4 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD173,-,DIPHEMANIL METHYLSULFATE,Bronchodilator Agents,small molecule,Approved before 1982,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD174,-,DIPHENHYDRAMINE,Anti-Allergic Agents; Hypnotics and sedatives; Antiemetics; Antipruritics; Antitussives,small molecule,1946,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD175,-,DIPHENIDOL,Antiemetics,small molecule,1967,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD175,-,DIPHENIDOL,Antiemetics,small molecule,1967,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD175,-,DIPHENIDOL,Antiemetics,small molecule,1967,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD176,-,DIPHENOXYLATE,Antidiarrheals,small molecule,Approved before 1982,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD177,-,DIPHENYLPYRALINE,Anti-Allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD178,-,DIPIVEFRIN,Ophthalmologicals,small molecule,Approved before 1982,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD179,-,DISOPYRAMIDE,Anti-Arrhythmia Agents,small molecule,1977,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD180,-,DISULFIRAM,Alcohol Deterrents,small molecule,1951,P05091,ALDH2_HUMAN,ALDH2,"Aldehyde dehydrogenase, mitochondrial OS=Homo sapiens GN=ALDH2 PE=1 SV=2",Enzymes,EC:1.2.1.3,Established target
NRDD181,-,DIVALPROEX SODIUM,Anticonvulsants; Antimanic Agents,small molecule,1983,P80404,GABT_HUMAN,ABAT,"4-aminobutyrate aminotransferase, mitochondrial OS=Homo sapiens GN=ABAT PE=1 SV=3",Enzymes,EC:2.6.1.19; 2.6.1.22,Established target
NRDD182,-,DOBUTAMINE,Cardiotonic Agents,small molecule,1978,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD183,-,DOFETILIDE,Anti-Arrhythmia Agents,small molecule,1999,Q12809,KCNH2_HUMAN,KCNH2,Potassium voltage-gated channel subfamily H member 2 OS=Homo sapiens GN=KCNH2 PE=1 SV=1,Transporters,TC:1.A.1.20.1,Established target
NRDD183,-,DOFETILIDE,Anti-Arrhythmia Agents,small molecule,1999,Q14500,IRK12_HUMAN,KCNJ12,ATP-sensitive inward rectifier potassium channel 12 OS=Homo sapiens GN=KCNJ12 PE=1 SV=2,Transporters,TC:1.A.2.1.9,Established target
NRDD183,-,DOFETILIDE,Anti-Arrhythmia Agents,small molecule,1999,O95069,KCNK2_HUMAN,KCNK2,Potassium channel subfamily K member 2 OS=Homo sapiens GN=KCNK2 PE=2 SV=2,Transporters,TC:1.A.1.8,Established target
NRDD184,-,DOMPERIDONE,Antiemetics,small molecule,not approved by the FDA,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD185,-,DOXACURIUM,Muscle Relaxants,small molecule,1991,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD185,-,DOXACURIUM,Muscle Relaxants,small molecule,1991,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD186,-,DOXACURIUM CHLORIDE,Muscle Relaxants,small molecule,1991,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD186,-,DOXACURIUM CHLORIDE,Muscle Relaxants,small molecule,1991,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD187,-,DOXAZOSIN,Anticholesteremic Agents; Antihypertensive Agents; Vasodilator Agents,small molecule,1990,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD187,-,DOXAZOSIN,Anticholesteremic Agents; Antihypertensive Agents; Vasodilator Agents,small molecule,1990,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD187,-,DOXAZOSIN,Anticholesteremic Agents; Antihypertensive Agents; Vasodilator Agents,small molecule,1990,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD188,-,DOXYLAMINE,Anti-Allergic Agents; Antiemetics; Antitussive Agents; Hypnotics and Sedatives,small molecule,1948,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD189,-,DROMOSTANOLONE,"Antineoplastic Agents, Hormonal",small molecule,Approved before 1982,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD190,-,DRONEDARONE,Anti-Arrhythmia Agents,small molecule,2009,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD190,-,DRONEDARONE,Anti-Arrhythmia Agents,small molecule,2009,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD190,-,DRONEDARONE,Anti-Arrhythmia Agents,small molecule,2009,Q12809,KCNH2_HUMAN,KCNH2,Potassium voltage-gated channel subfamily H member 2 OS=Homo sapiens GN=KCNH2 PE=1 SV=1,Transporters,TC:1.A.1.20.1,Established target
NRDD191,-,DROPERIDOL,"Adjuvants, Anesthesia",small molecule,Approved before 1982,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD192,-,DUTASTERIDE,"Anti-baldness Agents, Antihyperplasia Agents",small molecule,2001,P18405,S5A1_HUMAN,SRD5A1,3-oxo-5-alpha-steroid 4-dehydrogenase 1 OS=Homo sapiens GN=SRD5A1 PE=1 SV=1,Enzymes,EC:1.3.1.30,Established target
NRDD192,-,DUTASTERIDE,"Anti-baldness Agents, Antihyperplasia Agents",small molecule,2001,P31213,S5A2_HUMAN,SRD5A2,3-oxo-5-alpha-steroid 4-dehydrogenase 2 OS=Homo sapiens GN=SRD5A2 PE=1 SV=1,Enzymes,EC:1.3.1.30,Established target
NRDD193,-,DYCLONINE,"Anesthetics, Local",small molecule,Approved before 1982,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD194,-,DYDROGESTERONE,Antidysmennorheal Agents,small molecule,Approved before 1982,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
NRDD195,-,DYPHYLLINE,Bronchodilator Agents; Vasodilator Agents,small molecule,Approved before 1982,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
NRDD195,-,DYPHYLLINE,Bronchodilator Agents; Vasodilator Agents,small molecule,Approved before 1982,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
NRDD195,-,DYPHYLLINE,Bronchodilator Agents; Vasodilator Agents,small molecule,Approved before 1982,Q08493,PDE4C_HUMAN,PDE4C,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C OS=Homo sapiens GN=PDE4C PE=1 SV=2",Enzymes,EC:3.1.4.17,Established target
NRDD195,-,DYPHYLLINE,Bronchodilator Agents; Vasodilator Agents,small molecule,Approved before 1982,Q08499,PDE4D_HUMAN,PDE4D,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D OS=Homo sapiens GN=PDE4D PE=1 SV=2",Enzymes,EC:3.1.4.17,Established target
NRDD195,-,DYPHYLLINE,Bronchodilator Agents; Vasodilator Agents,small molecule,Approved before 1982,Q13946,PDE7A_HUMAN,PDE7A,"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A OS=Homo sapiens GN=PDE7A PE=1 SV=2",Enzymes,EC:3.1.4.17,Established target
NRDD195,-,DYPHYLLINE,Bronchodilator Agents; Vasodilator Agents,small molecule,Approved before 1982,Q9NP56,PDE7B_HUMAN,PDE7B,"cAMP-specific 3',5'-cyclic phosphodiesterase 7B OS=Homo sapiens GN=PDE7B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
NRDD196,-,ECALLANTIDE,Treatment for Hereditary Angiooedema,peptide,2009,P06870,KLK1_HUMAN,KLK1,Kallikrein-1 (EC 3.4.21.35) (Tissue kallikrein) (Kidney/pancreas/salivary gland kallikrein),Enzymes,EC:3.4.21.35,Established target
NRDD197,-,ECHOTHIOPHATE IODIDE,Miotics,small molecule,1960,P06276,CHLE_HUMAN,BCHE,Cholinesterase OS=Homo sapiens GN=BCHE PE=1 SV=1,Enzymes,EC:3.1.1.8,Established target
NRDD198,-,EDROPHONIUM,Anti-Arrhythmia Agents; Antidotes,small molecule,1951,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
NRDD199,-,EMEDASTINE,Anti-Allergic Agents,small molecule,1997,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD200,-,ENCAINIDE,Anti-Arrhythmia Agents,small molecule,not approved by the FDA,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD201,-,ENFLURANE,"Anesthetics, Inhalation",small molecule,1966,P98194,AT2C1_HUMAN,ATP2C1,Calcium-transporting ATPase type 2C member 1 OS=Homo sapiens GN=ATP2C1 PE=1 SV=3,Transporters,TC:3.A.3.2.5,Established target
NRDD201,-,ENFLURANE,"Anesthetics, Inhalation",small molecule,1966,P30049,ATPD_HUMAN,ATP5D,"ATP synthase subunit delta, mitochondrial OS=Homo sapiens GN=ATP5D PE=1 SV=2",Enzymes,EC:3.6.3.14,Established target
NRDD201,-,ENFLURANE,"Anesthetics, Inhalation",small molecule,1966,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD201,-,ENFLURANE,"Anesthetics, Inhalation",small molecule,1966,P23415,GLRA1_HUMAN,GLRA1,Glycine receptor subunit alpha-1 OS=Homo sapiens GN=GLRA1 PE=1 SV=2,Receptors,TC:1.A.9.3.1,Established target
NRDD201,-,ENFLURANE,"Anesthetics, Inhalation",small molecule,1966,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD201,-,ENFLURANE,"Anesthetics, Inhalation",small molecule,1966,Q09470,KCNA1_HUMAN,KCNA1,Potassium voltage-gated channel subfamily A member 1 OS=Homo sapiens GN=KCNA1 PE=1 SV=2,Transporters,TC:1.A.1.2.12,Established target
NRDD201,-,ENFLURANE,"Anesthetics, Inhalation",small molecule,1966,Q12791,KCMA1_HUMAN,KCNMA1,Calcium-activated potassium channel subunit alpha-1 OS=Homo sapiens GN=KCNMA1 PE=1 SV=2,Transporters,TC:1.A.1.3,Established target
NRDD201,-,ENFLURANE,"Anesthetics, Inhalation",small molecule,1966,P03886,NU1M_HUMAN,MT-ND1,NADH-ubiquinone oxidoreductase chain 1 OS=Homo sapiens GN=MT-ND1 PE=1 SV=1,Enzymes,EC:1.6.5.3,Established target
NRDD202,-,ENOXIMONE,Cardiotonic Agents; Vasodilator Agents,small molecule,not approved by the FDA,Q14432,PDE3A_HUMAN,PDE3A,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A OS=Homo sapiens GN=PDE3A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
NRDD203,-,ENPROFYLLINE,Anti-Asthmatic Agents; Antiarrhythmic Agents; Bronchodilator Agents,small molecule,not approved by the FDA,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
NRDD203,-,ENPROFYLLINE,Anti-Asthmatic Agents; Antiarrhythmic Agents; Bronchodilator Agents,small molecule,not approved by the FDA,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
NRDD204,-,EPHEDRINE,Central Nervous System Stimulants,small molecule,Approved before 1982,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD205,-,EPIRUBICIN,Antineoplastic Agents,small molecule,1999,O14646,CHD1_HUMAN,CHD1,Chromodomain-helicase-DNA-binding protein 1 OS=Homo sapiens GN=CHD1 PE=1 SV=1,Enzymes,EC:3.6.1.-,Established target
NRDD205,-,EPIRUBICIN,Antineoplastic Agents,small molecule,1999,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
NRDD206,-,EPOPROSTENOL,Antihypertensive Agents; Platelet Aggregation Inhibitors,small molecule,1995,P43119,PI2R_HUMAN,PTGIR,Prostacyclin receptor OS=Homo sapiens GN=PTGIR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD207,-,EPROSARTAN,Antihypertensive Agents,small molecule,1997,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD208,-,ERGOCALCIFEROL,Antihypocalcemic Agents,small molecule,Approved before 1982,P11473,VDR_HUMAN,VDR,Vitamin D3 receptor OS=Homo sapiens GN=VDR PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD209,-,ERGOLOID MESYLATE,Nootropic Agents; Vasodilator Agents,small molecule,Approved before 1982,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD209,-,ERGOLOID MESYLATE,Nootropic Agents; Vasodilator Agents,small molecule,Approved before 1982,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD210,-,ERGOTAMINE,Anti-migraine Agents,small molecule,Approved before 1982,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD210,-,ERGOTAMINE,Anti-migraine Agents,small molecule,Approved before 1982,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD211,-,ERYTHRITYL TETRANITRATE,Antianginal Agents; Vasodilator Agents,small molecule,Approved before 1982,P16066,ANPRA_HUMAN,NPR1,Atrial natriuretic peptide receptor A OS=Homo sapiens GN=NPR1 PE=2 SV=1,Receptors,EC:4.6.1.2,Established target
NRDD211,-,ERYTHRITYL TETRANITRATE,Antianginal Agents; Vasodilator Agents,small molecule,Approved before 1982,P20594,ANPRB_HUMAN,NPR2,Atrial natriuretic peptide receptor B OS=Homo sapiens GN=NPR2 PE=1 SV=1,Receptors,EC:4.6.1.2,Established target
NRDD212,-,ESMOLOL,Anti-Arrhythmia Agents,small molecule,1986,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD213,-,ESTAZOLAM,Anti-anxiety Agents; Anticonvulsants,small molecule,1990,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD214,-,ESTRIOL,Hormone Replacement Agents,small molecule,Approved before 1982,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD215,-,ESTRONE,Hormone Replacement Agents,small molecule,not approved by the FDA,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD216,-,ETHACRYNIC ACID,Antihypertensive Agents; Diuretics,small molecule,1967,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD217,-,ETHOPROPAZINE,Antidyskinetics,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD218,-,ETHOSUXIMIDE,Anticonvulsants,small molecule,1960,O43497,CAC1G_HUMAN,CACNA1G,Voltage-dependent T-type calcium channel subunit alpha-1G OS=Homo sapiens GN=CACNA1G PE=2 SV=3,Transporters,TC:1.A.1.11,Established target
NRDD219,-,ETHOTOIN,Anticonvulsants,small molecule,1957,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD220,-,ETHOXZOLAMIDE,"Antihypertensive Agents, Diuretics; Antiglaucoma agents",small molecule,Approved before 1982,P00915,CAH1_HUMAN,CA1,Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD221,-,ETHYNODIOL DIACETATE,"Contraceptives, Oral, Synthetic",small molecule,1966,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD221,-,ETHYNODIOL DIACETATE,"Contraceptives, Oral, Synthetic",small molecule,1966,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
NRDD222,-,ETOMIDATE,"Anesthetics, Intravenous",small molecule,1982,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD222,-,ETOMIDATE,"Anesthetics, Intravenous",small molecule,1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD223,-,ETOPOSIDE,Antineoplastic Agents,small molecule,1983,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
NRDD224,-,EZETIMIBE,Anticholesteremic Agents,small molecule,2002,Q9UHC9,NPCL1_HUMAN,NPC1L1,Niemann-Pick C1-like protein 1 OS=Homo sapiens GN=NPC1L1 PE=2 SV=1,Receptors,Miscellaneous;Patched,Established target
NRDD225,-,FELBAMATE,Anticonvulsants; Antiepileptics,small molecule,1993,Q12879,NMDE1_HUMAN,GRIN2A,Glutamate [NMDA] receptor subunit epsilon-1 OS=Homo sapiens GN=GRIN2A PE=1 SV=1,Receptors,TC:1.A.10.1,Established target
NRDD225,-,FELBAMATE,Anticonvulsants; Antiepileptics,small molecule,1993,Q13224,NMDE2_HUMAN,GRIN2B,Glutamate [NMDA] receptor subunit epsilon-2 OS=Homo sapiens GN=GRIN2B PE=1 SV=3,Receptors,TC:1.A.10.1,Established target
NRDD225,-,FELBAMATE,Anticonvulsants; Antiepileptics,small molecule,1993,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD226,-,FELYPRESSIN,Hemostatic agents; Vasoconstricting Agents,peptide,not approved by the FDA,P37288,V1AR_HUMAN,AVPR1A,Vasopressin V1a receptor OS=Homo sapiens GN=AVPR1A PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD227,-,FENCAMFAMINE,Central Nervous System Stimulants,small molecule,Approved before 1982,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
NRDD228,-,FENOPROFEN,NSAID,small molecule,1976,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD228,-,FENOPROFEN,NSAID,small molecule,1976,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD229,-,FENOTEROL,Bronchodilator Agents; Tocolytic Agents,small molecule,not approved by the FDA,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD230,-,FLAVOXATE,Antispasmodics,small molecule,1970,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD230,-,FLAVOXATE,Antispasmodics,small molecule,1970,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD231,-,FLECAINIDE,Anti-Arrhythmia Agents,small molecule,1985,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD232,-,FLUDIAZEPAM,Anti-anxiety Agents; Anticonvulsants,small molecule,not approved by the FDA,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD233,-,FLUDROCORTISONE,Anti-Inflammatory Agents; corticosteroid,small molecule,Approved before 1982,P08235,MCR_HUMAN,NR3C2,Mineralocorticoid receptor OS=Homo sapiens GN=NR3C2 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD234,-,FLUMAZENIL,"Antidotes, Benzodoazepine Overdose",small molecule,1991,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD234,-,FLUMAZENIL,"Antidotes, Benzodoazepine Overdose",small molecule,1991,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD234,-,FLUMAZENIL,"Antidotes, Benzodoazepine Overdose",small molecule,1991,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD234,-,FLUMAZENIL,"Antidotes, Benzodoazepine Overdose",small molecule,1991,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD235,-,FLUMETHASONE PIVALATE,Anti-Inflammatory Agents; corticosteroid,small molecule,Approved before 1982,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD236,-,FLUNARIZINE,Anticonvulsants; Vasodilator Agents,small molecule,not approved by the FDA,O43497,CAC1G_HUMAN,CACNA1G,Voltage-dependent T-type calcium channel subunit alpha-1G OS=Homo sapiens GN=CACNA1G PE=2 SV=3,Transporters,TC:1.A.1.11,Established target
NRDD236,-,FLUNARIZINE,Anticonvulsants; Vasodilator Agents,small molecule,not approved by the FDA,O95180,CAC1H_HUMAN,CACNA1H,Voltage-dependent T-type calcium channel subunit alpha-1H OS=Homo sapiens GN=CACNA1H PE=1 SV=4,Transporters,TC:1.A.1.11.5,Established target
NRDD236,-,FLUNARIZINE,Anticonvulsants; Vasodilator Agents,small molecule,not approved by the FDA,Q9P0X4,CAC1I_HUMAN,CACNA1I,Voltage-dependent T-type calcium channel subunit alpha-1I OS=Homo sapiens GN=CACNA1I PE=1 SV=1,Transporters,TC:1.A.1.11.7,Established target
NRDD236,-,FLUNARIZINE,Anticonvulsants; Vasodilator Agents,small molecule,not approved by the FDA,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD237,-,FLUNITRAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P30536,TSPOA_HUMAN,BZRP,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
NRDD237,-,FLUNITRAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD237,-,FLUNITRAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD237,-,FLUNITRAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD237,-,FLUNITRAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD237,-,FLUNITRAZEPAM,Hypnotics and Sedatives,small molecule,not approved by the FDA,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD238,-,FLUOROMETHOLONE,Anti-Inflammatory Agents; Anti-allergic agents; Glucocorticoids,small molecule,Approved before 1982,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD239,-,FLUOXYMESTERONE,Anabolic Agents; Antineoplastic Agents,small molecule,1956,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD240,-,FLUPENTHIXOL,Antipsychotic Agents,small molecule,not approved by the FDA,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD240,-,FLUPENTHIXOL,Antipsychotic Agents,small molecule,not approved by the FDA,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD241,-,FLUPHENAZINE,Antipsychotic Agents,small molecule,1959,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD241,-,FLUPHENAZINE,Antipsychotic Agents,small molecule,1959,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD242,-,FLURANDRENOLIDE,Anti-Inflammatory Agents; Glucocorticoids,small molecule,1965,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD243,-,FLURAZEPAM,Hypnotics and Sedatives,small molecule,1970,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD244,-,FLUSPIRILENE,Antipsychotic Agents,small molecule,Approved before 1982,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD245,-,FLUTAMIDE,"Antineoplastic Agents, Hormonal",small molecule,1989,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD246,-,FOLLITROPIN BETA,Fertility Agents,recombinant protein,1997,P23945,FSHR_HUMAN,FSHR,Follicle-stimulating hormone receptor OS=Homo sapiens GN=FSHR PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD247,-,FONDAPARINUX,Antithrombotic Agents,small molecule,2001,P01008,ANT3_HUMAN,SERPINC1,Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1,Other,Enzyme regulator,Established target
NRDD248,-,FORASARTAN,Antihypertensive Agents,small molecule,not approved by the FDA,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD249,-,FOSINOPRIL,Antihypertensive Agents,small molecule,1991,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
NRDD250,-,FUROSEMIDE,Antihypertensive Agents; Diuretics,small molecule,1966,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD251,-,GALLAMINE TRIETHIODIDE,"Muscle Relaxants, Skeletal",small molecule,Approved before 1982,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD252,-,GEMFIBROZIL,Antilipemic Agents,small molecule,1981,Q07869,PPARA_HUMAN,PPARA,Peroxisome proliferator-activated receptor alpha OS=Homo sapiens GN=PPARA PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD253,-,GLIBENCLAMIDE,Hypoglycemic Agents,small molecule,1984,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
NRDD253,-,GLIBENCLAMIDE,Hypoglycemic Agents,small molecule,1984,Q14654,IRK11_HUMAN,KCNJ11,ATP-sensitive inward rectifier potassium channel 11 OS=Homo sapiens GN=KCNJ11 PE=1 SV=2,Transporters,TC:1.A.2.1,Established target
NRDD254,-,GLICLAZIDE,Hypoglycemic Agents,small molecule,not approved by the FDA,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
NRDD255,-,GLIPIZIDE,Hypoglycemic Agents,small molecule,1984,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
NRDD256,-,GLUCAGON RECOMBINANT,Antihypoglycemic Agents,recombinant peptide,1960,P47871,GLR_HUMAN,GCGR,Glucagon receptor OS=Homo sapiens GN=GCGR PE=1 SV=1,Receptors,GPCR;Secretin,Established target
NRDD257,-,GLYCODIAZINE,Hypoglycemic Agents,small molecule,not approved by the FDA,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
NRDD258,-,GOLIMUMAB,Immunosuppressive Agents,monoclonal antibody,2009,P01375,TNFA_HUMAN,TNF,Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1,Other,Ligand;Cytokine,Established target
NRDD259,-,GONADORELIN,Fertility Agents,small molecule,1982,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD259,-,GONADORELIN,Fertility Agents,small molecule,1982,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD260,-,GOSERELIN,"Antineoplastic Agents, Hormonal",peptide,1989,P22888,LSHR_HUMAN,LHCGR,Lutropin-choriogonadotropic hormone receptor OS=Homo sapiens GN=LHCGR PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD261,-,GUANABENZ,Antihypertensive Agents,small molecule,1982,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD262,-,GUANADREL SULFATE,Antihypertensive Agents,small molecule,1982,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD263,-,GUANETHIDINE,Antihypertensive Agents,small molecule,1960,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD264,-,HALAZEPAM,Anti-anxiety Agents; Muscle Relaxants; Sedative,small molecule,1981,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD265,-,HALOBETASOL PROPIONATE,Anti-inflammatory Agents,small molecule,1990,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor ,Receptors,Nuclear receptor,Established target
NRDD266,-,HALOPERIDOL,Antipsychotic Agents,small molecule,1967,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD267,-,HALOTHANE,"Anesthetics, Inhalation",small molecule,1958,P30049,ATPD_HUMAN,ATP5D,"ATP synthase subunit delta, mitochondrial OS=Homo sapiens GN=ATP5D PE=1 SV=2",Enzymes,EC:3.6.3.14,Established target
NRDD268,-,HEXAFLURONIUM BROMIDE,Muscle Relaxants,small molecule,not approved by the FDA,P06276,CHLE_HUMAN,BCHE,Cholinesterase OS=Homo sapiens GN=BCHE PE=1 SV=1,Enzymes,EC:3.1.1.8,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD269,-,HEXOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD270,-,HEXYLCAINE,"Anesthetics, Local",small molecule,Approved before 1982,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD270,-,HEXYLCAINE,"Anesthetics, Local",small molecule,Approved before 1982,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD271,-,HOMATROPINE METHYLBROMIDE,"GI Anti-Ulcer Agents, Antimuscarinics",small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD271,-,HOMATROPINE METHYLBROMIDE,"GI Anti-Ulcer Agents, Antimuscarinics",small molecule,Approved before 1982,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD271,-,HOMATROPINE METHYLBROMIDE,"GI Anti-Ulcer Agents, Antimuscarinics",small molecule,Approved before 1982,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD271,-,HOMATROPINE METHYLBROMIDE,"GI Anti-Ulcer Agents, Antimuscarinics",small molecule,Approved before 1982,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD271,-,HOMATROPINE METHYLBROMIDE,"GI Anti-Ulcer Agents, Antimuscarinics",small molecule,Approved before 1982,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD272,-,HYDROCORTAMATE,Anti-Inflammatory Agents; Glucocorticoids,small molecule,1956,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor ,Receptors,Nuclear receptor,Established target
NRDD272,-,HYDROCORTAMATE,Anti-Inflammatory Agents; Glucocorticoids,small molecule,1956,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD273,-,HYDROFLUMETHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,Approved before 1982,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD274,-,HYDROXYUREA,Antineoplastic Agents,small molecule,1967,P23921,RIR1_HUMAN,RRM1,Ribonucleoside-diphosphate reductase large subunit OS=Homo sapiens GN=RRM1 PE=1 SV=1,Enzymes,EC:1.17.4.1,Established target
NRDD275,-,HYDROXYZINE,Antipruritics; Anxiolytics sedatives and hypnotics,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD276,-,IBRITUMOMAB,Antineoplastic Agents,monoclonal antibody,2002,P11836,CD20_HUMAN,MS4A1,B-lymphocyte antigen CD20 OS=Homo sapiens GN=MS4A1 PE=1 SV=1,Other,MS4A family,Established target
NRDD277,-,IBUTILIDE,Anti-Arrhythmia Agents,small molecule,1995,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
NRDD277,-,IBUTILIDE,Anti-Arrhythmia Agents,small molecule,1995,P54289,CA2D1_HUMAN,CACNA2D1,Voltage-dependent calcium channel subunit alpha-2/delta-1 OS=Homo sapiens GN=CACNA2D1 PE=1 SV=2,Transporters,TC:8.A.18.1.1,Established target
NRDD277,-,IBUTILIDE,Anti-Arrhythmia Agents,small molecule,1995,Q02641,CACB1_HUMAN,CACNB1,Voltage-dependent L-type calcium channel subunit beta-1 OS=Homo sapiens GN=CACNB1 PE=1 SV=3,Transporters,TC:8.A.22.1.1,Established target
NRDD277,-,IBUTILIDE,Anti-Arrhythmia Agents,small molecule,1995,Q12809,KCNH2_HUMAN,KCNH2,Potassium voltage-gated channel subfamily H member 2 OS=Homo sapiens GN=KCNH2 PE=1 SV=1,Transporters,TC:1.A.1.20.1,Established target
NRDD278,-,IDARUBICIN,Antineoplastic Agents,small molecule,1990,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
NRDD279,-,IDURSULFASE,Enzyme Replacement Agents,protein,2006,O60664,M6PBP_HUMAN,M6PRBP1,Mannose-6-phosphate receptor-binding protein 1 OS=Homo sapiens GN=M6PRBP1 PE=1 SV=2,Other,Vesicle transport,Established target
NRDD280,-,IFOSFAMIDE,Antineoplastic Agents,small molecule,1988,P26358,DNMT1_HUMAN,DNMT1,DNA (cytosine-5)-methyltransferase 1 OS=Homo sapiens GN=DNMT1 PE=1 SV=2,Enzymes,EC:2.1.1.37,Established target
NRDD281,-,IMIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,Approved before 1982,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD281,-,IMIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,Approved before 1982,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD283,-,INDAPAMIDE,Antihypertensive Agents; Diuretics,small molecule,1983,P15382,KCNE1_HUMAN,KCNE1,Potassium voltage-gated channel subfamily E member 1 OS=Homo sapiens GN=KCNE1 PE=1 SV=1,Transporters,TC:8.A.10.1.1,Established target
NRDD283,-,INDAPAMIDE,Antihypertensive Agents; Diuretics,small molecule,1983,P51787,KCNQ1_HUMAN,KCNQ1,Potassium voltage-gated channel subfamily KQT member 1 OS=Homo sapiens GN=KCNQ1 PE=1 SV=3,Transporters,TC:1.A.1.15.6,Established target
NRDD284,-,INDECAINIDE,Anti-Arrhythmia Agents,small molecule,1989,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD285,-,"INTERFERON ALFA-2A, RECOMBINANT",Antineoplastic Agents; Immunomodulatory Agents,recombinant protein,1986,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
NRDD285,-,"INTERFERON ALFA-2A, RECOMBINANT",Antineoplastic Agents; Immunomodulatory Agents,recombinant protein,1986,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
NRDD286,-,"INTERFERON ALFA-2B, RECOMBINANT",Antineoplastic Agents; Immunomodulatory Agents,recombinant protein,1986,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
NRDD286,-,"INTERFERON ALFA-2B, RECOMBINANT",Antineoplastic Agents; Immunomodulatory Agents,recombinant protein,1986,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
NRDD287,-,INTERFERON ALFACON-1,Antineoplastic Agents; Immunomodulatory Agents,recombinant protein,1997,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
NRDD287,-,INTERFERON ALFACON-1,Antineoplastic Agents; Immunomodulatory Agents,recombinant protein,1997,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
NRDD288,-,INTERFERON ALFA-N1,Immunomodulatory Agents,protein,not approved by the FDA,P17181,INAR1_HUMAN,IFNAR1,Interferon-alpha/beta receptor alpha chain OS=Homo sapiens GN=IFNAR1 PE=1 SV=3,Receptors,Receptor; Type 2 cytokine receptor,Established target
NRDD288,-,INTERFERON ALFA-N1,Immunomodulatory Agents,protein,not approved by the FDA,P48551,INAR2_HUMAN,IFNAR2,Interferon-alpha/beta receptor beta chain OS=Homo sapiens GN=IFNAR2 PE=1 SV=1,Receptors,Receptor; Type 2 cytokine receptor,Established target
NRDD289,-,ISOCARBOXAZID,Antidepressive Agents,small molecule,1959,P21397,AOFA_HUMAN,MAOA,Amine oxidase [flavin-containing] A OS=Homo sapiens GN=MAOA PE=1 SV=1,Enzymes,EC:1.4.3.4,Established target
NRDD289,-,ISOCARBOXAZID,Antidepressive Agents,small molecule,1959,P27338,AOFB_HUMAN,MAOB,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3.4,Established target
NRDD290,-,ISOETHARINE,Bronchodilator Agents,small molecule,Approved before 1982,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD291,-,ISOFLURANE,"Anesthetics, Inhalation",small molecule,1979,P98194,AT2C1_HUMAN,ATP2C1,Calcium-transporting ATPase type 2C member 1 OS=Homo sapiens GN=ATP2C1 PE=1 SV=3,Transporters,TC:3.A.3.2.5,Established target
NRDD291,-,ISOFLURANE,"Anesthetics, Inhalation",small molecule,1979,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD291,-,ISOFLURANE,"Anesthetics, Inhalation",small molecule,1979,P23415,GLRA1_HUMAN,GLRA1,Glycine receptor subunit alpha-1 OS=Homo sapiens GN=GLRA1 PE=1 SV=2,Receptors,TC:1.A.9.3.1,Established target
NRDD291,-,ISOFLURANE,"Anesthetics, Inhalation",small molecule,1979,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD291,-,ISOFLURANE,"Anesthetics, Inhalation",small molecule,1979,Q09470,KCNA1_HUMAN,KCNA1,Potassium voltage-gated channel subfamily A member 1 OS=Homo sapiens GN=KCNA1 PE=1 SV=2,Transporters,TC:1.A.1.2.12,Established target
NRDD292,-,ISOFLUROPHATE,Antiglaucomic Agents,small molecule,1957,P06276,CHLE_HUMAN,BCHE,Cholinesterase OS=Homo sapiens GN=BCHE PE=1 SV=1,Enzymes,EC:3.1.1.8,Established target
NRDD293,-,ISOPROTERENOL,Bronchodilator Agents; Cardiotonic Agents,small molecule,Approved before 1982,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD293,-,ISOPROTERENOL,Bronchodilator Agents; Cardiotonic Agents,small molecule,Approved before 1982,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD294,-,ISOSORBIDE-5-MONONITRATE,Antianginal Agents; Vasodilator Agents,small molecule,1991,P16066,ANPRA_HUMAN,NPR1,Atrial natriuretic peptide receptor A OS=Homo sapiens GN=NPR1 PE=2 SV=1,Receptors,EC:4.6.1.2,Established target
NRDD295,-,ISRADIPINE,Antihypertensive Agents; Vasodilator Agents,small molecule,1990,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
NRDD295,-,ISRADIPINE,Antihypertensive Agents; Vasodilator Agents,small molecule,1990,P54289,CA2D1_HUMAN,CACNA2D1,Voltage-dependent calcium channel subunit alpha-2/delta-1 OS=Homo sapiens GN=CACNA2D1 PE=1 SV=2,Transporters,TC:8.A.18.1.1,Established target
NRDD296,-,LABETALOL,Antihypertensive Agents,small molecule,1984,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD296,-,LABETALOL,Antihypertensive Agents,small molecule,1984,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD296,-,LABETALOL,Antihypertensive Agents,small molecule,1984,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD296,-,LABETALOL,Antihypertensive Agents,small molecule,1984,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD297,-,LEFLUNOMIDE,Antirheumatic Agents,small molecule,1998,Q02127,PYRD_HUMAN,DHODH,"Dihydroorotate dehydrogenase, mitochondrial OS=Homo sapiens GN=DHODH PE=1 SV=3",Enzymes,EC:1.3.5.2,Established target
NRDD298,-,LEVALLORPHAN,Opiate Antagonists,small molecule,Approved before 1982,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD299,-,LEVOBUNOLOL,Antiglaucomic Agents,small molecule,1985,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD299,-,LEVOBUNOLOL,Antiglaucomic Agents,small molecule,1985,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD300,-,LEVOBUPIVACAINE,"Anesthetics, Local",small molecule,1999,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD301,-,LEVOCABASTINE,Anti-Allergic Agents,small molecule,1993,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD302,-,LEVOMETHADYL ACETATE,"Analgesics, Opioid",small molecule,1993,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD303,-,LEVORPHANOL,"Analgesics, Opioid",small molecule,1953,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD304,-,LIOTHYRONINE,Hormone Replacement Agents,small molecule,1956,P10827,THA_HUMAN,THRA,Thyroid hormone receptor alpha OS=Homo sapiens GN=THRA PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD304,-,LIOTHYRONINE,Hormone Replacement Agents,small molecule,1956,P10828,THB_HUMAN,THRB,Thyroid hormone receptor beta OS=Homo sapiens GN=THRB PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD305,-,LIRAGLUTIDE RECOMBINANT,Antidiabetic agent,peptide,2010,P43220,GLP1R_HUMAN,GLP1R,Glucagon-like peptide 1 receptor OS=Homo sapiens GN=GLP1R PE=1 SV=1,Receptors,GPCR;Secretin,Established target
NRDD306,-,LISDEXAMFETAMINE,Central Nervous System Stimulants,small molecule,2007,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD306,-,LISDEXAMFETAMINE,Central Nervous System Stimulants,small molecule,2007,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD306,-,LISDEXAMFETAMINE,Central Nervous System Stimulants,small molecule,2007,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
NRDD307,-,LISURIDE,Antiparkinson Agents,small molecule,not approved by the FDA,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD307,-,LISURIDE,Antiparkinson Agents,small molecule,not approved by the FDA,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD307,-,LISURIDE,Antiparkinson Agents,small molecule,not approved by the FDA,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD308,-,LOPERAMIDE,Antidiarrheals,small molecule,Approved before 1982,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P30536,TSPOA_HUMAN,BZRP,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD309,-,LORAZEPAM,Anti-anxiety Agents; Anticonvulsants; Hypnotics and Sedatives,small molecule,1977,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD310,-,LOSARTAN,Antihypertensive Agents,small molecule,1995,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD311,-,LUTROPIN ALFA,Fertility Agents,peptide,2004,P22888,LSHR_HUMAN,LHCGR,Lutropin-choriogonadotropic hormone receptor OS=Homo sapiens GN=LHCGR PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD312,-,MAPROTILINE,"Antidepressive Agents, Second-Generation",small molecule,1980,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD313,-,MARIMASTAT,Antineoplastic Agents,small molecule,not approved by the FDA,P08253,MMP2_HUMAN,MMP2,72 kDa type IV collagenase OS=Homo sapiens GN=MMP2 PE=1 SV=2,Enzymes,EC:3.4.24.24,Novel Target
NRDD313,-,MARIMASTAT,Antineoplastic Agents,small molecule,not approved by the FDA,P08254,MMP3_HUMAN,MMP3,Stromelysin-1 OS=Homo sapiens GN=MMP3 PE=1 SV=2,Enzymes,EC:3.4.24.17,Novel Target
NRDD313,-,MARIMASTAT,Antineoplastic Agents,small molecule,not approved by the FDA,P14780,MMP9_HUMAN,MMP9,Matrix metalloproteinase-9 OS=Homo sapiens GN=MMP9 PE=1 SV=2,Enzymes,EC:3.4.24.35,Novel Target
NRDD314,-,MARINOL,Antiemetics,small molecule,1985,P21554,CNR1_HUMAN,CNR1,Cannabinoid receptor 1 OS=Homo sapiens GN=CNR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD315,-,MECLIZINE,Antiemetics,small molecule,1957,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD316,-,MECLOFENAMIC ACID,NSAID,small molecule,not approved by the FDA,P09917,LOX5_HUMAN,ALOX5,Arachidonate 5-lipoxygenase OS=Homo sapiens GN=ALOX5 PE=1 SV=2,Enzymes,EC:1.13.11.34,Established target
NRDD316,-,MECLOFENAMIC ACID,NSAID,small molecule,not approved by the FDA,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD316,-,MECLOFENAMIC ACID,NSAID,small molecule,not approved by the FDA,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD317,-,MEDRYSONE,"Anti-Inflammatory Agents, Topical",small molecule,1969,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD318,-,MEFENAMIC ACID,NSAID,small molecule,1967,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD318,-,MEFENAMIC ACID,NSAID,small molecule,1967,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD319,-,MEGESTROL,"Antineoplastic Agents, Hormonal; Contraceptives",small molecule,1971,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD319,-,MEGESTROL,"Antineoplastic Agents, Hormonal; Contraceptives",small molecule,1971,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
NRDD320,-,MELATONIN,Hypnotics and Sedatives,small molecule,not approved by the FDA,P48039,MTR1A_HUMAN,MTNR1A,Melatonin receptor type 1A OS=Homo sapiens GN=MTNR1A PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD320,-,MELATONIN,Hypnotics and Sedatives,small molecule,not approved by the FDA,P49286,MTR1B_HUMAN,MTNR1B,Melatonin receptor type 1B OS=Homo sapiens GN=MTNR1B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD321,-,MELOXICAM,NSAID,small molecule,2000,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD322,-,MENOTROPINS,Fertility Agents,protein,Approved before 1982,P23945,FSHR_HUMAN,FSHR,Follicle-stimulating hormone receptor OS=Homo sapiens GN=FSHR PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD322,-,MENOTROPINS,Fertility Agents,protein,Approved before 1982,P22888,LSHR_HUMAN,LHCGR,Lutropin-choriogonadotropic hormone receptor OS=Homo sapiens GN=LHCGR PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD323,-,MENTHOL,Antipruritics,small molecule,Approved before 1982,O75762,TRPA1_HUMAN,TRPA1,Transient receptor potential cation channel subfamily A member 1 OS=Homo sapiens GN=TRPA1 PE=2 SV=2,Transporters,TC:1.A.4.6.3,Established target
NRDD323,-,MENTHOL,Antipruritics,small molecule,Approved before 1982,Q7Z2W7,TRPM8_HUMAN,TRPM8,Transient receptor potential cation channel subfamily M member 8 OS=Homo sapiens GN=TRPM8 PE=2 SV=2,Transporters,TC:1.A.4.5.7,Established target
NRDD323,-,MENTHOL,Antipruritics,small molecule,Approved before 1982,Q8NET8,TRPV3_HUMAN,TRPV3,Transient receptor potential cation channel subfamily V member 3 OS=Homo sapiens GN=TRPV3 PE=1 SV=2,Transporters,TC:1.A.4.2.9,Established target
NRDD324,-,MEPENZOLATE,Antispasmodics,small molecule,1956,Q8TDS4,NIAR1_HUMAN,GPR109A,Niacin receptor 1 OS=Homo sapiens GN=NIACR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD324,-,MEPENZOLATE,Antispasmodics,small molecule,1956,P49019,G109B_HUMAN,GPR109B,Niacin receptor 2 OS=Homo sapiens GN=NIACR2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD325,-,MEPERIDINE,"Analgesics, Opioid",small molecule,1942,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD326,-,MEPHENTERMINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,Approved before 1982,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD327,-,MEPHENYTOIN,Anticonvulsants,small molecule,Approved before 1982,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD328,-,MEPROBAMATE,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD328,-,MEPROBAMATE,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD328,-,MEPROBAMATE,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD328,-,MEPROBAMATE,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD328,-,MEPROBAMATE,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD328,-,MEPROBAMATE,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD329,-,MEQUITAZINE,Anti-Allergic Agents,small molecule,not approved by the FDA,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD330,-,MERCAPTOPURINE,Antineoplastic Agents,small molecule,1953,P00492,HPRT_HUMAN,HPRT1,Hypoxanthine-guanine phosphoribosyltransferase OS=Homo sapiens GN=HPRT1 PE=1 SV=2,Enzymes,EC:2.4.2.8,Established target
NRDD331,-,MESORIDAZINE,Antipsychotic Agents,small molecule,1970,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD331,-,MESORIDAZINE,Antipsychotic Agents,small molecule,1970,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD332,-,MESTRANOL,"Contraceptives, Oral",small molecule,Approved before 1982,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD333,-,METARAMINOL,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,Approved before 1982,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD334,-,METHADONE,"Analgesics, Opioid; Antitussive Agents",small molecule,Approved before 1982,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD335,-,METHADYL ACETATE,"Analgesics, Opioid",small molecule,1993,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD336,-,METHANTHELINE,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,1951,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD337,-,METHARBITAL,Anticonvulsants,small molecule,Approved before 1982,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD338,-,METHAZOLAMIDE,"Antihypertensive Agents, Diuretics; Antiglaucoma agents",small molecule,Approved before 1982,P00915,CAH1_HUMAN,CA1,Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD339,-,METHDILAZINE,Anti-Allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD340,-,METHIMAZOLE,Antithyroid Agents,small molecule,1950,P07202,PERT_HUMAN,TPO,Thyroid peroxidase OS=Homo sapiens GN=TPO PE=1 SV=4,Enzymes,EC:1.11.1.8,Established target
NRDD341,-,METHOHEXITAL,"Anesthetics, Intravenous",small molecule,1960,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P35462,DRD3_HUMAN,DRD3,D(3) dopamine receptor OS=Homo sapiens GN=DRD3 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD342,-,METHOTRIMEPRAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD343,-,METHOXAMINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,Approved before 1982,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD343,-,METHOXAMINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,Approved before 1982,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD344,-,METHOXYFLURANE,"Anesthetics, Inhalation",small molecule,not approved by the FDA,P30049,ATPD_HUMAN,ATP5D,"ATP synthase subunit delta, mitochondrial OS=Homo sapiens GN=ATP5D PE=1 SV=2",Enzymes,EC:3.6.3.14,Established target
NRDD345,-,METHYCLOTHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,1960,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD346,-,METHYLDOPA,Antihypertensive Agents,small molecule,1962,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD347,-,METHYLERGONOVINE,Abortifacient Agents,small molecule,1946,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD348,-,METHYLNALTREXONE BROMIDE,OIC treatment,small molecule,2008,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD349,-,METHYLPHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD350,-,METHYLPREDNISOLONE,Anti-Inflammatory Agents; Glucocorticoids,small molecule,Approved before 1982,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor ,Receptors,Nuclear receptor,Established target
NRDD350,-,METHYLPREDNISOLONE,Anti-Inflammatory Agents; Glucocorticoids,small molecule,Approved before 1982,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD351,-,METHYLSCOPOLAMINE,Antispasmodics,small molecule,1953,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD352,-,METHYPRYLON,Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD353,-,METHYSERGIDE,Anti-migraine agents; Vasoconstrictor Agents,small molecule,1962,P08908,5HT1A_HUMAN,HTR1A,5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD353,-,METHYSERGIDE,Anti-migraine agents; Vasoconstrictor Agents,small molecule,1962,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD353,-,METHYSERGIDE,Anti-migraine agents; Vasoconstrictor Agents,small molecule,1962,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD353,-,METHYSERGIDE,Anti-migraine agents; Vasoconstrictor Agents,small molecule,1962,P34969,5HT7R_HUMAN,HTR7,5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD354,-,METIPRANOLOL,Anti-Arrhythmia Agents; Antihypertensive Agents; Anti-glaucoma agent,small molecule,1989,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD354,-,METIPRANOLOL,Anti-Arrhythmia Agents; Antihypertensive Agents; Anti-glaucoma agent,small molecule,1989,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD355,-,METIXENE,Antiparkinson Agents,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD355,-,METIXENE,Antiparkinson Agents,small molecule,Approved before 1982,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD355,-,METIXENE,Antiparkinson Agents,small molecule,Approved before 1982,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD355,-,METIXENE,Antiparkinson Agents,small molecule,Approved before 1982,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD355,-,METIXENE,Antiparkinson Agents,small molecule,Approved before 1982,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD356,-,METOCURINE,Muscle Relaxants,small molecule,Approved before 1982,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD357,-,METOCURINE IODIDE,Muscle Relaxants,small molecule,Approved before 1982,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD358,-,METOLAZONE,Antihypertensive Agents; Diuretics,small molecule,1973,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD358,-,METOLAZONE,Antihypertensive Agents; Diuretics,small molecule,1973,P55017,S12A3_HUMAN,SLC12A3,Solute carrier family 12 member 3 OS=Homo sapiens GN=SLC12A3 PE=1 SV=2,Transporters,TC:2.A.30.4.2,Established target
NRDD359,-,METOPROLOL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1978,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD360,-,METYRAPONE,Diagnostic Agents,small molecule,1961,P15538,C11B1_HUMAN,CYP11B1,"Cytochrome P450 11B1, mitochondrial OS=Homo sapiens GN=CYP11B1 PE=1 SV=5",Enzymes,EC:1.14.15.4,Established target
NRDD361,-,METYROSINE,Catecholamine synthesis inhibitors,small molecule,1979,P07101,TY3H_HUMAN,TH,Tyrosine 3-monooxygenase OS=Homo sapiens GN=TH PE=1 SV=4,Enzymes,EC:1.14.16.2,Established target
NRDD362,-,MEXILETINE,Anti-Arrhythmia Agents,small molecule,1985,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD363,-,MIANSERIN,"Antidepressive Agents, Second-Generation",small molecule,not approved by the FDA,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD363,-,MIANSERIN,"Antidepressive Agents, Second-Generation",small molecule,not approved by the FDA,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD363,-,MIANSERIN,"Antidepressive Agents, Second-Generation",small molecule,not approved by the FDA,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD363,-,MIANSERIN,"Antidepressive Agents, Second-Generation",small molecule,not approved by the FDA,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD364,-,MIDAZOLAM,"Adjuvants, Anesthesia; Hypnotics and Sedatives",small molecule,1985,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD365,-,MIDODRINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,1996,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD365,-,MIDODRINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,1996,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD366,-,MIGLITOL,Hypoglycemic Agents,small molecule,1996,O43451,MGA_HUMAN,MGAM,"Maltase-glucoamylase, intestinal OS=Homo sapiens GN=MGAM PE=1 SV=5",Enzymes,EC:3.2.1,Established target
NRDD367,-,MILRINONE,Cardiotonic Agents; Vasodilator Agents,small molecule,1987,Q14432,PDE3A_HUMAN,PDE3A,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A OS=Homo sapiens GN=PDE3A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
NRDD367,-,MILRINONE,Cardiotonic Agents; Vasodilator Agents,small molecule,1987,P27815,PDE4A_HUMAN,PDE4A,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A OS=Homo sapiens GN=PDE4A PE=1 SV=3",Enzymes,EC:3.1.4.17,Established target
NRDD368,-,MINAPRINE,Antidepressive Agents,small molecule,not approved by the FDA,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD368,-,MINAPRINE,Antidepressive Agents,small molecule,not approved by the FDA,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD368,-,MINAPRINE,Antidepressive Agents,small molecule,not approved by the FDA,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD368,-,MINAPRINE,Antidepressive Agents,small molecule,not approved by the FDA,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD368,-,MINAPRINE,Antidepressive Agents,small molecule,not approved by the FDA,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD368,-,MINAPRINE,Antidepressive Agents,small molecule,not approved by the FDA,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD369,-,MINOXIDIL,Antihypertensive Agents; Vasodilator Agents,small molecule,1979,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
NRDD370,-,MIVACURIUM,Muscle Relaxants,small molecule,1992,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD370,-,MIVACURIUM,Muscle Relaxants,small molecule,1992,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD371,-,MOEXIPRIL,Antihypertensive Agents,small molecule,1995,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
NRDD372,-,MOLINDONE,Antipsychotic Agents,small molecule,1974,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD373,-,MORICIZINE,Anti-Arrhythmia Agents,small molecule,1990,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD374,-,MUROMONAB,Immunosuppressive Agents,monoclonal antibody,1986,P07766,CD3E_HUMAN,CD3E,T-cell surface glycoprotein CD3 epsilon chain OS=Homo sapiens GN=CD3E PE=1 SV=2,Receptors,Receptor; T-cell receptor subunit,Established target
NRDD374,-,MUROMONAB,Immunosuppressive Agents,monoclonal antibody,1986,P04234 ,CD3D_HUMAN,CD3D,T-cell surface glycoprotein CD3 delta chain,Receptors,Receptor; T-cell receptor subunit,Established target
NRDD374,-,MUROMONAB,Immunosuppressive Agents,monoclonal antibody,1986,P09693 ,CD3G_HUMAN,CD3G,T-cell surface glycoprotein CD3 gamma chain,Receptors,Receptor; T-cell receptor subunit,Established target
NRDD374,-,MUROMONAB,Immunosuppressive Agents,monoclonal antibody,1986,P20963 ,CD3Z_HUMAN,CD247,T-cell surface glycoprotein CD3 zeta chain,Receptors,Receptor; T-cell receptor subunit,Established target
NRDD375,-,NABUMETONE,"Anti-Inflammatory Agents, Non-Steroidal",small molecule,1991,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD375,-,NABUMETONE,"Anti-Inflammatory Agents, Non-Steroidal",small molecule,1991,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD376,-,NADOLOL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1979,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD376,-,NADOLOL,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1979,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD377,-,NAFARELIN,Antiendometriosis Agent,small molecule,1990,P30968,GNRHR_HUMAN,GNRHR,Gonadotropin-releasing hormone receptor OS=Homo sapiens GN=GNRHR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD377,-,NAFARELIN,Antiendometriosis Agent,small molecule,1990,Q96P88,GNRR2_HUMAN,GNRHR2,Putative gonadotropin-releasing hormone II receptor OS=Homo sapiens GN=GNRHR2 PE=5 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD378,-,NANDROLONE,Antianemic Agents; anti-osteoporosis agents,small molecule,Approved before 1982,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD379,-,NEDOCROMIL,Anti-Allergic Agents; Anti-Asthmatic Agents,small molecule,1992,Q9Y271,CLTR1_HUMAN,CYSLTR1,Cysteinyl leukotriene receptor 1 OS=Homo sapiens GN=CYSLTR1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD380,-,NEFAZODONE,"Antidepressive Agents, Second-Generation",small molecule,1994,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD380,-,NEFAZODONE,"Antidepressive Agents, Second-Generation",small molecule,1994,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD380,-,NEFAZODONE,"Antidepressive Agents, Second-Generation",small molecule,1994,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD380,-,NEFAZODONE,"Antidepressive Agents, Second-Generation",small molecule,1994,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD380,-,NEFAZODONE,"Antidepressive Agents, Second-Generation",small molecule,1994,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD381,-,NEOSTIGMINE,Parasympathomimetics,small molecule,not approved by the FDA,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
NRDD382,-,NEPAFENAC,NSAID,small molecule,2005,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD382,-,NEPAFENAC,NSAID,small molecule,2005,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD383,-,NICARDIPINE,Anti-Arrhythmia Agents; Antihypertensive Agents,small molecule,1988,Q13936,CAC1C_HUMAN,CACNA1C,Voltage-dependent L-type calcium channel subunit alpha-1C OS=Homo sapiens GN=CACNA1C PE=1 SV=3,Transporters,TC:1.A.1.11.4,Established target
NRDD384,-,NICERGOLINE,Nootropic Agents; Vasodilator Agents,small molecule,not approved by the FDA,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD385,-,NICOTINE,Central Nervous System Stimulants,small molecule,1996,Q9GZZ6,ACH10_HUMAN,CHRNA10,Neuronal acetylcholine receptor subunit alpha-10 OS=Homo sapiens GN=CHRNA10 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD385,-,NICOTINE,Central Nervous System Stimulants,small molecule,1996,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD385,-,NICOTINE,Central Nervous System Stimulants,small molecule,1996,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD385,-,NICOTINE,Central Nervous System Stimulants,small molecule,1996,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD385,-,NICOTINE,Central Nervous System Stimulants,small molecule,1996,Q9UGM1,ACHA9_HUMAN,CHRNA9,Neuronal acetylcholine receptor subunit alpha-9 OS=Homo sapiens GN=CHRNA9 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD385,-,NICOTINE,Central Nervous System Stimulants,small molecule,1996,P17787,ACHB2_HUMAN,CHRNB2,Neuronal acetylcholine receptor subunit beta-2 OS=Homo sapiens GN=CHRNB2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD386,-,NIFEDIPINE,Antianginal Agents; Vasodilator Agents,small molecule,1981,P54289,CA2D1_HUMAN,CACNA2D1,Voltage-dependent calcium channel subunit alpha-2/delta-1 OS=Homo sapiens GN=CACNA2D1 PE=1 SV=2,Transporters,TC:8.A.18.1.1,Established target
NRDD387,-,NIFLUMIC ACID,NSAID,small molecule,not approved by the FDA,P04054,PA21B_HUMAN,PLA2G1B,Phospholipase A2,Enzymes,EC:3.1.1.4,Established target
NRDD387,-,NIFLUMIC ACID,NSAID,small molecule,not approved by the FDA,P35354 ,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2,Enzymes,EC:1.14.99.1,Established target
NRDD388,-,NILUTAMIDE,Antineoplastic Agents,small molecule,1996,P10275,ANDR_HUMAN,AR,Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD389,-,NIMODIPINE,Antihypertensive Agents; Vasodilator Agents,small molecule,1988,Q06432,CCG1_HUMAN,CACNG1,Voltage-dependent calcium channel gamma-1 subunit OS=Homo sapiens GN=CACNG1 PE=2 SV=1,Transporters,TC:8.A.16.1.1,Established target
NRDD390,-,NISOLDIPINE,Antihypertensive Agents; Vasodilator Agents,small molecule,1995,O00555,CAC1A_HUMAN,CACNA1A,Voltage-dependent P/Q-type calcium channel subunit alpha-1A OS=Homo sapiens GN=CACNA1A PE=1 SV=2,Transporters,TC:1.A.1.11,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD391,-,NITRAZEPAM,Anticonvulsants; Hypnotics and Sedatives,small molecule,not approved by the FDA,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
NRDD392,-,NITRENDIPINE,Antihypertensive Agents; Vasodilator Agents,small molecule,not approved by the FDA,Q06432,CCG1_HUMAN,CACNG1,Voltage-dependent calcium channel gamma-1 subunit OS=Homo sapiens GN=CACNG1 PE=2 SV=1,Transporters,TC:8.A.16.1.1,Established target
NRDD393,-,NITROPRUSSIDE,Antihypertensive Agents; Vasodilator Agents,small molecule,Approved before 1982,P16066,ANPRA_HUMAN,NPR1,Atrial natriuretic peptide receptor A OS=Homo sapiens GN=NPR1 PE=2 SV=1,Receptors,EC:4.6.1.2,Established target
NRDD394,-,NIZATIDINE,"GI Anti-Ulcer Agents, antihistamines",small molecule,1988,P25021,HRH2_HUMAN,HRH2,Histamine H2 receptor OS=Homo sapiens GN=HRH2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD395,-,NOREPINEPHRINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,1950,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD395,-,NOREPINEPHRINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,1950,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD395,-,NOREPINEPHRINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,1950,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD395,-,NOREPINEPHRINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,1950,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD395,-,NOREPINEPHRINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,1950,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD395,-,NOREPINEPHRINE,Antihypotensive Agents; Vasoconstrictor Agents,small molecule,1950,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD396,-,NORETHINDRONE,"Contraceptives, Oral, Synthetic",small molecule,Approved before 1982,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
NRDD397,-,NORGESTIMATE,"Contraceptives, Oral, Synthetic",small molecule,1989,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD397,-,NORGESTIMATE,"Contraceptives, Oral, Synthetic",small molecule,1989,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
NRDD398,-,NORGESTREL,"Contraceptives, Oral, Synthetic",small molecule,Approved before 1982,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD398,-,NORGESTREL,"Contraceptives, Oral, Synthetic",small molecule,Approved before 1982,P06401,PRGR_HUMAN,PGR,Progesterone receptor OS=Homo sapiens GN=PGR PE=1 SV=4,Receptors,Nuclear receptor,Established target
NRDD399,-,ORCIPRENALINE,Bronchodilator Agents,small molecule,Approved before 1982,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD400,-,ORPHENADRINE,"Antiparkinson Agents; Muscle Relaxants, Central",small molecule,1957,Q05586,NMDZ1_HUMAN,GRIN1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo sapiens GN=GRIN1 PE=1 SV=1,Receptors,TC:1.A.10.1.6,Established target
NRDD400,-,ORPHENADRINE,"Antiparkinson Agents; Muscle Relaxants, Central",small molecule,1957,O15399,NMDE4_HUMAN,GRIN2D,Glutamate [NMDA] receptor subunit epsilon-4 OS=Homo sapiens GN=GRIN2D PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD400,-,ORPHENADRINE,"Antiparkinson Agents; Muscle Relaxants, Central",small molecule,1957,Q8TCU5,NMD3A_HUMAN,GRIN3A,Glutamate [NMDA] receptor subunit 3A OS=Homo sapiens GN=GRIN3A PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD400,-,ORPHENADRINE,"Antiparkinson Agents; Muscle Relaxants, Central",small molecule,1957,O60391,NMD3B_HUMAN,GRIN3B,Glutamate [NMDA] receptor subunit 3B OS=Homo sapiens GN=GRIN3B PE=2 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD400,-,ORPHENADRINE,"Antiparkinson Agents; Muscle Relaxants, Central",small molecule,1957,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD401,-,OSPA LIPOPROTEIN,Vaccine against Lyme Disease,vaccine,not approved by the FDA,P20273,CD22_HUMAN,CD22,B-cell receptor CD22 OS=Homo sapiens GN=CD22 PE=1 SV=2,Other,StructuralAndAdhesion;IG_AdhesionProteins,Established target
NRDD402,-,OUABAIN,Cardiotonic Agents,small molecule,not approved by the FDA,P05023,AT1A1_HUMAN,ATP1A1,Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1,Transporters,TC:3.A.3.1.1,Established target
NRDD403,-,OXAPROZIN,NSAID,small molecule,1992,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD404,-,OXAZEPAM,Hypnotics and Sedatives,small molecule,1965,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD405,-,OXPRENOLOL,Antihypertensive Agents; Anti-Arrhythmia Agents,small molecule,1983,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD405,-,OXPRENOLOL,Antihypertensive Agents; Anti-Arrhythmia Agents,small molecule,1983,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD406,-,OXYBUPROCAINE,"Anesthetics, Local",small molecule,not approved by the FDA,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD407,-,OXYPHENCYCLIMINE,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD407,-,OXYPHENCYCLIMINE,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,Approved before 1982,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD407,-,OXYPHENCYCLIMINE,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,Approved before 1982,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD408,-,OXYPHENONIUM,Mydriatics,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD409,-,PAMIDRONATE,Bisphosphonates,small molecule,1991,P14324,FPPS_HUMAN,FDPS,Farnesyl pyrophosphate synthetase OS=Homo sapiens GN=FDPS PE=1 SV=4,Enzymes,EC:2.5.1.-,Established target
NRDD410,-,PANCURONIUM,Muscle Relaxants,small molecule,1972,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD411,-,PAPAVERINE,Antispasmodics; Anti-impotence Agents; Vasodilator Agents,small molecule,not approved by the FDA,Q07343,PDE4B_HUMAN,PDE4B,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B OS=Homo sapiens GN=PDE4B PE=1 SV=1",Enzymes,EC:3.1.4.17,Established target
NRDD412,-,PARAMETHADIONE,Anticonvulsants,small molecule,1949,Q9P0X4,CAC1I_HUMAN,CACNA1I,Voltage-dependent T-type calcium channel subunit alpha-1I OS=Homo sapiens GN=CACNA1I PE=1 SV=1,Transporters,TC:1.A.1.11.7,Established target
NRDD413,-,PARAMETHASONE,Anti-Inflammatory Agents; Glucocorticoids,small molecule,Approved before 1982,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD414,-,PEGFILGRASTIM,Antineutropenic Agents,recombinant protein,2002,Q99062,CSF3R_HUMAN,CSF3R,Granulocyte colony-stimulating factor receptor OS=Homo sapiens GN=CSF3R PE=1 SV=1,Receptors,Receptor; Type 1 cytokine receptor,Established target
NRDD415,-,PEMETREXED,Antineoplastic Agents,small molecule,2004,P00374,DYR_HUMAN,DHFR,Dihydrofolate reductase OS=Homo sapiens GN=DHFR PE=1 SV=2,Enzymes,EC:1.5.1.3,Established target
NRDD415,-,PEMETREXED,Antineoplastic Agents,small molecule,2004,P22102,PUR2_HUMAN,GART,Trifunctional purine biosynthetic protein adenosine-3 OS=Homo sapiens GN=GART PE=1 SV=1,Enzymes,EC:6.3.4.13; 6.3.3.1; 2.1.2.2,Established target
NRDD415,-,PEMETREXED,Antineoplastic Agents,small molecule,2004,P04818,TYSY_HUMAN,TYMS,Thymidylate synthase OS=Homo sapiens GN=TYMS PE=1 SV=3,Enzymes,EC:2.1.1.45,Established target
NRDD416,-,PEMIROLAST,Anti-Allergic Agents,small molecule,1999,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD417,-,PENBUTOLOL,Antihypertensive Agents,small molecule,1987,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD417,-,PENBUTOLOL,Antihypertensive Agents,small molecule,1987,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD418,-,PENTAGASTRIN,Diagnostic Agents,small molecule,1974,P32239,GASR_HUMAN,CCKBR,Gastrin/cholecystokinin type B receptor OS=Homo sapiens GN=CCKBR PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD419,-,PENTAZOCINE,"Analgesics, Opioid",small molecule,Approved before 1982,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD419,-,PENTAZOCINE,"Analgesics, Opioid",small molecule,Approved before 1982,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD420,-,PENTOBARBITAL,Hypnotics and Sedatives,small molecule,Approved before 1982,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD421,-,PENTOLINIUM,Antihypertensive Agents,small molecule,Approved before 1982,Q9GZZ6,ACH10_HUMAN,CHRNA10,Neuronal acetylcholine receptor subunit alpha-10 OS=Homo sapiens GN=CHRNA10 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD422,-,PERGOLIDE,Antiparkinson Agents,small molecule,1988,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD422,-,PERGOLIDE,Antiparkinson Agents,small molecule,1988,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD423,-,PERHEXILINE,Antianginal Agents; Vasodilator Agents,small molecule,not approved by the FDA,P50416,CPT1A_HUMAN,CPT1A,"Carnitine O-palmitoyltransferase 1, liver isoform OS=Homo sapiens GN=CPT1A PE=1 SV=2",Enzymes,EC:2.3.1,Established target
NRDD423,-,PERHEXILINE,Antianginal Agents; Vasodilator Agents,small molecule,not approved by the FDA,P23786,CPT2_HUMAN,CPT2,"Carnitine O-palmitoyltransferase 2, mitochondrial OS=Homo sapiens GN=CPT2 PE=1 SV=2",Enzymes,EC:2.3.1.21,Established target
NRDD424,-,PERINDOPRIL,Antihypertensive Agents,small molecule,1993,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
NRDD425,-,PERPHENAZINE,Antipsychotic Agents,small molecule,1957,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD425,-,PERPHENAZINE,Antipsychotic Agents,small molecule,1957,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD426,-,PHENACEMIDE,Anticonvulsants,small molecule,1951,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
NRDD427,-,PHENDIMETRAZINE,Appetite Depressants,small molecule,Approved before 1982,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD427,-,PHENDIMETRAZINE,Appetite Depressants,small molecule,Approved before 1982,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD428,-,PHENELZINE,Antidepressive Agents,small molecule,1961,P21397,AOFA_HUMAN,MAOA,Amine oxidase [flavin-containing] A OS=Homo sapiens GN=MAOA PE=1 SV=1,Enzymes,EC:1.4.3.4,Established target
NRDD428,-,PHENELZINE,Antidepressive Agents,small molecule,1961,P27338,AOFB_HUMAN,MAOB,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3.4,Established target
NRDD429,-,PHENFORMIN,Hypoglycemic Agents,small molecule,Approved before 1982,Q13131,AAPK1_HUMAN,PRKAA1,5'-AMP-activated protein kinase catalytic subunit alpha-1 OS=Homo sapiens GN=PRKAA1 PE=1 SV=3,Enzymes,EC:2.7.11.1,Established target
NRDD430,-,PHENINDIONE,Anticoagulants,small molecule,not approved by the FDA,Q9BQB6,VKOR1_HUMAN,VKORC1,Vitamin K epoxide reductase complex subunit 1 OS=Homo sapiens GN=VKORC1 PE=1 SV=1,Enzymes,EC:1.1.4.1,Established target
NRDD431,-,PHENIRAMINE,Anti-Allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD432,-,PHENMETRAZINE,Appetite Depressants,small molecule,Approved before 1982,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD432,-,PHENMETRAZINE,Appetite Depressants,small molecule,Approved before 1982,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD433,-,PHENOBARBITAL,Anticonvulsants; Hypnotics and Sedatives,small molecule,Approved before 1982,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD434,-,PHENOXYBENZAMINE,Anticonvulsants; Hypnotics and Sedatives,small molecule,1953,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD435,-,PHENPROCOUMON,Anticoagulants,small molecule,1957,Q9BQB6,VKOR1_HUMAN,VKORC1,Vitamin K epoxide reductase complex subunit 1 OS=Homo sapiens GN=VKORC1 PE=1 SV=1,Enzymes,EC:1.1.4.1,Established target
NRDD436,-,PHENTERMINE,Appetite Depressants,small molecule,Approved before 1982,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD436,-,PHENTERMINE,Appetite Depressants,small molecule,Approved before 1982,Q01959,SC6A3_HUMAN,SLC6A3,Sodium-dependent dopamine transporter OS=Homo sapiens GN=SLC6A3 PE=1 SV=1,Transporters,TC:2.A.22.1.3,Established target
NRDD436,-,PHENTERMINE,Appetite Depressants,small molecule,Approved before 1982,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD437,-,PHENTOLAMINE,Antihypertensive Agents,small molecule,1952,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD438,-,PHENYLBUTAZONE,NSAID,small molecule,Approved before 1982,Q16647,PTGIS_HUMAN,PTGIS,Prostacyclin synthase OS=Homo sapiens GN=PTGIS PE=1 SV=1,Enzymes,EC:5.3.99.4,Established target
NRDD438,-,PHENYLBUTAZONE,NSAID,small molecule,Approved before 1982,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD439,-,PHENYLPROPANOLAMINE,Appetite Depressants; Nasal Decongestants,small molecule,Approved before 1982,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD439,-,PHENYLPROPANOLAMINE,Appetite Depressants; Nasal Decongestants,small molecule,Approved before 1982,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD440,-,PHENYTOIN,Anticonvulsants,small molecule,Approved before 1982,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
NRDD440,-,PHENYTOIN,Anticonvulsants,small molecule,Approved before 1982,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD441,-,PHYTONADIONE,Antifibrinolytic Agents,small molecule,Approved before 1982,P38435,VKGC_HUMAN,GGCX,Vitamin K-dependent gamma-carboxylase OS=Homo sapiens GN=GGCX PE=1 SV=2,Enzymes,EC:6.4.-.-,Established target
NRDD442,-,PICROTOXIN,Central Nervous System Stimulants; Convulsants,small molecule,not approved by the FDA,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD442,-,PICROTOXIN,Central Nervous System Stimulants; Convulsants,small molecule,not approved by the FDA,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD443,-,PIMOZIDE,Antidyskinetics; Antipsychotic Agents,small molecule,1984,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD444,-,PINDOLOL,Antihypertensive Agents,small molecule,1982,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD444,-,PINDOLOL,Antihypertensive Agents,small molecule,1982,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD445,-,PIPECURONIUM,Muscle Relaxants,small molecule,1990,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD446,-,PIRENZEPINE,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,not approved by the FDA,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD447,-,PODOFILOX,"Antineoplastic Agents, Phytogenic; Keratolytic Agents",small molecule,not approved by the FDA,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
NRDD448,-,POLYTHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,1961,P55017,S12A3_HUMAN,SLC12A3,Solute carrier family 12 member 3 OS=Homo sapiens GN=SLC12A3 PE=1 SV=2,Transporters,TC:2.A.30.4.2,Established target
NRDD449,-,PRACTOLOL,Anti-Arrhythmia Agents,small molecule,not approved by the FDA,P08588,ADRB1_HUMAN,ADRB1,Beta-1 adrenergic receptor OS=Homo sapiens GN=ADRB1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD450,-,PRALATREXATE,Antineoplastic Agents,small molecule,2009,P00374,DYR_HUMAN,DHFR,Dihydrofolate reductase OS=Homo sapiens GN=DHFR PE=1 SV=2,Enzymes,EC:1.5.1.3,Established target
NRDD451,-,PRANLUKAST,Anti-Asthmatic Agents,small molecule,not approved by the FDA,Q9Y271,CLTR1_HUMAN,CYSLTR1,Cysteinyl leukotriene receptor 1 OS=Homo sapiens GN=CYSLTR1 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD452,-,PRAZEPAM,Anti-anxiety Agents; Hypnotics and Sedatives,small molecule,Approved before 1982,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD453,-,PRAZOSIN,Antihypertensive Agents; antispasmodics,small molecule,1976,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD453,-,PRAZOSIN,Antihypertensive Agents; antispasmodics,small molecule,1976,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD453,-,PRAZOSIN,Antihypertensive Agents; antispasmodics,small molecule,1976,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD454,-,PREDNICARBATE,Anti-Inflammatory Agents; Corticosteroids,small molecule,1991,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor ,Receptors,Nuclear receptor,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD455,-,PRIMIDONE,Anticonvulsants,small molecule,1954,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD456,-,PROBENECID,Uricosuric Agents,small molecule,Approved before 1982,Q9NSA0,S22AB_HUMAN,SLC22A11,Solute carrier family 22 member 11 OS=Homo sapiens GN=SLC22A11 PE=1 SV=1,Transporters,TC:2.A.1.19.10,Established target
NRDD456,-,PROBENECID,Uricosuric Agents,small molecule,Approved before 1982,Q8TCC7,S22A8_HUMAN,SLC22A8,Solute carrier family 22 member 8 OS=Homo sapiens GN=SLC22A8 PE=1 SV=1,Transporters,TC:2.A.1.19.34,Established target
NRDD457,-,PROCAINAMIDE,Anti-Arrhythmia Agents,small molecule,1951,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD458,-,PROCAINE,"Anesthetics, Local",small molecule,Approved before 1982,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD459,-,PROCATEROL,Bronchodilator Agents,small molecule,not approved by the FDA,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD460,-,PROCYCLIDINE,Antidyskinetics; Antiparkinson Agents,small molecule,1955,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD460,-,PROCYCLIDINE,Antidyskinetics; Antiparkinson Agents,small molecule,1955,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD460,-,PROCYCLIDINE,Antidyskinetics; Antiparkinson Agents,small molecule,1955,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD461,-,PROGABIDE,Anticonvulsants,small molecule,not approved by the FDA,Q9UBS5,GABR1_HUMAN,GABBR1,Gamma-aminobutyric acid type B receptor subunit 1 OS=Homo sapiens GN=GABBR1 PE=1 SV=1,Receptors,GPCR;Glutamate,Established target
NRDD461,-,PROGABIDE,Anticonvulsants,small molecule,not approved by the FDA,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD462,-,PROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,Approved before 1982,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD463,-,PROMETHAZINE,Hypnotics and Sedatives; Anti-anxiety agents; Anti-allergic Agents,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD463,-,PROMETHAZINE,Hypnotics and Sedatives; Anti-anxiety agents; Anti-allergic Agents,small molecule,Approved before 1982,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD463,-,PROMETHAZINE,Hypnotics and Sedatives; Anti-anxiety agents; Anti-allergic Agents,small molecule,Approved before 1982,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD463,-,PROMETHAZINE,Hypnotics and Sedatives; Anti-anxiety agents; Anti-allergic Agents,small molecule,Approved before 1982,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD463,-,PROMETHAZINE,Hypnotics and Sedatives; Anti-anxiety agents; Anti-allergic Agents,small molecule,Approved before 1982,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD463,-,PROMETHAZINE,Hypnotics and Sedatives; Anti-anxiety agents; Anti-allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD464,-,PROPANTHELINE,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,1953,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD465,-,PROPARACAINE,"Anesthetics, Local",small molecule,Approved before 1982,Q9Y5Y9,SCNAA_HUMAN,SCN10A,Sodium channel protein type 10 subunit alpha OS=Homo sapiens GN=SCN10A PE=1 SV=2,Transporters,TC:1.A.1.10,Established target
NRDD466,-,PROPERICIAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD466,-,PROPERICIAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD466,-,PROPERICIAZINE,Antipsychotic Agents,small molecule,not approved by the FDA,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD467,-,PROPIOMAZINE,Hypnotics and Sedatives,small molecule,1960,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD468,-,PROPOXYPHENE,"Analgesics, Opioid; Antitussive Agents",small molecule,Approved before 1982,P41143,OPRD_HUMAN,OPRD1,Delta-type opioid receptor OS=Homo sapiens GN=OPRD1 PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD468,-,PROPOXYPHENE,"Analgesics, Opioid; Antitussive Agents",small molecule,Approved before 1982,P41145,OPRK_HUMAN,OPRK1,Kappa-type opioid receptor OS=Homo sapiens GN=OPRK1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD468,-,PROPOXYPHENE,"Analgesics, Opioid; Antitussive Agents",small molecule,Approved before 1982,P35372,OPRM_HUMAN,OPRM1,Mu-type opioid receptor OS=Homo sapiens GN=OPRM1 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD469,-,PROPYLTHIOURACIL,Antithyroid Agents,small molecule,1947,P07202,PERT_HUMAN,TPO,Thyroid peroxidase OS=Homo sapiens GN=TPO PE=1 SV=4,Enzymes,EC:1.11.1.8,Established target
NRDD470,-,PROTRIPTYLINE,"Antidepressive Agents, Tricyclic",small molecule,1967,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD470,-,PROTRIPTYLINE,"Antidepressive Agents, Tricyclic",small molecule,1967,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD471,-,PYRIDOSTIGMINE,Antimyasthenics,small molecule,1955,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD472,-,QUAZEPAM,Hypnotics and Sedatives,small molecule,1985,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD473,-,QUINESTROL,Hormone Replacement Agents,small molecule,Approved before 1982,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD474,-,QUINETHAZONE,Antihypertensive Agents; Diuretics,small molecule,1963,P55017,S12A3_HUMAN,SLC12A3,Solute carrier family 12 member 3 OS=Homo sapiens GN=SLC12A3 PE=1 SV=2,Transporters,TC:2.A.30.4.2,Established target
NRDD475,-,QUINIDINE,Anti-Arrhythmia Agents,small molecule,Approved before 1982,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD476,-,RALOXIFENE,Hormone Replacement Agents,small molecule,1997,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD476,-,RALOXIFENE,Hormone Replacement Agents,small molecule,1997,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD477,-,RAMIPRIL,Antihypertensive Agents,small molecule,1991,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
NRDD478,-,REMIKIREN,Antihypertensive Agents,small molecule,not approved by the FDA,P00797,RENI_HUMAN,REN,Renin OS=Homo sapiens GN=REN PE=1 SV=1,Enzymes,EC:3.4.23.15,Established target
NRDD479,-,REMOXIPRIDE,Antipsychotic Agents,small molecule,not approved by the FDA,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD480,-,RESCINNAMINE,Antihypertensive Agents,small molecule,1956,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
NRDD481,-,RESERPINE,Antihypertensive Agents; Antipsychotic Agents,small molecule,Approved before 1982,Q05940,VMAT2_HUMAN,SLC18A2,Synaptic vesicular amine transporter OS=Homo sapiens GN=SLC18A2 PE=1 SV=2,Transporters,TC:2.A.1.2.29,Established target
NRDD482,-,RIMEXOLONE,Anti-Inflammatory Agents; Corticosteroids,small molecule,1994,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor ,Receptors,Nuclear receptor,Established target
NRDD482,-,RIMEXOLONE,Anti-Inflammatory Agents; Corticosteroids,small molecule,1994,P04150,GCR_HUMAN,NR3C1,Glucocorticoid receptor OS=Homo sapiens GN=NR3C1 PE=1 SV=1,Receptors,Nuclear receptor,Established target
NRDD483,-,RISEDRONATE,Bisphosphonates,small molecule,1998,P14324,FPPS_HUMAN,FDPS,Farnesyl pyrophosphate synthetase OS=Homo sapiens GN=FDPS PE=1 SV=4,Enzymes,EC:2.5.1.-,Established target
NRDD484,-,RISPERIDONE,Antipsychotic Agents,small molecule,1993,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD484,-,RISPERIDONE,Antipsychotic Agents,small molecule,1993,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD485,-,RITODRINE,Tocolytic Agents,small molecule,Approved before 1982,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD486,-,RIZATRIPTAN,Anti-migraine Agents,small molecule,1998,P28222,5HT1B_HUMAN,HTR1B,5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD486,-,RIZATRIPTAN,Anti-migraine Agents,small molecule,1998,P28221,5HT1D_HUMAN,HTR1D,5-hydroxytryptamine receptor 1D OS=Homo sapiens GN=HTR1D PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD487,-,SALICYLIC ACID,Keratolytic Agents,small molecule,Approved before 1982,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD487,-,SALICYLIC ACID,Keratolytic Agents,small molecule,Approved before 1982,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD488,-,SALSALATE,"Anti-Inflammatory Agents, Non-Steroidal",small molecule,not approved by the FDA,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD488,-,SALSALATE,"Anti-Inflammatory Agents, Non-Steroidal",small molecule,not approved by the FDA,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD489,-,SAPRISARTAN,Antihypertensive Agents,small molecule,not approved by the FDA,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD490,-,SAPROPTERIN,PKU-treatment,small molecule,2007,P00439,PH4H_HUMAN,PAH,Phenylalanine-4-hydroxylase OS=Homo sapiens GN=PAH PE=1 SV=1,Enzymes,EC:1.14.16.1,Established target
NRDD491,-,SCOPOLAMINE,"Adjuvants, Anesthesia; Antispasmodics; Mydriatics",small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD492,-,SECOBARBITAL,"Adjuvants, anesthesia; Hypnotics and Sedatives",small molecule,Approved before 1982,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD493,-,SECRETIN,Diagnostic Agents,peptide,Approved before 1982,P47872,SCTR_HUMAN,SCTR,Secretin receptor OS=Homo sapiens GN=SCTR PE=2 SV=2,Receptors,GPCR;Secretin,Established target
NRDD494,-,SERMORELIN,Hormone Replacement Agents,peptide,1990,Q02643,GHRHR_HUMAN,GHRHR,Growth hormone-releasing hormone receptor OS=Homo sapiens GN=GHRHR PE=1 SV=2,Receptors,GPCR;Secretin,Established target
NRDD496,-,SEVOFLURANE,"Anesthetics, Inhalation",small molecule,1995,P98194,AT2C1_HUMAN,ATP2C1,Calcium-transporting ATPase type 2C member 1 OS=Homo sapiens GN=ATP2C1 PE=1 SV=3,Transporters,TC:3.A.3.2.5,Established target
NRDD496,-,SEVOFLURANE,"Anesthetics, Inhalation",small molecule,1995,P30049,ATPD_HUMAN,ATP5D,"ATP synthase subunit delta, mitochondrial OS=Homo sapiens GN=ATP5D PE=1 SV=2",Enzymes,EC:3.6.3.14,Established target
NRDD496,-,SEVOFLURANE,"Anesthetics, Inhalation",small molecule,1995,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD496,-,SEVOFLURANE,"Anesthetics, Inhalation",small molecule,1995,P23415,GLRA1_HUMAN,GLRA1,Glycine receptor subunit alpha-1 OS=Homo sapiens GN=GLRA1 PE=1 SV=2,Receptors,TC:1.A.9.3.1,Established target
NRDD496,-,SEVOFLURANE,"Anesthetics, Inhalation",small molecule,1995,P42261,GRIA1_HUMAN,GRIA1,Glutamate receptor 1 OS=Homo sapiens GN=GRIA1 PE=1 SV=2,Receptors,TC:1.A.10.1,Established target
NRDD496,-,SEVOFLURANE,"Anesthetics, Inhalation",small molecule,1995,Q09470,KCNA1_HUMAN,KCNA1,Potassium voltage-gated channel subfamily A member 1 OS=Homo sapiens GN=KCNA1 PE=1 SV=2,Transporters,TC:1.A.1.2.12,Established target
NRDD496,-,SEVOFLURANE,"Anesthetics, Inhalation",small molecule,1995,P03886,NU1M_HUMAN,MT-ND1,NADH-ubiquinone oxidoreductase chain 1 OS=Homo sapiens GN=MT-ND1 PE=1 SV=1,Enzymes,EC:1.6.5.3,Established target
NRDD497,-,SODIUM TETRADECYL SULFATE,Sclerosing Agents,small molecule,1946,P04070,PROC_HUMAN,PROC,Vitamin K-dependent protein C OS=Homo sapiens GN=PROC PE=1 SV=1,Enzymes,EC:3.4.21.69,Established target
NRDD498,-,SOTALOL,Anti-Arrhythmia Agents,small molecule,1992,Q12809,KCNH2_HUMAN,KCNH2,Potassium voltage-gated channel subfamily H member 2 OS=Homo sapiens GN=KCNH2 PE=1 SV=1,Transporters,TC:1.A.1.20.1,Established target
NRDD499,-,SPIRAPRIL,Antihypertensive Agents,small molecule,1994,P12821,ACE_HUMAN,ACE,Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1,Enzymes,EC:3.4.15,Established target
NRDD500,-,STREPTOKINASE,Thrombolytic Agents,protein,1997,P00747,PLMN_HUMAN,PLG,Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2,Enzymes,EC:3.4.21.7,Established target
NRDD501,-,SUCCINYLCHOLINE,"Muscle Relaxants, Skeletal",small molecule,1952,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD502,-,SULFINPYRAZONE,Uricosuric Agents,small molecule,1959,P33527,MRP1_HUMAN,ABCC1,Multidrug resistance-associated protein 1 OS=Homo sapiens GN=ABCC1 PE=1 SV=2,Transporters,TC:3.A.1.208.8,Established target
NRDD502,-,SULFINPYRAZONE,Uricosuric Agents,small molecule,1959,Q92887,MRP2_HUMAN,ABCC2,Canalicular multispecific organic anion transporter 1 OS=Homo sapiens GN=ABCC2 PE=1 SV=2,Transporters,TC:3.A.1.208.8,Established target
NRDD503,-,SULINDAC,NSAID,small molecule,1978,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD503,-,SULINDAC,NSAID,small molecule,1978,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD504,-,SULPIRIDE,"Antidepressive Agents, Second-Generation; Antipsychotic Agents",small molecule,not approved by the FDA,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD505,-,SUPROFEN,NSAID,small molecule,Approved before 1982,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD505,-,SUPROFEN,NSAID,small molecule,Approved before 1982,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD506,-,TACRINE,Nootropic Agents,small molecule,1993,P22303,ACES_HUMAN,ACHE,Acetylcholinesterase OS=Homo sapiens GN=ACHE PE=1 SV=1,Enzymes,EC:3.1.1.7,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD507,-,TALBUTAL,Analgesics,small molecule,Approved before 1982,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD508,-,TAMOXIFEN,"Antineoplastic Agents, Hormonal",small molecule,1977,P03372,ESR1_HUMAN,ESR1,Estrogen receptor OS=Homo sapiens GN=ESR1 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD508,-,TAMOXIFEN,"Antineoplastic Agents, Hormonal",small molecule,1977,Q92731,ESR2_HUMAN,ESR2,Estrogen receptor beta OS=Homo sapiens GN=ESR2 PE=1 SV=2,Receptors,Nuclear receptor,Established target
NRDD509,-,TASOSARTAN,Antihypertensive Agents,small molecule,not approved by the FDA,P30556,AGTR1_HUMAN,AGTR1,Type-1 angiotensin II receptor OS=Homo sapiens GN=AGTR1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P30536,TSPOA_HUMAN,BZRP,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P18505,GBRB1_HUMAN,GABRB1,Gamma-aminobutyric acid receptor subunit beta-1 OS=Homo sapiens GN=GABRB1 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P47870,GBRB2_HUMAN,GABRB2,Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens GN=GABRB2 PE=1 SV=1,Receptors,TC:1.A.9.5.2,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P28472,GBRB3_HUMAN,GABRB3,Gamma-aminobutyric acid receptor subunit beta-3 OS=Homo sapiens GN=GABRB3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,O14764,GBRD_HUMAN,GABRD,Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta),Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P78334,GBRE_HUMAN,GABRE,Gamma-aminobutyric acid receptor subunit epsilon (GABA(A) receptor subunit epsilon),Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,Q8N1C3,GBRG1_HUMAN,GABRG1,Gamma-aminobutyric acid receptor subunit gamma-1 (GABA(A) receptor subunit gamma-1),Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P18507,GBRG2_HUMAN,GABRG2,Gamma-aminobutyric acid receptor subunit gamma-2 (GABA(A) receptor subunit gamma-2),Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,Q99928,GBRG3_HUMAN,GABRG3,Gamma-aminobutyric acid receptor subunit gamma-3 (GABA(A) receptor subunit gamma-3),Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,O00591,GBRP_HUMAN,GABRP,Gamma-aminobutyric acid receptor subunit pi (GABA(A) receptor subunit pi),Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,Q9UN88,GBRT_HUMAN,GABRQ,Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta),Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P24046,GBRR1_HUMAN,GABRR1,Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,P28476,GBRR2_HUMAN,GABRR2,Gamma-aminobutyric acid receptor subunit rho-2 (GABA(A) receptor subunit rho-2) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD510,-,TEMAZEPAM,Hypnotics and Sedatives,small molecule,1981,A8MPY1,GBRR3_HUMAN,GABRR3,Gamma-aminobutyric acid receptor subunit rho-3 (GABA(A) receptor subunit rho-3) (GABA(C) receptor),Receptors,TC:1.A.9,Established target
NRDD511,-,TENECTEPLASE,Thrombolytic Agents,recombinant protein,2000,P00747,PLMN_HUMAN,PLG,Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2,Enzymes,EC:3.4.21.7,Established target
NRDD512,-,TENIPOSIDE,Antineoplastic Agents,small molecule,1992,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
NRDD513,-,TENOXICAM,NSAID,small molecule,not approved by the FDA,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD513,-,TENOXICAM,NSAID,small molecule,not approved by the FDA,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD514,-,TERAZOSIN,Antineoplastic Agents; antihypertensive agents,small molecule,1987,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD514,-,TERAZOSIN,Antineoplastic Agents; antihypertensive agents,small molecule,1987,P35368,ADA1B_HUMAN,ADRA1B,Alpha-1B adrenergic receptor OS=Homo sapiens GN=ADRA1B PE=2 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD514,-,TERAZOSIN,Antineoplastic Agents; antihypertensive agents,small molecule,1987,P25100,ADA1D_HUMAN,ADRA1D,Alpha-1D adrenergic receptor OS=Homo sapiens GN=ADRA1D PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD515,-,TERBUTALINE,Bronchodilator Agents; Tocolytic Agents,small molecule,Approved before 1982,P07550,ADRB2_HUMAN,ADRB2,Beta-2 adrenergic receptor OS=Homo sapiens GN=ADRB2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD516,-,TERFENADINE,Anti-Allergic Agents,small molecule,1985,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD517,-,TESTOLACTONE,"Antineoplastic Agents, Hormonal",small molecule,Approved before 1982,P11511,CP19A_HUMAN,CYP19A1,Cytochrome P450 19A1 OS=Homo sapiens GN=CYP19A1 PE=1 SV=3,Enzymes,EC:1.14.14,Established target
NRDD518,-,THIAMYLAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD518,-,THIAMYLAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,Q14654,IRK11_HUMAN,KCNJ11,ATP-sensitive inward rectifier potassium channel 11 OS=Homo sapiens GN=KCNJ11 PE=1 SV=2,Transporters,TC:1.A.2.1,Established target
NRDD518,-,THIAMYLAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,Q15842,IRK8_HUMAN,KCNJ8,"ATP-sensitive inward rectifier potassium channel 8 (Inward rectifier K(+) channel Kir6.1) (Potassium channel, inwardly rectifying subfamily J member 8) (uKATP-1)",Transporters,TC:1.A.2.1,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P08912,ACM5_HUMAN,CHRM5,Muscarinic acetylcholine receptor M5 OS=Homo sapiens GN=CHRM5 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P21917,DRD4_HUMAN,DRD4,D(4) dopamine receptor OS=Homo sapiens GN=DRD4 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD519,-,THIETHYLPERAZINE,Antiemetics,small molecule,1961,P28335,5HT2C_HUMAN,HTR2C,5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,P43681,ACHA4_HUMAN,CHRNA4,Neuronal acetylcholine receptor subunit alpha-4 OS=Homo sapiens GN=CHRNA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,P36544,ACHA7_HUMAN,CHRNA7,Neuronal acetylcholine receptor subunit alpha-7 OS=Homo sapiens GN=CHRNA7 PE=1 SV=5,Receptors,TC:1.A.9.1.1,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,P48169,GBRA4_HUMAN,GABRA4,Gamma-aminobutyric acid receptor subunit alpha-4 OS=Homo sapiens GN=GABRA4 PE=1 SV=2,Receptors,TC:1.A.9,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,Q16445,GBRA6_HUMAN,GABRA6,Gamma-aminobutyric acid receptor subunit alpha-6 OS=Homo sapiens GN=GABRA6 PE=2 SV=2,Receptors,TC:1.A.9,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,P42262,GRIA2_HUMAN,GRIA2,"Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)",Receptors,TC:1.A.10.1.13,Established target
NRDD520,-,THIOPENTAL,"Anesthetics, Intravenous",small molecule,Approved before 1982,Q13002,GRIK2_HUMAN,GRIK2,"Glutamate receptor, ionotropic kainate 2 (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)",Receptors,TC:1.A.10.1,Established target
NRDD521,-,THIORIDAZINE,Antipsychotic Agents,small molecule,1962,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD521,-,THIORIDAZINE,Antipsychotic Agents,small molecule,1962,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD521,-,THIORIDAZINE,Antipsychotic Agents,small molecule,1962,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD521,-,THIORIDAZINE,Antipsychotic Agents,small molecule,1962,P28223,5HT2A_HUMAN,HTR2A,5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD522,-,THYROTROPIN ALFA,Diagnostic Agents,protein,1998,P16473,TSHR_HUMAN,TSHR,Thyrotropin receptor OS=Homo sapiens GN=TSHR PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD523,-,TIAGABINE,Anticonvulsants,small molecule,1997,P80404,GABT_HUMAN,ABAT,"4-aminobutyrate aminotransferase, mitochondrial OS=Homo sapiens GN=ABAT PE=1 SV=3",Enzymes,EC:2.6.1.19; 2.6.1.22,Established target
NRDD523,-,TIAGABINE,Anticonvulsants,small molecule,1997,P30531,SC6A1_HUMAN,SLC6A1,Sodium- and chloride-dependent GABA transporter 1 OS=Homo sapiens GN=SLC6A1 PE=2 SV=2,Transporters,TC:2.A.22.3.2,Established target
NRDD524,-,TIAPROFENIC ACID,NSAID,small molecule,not approved by the FDA,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD525,-,TICLOPIDINE,Platelet Aggregation Inhibitors,small molecule,1991,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD526,-,TILUDRONATE,Bisphosphonates,small molecule,1997,P18031,PTN1_HUMAN,PTPN1,Tyrosine-protein phosphatase non-receptor type 1 OS=Homo sapiens GN=PTPN1 PE=1 SV=1,Enzymes,EC:3.1.3,Established target
NRDD527,-,TIROFIBAN,Platelet Aggregation Inhibitors,small molecule,1998,P08514,ITA2B_HUMAN,ITGA2B,"Integrin alpha-IIb (GPalpha IIb) (GPIIb) (Platelet membrane glycoprotein IIb) (CD antigen CD41) [Cleaved into: Integrin alpha-IIb heavy chain; Integrin alpha-IIb light chain, form 1; Integrin alpha-IIb light chain, form 2]",Receptors,Receptors;Integrin,Established target
NRDD527,-,TIROFIBAN,Platelet Aggregation Inhibitors,small molecule,1998,P05106,ITB3_HUMAN,ITGB3,Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2,Receptors,Receptors;Integrin,Established target
NRDD528,-,TOCAINIDE,Anti-Arrhythmia Agents,small molecule,1984,Q14524,SCN5A_HUMAN,SCN5A,Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2,Transporters,TC:1.A.1.10.3,Established target
NRDD529,-,TOLAZAMIDE,Hypoglycemic Agents,small molecule,1966,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
NRDD530,-,TOLAZOLINE,Antihypertensive Agents,small molecule,1948,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD531,-,TOLBUTAMIDE,Hypoglycemic Agents,small molecule,Approved before 1982,P48048,IRK1_HUMAN,KCNJ1,ATP-sensitive inward rectifier potassium channel 1 OS=Homo sapiens GN=KCNJ1 PE=1 SV=1,Transporters,TC:1.A.2.1.1,Established target
NRDD532,-,TOLCAPONE,Antiparkinson Agents,small molecule,1998,P21964,COMT_HUMAN,COMT,Catechol O-methyltransferase OS=Homo sapiens GN=COMT PE=1 SV=2,Enzymes,EC:2.1.1.6,Established target
NRDD533,-,TOLMETIN,NSAID,small molecule,1976,P23219,PGH1_HUMAN,PTGS1,Prostaglandin G/H synthase 1 OS=Homo sapiens GN=PTGS1 PE=1 SV=1,Enzymes,EC:1.14.99.1,Established target
NRDD533,-,TOLMETIN,NSAID,small molecule,1976,P35354,PGH2_HUMAN,PTGS2,Prostaglandin G/H synthase 2 OS=Homo sapiens GN=PTGS2 PE=1 SV=2,Enzymes,EC:1.14.99.1,Established target
NRDD534,-,TOPIRAMATE,Anticonvulsants; anti-migraine agents,small molecule,1996,P00918,CAH2_HUMAN,CA2,Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD534,-,TOPIRAMATE,Anticonvulsants; anti-migraine agents,small molecule,1996,P22748,CAH4_HUMAN,CA4,Carbonic anhydrase 4 OS=Homo sapiens GN=CA4 PE=1 SV=2,Enzymes,EC:4.2.1,Established target
NRDD534,-,TOPIRAMATE,Anticonvulsants; anti-migraine agents,small molecule,1996,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD534,-,TOPIRAMATE,Anticonvulsants; anti-migraine agents,small molecule,1996,P39086,GRIK1_HUMAN,GRIK1,GRIK1 108 kDa protein,Receptors,TC:1.A.10.1,Established target
NRDD534,-,TOPIRAMATE,Anticonvulsants; anti-migraine agents,small molecule,1996,P35498,SCN1A_HUMAN,SCN1A,Sodium channel protein type 1 subunit alpha OS=Homo sapiens GN=SCN1A PE=1 SV=2,Transporters,TC:1.A.1.10.7,Established target
NRDD535,-,TORASEMIDE,Antihypertensive Agents; Diuretics,small molecule,1993,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD536,-,TRANYLCYPROMINE,Antidepressive Agents,small molecule,1961,P21397,AOFA_HUMAN,MAOA,Amine oxidase [flavin-containing] A OS=Homo sapiens GN=MAOA PE=1 SV=1,Enzymes,EC:1.4.3.4,Established target
NRDD536,-,TRANYLCYPROMINE,Antidepressive Agents,small molecule,1961,P27338,AOFB_HUMAN,MAOB,Amine oxidase [flavin-containing] B OS=Homo sapiens GN=MAOB PE=1 SV=3,Enzymes,EC:1.4.3.4,Established target
NRDD537,-,TREPROSTINIL,Antihypertensive Agents; Antithrombotic Agents,small molecule,2002,Q9H244,P2Y12_HUMAN,P2RY12,P2Y purinoceptor 12 OS=Homo sapiens GN=P2RY12 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD537,-,TREPROSTINIL,Antihypertensive Agents; Antithrombotic Agents,small molecule,2002,P37231,PPARG_HUMAN,PPARG,Peroxisome proliferator-activated receptor gamma OS=Homo sapiens GN=PPARG PE=1 SV=3,Receptors,Nuclear receptor,Established target
NRDD538,-,TRIAMTERENE,Antihypertensive Agents; Diuretics,small molecule,1964,P37088,SCNNA_HUMAN,SCNN1A,Amiloride-sensitive sodium channel subunit alpha OS=Homo sapiens GN=SCNN1A PE=1 SV=1,Transporters,TC:1.A.6.1.1,Established target
NRDD538,-,TRIAMTERENE,Antihypertensive Agents; Diuretics,small molecule,1964,P51168,SCNNB_HUMAN,SCNN1B,Amiloride-sensitive sodium channel subunit beta OS=Homo sapiens GN=SCNN1B PE=1 SV=2,Transporters,TC:1.A.6.1.1,Established target
NRDD538,-,TRIAMTERENE,Antihypertensive Agents; Diuretics,small molecule,1964,P51172,SCNND_HUMAN,SCNN1D,Amiloride-sensitive sodium channel subunit delta OS=Homo sapiens GN=SCNN1D PE=1 SV=2,Transporters,TC:1.A.6,Established target
NRDD538,-,TRIAMTERENE,Antihypertensive Agents; Diuretics,small molecule,1964,P51170,SCNNG_HUMAN,SCNN1G,Amiloride-sensitive sodium channel subunit gamma OS=Homo sapiens GN=SCNN1G PE=1 SV=4,Transporters,TC:1.A.6.1.1,Established target
NRDD539,-,TRICHLORMETHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,1960,P00915,CAH1_HUMAN,CA1,Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD539,-,TRICHLORMETHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,1960,P00918,CAH2_HUMAN,CA2,Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2,Enzymes,EC:4.2.1.1,Established target
NRDD539,-,TRICHLORMETHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,1960,P22748,CAH4_HUMAN,CA4,Carbonic anhydrase 4 OS=Homo sapiens GN=CA4 PE=1 SV=2,Enzymes,EC:4.2.1,Established target
NRDD539,-,TRICHLORMETHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,1960,Q12791,KCMA1_HUMAN,KCNMA1,Calcium-activated potassium channel subunit alpha-1 OS=Homo sapiens GN=KCNMA1 PE=1 SV=2,Transporters,TC:1.A.1.3,Established target
NRDD539,-,TRICHLORMETHIAZIDE,Antihypertensive Agents; Diuretics,small molecule,1960,Q13621,S12A1_HUMAN,SLC12A1,Solute carrier family 12 member 1 OS=Homo sapiens GN=SLC12A1 PE=1 SV=2,Transporters,TC:2.A.30.1.2,Established target
NRDD540,-,TRIDIHEXETHYL,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,1954,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD540,-,TRIDIHEXETHYL,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,1954,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD540,-,TRIDIHEXETHYL,"GI Anti-Ulcer Agents, anticholinergic; Antispasmodics",small molecule,1954,P20309,ACM3_HUMAN,CHRM3,Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD541,-,TRIFLUOPERAZINE,Antiemetics; Antipsychotic Agents,small molecule,1959,P35348,ADA1A_HUMAN,ADRA1A,Alpha-1A adrenergic receptor OS=Homo sapiens GN=ADRA1A PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD541,-,TRIFLUOPERAZINE,Antiemetics; Antipsychotic Agents,small molecule,1959,Q9NYX4,CALY_HUMAN,DRD1IP,Neuron-specific vesicular protein calcyon OS=Homo sapiens GN=CALY PE=1 SV=1,Other,Vesicle transport,Established target
NRDD541,-,TRIFLUOPERAZINE,Antiemetics; Antipsychotic Agents,small molecule,1959,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD542,-,TRIFLUPROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,1957,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD542,-,TRIFLUPROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,1957,P08172,ACM2_HUMAN,CHRM2,Muscarinic acetylcholine receptor M2 OS=Homo sapiens GN=CHRM2 PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD542,-,TRIFLUPROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,1957,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD542,-,TRIFLUPROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,1957,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD542,-,TRIFLUPROMAZINE,Antiemetics; Antipsychotic Agents,small molecule,1957,P41595,5HT2B_HUMAN,HTR2B,5-hydroxytryptamine receptor 2B OS=Homo sapiens GN=HTR2B PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD543,-,TRIHEXYPHENIDYL,Antiparkinson Agents,small molecule,Approved before 1982,P11229,ACM1_HUMAN,CHRM1,Muscarinic acetylcholine receptor M1 OS=Homo sapiens GN=CHRM1 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD544,-,TRILOSTANE,Antiadrenal,small molecule,1984,P14060,3BHS1_HUMAN,HSD3B1,3 beta-hydroxysteroid dehydrogenase/Delta 5--4-isomerase type 1 OS=Homo sapiens GN=HSD3B1 PE=1 SV=2,Enzymes,EC:1.1.1.145/5.3.3.1,Established target
NRDD544,-,TRILOSTANE,Antiadrenal,small molecule,1984,P26439,3BHS2_HUMAN,HSD3B2,3 beta-hydroxysteroid dehydrogenase/Delta 5--4-isomerase type 2 OS=Homo sapiens GN=HSD3B2 PE=1 SV=2,Enzymes,EC:1.1.1.145/5.3.3.1,Established target
NRDD545,-,TRIMEPRAZINE,Antipruritics,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD546,-,TRIMETHADIONE,Anticonvulsants,small molecule,1946,O43497,CAC1G_HUMAN,CACNA1G,Voltage-dependent T-type calcium channel subunit alpha-1G OS=Homo sapiens GN=CACNA1G PE=2 SV=3,Transporters,TC:1.A.1.11,Established target
NRDD547,-,TRIMETHAPHAN,Antihypertensive Agents; Vasodilator Agents,small molecule,Approved before 1982,Q9GZZ6,ACH10_HUMAN,CHRNA10,Neuronal acetylcholine receptor subunit alpha-10 OS=Homo sapiens GN=CHRNA10 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD548,-,TRIMETREXATE,Antineoplastic Agents,small molecule,1993,P00374,DYR_HUMAN,DHFR,Dihydrofolate reductase OS=Homo sapiens GN=DHFR PE=1 SV=2,Enzymes,EC:1.5.1.3,Established target
NRDD549,-,TRIMIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,1979,P23975,SC6A2_HUMAN,SLC6A2,Sodium-dependent noradrenaline transporter OS=Homo sapiens GN=SLC6A2 PE=1 SV=1,Transporters,TC:2.A.22.1.2,Established target
NRDD549,-,TRIMIPRAMINE,"Antidepressive Agents, Tricyclic",small molecule,1979,P31645,SC6A4_HUMAN,SLC6A4,Sodium-dependent serotonin transporter OS=Homo sapiens GN=SLC6A4 PE=1 SV=1,Transporters,TC:2.A.22.1.1,Established target
NRDD550,-,TRIPELENNAMINE,Anti-Allergic Agents,small molecule,1948,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD551,-,TRIPROLIDINE,Anti-Allergic Agents,small molecule,Approved before 1982,P35367,HRH1_HUMAN,HRH1,Histamine H1 receptor OS=Homo sapiens GN=HRH1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD552,-,TROPICAMIDE,Diagnostic Agents; Mydriatics,small molecule,1960,P08173,ACM4_HUMAN,CHRM4,Muscarinic acetylcholine receptor M4 OS=Homo sapiens GN=CHRM4 PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD553,-,TUBOCURARINE,"Muscle Relaxants, Skeletal",small molecule,1945,Q15822,ACHA2_HUMAN,CHRNA2,Neuronal acetylcholine receptor subunit alpha-2 OS=Homo sapiens GN=CHRNA2 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD554,-,UROFOLLITROPIN,Fertility Agents,protein,1986,P23945,FSHR_HUMAN,FSHR,Follicle-stimulating hormone receptor OS=Homo sapiens GN=FSHR PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD555,-,UROKINASE,Thrombolytic Agents,protein,Approved before 1982,P00747,PLMN_HUMAN,PLG,Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2,Enzymes,EC:3.4.21.7,Established target
NRDD556,-,USTEKINUMAB,Antipsoriatic Agents,monoclonal antibody,2009,P29460,IL12B_HUMAN,IL12B,Cytotoxic lymphocyte maturation factor 40 kDa subunit,Other,Receptor; Type 1 cytokine receptor,Established target
NRDD556,-,USTEKINUMAB,Antipsoriatic Agents,monoclonal antibody,2009,Q9NPF7,IL23A_HUMAN,IL23A,Interleukin-23 subunit alpha (IL-23 subunit alpha) (IL-23-A) (Interleukin-23 subunit p19) (IL-23p19),Other,Receptor; Type 1 cytokine receptor,Established target
NRDD557,-,VALPROIC ACID,Anticonvulsants,small molecule,1978,P80404,GABT_HUMAN,ABAT,"4-aminobutyrate aminotransferase, mitochondrial OS=Homo sapiens GN=ABAT PE=1 SV=3",Enzymes,EC:2.6.1.19; 2.6.1.22,Established target
NRDD558,-,VALRUBICIN,Antineoplastic Agents,small molecule,1998,P11388,TOP2A_HUMAN,TOP2A,DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3,Enzymes,EC:5.99.1.3,Established target
NRDD559,-,WARFARIN,Anticoagulants,small molecule,Approved before 1982,Q9BQB6,VKOR1_HUMAN,VKORC1,Vitamin K epoxide reductase complex subunit 1 OS=Homo sapiens GN=VKORC1 PE=1 SV=1,Enzymes,EC:1.1.4.1,Established target
NRDD559,-,WARFARIN,Anticoagulants,small molecule,Approved before 1982,Q8N0U8,VKORL_HUMAN,VKORC1L1,Vitamin K epoxide reductase complex subunit 1-like protein 1 OS=Homo sapiens GN=VKORC1L1 PE=1 SV=2,Enzymes,EC:1.1.4.1,Established target
NRDD560,-,VASOPRESSIN,Antidiuretic Agents,peptide,Approved before 1982,P37288,V1AR_HUMAN,AVPR1A,Vasopressin V1a receptor OS=Homo sapiens GN=AVPR1A PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD560,-,VASOPRESSIN,Antidiuretic Agents,peptide,Approved before 1982,P47901,V1BR_HUMAN,AVPR1B,Vasopressin V1b receptor OS=Homo sapiens GN=AVPR1B PE=2 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD560,-,VASOPRESSIN,Antidiuretic Agents,peptide,Approved before 1982,P30518,V2R_HUMAN,AVPR2,Vasopressin V2 receptor OS=Homo sapiens GN=AVPR2 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD561,-,VINBLASTINE,Antineoplastic Agents,small molecule,1965,P07437,TBB5_HUMAN,TUBB2A,Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2,Other,StructuralAndAdhesion;Cytoskeleton,Established target
NRDD562,-,VINDESINE,Antineoplastic Agents,small molecule,not approved by the FDA,Q9H4B7,TBB1_HUMAN,TUBB1,Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1,Other,StructuralAndAdhesion;Cytoskeleton,Established target
NRDD563,-,XIMELAGATRAN,Anticoagulants,small molecule,not approved by the FDA,P00734,THRB_HUMAN,F2,Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2,Enzymes,EC:3.4.21.5,Established target
NRDD564,-,YOHIMBINE,Mydriatics; Anti-impotence Agents,small molecule,not approved by the FDA,P08913,ADA2A_HUMAN,ADRA2A,Alpha-2A adrenergic receptor OS=Homo sapiens GN=ADRA2A PE=1 SV=3,Receptors,GPCR;Rhodopsin,Established target
NRDD564,-,YOHIMBINE,Mydriatics; Anti-impotence Agents,small molecule,not approved by the FDA,P18089,ADA2B_HUMAN,ADRA2B,Alpha-2B adrenergic receptor OS=Homo sapiens GN=ADRA2B PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD564,-,YOHIMBINE,Mydriatics; Anti-impotence Agents,small molecule,not approved by the FDA,P18825,ADA2C_HUMAN,ADRA2C,Alpha-2C adrenergic receptor OS=Homo sapiens GN=ADRA2C PE=2 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD566,-,ZOPICLONE,Hypnotics and Sedatives,small molecule,2004,P30536,TSPOA_HUMAN,BZRP,Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=2,Transporters,"Miscellaneous; benzodiazepine translocator protein,",Established target
NRDD566,-,ZOPICLONE,Hypnotics and Sedatives,small molecule,2004,P14867,GBRA1_HUMAN,GABRA1,Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens GN=GABRA1 PE=1 SV=3,Receptors,TC:1.A.9,Established target
NRDD566,-,ZOPICLONE,Hypnotics and Sedatives,small molecule,2004,P47869,GBRA2_HUMAN,GABRA2,Gamma-aminobutyric acid receptor subunit alpha-2 OS=Homo sapiens GN=GABRA2 PE=2 SV=2,Receptors,TC:1.A.9.5.2,Established target
NRDD566,-,ZOPICLONE,Hypnotics and Sedatives,small molecule,2004,P34903,GBRA3_HUMAN,GABRA3,Gamma-aminobutyric acid receptor subunit alpha-3 OS=Homo sapiens GN=GABRA3 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD566,-,ZOPICLONE,Hypnotics and Sedatives,small molecule,2004,P31644,GBRA5_HUMAN,GABRA5,Gamma-aminobutyric acid receptor subunit alpha-5 OS=Homo sapiens GN=GABRA5 PE=1 SV=1,Receptors,TC:1.A.9,Established target
NRDD567,-,ZUCLOPENTHIXOL,Antipsychotic Agents,small molecule,1962,P21728,DRD1_HUMAN,DRD1,D(1A) dopamine receptor OS=Homo sapiens GN=DRD1 PE=1 SV=1,Receptors,GPCR;Rhodopsin,Established target
NRDD567,-,ZUCLOPENTHIXOL,Antipsychotic Agents,small molecule,1962,P14416,DRD2_HUMAN,DRD2,D(2) dopamine receptor OS=Homo sapiens GN=DRD2 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
NRDD567,-,ZUCLOPENTHIXOL,Antipsychotic Agents,small molecule,1962,P21918,DRD5_HUMAN,DRD5,D(1B) dopamine receptor OS=Homo sapiens GN=DRD5 PE=1 SV=2,Receptors,GPCR;Rhodopsin,Established target
